<SEC-DOCUMENT>0001193125-18-011167.txt : 20180116
<SEC-HEADER>0001193125-18-011167.hdr.sgml : 20180116
<ACCEPTANCE-DATETIME>20180116160439
ACCESSION NUMBER:		0001193125-18-011167
CONFORMED SUBMISSION TYPE:	F-1
PUBLIC DOCUMENT COUNT:		21
FILED AS OF DATE:		20180116
DATE AS OF CHANGE:		20180116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UroGen Pharma Ltd.
		CENTRAL INDEX KEY:			0001668243
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-222558
		FILM NUMBER:		18528641

	BUSINESS ADDRESS:	
		STREET 1:		9 HA'TA'ASIYA ST
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4365007
		BUSINESS PHONE:		972 9 770 7601

	MAIL ADDRESS:	
		STREET 1:		9 HA'TA'ASIYA ST
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4365007
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1
<SEQUENCE>1
<FILENAME>d504802df1.htm
<DESCRIPTION>F-1
<TEXT>
<HTML><HEAD>
<TITLE>F-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>As filed with the Securities and Exchange Commission on January&nbsp;16, 2018. </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE
COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">F-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>THE SECURITIES ACT OF 1933 </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>UroGen Pharma Ltd. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Exact name of Registrant as
specified in its charter) </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Not Applicable </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Translation of Registrant&#146;s name into English) </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>State of Israel</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center">(State or other jurisdiction of<BR>incorporation or organization)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(Primary Standard Industrial<BR>Classification Code Number)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(I.R.S. Employer<BR>Identification Number)</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>9 Ha&#146;Ta&#146;asiya Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Ra&#146;anana 4365007, Israel </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Tel: +972 (9) <FONT
STYLE="white-space:nowrap">770-7601</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Address, including zip code, and telephone number, including area code, of Registrant&#146;s principal
executive offices) </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Urogen Pharma, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>499 Park Avenue, 12th
Floor </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>New York, New York 10022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Telephone: +1 (646) <FONT STYLE="white-space:nowrap">768-9780</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Name, address, including zip code, and telephone number, including area code, of agent for service) </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Copies to:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Divakar Gupta</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Daniel I. Goldberg</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Joshua A. Kaufman<BR>Cooley
LLP<BR>The Grace Building<BR>1114 Avenue of the Americas<BR>New York, NY 10036<BR>Telephone: (212) <FONT STYLE="white-space:nowrap">479-6000</FONT><BR>Facsimile: (212) <FONT STYLE="white-space:nowrap">479-6275</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Yaron Sobol</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Steven Berelowitz</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Hamburger Evron&nbsp;&amp;
Co.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>The Museum Tower</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>4 Berkowitz
Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Tel-Aviv</FONT> 6423806, Israel</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Telephone: +972 (3) <FONT STYLE="white-space:nowrap">607-4040</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Facsimile: +972 (3) <FONT STYLE="white-space:nowrap">607-4004</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Eric W. Blanchard</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Brian K. Rosenzweig</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Covington&nbsp;&amp;
Burling LLP<BR>The New York Times Building<BR>620 Eighth Avenue<BR>New York, NY 10018-1405<BR>Telephone: (212) <FONT STYLE="white-space:nowrap">841-1000</FONT><BR>Facsimile: (212) <FONT STYLE="white-space:nowrap">841-1010</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Chaim Friedland</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Ari Fried</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Gornitzky&nbsp;&amp; Co.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Zion House</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>45 Rothschild Blvd.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Tel Aviv 6578403, Israel</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Telephone: +972 (3) <FONT
STYLE="white-space:nowrap">710-9191</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Facsimile: +972 (3) <FONT STYLE="white-space:nowrap">560-6555</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Approximate date of commencement of proposed sale to the public: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">As soon as practicable after the effective date of this Registration Statement. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the
following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is filed to register additional securities for an offering pursuant
to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the
Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933. Emerging growth company&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9746;</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9746;</FONT> </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>TITLE OF EACH CLASS OF SECURITIES<BR>TO BE REGISTERED</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>PROPOSED MAXIMUM<BR>AGGREGATE</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>OFFERING&nbsp;PRICE&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>AMOUNT OF<BR>REGISTRATION<BR>FEE&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Ordinary Shares, par value NIS 0.01 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$57,500,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$7,158.75</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended. Includes the ordinary shares that the underwriters have the
option to purchase. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">(2)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price. </TD></TR></TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall
thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine.
</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#cc062a"><B>The information
contained in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an
offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><FONT COLOR="#cc062a">SUBJECT TO COMPLETION, DATED JANUARY&nbsp;16, 2018 </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PRELIMINARY PROSPECTUS </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>1,135,847 Ordinary Shares </B></P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g504802g15c64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>UroGen Pharma Ltd. </B></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are
offering 1,135,847 ordinary shares. Our ordinary shares are listed on the NASDAQ Global Market under the symbol &#147;URGN.&#148; On&nbsp;January&nbsp;11, 2018, the last reported sale price of our ordinary shares on the NASDAQ Global Market was
$44.02. The public offering price will be determined through negotiation between us and the underwriters for this offering and the recent market price used throughout this prospectus may not be indicative of the actual offering price. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012 and, as such, we have elected to comply with certain reduced
public company reporting requirements for this prospectus and future filings. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investing in our ordinary shares involves a high degree of risk. Please read
&#147;<A HREF="#toc504802_3">Risk Factors</A>&#148; beginning on page 15 of this prospectus. </B></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Public Offering Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Underwriting Discounts and
Commissions<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds to UroGen Pharma Ltd. Before Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>We have agreed to reimburse the underwriters for certain expenses. See &#147;Underwriting.&#148; </TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Delivery of the ordinary shares is expected to be made on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. We have granted the underwriters an option for a period of 30 days from the date of this prospectus to
purchase up to an additional 170,377 ordinary shares. If the underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
and the total proceeds to us, before expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top" ALIGN="center"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Cowen</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:12pt">
<TD VALIGN="top" ALIGN="center"><B>Oppenheimer&nbsp;&amp;&nbsp;Co.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>National&nbsp;Securities&nbsp;Corporation</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Prospectus
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_1">Market, Industry and Other Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_2">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_4">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_6">Market Price of Ordinary Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_7">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_8">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_9">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_10">Selected Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_11">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_12">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_13">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_14">Principal Shareholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_15">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_16">Description of Share Capital</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_17">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_18">Taxation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_19">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_20">Expenses of this Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_21">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_22">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_23">Enforcement of Civil Liabilities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_24">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc504802_25">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we nor the underwriters have authorized anyone to provide you with information that is different from that contained in this prospectus, any amendment or
supplement to this prospectus, or in any free writing prospectus we may authorize to be delivered or made available to you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may
give you. We and the underwriters are offering to sell ordinary shares and seeking offers to purchase ordinary shares only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the
date on the front of this prospectus, regardless of the time of delivery of this prospectus or any sale of ordinary shares. Our business, financial condition, results of operations and prospects may have changed since the date on the front cover of
this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For investors outside of the United States: Neither we nor any of the underwriters have taken any action to permit this offering or possession or
distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the
distribution of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MitoGel, VesiGel, Vesimune, UroGen and RTGel are trademarks of ours that we use in this prospectus. This prospectus also includes
trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this prospectus appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
or &#153; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to our trademark and tradenames. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_1"></A>MARKET, INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus contains estimates, projections and other information concerning our industry, our business, and the markets for our product candidates. Information
that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this
information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research
firms and other third parties, industry, medical and general publications, government data and similar sources. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, assumptions and estimates of our and
our industry&#146;s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#147;Risk Factors.&#148; These and other factors could cause our future performance to
differ materially from our assumptions and estimates. See &#147;Special Note Regarding Forward-Looking Statements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>This summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making
your investment decision. Before deciding to invest in our ordinary shares, you should read this entire prospectus carefully, including the sections of this prospectus entitled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the related notes included elsewhere in this prospectus. Unless the context otherwise requires, references in this prospectus to the
&#147;company,&#148; &#147;UroGen Pharma,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to UroGen Pharma Ltd. and its subsidiary, Urogen Pharma, Inc. The terms &#147;shekel,&#148; &#147;Israeli shekel&#148; and &#147;NIS&#148; refer
to New Israeli Shekels, the lawful currency of the State of Israel, and the terms &#147;dollar,&#148; &#147;U.S. dollar&#148; or &#147;$&#148; refer to United States dollars, the lawful currency of the United States. All references to
&#147;shares&#148; in this prospectus refer to ordinary shares of UroGen Pharma Ltd., par value NIS 0.01 per share. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. We have an
innovative and broad pipeline of product candidates that we believe can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on <FONT STYLE="white-space:nowrap">uro-oncology.</FONT> Our lead
product candidates, MitoGel and VesiGel, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is currently used <FONT STYLE="white-space:nowrap">off-label</FONT> for urothelial cancer treatment only in a
water-based formulation as an adjuvant, or supplemental post-surgery, therapy. We are developing our product candidates as chemoablation agents, which means they are designed to remove tumors by <FONT STYLE="white-space:nowrap">non-surgical</FONT>
means, to treat several forms of <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive urothelial cancer, including <FONT STYLE="white-space:nowrap">low-grade</FONT> upper tract urothelial carcinoma, or UTUC, and
<FONT STYLE="white-space:nowrap">low-grade</FONT> bladder cancer. We believe that MitoGel and VesiGel, which are both local drug therapies, have the potential to significantly improve patients&#146; quality of life by replacing costly, <FONT
STYLE="white-space:nowrap">sub-optimal</FONT> and burdensome tumor resection and kidney removal surgeries as the first-line standard of care. MitoGel and VesiGel may also reduce the need for bladder and upper urinary tract surgeries, including
removal of the upper urinary tract, which are major surgical procedures typically performed when local endoscopic tumor resection fails to control the disease progression. Additionally, we believe that our product candidates, which are based on
novel formulations of previously approved drugs, may qualify for streamlined regulatory pathways to market approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that urothelial cancer, which is
comprised of bladder cancer and UTUC, affects a large and underserved patient population. Annual expenditures for Medicare alone in the United States for the treatment of urothelial cancer were estimated to have been at least $4.0&nbsp;billion in
2010 and are projected to be at least $5.0&nbsp;billion in 2020. The majority of the expenditures is spent on tumor resection surgeries such as TURBT and upper urinary tract removals. In 2012, the estimated prevalence of urothelial cancer in the
United States was 625,000 with an annual incidence of approximately 80,000. The 2012 prevalence of each of <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC and <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC in the United States was
approximately 325,000 and 14,500, respectively. No drugs have been approved by the U.S. Food and Drug Administration, or the FDA, for the treatment of NMIBC in more than 15 years. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our lead product candidates, MitoGel and VesiGel, are formulated using our proprietary reverse thermally triggered hydrogel, or RTGel, technology. We believe that
RTGel-based drug formulations, which provide for the sustained release of an active drug, may improve the efficacy of treatment of various types of urothelial cancer without compromising the safety of the patient or interfering with the natural flow
of fluids from the urinary tract to the bladder. Our formulations are designed to achieve this by increasing the dwell time as well as the tissue coverage of the active drug throughout the organ. Consequently, we believe that RTGel-based drug
formulations may enable us to overcome the anatomical and physiological challenges that have historically contributed to the lack of drug development for the treatment of urothelial cancer. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our product candidates are administered locally using the standard practice of intravesical instillation directly into the bladder or upper urinary tract via a
catheter. The instillation into the bladder is expected to take place </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
in a physician&#146;s office as a <FONT STYLE="white-space:nowrap">same-day</FONT> treatment, in comparison with TURBT or similar tumor surgical procedures, which are operations conducted under
general anesthesia in a hospital setting and may require at least an overnight stay. Tumor surgical procedures often have limited success due to the inability to properly identify, reach and resect all tumors. We believe that an effective
chemoablation agent can potentially provide better eradication of tumors irrespective of the detectability and location of the tumors. In addition, by removing the need for surgery, patients may avoid potential complications associated with surgery
and hospital-acquired infections. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are currently evaluating the safety and efficacy of MitoGel, our novel sustained-release formulation of MMC, in patients with <FONT
STYLE="white-space:nowrap">low-grade</FONT> UTUC in a Phase 3 pivotal, <FONT STYLE="white-space:nowrap">single-arm,</FONT> open label clinical trial, which follows a recently completed &#147;Compassionate Use&#148; program for MitoGel for the
treatment of the same indication. &#147;Compassionate Use&#148; is the use outside of a clinical trial of an investigational, or not approved, medical product when patient enrollment in a clinical trial is not possible, typically due to patient
ineligibility or a lack of ongoing clinical trials. In the Compassionate Use Program, 22 patients were enrolled, 18 of which had confirmed <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC. Of the 18 patients, 13&nbsp;patients had completed the
<FONT STYLE="white-space:nowrap">six-weekly</FONT> treatment regimen and were evaluated for tumor response. These 13 patients were evaluated for tumor response at the primary evaluation time either endoscopically or through the use of a nonsurgical
viewing instrument. Complete response was confirmed by a cytology (urine) confirmation in most cases. Of these 13 patients, eight, or approximately 62%, achieved a complete response, with a median durability of response without recurrence of greater
than nine months to date, based on investigator reports. Our analysis of the median recurrence-free durability of those patients who achieved a complete response is still ongoing, with, to our knowledge, only three of the eight patients recurring to
date. To date, of the five patients still ongoing without recurrence, to our knowledge, three have durability of response of 12 months or greater. Recurrences were generally of small tumors, presenting with diameters of several millimeters in size
that were consequently managed by endoscopic tumor resection. Importantly, of the eight patients that achieved a complete response, or a complete response following an initial partial response, four had a solitary kidney. As all the patients in the
Compassionate Use program were candidates for a nephroureterectomy, these four patients otherwise may have had their solitary kidney removed and become dialysis patients. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Five out of the 13 evaluated patients achieved a partial response at the primary evaluation time. One patient who achieved a partial response received three additional
monthly courses of MitoGel, and thereafter achieved a complete response. In this Compassionate Use program, MitoGel had been observed to be well-tolerated. We have obtained Orphan Drug Designation for MitoGel for the treatment of UTUC as well as
Fast Track Designation for the treatment of patients with <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC not amenable to endoscopic resection or contraindicated for nephroureterectomy, which is the removal of the kidney and upper tract,
including impaired renal function.&nbsp;We believe that MitoGel has the potential to become the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC serving as a
first-line chemoablation agent, sparing patients from repeated tumor resection surgeries and potentially reducing the need for bladder and upper urinary tract surgeries, including upper urinary tract removals. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we completed evaluating the safety and efficacy of VesiGel, our novel sustained-release high dose formulation of MMC, for the treatment of <FONT
STYLE="white-space:nowrap">low-grade</FONT> NMIBC in a Phase 2a study that was conducted in Europe and Israel. Of the 22 patients treated in the VesiGel high dose group (80mg MMC), 19, or approximately 86%, of the patients achieved a complete
response at the primary evaluation time. Moreover, approximately 79% of the patients who achieved a complete response at the primary evaluation time with VesiGel in the study and who have been followed for 12 months thereafter, without receiving
additional treatments, remained recurrence free. This compares to approximately 40% to 60% of patients who historically achieve <FONT STYLE="white-space:nowrap">a&nbsp;12-month&nbsp;durable</FONT> complete response with TURBT as first-line
treatment, followed by adjuvant treatments of MMC instillations into the bladder. We plan to file an IND for VesiGel in the first half of 2018; and, if accepted, we expect to commence a U.S.-based Phase 2b clinical trial for VesiGel shortly
thereafter. We also intend to pursue a 505(b)(2) regulatory pathway for VesiGel. We believe that VesiGel has the potential to </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
replace tumor resection surgery and become the new first-line standard of care for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our clinical stage pipeline also includes Vesimune, our proprietary immunotherapy product candidate for the treatment of high-grade NMIBC, which may include Carcinoma
in Situ, or CIS. Vesimune is a novel, liquid formulation of Imiquimod, a generic toll-like receptor 7, or TLR7, agonist. Toll-like receptor agonists play a key role in initiating the innate immune response system. We believe that the combination of
Vesimune with additional immunotherapy drugs, such as immune checkpoint inhibitors or chemotherapy drugs like VesiGel, could represent a valid alternative to the current standard of care for the post-TURBT adjuvant treatment of high-grade NMIBC.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">BotuGel is our proprietary novel RTGel-based formulation of BOTOX, a branded drug, that we believe can potentially serve as an effective treatment option for
patients suffering from overactive bladder. In October&nbsp;2016, we announced the licensing of the worldwide rights to RTGel in combination with neurotoxins, including BOTOX, to Allergan Pharmaceuticals International Limited, or Allergan, a wholly
owned subsidiary of Allergan plc, or the Allergan Agreement. In August 2017, we announced that Allergan had submitted an IND to the FDA in order to be able to commence clinical trials in the United States using the RTGel in combination with BOTOX.
In October 2017, Allergan commenced a Phase 2 clinical trial of BotuGel for the treatment of overactive bladder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Product Candidate Pipeline </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following chart summarizes the current status of our product candidate pipeline. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g504802g94n34.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview of Upper Tract Urothelial Carcinoma </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">UTUC refers to malignant changes of the transitional urothelial cells lining the upper urinary tract of the renal pelvis and ureter. UTUC typically exhibits high local
recurrence and development of metastases. Similar to NMIBC, the prognosis of patients with UTUC correlates with the stage and grade of disease at the time of initial diagnosis. The key prognostic factor at the time of diagnosis of UTUC is whether
the tumor is in the muscle-invasive or <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive stage. The number, size and location of tumors presented also represent important prognostic factors for UTUC. Approximately 40% of the patients
diagnosed annually with UTUC in the United States present with <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive UTUC. <FONT STYLE="white-space:nowrap">Non-muscle</FONT> invasive UTUC is also divided into two grades, low and high. In two
studies conducted in 1997 and 2003 of 30 and 20 patients with <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive UTUC, 87% and 75% of patients were diagnosed with <FONT STYLE="white-space:nowrap">low-grade</FONT> <FONT
STYLE="white-space:nowrap">non-muscle</FONT> invasive UTUC, respectively. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Limitations of Current Treatment Options for Upper Tract Urothelial Carcinoma </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are currently no drugs approved by the FDA for the treatment of UTUC, representing a significant unmet medical need. Moreover, the anatomical complexity of the
upper urinary tract, particularly the renal pelvis, presents significant challenges to the proper identification and ability to reach and resect all tumors in tumor resection surgical procedures. Consequently, patients with high-grade disease or
patients with <FONT STYLE="white-space:nowrap">low-grade</FONT> disease that present with a large number of tumors typically undergo nephroureterectomy, which is kidney and upper urinary tract removal. In addition, the stage and grade of UTUC are
often misdiagnosed, which we believe is due to the structural complexity of the upper urinary tract. Due to these factors, the current standard of care for the treatment of UTUC is nephroureterectomy. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Tumor resection, which aims to be a kidney sparing surgical procedure, is conducted only in patients with <FONT STYLE="white-space:nowrap">low-grade</FONT> disease that
present with a limited number of tumors. Such procedures are followed by adjuvant chemotherapy treatment, typically with MMC. However, the upper urinary tract&#146;s anatomical constraints limit the effectiveness of surgical procedures and adjuvant
chemotherapy treatments, leading to high rates of recurrence and risk for progression in this patient population. In a study published in 2009 in the Journal of Endourology evaluating 57 patients with
<FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC who underwent tumor resections, 89.5% of patients recurred with a mean of 5.5 recurrences per patient over a four-year period. Moreover, approximately 20% of the patients in this trial
progressed and ultimately underwent kidney and upper urinary tract removal. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that because tumor resection procedures followed by adjuvant chemotherapy
therapy are <FONT STYLE="white-space:nowrap">sub-optimal,</FONT> nephroureterectomy is often used even in patients that may otherwise be candidates for organ-sparing treatments. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>MitoGel: Our Solution for the Treatment of <FONT STYLE="white-space:nowrap">Low-Grade</FONT> Upper Tract Urothelial Carcinoma </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MitoGel is our novel sustained-release RTGel-based formulation of MMC that we are developing for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT>
UTUC. RTGel is liquid at lower temperatures and converts into gel form at body temperature. This temperature-dependent viscosity characteristic allows for simple and convenient instillation of the cooled MitoGel in its liquid form to the upper
urinary tract via standard catheters. Once instilled, MitoGel converts into gel form in less than 10 minutes at body temperature. Subsequently, upon contact with urine, MitoGel gradually dissolves and releases the active drug, MMC, over a period of
several hours versus several minutes for MMC in its water-based formulation. We believe that this substantial increase in dwell time of MMC positions MitoGel as a potential first-line chemoablation treatment for
<FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC, potentially sparing patients from repeated tumor resection surgeries and reducing the need for bladder and upper urinary tract surgeries, including upper urinary tract removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview of <FONT STYLE="white-space:nowrap">Non-Muscle</FONT> Invasive Bladder Cancer </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Bladder cancer accounts for approximately 90% to 95% of all new cases of urothelial cancer in the United States, with a prevalence of approximately 580,000. Bladder
cancer is nearly three to four times more common in men than women, and, with an average age at diagnosis of 73, mostly affects the elderly. Bladder cancers are described as <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive or
muscle-invasive based on how far into the wall of the bladder they have invaded. The magnitude and rate of the spreading of the cancer is called &#147;staging,&#148; which ranges from Ta to T1 for NMIBC, and T2 to T4 for muscle-invasive bladder
cancers, as defined by the American Joint Committee on Cancer TNM System. In addition, Carcinoma in Situ, or CIS, a form of NMIBC, has a staging designation of Tis. Muscle-invasive bladder cancer, or MIBC, has an average five-year survival rate of
15% to 63%, depending on severity. MIBC represents a worse prognosis than NMIBC, which has a five-year survival rate of approximately 90%. NMIBC accounts for approximately 80% of all new cases of bladder cancer diagnosed in the United States each
year, which corresponds to an estimated annual incidence and prevalence of approximately 60,000 and 465,000 cases, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Limitations of Current
Treatment Options for <FONT STYLE="white-space:nowrap">Non-Muscle</FONT> Invasive Bladder Cancer </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The standard of care for treating NMIBC patients is TURBT
followed by adjuvant chemotherapy or immunotherapy treatment. TURBT is a surgical operation for tumor removal conducted under general </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
anesthesia in a hospital setting and may require at least an overnight stay. Moreover, TURBT&#146;s success is tied to the physician&#146;s ability to overcome challenges in properly identifying,
reaching and resecting all tumors. No drugs have been approved by the FDA as first-line treatment for NMIBC and only three drugs have been approved by the FDA for NMIBC, all used as adjuvant treatment, following TURBT. Efficacy of drug treatments
has historically been limited due to challenges presented by bladder physiology, specifically the fact that urine is produced and voided frequently, thus diluting the concentration of the drug almost immediately and causing the excretion of the drug
from the bladder at first urine voiding. Patients treated with the current standard of care have up to an approximately 60% rate of recurrence of NMIBC within one year, and the rate of progression of NMIBC to MIBC is between 20% and 30%. As a
consequence, NMIBC patients often undergo multiple repeat TURBT procedures and adjuvant chemotherapy and immunotherapy treatments. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>VesiGel: Our Solution for
the Treatment of <FONT STYLE="white-space:nowrap">Low-Grade</FONT> <FONT STYLE="white-space:nowrap">Non-Muscle</FONT> Invasive Bladder Cancer </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">VesiGel, an
RTGel-based formulation of high dose MMC, is our product candidate for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC. VesiGel is administered locally using standard catheters and is designed to conform to the
bladder&#146;s anatomy and persist in the bladder despite urine flow and bladder movement. Once instilled, VesiGel converts into gel form within approximately 10 minutes at body temperature. Subsequently, upon contact with urine, VesiGel gradually
dissolves and releases the active drug, MMC, over a period of several hours versus the time until first voiding, often less than an hour, for MMC in its current water-based formulation, without compromising the safety of the patient or interfering
with the natural flow of urine out of the bladder. We believe that the resulting significantly increased dwell time of MMC in the bladder prolongs exposure of MMC to the tissue and therefore has the potential to chemoablate visible and unseen
tumors. As a result of these properties, our goal is to develop VesiGel as a first-line chemoablation <FONT STYLE="white-space:nowrap">non-surgical</FONT> alternative to TURBT for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT>
NMIBC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>RTGel: Our Reverse Thermally Triggered Hydrogel Platform Technology </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have developed RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel, which, unlike the general characteristics of most forms of
matter, is liquid at lower temperatures and converts into gel form when heated. We believe that these characteristics promote ease of delivery into and retention of drugs in body cavities, including the bladder and the upper urinary tract, by
conforming to the anatomy of the target organ while preventing rapid excretion of the drug. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that RTGel, when formulated with an active drug, may allow
for the improved efficacy of treatment of various types of urothelial cancer without compromising the safety of the patient or interfering with the natural flow of fluids from the urinary tract to the bladder. RTGel achieves this by: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increasing the exposure of active drugs in the bladder and upper urinary tract by significantly extending the dwell time of the active drug while conforming to the anatomy of the bladder and the upper urinary tract,
which allows for enhanced drug tissue coverage. For example, the average dwell time of the standard MMC water formulation, currently used as adjuvant treatment, in the upper urinary tract is approximately five minutes, compared to approximately six
hours when MMC is formulated with RTGel; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administering higher doses of an active drug than would otherwise be possible using standard water-based formulations. For instance, it is only possible to dissolve 0.5 mg of MMC in 1 ml of water while it is possible to
formulate up to 8 mg of MMC with 1 ml of RTGel; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining the active drug&#146;s molecular structure and mode of action. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These characteristics of RTGel enable
sustained release of MMC in the urinary tract for both MitoGel and VesiGel, and of botulinum toxin in the case of BotuGel. Further, RTGel may be particularly effective in the bladder and upper urinary tract where tumor visibility and access are
challenging, and where there exists a significant amount of urine flow and voiding. We believe that these characteristics of RTGel may prove useful for the local delivery of active drugs to other bodily cavities in addition to the bladder and upper
urinary tract. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Competitive Strengths </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Potential ability to develop <FONT STYLE="white-space:nowrap">non-surgical,</FONT> first-line drug therapies for
<FONT STYLE="white-space:nowrap">uro-oncology.</FONT></I></B><B></B>&nbsp;Leveraging our innovative formulation technology, we are developing two lead product candidates, MitoGel and VesiGel, as potential replacements to first-line treatment for <FONT
STYLE="white-space:nowrap">low-grade</FONT> UTUC and NMIBC, respectively. Both MitoGel and VesiGel are chemoablation agents designed to overcome the challenges posed by the anatomy of the urinary tract by increasing the dwell time and enhancing the
tissue coverage of MMC. Clinical data generated to date supports our belief that our lead product candidates may be able to replace the current first-line tumor surgical procedures, providing a chemoablation treatment that has the potential to
better eradicate tumors irrespective of their detectability and location within the urinary tract. Of the 13 <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC patients treated with MitoGel in a recently-completed Compassionate Use program and
evaluated endoscopically or through the use of a nonsurgical viewing instrument for efficacy, eight achieved a complete response and the remaining five achieved a partial response at the primary evaluation time. In the case of VesiGel, 19 of 22, or
approximately 86%, of the patients treated with the high dose of VesiGel in a recently-completed Phase 2a trial conducted in Europe and Israel, evaluating the efficacy and safety of VesiGel&#146;s chemoablation properties, achieved a complete
response at the primary evaluation time. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Expertise in developing proprietary formulations of drugs for clinical benefit.</I></B> We focus on
developing proprietary RTGel formulations of previously approved drugs whose efficacy for a particular indication is limited by current formulations or routes of administration. While we have not yet brought a drug to market, our expertise has
enabled us to develop proprietary RTGel-based formulations for several previously approved drugs to date, including clinical stage proprietary formulations of MMC and botulinum toxin. Our formulations are designed to significantly increase the dwell
time and exposure of the drugs to the target sites and limit the need for urine retention, potentially providing enhanced clinical activity, reduced patient burden and increased patient compliance over existing formulations and modes of
administration. With 13 Ph.Ds. and medical doctors on our staff, we have a strong research and development team to advance our product candidates. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Lower development risks and costs for our pipeline product candidates. </I></B>We expect the approval process for each of our current <FONT
STYLE="white-space:nowrap">uro-oncology</FONT> product candidates to be conducted according to the FDA&#146;s 505(b)(2) regulatory pathway, a streamlined, lower-cost and more well-defined pathway to drug approval when compared to traditional drug
development. Furthermore, two of our product candidates, MitoGel and Vesimune, have received Orphan Drug Designation from the FDA for the treatment of UTUC and CIS, respectively, which we expect will provide seven years of marketing exclusivity
following FDA approval, if received. We submitted an IND for MitoGel in November 2016, which was accepted by the FDA in December 2016. We commenced a single pivotal, open-label, <FONT STYLE="white-space:nowrap">single-arm</FONT> Phase 3 clinical
trial for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC in the first quarter of 2017. The clinical trial is being conducted in the United States and Europe with anticipated enrollment of approximately 74 patients.
Additionally, we expect that our product candidates are more likely to be safe and well-tolerated because they are novel formulations of previously approved drugs. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Leverageable proprietary formulation technology</I></B><B>.</B><B></B>&nbsp;We believe that RTGel has multiple potential applications beyond
urology. Our formulation <FONT STYLE="white-space:nowrap">know-how</FONT> may enable us to develop different drug formulations to facilitate the delivery, retention and sustained release of active drugs to a variety of targeted body cavities. We
believe that our proprietary formulation technology can improve the efficacy of locally administered drugs in body cavities such as the stomach, uterus and rectum that present anatomical and physiological challenges related to frequent wash out,
rapid excretion and bodily secretions. In October 2016, we announced that we licensed worldwide rights to a proprietary RTGel formulation with BOTOX to Allergan for the treatment of overactive bladder and related indications pursuant to the Allergan
Agreement. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Strong intellectual property position. </I></B>We have a robust intellectual property portfolio that includes 28 issued patents
worldwide and more than 45 pending patent applications filed worldwide. In the United States, we have 13 granted patents that are directed to protect our lead product candidates MitoGel, VesiGel and Botugel as well as our RTGel technology and our
other potential product candidates that are under preclinical review. These patents claim methods, systems, and novel compositions for treating </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">
cancer in internal cavities, in particular treating a urinary tract cancer. These issued patents are expected to expire between 2024 and 2035. Additionally, the FDA has granted Orphan Drug
Designation to MitoGel for the treatment of UTUC and Vesimune for the treatment of CIS bladder cancer, which potentially entitles us to marketing exclusivity for MitoGel and Vesimune for seven years following approval, if granted, by the FDA. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Experienced and accomplished leadership team with proven track record</I></B><B>.</B> We have an experienced management team, with each member
possessing more than 15 years of biopharmaceutical and related industry experience. Our Chief Executive Officer, Ron Bentsur, successfully navigated Auryxia (ferric citrate) through the 505(b)(2) streamlined regulatory pathway to FDA approval. In
addition, our Chairman, Arie Belldegrun, M.D., is a seasoned biotech executive and was the founder, Chairman, Chief Executive Officer and President of Kite Pharma, which was recently sold to Gilead Sciences, Inc. for $11.8&nbsp;billion.
Dr.&nbsp;Belldegrun is also a urologist by training. We believe that our leadership team is well-positioned to lead us through clinical development, regulatory approval and commercialization for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Growth Strategy </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Establish each of our lead
product candidates, MitoGel and VesiGel, as the first-line treatment in its target indication.</I></B> We believe that data from treatments in our Compassionate Use program conducted in the United States, Europe and Israel provide preliminary
evidence of the potential safety and efficacy of MitoGel for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC. We submitted an IND for MitoGel with the FDA in November 2016, which was accepted by the FDA in December 2016, and
we commenced a single pivotal Phase 3 clinical trial in the first quarter of 2017 pursuant to the FDA&#146;s 505(b)(2) regulatory pathway. We recently completed a Phase 2a randomized, open-label, <FONT STYLE="white-space:nowrap">single-arm,</FONT>
active-controlled clinical trial of VesiGel for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC, conducted in Europe and Israel. We expect to file an IND for VesiGel in the first half of 2018, and, if accepted, to commence a
Phase 2b U.S.-based clinical trial shortly thereafter. We also expect to pursue a 505(b)(2) regulatory pathway for VesiGel. We believe that these local drug treatments have the potential to replace costly,
<FONT STYLE="white-space:nowrap">sub-optimal</FONT> and burdensome tumor resection and kidney removal surgeries to become the first-line standard of care. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Expand our <FONT STYLE="white-space:nowrap">uro-oncology</FONT> product pipeline.</I></B> A Phase 1 clinical trial of Vesimune was completed under
an IND in 12 patients with CIS, an aggressive form of high-grade urinary bladder cancer. In the trial, 10 patients were evaluated for response, of which 40% achieved a complete response rate with Vesimune as a single-agent treatment. We believe that
combining Vesimune with immune checkpoint inhibitors or chemotherapy has the potential to serve as a treatment option for high-grade urothelial tumors. We are also pursuing preclinical oncology programs that take advantage of our RTGel technology.
We are conducting preclinical programs for high-grade bladder cancer and high-grade UTUC. We may also evaluate <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquiring additional product candidates for the treatment of urological cancers.
</P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Utilize our proprietary technology to expand our pipeline to other body cavities and indications.</I></B> We believe that RTGel may be
suitable for multiple additional applications. Our <FONT STYLE="white-space:nowrap">know-how</FONT> may enable us to develop different drug formulations to facilitate the delivery, retention and sustained release of active drugs to a variety of
targeted body cavities. Beyond the urinary tract, we may target the gastrointestinal tract and the female reproductive system. In the future, we may also choose to develop our RTGel technology in combination with other drugs to treat cancer and
other indications endemic to such body cavities. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Evaluate and selectively pursue potential collaborations to develop improved formulations
and product life-cycle management strategies.</I></B> We entered into the Allergan Agreement to research, develop, manufacture and commercialize pharmaceutical products that contain RTGel and clostridial toxins (including BOTOX), alone or in
combination with certain other active ingredients. This collaboration provides us with funding for our research and development efforts, and may accelerate the development and commercialization of our approved products, if any. In addition, we may <FONT
STYLE="white-space:nowrap">in-license</FONT> or acquire additional product candidates for urological indications. Such collaborations would allow us to obtain financial support and to capitalize on the expertise and resources of our potential
partners, which could allow for new and improved versions of approved or clinical stage drugs, and could accelerate the development and commercialization of additional product candidates. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in the &#147;Risk
Factors&#148; section of this prospectus immediately following this prospectus summary. These risks include the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have a limited operating history and have incurred significant losses and negative cash flows since our inception, and we anticipate that we will continue to incur significant losses and negative cash flows for the
foreseeable future, which makes it difficult to assess our future viability. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have limited clinical trial experience with our product candidates and to date have generated only limited clinical data for our product candidates. Results of earlier studies and trials may not be predictive of
future trial results, and our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have not applied for regulatory approvals to market any of our product candidates, and we may be delayed in obtaining or fail to obtain such regulatory approvals and to commercialize our product candidates.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If the FDA does not conclude that MitoGel, VesiGel or our other product candidates satisfy the requirements under Section&nbsp;505(b)(2) of the Federal Food Drug and Cosmetic Act, or if the requirements for such product
candidates are not as we expect, the regulatory approval pathway for these product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either
case may not be successful. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Even if our product candidates receive regulatory approval, they may fail to achieve the broad degree of physician adoption and use and market acceptance necessary for commercial success. Further, if MitoGel or VesiGel
or any of our other product candidates produces undesirable side effects that we may not have detected in our previous preclinical studies and clinical trials, our ability to obtain and maintain marketing approval or physician and market acceptance
for these product candidates would be significantly harmed. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We are and expect to continue to be dependent on third-party subcontractors and single-source suppliers for the supply of sufficient quantities at acceptable costs of certain raw materials, compounds and components
necessary to produce MitoGel, VesiGel and Vesimune for preclinical studies, clinical trials and, if approved, commercial supply. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may receive only limited protection, or no protection, from our issued patents and patent applications. If our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our
product candidates and technologies are not adequate, we may not be able to compete effectively. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The market opportunities for our product candidates may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our product candidates, if approved, will face significant competition from competing technologies and our failure to compete effectively may prevent us from achieving significant market penetration. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">It may be difficult for us to profitably sell our product candidates if coverage and reimbursement for these products is limited by government authorities and/or third-party payor policies. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We must determine our PFIC status annually based on tests which are factual in nature, and our status will depend on our income, assets and activities each year. In addition, our status as a PFIC may depend on how
quickly we use the cash proceeds from this offering in our business. We do not believe that we were classified as a PFIC for the taxable year ended December 31, 2017. However, based upon the expected nature and composition of our income and assets,
we presently anticipate that we will be classified as a PFIC for the taxable year ending December 31, 2018. We cannot provide any assurances regarding our PFIC status for the current or future taxable years, and our U.S. tax counsel has not provided
any opinion regarding our PFIC status. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate Information </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were incorporated under the laws of the State of Israel in April 2004 under the name TheraCoat Ltd. In September 2015, we changed our name to UroGen Pharma Ltd. Our
principal executive offices are located at 9 Ha&#146;Ta&#146;asiya Street, Ra&#146;anana 4365007, Israel, and our telephone number is +972 (9) <FONT STYLE="white-space:nowrap">770-7601.</FONT> Our website address is <I>http://www.urogen.com</I>. The
information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus. We have included our website address as an inactive textual reference only. Our agent for service of process in the United
States is Urogen Pharma, Inc., located at 499 Park Avenue, 12th Floor, New York, New York 10022, and its telephone number is +1 (646) <FONT STYLE="white-space:nowrap">768-9780.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Implications of Being an &#147;Emerging Growth Company&#148; and a Foreign Private Issuer </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a company with less than $1.07&nbsp;billion in revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart
Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a requirement to have only two years of audited financial statements and only two years of related Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations disclosure in our initial
registration statement; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may take advantage of these provisions for up to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging
growth company upon the earlier to occur of: (1)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more; (2)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible
debt during the previous three years; or (3)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or the SEC. We may choose to take advantage of some but not all of these
reduced burdens, and therefore the information that we provide holders of our ordinary shares may be different than the information you might receive from other public companies in which you hold equity. In addition, Section&nbsp;107 of the JOBS Act
also provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards applicable to public companies. We have irrevocably elected to opt out of such extended
transition period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We report under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
company with foreign private issuer status. Even after we no longer qualify as an emerging growth company, as long as we continue to qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the
Exchange Act that are applicable to U.S. domestic public companies, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations with respect to a security registered under the Exchange Act; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sections of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and
</TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> containing unaudited financial statements and other specified information, and
current reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> upon the occurrence of specified significant events. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Both foreign private issuers
and emerging growth companies are also exempt from certain more stringent executive compensation disclosure rules. Thus, even if we no longer qualify as an emerging growth company, but remain a foreign private issuer, we will continue to be exempt
from the more stringent compensation disclosures required of companies that are neither an emerging growth company nor a foreign private issuer. However, we cannot assure you that at June 30, 2018, the next determination date of our foreign private
issuer status, we will qualify as a foreign private issuer. If we cease to qualify as a foreign private issuer at this determination date, we will be required to begin reporting as a domestic issuer on January 1, 2019. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE OFFERING </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Ordinary shares offered by us </P></TD>
<TD>1,135,847&nbsp;ordinary shares </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Ordinary shares to be outstanding immediately after this offering </P></TD>
<TD>14,887,237&nbsp;ordinary shares </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Option to purchase additional ordinary shares </P></TD>
<TD>We have granted the underwriters an option for a period of 30 days after the date of this prospectus to purchase up to&nbsp;170,377&nbsp;additional ordinary shares. </TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds to us from this offering will be approximately $46.3&nbsp;million, or approximately $53.3&nbsp;million if the underwriters exercise their option to purchase additional ordinary shares in full, after deducting
the underwriting discounts and commissions and estimated offering expenses payable by us, based on an assumed public offering price of $44.02&nbsp;per ordinary share, which was the last reported sale price of our ordinary shares on the NASDAQ Global
Market on January&nbsp;11, 2018. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We expect to use the net proceeds from this offering, together with our existing cash resources, to complete our single pivotal Phase 3 clinical trial of MitoGel for the treatment of
<FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC, to begin preparing for the commercial launch of MitoGel, if approved, to file an IND for, and to initiate our Phase 2b clinical trial of, VesiGel, for the treatment of <FONT
STYLE="white-space:nowrap">low-grade</FONT> NMIBC, and the remainder to fund continued research and clinical development of our other product candidates, including Vesimune, and for working capital and other general corporate purposes.
</TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Use of Proceeds&#148; for more information about the intended use of proceeds from this offering. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Tax considerations </P></TD>
<TD>We must determine our PFIC status annually based on tests which are factual in nature, and our status will depend on our income, assets and activities each year. In addition, our status as a PFIC may depend on how quickly we use the cash
proceeds from this offering in our business. We do not believe that we were classified as a PFIC for the taxable year ended December&nbsp;31, 2017. However, based upon the expected nature and composition of our income and assets, we presently
anticipate that we will be classified as a PFIC for the taxable year ending December 31, 2018. We cannot provide any assurances regarding our PFIC status for the current or future taxable years, and our U.S. tax counsel has not provided any opinion
regarding our PFIC status. For information about the potential adverse consequences to you of our being classified as a PFIC, see &#147;Taxation&#151;Material U.S. Federal Income Tax Consequences to U.S. Holders&#151;Passive Foreign Investment
Company Considerations.&#148; </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Risk factors </P></TD>
<TD>See &#147;Risk Factors&#148; and other information included in this prospectus for a discussion of factors that you should consider carefully before deciding to invest in our ordinary shares. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">NASDAQ Global Market symbol </P></TD>
<TD>&#147;URGN&#148; </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise stated, the number of ordinary shares to be outstanding after this offering is based on
13,751,390&nbsp;ordinary shares outstanding as of December&nbsp;31, 2017 and assumes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance by us of 1,135,847&nbsp;ordinary shares in this offering; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise of the underwriters&#146; option to purchase up to 170,377&nbsp;additional ordinary shares </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">but excludes:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,703,531 ordinary shares reserved for issuance under our 2010 Israeli Share Option Plan upon the exercise of outstanding options at a weighted-average exercise price of $5.03 per share; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">580,000 ordinary shares reserved for issuance under our 2017 Equity Incentive Plan upon the exercise of outstanding options at a weighted-average exercise price of $26.62 per share; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">276,560 ordinary shares reserved for issuance upon the vesting of outstanding restricted share units; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">278,400 ordinary shares reserved for issuance upon the achievement of certain milestones under the Vesimune asset purchase agreement with Telormedix SA; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">725,500 ordinary shares reserved for issuance pursuant to the terms of our 2017 Equity Incentive Plan. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following tables present summary financial data for our business. We derived the summary statements of operations data for the years ended December&nbsp;31,
2015 and 2016 from our consolidated audited financial statements and related notes appearing elsewhere in this prospectus. We derived the summary statements of operations data for the nine months ended September&nbsp;30, 2016 and 2017 and the
summary balance sheet data as of September&nbsp;30, 2017 from our condensed consolidated unaudited financial statements and related notes appearing elsewhere in this prospectus. Our condensed consolidated unaudited financial statements have been
prepared on the same basis as our consolidated audited financial statements, and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly our financial position as of
September&nbsp;30, 2017 and the results of operations for the nine months ended September&nbsp;30, 2016 and 2017. We maintain our books and records in U.S. dollars, and prepare our financial statements in accordance with accounting principles
generally accepted in the United States, or U.S. GAAP, as issued by the Financial Accounting Standards Board, or FASB. You should read this data together with our financial statements and related notes appearing elsewhere in this prospectus and the
information under the captions &#147;Capitalization&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results are not necessarily indicative of our future results, and
our interim period results are not necessarily indicative of results to be expected for a full year or any other interim period. </I></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED</B><br><B>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Statements of operations data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating loss (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Finance expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss per ordinary share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average number of ordinary shares outstanding used in computing loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,223,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;SEPTEMBER&nbsp;30,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;ACTUAL&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS</B><br><B>&nbsp;&nbsp;&nbsp;&nbsp;ADJUSTED<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)(2)</SUP>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">121,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Data presented on an as adjusted basis to give effect to the sale of 1,135,847 ordinary shares in this offering at the assumed public offering price of $44.02 per ordinary share, which was the last reported sale price
of our ordinary shares on the NASDAQ Global Market on January&nbsp;11, 2018, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each $1.00 increase or decrease in the assumed public offering price of $44.02 per ordinary share, which was the last reported sale price of our ordinary shares on the NASDAQ Global Market on January&nbsp;11, 2018,
would increase or decrease, respectively, each of cash and cash equivalents, working capital, total assets and total shareholders&#146; equity on an as adjusted basis by approximately $1.1&nbsp;million, assuming the number of ordinary shares offered
by us, as set forth on the cover of this prospectus, remains the same, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 100,000 in the number of
ordinary shares we are offering would increase or decrease, respectively, each of cash and cash equivalents, working capital, total assets and total shareholders&#146; equity on an as adjusted basis by approximately $4.1&nbsp;million, assuming the
assumed public offering price per ordinary share remains the same, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. The as adjusted information is illustrative only, and we will adjust
this information based on the actual public offering price and other terms of this offering determined at pricing. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Working capital is defined as total current assets minus total current liabilities. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing in our ordinary shares involves a high degree of risk. You should carefully consider the risks and uncertainties described below, in addition to the other
information set forth in this prospectus, including the financial statements and the related notes included elsewhere in this prospectus, before purchasing our ordinary shares. If any of the following risks actually occurs, our business, financial
condition, cash flows and results of operations could be negatively impacted. In that case, the trading price of our ordinary shares would likely decline and you might lose all or part of your investment. Additional risks and uncertainties not
currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, cash flows and results of operations. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have a limited operating history and have incurred significant losses and negative cash flows since our inception, and we anticipate that we will continue to
incur significant losses and negative cash flows for the foreseeable future, which makes it difficult to assess our future viability. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical
stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We are not profitable and have incurred net losses in each period since we commenced operations in 2004, including net losses of
$1.9&nbsp;million and $12.7&nbsp;million for the years ended December&nbsp;31, 2016 and 2015, respectively, and $9.9&nbsp;million and $14.9&nbsp;million for the nine months ended September&nbsp;30, 2017 and 2016, respectively. We expect to continue
to incur significant expenses and increasing operating losses for the foreseeable future. Our ability to ultimately achieve recurring revenues and profitability is dependent upon our ability to successfully complete the development of our product
candidates and obtain necessary regulatory approvals for and successfully manufacture, market and commercialize our products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that we will continue to
expend substantial resources in the foreseeable future for the clinical development of our current product candidates or any additional product candidates and indications that we may choose to pursue in the future. These expenditures will include
costs associated with research and development, conducting preclinical studies and clinical trials, and payments for third-party manufacturing and supply, as well as sales and marketing of any of our product candidates that are approved for sale by
regulatory agencies. Because the outcome of any clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our clinical stage and preclinical drug
candidates and any other drug candidates that we may develop in the future. Other unanticipated costs may also arise. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our future capital requirements depend on
many factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of, and the costs involved in, clinical development and obtaining regulatory approvals for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in regulatory requirements during the development phase that can delay or force us to stop our activities related to any of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of commercialization activities if our products are approved for sale, including marketing, sales and distribution costs; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of third-party manufacturing of our products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of any other product candidates we develop or acquire; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish and maintain strategic collaborations, licensing or other commercialization arrangements, and the terms and timing of such arrangements; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent and rate of market acceptance of any approved products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the expenses needed to attract and retain skilled personnel; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs associated with being a public company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including potential litigation costs, and the outcome of such litigation; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing, receipt and amount of sales of, or royalties on, future approved products, if any; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any product liability or other lawsuits related to our products; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">scientific breakthroughs in the field of urothelial cancer treatment and diagnosis that could significantly diminish the need for our product candidates or make them obsolete; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in reimbursement policies that could have a negative impact on our future revenue stream. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we have
limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Drug
development is a highly speculative undertaking and involves a substantial degree of risk. To date, we have not obtained any regulatory approvals for any of our product candidates, commercialized any of our product candidates or generated any
material revenue from product sales. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will require substantial additional financing to achieve our goals, and a failure to obtain this capital when needed
and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, commercialization efforts or other operations. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our inception, almost all of our resources have been dedicated to the preclinical and clinical development of our lead product candidates, MitoGel and VesiGel. As
of September&nbsp;30, 2017, we had cash and cash equivalents of $79.2&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe we have sufficient cash and cash equivalents to fund our operating
expenses and capital expenditure requirements for at least the next 18 months. We expect that we will require additional capital to complete clinical trials, obtain regulatory approval for and commercialize our product candidates. However, our
operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity, convertible debt or debt financings, third-party funding, marketing and
distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or a combination of these approaches. In any event, we will require additional capital to pursue preclinical and clinical activities, and
pursue regulatory approval for, and to commercialize, our pipeline product candidates. Even if we believe that we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or
if we have specific strategic considerations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any additional fundraising efforts may divert the attention of our management from <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient
amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may negatively impact the holdings or the rights of our shareholders, and the issuance of additional securities, whether equity or debt, by us or the possibility
of such issuance may cause the market price of our shares to decline. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our
ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek
funds through arrangements with collaborative partners or otherwise at an earlier stage than would be desirable and we may be required to relinquish rights to some of our technologies, intellectual property or product candidates or otherwise agree
to terms unfavorable to us, any of which may harm our business, financial condition, cash flows, operating results and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If adequate funds are not
available to us on a timely basis, we may be required or choose to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for our product candidates or any of our future product candidates; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay, limit, reduce or terminate our other research and development activities; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay, limit, reduce or terminate our establishment or expansion of manufacturing, sales and marketing or distribution capabilities or other activities that may be necessary to commercialize MitoGel, VesiGel or any of
our other product candidates. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which
could harm our business, financial condition, cash flows and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to our shareholders, including purchasers of ordinary shares in
this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Until such time, if ever, as we can
generate substantial product revenues, we expect to finance our cash needs through equity, convertible debt or debt financings, as well as selectively continuing to enter into collaborations, strategic alliances and licensing arrangements. We do not
currently have any committed external source of funds other than funding under the existing exclusive license agreement we entered into with Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, in
October 2016, or the Allergan Agreement. Under the Allergan Agreement, we may receive additional material milestone payments upon the successful completion of certain development, regulatory and commercial milestones and royalties with respect to
future sales of collaboration products by Allergan. Allergan may unilaterally terminate our existing collaboration for any reason upon advance notice. To the extent that we raise additional capital through the sale of equity or convertible debt
securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as an ordinary shareholder. Debt financing, if available, may involve agreements
that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring and distributing dividends, and may be secured by all or a portion of our assets. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we raise funds by selectively continuing to enter into additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to
relinquish additional valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity,
convertible debt or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise
prefer to develop and market ourselves. If we are unable to raise additional funds through other collaborations, strategic alliances or licensing arrangements, we may be required to terminate product development or future commercialization efforts
or to cease operations altogether. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Business and Strategy </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are dependent on the success of our lead product candidates, including obtaining regulatory approval to market our product candidates in the United States.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have invested almost all of our efforts and financial resources in the research and development of our lead product candidates, MitoGel and VesiGel. Our
future success depends on our ability to market and sell these product candidates. However, these drugs are in various stages of clinical development and each of these drugs has yet to receive marketing approval from the U.S. Food and Drug
Administration, or the FDA, or any other regulatory agency. Our product candidates&#146; marketability is subject to significant risks associated with successfully completing current and future clinical trials, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s timely acceptance of our IND filing for VesiGel, which we intend to submit in the first half of 2018, and our other product candidates for which we plan to file an IND. Without such IND acceptances, we
will be unable to commence clinical trials in the United States; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s acceptance of our parameters for regulatory approval relating to MitoGel, VesiGel and our other product candidates, including our proposed indications, primary and secondary endpoint assessments and
measurements, safety evaluations and regulatory pathways; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s acceptance of the number, design, size, conduct and implementation of our clinical trials, our trial protocols and the interpretation of data from preclinical studies or clinical trials;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully complete the clinical trials of our product candidates, including timely patient enrollment and acceptable safety and efficacy data and our ability to demonstrate the safety and efficacy of
the product candidates undergoing such clinical trials; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to complete in a timely fashion the single pivotal Phase 3 clinical trial for MitoGel for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC, and that the single pivotal Phase 3 clinical
trial, even if successfully completed, will be sufficient to support a New Drug Application, or NDA, submission and subsequently, FDA approval; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s acceptance of the sufficiency of the data we collected from our preclinical studies and our Phase 2a clinical trial with VesiGel in <FONT STYLE="white-space:nowrap">low-grade</FONT> <FONT
STYLE="white-space:nowrap">non-muscle</FONT> invasive bladder cancer, or NMIBC, and expect to collect from toxicological studies that we may conduct to support the submission of an IND without requiring additional preclinical studies or clinical
trials, and our ability to commence a Phase 2b clinical trial in the United States for VesiGel in <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC following an IND submission, if accepted; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s willingness to schedule an advisory committee meeting in a timely manner to evaluate and decide on the approval of our potential future NDAs for MitoGel and VesiGel; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the recommendation of the FDA&#146;s advisory committee to approve our applications to market MitoGel and VesiGel and our other product candidates in the United States, without limiting the approved labeling,
specifications, distribution or use of the products, or imposing other restrictions; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s satisfaction with the safety and efficacy of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of adverse events associated with our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timely and satisfactory performance by third-party contractors of their obligations in relation to our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our success in educating physicians and patients about the benefits, administration and use of our product candidates, if approved, particularly in light of the fact that there are currently no drugs approved by the FDA
for the treatment of UTUC and the FDA has not approved a drug for the treatment of NMIBC in more than 15 years; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability, perceived advantages, relative cost, safety and efficacy of alternative and competing treatments for the indications addressed by our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our marketing, sales and distribution strategy, and operations, as well as that of any current and future licensees; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to develop, validate and maintain a commercially viable manufacturing process that is compliant with current good manufacturing practices, or cGMP; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain, protect and enforce our intellectual property rights with respect to our product candidates; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully train users with respect to the safe instillation of MitoGel and VesiGel. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of these
clinical, regulatory and commercial risks are beyond our control. Accordingly, we cannot assure you that we will be able to advance any of our product candidates through clinical development, or to obtain regulatory approval of or commercialize any
of our product candidates. If we fail to achieve these objectives or overcome the challenges presented above, we could experience significant delays or an inability to successfully commercialize our product candidates. Accordingly, we may not be
able to generate sufficient revenues through the sale of our product candidates to enable us to continue our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be unable to obtain regulatory
approval for our product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The research, development, testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage,
recordkeeping, marketing, distribution, post-approval monitoring and reporting, and export and import of drug products are subject to extensive regulation by the FDA, and by foreign regulatory authorities in other countries. These regulations differ
from country to country. To gain approval to market our product candidates, we must provide clinical data that adequately demonstrate the safety and efficacy of the product for the intended indication. We have not yet obtained regulatory approval to
market any of our product candidates in the United States or any other country. Our business depends upon obtaining these regulatory approvals. There are currently no drugs approved by the FDA for the treatment of UTUC and only three drugs have been
approved by the FDA for NMIBC, with the last approval having occurred over 15 years ago. The FDA can delay, limit or deny approval of our product candidates for many reasons, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to satisfactorily demonstrate that the product candidates are safe and effective for the target indication; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s disagreement with our trial protocol, the interpretation of data from preclinical studies or clinical trials or conduct and control of clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the population studied in the clinical trial may not be sufficiently broad or representative to assess efficacy and safety in the patient population for which we seek approval; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to demonstrate that clinical or other benefits of our product candidates outweigh any safety or other perceived risks; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s determination that the 505(b)(2) regulatory pathway is not available for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s determination that additional preclinical studies or clinical trials are required; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s <FONT STYLE="white-space:nowrap">non-approval</FONT> of the quality of our drug substance or drug product, formulation, labeling or the specifications of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s failure to accept the manufacturing processes or facilities of third-party manufacturers with which we contract; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential for approval policies or regulations of the FDA to significantly change in a manner rendering our clinical data insufficient for approval; or </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">resistance to approval from the FDA&#146;s advisory committee for any reason including safety or efficacy concerns. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we eventually complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA may grant approval contingent on the
performance of costly and potentially time-consuming additional post-approval clinical trials or subject to restrictive Risk Evaluation and Mitigation Strategies. The FDA may also approve our product candidates for a more limited indication or a
narrower patient population than we originally requested, and the FDA may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. To the extent we seek regulatory approval in
foreign countries, we may face challenges similar to those described above with regulatory authorities in applicable jurisdictions. Any delay in obtaining, or inability to obtain, applicable regulatory approval for any of our product candidates
would delay or prevent commercialization of our product candidates and would thus negatively impact our business, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>To
date, we have only generated limited clinical data for our product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Positive results in preclinical testing and early clinical trials do not
ensure that later clinical trials will be successful. A number of pharmaceutical companies have suffered significant setbacks in clinical trials, including in Phase 3 clinical trials, after promising results in preclinical testing and early clinical
trials. These setbacks have included negative safety and efficacy observations in later clinical trials, including previously unreported adverse effects. For example, we have enrolled only 22 patients into the recently completed UTUC Compassionate
Use program of MitoGel. In the Compassionate Use Program, only 13 patients who were confirmed with <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC disease and had completed the <FONT STYLE="white-space:nowrap">six-weekly</FONT> administration
treatment regimen were evaluated for response, and eight of the 13 patients achieved a complete response and the remaining five achieved a partial response at the primary evaluation time. Of the eight patients who achieved a complete response at the
primary evaluation time, three have subsequently experienced recurrences to date. The data generated by our Compassionate Use program may not be as reliable as data generated from a clinical trial. For instance, consistent with the nature of
Compassionate Use programs, our Compassionate Use program is investigator-initiated and driven, with no uniform protocol with respect to dosing, primary endpoint or frequency or timing of follow-up evaluations. The data collected in our
Compassionate Use program is based on individual physician reports and has not undergone independent monitoring or quality assurance. The follow-up evaluation plan for patients is determined by each individual investigator and varies from patient to
patient, and some patients have not undergone follow-up evaluation or have been lost to follow-up. Due to the intricate anatomy of the renal pelvis and the calyceal system, we also face the risk that MitoGel may not reach all tumors. To date in our
preclinical testing, Compassionate Use program and clinical trials, we have observed several adverse events and serious adverse events, consisting primarily of burning sensation, rash, kidney swelling, kidney infection, urgency in urination and pain
during urination. In addition we have observed transient perturbation of laboratory measures of renal and hematopoietic function. No study participants have required medical intervention to address these changes. These adverse events are known <FONT
STYLE="white-space:nowrap">MMC-related</FONT> adverse events and are indicated as potential side effects of MMC usage on the MMC label. However, we cannot assure you that adverse events related to MitoGel and VesiGel that are not directly
attributable to MMC specifically will not occur. In addition, this trial may not be successful. If our clinical trials do not ultimately indicate that our product candidates are safe and efficacious for their intended application, the FDA may not
approve any NDA that we may file to market such product candidates, and our business would not be able to generate revenue from the sale of any such product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have limited experience in conducting clinical trials and have never obtained approval for any product
candidates, and may be unable to do so successfully. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a company, we have limited experience in conducting clinical trials and have never progressed a
product candidate through to regulatory approval. In part because of this lack of experience, our clinical trials may require more time and incur greater costs than we anticipate. We cannot be certain that the planned clinical trials will begin or
conclude on time, if at all. Large-scale trials will require significant additional financial and management resources. In addition, due to the significant lack of drug development for <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive
urothelial cancers over the past 15 years, neither we nor any third-party clinical investigators, clinical research organizations, or CROs, and/or consultants are likely to have extensive experience conducting clinical trials for the indications we
are targeting. Third-party clinical investigators do not operate under our control. Any performance failure on the part of such third parties could delay the clinical development of our product candidates or delay or prevent us from obtaining
regulatory approval or commercializing our current or future product candidates, depriving us of potential product revenue and resulting in additional losses. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have not applied for regulatory approvals to market any of our product candidates, and we may be delayed in obtaining or failing to obtain such regulatory
approvals and to commercialize our product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The process of developing, obtaining regulatory approval for and commercializing our product
candidates is long, complex, costly and uncertain, and delays or failure can occur at any stage. The research, testing, manufacturing, labeling, marketing, sale and distribution of drugs are subject to extensive and rigorous regulation by the FDA
and foreign regulatory agencies, as applicable. These regulations are agency-specific and differ by jurisdiction. We are not permitted to market any product candidate in the United States until we receive approval of an NDA from the FDA, or in any
foreign countries until we receive the requisite approval from the respective regulatory agencies in such countries. To gain approval of an NDA or other equivalent regulatory approval, we must provide the FDA or relevant foreign regulatory authority
with preclinical and clinical data that demonstrates the safety and efficacy of the product for the intended indication. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before we can submit an NDA to the FDA or
comparable similar applications to foreign regulatory authorities, we must conduct Phase 3 clinical trials, or a pivotal/registration trial equivalent, for each product candidate. We commenced a single pivotal, open-label, <FONT
STYLE="white-space:nowrap">single-arm</FONT> Phase 3 clinical trial of MitoGel for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC in the first quarter of 2017. This clinical trial is substantially broader than the previous
Compassionate Use program for MitoGel for the treatment of patients with UTUC and requires us to enroll a considerably larger number of patients in multiple clinics and medical centers across multiple countries. Based on our discussions with the
FDA, our current expectation is that our pivotal clinical trial for MitoGel will evaluate approximately 74 patients. We are also planning to commence a Phase 2b clinical trial of VesiGel in 2018. Before commencing a clinical trial for VesiGel in the
United States, we must first file an IND, which must be accepted by the FDA. We cannot assure you that the FDA will not decide to materially alter these parameters, including potentially requiring a pivotal study with a control arm, during the trial
or require us to conduct more than one pivotal trial before submitting an NDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Phase 3 clinical trials often produce unsatisfactory results even though prior
clinical trials were successful. Moreover, the results of clinical trials may be unsatisfactory to the FDA or foreign regulatory authorities even if we believe those clinical trials to be successful. The FDA or applicable foreign regulatory agencies
may suspend one or all of our clinical trials or require that we conduct additional clinical, preclinical, manufacturing, validation or drug product quality studies and submit that data before considering or reconsidering any NDA or comparable
foreign regulatory application that we may submit. Depending on the extent of these additional studies, approval of any applications that we submit may be significantly delayed or may cause the termination of such programs, or may require us to
expend more resources than we have available. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of these outcomes occur, we may not receive regulatory approval for the corresponding product candidates, and
our business would not be able to generate revenue from the sale of any such product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be able to advance our preclinical product candidates into clinical development and through
regulatory approval and commercialization. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain of our product candidates are currently in preclinical development and are therefore currently subject
to the risks associated with preclinical development, including the risks associated with: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">generating adequate and sufficient preclinical safety and efficacy data in a timely fashion to support the initiation of clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining regulatory approval to commence clinical trials in any jurisdiction, including the filing and acceptance of INDs; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">contracting with the necessary parties to conduct a clinical trial; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enrolling sufficient numbers of patients in clinical trials in timely fashion, if at all; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">timely manufacture of sufficient quantities of the product candidate for use in clinical trials. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are unsuccessful
in advancing our preclinical product candidates into clinical trials in a timely fashion, our business may be harmed. Even if we are successful in advancing our preclinical product candidates into clinical development, their success will be subject
to all of the clinical, regulatory and commercial risks described elsewhere in &#147;Risk Factors.&#148; Accordingly, we cannot assure you that we will be able to develop, obtain regulatory approval for, commercialize or generate significant revenue
from our product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical drug development involves a lengthy and expensive process with an uncertain outcome, results of earlier studies and
trials may not be predictive of future trial results, and our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. A failure of one or more of our clinical trials can occur at
any time during the clinical trial process. We do not know whether future clinical trials, if any, will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. Clinical trials can
be delayed, suspended or terminated for a variety of reasons, including failure to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">generate sufficient preclinical, toxicology, or other <I>in vivo</I> or <I>in vitro </I>data to support the initiation or continuation of clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain regulatory approval, or feedback on trial design, in order to commence a trial; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identify, recruit and train suitable clinical investigators; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reach agreement on acceptable terms with prospective CROs and clinical trial sites, and have such CROs and sites effect the proper and timely conduct of our clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain and maintain institutional review board, or IRB, approval at each clinical trial site; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identify, recruit and enroll suitable patients to participate in a trial; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">have a sufficient number of patients complete a trial or return for post-treatment <FONT STYLE="white-space:nowrap">follow-up;</FONT> </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ensure clinical investigators and clinical trial sites observe trial protocol or continue to participate in a trial; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">address any patient safety concerns that arise during the course of a trial; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">address any conflicts with new or existing laws or regulations; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add a sufficient number of clinical trial sites; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacture sufficient quantities at the required quality of product candidate for use in clinical trials; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">raise sufficient capital to fund a trial. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patient enrollment is a significant factor in the timing and success of
clinical trials and is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical
trials and clinicians&#146; and patients&#146; or caregivers&#146; perceptions as to the potential advantages of the drug candidate being studied in relation to other available therapies, including any new drugs or treatments that may be developed
or approved for the indications we are investigating. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the
institutions in which such trials are being conducted, by the trial&#146;s data safety monitoring board, by the FDA or by the applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
foreign regulatory authorities. Such authorities may suspend or terminate one or more of our clinical trials due to a number of factors, including our failure to conduct the clinical trial in
accordance with relevant regulatory requirements or clinical protocols, inspection of the clinical trial operations or trial site by the FDA or foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues
or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we experience delays in carrying out or completing any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed,
and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process
and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business and financial condition. In addition, many of the factors that cause, or lead to, a delay in the commencement or
completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The market opportunities for our
product candidates may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Cancer therapies are sometimes characterized as first-line, second-line or third-line. When cancer is detected early enough, first-line therapy, often chemotherapy,
hormone therapy, surgery, radiotherapy or a combination of these, is sometimes adequate to cure the cancer or prolong life. Second- and third-line therapies are administered to patients when prior therapy is not or is no longer effective. For
urothelial cancers, the current first-line standard of care is surgery designed to remove one or more tumors. Chemotherapy is currently used in treating urothelial cancer only as an adjuvant, or supplemental therapy, after tumor resection. We are
designing our lead product candidates with the goal of replacing surgery as the first-line standard of care for certain urothelial cancers. We intend to seek approval of MitoGel for the first-line treatment of
<FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC and of VesiGel for the first-line treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC in both cases as a chemoablation agent to replace tumor resection surgeries. However, there
is no guarantee that our product candidates, if approved, would be approved for first-line or even later lines of therapy, and, that prior to any such approvals, we will not have to conduct additional clinical trials. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers who have previously failed prior
treatments, and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics,
patient foundations or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers and the number of patients may turn out to be lower than expected. Additionally, the
potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if we receive regulatory approval for our product candidates and obtain significant market
share, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications, including the use of the products as first- or second-line therapy. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>MitoGel or VesiGel or any of our other product candidates may produce undesirable side effects that we may not have detected in our previous preclinical studies
and clinical trials. This could prevent us from gaining marketing approval or market acceptance for these product candidates, or from maintaining such approval and acceptance, and could substantially increase commercialization costs and even force
us to cease operations. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As with most pharmaceutical products, use of MitoGel or VesiGel or our other product candidates may be associated with side effects
or adverse events that can vary in severity and frequency. Our proprietary reverse thermal gelation hydrogel, or RTGel, which is used in the formulation of MitoGel and VesiGel, has not undergone extensive testing in humans. Side effects or adverse
events associated with the use of MitoGel and VesiGel may be observed at any time, including in clinical trials or once a product is commercialized, and any such side effects or adverse events may negatively affect our ability to obtain regulatory
approval or market our product candidates. To date in our clinical trials, we have observed several adverse events and serious adverse events, consisting primarily of burning sensation, rash, kidney swelling, kidney infection, urgency in urination
and pain during urination. In addition, we have observed transient perturbation of laboratory measures of renal and hematopoietic function. These adverse events are known <FONT STYLE="white-space:nowrap">MMC-related</FONT> adverse events and are
indicated as potential side effects of MMC usage on the MMC label. However, we cannot assure you that we will not observe additional drug-related serious adverse events in the future or that the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
FDA will not determine them as such. Side effects such as toxicity or other safety issues associated with the use of our product candidates could require us to perform additional studies or halt
development or sale of these product candidates or expose us to product liability lawsuits, which will harm our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, the commenced single pivotal
Phase 3 clinical trial for MitoGel and the planned Phase 2b clinical trial for VesiGel will involve a larger patient base than that previously studied, and the commercial marketing of MitoGel and VesiGel, if approved, will further expand the
clinical exposure of the drugs to a wider and more diverse group of patients than those participating in the clinical trials, which may identify undesirable side effects caused by these products that were not previously observed or reported. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA and foreign regulatory agency regulations require that we report certain information about adverse medical events if our products may have caused or contributed
to those adverse events. The timing of our obligation to report would be triggered by the date upon which we become aware of the adverse event as well as the nature and severity of the event. We may fail to report adverse events of which we become
aware within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in
time from the use of our products. If we fail to comply with our reporting obligations, the FDA or a foreign regulatory agency could take action including enforcing a hold on or cessation of clinical trials, withdrawal of approved drugs from the
market, criminal prosecution, the imposition of civil monetary penalties or seizure of our products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, in the event we discover the existence of
adverse medical events or side effects caused by one of our product candidates, a number of other potentially significant negative consequences could result, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to file an NDA or similar application for our product candidates because of insufficient risk-reward, or the denial of such application by the FDA or foreign regulatory authorities; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authorities suspending or withdrawing their approval of the product; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authorities requiring the addition of labeling statements, such as Box or other warnings or contraindications or distribution and use restrictions; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authorities requiring us to issue specific communications to healthcare professionals, such as letters alerting them to new safety information about our product, changes in dosage or other
important information; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authorities issuing negative publicity regarding the affected product, including safety communications; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our being limited with respect to the safety-related claims that we can make in our marketing or promotional materials; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our being required to change the way the product is administered, conduct additional preclinical studies or clinical trials or restrict or cease the distribution or use of the product; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our being sued and held liable for harm caused to patients. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any of these events could prevent us from achieving
approval or market acceptance of the affected product candidate and could substantially increase commercialization costs or even force us to cease operations. We cannot assure you that we will resolve any issues related to any product-related
adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if our product candidates receive marketing approval, we may continue to face future developmental and regulatory difficulties. In addition, we are subject
to government regulations and we may experience delays in obtaining required regulatory approvals to market our proposed product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we
complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA or applicable foreign regulatory agency may grant approval contingent on the performance of additional costly post-approval clinical trials,
risk mitigation requirements and surveillance requirements to monitor the safety or efficacy of the product, which could negatively impact us by reducing revenues or increasing expenses, and cause the approved product candidate not to be
commercially viable. Absence of long-term safety data may further limit the approved uses of our products, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA or applicable foreign regulatory agency also may approve our product candidates for a more limited indication
or a narrower patient population than we originally requested, or may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. Furthermore, any such approved product will
remain subject to extensive regulatory requirements, including requirements relating to manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, distribution and recordkeeping. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we fail to comply with the regulatory requirements of the FDA or other applicable foreign regulatory authorities, or previously unknown problems with any approved
commercial products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed sanctions or other setbacks, including the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or imposition of restrictions on operations, including costly new manufacturing requirements; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory agency refusal to approve pending applications or supplements to applications; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension of any ongoing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or withdrawal of marketing approval; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an injunction or imposition of civil or criminal penalties or monetary fines; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seizure or detention of products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">bans or restrictions on imports and exports; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issuance of warning letters or untitled letters; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or imposition of restrictions on operations, including costly new manufacturing requirements; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal of regulatory authorities to approve pending applications or supplements to applications. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, various
aspects of our operations are subject to federal, state or local laws, rules and regulations, any of which may change from time to time. Costs arising out of any regulatory developments could be time-consuming and expensive and could divert
management resources and attention and, consequently, could adversely affect our business, financial condition, cash flows and results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if
our product candidates receive regulatory approval, they may fail to achieve the broad degree of physician adoption and use and market acceptance necessary for commercial success. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we obtain FDA or foreign regulatory approvals for our product candidates, the commercial success of such products will depend significantly on their broad
adoption and use by physicians, for approved indications, including, in the case of MitoGel, for the first-line treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC, and in the case of VesiGel, for the first-line treatment of <FONT
STYLE="white-space:nowrap">low-grade</FONT> NMIBC, and for other therapeutic indications that we may seek to pursue with any of our product candidates. Physicians treating <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC and <FONT
STYLE="white-space:nowrap">low-grade</FONT> NMIBC have never had to consider first-line treatments other than surgery. The degree and rate of physician and patient adoption of our product candidates, if approved, will depend on a number of factors,
including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical indications for which the product is approved; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of adverse side effects and the level of risk/reward observed in our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patient satisfaction with the results and administration of our product and overall treatment experience, including relative convenience, ease of use and avoidance of, or reduction in, adverse side effects;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which physicians recommend our products to patients; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">physicians&#146; and patients&#146; willingness to adopt new therapies in lieu of other products or treatments, including willingness to adopt our lead product candidates as locally-administered drug replacements to
current surgical standards of care; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of treatment, safety and efficacy in relation to alternative treatments, including the recurrence rate of our treatments; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which the costs of our product candidates are reimbursed by third-party payors, and patients&#146; willingness to pay for our products; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether treatment with our product candidates, including the treatment of
<FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC with MitoGel and the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC with VesiGel, will be deemed to be an elective procedure by
third-</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
party payors; if so, the cost of treatment would be borne by the patient and would be less likely to be broadly adopted; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">proper training and administration of our products by physicians or nurses; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the revenues and profitability that our products will offer physicians as compared to alternative therapies; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our sales and marketing efforts, especially the success of any targeted marketing efforts directed toward physicians and clinics and any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> marketing efforts we may initiate. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If MitoGel, VesiGel or any of our other product
candidates is approved for use, but fails to achieve the broad degree of physician adoption and market acceptance necessary for commercial success, our operating results and financial condition would be adversely affected. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are not successful in developing, receiving regulatory approval for and commercializing our preclinical and clinical product candidates other than MitoGel
or VesiGel, our ability to expand our business and achieve our strategic objectives could be impaired. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we will devote a substantial portion of our
resources on the continued clinical testing and potential approval of MitoGel for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC and VesiGel for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC,
another key element of our strategy is to discover, develop and commercialize a portfolio of products based on our proprietary RTGel platforms to serve additional therapeutic markets. We are seeking to do so through our internal research programs,
but our resources are limited, and those that we have are geared towards clinical testing and seeking regulatory approval of MitoGel, VesiGel and our other existing product candidates. We may also explore strategic collaborations for the development
or acquisition of new products, but we may not be successful in entering into such relationships. While we have commenced a single pivotal Phase 3 clinical trial for MitoGel and plan to commence a Phase 2b clinical trial for VesiGel, all of our
other potential product candidates remain in the preclinical and/or early clinical stages of development. Research programs to identify product candidates require substantial technical, financial and human resources, regardless of whether any
product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the research methodology used may not be successful in identifying potential product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competitors may develop alternatives that render our product candidates obsolete or less attractive; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may in a subsequent trial be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">intellectual property or other proprietary rights of third parties for product candidates we develop may potentially block our entry into certain markets, or make such entry economically impracticable.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we fail to develop and successfully commercialize other product candidates, our business and future prospects may be harmed and our business will
be more vulnerable to any problems that we encounter in developing and commercializing our product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our product candidates, if approved, will face
significant competition with competing technologies and our failure to compete effectively may prevent us from achieving significant market penetration. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biopharmaceutical industry is intensely competitive and subject to rapid and significant technological change. Our potential competitors include large and
experienced companies that enjoy significant competitive advantages over us, such as greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition and more experience and expertise in
obtaining marketing approvals from the FDA and foreign regulatory authorities. These companies may develop new drugs to treat the indications that we target, or seek to have existing drugs approved for use for the treatment of the indications that
we target. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are aware that other companies, such as Merck Sharp&nbsp;&amp; Dohme Corp., Viventia Bio Inc., Telesta Therapeutics Inc., Heat Biologics, Inc.,
Viralytics Limited, AADi, LLC, Biocancell Ltd., Halozyme Therapeutics, Inc., Astellas </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Pharma Inc., Cold Genesys, Inc., Altor BioScience Corporation, FKD Therapies Oy, Nippon Kayaku Co., Ltd, Spectrum Pharmaceuticals, Inc., Taris Biomedical LLC and Handok Inc., are conducting or
have recently conducted clinical trials for product candidates for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> and high-grade NMIBC, including CIS. In addition, we are aware of several pharmaceutical companies that are
developing drug candidates for muscle-invasive bladder cancer. On May&nbsp;18, 2016, the FDA approved Tecentriq (Atezolizumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma, a form of muscle invasive bladder
cancer. We do not know whether these potential competitors are already developing, or plan to develop, <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC or high-grade UTUC treatments or treatments for other indications that we are pursuing, and
we may be unable to ascertain whether such activities are underway in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competition may increase further as a result of advances in the commercial
applicability of technologies and greater availability of capital for investment in this industry. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis products that are more effective, easier to administer or less
costly than our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we face competition from existing standards of treatment, including transurethral resection of bladder tumor, or
TURBT, surgery for bladder cancer. If we are not able to demonstrate that our product candidates are at least as safe and effective as such courses of treatment, medical professionals may not adopt our product candidates in replacement of the
existing standard of care, which is first-line tumor surgical procedures. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have no experience in marketing or distributing products and no internal
capability to do so, and are therefore subject to certain risks in relation to the commercialization of our product candidates once approved. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not
yet established a commercial organization for the marketing, sale and distribution of our product candidates. Therefore, even if we receive approval to market our product candidates in the United States or other markets, in order to successfully
commercialize our product candidates, we will need to either build marketing, sales, distribution, managerial and other <FONT STYLE="white-space:nowrap">non-technical</FONT> capabilities or contract with third parties to obtain these capabilities.
This involves many challenges, such as recruiting and retaining talented personnel, training employees, setting the appropriate system of incentives, managing additional headcount and integrating new business units into an existing corporate
infrastructure. The development of our own sales infrastructure or contracting with third parties will involve substantial expense, much of which we will incur well in advance of any marketing or sales. Moreover, we do not have experience as a
company in establishing a significant sales infrastructure, and we cannot be certain that we will successfully develop this capability or contract successfully with third parties for the necessary services. We will have to compete with other
pharmaceutical and biotechnology companies to recruit, hire, train and retain personnel for medical affairs, marketing and sales. If we fail to establish an effective sales and marketing infrastructure or contract with third parties to do so, we
will be unable to successfully commercialize our product candidates, which in turn would have an adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have entered into a licensing agreement and in the future may enter into collaborations with other third parties for the development or commercialization of
our product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
October 2016, we entered into the Allergan Agreement. Under the Allergan Agreement, we granted Allergan an exclusive worldwide license to research, develop, manufacture and commercialize pharmaceutical products that contain RTGel and clostridial
toxins (including BOTOX), alone or in combination with certain other active ingredients, which we refer to collectively as the Licensed Products. Either party may terminate the Allergan Agreement for uncured material breach by the other party and
for the insolvency of the other party. We may terminate the Allergan Agreement if Allergan or its affiliates challenges any of our patents licensed to Allergan and such patent challenge is not required under a court order or subpoena and is not a
defense against a claim, action or proceeding asserted by us, our affiliates or licensees against Allergan, its affiliates or sublicensees. In addition, Allergan may unilaterally terminate the Allergan Agreement for any reason upon advance notice.
If Allergan has the right to terminate the Allergan Agreement due to our uncured material breach, Allergan may elect to continue the agreement and reduce all future milestone and royalty payment obligations to us by a specified percentage. In the
event of any termination of the Allergan Agreement, Allergan will assign or grant a right of reference to any regulatory documentation related to RTGel to us, all rights and licenses to Allergan will terminate, and the license Allergan granted to us
under their improvements to RTGel will continue. If any of these events occurs, we will not be able to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
obtain, or may be delayed in obtaining, marketing approvals for the Licensed Products and will not be able to, or may be delayed in our efforts to, successfully commercialize the Licensed
Products, and our business will be harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may utilize a variety of types of collaboration, distribution and other marketing arrangements with third parties to
develop our product candidates and commercialize our approved product candidates, if any. We are not currently party to any such arrangement. Our ability to generate revenues from these arrangements will depend on our collaborators&#146; abilities
and efforts to successfully perform the functions assigned to them in these arrangements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our existing collaboration with Allergan and any future collaborations
that we enter into, may pose a number of risks, including the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not perform their obligations as expected; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product candidates developed by collaborators may not perform sufficiently in clinical trials to be determined to be safe and effective, thereby delaying or terminating the drug approval process and reducing or
eliminating milestone payments to which we would otherwise be entitled if the product candidates had successfully met their endpoints and/or received FDA approval; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trials conducted by collaborators could give rise to new safety concerns; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not pursue development and commercialization of our product candidates that receive marketing approval or may elect not to continue or renew development or commercialization programs based on clinical
trial results, changes in the collaborators&#146; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new
formulation of a product candidate for clinical testing; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are
more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the
commercialization of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or
products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or
commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would divert management attention and resources, be
time-consuming and expensive; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual
property or proprietary information or expose us to potential litigation; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product
candidates. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all.
If the Allergan Agreement, and any future collaborations that we enter into, do not result </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or
royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our product candidates could be delayed and we may need additional resources to develop our product candidates. All of
the risks relating to product development, regulatory approval and commercialization described in this prospectus also apply to the activities of our collaborators. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, subject to its contractual obligations to us, if a collaborator of ours were to be involved in a business combination, it might deemphasize or terminate
the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and
financial communities could be harmed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If in the future we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> technologies or product candidates,
we may incur various costs, may have integration difficulties and may experience other risks that could harm our business and results of operations. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the
future, we may acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional product candidates and technologies. Any product candidate or technologies we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire will likely require
additional development efforts prior to commercial sale, including extensive preclinical or clinical testing, or both, and approval by the FDA and applicable foreign regulatory authorities, if any. All product candidates are prone to risks of
failure inherent in pharmaceutical product development, including the possibility that the product candidate, or product developed based on <FONT STYLE="white-space:nowrap">in-licensed</FONT> technology, will not be shown to be sufficiently safe and
effective for approval by regulatory authorities. If intellectual property related to product candidates or technologies we <FONT STYLE="white-space:nowrap">in-license</FONT> is not adequate, we may not be able to commercialize the affected products
even after expending resources on their development. In addition, we may not be able to manufacture economically or successfully commercialize any product candidate that we develop based on acquired or
<FONT STYLE="white-space:nowrap">in-licensed</FONT> technology that is granted regulatory approval, and such products may not gain wide acceptance or be competitive in the marketplace. Moreover, integrating any newly acquired or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> product candidates could be expensive and time-consuming. If we cannot effectively manage these aspects of our business strategy, our business may be materially harmed. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We currently contract with third-party subcontractors and single-source suppliers for certain raw materials, compounds and components necessary to produce
MitoGel, VesiGel and Vesimune for preclinical studies and clinical trials, and expect to continue to do so to support commercial scale production of MitoGel, VesiGel and Vesimune, if approved. There are significant risks associated with the
manufacture of pharmaceutical products and contracting with contract manufacturers and with single-source suppliers. Furthermore, our existing third-party subcontractors and single-source suppliers may not be able to meet the increased need for
certain raw materials, compounds and components that may result from our potential commercialization efforts. This increases the risk that we will not have sufficient quantities of MitoGel, VesiGel or Vesimune or be able to obtain such quantities at
an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently rely on third party subcontractors and
suppliers for certain compounds and components necessary to produce MitoGel, VesiGel and Vesimune for our preclinical studies and clinical trials. We currently depend on Teva Pharmaceuticals Industries Ltd., or Teva, as our single-source supplier of
MMC for MitoGel and VesiGel. Teva is in the midst of a corporate restructuring. Although we are not aware of any impact of the restructuring as currently in effect on Teva&#146;s ability or willingness to supply us with MMC in the quantities and on
the timeline required, it is possible that the restructuring could adversely affect our ability to obtain MMC in any given period and could require us to expend funds and effort to identify and engage one or more alternate suppliers of MMC. We also
currently depend on single sources for the gel contained in MitoGel and VesiGel, and Imiquimod for Vesimune. Because there are a limited number of suppliers for the raw materials that we use to manufacture our product candidates, we may need to
engage alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical trials, and if approved, ultimately for commercial sale. We do not have any control over the
availability of raw materials. If we or our manufacturers are unable to purchase these raw materials on acceptable terms, at sufficient quality levels, or in adequate quantities, if at all, the development and commercialization of our product
candidates or any future product candidates, would be delayed or there would be a shortage in supply, which would impair our ability to meet our development objectives for our product candidates or generate revenues from the sale of any approved
products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to continue to rely on these or other subcontractors and suppliers to support our commercial requirements
if MitoGel, VesiGel or any of our other product candidates is approved for marketing by the FDA or foreign regulatory authorities. Even if we establish ourselves as an approved commercial supplier of MMC, we plan to continue to rely on third parties
for such production of MMC, as well as for the raw materials, compounds and components necessary to produce our product candidates and for preclinical studies and clinical trials. We would expect that if we become a commercial supplier of MMC,
through a third party manufacturer of MMC, it would provide us with enhanced control of material supply for both clinical trials and the commercial market, enable the more rapid implementation of process changes, and allow for better long-term
margins. However, we have no experience as a company in the commercial supply of drugs and may never be successful as a commercial supplier of MMC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we are
successful in being approved as a commercial supplier of MMC, cost-overruns, unexpected delays, equipment failures, labor shortages, natural disasters, power failures, production failures or product recalls, and numerous other factors could prevent
us from realizing the intended benefits of our sales strategy and have a material adverse effect on our business. Further, establishing ourselves as a commercial supplier of MMC, if we choose to pursue this, will require additional investment, will
be time-consuming and may be subject to delays, including because of shortage of labor, compliance with regulatory requirements or receipt of necessary regulatory approvals. In addition, building out our MMC commercial supply capabilities may cost
more than we currently anticipate, and delays or problems may adversely impact our ability to provide supply for the development and commercialization of our product candidates as well as our financial condition. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, before we can begin to commercially manufacture our product candidates, whether in a third-party facility or in our own facility, once established, we must
obtain regulatory approval from FDA for our manufacturing process and facility in order to sell such products in the United States. A manufacturing authorization would also have to be obtained from the appropriate European Union regulatory
authorities in order sell such products in the European Union. In order to obtain approval, we will need to ensure that all of the processes, methods and equipment of such manufacturing facilities are compliant with cGMP, and perform extensive
audits of vendors, contract laboratories and suppliers. If any vendors, contract laboratories or suppliers is found to be out of compliance with cGMP, we may experience delays or disruptions in manufacturing while we work with these third parties to
remedy the violation or while we work to identify suitable replacement vendors. The cGMP requirements govern quality control of the manufacturing process and documentation policies and procedures. In complying with cGMP, we will be obligated to
expend time, money and effort in production, record keeping and quality control to assure that the product meets applicable specifications and other requirements. If we fail to comply with these requirements, we would be subject to possible
regulatory action and may not be permitted to sell any product candidate that we may develop. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our continuing reliance on third party subcontractors and suppliers
entails a number of risks, including reliance on the third party for regulatory compliance and quality assurance, the possible breach of the manufacturing or supply agreement by the third party, and the possible termination or nonrenewal of the
agreement by the third party at a time that is costly or inconvenient for us. In addition, third party subcontractors and suppliers may not be able to comply with cGMP or quality system regulation, also called QSR, or similar regulatory requirements
outside the United States. If any of these risks transpire, we may be unable to timely retain alternate subcontractors or suppliers on acceptable terms and with sufficient quality standards and production capacity, which may disrupt and delay our
clinical trials or the manufacture and commercial sale of our product candidates, if approved. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our failure or the failure of our third-party subcontractors and
suppliers to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products,
operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of MitoGel, VesiGel or any of our other product candidates that we may develop. Any failure or refusal to supply or any interruption in
supply of the components for MitoGel, VesiGel or any other product candidates or products that we may develop could delay, prevent or impair our clinical development or commercialization efforts. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to market and sell our products in the European Union and other jurisdictions, we or our third-party collaborators must obtain separate marketing approvals and
comply with numerous and varying regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA
approval. Regulatory approval processes outside the United States generally include all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for
reimbursement before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory
authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for
marketing approvals and may not receive the necessary approvals to commercialize our product candidates in any particular market. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We intend to rely on third
parties and consultants to assist us in conducting our single pivotal Phase 3 clinical trial for MitoGel, our Phase 2b clinical trial for VesiGel and certain clinical trials for our other product candidates. If these third parties or consultants do
not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize MitoGel, VesiGel or any of our other product candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not have the ability to independently conduct many of our preclinical studies or our clinical trials. We rely on medical institutions, clinical investigators,
contract laboratories, and other third parties, such as CROs to conduct clinical trials on our product candidates. Third parties play a significant role in the conduct of our clinical trials and the subsequent collection and analysis of data. These
third parties are not our employees, and except for remedies available to us under our agreements, we have limited ability to control the amount or timing of resources that any such third party will devote to our clinical trials. Due to the limited
drug development for <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive urothelial cancers over the past 15 years, neither we nor any third-party clinical investigators, CROs and/or consultants are likely to have extensive experience
conducting clinical trials for the indications we are targeting. If our CROs or any other third parties upon which we rely for administration and conduct of our clinical trials do not successfully carry out their contractual duties or obligations or
meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, or if they
otherwise perform in a substandard manner, our clinical trials may be extended, delayed, suspended or terminated, and we may not be able to complete development of, obtain regulatory approval for, or successfully commercialize our product
candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We and the third parties upon whom we rely are required to comply with Good Clinical Practice, or GCP, regulations, which are regulations and
guidelines enforced by regulatory authorities around the world for products in clinical development. Regulatory authorities enforce these GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and clinical
trial sites. If we or our third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and our submission of marketing applications may be delayed or the regulatory
authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, a regulatory authority will determine that any of our clinical trials comply or complied with
applicable GCP regulations. In addition, our clinical trials must be conducted with material produced under current cGMP regulations, which are enforced by regulatory authorities. Our failure to comply with these regulations may require us to repeat
clinical trials, which would delay the regulatory approval process. Moreover, our business may be impacted if our CROs, clinical investigators or other third parties violate federal or state fraud and abuse or false claims laws and regulations or
healthcare privacy and security laws. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order for our clinical trials to be carried out effectively and efficiently, it is imperative that our CROs and other
third parties communicate and coordinate with one another. Moreover, our CROs and other third parties may also have relationships with other commercial entities, some of which may compete with us. Our CROs and other third parties may terminate their
agreements with us upon as few as 30 days&#146; notice under certain circumstances. If our CROs or other third parties conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet
expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other
reason, we may need to conduct additional clinical trials or enter </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
into new arrangements with alternative CROs, clinical investigators or other third parties. We may be unable to enter into arrangements with alternative CROs on commercially reasonable terms, or
at all. Switching or adding CROs, clinical investigators or other third parties can involve substantial cost and require extensive management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a
result, delays may occur, which can impact our ability to meet our desired clinical development timelines. Although we carefully manage our relationship with our CROs, clinical investigators and other third parties, there can be no assurance that we
will not encounter such challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, prospects, financial condition or results of operations </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our ability to market our product candidates, if approved, will be limited to certain indications. If we want to expand the indications for which we may market
our products, we will need to obtain additional regulatory approvals, which may not be granted. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are currently developing MitoGel for the treatment of <FONT
STYLE="white-space:nowrap">low-grade</FONT> UTUC, and VesiGel and Vesimune for the treatment of bladder cancer. The FDA and other applicable regulatory agencies will restrict our ability to market or advertise our products to the scope of the
approved label for the applicable product and for no other indications, which could limit physician and patient adoption. We may attempt to develop and, if approved, promote and commercialize new treatment indications for our products in the future,
but we cannot predict when or if we will receive the regulatory approvals required to do so. Failure to receive such approvals will prevent us from promoting or commercializing new treatment indications. In addition, we would be required to conduct
additional clinical trials or studies to support approvals for additional indications, which would be time consuming and expensive, and may produce results that do not support regulatory approvals. If we do not obtain additional regulatory
approvals, our ability to expand our business will be limited. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If our product candidates are approved for marketing, and we are found to have improperly
promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses, or if physicians misuse our products, we may become subject to prohibitions on the sale or marketing of our products, significant sanctions, and product liability claims, and our image
and reputation within the industry and marketplace could be harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA and other regulatory agencies strictly regulate the marketing and promotional
claims that are made about drug products. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or such other regulatory agencies as reflected in the product&#146;s approved labeling. For example, if
we receive marketing approval for MitoGel for treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC, the first indication we are pursuing, we cannot promote the use of our product in a manner that is inconsistent with the approved
label. However, physicians are able, in their independent medical judgment, to use MitoGel on their patients in an <FONT STYLE="white-space:nowrap">off-label</FONT> manner, such as for the treatment of other urology indications. If we are found to
have promoted such <FONT STYLE="white-space:nowrap">off-label</FONT> uses, we may receive warning letters and become subject to significant liability, which would harm our business. The federal government has levied large administrative, civil and
criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. If we become the target of such an investigation or prosecution based on
our marketing and promotional practices, we could face similar sanctions, which would harm our business. In addition, management&#146;s attention could be diverted from our business operations, significant legal expenses could be incurred, and our
reputation could be damaged. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we are deemed by the FDA to have engaged in the
promotion of our products for <FONT STYLE="white-space:nowrap">off-label</FONT> use, we could be subject to prohibitions on the sale or marketing of our products or significant fines and penalties, and the imposition of these sanctions could also
affect our reputation with physicians, patients and caregivers, and our position within the industry. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Physicians may also misuse our products or use improper
techniques, potentially leading to adverse results, side effects or injury, which may lead to product liability claims. If our products are misused or used with improper technique, we may become subject to costly litigation. Product liability claims
could divert management&#146;s attention from our core business, be expensive to defend, and result in sizable damage awards against us that may not be covered by insurance. We currently carry product liability insurance covering our clinical trials
with policy limits that we believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain such insurance, any claim that may be brought against us could result in a court
judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Furthermore, the use of our products for conditions other than those approved
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
by the FDA may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to manage our growth effectively, our business could be disrupted. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2017, we had 43 full-time employees and four part-time employees, of whom all except 11 are based in Israel. We will need to continue to expand
our development, quality, sales, managerial, operational, finance, marketing and other resources to manage our operations and clinical trials, continue our development activities and commercialize our product candidates, if approved. Our management,
personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our expansion strategy requires that we: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manage our clinical trials effectively; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identify, recruit, retain, incentivize and integrate additional employees; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manage our internal development efforts effectively while carrying out our contractual obligations to third parties; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue to improve our operational, financial and management controls, reporting systems and procedures. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Due to our
limited financial resources and our limited experience in managing a larger company, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our
operations may lead to significant costs and may divert our management and business development resources. Any inability to manage expansion could delay the execution of our development and strategic objectives, or disrupt our operations; and if we
are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our revenues will suffer and we would incur significant additional losses. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any of our other
products we develop. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even
greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability
claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer
protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant
financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for our product candidates or products we develop; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injury to our reputation and significant negative media attention; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial participants or cancellation of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs to defend the related litigation, which may be only partially recoverable even in the event of successful defenses; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a diversion of management&#146;s time and our resources; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to trial participants or patients; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of revenues; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exhaustion of any available insurance and our capital resources; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize any product we develop. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our inability to obtain and maintain sufficient product
liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of products we may develop. We currently carry general clinical trial product
liability insurance in an amount that we believe is adequate to cover the scope of our ongoing clinical programs. Although we maintain such insurance, any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of
our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a
settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage
at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing MitoGel, VesiGel or any other product candidate, we intend to expand our insurance coverage to include the commercialization of
MitoGel, VesiGel or any other approved product that we may have; however, we may be unable to obtain this liability insurance on commercially reasonable terms. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop our product candidates, conduct our
clinical trials and commercialize any of the products we develop. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our success depends in part on our continued ability to attract, retain and motivate
highly qualified management, clinical and scientific personnel. We believe that our future success is highly dependent upon the contributions of members of our senior management, as well as our senior scientists and other members of our management
team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of our product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we have not historically experienced unique difficulties in attracting and retaining qualified employees, we could experience such problems in the future. For
example, competition for qualified personnel in the pharmaceutical field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our
clinical development and commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have
been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output. Moreover, although we have established a U.S. subsidiary, we are domiciled in Israel and
are predominantly based in Israel, which may make it difficult to hire necessary U.S.-based personnel. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our internal computer systems, or those of our CROs or
other contractors or consultants, may fail or suffer security breaches, which could result in a disruption of our drug development programs. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Despite the
implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from cyber-security threats, including computer viruses, harmful code and unauthorized access,
natural disasters, fire, terrorism, war and telecommunication and electrical failures. If a disruption event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For
example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any
disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be
delayed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Under applicable employment laws, we may not be able to enforce covenants not to compete. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We generally enter into <FONT STYLE="white-space:nowrap">non-competition</FONT> agreements as part of our employment agreements with our employees. These agreements
generally prohibit our employees, if they cease working for us, from competing directly with us or working for our competitors or clients for a limited period. We may be unable to enforce these agreements under the laws of the jurisdictions in which
our employees work and it may be difficult for us to restrict our competitors from benefitting from the expertise our former employees or consultants developed while working for us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, Israeli labor courts have required employers seeking to enforce <FONT STYLE="white-space:nowrap">non-compete</FONT> undertakings of a former employee to
demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts as justification for the enforcement of <FONT
STYLE="white-space:nowrap">non-compete</FONT> undertakings, such as the protection of a company&#146;s trade secrets or other intellectual property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our employees, independent contractors, clinical investigators, CROs, consultants and vendors may engage in
misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are exposed to the risk
that our employees, independent contractors, clinical investigators, CROs, consultants and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct,
breach of contract or other unauthorized activities that violate: FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA; manufacturing standards; federal, state and foreign healthcare
fraud and abuse laws; or laws that require the reporting of financial information or data accurately. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Specifically, research, sales, marketing, education and other
business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of pricing, discounting,
marketing and promotion, sales commission, customer incentive and other business arrangements. Activities subject to these laws also include the improper use of information obtained in the course of clinical trials, which could result in regulatory
sanctions and serious harm to our reputation. We have adopted a Corporate Code of Ethics and Conduct, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and
prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such
actions are instituted against us, even if we are successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business. Violations of such laws subject us to numerous penalties, including, but not
limited to, the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or
similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational
harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our business involves the use of hazardous materials and we and our third party manufacturers and suppliers must comply with environmental laws and regulations,
which can be expensive and restrict how we do business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our research and development activities and our third party subcontractors&#146; and
suppliers&#146; activities involve the controlled storage, use and disposal of hazardous materials owned by us, including Mitomycin C, or MMC, key components of our product candidates, and other hazardous compounds. We and our manufacturers and
suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. Despite our efforts, we cannot eliminate the risk of contamination. This could cause an interruption of our
commercialization efforts and business operations, environmental damage resulting in costly <FONT STYLE="white-space:nowrap">clean-up</FONT> and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of
these materials and specified waste products. Although we believe that the safety procedures utilized by us and our subcontractors and suppliers for handling and disposing of these materials generally comply with the standards prescribed by these
laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our
resources and state or federal or other applicable authorities may curtail our use of certain materials and interrupt our business operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore,
environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Exchange rate fluctuations between the U.S.&nbsp;Dollar and the New Israeli Shekel may negatively affect our earnings. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The U.S. dollar is our functional and reporting currency. However, a significant portion of our operating expenses are incurred in New Israeli Shekels, or NIS, which is
the lawful currency of the State of Israel. As a result, we are exposed to the risks that the NIS may appreciate relative to the dollar, or, if the NIS instead devalues relative to the dollar, that the inflation rate in Israel may exceed such rate
of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations in Israel would increase and our dollar-denominated results of operations would be adversely
affected. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation (if any) of the NIS against the dollar. For example, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
although the dollar appreciated against the NIS in 2015 by 0.3%, the level of devaluation of the dollar against the NIS in 2016 was 1.5%. If the dollar cost of our operations in Israel increases,
our dollar-measured results of operations will be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our product candidates and technologies are not
adequate, we may not be able to compete effectively and we otherwise may be harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial success depends in part upon our ability to obtain and
maintain patent protection and utilize trade secret protection for our intellectual property and proprietary technologies, our products and their uses, as well as our ability to operate without infringing upon the proprietary rights of others. We
rely upon a combination of patents, trade secret protection and confidentiality agreements, assignment of invention agreements and other contractual arrangements to protect the intellectual property related to hydrogel-based pharmaceutical
compositions for optimal delivery of a drug in internal cavities such as the bladder, the method for treating urothelial cancer using hydrogel-based compositions, the method for treating overactive bladder topically without the need for injections,
an <FONT STYLE="white-space:nowrap">in-dwelling</FONT> ureter catheter system for optimal delivery of a drug into the renal cavity, and pharmaceutical compositions comprising an imidazoquinolin (amine) and lactic acid for use in a method for the
treatment of bladder diseases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We seek patent protection for all of our product candidates, and we have established several patent families comprised of issued
patents and pending patent applications covering our proprietary RTGel formulation technology and the formulations, methods of use and manufacturing aspects of our product candidates. In the United States, we currently have&nbsp;13 granted patents
that are directed to protect our lead product candidates, MitoGel, VesiGel, BotuGel, Vesimune and RTGel as well as to our future product candidates that are under company research. These patents claim methods, systems, and novel compositions for
treating cancer in internal cavities, in particular urinary tract cancer. These issued patents are expected to expire between 2024 and 2035.&nbsp;Moreover, our IP portfolio includes&nbsp;more than 45&nbsp;patent applications filed worldwide that are
directed to various methods, systems and compositions for treating cancer locally, by intravesical means. We have four pending patent applications relating to the product candidate BotuGel in the European Union, China and Israel as well as one
granted patent in Russia. In addition, we have two granted patents related to Vesimune in the United States as well as two granted patents in the European Union, two granted patents in Japan and one granted patent in each of Australia, Mexico,
China, Russia, and Hong Kong, each of which is expected to remain in effect until 2030. In addition to the issued patents mentioned above, our portfolio includes pending patent applications relating to Vesimune in the European Union, Hong Kong,
Canada, Brazil and Israel. Moreover, we hold five granted patents in the United States as well as patent applications filed worldwide that relate to novel formulations of phospholipid drug analogs (saturated lipid conjugate compositions) for the
treatment of urinary tract cancer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Limitations on the scope of our intellectual property rights may limit our ability to prevent third parties from designing
around such rights and competing against us. For example, our patents do not claim a new compound. Rather, the active pharmaceutical ingredients of our products are existing compounds and our granted patents and pending patent applications are
directed to, among other things, novel formulations of these existing compounds with our RTGel. Accordingly, other parties may compete with us, for example, by independently developing or obtaining competing topical formulations that design around
our patent claims, but which may contain the same active ingredients, or by seeking to invalidate our patents. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly
duplicate or surpass our technological achievements, eroding our competitive position in the market. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">However, the patent applications that we own or license may
fail to result in granted patents in the United States or foreign jurisdictions, or if granted may fail to prevent a potential infringer from marketing its product or be deemed invalid and unenforceable by a court. Competitors in the field of
reverse thermal gel therapies have created a substantial amount of scientific publications, patents and patent applications and other materials relating to their technologies. Our ability to obtain and maintain valid and enforceable patents depends
on various factors, including interpretation of our technology and the prior art and whether the differences between them allow our technology to be patentable. Patent applications and patents granted from them are complex, lengthy and highly
technical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
documents that are often prepared under very limited time constraints and may not be free from errors that make their interpretation uncertain. The existence of errors in a patent may have an
adverse effect on the patent, its scope and its enforceability. Our pending patent applications may not issue, and the scope of the claims of patent applications that do issue may be too narrow to adequately protect our competitive advantage. Also,
our granted patents may be subject to challenges or narrowly construed and may not provide adequate protection. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to claims that we infringe,
misappropriate or otherwise violate the intellectual property rights of third parties. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if our patents do successfully issue, third parties may
challenge the validity, enforceability or scope of such granted patents or any other granted patents we own or license, which may result in such patents being narrowed, invalidated or held unenforceable. For example, patents granted by the European
Patent Office may be opposed by any person within nine months from the publication of their grant. Also, patents granted by the United States Patent and Trademark Office, or USPTO, may be subject to reexamination and other challenges. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, even if they are not challenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing
around our claims. To meet such challenges, which are part of the risks and uncertainties of developing and marketing product candidates, we may need to evaluate third party intellectual property rights and, if appropriate, to seek licenses for such
third party intellectual property or to challenge such third party intellectual property, which may be costly and may or may not be successful, which could also have an adverse effect on the commercial potential for MitoGel, VesiGel and any of our
product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may receive only limited protection, or no protection, from our issued patents and patent applications. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we encounter delays in our clinical trials or regulatory approval of our product candidates, the period of time during which we could market any of our product
candidates under patent protection could be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (i)&nbsp;file any
patent application related to hydrogel-based pharmaceutical compositions for optimal delivery of a drug in internal cavities such as the bladder, the method for treating urothelial cancer using hydrogel-based compositions, the method for treating
overactive bladder topically without the need for injections, an <FONT STYLE="white-space:nowrap">in-dwelling</FONT> ureter catheter system for optimal delivery of a drug into the renal cavity, and pharmaceutical compositions comprising an
imidazoquinolin (amine) and lactic acid for use in a method for the treatment of bladder diseases or any of our product candidates or (ii)&nbsp;conceive and invent any of the inventions claimed in our patents or patent applications. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent application process, also known as patent prosecution, is expensive and time consuming, and we or any future licensors and licensees may not be able to
prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or any future licensors or licensees will fail to identify patentable aspects of inventions made in
the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, these and any of our patents and applications may not be prosecuted and<B></B>&nbsp;enforced in a manner consistent with
the best interests of our business. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, etc.,
although we are unaware of any such defects that we believe are of material import. If we or any future licensors or licensees fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or
eliminated. If any future licensors or licensees, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the
form or preparation of our patents or patent applications, such patents or applications may be invalid and unenforceable. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on
our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The strength of patents in the pharmaceutical field involves complex legal and scientific questions and can be uncertain. This uncertainty includes
changes to the patent laws through either legislative action to change statutory patent law or court action that may reinterpret existing law in ways affecting the scope or validity of issued patents. The patent applications that we own or <FONT
STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents in the United States or foreign countries with claims that cover our product candidates. Even if patents do successfully issue from the patent applications that we own
or <FONT STYLE="white-space:nowrap">in-license,</FONT> third parties may challenge the validity, enforceability or scope of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
patents, which may result in such patents being narrowed, invalidated or held unenforceable. For example, patents granted by the European Patent Office may be challenged, also known as opposed,
by any person within nine months from the publication of their grant. Any successful challenge to our patents could deprive us of exclusive rights necessary for the successful commercialization of our product candidates. Furthermore, even if they
are unchallenged, our patents may not adequately protect our product candidates, provide exclusivity for our product candidates, or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents we
hold or pursue with respect to our product candidates is challenged, it could dissuade companies from collaborating with us to develop, or threaten our ability to commercialize our product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available;
however the life of a patent, and the protection it affords, is limited. Without patent protection for our product candidates, we may be open to competition from generic versions of our product candidates. Further, if we encounter delays in our
development efforts, including our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A considerable number of our patents and patent applications are entitled to effective filing dates prior to March&nbsp;16, 2013. For U.S. patent applications in which
patent claims are entitled to a priority date before March&nbsp;16, 2013, an interference proceeding can be provoked by a third party, for example a competitor, or instituted by the USPTO to determine who was the first to invent any of the subject
matter covered by those patent claims. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a
license on commercially reasonable terms. Our participation in an interference proceeding may fail and, even if successful, may result in substantial costs and distract our management. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our trade secrets may not have sufficient intellectual property protection. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the protection afforded by patents, we also rely on trade secret protection to protect proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> that
may not be patentable or that we elect not to patent, processes for which patents may be difficult to obtain or enforce, and any other elements of our product candidates, and our product development processes (such as manufacturing and formulation
technologies) that involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information or technology that is not covered by patents. However, trade secrets can be difficult to protect. If the steps taken to maintain our trade secrets
are deemed inadequate, we may have insufficient recourse against third parties for misappropriating any trade secrets. Misappropriation or unauthorized disclosure of our trade secrets could significantly affect our competitive position and may have
an adverse effect on our business. Furthermore, trade secret protection does not prevent competitors from independently developing substantially equivalent information and techniques and we cannot guarantee that our competitors will not
independently develop substantially equivalent information and techniques. The FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information
that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#146;s disclosure policies may change in the future, if at all. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In an effort to protect our trade secrets and other confidential information, we require our employees, consultants, advisors, and any other third parties that have
access to our proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information or technology, for example, third parties involved in the formulation and manufacture of our product candidates, and third parties involved in our clinical
trials to execute confidentiality agreements upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the
individual&#146;s relationship with us is kept confidential and not disclosed to third parties. However, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed despite having such
confidentiality agreements. Adequate remedies may not exist in the event of unauthorized use or disclosure of our trade secrets. In addition, in some situations, these confidentiality agreements may conflict with, or be subject to, the rights of
third parties with whom our employees, consultants, or advisors have previous employment or consulting relationships. To the extent that our employees, consultants or contractors use any intellectual property owned by third parties in their work for
us, disputes may arise as to the rights in any related or resulting <FONT STYLE="white-space:nowrap">know-how</FONT> and inventions. If we are unable to prevent unauthorized material disclosure of our trade secrets to third parties, we may not be
able to establish or maintain a competitive advantage in our market, which could harm our business, operating results and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to
protect our products. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly on
obtaining and enforcing patents. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity, and therefore, is costly, time-consuming and inherently uncertain. In addition, the United States has
recently enacted and is currently implementing wide-ranging patent reform legislation. Further, recent U.S. Supreme Court rulings have either narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent
owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For our U.S. patent applications containing a claim not entitled to priority before March&nbsp;16, 2013, there is a greater level of uncertainty in the patent law. In
September 2011, the Leahy-Smith America Invents Act, or the America Invents Act, or AIA, was signed into law. The AIA includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be
prosecuted and may also affect patent litigation. The USPTO is currently developing regulations and procedures to govern administration of the AIA, and many of the substantive changes to patent law associated with the AIA. It is not clear what
other, if any, impact the AIA will have on the operation of our business. Moreover, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of
our issued patents, all of which could harm our business and financial condition. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An important change introduced by the AIA is that, as of March&nbsp;16, 2013, the
United States transitioned to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system for deciding which party should be granted a patent when two or more patent applications are filed by
different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was
made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the
differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be
certain that we were the first to either (i)&nbsp;file any patent application related to our product candidates or (ii)&nbsp;invent any of the inventions claimed in our patents or patent applications. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third
parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March&nbsp;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United
States federal court necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate
the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in
a district court action. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in
unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by
governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during
the patent prosecution process. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Periodic maintenance fees and various other governmental fees on any issued patent and/or pending patent applications are due to be
paid to the USPTO and foreign patent agencies in several stages over the lifetime of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
patent or patent application. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees. While an inadvertent lapse
may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are many situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial
or complete loss of patent rights in the relevant jurisdiction. If we fail to maintain the patents and patent applications directed to our product candidates, our competitors might be able to enter the market earlier than should otherwise have been
the case, which could harm our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive. The requirements for
patentability may differ in certain countries, particularly developing countries. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a
claimed drug. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in
all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we
have patent protection, but enforcement on infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of
certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the
infringement of our patents or marketing of competing products in violation of our proprietary rights generally. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Proceedings to enforce our patent rights in
foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not
issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, certain countries in Europe
and certain developing countries, including India and China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if our patents are infringed
or if we are compelled to grant a license to our patents to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual
property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. Finally, our ability to protect and enforce our intellectual property rights may be adversely
affected by unforeseen changes in foreign intellectual property laws. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to protect our trademarks from infringement, our business prospects
may be harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We own trademarks that identify MitoGel, VesiGel and Vesimune and have registered these trademarks in the United States and Israel. Although
we take steps to monitor the possible infringement or misuse of our trademarks, it is possible that third parties may infringe, dilute or otherwise violate our trademark rights. Any unauthorized use of our trademarks could harm our reputation or
commercial interests. In addition, our enforcement against third-party infringers or violators may be unduly expensive and time-consuming, and the outcome may be an inadequate remedy. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and
time consuming. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third parties may infringe or misappropriate our intellectual property, including our existing patents, patents that may issue to us in the
future, or the patents of our licensors to which we have a license. As a result, we may be required to file infringement claims to stop third-party infringement or unauthorized use. Further, we may not be able to prevent, alone or with our
licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Generic drug manufacturers may develop, seek approval for, and launch generic versions of our products. If we file an
infringement action against such a generic drug manufacturer, that company may challenge the scope, validity or enforceability of our or our licensors&#146; patents, requiring us and/or our licensors to engage in complex, lengthy and costly
litigation or other proceedings. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, if we or one of our licensors initiated legal proceedings against a third party to enforce a patent covering our
product candidates, the defendant could counterclaim that the patent covering our product candidates is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are
commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, within and outside of the
United States, there has been a substantial amount of litigation and administrative proceedings, including interference and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in various foreign jurisdictions,
regarding patent and other intellectual property rights in the pharmaceutical industry. Recently, the AIA introduced new procedures including <I>inter partes</I> review and post grant review. The implementation of these procedures brings uncertainty
to the possibility of challenges to our patents in the future, including challenges by competitors who perceive our patents as blocking entry into the market for their products, and the outcome of such challenges. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Such litigation and administrative proceedings could result in revocation of our patents or amendment of our patents such that they do not cover our product candidates.
They may also put our pending patent applications at risk of not issuing, or issuing with limited and potentially inadequate scope to cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is
unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. Additionally, it is also possible that prior art of
which we are aware, but which we do not believe affects the validity or enforceability of a claim, may, nonetheless, ultimately be found by a court of law or an administration panel to affect the validity or enforceability of a claim. If a defendant
were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a negative impact on our
business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Enforcing our or our licensor&#146;s intellectual property rights through litigation is very expensive, particularly for a company of our size, and
time-consuming. Some of our competitors may be able to sustain the costs of litigation more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The
occurrence of any of the foregoing could harm our business, financial condition or results of operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, because of the substantial amount of
discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, during the course of litigation or
administrative proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market
price for our ordinary shares could be significantly harmed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may become subject to claims for remuneration or royalties for assigned service invention
rights by our employees, which could result in litigation and adversely affect our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A significant portion of our intellectual property has been
developed by our employees in the course of their employment for us. Under the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee during the scope of his or her employment with a company are regarded as
&#147;service inventions.&#148; The Israeli Compensation and Royalties Committee, or the Committee, a body constituted under the Patent Law, has previously held, in certain cases, that employees may be entitled to remuneration for service inventions
that they develop during their service for a company despite their explicit waiver of such right. Therefore, although we enter into agreements with all of our employees pursuant to which they waive their right to special remuneration for service
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
inventions created in the scope of their employment or engagement and agree that any such inventions are owned exclusively by us, we may face claims by employees demanding remuneration beyond
their regular salary and benefits. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Third-party claims alleging intellectual property infringement may adversely affect our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties, for example, the intellectual property
rights of competitors. Our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents owned or controlled by third parties. Numerous U.S. and foreign issued patents and pending
patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our
activities related to our product candidates may give rise to claims of infringement of the patent rights of others. We cannot assure you that our product candidates will not infringe existing or future patents. We may not be aware of patents that
have already issued that a third party might assert are infringed by our product candidates. It is also possible that patents of which we are aware, but which we do not believe are relevant to our product candidates, could nevertheless be found to
be infringed by our product candidates. Nevertheless, we are not aware of any issued patents that we believe would prevent us from marketing our product candidates, if approved. There may also be patent applications that have been filed but not
published that, when issued as patents, could be asserted against us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third parties making claims against us for infringement or misappropriation of their
intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Further, if a patent infringement suit were brought against
us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. Defense of these claims, regardless of their merit, would cause us to incur substantial
expenses and, and would be a substantial diversion of management time and employee resources from our business. In the event of a successful claim of infringement against us by a third party, we may have to (i)&nbsp;pay substantial damages,
including treble damages and attorneys&#146; fees if we are found to have willfully infringed the third party&#146;s patents; (ii)&nbsp;obtain one or more licenses from the third party; (iii)&nbsp;pay royalties to the third party; and/or
(iv)&nbsp;redesign any infringing products. Redesigning any infringing products may be impossible or require substantial time and monetary expenditure. Further, we cannot predict whether any required license would be available at all or whether it
would be available on commercially reasonable terms. In the event that we could not obtain a license, we may be unable to further develop and commercialize our product candidates, which could harm our business significantly. Even if we are able to
obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately,
we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Defending ourselves or our licensors in litigation is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to
sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the
initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could harm our business, financial condition or results of operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third
parties. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our
employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of these third parties or our employees&#146; former employers. Further, we may be subject to ownership disputes
in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. We may also be subject to claims that former employees, consultants, independent contractors,
collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging our right to and use of confidential and proprietary
information. If we fail in defending </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
any such claims, in addition to paying monetary damages, we may lose our rights therein. Such an outcome could have a negative impact on our business. Even if we are successful in defending
against these claims, litigation could result in substantial cost and be a distraction to our management and employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Government Regulation
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If the FDA does not conclude that MitoGel, VesiGel, or our other product candidates satisfy the requirements under Section&nbsp;505(b)(2) of the Federal
Food Drug and Cosmetic Act, or Section&nbsp;505(b)(2), or if the requirements for such product candidates are not as we expect, the approval pathway for these product candidates will likely take significantly longer, cost significantly more and
entail significantly greater complications and risks than anticipated, and in either case may not be successful. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We commenced a single pivotal Phase 3
clinical trial for MitoGel and expect to commence a Phase 2b clinical trial of VesiGel under the FDA&#146;s Section&nbsp;505(b)(2) regulatory pathway. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman
Act, added Section&nbsp;505(b)(2) to the Federal Food, Drug and Cosmetic Act. Section&nbsp;505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies that were not conducted by or for the
applicant, and for which the applicant has not received a right of reference, which could expedite the development program for MitoGel, VesiGel and our other product candidates by potentially decreasing the amount of preclinical and clinical data
that we would need to generate in order to obtain FDA approval. However, while we believe that our product candidates are reformulations of existing drugs or biologics and, therefore, will not be treated as new chemical entities, or NCEs, the
submission of an NDA under the Section&nbsp;505(b)(2) or similar regulatory pathway does not preclude the FDA from determining that the product candidate that is the subject of such submission is an NCE and therefore not eligible for review under
such regulatory pathway. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the FDA does not allow us to pursue the Section&nbsp;505(b)(2) or similar regulatory pathway as anticipated, we may need to conduct
additional preclinical experiments and clinical trials, provide additional data and information, and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for these
product candidates, and complications and risks associated with these product candidates, would likely increase significantly. Moreover, inability to pursue the Section&nbsp;505(b)(2) or similar regulatory pathway could result in new competitive
products reaching the market more quickly than our product candidates, which would likely harm our competitive position and prospects. Even if we are allowed to pursue the Section&nbsp;505(b)(2) or similar regulatory pathway, our product candidates
may not receive the requisite approvals for commercialization. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, notwithstanding the approval of a number of products by the FDA under
Section&nbsp;505(b)(2) over the last few years, certain competitors and others have objected to the FDA&#146;s interpretation of Section&nbsp;505(b)(2). If the FDA&#146;s interpretation of Section&nbsp;505(b)(2) is successfully challenged, the FDA
may be required to change its 505(b)(2) policies and practices, which could delay or even prevent the FDA from approving any NDA that we submit under Section&nbsp;505(b)(2). In addition, the pharmaceutical industry is highly competitive, and
Section&nbsp;505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved drugs that are referenced in a Section&nbsp;505(b)(2) NDA. These requirements may give rise to patent litigation
and mandatory delays in approval of our potential future NDAs for up to 30 months depending on the outcome of any litigation. It is not uncommon for a manufacturer of an approved product to file a citizen petition with the FDA seeking to delay
approval of, or impose additional approval requirements for, pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a
petition, the FDA may substantially delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section&nbsp;505(b)(2) regulatory pathway for our product candidates, there is no guarantee this
would ultimately lead to faster product development or earlier approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, even if these product candidates are approved under the Section&nbsp;505(b)(2)
pathway, as the case may be, the approval may be subject to limitations on the indicated uses for which the products may be marketed or to other conditions of approval, or may contain requirements for costly post-marketing testing and surveillance
to monitor the safety or efficacy of the products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fast track designation for one or more of our product candidates may not actually lead to a faster development
or regulatory review or approval process. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2017, we received fast track designation for MitoGel for the treatment of UTUC. If a product is
intended for the treatment of a serious condition, and nonclinical or clinical data demonstrate the potential to address unmet medical need for this condition, a product sponsor may apply for FDA fast track designation. Even though we have received
fast track designation for MitoGel for the treatment of UTUC, fast track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular timeframe. We may not experience a faster development
or regulatory review or approval process with fast track designation compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our
clinical development program. Fast track designation alone does not guarantee qualification for the FDA&#146;s priority review procedures. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We expect current
and future legislation affecting the healthcare industry, including healthcare reform, to impact our business generally and to increase limitations on reimbursement, rebates and other payments, which could adversely affect third-party coverage of
our products, our operations, and/or how much or under what circumstances healthcare providers will prescribe or administer our products, if approved. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers
and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the
pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, in March
2010, President Obama signed into law the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act of 2010, or collectively, the ACA, a law intended, among other things, to broaden access to
health insurance, improve quality of care, and reduce or constrain the growth of healthcare spending. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Provisions of the ACA relevant to the pharmaceutical industry
include the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government
healthcare programs, not including orphan drug sales; </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively;
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts on negotiated
prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain
individuals with income at or below 133% of the Federal Poverty Level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability; </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">new requirements to report annually certain financial arrangements with physicians and teaching hospitals; as defined in the ACA and its implementing regulations, including reporting any payment or &#147;transfer of
value&#148; provided to physicians and teaching hospitals and any ownership and investment interests held by physicians and their immediate family members during the preceding calendar year; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of healthcare fraud and abuse laws, including the federal civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance; and
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There have been judicial and Congressional challenges to certain aspects of the ACA. As a result, there have been delays in the implementation of, and action taken to
repeal or replace, certain aspects of the ACA. In January 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the
implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. For example, since January 2017,
President Trump has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or
part of the ACA. The recently enacted Tax Cuts and the Jobs Act includes a provision that repeals, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain
individuals who fail to maintain qualifying health coverage for all or part of a year. We continue to evaluate how the ACA and recent efforts to repeal and replace or limit the implementation of the ACA will impact our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, in August 2011, President Obama signed into law the Budget
Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of an amount
greater than $1.2 trillion for the years 2013 through 2021, triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per
fiscal year, which started in 2013 and, following passage of the Bipartisan Budget Act of 2015, will stay in effect through 2025 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer
Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.
Additionally, there have been several recent U.S. Congressional inquiries and proposed and enacted legislation at the federal and state levels designed to, among other things, bring more transparency to drug pricing, review the relationship between
pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. Further, the U.S. House of Representatives formed an Affordable Drug Pricing Task Force to
advance legislation intended to control pharmaceutical drug costs and investigate pharmaceutical drug pricing, and the U.S. Senate requested information from certain pharmaceutical companies in connection with an investigation into pharmaceutical
drug pricing practices. If healthcare policies or reforms intended to curb healthcare costs are adopted, or if we experience negative publicity with respect to the pricing of our products or the pricing of pharmaceutical drugs generally, the prices
that we charge for any approved products may be limited, our commercial opportunity may be limited and/or our revenues from sales of our products may be negatively impacted. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we obtain regulatory approval and commercialization of MitoGel, VesiGel or any of our other product candidates, these laws may result in additional reductions in
healthcare funding, which could have an adverse effect on our customers and accordingly, our financial operations. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities
for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of
MitoGel, VesiGel or our other product candidates may be. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we cannot predict the full effect on our business of the implementation of existing legislation
or the enactment of additional legislation pursuant to healthcare and other legislative reform, we believe that legislation or regulations that would reduce reimbursement for, or restrict coverage of, our products could adversely affect how much or
under what circumstances healthcare providers will prescribe or administer our products. This could adversely affect our business by reducing our ability to generate revenues, raise capital, obtain additional licensees
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and market our products. In addition, we believe the increasing emphasis on managed care in the United States has and will continue to put pressure on the price and usage of pharmaceutical
products, which may adversely impact product sales. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be unable to obtain Orphan Drug Designation or exclusivity for future product candidates we may
develop. If our competitors are able to obtain orphan drug exclusivity for their products that are for the same indication as our product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a
significant period of time. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Orphan Drug Act of 1983, the FDA may designate a product as an orphan drug if it is intended to treat an orphan
disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be
recovered from sales in the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, Orphan Drug Designation entitles a party to financial incentives, such as opportunities for grant
funding towards clinical trial costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. In addition, if a product receives the first FDA approval for the indication for which it has Orphan Drug Designation, the product is
entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority
over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although the FDA has granted MitoGel orphan
drug designation for the treatment of UTUC and to Vesimune for treatment of CIS, we may not receive orphan drug designation for any of our other product candidates. If our competitors are able to obtain orphan drug exclusivity for their products
that are the same or similar to our product candidates before our drug candidates are approved, we may not be able to have competing product candidates approved by the FDA for a significant period of time. Any delay in our ability to bring our
product candidates to market would negatively impact our business, revenue, cash flows and operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Orphan Drug Designation may not ensure that we will
enjoy market exclusivity in a particular market, and if we fail to obtain or maintain orphan drug exclusivity for our product candidates, we may be subject to earlier competition and our potential revenue will be reduced. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Orphan Drug Designation entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax advantages, <FONT
STYLE="white-space:nowrap">user-fee</FONT> waivers and market exclusivity for certain periods of time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MitoGel and Vesimune have been granted Orphan Drug
Designation for the treatment of UTUC and CIS, respectively, in the United States. Even if we obtain Orphan Drug Designation for our other product candidates, we may not be the first to obtain regulatory approval for any particular orphan indication
due to the uncertainties associated with developing biopharmaceutical products. Further, even if we obtain Orphan Drug Designation for a product candidate, that exclusivity may not effectively protect the product from competition because different
drugs with different active moieties can be approved for the same condition. In addition, if a competitor obtains approval and marketing exclusivity for a drug product with an active moiety that is the same as that in a product candidate we are
pursuing for the same indication, approval of our product candidate would be blocked during the period of marketing exclusivity unless we could demonstrate that our product candidate is clinically superior to the approved product. In addition, if a
competitor obtains approval and marketing exclusivity for a drug product with an active moiety that is the same as that in a product candidate we are pursuing for a different orphan indication, this may negatively impact the market opportunity for
our product candidate. There have been legal challenges to aspects of the FDA&#146;s regulations and policies concerning the exclusivity provisions of the Orphan Drug Act, and future challenges could lead to changes that affect the protections
afforded our product candidates in ways that are difficult to predict. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we receive regulatory approval for our product candidates, we will be subject
to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expenses, limit or withdraw regulatory approval and subject us to penalties if we fail to comply with applicable regulatory requirements.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If and when regulatory approval has been granted, our product candidates or any approved product will be subject to continual regulatory review by the FDA
and/or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities. Additionally, any product candidates, if approved, will be subject to extensive and ongoing regulatory requirements, including labeling and other restrictions and market
withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the
approved indications for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and
efficacy of the product. In addition, if the applicable regulatory agency approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for
the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and GCP for any
clinical trials that we conduct post-approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Later discovery of previously unknown problems with our product candidates, including adverse events of
unanticipated severity or frequency, or problems with our third-party manufacturers&#146; processes, or failure to comply with regulatory requirements, may result in, among other things: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, warnings letters or holds on clinical trials </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizure or detention, or refusal to permit the import or export of products; and injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. We cannot predict the
likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or other countries. If we are slow or unable to adapt to changes in existing requirements or the
adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our
business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our relationships with healthcare professionals, independent contractors, clinical investigators, CROs, consultants and vendors in connection with
our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws. If we are unable to
comply, or have not fully complied, with such laws, we could face penalties. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may currently be or may become subject to various U.S. federal and state
health care laws, including those intended to prevent health care fraud and abuse. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal Anti-Kickback Statute prohibits, among other things, persons or
entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for,
either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, by a federal healthcare program such as Medicare and Medicaid.
Remuneration has been broadly defined to include anything of value, including, but not limited to, cash, improper discounts, and free or reduced price items and services. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Federal false claims laws, including the federal False Claims Act, or FCA, and civil monetary penalties law impose penalties against individuals or entities for, among
other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent or making a false record or statement to avoid, decrease or conceal an obligation to pay money to
the federal government. The FCA has been used to, among other things, prosecute persons and entities submitting claims for payment that are inaccurate or fraudulent, that are for services not provided as claimed, or for services that are not
medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many states have similar fraud and abuse statutes and regulations that may be broader in scope and may apply regardless of payor, in addition to items and services
reimbursed under Medicaid and other state programs. State </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and federal authorities have aggressively targeted medical technology companies for, among other things, alleged violations of these anti-fraud statutes, based on unlawful financial inducements
paid to prescribers and beneficiaries, as well as impermissible promotional practices, including certain marketing arrangements that rely on volume-based pricing and <FONT STYLE="white-space:nowrap">off-label</FONT> promotion of <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, among other things,
imposes criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including public and private payors, or knowingly and willfully falsifying, concealing or covering up a
material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally,
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, impose, among other things, specified requirements on covered entities and their business associates relating
to the privacy and, security and transmission of individually identifiable health information, including mandatory contractual terms and required implementation of certain safeguards of such information. Among other things, HITECH makes HIPAA&#146;s
security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH
also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions
in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in some circumstances, many of
which differ from each other in significant ways, may not have the same effect and may not be preempted by HIPAA, thus complicating compliance efforts. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
operations will also be subject to the federal Open Payments program pursuant to the Physician Payments Sunshine Act, created under Section&nbsp;6002 of the ACA and its implementing regulations, which requires certain manufacturers of drugs,
devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#146;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicare&nbsp;&amp; Medicaid
Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS, information related to payments and other transfers of value provided to physicians and teaching hospitals and certain ownership and investment interests
held by physicians and their immediate family members. We may also be subject to state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or
marketing expenditures, and/or state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidelines promulgated by the federal government. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any payor,
including commercial insurers. We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the
federal government, and/or state laws that require drug manufacturers to report information related to marketing expenditures or payments and other transfers of value to physicians and other healthcare providers. If any of our business activities,
including but not limited to our relationships with healthcare providers, are found to violate any of the aforementioned laws, we may be subject to administrative, civil and/or criminal penalties, damages, monetary fines, disgorgement, individual
imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity
agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, diminished profits and future earnings and curtailment or restructuring of our operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Also, the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments
to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> officials for the purpose of obtaining or retaining business. We cannot assure you that our internal control policies and procedures will protect us from reckless or negligent acts committed by our
employees, future distributors, partners, collaborators or agents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Legislative or regulatory healthcare reforms in the United States or abroad may make it more difficult and costly for us to obtain regulatory clearance or
approval of our product candidates or any future product candidates and to produce, market, and distribute our products after clearance or approval is obtained. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, legislation is drafted and introduced in Congress in the United States or by governments in foreign jurisdictions that could significantly change the
statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA or foreign regulatory agency regulations and guidance are often revised or
reinterpreted by the FDA or the applicable foreign regulatory agency in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or
lengthen review times of our product candidates or any future product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our
business in the future. Such changes could, among other things, require: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes to manufacturing methods; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recall, replacement, or discontinuance of one or more of our products; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional recordkeeping. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each of these would likely entail substantial time and cost and could harm our business and
our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition, and results of operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could
negatively impact our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory
procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce
hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from
our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We maintain workers compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous
materials or other work-related injuries with policy limits that we believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain such insurance, this insurance may not
provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may
impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>It may be difficult for us to profitably sell our product candidates if coverage and reimbursement for these products is limited by government authorities and/or
third-party payor policies. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to any healthcare reform measures which may affect reimbursement, market acceptance and sales of MitoGel, VesiGel
and our other product candidates, if approved, will depend on the coverage and reimbursement policies of third-party payors, like government authorities, private health insurers, and health maintenance organizations. Third-party payors decide which
medications they will cover and separately establish reimbursement levels. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A primary trend in the U.S. healthcare industry and elsewhere is cost containment.
Government and other third-party payors are increasingly challenging the prices charged for health care products, examining the cost effectiveness of drugs in addition to their safety and efficacy, and limiting or attempting to limit both coverage
and the level of reimbursement for prescription drugs. We cannot be sure that coverage will be available for MitoGel, VesiGel or our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
other product candidates, if approved, or, if coverage is available, the level of reimbursement will be adequate to make our products affordable for patients or profitable for us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, decisions about reimbursement for
new medicines under Medicare are made by CMS, as the administrator for the Medicare program. Private payors often use CMS as a model for their coverage and reimbursement decisions. It is difficult to predict what CMS as well as other payors will
decide with respect to reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Reimbursement may impact the demand for, and/or the price of, any product for which we obtain marketing approval. Assuming we obtain coverage for a given product by a
third-party payor, the resulting reimbursement payment rates may not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. Patients who are prescribed medications for the treatment of
their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and
reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards
that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. There may be significant delays in obtaining coverage and reimbursement for newly approved drugs,
and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases
or at a rate that covers our costs, including research, development, manufacture, sale and distribution. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Reimbursement by a third-party payor may depend upon a
number of factors including the third-party payor&#146;s determination that use of a product is: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a covered benefit under its health plan; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">safe, effective and medically necessary; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appropriate for the specific patient; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost-effective; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">neither experimental nor investigational. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Obtaining coverage and reimbursement approval for a product from a government
or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. Further, no uniform policy requirement for
coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process
may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. We may not be
able to provide data sufficient to gain acceptance with respect to coverage and/or sufficient reimbursement levels. We cannot be sure that coverage or adequate reimbursement will be available for MitoGel, VesiGel or any of our other product
candidates, if approved. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our future products. If reimbursement is not available, or is available only to limited levels, we may not be able to
commercialize MitoGel, VesiGel or our other product candidates, or achieve profitably at all, even if approved. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Legislative or regulatory healthcare reforms
in the United States may make it more difficult and costly for us to obtain regulatory clearance or approval of MitoGel, VesiGel or any of our other product candidates and to produce, market, and distribute our products after clearance or approval
is obtained. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the
regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our
business and our products. Any new regulations or revisions or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
reinterpretations of existing regulations may impose additional costs or lengthen review times of MitoGel, VesiGel or any of our other product candidates. We cannot determine what effect changes
in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes to manufacturing methods; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change in protocol design; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional treatment arm (control); </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recall, replacement, or discontinuance of one or more of our products; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional recordkeeping. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each of these would likely entail substantial time and cost and could harm our business and
our financial results. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to This Offering and Ownership of Our Ordinary Shares </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The market price of our ordinary shares has been and may continue to be subject to fluctuation and you could lose all or part of your investment. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The stock market in general has been, and the market price of our ordinary shares in particular has been and may continue to be, subject to fluctuation, whether due to,
or irrespective of, our operating results and financial condition. The market price of our ordinary shares on the NASDAQ Global Market may fluctuate as a result of a number of factors, some of which are beyond our control, including, but not limited
to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated variations in our and our competitors&#146; results of operations and financial condition; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">physician and market acceptance of our products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the mix of products that we sell; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our success or failure to obtain approval for and commercialize our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in earnings estimates or recommendations by securities analysts, if our ordinary shares are covered by analysts; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">development of technological innovations or new competitive products by others; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of technological innovations or new products by us; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">publication of the results of preclinical or clinical trials for MitoGel, VesiGel or our other product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure by us to achieve a publicly announced milestone; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays between our expenditures to develop and market new or enhanced product candidates and the generation of sales from those products; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments concerning intellectual property rights, including our involvement in litigation brought by or against us; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments and the decisions of regulatory authorities as to the approval or rejection of new or modified products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the amounts that we spend to develop, acquire or license new products, technologies or businesses; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in our expenditures to promote our products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our sale or proposed sale, or the sale by our significant shareholders, of our ordinary shares or other securities in the future; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in key personnel; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">success or failure of our research and development projects or those of our competitors; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the trading volume of our ordinary shares; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic and market conditions and other factors, including factors unrelated to our operating performance. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These factors and any corresponding price fluctuations may negatively impact the market price of our ordinary shares and result in substantial losses being incurred by
our investors. In the past, following periods of market volatility, public company shareholders have often instituted securities class action litigation. If we were to become involved in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
securities litigation, it could impose a substantial cost upon us and divert the resources and attention of our management from our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our ordinary shares, the
price of our ordinary shares could decline. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading market for our ordinary shares relies in part on the research and reports that equity research
analysts publish about us and our business, if at all. We do not have control over these analysts and we do not have commitments from them to write research reports about us. The price of our ordinary shares could decline if no research reports are
published about us or our business, or if one or more equity research analysts downgrade our ordinary shares or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Future sales of our ordinary shares could reduce the market price of our ordinary shares. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our existing shareholders, particularly our directors, their affiliates, or our executive officers, sell a substantial number of our ordinary shares in the public
market, the market price of our ordinary shares could decrease significantly. The perception in the public market that our shareholders might sell our ordinary shares could also depress the market price of our ordinary shares and could impair our
future ability to obtain capital, especially through an offering of equity securities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of the date of this prospectus, the holders of approximately 4,515,674
ordinary shares are entitled to registration rights, of which approximately 3,064,345 will be subject to the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in the &#147;Underwriting&#148; section of this
prospectus. In addition, our sale of additional ordinary shares or similar securities in order to raise capital might have a similar negative impact on the share price of our ordinary shares. A decline in the price of our ordinary shares might
impede our ability to raise capital through the issuance of additional ordinary shares or other equity securities, and may cause you to lose part or all of your investment in our ordinary shares. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Investors in this offering will experience immediate substantial dilution in net tangible book value. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The assumed public offering price of our ordinary shares in this offering is considerably greater than the net tangible book value per share of our outstanding ordinary
shares immediately after this offering. Accordingly, investors in this offering will incur immediate dilution of $35.46 per share, as of September&nbsp;30, 2017, based on an assumed public offering price of $44.02 per share, which was the last
reported sale price of our ordinary shares on the NASDAQ Global Market on January&nbsp;11, 2018. In addition, if outstanding options to purchase our ordinary shares are exercised in the future, you will experience additional dilution. Please see the
section entitled &#147;Dilution.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The significant share ownership position of our officers, directors and entities affiliated with certain of our
directors may limit your ability to influence corporate matters. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After giving effect to this offering, our officers, directors and entities affiliated with
certain of our directors will beneficially own or control, directly or indirectly, approximately 24.7% of our outstanding ordinary shares (or 24.4% if the underwriters exercise in full their option to purchase additional ordinary shares).
Accordingly, these persons will be able to significantly influence, though not independently determine, the outcome of matters required to be submitted to our shareholders for approval, including decisions relating to the election of our board of
directors, and the outcome of any proposed merger or consolidation of our company. These interests may not be consistent with those of our other shareholders. In addition, these persons&#146; significant interest in us may discourage third parties
from seeking to acquire control of us, which may adversely affect the market price of our ordinary shares. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have broad discretion as to the use of the net
proceeds from this offering and may not use them effectively. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to use the net proceeds from this offering, together with our existing cash
resources, to complete our single pivotal Phase 3 clinical trial of MitoGel for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC, to begin preparation for the commercial launch of MitoGel, if approved, to file an IND for, and
to initiate our Phase 2b clinical trial of, VesiGel, for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC, and the remainder to fund continued research and clinical development of our other product candidates, including
Vesimune, and for working capital and other general corporate purposes. However, our management will have broad discretion in the application of the net proceeds. Our shareholders may not agree with the manner in which our management chooses to
allocate the net proceeds from this offering. The failure by our management to apply these funds effectively could harm our business, financial condition and results of operation. Pending their use, we may invest the net proceeds from this offering
in a manner that does not produce income. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have never paid cash dividends on our share capital, and we do not anticipate paying any cash dividends in
the foreseeable future. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never declared or paid cash dividends on our share capital, nor do we anticipate paying any cash dividends on our share
capital in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our ordinary shares will be
investors&#146; sole source of gain for the foreseeable future. In addition, Israeli law limits our ability to declare and pay dividends, and may subject our dividends to Israeli withholding taxes. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are classified as a passive foreign investment company, our U.S. shareholders may suffer adverse tax consequences. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Generally, for any taxable year, if at least 75% of our gross income is passive income, or at least 50% of the value of our assets is attributable to assets that
produce passive income or are held for the production of passive income, including cash, we would be characterized as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. We do not believe that we were classified as a
PFIC for the taxable year ended December&nbsp;31, 2017. However, based upon the expected nature and composition of our income and assets, we anticipate that we will be classified as a PFIC for the taxable year ending December&nbsp;31, 2018. For
purposes of these tests, passive income includes dividends, interest gains from commodities and securities transactions, the excess of gains over losses from the disposition of assets which produce passive income (including amounts derived by reason
of the temporary investment of funds raised in offerings of our shares) and rents and royalties other than rents and royalties which are received from unrelated parties in connection with the active conduct of a trade or business. If we are
characterized as a PFIC, our U.S. shareholders may suffer adverse tax consequences, including having gains realized on the sale of our ordinary shares treated as ordinary income, rather than capital gain, the loss of the preferential rate applicable
to dividends received on our ordinary shares by individuals who are U.S. holders, and having interest charges apply to distributions by us and gains from the sales of our shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our status as a PFIC will depend on the nature and composition of our income and the nature, composition and value of our assets (which may be determined based on the
fair market value of each asset, with the value of goodwill and going concern value determined in large part by reference to the market value of our common shares, which may be volatile) from time to time. We cannot provide any assurances regarding
our PFIC status for the current or future taxable years, and our U.S. tax counsel has not provided any opinion regarding our PFIC status. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not currently
intend to provide the information necessary for our U.S. shareholders to make QEF elections. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>As a foreign private issuer, we are permitted, and intend, to
follow certain home country corporate governance practices instead of otherwise applicable NASDAQ requirements, and we will not be subject to certain U.S. securities laws including, but not limited to, U.S. proxy rules and the filing of certain
Exchange Act reports. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a foreign private issuer, we are permitted to and follow certain home country corporate governance practices instead of those
otherwise required by the NASDAQ Stock Market for domestic U.S. issuers. Following our home country governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on the NASDAQ Global Market may provide less
protection to you than what is accorded to investors under the NASDAQ Rules applicable to domestic U.S. issuers. See the section titled &#147;Management&#151;Corporate Governance Practices.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a foreign private issuer, we are exempt from the rules and regulations under the Securities Exchange Act of 1934, or the Exchange Act, related to the furnishing and
content of proxy statements, including the requirement to disclose the compensation of our Chief Executive Officer, Chief Financial Officer, President of Israel Operations and the other two most highly compensated executive officers on an individual
basis. Nevertheless, pursuant to regulations promulgated under the Israeli Companies Law, 5759-1999, or the Israeli Companies Law, we are required to disclose the annual compensation of our five most highly compensated office holders on an
individual basis. Such disclosure is not as extensive as that required of a U.S. domestic issuer. Our officers, directors and principal shareholders are also exempt from the reporting and short-swing profit recovery provisions contained in
Section&nbsp;16 of the Exchange Act. In addition, we are not required under the Exchange Act to file reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the
Exchange Act and we are exempt from filing quarterly reports with the SEC under the Exchange Act. Moreover, we are not required to comply with Regulation FD, which restricts the selective disclosure of material information, although we have
voluntarily adopted a corporate disclosure policy substantially similar to Regulation FD. These </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
exemptions and leniencies will reduce the frequency and scope of information and protections to which you may otherwise have been eligible in relation to a U.S. domestic issuer. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Loss of foreign private issuer status in the future could result in significantly increased costs and divert management attention. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We would lose our foreign private issuer status if a majority of our shares are owned by U.S. residents and a majority of our directors or executive officers are U.S.
citizens or residents or we fail to meet additional requirements necessary to avoid loss of foreign private issuer status. However, we cannot assure you that at June&nbsp;30, 2018, the next determination date of our foreign private issuer status, we
will qualify as a foreign private issuer. If we cease to qualify as a foreign private issuer at this determination date, we will be required to begin reporting as a domestic issuer on January&nbsp;1, 2019. The regulatory and compliance costs to us
under U.S. securities laws as a U.S. domestic issuer may be significantly higher. If we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are
more detailed and extensive than the forms available to a foreign private issuer. We may also be required to modify certain of our policies to comply with accepted governance practices associated with U.S. domestic issuers. Such conversion and
modifications will involve additional costs. In addition, we would lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are an emerging growth company and the reduced disclosure requirements applicable to emerging growth companies may make our ordinary shares less attractive to
investors. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an emerging growth company, as defined in the JOBS Act, and we may take advantage of certain exemptions from various requirements that
are applicable to other public companies that are not emerging growth companies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For as long as we remain an emerging growth company we are permitted and intend to
rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not &#147;emerging growth companies.&#148; These exemptions include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being permitted to provide only two years of audited financial statements, in addition to any required unaudited condensed consolidated interim financial statements, with correspondingly reduced &#147;Management&#146;s
discussion and analysis of financial condition and results of operations&#148; disclosure; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing
additional information about the audit and the financial statements; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations regarding executive compensation; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will remain an emerging growth company until the earliest of: (i)&nbsp;the last day of our fiscal year during which we have total annual gross revenues of at least
$1.07&nbsp;billion; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the closing of this offering; (iii)&nbsp;the date on which we have, during the previous three-year period, issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt; or (iv)&nbsp;the date on which we are deemed to be a &#147;large accelerated filer&#148; under the Exchange Act. We have opted out of the extended transition period made available to emerging
growth companies to comply with newly adopted public company accounting requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When we are no longer deemed to be an emerging growth company, we will not be
entitled to the exemptions provided in the JOBS Act discussed above. We cannot predict if investors will find our ordinary shares less attractive as a result of our reliance on exemptions under the JOBS Act. If some investors find our ordinary
shares less attractive as a result, there may be a less active trading market for our ordinary shares and our share price may be more volatile. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to our Operations in Israel </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our headquarters, research and development and other significant operations are located in Israel and, therefore, our results may be adversely affected by
political, economic and military instability in Israel. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our headquarters and research and development facilities are located in Ra&#146;anana, Israel. In
addition, the majority of our key employees, officers and directors are residents of Israel. If these or any future facilities in Israel were to be damaged, destroyed or otherwise unable to operate, whether due to war, acts of hostility,
earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural disasters, employee malfeasance, terrorist acts, power outages or otherwise, or if performance of our research and development is disrupted for any other reason, such an event
could delay our clinical trials or, if our product candidates are approved and we choose to manufacture all or any part of them internally, jeopardize our ability to manufacture our products as promptly as our prospective customers will likely
expect, or possibly at all. If we experience delays in achieving our development objectives, or if we are unable to manufacture an approved product within a timeframe that meets our prospective customers&#146; expectations, our business, prospects,
financial results and reputation could be harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Political, economic and military conditions in Israel may directly affect our business. Since the establishment
of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its neighboring countries, Hamas (an Islamist militia and political group that controls the Gaza Strip) and Hezbollah (an Islamist militia and political
group based in Lebanon). In addition, several countries, principally in the Middle East, restrict doing business with Israel, and additional countries may impose restrictions on doing business with Israel and Israeli companies whether as a result of
hostilities in the region or otherwise. Any hostilities involving Israel, terrorist activities, political instability or violence in the region or the interruption or curtailment of trade or transport between Israel and its trading partners could
adversely affect our operations and results of operations and adversely affect the market price of our ordinary shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial insurance does not cover
losses that may occur as a result of an event associated with the security situation in the Middle East. Although the Israeli government is currently committed to covering the reinstatement value of direct damages that are caused by terrorist
attacks or acts of war, there can be no assurance that this government coverage will be maintained, or if maintained, will be sufficient to compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse
effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, our operations could be disrupted by the obligations of our employees to perform
military service. As of December&nbsp;31, 2017, we had 36&nbsp;employees based in Israel. Of these employees, some may be military reservists, and may be called upon to perform military reserve duty of up to 36 days per year (and in some cases more)
until they reach the age of 40 (and in some cases, up to the age of 45 or older). Additionally, they may be called to active duty at any time under emergency circumstances. In response to increased tension and hostilities in the region, there have
been, at times, <FONT STYLE="white-space:nowrap">call-ups</FONT> of military reservists, and it is possible that there will be additional <FONT STYLE="white-space:nowrap">call-ups</FONT> in the future. Our operations could be disrupted by the
absence of these employees due to military service. Such disruption could harm our business and operating results. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The Israeli government grants we have
received for research and development activities restrict our ability to manufacture products and transfer technologies outside of Israel and require us, in addition to the payment of royalties, to satisfy specified conditions. If we fail to satisfy
these conditions, we may be required to refund grants previously received and incur financial penalties. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have received grants under the Israeli Law for
the Encouragement of Industrial Research, Development and Technological Innovation, 5754-1984, or the R&amp;D Law, from the Israel Innovation Authority of the Ministry of Economy and Industry in Israel, or the IIA, formerly known as the Office of
the Chief Scientist, an independent and impartial public entity, for some of our development programs. Through September&nbsp;30, 2017, we had received grants in the aggregate amount of $2.1&nbsp;million. We may in the future apply to receive
additional grants from the IIA. However, we cannot predict whether we will be entitled to any future grants, or the amounts of any such grants. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A recipient of a
grant from the IIA is obligated to pay royalties generally at a rate of 3% to 5% on revenues from sales of products developed with <FONT STYLE="white-space:nowrap">IIA-funded</FONT> technology, up to the amount of the grant related to any such
products plus accrued interest. Under the R&amp;D Law, a company that received grants from the IIA may not transfer <FONT STYLE="white-space:nowrap">IIA-funded</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
technology or manufacture products developed with <FONT STYLE="white-space:nowrap">IIA-funded</FONT> technology outside of the State of Israel without first obtaining the approval of the IIA. For
example, under the Allergan Agreement, Allergan has the option to manufacture products developed with <FONT STYLE="white-space:nowrap">IIA-funded</FONT> technology outside of Israel and, although Allergan has not yet exercised this option, we have
requested approval from the IIA for a possible transfer, and are currently awaiting their response. We may not receive any such approval upon any request, which could prevent us, for example, from
<FONT STYLE="white-space:nowrap">out-licensing</FONT> our product candidates or complying with our existing agreements. Even if we do receive such approvals, we may be required to pay increased royalties of up to 300% of the amount of the original
grant and other amounts. If we do not receive such approvals, we may be required to pay significant penalties. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2017, new rules published by the IIA for
granting a right to use know- how developed from research and development that was conducted pursuant to a plan approved by the IIA outside of Israel, or Licensing Rules, came into effect. The Licensing Rules allow a recipient of a grant from the
IIA to grant third parties outside of Israel the right to use <FONT STYLE="white-space:nowrap">know-how,</FONT> or License, provided that the IIA authorized the grant of the License. In such case, the recipient of the grant has to pay the IIA for
the License. The amount of payment is based on various factors, including the consideration received by the licensor and, in accordance with the formulas set forth in the Licensing Rules, may equal up to six times the
<FONT STYLE="white-space:nowrap">IIA-funding</FONT> amount plus interest. When the consideration for the grant includes nonmonetary compensation or monetary compensation that is not fixed, or when a &#147;special relationship&#148; exists between
the licensor and licensee (<I>e.g.</I>, when a party controls the other party or is the other party&#146;s exclusive distributor) or when the agreed consideration does not reflect, in the IIA&#146;s opinion, the market value, the IIA may base the
value of the transaction on an economic assessment that it obtains for such purpose. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The IIA may also impose certain conditions on any arrangement under which it
permits us to transfer <FONT STYLE="white-space:nowrap">IIA-funded</FONT> technology outside of the State of Israel. Furthermore, the consideration available to our shareholders in a transaction involving the transfer outside of the State of Israel
of <FONT STYLE="white-space:nowrap">IIA-funded</FONT> technology (such as a merger or similar transaction) may be reduced by any amounts that we are required to pay to IIA. The restrictions under the R&amp;D Law will continue to apply even after we
have repaid the full amount of royalties due to the IIA. If we fail to satisfy the conditions of the R&amp;D Law, we may be required to refund the amounts of the grants previously received, together with interest and penalties, and may become
subject to criminal charges. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Provisions of Israeli law and our amended and restated articles of association may delay, prevent or otherwise impede a merger
with, or an acquisition of, us, even when the terms of such a transaction are favorable to us and our shareholders. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Israeli corporate law regulates
mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such
types of transactions. For example, a tender offer for all of a company&#146;s issued and outstanding shares can only be completed if shareholders not accepting the tender offer hold less than 5% of the issued share capital. Completion of the tender
offer also requires approval of a majority of the offerees that do not have a personal interest in the tender offer, unless shareholders not accepting the tender offer hold less than 2% of the company&#146;s outstanding shares. Furthermore, the
shareholders, including those who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the tender offer, petition an Israeli court to alter the consideration for the acquisition, unless the
acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek such appraisal rights. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, Israeli tax considerations may
make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize <FONT
STYLE="white-space:nowrap">tax-free</FONT> share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of a number
of conditions, including, in some cases, a holding period of two years from the date of the transaction during which sales and dispositions of shares of the participating companies are subject to certain restrictions. Moreover, with respect to
certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no disposition of the shares has occurred. These provisions could delay, prevent or impede an acquisition of us or our
merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>It may be difficult to enforce a judgment of a U.S. court against us, our officers and directors or the Israeli
experts named in this prospectus in Israel or the United States, to assert U.S. securities laws claims in Israel or to serve process on our officers and directors and these experts. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are incorporated in Israel. The majority of our directors and most of our executive officers listed in this prospectus reside outside of the United States, and most
of our assets and most of the assets of these persons are located outside of the United States. Therefore, a judgment obtained against us, or any of these persons, including a judgment based on the civil liability provisions of the U.S. federal
securities laws, may not be collectible in the United States and may not be enforced by an Israeli court. It may also be difficult for you to effect service of process on these persons in the United States or to assert U.S. securities law claims in
original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an
Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be
a time consuming and costly process. Certain matters of procedure will also be governed by Israeli law. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is little binding case law in Israel that addresses
the matters described above. As a result of the difficulty associated with enforcing a judgment against us in Israel, you may not be able to collect any damages awarded by either a U.S. or foreign court. Please see the section entitled
&#147;Enforcement of Civil Liabilities&#148; for additional information on your ability to enforce a civil claim against us and our executive officers or directors named in this prospectus. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Your rights and responsibilities as a shareholder will be governed by Israeli law, which differs in some material respects from the rights and responsibilities of
shareholders of U.S. companies. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The rights and responsibilities of the holders of our ordinary shares are governed by our amended and restated articles of
association and by Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders in U.S. companies. In particular, a shareholder of an Israeli company has a duty to act in good
faith and in a customary manner in exercising its rights and performing its obligations towards the company and other shareholders, and to refrain from abusing its power in the company, including, among other things, in voting at a general meeting
of shareholders on matters such as amendments to a company&#146;s articles of association, increases in a company&#146;s authorized share capital, mergers and acquisitions and related party transactions requiring shareholder approval, as well as a
general duty to refrain from discriminating against other shareholders. In addition, a shareholder who is aware that it possesses the power to determine the outcome of a vote at a meeting of the shareholders or to appoint or prevent the appointment
of a director or executive officer in the company has a duty of fairness toward the company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is limited case law available to assist us in understanding the
nature of these duties or the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities on holders of our ordinary shares that are not typically imposed on shareholders of U.S. companies.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and
expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;assume,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;due,&#148; &#147;estimate,&#148;
&#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;positioned,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148;
&#147;will,&#148; &#147;would,&#148; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are
not limited to, statements about: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and conduct of our clinical trials of MitoGel, VesiGel and our other product candidates, including statements regarding the timing, progress and results of current and future preclinical studies and clinical
trials, and our research and development programs; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of MitoGel, VesiGel and our other product candidates; </TD></TR></TABLE>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans regarding utilization of regulatory pathways that would allow for accelerated marketing approval in the United States; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding timing for application for and receipt of regulatory approval for any of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ongoing and planned discovery and development of product candidates; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding future growth, including our ability to develop, and obtain regulatory approval for, new product candidates; </TD></TR></TABLE>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain adequate intellectual property rights and adequately protect and enforce such rights; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to maintain our collaboration with Allergan, enter into and successfully complete other collaborations, licensing arrangements or <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire rights to other
products, product candidates or technologies; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans to develop and commercialize our product candidates; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding the market opportunity for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding expenses, future revenues, capital requirements and the need for additional financing; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our planned level of capital expenditures and our belief that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next 18
months; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the impact of our research and development expenses as we continue developing product candidates; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the maintenance of our foreign private issuer status; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the impact of government laws and regulations; and </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the use of proceeds from this offering. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Forward-looking statements are based on our
management&#146;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management&#146;s beliefs and assumptions, and are not guarantees of future performance or development and
involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this prospectus may turn out to be inaccurate. Factors that may cause actual
results to differ materially from current expectations include, among other things, those listed under &#147;Risk Factors&#148; and elsewhere in this prospectus. Potential investors are urged to consider these factors carefully in evaluating the
forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The forward-looking statements included in this prospectus speak only as of the date of this prospectus. Although we
believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be
achieved or will occur. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors and
risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus. See &#147;Where You Can Find More Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that the net proceeds from the sale of 1,135,847 ordinary shares in this offering will be approximately $46.3&nbsp;million (or approximately
$53.3&nbsp;million if the underwriters exercise their option to purchase additional ordinary shares in full), after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, based on an assumed public
offering price of $44.02 per ordinary share, which was the last reported sale price of our ordinary shares on the NASDAQ Global Market on January&nbsp;11, 2018. Each $1.00 increase (decrease) in the assumed public offering price of $44.02 per
ordinary share would increase (decrease) the net proceeds to us from this offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, by $1.1&nbsp;million, assuming that the number of ordinary
shares offered by us, as set forth on the cover of this prospectus, remains the same. We may also increase or decrease the number of ordinary shares we are offering. An increase (decrease) of 100,000 in the number of ordinary shares we are offering
would increase (decrease) the net proceeds to us from this offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, by $4.1 million, assuming the assumed public offering price stays the
same. The actual net proceeds we receive will depend on the actual number of ordinary shares offered by us, the actual public offering price and other terms of this offering determined at pricing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to use the net proceeds from this offering, together with our existing cash resources, as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $15.0 million to complete our single pivotal Phase 3 clinical trial of MitoGel for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC; </TD></TR></TABLE>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $10.0 million to begin preparing for the commercial launch of MitoGel, if approved; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $2.0 million to file an IND for, and to initiate our Phase 2b clinical trial of, VesiGel for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC; and </TD></TR></TABLE>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the remainder to fund continued research and clinical development of our other product candidates, including Vesimune, and for working capital and other general corporate purposes. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Due to the uncertainties inherent in the clinical development and regulatory approval process, it is difficult to estimate with certainty the exact amounts of the net
proceeds from this offering that may be used for any of the above purposes on a stand-alone basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pending our application of the net proceeds from this offering,
we plan to invest such proceeds in depositary institutions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_6"></A>MARKET PRICE OF ORDINARY SHARES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ordinary shares have been listed on the NASDAQ Global Market under the symbol &#147;URGN&#148; since May&nbsp;4, 2017. Prior to that date, there was no public
trading market for our ordinary shares. The following table sets forth for the periods indicated the high and low intraday sales prices per ordinary share, as reported on the NASDAQ Global Market: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>HIGH</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LOW</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Annual:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2018 (through January&nbsp;11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Quarterly:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Second quarter 2017 (beginning May&nbsp;4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Third quarter 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fourth quarter 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">First quarter 2018 (through January&nbsp;11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Most Recent Six Months:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">August 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">September 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">October 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">November 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">December 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">January 2018 (through January&nbsp;11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January&nbsp;11, 2018, the last reported sale price of our ordinary shares on the NASDAQ Global Market was $44.02 per share. As of January&nbsp;11, 2018, we had 51
holders of record of our ordinary shares. The actual number of shareholders is greater than this number of record holders and includes shareholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees.
This number of holders of record also does not include shareholders whose ordinary shares may be held in trust or by other entities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never declared or paid cash dividends to our shareholders and we do not intend to pay cash dividends in the foreseeable future. We intend to reinvest any
earnings in developing and expanding our business. Any future determination relating to our dividend policy will be at the discretion of our board of directors in compliance with applicable legal requirements and will depend on a number of factors,
including future earnings, our financial condition, operating results, contractual restrictions, capital requirements, business prospects, our strategic goals and plans to expand our business, applicable law and other factors that our board of
directors may deem relevant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See &#147;Risk Factors&#151;Risks Related to This Offering and Ownership of Our Ordinary Shares&#151;We have never paid cash dividends
on our share capital, and we do not anticipate paying any cash dividends in the foreseeable future&#148; and, for an explanation concerning the payment of dividends under Israeli law, see &#147;Description of Share Capital&#151;Dividend and
Liquidation Rights.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth our cash and cash equivalents and capitalization as of September&nbsp;30, 2017 on an: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual basis; and </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as adjusted basis to give effect to the sale of 1,135,847 ordinary shares in this offering at the assumed public offering price of $44.02 per ordinary share, which was the last reported sale price of our ordinary shares
on the NASDAQ Global Market on January&nbsp;11, 2018, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The as adjusted data included in the table below is also unaudited. You should read this information together with our condensed consolidated interim financial
statements appearing elsewhere in this prospectus and the information set forth under the headings &#147;Selected Financial Data,&#148; &#147;Use of Proceeds&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations.&#148; </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF SEPTEMBER&nbsp;30, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;ADJUSTED<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares, NIS 0.01 par value: 100,000,000 shares authorized at September&nbsp;30, 2017 actual and as
adjusted; 13,178,400 issued and outstanding at September&nbsp;30, 2017, actual; 14,314,247&nbsp;shares issued and outstanding, as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>Each $1.00 increase or decrease in the assumed public offering price of $44.02 per ordinary share, which was the last reported sale price of our ordinary shares on
the NASDAQ Global Market on January&nbsp;11, 2018, would increase or decrease, respectively, each of cash and cash equivalents, total shareholders&#146; equity and total capitalization by $1.1&nbsp;million, assuming the number of ordinary shares
offered by us, as set forth on the cover of this prospectus, remains the same, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 100,000 in the
number of ordinary shares we are offering would increase or decrease, respectively, each of cash and cash equivalents, total equity and total capitalization by $4.1&nbsp;million, assuming the assumed public offering price per ordinary share remains
the same, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. The as adjusted information is illustrative only, and we will adjust this information based on the actual public offering price
and other terms of this offering determined at pricing. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_9"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you invest in our ordinary shares in this offering, your interest will be immediately diluted to the extent of the difference between the public offering price per
ordinary share in this offering and the net tangible book value per ordinary share after this offering. Dilution results from the fact that the public offering price per ordinary share is substantially in excess of the net tangible book value per
ordinary share. As of September&nbsp;30, 2017, we had a historical net tangible book value per ordinary share of $5.79. Our net tangible book value per share represents total tangible assets less total liabilities, all divided by the number of
shares outstanding on September&nbsp;30, 2017. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After giving effect to the sale of ordinary shares in this offering at the assumed public offering price of
$44.02&nbsp;per ordinary share, which was the last reported sale price of our ordinary shares on the NASDAQ Global Market on January&nbsp;11, 2018, and after deducting the underwriting discounts and commissions and estimated offering expenses, our
as adjusted net tangible book value at September&nbsp;30, 2017 would have been $8.56&nbsp;per share. This represents an immediate increase in as adjusted net tangible book value of $2.78&nbsp;per share attributable to this offering and immediate
dilution of $35.46 per ordinary share to investors participating in the offering. The following table illustrates this dilution per ordinary share: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Assumed public offering price per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Historical net tangible book value per ordinary share as of September&nbsp;30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in net tangible book value per share attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">As adjusted net tangible book value per ordinary share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dilution per ordinary share to investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each $1.00 increase or decrease in the assumed public offering price of $44.02&nbsp;per ordinary share, which was the last reported sale price of our ordinary shares on
the NASDAQ Global Market on January&nbsp;11, 2018, would increase or decrease, respectively, our as adjusted net tangible book value as of September&nbsp;30, 2017 after this offering by approximately $0.07&nbsp;per ordinary share, and would increase
or decrease, respectively, dilution to investors in this offering by $0.93&nbsp;per ordinary share, assuming that the number of ordinary shares offered by us, as set forth on the cover of this prospectus, remains the same, and after deducting the
underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 100,000 in the number of ordinary shares we are offering would increase or decrease, respectively, our as adjusted net
tangible book value as of September&nbsp;30, 2017 after this offering by approximately $0.23&nbsp;per ordinary share, and would increase or decrease, respectively, dilution to investors in this offering by approximately $0.23&nbsp;per ordinary
share, assuming the assumed public offering price per ordinary share remains the same, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. The as adjusted information is illustrative only,
and we will adjust this information based on the actual public offering price and other terms of this offering determined at pricing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the underwriters exercise
in full their option to purchase 170,377&nbsp;additional ordinary shares, the as adjusted net tangible book value will increase to $8.95&nbsp;per ordinary share, representing an immediate increase in as adjusted net tangible book value to existing
shareholders of $0.39&nbsp;per ordinary share and an immediate dilution of $35.07&nbsp;per ordinary share to investors participating in this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may
choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity
or convertible debt securities, the issuance of these securities could result in further dilution to our equity holders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The information above is based on
13,178,400 ordinary shares outstanding as of September&nbsp;30, 2017 and assumes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance by us of 1,135,847 ordinary shares in this offering; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">except where indicated otherwise, no exercise of the underwriters&#146; option to purchase up to 170,377&nbsp;additional ordinary shares </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">but excludes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,208,663 ordinary shares reserved for issuance under our 2010 Israeli Share Option Plan upon the exercise of outstanding options at a weighted average exercise price of $4.85 per share; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">375,000 ordinary shares reserved for issuance under our 2017 Equity Incentive Plan upon the exercise of outstanding options at a weighted average exercise price of $20.54 per share; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">329,000 ordinary shares reserved for issuance upon the vesting of outstanding restricted share units; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">278,400 ordinary shares reserved for issuance upon the achievement of certain milestones under the Vesimune asset purchase agreement with Telormedix SA; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,000,000 ordinary shares available for issuance pursuant to the terms of our 2017 Equity Incentive Plan. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_10"></A>SELECTED FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following tables present selected financial data for our business. We derived the statements of operations data for the years ended December&nbsp;31, 2016 and
2015 and the balance sheet data as of December&nbsp;31, 2016 and 2015 from our consolidated audited financial statements and related notes appearing elsewhere in this prospectus. We derived the statements of operations data for the nine months ended
September&nbsp;30, 2017 and 2016 and the balance sheet data as of September&nbsp;30, 2017 from our condensed consolidated unaudited financial statements and related notes appearing elsewhere in this prospectus. Our condensed consolidated unaudited
financial statements have been prepared on the same basis as our consolidated audited financial statements, and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly our
financial position as of September&nbsp;30, 2017 and the results of operations for the nine months ended September&nbsp;30, 2016 and 2017. We maintain our books and records in U.S. dollars, and prepare our financial statements in accordance with
accounting principles generally accepted in the United States, or U.S. GAAP, as issued by the Financial Accounting Standards Board, or FASB. You should read this data together with our financial statements and related notes appearing elsewhere in
this prospectus and the information under the captions &#147;Capitalization&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results are not necessarily indicative of
our future results, and our interim period results are not necessarily indicative of results to be expected for a full year or any other interim period. </I></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED</B><br><B>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Statements of operations data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating loss (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Finance expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss per ordinary share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average number of ordinary shares outstanding used in computing loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,223,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance sheet data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Working capital is defined as total current assets minus total current liabilities. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_11"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following discussion
and analysis should be read in conjunction with &#147;Selected Financial Data&#148; and our financial statements and related notes included elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain
forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the
timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under &#147;Risk Factors&#148; and elsewhere in this prospectus. You should
carefully read the &#147;Risk Factors&#148; section of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled
&#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. We have an
innovative and broad pipeline of product candidates that we believe can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on <FONT STYLE="white-space:nowrap">uro-oncology.</FONT> Our lead
product candidates, MitoGel and VesiGel, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is currently used <FONT STYLE="white-space:nowrap">off-label</FONT> for urothelial cancer treatment only in a
water-based formulation as an adjuvant, or supplemental post-surgery, therapy. We are developing our product candidates as chemoablation agents, which means they are designed to remove tumors by <FONT STYLE="white-space:nowrap">non-surgical</FONT>
means, to treat several forms of <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive urothelial cancer, including <FONT STYLE="white-space:nowrap">low-grade</FONT> upper tract urothelial carcinoma, or UTUC, and
<FONT STYLE="white-space:nowrap">low-grade</FONT> bladder cancer. We believe that MitoGel and VesiGel, which are both local drug therapies, have the potential to significantly improve patients&#146; quality of life by replacing costly, <FONT
STYLE="white-space:nowrap">sub-optimal</FONT> and burdensome tumor resection and kidney removal surgeries as the first-line standard of care. MitoGel and VesiGel may also reduce the need for bladder and upper urinary tract surgeries, including
removal of the upper urinary tract, which are major surgical procedures typically performed when local endoscopic tumor resection fails to control the disease progression. Additionally, we believe that our product candidates, which are based on
formulations of previously approved drugs, may qualify for streamlined regulatory pathways to market approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our lead product candidates, MitoGel and VesiGel,
are formulated using our proprietary reverse thermally triggered hydrogel, or RTGel, technology. We believe that RTGel-based drug formulations, which provide for the sustained release of an active drug, may improve the efficacy of treatment of
various types of urothelial cancer without compromising the safety of the patient or interfering with the natural flow of fluids from the urinary tract to the bladder. Our formulations are designed to achieve this by increasing the dwell time as
well as the tissue coverage of the active drug throughout the organ. Consequently, we believe that RTGel-based drug formulations may enable us to overcome the anatomical and physiological challenges that have historically contributed to the lack of
drug development for the treatment of urothelial cancer. No drugs have been approved by the U.S. Food and Drug Administration, or the FDA, for the treatment of <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive bladder cancer, or NMIBC, in
more than 15 years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our clinical stage pipeline also includes Vesimune, our proprietary immunotherapy product candidate for the treatment of high-grade NMIBC,
which may include Carcinoma in Situ, or CIS. Vesimune is a novel, liquid formulation of Imiquimod, a generic toll-like receptor 7, or TLR7, agonist. Toll-like receptor agonists play a key role in initiating the innate immune response system. We
believe that the combination of Vesimune with additional immunotherapy drugs, such as immune checkpoint inhibitors or chemotherapy drugs like VesiGel, could represent a valid alternative to the current standard of care for the post-TURBT adjuvant
treatment of high-grade NMIBC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">BotuGel is our proprietary novel RTGel-based formulation of BOTOX, a branded drug, that we believe can potentially serve as an
effective treatment option for patients suffering from overactive bladder. In October&nbsp;2016, we announced the licensing of the worldwide rights to RTGel in combination with neurotoxins, including BOTOX, to Allergan Pharmaceuticals International
Limited, or Allergan, a wholly owned subsidiary of Allergan plc, or the Allergan Agreement. In August 2017, we announced that Allergan had submitted an IND to the FDA in order to be able to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
commence clinical trials in the United States using the RTGel in combination with BOTOX. In October 2017, Allergan commenced a Phase 2 clinical trial of BotuGel for the treatment of overactive
bladder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have incurred net losses in each period since our formation in 2004. We incurred net losses of $9.9&nbsp;million and $1.9&nbsp;million for the nine
months ended September&nbsp;30, 2017 and the year ended December&nbsp;31, 2016, respectively. As of September&nbsp;30, 2017, and December&nbsp;31, 2016, our accumulated deficit was $37.1&nbsp;million and $27.2&nbsp;million, respectively. We expect
to continue to incur losses for the foreseeable future, and our losses may fluctuate significantly from year to year. We expect that our expenses will increase substantially in connection with our ongoing activities as we: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conduct the single pivotal Phase 3 clinical trial for MitoGel, and plan to initiate a Phase 2b clinical trial for VesiGel, each pursuant to the FDA&#146;s 505(b)(2) regulatory pathway; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiate an additional clinical trial for Vesimune in combination with another agent; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue the preclinical development of our other product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">file an NDA seeking regulatory approval for any product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any products for which we obtain regulatory approval; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, expand and protect our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add equipment and physical infrastructure to support our research and development; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hire additional clinical development, regulatory, commercial, quality control and manufacturing personnel; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will need substantial additional funding to support our operating activities as we advance our product candidates through clinical development, seek regulatory
approval and prepare for and, if any of our product candidates are approved, proceed to commercialization. Adequate funding may not be available to us on acceptable terms, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Allergan License Agreement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We entered into an exclusive license agreement
with Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc in October 2016, which we refer to as the Allergan Agreement. Allergan paid us a nonrefundable upfront license fee of $17.5&nbsp;million, and
we are eligible to receive additional milestone payments upon the successful completion of certain development, regulatory and commercial milestones. Under the Allergan Agreement, Allergan is solely responsible, at its expense, for developing,
obtaining regulatory approvals for and commercializing on a worldwide basis pharmaceutical products that contain RTGel and clostridial toxins (including BOTOX), alone or in combination with certain other active ingredients, which we refer to
collectively as the Licensed Products. Allergan is obligated to pay us a tiered royalty in the low single digits based on worldwide annual net sales of Licensed Products, subject to certain reductions for the market entry of competing products
and/or loss of our patent coverage of Licensed Products. We are responsible for payments to any third party for certain RTGel-related third party intellectual properties. In July 2017, Allergan notified us that they had submitted their
Investigational New Drug, or IND, application for BotuGel, our proprietary novel RTGel-based formulation of BOTOX for the treatment of overactive bladder, to the FDA. The submission of the IND triggered the second milestone under the Allergan
Agreement, pursuant to which we received a payment of $7.5&nbsp;million in August 2017. Allergan commenced a Phase 2 clinical trial of BotuGel in October 2017, pursuant to Allergan Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Components of Results of Operations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenues </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not currently have any products approved for sale and, to date, we have not recognized any revenues from sales of MitoGel, VesiGel or Vesimune. During the year
ended December&nbsp;31, 2016, we recognized revenues of $17.5&nbsp;million from a payment received under the Allergan Agreement. For the nine months ended September&nbsp;30, 2017, we generated revenues of $7.5&nbsp;million under the Allergan
Agreement upon the achievement of a milestone in August 2017. The remaining revenues we recognized during the nine months ended September&nbsp;30, 2017 are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
related to sales of RTGel to Allergan, per the Allergan Agreement. In the future, we may generate revenue from a combination of product sales, reimbursements,
<FONT STYLE="white-space:nowrap">up-front</FONT> payments, milestone payments and royalties in connection with the Allergan Agreement and future collaborations. If we fail to achieve clinical success and/or to obtain regulatory approval of any of
our product candidates in a timely manner, our ability to generate future revenue will be impaired. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and development expenses, net </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The largest component of our total operating expenses has historically been, and we expect will continue to be, research and development. Research and development
expenses consist primarily of: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">salaries and related costs, including share-based compensation expense, for our personnel in research and development functions; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses incurred under agreements with third parties, including CROs, subcontractors, suppliers and consultants, preclinical studies and clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses incurred to acquire, develop and manufacture preclinical study and clinical trial materials; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">facility and equipment costs, including depreciation expense, maintenance and allocated direct and indirect overhead costs. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expense all research and development costs as incurred. In light of the fact that our employees and internal resources may be engaged in projects for multiple
programs at any time, our focus is on total research and development expenditures, and we do not allocate our internal research and development expenses by project. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Through September&nbsp;30, 2017, we had received grants of $2.1&nbsp;million in the aggregate from the Israeli Innovation Authority, or the IIA, for research and
development funding. Pursuant to the terms of the grants, we are obligated to pay the IIA royalties of 3.0% to 4.5% on revenues from sales of products developed from a project financed in whole or in part by IIA grants, up to a limit of 100% of the
amount of the grant received, plus annual interest calculated at a rate based on <FONT STYLE="white-space:nowrap">12-month</FONT> LIBOR. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to paying any
royalties due, we must abide by other restrictions associated with receiving such grants under the R&amp;D Law, which will continue to apply to us following full repayment to the IIA. For example, under the Allergan Agreement, Allergan has the
option to manufacture products developed with <FONT STYLE="white-space:nowrap">IIA-funded</FONT> technology outside of Israel, which would require approval from the IIA. Although Allergan has not yet exercised this option, we have requested approval
from the IIA for a possible transfer. We may not receive such approval. Even if we do receive such approval, we may be required to pay increased royalties of up to 300% of the amount of the original grant received and other amounts. If the IIA deems
the license to Allergan a technology transfer, we may be required to pay up to 600% of the amount of the original grant and other amounts. The Israeli government grants we have received for research and development activities restrict our ability to
manufacture products and transfer technologies outside of Israel and require us, in addition to the payment of royalties, to satisfy specified conditions. If we fail to satisfy these conditions, we may be required to refund grants previously
received and incur financial penalties. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2017, new rules published by the IIA for granting a right to use know- how developed from research and development
that was conducted pursuant to a plan approved by the IIA outside of Israel, or Licensing Rules, came into effect. The Licensing Rules allow a recipient of a grant from the IIA to grant third parties outside of Israel the right to use <FONT
STYLE="white-space:nowrap">know-how,</FONT> or License, provided that the IIA authorized the grant of the License. In such case, the recipient of the grant has to pay the IIA for the License. The amount of payment is based on various factors,
including the consideration received by the licensor and, in accordance with the formulas set forth in the Licensing Rules, may equal up to six times the <FONT STYLE="white-space:nowrap">IIA-funding</FONT> amount plus interest. When the
consideration for the grant includes nonmonetary compensation or monetary compensation that is not fixed, or when a &#147;special relationship&#148; exists between the licensor and licensee (<I>e.g.</I>, when a party controls the other party or is
the other party&#146;s exclusive distributor) or when the agreed consideration does not reflect, in the IIA&#146;s opinion, the market value, the IIA may base the value of the transaction on an economic assessment that it obtains for such purpose.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are currently focused on advancing our product candidates, and our future research and development expenses will depend on their clinical success. Research and
development expenses will continue to be significant and will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
increase over at least the next several years as we continue to develop our product candidates and conduct preclinical studies and clinical trials of our product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not believe that it is possible at this time to accurately project total expenses required for us to reach commercialization of our product candidates. Due to the
inherently unpredictable nature of preclinical and clinical development, we are unable to estimate with certainty the costs we will incur and the timelines that will be required in the continued development and approval of our product candidates.
Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, if and when
such arrangements will be entered into, if at all, and to what degree such arrangements would affect our development plans and capital requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under
applicable accounting rules, we deduct the IIA grants from research and development expenses as the applicable costs are incurred. We also had a preclinical collaboration for BotuGel with Allergan into which we initially entered into in February
2014. We deduct amounts received from the preclinical collaboration with Allergan from our research and development expenses as the applicable costs are incurred. As a result, our research and development expenses are shown on our financial
statements net of the IIA grants and amounts received from the preclinical collaboration. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>General and administrative expenses </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses consist primarily of personnel costs, including share-based compensation, related to directors, executive, finance, and human
resource functions, facility costs and external professional service costs, including legal, accounting and audit services and other consulting fees. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We anticipate
that our general and administrative expenses will increase in the future as we increase our administrative headcount and infrastructure to support our continued research and development programs and the potential approval and commercialization of
our product candidates. We also anticipate that we will incur increased expenses related to audit, legal, regulatory and <FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with NASDAQ and SEC
requirements, director and officer insurance premiums, executive compensation, and other costs associated with being a public company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, if any of our
product candidates receives regulatory approval and if we invest in building a commercial infrastructure to support the marketing of our products, we expect to incur greater expenses. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Finance expenses, net </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Finance expenses, net, consist primarily of
finance expenses on warrants. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Income taxes </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have yet to
generate taxable income in Israel, as we have historically incurred operating losses resulting in carry forward tax losses totaling approximately $14.2&nbsp;million as of December&nbsp;31, 2016. We anticipate that we will continue to generate tax
losses for the foreseeable future and that we will be able to carry forward these tax losses indefinitely to future taxable years. Accordingly, we do not expect to pay taxes in Israel until we have taxable income after the full utilization of our
carry forward tax losses. We have provided a full valuation allowance with respect to the deferred tax assets related to these carry forward losses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Analysis of Results of Operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparison of the nine months ended September&nbsp;30, 2017 and 2016 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our results of operations for nine months ended September&nbsp;30, 2017 and 2016: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED</B><br><B>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited,&nbsp;in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses, net<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Finance expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes share-based compensation expense as follows: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED</B><br><B>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited,&nbsp;in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Revenues </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our total revenues increased by $7.8&nbsp;million from $0 in the
nine months ended September&nbsp;30, 2016 to $7.8&nbsp;million in the nine months ended September&nbsp;30, 2017. The increase is mainly due to proceeds of $7.5&nbsp;million received from Allergan upon the achievement of a milestone under the
Allergan Agreement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and development expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and
development expenses increased by $4.0&nbsp;million to $11.9&nbsp;million in the nine months ended September&nbsp;30, 2017 from $7.9&nbsp;million in the nine months ended September&nbsp;30, 2016. The increase was attributable mainly to an increase
in direct costs associated with the MitoGel Phase 3 clinical trial of approximately $1.3&nbsp;million, an increase of approximately $1.8&nbsp;million of share-based compensation expenses, and an increase of approximately $672,000 in headcount and
related costs to support increased clinical trial activities. Total research and development <FONT STYLE="white-space:nowrap">non-cash</FONT> share-based expense compensation for the nine months ended September&nbsp;30, 2017 was $2.5&nbsp;million.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and administrative expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative
expenses increased by approximately $186,000 to $5.4&nbsp;million in the nine months ended September&nbsp;30, 2017 from $5.2&nbsp;million in the nine months ended September&nbsp;30, 2016. The increase in general and administrative expenses resulted
primarily from an increase in share-based compensation expense of approximately $892,000, an increase of $937,000 in payroll and recruitment costs due to headcount and related costs to support our growing business, and an increase of $231,000 in
professional service expenses, mostly for consultants we hired in preparation for our initial public offering, or the IPO, director and officer insurance premiums, and other costs associated with being a public company. These increases were offset
by the recording of $1.8&nbsp;million of IPO expenses in the statement of operations in 2016. Total general and administrative <FONT STYLE="white-space:nowrap">non-cash</FONT> share-based expense compensation for the nine months ended
September&nbsp;30, 2017 was $1.5&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Finance expenses, net </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Finance expenses, net, decreased by approximately $1.6&nbsp;million to $122,000 in the nine months ended September&nbsp;30, 2017 from $1.8&nbsp;million in the nine
months ended September&nbsp;30, 2016. The change in finance expenses was primarily due to the increased fair value of the warrants converted to Preferred <FONT STYLE="white-space:nowrap">A-1</FONT> shares, which were recorded in the statement of
operations in 2016. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparison of the years ended December&nbsp;31, 2016 and 2015 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our results of operations for the years ended December&nbsp;31, 2016 and 2015: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED</B><br><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses, net<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Finance expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes share-based compensation expense as follows: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED</B><br><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Revenues </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our total revenues increased by $17.5&nbsp;million from $0 in the
year ended December&nbsp;31, 2015 to $17.5&nbsp;million in the year ended December&nbsp;31, 2016, due to the nonrefundable upfront license fee received under the Allergan Agreement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and development expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses
decreased by $228,000, or 2%, to $10.3&nbsp;million in the year ended December&nbsp;31, 2016 from $10.5&nbsp;million in the year ended December&nbsp;31, 2015. Approximately $4.1&nbsp;million of the decrease relates to
<FONT STYLE="white-space:nowrap">in-process</FONT> research and development costs in connection with intellectual property related to Vesimune that we purchased from Telormedix SA in 2015. This decrease is partly offset by an increase of
$3.9&nbsp;million primarily attributable to an increase in share-based compensation to consultants and employees of $997,000, an increase of $546,000 in payroll mainly due to increased headcount and a $1.2&nbsp;million increase relating to research
and development expense offsets in 2015 from IIA grants and from our prior preclinical collaboration with Allergan for BotuGel. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have assessed that, of our
$10.3&nbsp;million aggregate research and development expenditures in 2016 (after adjusting for an aggregate $49,000 of <FONT STYLE="white-space:nowrap">off-setting</FONT> third-party contributions) approximately 34% were allocated to the
development of MitoGel, approximately 8% were allocated to the development of VesiGel, and approximately 57% were allocated to other products and unallocated expenses. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have assessed that, of our $10.5&nbsp;million aggregate research and development expenditures in 2015 (after adjusting for an aggregate $1.2&nbsp;million of <FONT
STYLE="white-space:nowrap">off-setting</FONT> third-party contributions) approximately 30% were allocated to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the development of MitoGel, approximately 5% were allocated to the development of VesiGel, approximately 35% were allocated to the development of Vesimune, and approximately 30% were allocated to
other products and unallocated expenses. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and administrative expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses increased by $4.5&nbsp;million, or 237%, to $6.4&nbsp;million in the year ended December&nbsp;31, 2016 from $1.9&nbsp;million in the
year ended December&nbsp;31, 2015. The increase in general and administrative expenses resulted primarily from an increase in share-based compensation expense to employees and directors of $521,000, an increase of $773,000 in payroll and an increase
in professional services expenses of $2.8&nbsp;million of which $1.7&nbsp;million relates to this offering. The increase was primarily related to our strengthening of our senior management team and payments to professional services consultants hired
by us in preparation for this offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Finance expenses, net </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Finance
expenses, net increased by $2.4&nbsp;million, or 800%, to $2.7&nbsp;million in the year ended December&nbsp;31, 2016 from $279,000 in the year ended December&nbsp;31, 2015. The change in finance expense was primarily due to the increased fair value
of the warrants converted to Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidity </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our inception, we have incurred losses and negative
cash flows from our operations. For the year ended December&nbsp;31, 2016, we incurred a net loss of $1.9&nbsp;million while net cash of $4.2&nbsp;million was provided from our operating activities. As of December&nbsp;31, 2016, we had working
capital of $18.9&nbsp;million, and an accumulated deficit of $27.2&nbsp;million. Our principal source of liquidity as of December&nbsp;31, 2016 consisted of cash and cash equivalents of $21.4&nbsp;million. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the nine months ended September&nbsp;30, 2017, we incurred a net loss of $9.9&nbsp;million and used net cash of $3.6&nbsp;million in our operating activities. As of
September&nbsp;30, 2017, we had working capital of $75.5&nbsp;million, and an accumulated deficit of $37.1&nbsp;million. Our principal source of liquidity as of September&nbsp;30, 2017 consisted of cash and cash equivalents of $79.2&nbsp;million. We
believe that our existing cash and cash equivalents will enable us to fund our operating and capital expenditure requirements for at least the next 18 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Capital resources </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Overview </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Through December&nbsp;31, 2016, we have financed our operations primarily through private placements of equity securities and through the upfront payment received under
the Allergan Agreement. In May 2017, we raised $60.8&nbsp;million, net of issuance costs and underwriting discounts and commissions, in our IPO on the NASDAQ Stock Market. In August 2017, we received $7.5&nbsp;million from Allergan upon the
achievement of a milestone under the Allergan Agreement. In addition, during the year ended December&nbsp;31, 2016, we recorded $1.7&nbsp;million in general and administrative expenses related to IPO costs, in accordance with SEC staff Bulletin
Topic 5A. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash flows </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our
statement of cash flows for the nine months ended September&nbsp;30, 2017 and 2016: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED</B><br><B>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited,&nbsp;in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,609</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(672</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Net cash provided by (used in) operating activities </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The cash used in operating activities during the aforementioned periods resulted primarily from our net losses incurred during such periods, as adjusted for <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges and measurements and changes in components of working capital. Adjustments to net losses for <FONT STYLE="white-space:nowrap">non-cash</FONT> items mainly included depreciation and amortization,
fair value adjustment of the Preferred <FONT STYLE="white-space:nowrap">A-1</FONT> warrants and share-based compensation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities was
$3.6&nbsp;million during the nine months ended September&nbsp;30, 2017, compared to $9.2&nbsp;million used in operating activities during the nine months ended September&nbsp;30, 2016. The $5.6&nbsp;million decrease in cash used was attributable
primarily to the receipt of the milestone payment from Allergan of $7.5&nbsp;million, which was partially offset by an increase in expenditures related to the MitoGel Phase 3 clinical trial of approximately $1.3&nbsp;million, as well as an increase
in personnel related costs to support our growing business and service provider costs related to becoming a public company. These increases were offset by the recording of $1.8&nbsp;million of IPO expenses in 2016. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Net cash used in investing activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The use of cash in investing
activities relates primarily to the purchase of property and equipment and changes in restricted deposits. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities was $223,000
during the nine months ended September&nbsp;30, 2017, compared to $672,000 during the nine months ended September&nbsp;30, 2016. The decrease of $449,000 is primarily related to leasehold improvements in our Israel and U.S. offices performed during
the nine months ended September&nbsp;30, 2016, which costs did not recur in the nine months ended September&nbsp;30, 2017. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Net cash provided by (used in)
financing activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities was $61.6&nbsp;million during the nine months ended September&nbsp;30, 2017, compared to $60,000
during the nine months ended September&nbsp;30, 2016. The difference is primarily related to the net proceeds received from our IPO in May 2017. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following
table summarizes our statement of cash flows for the years ended December&nbsp;31, 2016 and 2015: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED</B><br><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Net cash provided by (used in) operating activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The use of cash in 2015
and the cash provided in 2016 resulted primarily from our net losses adjusted for <FONT STYLE="white-space:nowrap">non-cash</FONT> charges and measurements and changes in components of working capital. Adjustments to net loss for <FONT
STYLE="white-space:nowrap">non-cash</FONT> items mainly include depreciation and amortization, fair value adjustment of the preferred <FONT STYLE="white-space:nowrap">A-1</FONT> warrants, share-based compensation and
<FONT STYLE="white-space:nowrap">in-process</FONT> R&amp;D. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by operating activities was $4.2&nbsp;million in the year ended December&nbsp;31,
2016, compared to $7.2&nbsp;million used in operating activities in the year ended December&nbsp;31, 2015. The $11.4&nbsp;million increase was attributable primarily to the decrease of $10.8&nbsp;million in losses for the year which mainly related
to the $17.5&nbsp;million revenue from Allergan, partly offset by an increase of $4.5&nbsp;million in general and administrative expenses as a result of strengthening our senior management team and payments to professional services consultants hired
by us in preparation for this offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Net cash used in investing activities </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The use of cash in investing activities relates primarily to the purchase of property and equipment and changes in restricted deposits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities was $793,000 in the year ended December&nbsp;31, 2016, compared to $301,000 in
the year ended December&nbsp;31, 2015. The use of cash in investing activities mainly related to leasehold improvements in the Israeli and U.S. offices. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Net
cash provided by (used in) financing activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2015, we entered into a share purchase agreement, or the 2015 Share Purchase Agreement. In September
2014, we entered into a share purchase agreement, or the 2014 Share Purchase Agreement. During 2015, we raised $18.1&nbsp;million from the 2015 Share Purchase Agreement and $3.6&nbsp;million from the 2014 Share Purchase Agreement. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in financing activities was $9,000 in the year ended December&nbsp;31, 2016, compared to $21.6&nbsp;million provided by financing activities in the year
ended December&nbsp;31, 2015, the difference of which mainly related to funds raised pursuant to the 2015 and 2014 Share Purchase Agreements. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Funding
Requirements </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements for at
least the next 18 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our present and future funding requirements will depend on many factors, including, among other things: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the progress, timing and completion of clinical trials for MitoGel and VesiGel; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preclinical studies and clinical trials for Vesimune or any of our other product candidates; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs related to obtaining regulatory approval for MitoGel, VesiGel and Vesimune and any of our other product candidates, and any delays we may encounter as a result of regulatory requirements or adverse clinical
trial results with respect to any of these product candidates; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selling, marketing and patent-related activities undertaken in connection with the commercialization of MitoGel and VesiGel and any of our other product candidates, and costs involved in the development of an effective
sales and marketing organization; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs involved in filing and prosecuting patent applications and obtaining, maintaining and enforcing patents or defending against claims or infringements raised by third parties, and license royalties or other
amounts we may be required to pay to obtain rights to third party intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential new product candidates we identify and attempt to develop; and </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">revenues we may derive either directly or in the form of royalty payments from future sales of MitoGel, VesiGel, Vesimune, BotuGel and any other product candidates. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional
funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization
efforts<B>.</B> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Until such time, if ever, as we can generate substantial product revenue, we may finance our cash needs through a combination of equity offerings,
debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of any
additional securities may include liquidation or other preferences that adversely affect your rights as a shareholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific
actions, such as incurring additional debt, making capital expenditures or declaring dividends. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we raise funds through additional collaborations, strategic
alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If
we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product
candidates that we would otherwise prefer to develop and market ourselves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For more information as to the risks associated with our future funding needs, see &#147;Risk Factors&#151;We will
require substantial additional financing to achieve our goals, and a failure to obtain this capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, commercialization
efforts or other operations.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Contractual obligations and commitments </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our known contractual obligations as of December&nbsp;31, 2016 are summarized in the following table. The obligations detailed below do not include grants received from
the IIA pursuant to which we will owe royalties or reimbursement upon commercialization of our product candidates. As of December&nbsp;31, 2016, the maximum royalty amount payable by us under these funding arrangements is $2.1&nbsp;million,
excluding interest. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAYMENTS DUE BY PERIOD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LESS&nbsp;THAN&nbsp;1&nbsp;YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>1&nbsp;TO&nbsp;3&nbsp;YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>3&nbsp;TO&nbsp;7&nbsp;YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease obligations<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Operating lease obligations consist of payments pursuant to lease agreements for our Israeli offices and laboratory facility and our New York offices. In November 2014, we entered into a lease agreement for our Israeli
offices effective from February&nbsp;1, 2015 for a period of three years, with an option to extend the lease agreement by an additional three years. In April 2016, we signed an addendum to the November 2014 lease agreement in order to increase the
office space rented and extend the rental period. In November 2017, we signed an additional addendum to the November 2014 lease agreement in order to increase the office space rented. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In November 2015, Urogen Pharma, Inc. entered into a lease agreement for its previous New York office for a period of seven years, which period commenced on May&nbsp;1, 2016. In September 2017, Urogen Pharma, Inc.
entered into a new lease agreement for its current New York office for a period of approximately 41 months, which period commenced in October 2017. The new lease agreement will terminate on February&nbsp;1, 2021, unless earlier terminated in
accordance with its terms. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Off-balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of the date of this prospectus and during the periods presented, we do not and did not, respectively, have any <FONT STYLE="white-space:nowrap">off-balance</FONT>
sheet arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quantitative and Qualitative Disclosure about Market Risk </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Market risk is the risk of loss related to changes in market prices, including interest rates and foreign exchange rates, of financial instruments that may adversely
impact our financial position, results of operations or cash flows. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Foreign currency exchange risk </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The U.S. dollar is our functional and reporting currency. However, a significant portion of our operating expenses are incurred in NIS. As a result, we are exposed to
the risk that the NIS may appreciate relative to the dollar, or, if the NIS instead devalues relative to the dollar, that the inflation rate in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag
behind inflation in Israel. In any such event, the dollar cost of our operations in Israel would increase and our dollar-denominated results of operations would be adversely affected. We cannot predict any future trends in the rate of inflation in
Israel or the rate of devaluation, if any, of the NIS against the dollar. For example, although the dollar appreciated against the NIS in 2015 by 0.3%, the level of devaluation of the dollar against the NIS in 2016 was 1.5%. If the dollar cost of
our operations in Israel increases, our dollar-measured results of operations will be adversely affected. Our operations also could be adversely affected if we are unable to effectively hedge against currency fluctuations in the future. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not currently engage in currency hedging activities in order to reduce this currency exposure, but we may begin to do so in the future. Instruments that may be
used to hedge future risks may include foreign currency forward and swap contracts. These instruments may be used to selectively manage risks, but there can be no assurance that we will be fully protected against material foreign currency
fluctuations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidity risk </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We monitor forecasts of our
liquidity reserve (comprising cash and cash equivalents and deposits). We generally carry this out based on our expected cash flows in accordance with practice and limits set by our management. We are in the research and development stage and we are
therefore exposed to liquidity risk. However, we believe that our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements for at least the next 18 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical Accounting Policies and Estimates </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our management&#146;s discussion
and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. GAAP, as issued by the FASB. The preparation of our financial statements requires us to make
estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting
periods. Actual results may differ from these estimates under different assumptions or conditions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While our significant accounting policies are more fully
described in the notes to our financial statements appearing elsewhere in this prospectus, we believe that the accounting policies discussed below are critical to our financial results and to the understanding of our past and future performance, as
these policies relate to the more significant areas involving management&#146;s estimates and assumptions. We consider an accounting estimate to be critical if: (i)&nbsp;it requires us to make assumptions because information was not available at the
time or it included matters that were highly uncertain at the time we were making our estimate and (ii)&nbsp;changes in the estimate could have a material impact on our financial condition or results of operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Share-Based Compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We account for our share-based compensation
for employees and directors in accordance with the provisions of ASC 718, Compensation&#151;Stock Compensation, U.S. GAAP &#147;Stock-based Payment,&#148; which requires us to measure the cost of share-based compensation based on the fair value of
the award on the grant date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We <FONT STYLE="white-space:nowrap">re-measure</FONT> equity awards granted to <FONT STYLE="white-space:nowrap">non-employees</FONT>
at each reporting period at fair value until they have vested. The fair value of equity awards is charged to the statement of operations over the service period using the straight- line method. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Option Valuations </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We selected the Black-Scholes option pricing model
as the most appropriate method for determining the estimated fair value of our share-based awards. The resulting cost of a share incentive award is recognized as an expense over the requisite service period of the award, which is usually the vesting
period. We recognize compensation expense over the vesting period using the straight-line method, and classify these amounts in the financial statements based on the department to which the related employee reports. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The determination of the grant date fair value of options using an option pricing model is affected by estimates and assumptions regarding a number of complex and
subjective variables. These variables include the expected volatility of our share price over the expected term of the options, share option exercise and cancellation behaviors, risk-free interest rates and expected dividends, which are estimated as
follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Fair value of our ordinary shares</I>. Because our shares are not publicly traded, we must estimate the fair value of ordinary shares, as discussed below in &#147;&#151;Valuation of our ordinary shares.&#148;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Volatility</I>. The expected share price volatility was based on the historical volatility of the ordinary shares of comparable companies that are publicly traded. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected term</I>. The expected term of options granted represents the period of time that options granted are expected to be outstanding. Since adequate historical experience is not available to provide a reasonable
estimate, the expected term for grants to employees for at the money options (except senior management) is determined based on the midpoint between the available exercise dates (the end of the vesting periods) and the last available exercise date
(the contracted expiry date). The expected term for grants to <FONT STYLE="white-space:nowrap">non-employees,</FONT> senior management, directors, and out of the money options granted to employees, is determined based on the contractual life of the
options. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Risk-free rate</I>. The risk-free interest rate is based on the yield from U.S. Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> bonds with a term equivalent to the expected term of the options.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected dividend yield</I>. We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future. Consequently, we used an expected dividend yield of zero.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of the assumptions used in the Black-Scholes option pricing model change significantly, share-based
compensation for future awards may differ materially compared with the awards granted previously. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table presents the weighted-average assumptions
used to estimate the fair value of options granted on the dates indicated below. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED</B><br><B>DECEMBER&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED</B><br><B>DECEMBER&nbsp;31,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility (%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">72.72&nbsp;-&nbsp;80.00</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">69.78&nbsp;-&nbsp;76.68</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.8&nbsp;-&nbsp;8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;-&nbsp;7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free rate (%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4&nbsp;-&nbsp;2.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38&nbsp;-&nbsp;2.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield (%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table presents the grant dates, number of underlying shares and related exercise prices of options granted to employees and
<FONT STYLE="white-space:nowrap">non-employees</FONT> since January&nbsp;1, 2015 through December&nbsp;31, 2016, as well as the estimated fair value of the underlying ordinary shares on the grant date. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:60.15pt; font-size:8pt; font-family:ARIAL"><B>DATE OF GRANT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>SHARES</B><br><B>SUBJECT TO</B><br><B>AWARDS</B><br><B>GRANTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CLASS&nbsp;OF</B><br><B>SHARES</B><br><B>SUBJECT&nbsp;TO</B><br><B>THE</B><br><B>AWARDS</B><br><B>GRANTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TYPE OF</B><br><B>EQUITY</B><br><B>INSTRUMENT</B><br><B>AWARDED</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EXERCISE</B><br><B>PRICE&nbsp;PER</B><br><B>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ESTIMATED</B><br><B>FAIR&nbsp;VALUE</B><br><B>PER&nbsp;ORDINARY</B><br><B>SHARE AT</B><br><B>GRANT DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">August &#150; September 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291,405<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">ordinary</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Options&nbsp;and&nbsp;RSUs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0&nbsp;-&nbsp;5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">October &#150; December 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,011,192<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">ordinary</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">1.78&nbsp;-&nbsp;5.94</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">January 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">ordinary</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">April &#150; June 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">ordinary</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0&nbsp;-&nbsp;5.94</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">3.19&nbsp;-&nbsp;3.28</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">November 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">ordinary</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes 28,800 ordinary shares issuable upon the vesting of restricted share units, which were granted contingent upon the consummation of the completed purchase of intellectual property from Telormedix SA, and
excludes 28,800 ordinary shares issuable upon the vesting of restricted share units, the grant of which was contingent upon the closing of our IPO. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Excludes 9,600 ordinary shares issuable upon the vesting of options, the grant of which was contingent upon the closing of our IPO. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on our initial public offering price of $13.00 per share, the intrinsic value of the awards outstanding as of December&nbsp;31, 2016 was $23.3&nbsp;million, of
which $12.7&nbsp;million related to vested options and $10.6&nbsp;million related to unvested options. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Valuation of our ordinary shares </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Due to the absence of an active market for our ordinary shares, the fair value of our ordinary shares for purposes of determining the exercise price for award grants
was determined in good faith by our management during the fourth quarter of 2015 in relation to grants up to September&nbsp;30, 2015 and during the first, second, third and fourth quarters of 2016. In connection with preparing our financial
statements, our management considered the fair value of our ordinary shares based on a number of objective and subjective factors, consistent with the methodologies outlined in the American Institute of Certified Public Accountants Practice Aid,
Valuation of Privately-Held- Company Equity Securities Issued as Compensation, referred to as the AICPA Practice Aid. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2010-2013 Awards </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ordinary share price was estimated based on the price at which the most recent financing (from external investors) took place, based on our assumption that no
significant changes have occurred between the financing closing date and the grant date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2014 Awards </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ordinary
share price was derived from the price used in the financing round on October&nbsp;20, 2014, based on our assumption that no significant changes have occurred between grant date and the financing round closing date. The derivation of ordinary share
price was performed under the option pricing method, or OPM, valuation framework, as described below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2015 and 2016 Awards </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ordinary share price was estimated based on valuations performed as of September&nbsp;30, 2015, November&nbsp;15, 2015, December&nbsp;31, 2015, March&nbsp;31, 2016,
June&nbsp;30, 2016, September&nbsp;30, 2016 and December&nbsp;31, 2016, as described below, and based on our assumption that no significant changes have occurred between grant date and the valuation date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Fair value of our ordinary shares for 2014 Awards&#151;Methodology </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
valuation of the ordinary shares as of October&nbsp;20, 2014 was performed under the OPM framework and using the Backsolve method, which infers the equity value consistent with the financing round on October&nbsp;20, 2014. The OPM method is regarded
as a common framework for allocating the equity value between the different share classes and other securities. Under this approach, the financial instruments issued by the company (preferred shares, warrants, employee options and ordinary shares)
are deemed as contingent claims whose future payoffs depends on our (future) equity value. The OPM was implemented by using the Monte Carlo simulation technique, which generates different scenarios of the equity value and the resulting payoff to the
holders of our financial instruments. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underlying asset, or the equity value, was estimated by implementing the Backsolve method. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the above allocation process, we applied a discount of lack of marketability, or DLOM, to the price of an ordinary share. Specifically, we applied the average
strike put option in order to estimate the DLOM. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Fair value of our ordinary shares for 2015 and 2016 Awards&#151;Methodology </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The probability of an IPO event in the near future was estimated to be 20% as of December&nbsp;31, 2016, September&nbsp;30, 2016, June&nbsp;30, 2016 and March&nbsp;31,
2016, and 15% as of December&nbsp;31, 2015. The valuation was conducted through the use of the Hybrid model. The Hybrid approach combines two probability-weighted scenarios: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Scenario I&#151;IPO Event. The probability of this scenario was estimated at 20% and 15% as of the valuation dates described above. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The valuation of our financial instruments was based on the estimated range of equity value upon an IPO and the resulting payoff per each financial instrument. </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Scenario II&#151;Liquidation Event. The probability of this scenario was estimated at 80% and 85% as of the valuation dates described above. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The valuation of the ordinary share price under this scenario was performed under the OPM framework using the Monte Carlo simulation technique, in similar fashion to
the approach used for the 2014 valuation, as described above. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of September&nbsp;30, 2015, the financing round in October 2015 was highly expected to be closed.
As such the equity value used in the OPM method was derived from this financing round (the Backsolve method). The closing date of this round was November&nbsp;15, 2015. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of September&nbsp;30, 2016, the equity value used in the OPM method was derived from the financing round in October 2015 and the incremental value derived from the
Allergan Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2016, the equity value used in the OPM method was derived from a DCF calculation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We applied a DLOM to the ordinary share price, using the average strike put option. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of an ordinary share was calculated as the weighted average of the ordinary share prices, derived from the calculations made under the two scenarios
described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Future option awards </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the completion of our initial public offering and the listing of our shares on the NASDAQ Global Market, the determination of the fair market value of our
ordinary shares for purposes of setting the exercise price of future option awards or other share-based compensation to employees and other grantees is based on the market price of our shares and no longer requires good faith estimates by our board
of directors based on various comparisons or benchmarks. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Accounting treatment of the warrants to purchase preferred shares </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our warrants to purchase preferred shares were exercisable into <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> preferred shares of the company, nominal value
NIS&nbsp;0.01 per share, for an exercise price of $7.81 per share commencing on the date of the issuance and expiring at the earlier of a qualified IPO, certain M&amp;A events, or four years from the date of issuance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event that the warrants were exercised in connection with a qualified IPO or certain M&amp;A events, the holder had the option to elect to convert the warrants
on a net share basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The warrants were classified as liabilities in accordance with ASC&nbsp;480, as they were freestanding instruments, exercisable into <FONT
STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> preferred shares, which were redeemable upon certain events that represent &#147;Deemed Liquidation&#148; events. Accordingly, the warrants were measured at fair value at the end of every reporting
period, and changes in their fair value were recognized in earnings. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Accounting treatment of the Series A Preferred Shares </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Series A preferred shares were classified within permanent equity because they were not subject to liability classification under the scope of ASC&nbsp;480, and
because they met all of the requirements for equity classification under <FONT STYLE="white-space:nowrap">ASC&nbsp;480-10S99.</FONT> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Accounting treatment of
intellectual property assets purchased from Telormedix SA </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2015, we entered into an asset purchase agreement with Telormedix SA pursuant to which
we purchased all of the intellectual property assets of Telormedix in consideration of 691,200 shares of our Series A preferred shares at a price per share of $5.94. Upon the occurrence of each of three specified regulatory milestones, we are
required to issue an additional 92,800 ordinary shares to Telormedix, for an aggregate potential maximum amount of 278,400 ordinary shares. In April 2017, Telormedix transferred 135,200 Series A preferred shares and the right to receive an
additional aggregate of 54,462 Series A preferred shares upon the occurrence of the milestones to ProQuest, and 80,800 Series A preferred shares and the right to receive an additional 32,538 Series A preferred shares upon the occurrence of the
milestones to Aravis Venture I L.P. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The acquired intellectual property costs totaling $4.1&nbsp;million were expensed as incurred to research and development costs
in accordance with ASC&nbsp;730, as the intellectual property is purchased from others for a particular research and development project and has no alternative future uses and therefore no separate economic value. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenue recognition </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Virtually all the Company&#146;s revenues are
derived from the license agreement with Allergan, to license worldwide rights to some of its products. Revenue is recognized only when all of the following conditions have been met: (i)&nbsp;there is persuasive evidence of an arrangement;
(ii)&nbsp;delivery has occurred: (iii)&nbsp;the fee is fixed or determinable: and (iv)&nbsp;collectability of the fee is reasonably assured. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The license agreement
contains two deliverables: (a)&nbsp;the license component and (b)&nbsp;Allergan&#146;s right to require supply services of RTGel vials from the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In an
arrangement with multiple deliverables, the delivered item or items shall be considered a separate unit of accounting if all of the following criteria are met: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(a)&nbsp;The delivered item or items have value to the customer on a standalone basis. The item or items have value on a standalone if they are sold separately by any
vendor or the customer could resell the delivered item(s) on a standalone basis. In the context of a customer&#146;s ability to resell the delivered item(s), this criterion does not require the existence of an observable market for the
deliverable(s), and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(b)&nbsp;If the arrangement includes a general right of return relative to the delivered item(s), delivery or
performance of the undelivered item or items is considered probable and substantially in the control of the vendor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When deliverables are separable, arrangement
consideration is allocated to the separate units of accounting based on the relative selling price of each deliverable (where the amount allocable to the delivered element is limited to the amount not contingent on the delivery of future products or
services) and the appropriate revenue recognition principles are applied to each unit. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The license component has standalone value (and therefore is accounted for
separately from the supply services) since Allergan can use the license for its intended purposes without the Company&#146;s supply services. The four conditions of ASC&nbsp;605 were met as of December&nbsp;31, 2016: (1)&nbsp;persuasive evidence of
an arrangement exists since the Company and Allergan engaged with a binding agreement; (2)&nbsp;delivery has occurred or services have been rendered since all documents and data Allergan has requested relating to the Company&#146;s <FONT
STYLE="white-space:nowrap">know-how</FONT> were provided before December&nbsp;31, 2016 and Allergan can use the license for its intended purposes without the supply services (except for immaterial support services); (3)&nbsp;the fee is fixed or
determinable, as indicated in the license agreement; and (4)&nbsp;collectability is reasonably assured. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Therefore, as of December&nbsp;31, 2016, the consideration
received in an amount of $17.5&nbsp;million represents arrangement consideration for both the license of the intellectual property as well as Allergan&#146;s right to future supply services (which would be provided in consideration for future
payments to the Company according to the pricing stipulated in the supply agreement). The Company determined that the pricing of the supply services represents their standalone selling price. Accordingly, the Company allocated the entire upfront fee
of $17.5&nbsp;million to the license component. In addition, revenue from the supply services would be recorded in an amount equal to the consideration stipulated in the agreement for these services, when these services are provided. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As described in Note&nbsp;1, the Company is also entitled to milestone payments and royalties based on Allergan&#146;s revenue from its product, which are not
considered fixed or determinable until their occurrence. Therefore, these amounts would only be recognized when the conditions for payment are met, and they become due and payable. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Deferred taxes </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Income taxes are computed using the asset and
liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently
enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. We have provided a full valuation allowance with respect to its
deferred tax assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See note 2r of
the accompanying audited financial statements and note&nbsp;3 of the accompanying unaudited financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Internal Control Over Financial Reporting
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Failure to achieve and maintain effective internal controls in accordance with Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act,
could have a material adverse effect on our business, results of operation or financial condition. In addition, current and potential shareholders could lose confidence in our financial reporting, which could have a material adverse effect on the
price of our ordinary shares. Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act and the related rules adopted by the SEC and the Public Company Accounting Oversight Board, starting with the second annual report that we file with the SEC
following the consummation of our initial public offering, our management will be required to report on the effectiveness of our internal control over financial reporting. In addition, once we no longer qualify as an &#147;emerging growth
company&#148; under the JOBS Act and lose the ability to rely on the exemptions related thereto discussed above, our independent registered public accounting firm will also need to attest to the effectiveness of our internal control over financial
reporting under Section&nbsp;404. We have not yet commenced the process of determining whether our existing internal controls over financial reporting systems are compliant with Section&nbsp;404 and whether there are any material weaknesses or
significant deficiencies in our existing internal controls. This process will require the investment of substantial time and resources, including by our Chief Financial Officer and other members of our senior management. In addition, we cannot
predict the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
outcome of this determination and whether we will need to implement remedial actions in order to implement effective control over financial reporting. The determination and any remedial actions
required could result in us incurring additional costs that we did not anticipate. Irrespective of compliance with Section&nbsp;404, any failure of our internal controls could have a material adverse effect on our stated results of operations and
harm our reputation. As a result, we may experience higher than anticipated operating expenses, as well as higher independent auditor fees during and after the implementation of these changes. If we are unable to implement any of the required
changes to our internal control over financial reporting effectively or efficiently or are required to do so earlier than anticipated, it could adversely affect our operations, financial reporting and/or results of operations and could result in an
adverse opinion on internal controls from our independent auditors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>JOBS Act </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As an &#147;emerging growth company,&#148; as defined in the JOBS Act, we may take advantage of certain temporary exemptions from various reporting requirements,
including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes Oxley Act (and the rules and regulations of the SEC thereunder). When these exemptions cease to apply, we
expect to incur additional expenses and devote increased management effort toward ensuring compliance with them. We cannot predict or estimate the amount of additional costs we may incur as a result of becoming a public company or the timing of such
costs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The JOBS Act additionally permits emerging growth companies such as us to take advantage of an extended transition period to comply with new or revised
accounting standards applicable to public companies. We have irrevocably elected not to avail ourselves of this provision and, as a result, we will comply with new or revised accounting standards as other public companies that are not emerging
growth companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_12"></A>BUSINESS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical stage biopharmaceutical company focused on
developing novel therapies designed to change the standard of care for urological pathologies. We have an innovative and broad pipeline of product candidates that we believe can overcome the deficiencies of current treatment options for a variety of
urological conditions with a focus on <FONT STYLE="white-space:nowrap">uro-oncology.</FONT> Our lead product candidates, MitoGel and VesiGel, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is
currently used <FONT STYLE="white-space:nowrap">off-label</FONT> for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. We are developing our product candidates as chemoablation
agents, which means they are designed to remove tumors by <FONT STYLE="white-space:nowrap">non-surgical</FONT> means, to treat several forms of <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive urothelial cancer, including <FONT
STYLE="white-space:nowrap">low-grade</FONT> upper tract urothelial carcinoma, or UTUC, and <FONT STYLE="white-space:nowrap">low-grade</FONT> bladder cancer. We believe that MitoGel and VesiGel, which are both local drug therapies, have the potential
to significantly improve patients&#146; quality of life by replacing costly, <FONT STYLE="white-space:nowrap">sub-optimal</FONT> and burdensome tumor resection and kidney removal surgeries as the first-line standard of care. MitoGel and VesiGel may
also reduce the need for bladder and upper urinary tract surgeries, including removal of the upper urinary tract, which are major surgical procedures typically performed when local endoscopic tumor resection fails to control the disease progression.
Additionally, we believe that our product candidates, which are based on novel formulations of previously approved drugs, may qualify for streamlined regulatory pathways to market approval. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our lead product candidates, MitoGel and VesiGel, are formulated using our proprietary reverse thermally triggered hydrogel, or RTGel, technology. We believe that
RTGel-based drug formulations, which provide for the sustained release of an active drug, may improve the efficacy of treatment of various types of urothelial cancer without compromising the safety of the patient or interfering with the natural flow
of fluids from the urinary tract to the bladder. Our formulations are designed to achieve this by increasing the dwell time as well as the tissue coverage of the active drug throughout the organ. Consequently, we believe that RTGel-based drug
formulations may enable us to overcome the anatomical and physiological challenges that have historically contributed to the lack of drug development for the treatment of urothelial cancer. No drugs have been approved by the U.S. Food and Drug
Administration, or the FDA, for the treatment of <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive bladder cancer, or NMIBC, in more than 15 years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
are currently evaluating the safety and efficacy of MitoGel, our novel sustained-release formulation of MMC, in patients with <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC in a Phase 3 pivotal,
<FONT STYLE="white-space:nowrap">single-arm,</FONT> open label clinical trial, which follows a recently completed &#147;Compassionate Use&#148; program for MitoGel for the treatment of the same indication. &#147;Compassionate Use&#148; is the use
outside of a clinical trial of an investigational, or not approved, medical product when patient enrollment in a clinical trial is not possible, typically due to patient ineligibility or a lack of ongoing clinical trials. In the Compassionate Use
Program, 22 patients were enrolled, 18 of which had confirmed <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC. Of the 18 patients, 13&nbsp;patients had completed the <FONT STYLE="white-space:nowrap">six-weekly</FONT> treatment regimen and
were evaluated for tumor response. These 13 patients were evaluated for tumor response at the primary evaluation time either endoscopically or through the use of a nonsurgical viewing instrument. Complete response was confirmed by a cytology (urine)
confirmation in most cases. Of these 13 patients, eight, or approximately 62%, achieved a complete response, with a median durability of response without recurrence of greater than nine months to date, based on investigator reports. Our analysis of
the median recurrence-free durability of those patients who achieved a complete response is still ongoing, with, to our knowledge, only three of the eight patients recurring to date. To date, of the five patients still ongoing without recurrence, to
our knowledge, three have durability of response of 12 months or greater. Recurrences were generally of small tumors, presenting with diameters of several millimeters in size that were consequently managed by endoscopic tumor resection. Importantly,
of the eight patients that achieved a complete response, or a complete response following an initial partial response, four had a solitary kidney. As all the patients in the Compassionate Use program were candidates for a nephroureterectomy, these
four patients otherwise may have had their solitary kidney removed and become dialysis patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Five out of the 13 evaluated patients achieved a partial response
at the primary evaluation time. One patient who achieved a partial response received three additional monthly courses of MitoGel, and thereafter achieved a complete response. In this Compassionate Use program, MitoGel had been observed to be
well-tolerated. We have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
obtained Orphan Drug Designation for MitoGel for the treatment of UTUC as well as Fast Track Designation for the treatment of patients with <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC
not amenable to endoscopic resection or contraindicated for nephroureterectomy, which is the removal of the kidney and upper tract, including impaired renal function.&nbsp;We believe that MitoGel has the potential to become the first <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> drug for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC serving as a first-line chemoablation agent, sparing patients from repeated tumor resection surgeries and potentially
reducing the need for bladder and upper urinary tract surgeries, including upper urinary tract removals. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we completed evaluating the safety and
efficacy of VesiGel, our novel sustained-release high dose formulation of MMC, for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC in a Phase 2a study that was conducted in Europe and Israel. Of the 22 patients treated in
the VesiGel high dose group (80mg MMC), 19, or approximately 86%, of the patients achieved a complete response at the primary evaluation time. Moreover, approximately 79% of the patients who achieved a complete response at the primary evaluation
time with VesiGel in the study and who have been followed for 12 months thereafter, without receiving additional treatments, remained recurrence free. This compares to approximately 40% to 60% of patients who historically achieve <FONT
STYLE="white-space:nowrap">a&nbsp;12-month&nbsp;durable</FONT> complete response with TURBT as first-line treatment, followed by adjuvant treatments of MMC instillations into the bladder. We plan to file an IND for VesiGel in the first half of 2018;
and, if accepted, we expect to commence a U.S.-based Phase 2b clinical trial for VesiGel shortly thereafter. We also intend to pursue a 505(b)(2) regulatory pathway for VesiGel. We believe that VesiGel has the potential to replace tumor resection
surgery and become the new first-line standard of care for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that urothelial
cancer, which is comprised of bladder cancer and UTUC, affects a large and underserved patient population. Annual expenditures for Medicare alone in the United States for the treatment of urothelial cancer were estimated to have been at least
$4.0&nbsp;billion in 2010 and are projected to be at least $5.0&nbsp;billion in 2020. The majority of the expenditures is spent on tumor resection surgeries such as TURBT and upper urinary tract removals. In 2012, the estimated prevalence of
urothelial cancer in the United States was 625,000 with an annual incidence of approximately 80,000. The 2012 prevalence of each of <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC and <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC in
the United States was approximately 325,000 and 14,500, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our clinical stage pipeline also includes Vesimune, our proprietary immunotherapy product
candidate for the treatment of high-grade NMIBC, which may include Carcinoma in Situ, or CIS. Vesimune is a novel, liquid formulation of Imiquimod, a generic toll-like receptor 7, or TLR7, agonist. Toll-like receptor agonists play a key role in
initiating the innate immune response system. We believe that the combination of Vesimune with additional immunotherapy drugs, such as immune checkpoint inhibitors or chemotherapy drugs like VesiGel, could represent a valid alternative to the
current standard of care for the post-TURBT adjuvant treatment of high-grade NMIBC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">BotuGel is our proprietary novel RTGel-based formulation of BOTOX, a branded
drug, that we believe can potentially serve as an effective treatment option for patients suffering from overactive bladder. In October&nbsp;2016, we announced the licensing of the worldwide rights to RTGel in combination with neurotoxins, including
BOTOX, to Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, or the Allergan Agreement. In August 2017, we announced that Allergan had submitted an IND to the FDA in order to be able to commence
clinical trials in the United States using the RTGel in combination with BOTOX. In October 2017, Allergan commenced a Phase 2 clinical trial of BotuGel for the treatment of overactive bladder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Product Candidate Pipeline </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following chart summarizes the current status of our product candidate pipeline. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g504802g94n34.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Uro-Oncological</FONT> Indications Targeted by Our Product Candidates </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our product candidates are administered locally using the standard practice of intravesical instillation directly into the bladder or upper urinary tract via a
catheter. The instillation into the bladder is expected to take place in a physician&#146;s office as a <FONT STYLE="white-space:nowrap">same-day</FONT> treatment, in comparison with TURBT or similar tumor surgical procedures, which are operations
conducted under general anesthesia in a hospital setting and may require at least an overnight stay. Tumor surgical procedures often have limited success due to the inability to properly identify, reach and resect all tumors. We believe that an
effective chemoablation agent can potentially provide better eradication of tumors irrespective of the detectability and location of the tumors. In addition, by removing the need for surgery, patients may avoid potential complications associated
with surgery and hospital-acquired infections. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Bladder Cancer </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
bladder is a hollow organ in the pelvis with flexible muscular walls. Its main function is to store urine before it leaves the body. Urine is produced by the kidneys and is then carried to the bladder through the upper urinary tract tubes, called
ureters. The bladder wall has four main layers. The innermost lining is comprised of cells called urothelial or transitional cells, and this inner layer is called the urothelium or transitional epithelium. Beneath the urothelium, there is a layer
called the lamina propria. Next is a thick layer of muscle called the muscularis propria followed by a layer of perivesical fat. </P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g504802g32j62.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">NMIBC tumor types are circled </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Bladder cancer accounts for approximately 90% to 95% of all new cases of urothelial cancer in the United States, with a prevalence of approximately 580,000. Bladder
cancer is nearly three to four times more common in men than women, and, with an average age at diagnosis of 73, mostly affects the elderly. Bladder cancers are described as <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive or
muscle-invasive based on how far into the wall of the bladder they have invaded. The magnitude and rate of the spreading of the cancer is called &#147;staging,&#148; which ranges from Ta to T1 for NMIBC, and T2 to T4 for muscle-invasive bladder
cancers, as defined by the American Joint Committee on Cancer TNM System. In addition, Carcinoma in Situ, or CIS, a form of NMIBC, has a staging designation of Tis. Muscle-invasive bladder cancer, or MIBC, has an average five-year survival rate of
15% to 63%, depending on severity. MIBC represents a worse prognosis than NMIBC, which has a five-year survival rate of approximately 90%. NMIBC accounts for approximately 80% of all new cases of bladder cancer diagnosed in the United States each
year, which corresponds to an estimated annual incidence and prevalence of approximately 60,000 and 465,000 cases, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-muscle</FONT> invasive bladder cancers are divided into two grades, low and high, with high-grade tumors more likely to recur and
progress into muscle-invasive tumors. CIS tumors are all high-grade. Overall, approximately 70% of patients with NMIBC present with <FONT STYLE="white-space:nowrap">low-grade</FONT> disease at diagnosis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The chart below indicates the prevalence of stage and grade of bladder cancer in the United States. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g504802g59q99.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Upper Tract Urothelial Carcinoma </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">UTUC refers to malignant changes of the transitional urothelial cells lining the upper urinary tract of the renal pelvis and ureter. UTUC typically exhibits high local
recurrence and development of metastases. Similar to NMIBC, the prognosis of patients with UTUC correlates with the stage and grade of disease at the time of initial diagnosis. The key prognostic factor at the time of diagnosis of UTUC is whether
the tumor is in the muscle-invasive or <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive stage. The number, size and location of tumors presented also represent important prognostic factors for UTUC. Approximately 40% of the patients
diagnosed annually with UTUC in the United States present with <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive UTUC. <FONT STYLE="white-space:nowrap">Non-muscle</FONT> invasive UTUC is also divided into two grades, low and high. In two
studies conducted in 1997 and 2003 of 30 and 20 patients with <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive UTUC, 87% and 75% of patients were diagnosed with <FONT STYLE="white-space:nowrap">low-grade</FONT> <FONT
STYLE="white-space:nowrap">non-muscle</FONT> invasive UTUC, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The chart below indicates the prevalence of stage and grade of UTUC in the United States. </P>
<P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g504802g64i82.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">UTUC accounts for approximately 5% to 10% of all new cases of urothelial cancer, which corresponds to an estimated annual incidence
in the United States of up to 7,500 cases. In 2012, the estimated prevalence of UTUC in the United States was approximately 45,000, of which approximately 14,500 had <FONT STYLE="white-space:nowrap">low-grade</FONT> disease. UTUC is nearly three
times more common in men than women and affects mostly the elderly. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are currently no drugs approved by the FDA for the treatment of UTUC, representing a
significant unmet medical need. Moreover, the anatomical complexity of the upper urinary tract, particularly the renal pelvis, presents significant challenges to the proper identification and ability to reach and resect all tumors in tumor resection
surgical procedures. Consequently, patients with high-grade disease or patients with <FONT STYLE="white-space:nowrap">low-grade</FONT> disease that present with a large number of tumors typically undergo nephroureterectomy, which is kidney and upper
urinary tract removal. In addition, the stage and grade of UTUC are often misdiagnosed, which we believe is due to the structural complexity of the upper urinary tract. Due to these factors, the current standard of care for the treatment of UTUC is
nephroureterectomy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Tumor resection, which aims to be a kidney sparing surgical procedure, is conducted only in patients with
<FONT STYLE="white-space:nowrap">low-grade</FONT> disease that present with a limited number of tumors. Such procedures are followed by adjuvant chemotherapy treatment, typically with MMC. However, the upper urinary tract&#146;s anatomical
constraints limit the effectiveness of surgical procedures and adjuvant chemotherapy treatments, leading to high rates of recurrence and risk for progression in this patient population. In a study published in 2009 in the Journal of Endourology
evaluating 57 patients with <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC who underwent tumor resections, 89.5% of patients recurred with a mean of 5.5 recurrences per patient over a four-year period. Moreover, approximately 20% of the
patients in this study progressed and ultimately underwent kidney and upper urinary tract removal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that because tumor resection procedures followed by
adjuvant chemotherapy therapy are <FONT STYLE="white-space:nowrap">sub-optimal,</FONT> nephroureterectomy is often used even in patients that may be otherwise candidates for organ-sparing treatments. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Non-Muscle</FONT> Invasive Bladder Cancer </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patients treated with the current standard of care have up to an approximately 60% rate of recurrence of NMIBC within one year, and the rate of progression of NMIBC to
MIBC is between 20% and 30%. As a consequence, NMIBC patients often undergo multiple repeat TURBT procedures and adjuvant chemotherapy and immunotherapy treatments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The standard of care for treating NMIBC patients is TURBT followed by adjuvant chemotherapy or immunotherapy
treatment. TURBT is a surgical operation for tumor removal conducted under general anesthesia in a hospital setting and may require at least an overnight stay. Moreover, TURBT&#146;s success is tied to the physician&#146;s ability to overcome
challenges in properly identifying, reaching and resecting all tumors. No drugs have been approved by the FDA as first-line treatment for NMIBC and only three drugs have been approved by the FDA for NMIBC, all used as adjuvant treatment, following
TURBT. Efficacy of drug treatments has historically been limited due to challenges presented by bladder physiology, specifically the fact that urine is produced and voided frequently, thus diluting the concentration of the drug almost immediately
and causing the excretion of the drug from the bladder at first urine voiding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Competitive Strengths </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe our lead product candidates for <FONT STYLE="white-space:nowrap">uro-oncology,</FONT> which are being developed by leveraging our expertise in drug
development and our proprietary formulation technology, have the ability to replace the costly, <FONT STYLE="white-space:nowrap">sub-optimal</FONT> and burdensome tumor resection procedures that represent the current first-line standard of care.
Furthermore, we believe our proprietary formulation technology has broad applications and may allow us to develop additional product candidates for indications within and beyond the urinary tract. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Potential ability to develop <FONT STYLE="white-space:nowrap">non-surgical,</FONT> first-line drug therapies for
<FONT STYLE="white-space:nowrap">uro-oncology.</FONT></I></B><B></B>&nbsp;Leveraging our innovative formulation technology, we are developing two lead product candidates, MitoGel and VesiGel, as potential replacements to first-line treatment for <FONT
STYLE="white-space:nowrap">low-grade</FONT> UTUC and NMIBC, respectively. Both MitoGel and VesiGel are chemoablation agents designed to overcome the challenges posed by the anatomy of the urinary tract by increasing the dwell time and enhancing the
tissue coverage of MMC. Clinical data generated to date supports our belief that our lead product candidates may be able to replace the current first-line tumor surgical procedures, providing a chemoablation treatment that has the potential to
better eradicate tumors irrespective of their detectability and location within the urinary tract. Of the 13 <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC patients treated with MitoGel in a recently-completed Compassionate Use program and
evaluated endoscopically or through the use of a nonsurgical viewing instrument for efficacy, eight achieved a complete response and the remaining five achieved a partial response at the primary evaluation time. In the case of VesiGel, 19 of 22, or
approximately 86%, of the patients treated with the high dose of VesiGel in a recently-completed Phase 2a trial conducted in Europe and Israel, evaluating the efficacy and safety of VesiGel&#146;s chemoablation properties, achieved a complete
response at the primary evaluation time. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Expertise in developing proprietary formulations of drugs for clinical benefit.</I></B> We focus on
developing proprietary RTGel formulations of previously approved drugs whose efficacy for a particular indication is limited by current formulations or routes of administration. While we have not yet brought a drug to market, our expertise has
enabled us to develop proprietary RTGel-based formulations for several previously approved drugs to date, including clinical stage proprietary formulations of MMC and botulinum toxin. Our formulations are designed to significantly increase the dwell
time and exposure of the drugs to the target sites and limit the need for urine retention, potentially providing enhanced clinical activity, reduced patient burden and increased patient compliance over existing formulations and modes of
administration. With 13 Ph.Ds. and medical doctors on our staff, we have a strong research and development team to advance our product candidates. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Lower development risks and costs for our pipeline product candidates. </I></B>We expect the approval process for each of our current <FONT
STYLE="white-space:nowrap">uro-oncology</FONT> product candidates to be conducted according to the FDA&#146;s 505(b)(2) regulatory pathway, a streamlined, lower-cost and more well-defined pathway to drug approval when compared to traditional drug
development. Furthermore, two of our product candidates, MitoGel and Vesimune, have received Orphan Drug Designation from the FDA for the treatment of UTUC and CIS, respectively, which we expect will provide seven years of marketing exclusivity
following FDA approval, if received. We submitted an IND for MitoGel in November 2016, which was accepted by the FDA in December 2016. We commenced a single pivotal, open-label, <FONT STYLE="white-space:nowrap">single-arm</FONT> Phase 3 clinical
trial for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC in the first quarter of 2017. The clinical trial is being conducted in the United States and Europe with anticipated enrollment of approximately 74 patients.
Additionally, we expect that our product candidates are more likely to be safe and well-tolerated because they are novel formulations of previously approved drugs. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Leverageable proprietary formulation technology</I></B><B>.</B><B></B>&nbsp;We believe that RTGel has multiple potential applications beyond
urology. Our formulation <FONT STYLE="white-space:nowrap">know-how</FONT> may enable us to develop different drug formulations to facilitate the delivery, retention and sustained release of active drugs to a variety of targeted body cavities. We
believe that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">
our proprietary formulation technology can improve the efficacy of locally administered drugs in body cavities such as the stomach, uterus and rectum that present anatomical and physiological
challenges related to frequent wash out, rapid excretion and bodily secretions. In October 2016, we announced that we licensed worldwide rights to a proprietary RTGel formulation with BOTOX to Allergan for the treatment of overactive bladder and
related indications pursuant to the Allergan Agreement. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Strong intellectual property position. </I></B>We have a robust intellectual property
portfolio that includes 28 issued patents worldwide and more than 45 pending patent applications filed worldwide. In the United States, we have 13 granted patents that are directed to protect our lead product candidates MitoGel, VesiGel and Botugel
as well as our RTGel technology and our other potential product candidates that are under preclinical review. These patents claim methods, systems, and novel compositions for treating cancer in internal cavities, in particular treating a urinary
tract cancer. These issued patents are expected to expire between 2024 and 2035. Additionally, the FDA has granted Orphan Drug Designation to MitoGel for the treatment of UTUC and Vesimune for the treatment of CIS bladder cancer, which potentially
entitles us to marketing exclusivity for MitoGel and Vesimune for seven years following approval, if granted, by the FDA. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Experienced and
accomplished leadership team with proven track record</I></B><B>.</B> We have an experienced management team, with each member possessing more than 15 years of biopharmaceutical and related industry experience. Our Chief Executive Officer, Ron
Bentsur, successfully navigated Auryxia (ferric citrate) through the 505(b)(2) streamlined regulatory pathway to FDA approval. In addition, our Chairman, Arie Belldegrun, M.D., is a seasoned biotech executive and was the founder, Chairman, Chief
Executive Officer and President of Kite Pharma, which was recently sold to Gilead Sciences, Inc. for $11.8&nbsp;billion. Dr.&nbsp;Belldegrun is also a urologist by training. We believe that our leadership team is well-positioned to lead us through
clinical development, regulatory approval and commercialization for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Growth Strategy </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to become the leading biopharmaceutical company focused on the development of novel therapies for local treatment of urological pathologies. The key elements
of our strategy are as follows: </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Establish each of our lead product candidates, MitoGel and VesiGel, as the first-line treatment in its target
indication.</I></B> We believe that data from treatments in our Compassionate Use program conducted in the United States, Europe and Israel provide preliminary evidence of the potential safety and efficacy of MitoGel for the treatment of <FONT
STYLE="white-space:nowrap">low-grade</FONT> UTUC. We submitted an IND for MitoGel with the FDA in November 2016, which was accepted by the FDA in December 2016, and we commenced a single pivotal Phase 3 clinical trial in the first quarter of 2017
pursuant to the FDA&#146;s 505(b)(2) regulatory pathway. We recently completed a Phase 2a randomized, open-label, <FONT STYLE="white-space:nowrap">single-arm,</FONT> active-controlled clinical trial of VesiGel for the treatment of <FONT
STYLE="white-space:nowrap">low-grade</FONT> NMIBC, conducted in Europe and Israel. We expect to file an IND for VesiGel in the first half of 2018, and, if accepted, to commence a Phase 2b U.S.-based clinical trial shortly thereafter. We also expect
to pursue a 505(b)(2) regulatory pathway for VesiGel. We believe that these local drug treatments have the potential to replace costly, <FONT STYLE="white-space:nowrap">sub-optimal</FONT> and burdensome tumor resection and kidney removal surgeries
to become the first-line standard of care. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Expand our <FONT STYLE="white-space:nowrap">uro-oncology</FONT> product pipeline.</I></B> A Phase
1 clinical trial of Vesimune was completed under an IND in 12 patients with CIS, an aggressive form of high-grade urinary bladder cancer. In the trial, 10 patients were evaluated for response, of which 40% achieved a complete response rate with
Vesimune as a single-agent treatment. We believe that combining Vesimune with immune checkpoint inhibitors or chemotherapy has the potential to serve as a treatment option for high-grade urothelial tumors. We are also pursuing preclinical oncology
programs that take advantage of our RTGel technology. We are conducting preclinical programs for high-grade bladder cancer and high-grade UTUC. We may also evaluate <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquiring additional product
candidates for the treatment of urological cancers. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Utilize our proprietary technology to expand our pipeline to other body cavities and
indications.</I></B> We believe that RTGel may be suitable for multiple additional applications. Our <FONT STYLE="white-space:nowrap">know-how</FONT> may enable us to develop different drug formulations to facilitate the delivery, retention and
sustained release of active drugs to a variety of targeted body cavities. Beyond the urinary tract, we may target the gastrointestinal tract and the female reproductive system. In the future, we may also choose to develop our RTGel technology in
combination with other drugs to treat cancer and other indications endemic to such body cavities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Evaluate and selectively pursue potential collaborations to develop improved formulations and
product life-cycle management strategies.</I></B> We entered into the Allergan Agreement to research, develop, manufacture and commercialize pharmaceutical products that contain RTGel and clostridial toxins (including BOTOX), alone or in combination
with certain other active ingredients. This collaboration provides us with funding for our research and development efforts, and may accelerate the development and commercialization of our approved products, if any. In addition, we may <FONT
STYLE="white-space:nowrap">in-license</FONT> or acquire additional product candidates for urological indications. Such collaborations would allow us to obtain financial support and to capitalize on the expertise and resources of our potential
partners, which could allow for new and improved versions of approved or clinical stage drugs, and could accelerate the development and commercialization of additional product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>RTGel: Our Reverse Thermally Triggered Hydrogel Platform Technology </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have
developed RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel, which, unlike the general characteristics of most forms of matter, is liquid at lower temperatures and converts into gel form when heated. We believe
that these characteristics promote ease of delivery into and retention of drugs in body cavities, including the bladder and the upper urinary tract, by conforming to the anatomy of the target organ while preventing rapid excretion of the drug. The
following images show the progression of five stages of RTGel at different temperatures. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g504802g07p99.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:-2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">LT: Liquid at low temperature </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">BT: Converts into gel form at body temperature </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RTGel&#146;s
components are polymer-based and are inactive ingredients that have been approved by the FDA for use in other products such as Oraqix, a periodontal gel, Namenda, an oral solution for Alzheimer&#146;s disease, and Xeloda, an oral chemotherapy. We
formulate RTGel with an active drug: MMC in the case of MitoGel and VesiGel, and botulinum toxin in the case of BotuGel. The resulting formulations are instilled intravesically in liquid form directly into the bladder or upper urinary tract using
standard instillation methodologies via catheters and thereafter convert into gel form at body temperature. Subsequently, upon contact with urine, RTGel gradually dissolves and releases the active drug over a period of several hours, and is less
affected by urine creation and voiding cycles as compared to water formulations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that RTGel, when formulated with an active drug, may allow for the
improved efficacy of treatment of various types of urothelial cancer without compromising the safety of the patient or interfering with the natural flow of fluids from the urinary tract to the bladder. RTGel achieves this by: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increasing the exposure of active drugs in the bladder and upper urinary tract by significantly extending the dwell time of the active drug while conforming to the anatomy of the bladder and the upper urinary tract,
which allows for enhanced drug tissue coverage. For example, the average dwell time of the standard MMC water formulation, currently used as adjuvant treatment, in the upper urinary tract is approximately five minutes, compared to approximately six
hours when MMC is formulated with RTGel; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administering higher doses of an active drug than would otherwise be possible using standard water-based formulations. For instance, it is only possible to dissolve 0.5 mg of MMC in 1 ml of water while it is possible to
formulate up to 8 mg of MMC with 1 ml of RTGel; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining the active drug&#146;s molecular structure and mode of action. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These characteristics of RTGel enable
sustained release of MMC in the urinary tract for both MitoGel and VesiGel, and of botulinum toxin in the case of BotuGel. Further, RTGel may be particularly effective in the bladder and upper urinary tract where tumor visibility and access are
challenging, and where there exists a significant amount of urine flow and voiding. We believe that these characteristics of RTGel may prove useful for the local delivery of active drugs to other bodily cavities in addition to the bladder and upper
urinary tract. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>MMC&#151;Our Target Active Drug for the Treatment of UTUC and NMIBC </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MMC is a generic drug currently utilized <FONT STYLE="white-space:nowrap">off-label</FONT> as the standard adjuvant chemotherapy for the treatment of <FONT
STYLE="white-space:nowrap">low-grade</FONT> UTUC and NMIBC after tumor resection, such as TURBT. MMC, a chemotherapy agent, is typically administered using a water-based formulation, which has a relatively short dwell time in the bladder limited to
first voiding. MMC often causes temporary irritation of the bladder, including the need to urinate frequently and urgently. This often results in first voiding occurring shortly after instillation. In the upper urinary tract, the dwell time is
limited to approximately five minutes as urine flows continuously and no active retention by the patient is feasible. Numerous <I>in vitro</I> models, <I>in vivo</I> studies and computer simulations have shown that increased dwell time of MMC in the
bladder results in more efficacious treatment of bladder cancer. In one such study, it was shown that MMC activity increased with exposure time. Specifically, the MIC90, or mean inhibitory concentration that causes 90% inhibition in cell growth, was
<FONT STYLE="white-space:nowrap">11-fold</FONT> lower when exposure time was increased from 30 minutes to eight hours. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MMC&#146;s main effect is on the cancer
cell&#146;s DNA, and has been demonstrated to be most effective when the cancer cell is in its <FONT STYLE="white-space:nowrap">S-phase,</FONT> or synthesis phase, during which the DNA is replicated. Each cancer cell goes through various phases
during the cell cycle. However, the cell cycle is not synchronized in all cancer cells, which means that at any given point in time only a portion of the cancer cells are at their <FONT STYLE="white-space:nowrap">S-phase,</FONT> or susceptible to
the instilled MMC in the bladder. Thus, because our RTGel-based MMC sustained-release formulations, MitoGel and VesiGel, provide for a significantly longer dwell time of MMC in the upper urinary tract and in the bladder as compared to standard MMC
water formulations, there is a greater chance that tumor cells will go through their <FONT STYLE="white-space:nowrap">S-phase</FONT> while the instilled MMC is still present using MitoGel or VesiGel, potentially resulting in a higher percentage of
tumor cells being affected by the instilled MMC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>MitoGel: Our Product Candidate for the Treatment of <FONT STYLE="white-space:nowrap">Low-Grade</FONT> Upper
Tract Urothelial Carcinoma </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are developing MitoGel, our novel sustained-release formulation of MMC, for the treatment of
<FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC. We have observed preliminary evidence of the efficacy of MitoGel in an investigator-initiated Compassionate Use program for the treatment of unresectable UTUC. Additionally, the FDA granted
MitoGel Orphan Drug Designation for the treatment of UTUC and Fast Track Designation. We plan to develop MitoGel through the FDA&#146;s 505(b)(2) regulatory pathway. We commenced a pivotal, open-label,
<FONT STYLE="white-space:nowrap">single-arm</FONT> Phase 3 clinical trial for MitoGel in the first quarter of 2017. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Limitations of Current Therapies for
Upper Tract Urothelial Carcinoma </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are currently no drugs approved by the FDA for the treatment of UTUC, representing a significant unmet medical need.
The current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> for the treatment of UTUC is nephroureterectomy, which is complete kidney and ureter removal. Recent advances in resection instrument
technology have allowed physicians in some cases to treat patients with <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC using endoscopic tumor resection, a kidney-sparing treatment, rather than nephroureterectomy followed by adjuvant
chemotherapy, typically MMC, treatment. However, the specific anatomy and physiology of the upper urinary tract make the performance of organ-sparing endoscopic tumor resection and instillation of adjuvant chemotherapy challenging, leading to high
recurrence rates. Patients often undergo multiple endoscopic resection procedures, which increases the probability of potential complications of resection, including perforation and ureteral stricture, or a narrowing of the ureter. A recent study
published in 2009 in the Journal of Endourology, evaluating 57 patients with <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC who underwent tumor resections showed that recurrence occurred in 89.5% of patients, with a mean of 5.5 recurrences
per patient, over a four-year period. Moreover, approximately 20% of the patients in this study progressed and ultimately underwent kidney and upper tract removal. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MMC is currently administered using a water-based formulation, which limits the dwell time in the bladder until first voiding. In the upper urinary tract, the dwell
time of MMC is approximately five minutes as urine flows continuously and no active retention by the patient is feasible. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Solution: MitoGel </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MitoGel is our novel sustained-release RTGel-based formulation of MMC that we are developing for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT>
UTUC. RTGel is liquid at lower temperatures and converts into gel form at body temperature. This temperature-dependent viscosity characteristic allows for simple and convenient instillation of the cooled MitoGel in its liquid form to the upper
urinary tract via standard catheters. Once instilled, MitoGel converts into gel form in less </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
than 10 minutes at body temperature. Subsequently, upon contact with urine, MitoGel gradually dissolves and releases the active drug, MMC, over a period of several hours versus several minutes
for MMC in its water-based formulation. We believe that this substantial increase in dwell time of MMC positions MitoGel as a potential first-line chemoablation treatment for <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC, potentially
sparing patients from repeated tumor resection surgeries and potentially reducing the need for bladder and upper urinary tract surgeries, including upper urinary tract removal. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Orphan Drug Designation granted to MitoGel for the treatment of UTUC potentially entitles us to marketing exclusivity for MitoGel for seven years following approval
by the FDA, if granted, as well as priority review of our New Drug Application, or NDA. We believe Fast Track Designation may allow us to obtain priority or expedited review of our NDA filing as well as the possibility for a rolling NDA submission.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Initial Clinical Results for MitoGel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MitoGel was evaluated in
an investigator-initiated Compassionate Use program for the treatment of severe, <FONT STYLE="white-space:nowrap">non-resectable</FONT> UTUC, which commenced in September 2014. The Compassionate Use program, which was conducted in the United States,
Europe and Israel, included patients diagnosed with unilateral and bilateral <FONT STYLE="white-space:nowrap">low-</FONT> and high-grade UTUC, as well as patients with a solitary kidney. Patients in the Compassionate Use program received six weekly
instillations of MitoGel administered directly to the upper urinary tract. Consistent with the nature of Compassionate Use programs, which are investigator-initiated programs, a statistical plan or primary endpoint was not used as in a regular
clinical trial. Approximately four weeks following the completion of the treatment course, the patients were evaluated for response. Patients were visually evaluated endoscopically or through the use of a nonsurgical viewing instrument, with
additional confirmation through urine cytology, or examination of cells collected from a urine specimen. At the evaluation time, which was approximately four weeks following the completion of the treatment course, patients were deemed to have
achieved a complete response if, in the judgment of the physician, no tumors initially diagnosed by the physician were detected and a partial response if, in the judgment of the physician, the size or number of tumors had decreased or if, following
an initial complete response, there is tumor recurrence within three months after the evaluation time. Safety and feasibility of treatment with MitoGel were also evaluated. <FONT STYLE="white-space:nowrap">Twenty-two</FONT> patients were treated in
the study, with more than 130 instillations of MitoGel performed. Of the 22 patients treated, 18 were assessed as having <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC. Of the 18 patients assessed as having
<FONT STYLE="white-space:nowrap">low-grade</FONT> disease, 14 completed six instillations of MitoGel. Of these 14 patients, 13 were evaluated for response and one could not be evaluated to confirm response. Of the 13 patients who were evaluated for
response, eight, or approximately 62%, achieved a complete response and five, or approximately 38%, achieved a partial response at the primary evaluation time. One of the patients who received a partial response subsequently received an additional
three courses of MitoGel and thereafter achieved a complete response. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Of the eight patients who have achieved a complete response at the primary evaluation time,
we are aware of three patients who have subsequently experienced recurrences to date. Recurrences were generally of small tumors, a few millimeters in diameter, and were manageable by endoscopic tumor resection. To our knowledge, five of the eight
patients have not recurred to date, with three of the five patients having achieved durability of 12 months or greater to date. The median durability for these eight patients is still ongoing and is now greater than nine months, based on
investigator reports. The follow-up evaluation plan for patients in our Compassionate Use program is determined by each individual investigator and varies from patient to patient, and some patients have not undergone follow-up evaluation or have
been lost to follow-up. As part of the ongoing single pivotal Phase 3 clinical trial, in order to potentially further extend durability, patients who achieve a complete response at the primary disease evaluation visit will be followed for durability
of response and will receive monthly MitoGel maintenance instillations for up to 12 months. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MitoGel was observed to be well-tolerated in the Compassionate Use
Program. The main observed adverse events, or AEs, related to MitoGel have been fatigue, allergic reaction, nausea, fever, and dysuria, which is pain or difficulty while urinating. All of the AEs that have been observed to date are known side
effects associated with the use of MMC and appear on the MMC label as potential side effects. Various serious adverse events, or SAEs, were also reported most of which were determined to be unrelated to treatment with MitoGel. These SAEs include
acute pyelonephritis, a kidney infection caused by bacteria; hydronephrosis, which is the swelling of the upper urinary tract due to a <FONT STYLE="white-space:nowrap">build-up</FONT> of urine caused by some degree of obstruction; severe arrhythmia,
which is a severe abnormal heart rhythm; cardiac asthma, which is a medical diagnosis of wheezing, coughing or shortness of breath due to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
congestive heart failure; aggravation of renal function; hyperkalemia, which is a condition of elevated levels of potassium in the blood; pancytopenia, which is a deficiency of red cells, white
cells and platelets in the blood; scarring and narrowing of the calyceal infundibulum, which was most probably present at baseline; asymptomatic extravasation from the upper tract, which is leakage of fluids from the upper tract to the surrounding
tissue; and death. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This Compassionate Use program was allowed by the FDA to accumulate safety and efficacy data. In the first quarter of 2017, we commenced a
pivotal, open-label, <FONT STYLE="white-space:nowrap">single-arm</FONT> Phase 3 clinical trial of MitoGel for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following images show <FONT STYLE="white-space:nowrap">pre-treatment</FONT> and post-MitoGel treatment results from one
<FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC patient in the Compassionate Use program. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g504802g04e65.jpg" ALT="LOGO">



<IMG SRC="g504802g21v14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">(Courtesy of Dr.&nbsp;J. Gregory Wirth, Geneva Hospital, Switzerland) </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The top left image is a <FONT STYLE="white-space:nowrap">pre-treatment</FONT> ureteroscopic view of a tumor located in the ureter. The bottom left image is a <FONT
STYLE="white-space:nowrap">pre-treatment</FONT> <FONT STYLE="white-space:nowrap">x-ray</FONT> revealing an obstruction within the ureter in which no contrast (black) can be visualized in the distal ureter (denoted by arrow). The top right image is a
post-treatment ureteroscopic view of the same location following MitoGel chemoablation treatment. The bottom right image is a post-treatment <FONT STYLE="white-space:nowrap">x-ray</FONT> of the ureter which reveals no obstruction within the ureter.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">IND-Enabling</FONT> Studies for MitoGel </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of our <FONT STYLE="white-space:nowrap">IND-enabling</FONT> work for MitoGel, we have completed a large-scale Good Laboratory Practices, or GLP, toxicity study
in an upper urinary tract swine model in which more than 250 instillations of MitoGel were performed. This study evaluated the safety of the procedure and MitoGel administration, also utilizing higher dosage levels than those used in the clinical
settings. In this GLP toxicology study, the instillation of MitoGel was found to be safe. We are also currently conducting chemistry, manufacturing and controls, or CMC, studies as part of our <FONT STYLE="white-space:nowrap">IND-enabling</FONT>
efforts. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Next Steps in the Clinical Development of MitoGel </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on discussions with the FDA, we intend to develop MitoGel through the FDA&#146;s 505(b)(2) regulatory pathway. We submitted an IND for MitoGel in November 2016,
which was accepted by the FDA in December 2016. We </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
commenced a pivotal, open-label, <FONT STYLE="white-space:nowrap">single-arm</FONT> Phase 3 clinical trial of MitoGel for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC
in the first quarter of 2017. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g504802g50p86.jpg" ALT="LOGO">
 </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:10%; font-size:8pt; font-family:ARIAL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(*)</SUP> Only if clinical trial is successfully completed </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This Phase 3 clinical trial is being conducted in the United
States and Europe with anticipated enrollment of approximately 74 patients. We expect this clinical trial, if successfully completed, to support an NDA for <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC for MitoGel. The patients will
initially receive six weekly instillations of MitoGel. The primary efficacy endpoint is expected to be the complete response rate, defined as the percentage of patients with a complete response at the primary disease evaluation visit, which occurs
approximately four weeks following the sixth weekly instillation. In addition, patients who achieve a complete response at the primary disease evaluation visit will be followed for durability of response. Such patients will also receive monthly
MitoGel maintenance instillations for up to 12 months. If this clinical trial is successfully completed, we currently anticipate submitting an NDA for MitoGel in the first quarter of 2019. In the Phase 3 trial, to date, MitoGel therapy has been well
tolerated. Adverse events encountered in treated subjects include the expected effects of Mitomycin C administration to the urinary tract (pain and urinary tract irritation). In addition, transient perturbation of laboratory measures of renal and
hematopoietic function has been observed. No study participants have required medical intervention to address these changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>VesiGel: Our Product Candidate for
the Treatment of <FONT STYLE="white-space:nowrap">Low-Grade</FONT> <FONT STYLE="white-space:nowrap">Non-Muscle</FONT> Invasive Bladder Cancer </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">VesiGel is our
novel sustained-release formulation of high dose MMC that we are developing for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC as a first-line <FONT STYLE="white-space:nowrap">non-surgical</FONT> chemoablation alternative
to TURBT. We recently completed a Phase 2a randomized, open-label, <FONT STYLE="white-space:nowrap">single-arm</FONT> active-controlled clinical trial in Europe and Israel that evaluated the safety and efficacy of VesiGel (40mg and 80mg MMC) in <FONT
STYLE="white-space:nowrap">low-grade</FONT> NMIBC. We commenced the trial in September 2013 and the last patient was enrolled in March 2016. 19 of 22, or approximately 86%, of the patients with confirmed
<FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC treated in this trial achieved complete responses in the 80mg MMC dose group of VesiGel at the primary evaluation time, and therefore did not require surgical intervention. Approximately 79% of
the patients who achieved a complete response at the primary evaluation time with VesiGel treatment and who had been followed for 12 months thereafter remained recurrence free, and were able to sustain this durable complete response without
receiving any additional treatment during this period. This compares to approximately 40% to 60% of patients who historically have been able to sustain a <FONT STYLE="white-space:nowrap">12-month</FONT> durable complete response following TURBT as
first-line treatment followed by additional adjuvant treatments of MMC instillations into the bladder. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to file an IND for VesiGel in the first half of
2018, and, if accepted, to commence a Phase 2b U.S. based clinical trial shortly thereafter. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Limitations of Current Therapies for <FONT
STYLE="white-space:nowrap">Non-Muscle</FONT> Invasive Bladder Cancer </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Tumor grade and stage are the most important variables for determining the likelihood
of progression from NMIBC to MIBC. The three stages of NMIBC are: Ta (70%), T1 (20%) and CIS or Tis (10%). Approximately 70% of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">NMIBC patients have a tumor that is
classified as <FONT STYLE="white-space:nowrap">low-grade</FONT> upon diagnosis. Ta and CIS are limited to the urothelial layer, and T1 is limited to the layer below, which is the lamina propria. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Recurrence, which occurs in approximately 80% of patients, is the primary threat for NMIBC patients. Multiplicity, or number of tumors, tumor size and prior recurrence
rate are the most important variables in determining the likelihood and potential severity of recurrence. In T1 and CIS NMIBC patients, progression, which occurs in approximately 45% of patients, is the main threat. Treatment ranges from one or more
TURBT procedures followed by adjuvant chemotherapy or immunotherapy instillation(s) in NMIBC patients with a low risk of recurrence to cystectomy for the treatment of NMIBC patients with a high risk of recurrence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TURBT is conducted in a hospital setting under general anesthesia and can often have side effects and complications.
The most common complications, risks and limitations of TURBT include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">bleeding at the time of surgery that requires clot irrigation and mild burning; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">infection of the bladder; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injured urethra and bladder perforation with potential intra-abdominal leakage; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reimplantation and cell migration; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">repeat TURBT procedures, which are necessary for approximately 10% of patients within three months; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">complete removal of tumor tissue often not being feasible; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential recurrence of up to 25% of the tumors at the original treatment site; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">some tumors not being detectable. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Post-operative adjuvant treatments for NMIBC, which are given to prevent
reimplantation of the cancerous cells, consist primarily of chemotherapy in the case of <FONT STYLE="white-space:nowrap">low-grade</FONT> tumors and immunotherapy in the case of high-grade tumors, and are administered intravesically via catheter.
Adjuvant intravesical chemotherapy is used primarily in <FONT STYLE="white-space:nowrap">low-grade</FONT> tumors following TURBT in order to try to delay tumor recurrence, but is not used as a chemoablation agent. The rationale is to expose tumors
to high local drug concentrations while minimizing the systemic exposure, thereby enhancing the treatment effect and reducing the drug toxicity. However, these traditional adjuvant treatments to treating bladder cancer have been limited because,
after instillation, the drug concentration is reduced and the drug is washed out due to urine voiding. As a result, the cancerous tissue is not exposed to the chemotherapy drug for the optimal length of time. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No drugs have been approved by the FDA as first-line treatment for NMIBC and only three drugs have been </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">approved for NMIBC, all used as adjuvant treatment: Thiotepa, which was approved in 1959; bacille Calmette-Guerin, or BCG, which was approved in 1989; and Valstar,
which was approved in 1998. MMC is the drug used most often for intravesical chemotherapy. It is used <FONT STYLE="white-space:nowrap">off-label</FONT> as an adjuvant treatment in the post-operative setting for
<FONT STYLE="white-space:nowrap">low-grade</FONT> tumors with high risk of recurrence. Other drugs that can be used include docetaxel and gemcitabine. BCG, an immunotherapy-based drug, is used as an adjuvant treatment for patients with high-grade
NMIBC. Upon recurrence, which occurs in approximately 35% of patients, the patients undergo another round of BCG therapy with a response rate of 30% to 50%. Radical cystectomy, or surgical removal of the bladder, is also a common treatment option
for patients who fail multiple intravesical BCG therapies. However, treatment with BCG is associated with severe side effects, as evidenced by a Black Box warning on the label, which is a warning placed on a prescription drug&#146;s label by the FDA
and is designed to call attention to serious or life-threatening risks. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are not aware of any drugs currently in development for the treatment of NMIBC that take
into consideration bladder physiology, specifically the fact that urine is produced and voided frequently, thus diluting the concentration of the active drug almost immediately. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Solution: VesiGel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">VesiGel, an RTGel-based formulation of high
dose MMC, is our product candidate for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC. VesiGel is administered locally using standard catheters and is designed to conform to the bladder&#146;s anatomy and persist in the
bladder despite urine flow and bladder movement. Once instilled, VesiGel converts into gel form within approximately 10 minutes at body temperature. Subsequently, upon contact with urine, VesiGel gradually dissolves and releases the active drug,
MMC, over a period of several hours versus the time until first voiding, often less than an hour, for MMC in its current water-based formulation, without compromising the safety of the patient or interfering with the natural flow of urine out of the
bladder. We believe that the resulting significantly increased dwell time of MMC in the bladder prolongs exposure of MMC to the tissue and therefore has the potential to chemoablate visible and unseen tumors. As a result of these properties, our
goal is to develop VesiGel as a first-line chemoablation <FONT STYLE="white-space:nowrap">non-surgical</FONT> alternative to TURBT for the treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Phase 2a Clinical Trial </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We completed a Phase 2a randomized,
open-label, <FONT STYLE="white-space:nowrap">single-arm,</FONT> active-controlled clinical trial in Europe and Israel that evaluated the safety and efficacy of VesiGel 0.06% (40 mg MMC in 64 ml gel) and VesiGel 0.12% (80 mg MMC in 64 ml gel) in <FONT
STYLE="white-space:nowrap">low-grade</FONT> NMIBC compared to the intravesical instillation of 40 mg of MMC in water (MMC </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
0.1%). We commenced the trial in September 2013 and the last patient was enrolled in March 2016. In this trial, patients underwent six weekly instillations according to their assigned treatment
arm. The primary endpoint of the trial used for observational purposes only is the complete response rate at the primary disease endpoint, which is evaluated approximately four weeks after the sixth weekly installation. Safety, feasibility of local
treatment with VesiGel and durability of response are also being evaluated. 81 patients were enrolled, 65 of whom have been evaluated for response. Of the 65 evaluable patients in the study, 20, 22 and 23 patients were in the VesiGel 40mg MMC,
VesiGel 80mg MCC and the water-based 40mg MMC control arm, respectively. The results to date indicate complete response rates at the primary evaluation time of 45%, 86% and 70% for VesiGel 40mg MMC, VesiGel 80mg MMC and water-based 40mg MMC control
arm, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In treating <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC, resection of small tumors is primarily conducted in the outpatient setting,
typically without anesthesia using fulguration, a procedure that destroys the diseased area in the lining of the bladder by burning using electric current. The effectiveness of tumor resection in these cases is high and the one-year recurrence rate
is estimated to be only 10%. However in patients with larger tumors and multiple tumors, standard management includes surgical removal using TURBT, a procedure conducted in the operating room in a hospital setting under general anesthesia, which may
requires at least an overnight stay. TURBT is associated with increased risks and costs and higher recurrence rates that can reach up to 60%. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When evaluating the
effect of chemoablation on large tumors that would typically be treated with TURBT, we observed a more profound difference in the complete response rate between the VesiGel 80mg MMC arm compared to the water-based 40mg MMC control arm. In tumors
less than or equal to 1 cm<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> in size, the complete response rate at the primary evaluation time was 78% (18 patients) and 88% (16 patients) in the water-based 40mg MMC control group and the VesiGel
80mg MMC group, respectively. However, in tumors greater than 1 cm<SUP STYLE="font-size:85%; vertical-align:top">2 </SUP>in size, the complete response rate at the primary evaluation time was 40% (five patients) and 83% (six patients) in the control
group and VesiGel 80mg MMC group, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The graph below illustrates the complete response rates by tumor size for the VesiGel 80mg MMC and water-based 40mg
MMC control treatment arms. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g504802g61v53.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also observed a difference in the complete response rate between the VesiGel 80mg MMC arm compared to the water-based 40mg MMC
control arm when evaluating the effect of chemoablation on the number of tumors. In cases of three or fewer tumors, the complete response rate at the primary evaluation time was 80% (15 patients) and 81% (16 patients) in the water-based 40mg MMC
control group and the VesiGel 80mg MMC group, respectively. However, in cases of more than three tumors, cases that would typically be treated using TURBT, the complete response rate at the primary evaluation time was 50% (eight patients) and 100%
(six patients) in the water-based 40mg MMC control group and the VesiGel 80mg MMC group, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The graph below illustrates the complete response rates by tumor volume for the VesiGel 80mg MMC and water-based 40mg
MMC control treatment arms. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g504802g51j14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, the incidence of AEs reported for both VesiGel groups in the study has been low and appears similar to that of the active
control group, with the majority of the AEs having occurred in the VesiGel 80mg MMC group. The main observed AEs related to VesiGel have been dysuria, allergy, lower urinary tract symptoms, and hematuria, or the presence of blood in the urine. The
AEs that have occurred were associated with the use of MMC, MMC intravesical instillation or the cystoscopy procedure itself. The <FONT STYLE="white-space:nowrap">MMC-related</FONT> AEs were primarily burning sensation, rash, urgency, and dysuria,
which is painful or difficult urination. These AEs appear on the MMC label as potential side effects. SAEs were also reported, including allergy, weakness, hematuria, difficult or labored breathing, lower urinary tract symptoms other than dysuria,
and death. None were determined to be related to VesiGel, except for two allergy cases that were resolved. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following images show cytoscopic views of complete
responses in a <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC patient treated with VesiGel. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g504802g03a96.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The image to the left is a <FONT STYLE="white-space:nowrap">pre-treatment</FONT> cystoscopic view of a tumor located in the bladder.
The image to the right is a post-treatment cystoscopic view of the same location following VesiGel chemoablation treatment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Dose Escalation Study for VesiGel </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In parallel to our Phase 2a clinical trial, in the first half of 2015, we initiated a dose escalation study for patients with NMIBC in Europe and Israel to evaluate the
safety and efficacy of VesiGel at dose levels higher than 80 mg MMC. To date, we have enrolled 14 patients. All patients to date have been treated with the 120 mg MMC in 60 ml gel dose, or 0.2% concentration. Of the 12
<FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC patients evaluated to date, 10 have achieved a complete response (83%). However, at the 120 mg MMC dose level, we also observed a higher rate of
<FONT STYLE="white-space:nowrap">MMC-related</FONT> AEs than in patients treated with the 80 mg MMC dose. Five of 12 patients did not complete six weekly instillations due to their <FONT STYLE="white-space:nowrap">non-compliance,</FONT> although
three of these five patients achieved a complete response. As a result, we have determined to focus our development efforts going forward on the 80 mg MMC dose level. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Phase 1 Clinical Trial for VesiGel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In early 2014, we completed a
Phase 1 clinical trial in India evaluating two earlier formulations of VesiGel. Patients underwent six weekly instillations according to their assigned treatment of RTGel (40 ml) formulated with either 40 mg MMC or 80 mg MMC. Following completion of
the six instillations, patients were evaluated for safety and efficacy. We enrolled 19 patients, 15 of whom were evaluated for response to treatment. Of the 15 evaluable patients, seven achieved a complete response, with two out of five from the 40
mg MMC arm and five out of 10 from the 80 mg MMC arm. Patients were followed for one year after treatment. The results of this study led to the initiation of our Phase 2a clinical trial, in which we are using a higher volume of RTGel, 64 ml compared
to 40 ml, in an attempt to further enhance the efficacy of the 40 mg and 80 mg MMC VesiGel dose groups, by increasing the dwell time of the drug. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Durability
of Response </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Per protocol, the patients in our Phase 2a and Phase 1 clinical trials were followed for 12 months after the primary disease evaluation time
point. To date, 41 patients treated with different VesiGel formulations completed the <FONT STYLE="white-space:nowrap">12-month</FONT> <FONT STYLE="white-space:nowrap">follow-up</FONT> period, 28 of whom achieved a complete response at the primary
disease evaluation time point and did not receive any additional treatments. Of these 28 patients, 28 (100%), 25 (89%), 24 (86%) and 22 (79%) had durable complete responses at three, six, nine and 12 months, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The graph below demonstrates the durability data for the patients treated with VesiGel who achieved a complete response at the primary disease evaluation time point and
were followed for 12 months. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g504802g53f75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that these results support our belief that VesiGel, acting as a chemoablation agent, can replace TURBT, with the
possibility of improving durability of response. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Next Steps in the Clinical Development of VesiGel </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We completed the Phase 2a clinical trial in the first half of 2017. We recently met with the FDA to discuss next steps in the clinical development program for VesiGel.
We plan to file an IND for VesiGel in the first half of 2018 and, if accepted, to commence a U.S. based Phase 2b clinical trial for VesiGel shortly thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Vesimune: Our Product Candidate for the Treatment of High-Grade NMIBC </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
are developing Vesimune, our immune-modulation product candidate, for the treatment of high-grade NMIBC. A Phase 1 dose escalation study was conducted in 23 NMIBC patients and Vesimune appeared to be well-tolerated in the study. This was followed by
a Phase 1 pilot study under an IND in 12 patients with CIS bladder cancer in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
United States. 40% of the 10 evaluable patients achieved a complete response, and Vesimune was observed to be well-tolerated in the trial. We intend to further investigate the use of Vesimune for
the treatment of high-grade NMIBC, as a single agent or possibly combining it with VesiGel, MitoGel or with immune checkpoint inhibitors. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Limitations of
Current Therapies for High-Grade NMIBC </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">High-grade NMIBC is a highly aggressive form of bladder cancer. TURBT is the initial treatment of choice for
high-grade NMIBC; however, the high rates of recurrence and significant risk of progression to muscle-invasive tumors are particularly dangerous. Bladder removal can be the first treatment of choice for young, otherwise healthy patients with
high-grade disease or for patients who cannot tolerate BCG. BCG, an immunotherapy-based drug, is the current standard of care as an adjuvant therapy post-resection in high-grade tumors. However, treatment with BCG is associated with severe side
effects, as evidenced by a Black Box warning on the label. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Solution: Vesimune </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that Vesimune, our immune-modulation product candidate, could represent a valid alternative to the current standard of care for the BCG adjuvant, post-TURBT
treatment of high-grade NMIBC. Vesimune&#146;s active ingredient is Imiquimod, an imidazoquinoline, synthetic immune modulator, which specifically targets TLR7, which is expressed in bladder cancer cells. Toll-like receptors are pattern recognition
receptors whose importance in stimulating innate and adaptive immunity has been established by recent studies. Toll-like receptors are able to sense microbial components as well as host-derived endogenous molecules released by injured tissues and
play a critical role in defending against invading pathogens. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Imiquimod, in its topical formulation, is FDA approved for several indications, including superficial
basal cell carcinoma. Vesimune is a liquid formulation of Imiquimod for intravesical administration that has been optimized for delivery in the urinary tract. Vesimune does not use our RTGel technology. We believe that Vesimune may elicit an
adaptive immune response in the presence of released bladder cancer antigens, which may translate into a long lasting acquired immune response. We also believe the combination of Vesimune with immune checkpoint inhibitors could further increase the
adaptive immune response and potentially represent a viable alternative to BCG for the adjuvant treatment of high-grade NMIBC or UTUC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have obtained Orphan Drug
Designation for Vesimune for the treatment of CIS in the bladder. We have an active IND for Vesimune, which has been effective since 2013. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We acquired Vesimune
from Telormedix SA, a private Swiss-based biotechnology company, in the fourth quarter of 2015. Telormedix conducted all of the previous studies related to Vesimune, including the Phase 1 and Phase 1b studies. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Vesimune Clinical Results and Post-Study <FONT STYLE="white-space:nowrap">Follow-Up</FONT> </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Vesimune was evaluated in a Phase 1 dose escalation study that enrolled 23 patients diagnosed with NMIBC. Vesimune was well-tolerated at the doses used. Subsequently, a
Phase 1b study of Vesimune was conducted under an IND in patients with CIS bladder cancer in the United States. The Phase 1b study was commenced in April 2013 and completed in February 2014. Patients were dosed with Vesimune 0.4% weekly for six
weeks. The study was designed to evaluate the safety and preliminary efficacy of Vesimune in CIS patients. The primary efficacy endpoint for observational purposes only was the rate of complete response at five to seven weeks after the sixth weekly
instillation. Twelve patients were enrolled into the pilot study, of which 10 patients were evaluable for response. Four of the 10 patients, or 40%, achieved a complete response. Vesimune was observed to be well tolerated in this trial. The most
common AEs related to Vesimune were urination urgency, dysuria, fatigue, urinary tract infections and hematuria. One SAE, a urinary tract infection, was observed and was resolved. For observational purposes, patients were followed for an additional
six month period beyond the completion of the study, referred to as the Post-Study Follow Up. Of the four patients who had achieved a complete response with Vesimune in the study, two patients remained disease free at the end of the Post-Study
Follow Up while receiving no additional therapy. The two other patients who had achieved a complete response with Vesimune in the study also remained disease free at the end of the Post-Study Follow Up while receiving BCG therapy during this period.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The chart below represents the complete response rates for patients receiving only Vesimune: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g504802g87e13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Next Steps in the Clinical Development of Vesimune </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to further investigate the use of Vesimune for the treatment of high-grade NMIBC, as a single agent or possibly combined with MitoGel, VesiGel or other
immunotherapy agents. Such a combination study would evaluate whether this multimodality approach, harnessing the power of the immune system together with the chemoablation properties of VesiGel or MitoGel, can provide a safe and effective approach
for the treatment of high-grade urothelial tumors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preclinical Programs </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Using our proprietary RTGel formulation technology, we are pursuing additional preclinical programs to expand and enhance our
<FONT STYLE="white-space:nowrap">uro-oncology</FONT> product portfolio. In particular, we are pursuing preclinical programs for high-grade bladder cancer and high-grade UTUC using checkpoint inhibitors such as an anti
<FONT STYLE="white-space:nowrap">PD-L1</FONT> or an anti <FONT STYLE="white-space:nowrap">CTLA-4.</FONT> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>License Agreement with Allergan </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2016, we entered into the Allergan Agreement with Allergan and granted Allergan an exclusive worldwide license to research, develop, manufacture and
commercialize pharmaceutical products that contain RTGel and clostridial toxins (including BOTOX), alone or in combination with certain other active ingredients, to which we refer as the Licensed Products, which are approved for the treatment of
adults with overactive bladder who cannot use or do not adequately respond to anticholinergics. Additionally, we granted Allergan a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide license to use certain of our trademarks as required
for Allergan to practice its exclusive license with respect to the Licensed Products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Allergan Agreement, Allergan is solely responsible, at its expense,
for developing the Licensed Products and obtaining all regulatory approvals for Licensed Products worldwide. Allergan is also solely responsible, at its expense, for commercializing the Licensed Products worldwide after receiving the regulatory
approval to do so. Allergan is required to use commercially reasonable efforts to develop and commercialize the Licensed Products for overactive bladder in certain major market countries. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will supply Allergan with certain quantities of RTGel for development of Licensed Products through Phase 2 clinical trials using BOTOX together with RTGel in
patients with overactive bladder, at Allergan&#146;s request and expense. Allergan has the right to reduce the next milestone payment to us if there is a material supply failure from us. Prior to completion of the first Phase 2 clinical trial,
Allergan has the right to request that we transfer to Allergan our manufacturing process for RTGel and Allergan will assume the responsibility to manufacture RTGel and Licensed Product for its own development and commercialization activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Allergan paid us a nonrefundable upfront license fee of $17.5&nbsp;million upon signing the agreement, and, in the
third quarter of 2017, we received an additional $7.5&nbsp;million milestone payment upon the submission by Allergan of an IND to the FDA for a Licensed Product. In October 2017, we announced that Allergan had begun a Phase 2 study of RTGel in
combination with BOTOX for the treatment of overactive bladder. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, we are eligible to receive additional material milestone payments of up to an aggregate of
$200.0&nbsp;million upon the successful completion of certain development, regulatory and commercial milestones, including $20.0&nbsp;million upon initiation of a Phase 3 clinical trial for a Licensed Product for overactive bladder;
$15.0&nbsp;million upon initiation of a Phase 3 clinical trial for a Licensed Product for a specified second indication; $50.0&nbsp;million and $25.0&nbsp;million upon the first commercial sale of a Licensed Product for overactive bladder in the
United States and the European Union, respectively; $25.0&nbsp;million and $15.0&nbsp;million upon the first commercial sale of a Licensed Product for a specified second indication in the United States and the European Union, respectively; and
$50.0&nbsp;million upon net sales of all Licensed Products of $500.0&nbsp;million. Allergan will pay us a tiered royalty in the low single digits based on worldwide annual net sales of Licensed Products, subject to certain reductions for the market
entry of competing products and/or loss of our patent coverage of Licensed Products. We are responsible for payments to any third party for certain RTGel-related third party intellectual properties. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Allergan Agreement, Allergan granted us a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable, fully
<FONT STYLE="white-space:nowrap">paid-up,</FONT> perpetual, worldwide license under any improvements Allergan makes to the composition, formulation, or manufacture of RTGel for the research, development, manufacture and commercialization of any
product containing RTGel and any active ingredient (other than a clostridial toxin) for all indications other than indications covered by the agreement and an exclusive, sublicensable, royalty-bearing (in low single digits), perpetual worldwide
license under such improvements for use in the prevention or treatment of oncology indications. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to continue to research, develop and commercialize other
products combining RTGel with other active ingredients, except that there are certain restrictions with respect to the overactive bladder and neurogenic detrusor overactivity indications. Neurogenic detrusor overactivity is when a known neurologic
abnormality impairs the signaling systems between the bladder and the central nervous system, and the brain is unable to inhibit the detrusor muscles controlling urination. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Either party may terminate the Allergan Agreement for uncured material breach by the other party and for the insolvency of the other party. We may terminate the
Allergan Agreement if Allergan or its affiliates challenges any of our patents licensed to Allergan and such patent challenge is not required under a court order or subpoena and is not a defense against a claim, action or proceeding asserted by us,
our affiliates or licensees against Allergan, its affiliates or sublicensees. In addition, Allergan may unilaterally terminate the Allergan Agreement for any reason upon advance notice. If Allergan has the right to terminate the Allergan Agreement
due to our uncured material breach, Allergan may elect to continue the agreement and reduce all future milestone and royalty payment obligations to us by a specified percentage. In the event of any termination of the Allergan Agreement, Allergan
will assign or grant a right of reference to any regulatory documentation related to RTGel to us, all rights and licenses to Allergan will terminate, and the license Allergan granted to us under their improvements to RTGel will continue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual Property </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our patent estate includes patents and applications
with claims directed to our MitoGel, VesiGel, RTGel, BotuGel and Vesimune product candidates, as well as broader claims for potential future product candidates. On a worldwide basis, our patent estate includes more than 70 issued patents and pending
patent applications for our product candidates as well as for new treatment methods, manufacturing process, novel intravesical devices and systems and future combination products that are mainly designed to treat internal cavity cancers. In the
United States, we currently have 12 issued patents and more than 45 patent applications filed worldwide that directed to methods, systems and compositions for treating internal cavity cancers, and in particular, urinary tract cancer and bladder
cancer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These U.S.-issued patents are expected to remain in effect until between 2024 and 2035. Our worldwide intellectual property portfolio includes four pending
patent applications relating to BotuGel in the European Union, China and Israel, as well as one granted patent in each of the United States and Russia. In addition, we have two </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
granted patents related to Vesimune in the United States as well as two granted patents in the European Union, two granted patents in Japan, and one granted patent in each of Hong Kong and
Brazil, each of which are expected to remain in effect until 2030. In addition to the issued patents mentioned above, our portfolio includes pending patent applications relating to Vesimune in the European Union, Canada, Brazil, Hong Kong and
Israel. Moreover, we hold five granted patents in the United States, four in Europe, one in each of Israel, Japan, New Zealand and Australia, as well as pending patent applications filed worldwide that relate to novel formulations of phospholipid
drug analogs (saturated lipid conjugate compositions) for the treatment of urinary tract cancer. Our patents and patent applications mainly relate to hydrogel-based pharmaceutical compositions for optimal delivery of any drug to the internal cavity
such as a bladder and/or urinary tract; the method for treating urothelial cancer using hydrogel based composition; the method for treating overactive bladder topically without a need for injections; special catheters and <FONT
STYLE="white-space:nowrap">in-dwelling</FONT> ureter-catheter systems for optimal delivery of a drug into the renal cavity; pharmaceutical compositions comprising an imidazoquinolin-amine (specifically imiquimod) and lactic acid for treating bladder
cancer diseases, and novel phospholipid drug analogs for treating cancer or infections. In addition to patents, we have filed for trademark registration with the United States Patent and Trademark Office, or the USPTO, for &#147;MitoGel,&#148;
&#147;VesiGel,&#148; &#147;RTGel&#148; and &#147;BotuGel.&#148; Furthermore, we rely upon trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our competitive position.
Preparing and filing patent applications is a joint endeavor of our research and development team and our <FONT STYLE="white-space:nowrap">in-house</FONT> and external patent attorneys. Our patent attorneys conduct patent <FONT
STYLE="white-space:nowrap">prior-art</FONT> searches and then analyze the data in order to provide our research and development team with recommendations on a routine basis. This results in: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">protecting our product candidates that are under development; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">encouraging pharmaceutical companies to negotiate development agreements with us; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preventing competitors from attempting to design-around our inventions. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We submit patent applications directly with the
USPTO as provisional patent applications. We would then continue filing under the Patent Cooperation Treaty, or PCT, which is an international patent law treaty that provides a unified procedure for filing a single initial patent application to seek
patent protection for an invention simultaneously in any one of the designated member states. Although a PCT application does not issue as a patent, it allows the applicant to seek protection in any of the member states through national-phase
applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Competition </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The standard of care for treating NMIBC
patients is the TURBT procedure for tumor resection, followed by post-operative adjuvant chemotherapy or immunotherapy instillations, administered to prevent reimplantation of the cancerous cells. The adjuvant agents used are predominately generic
treatments and regimens. Only four drugs have been approved for bladder cancer: Thiotepa, which was approved by the FDA in 1959; BCG, which was approved by the FDA in 1989; Valstar, which was approved by the FDA in 1998; and Tecentriq, which was
approved by the FDA in 2016. Despite the approval of these drugs, there remain high unmet needs in the bladder cancer market. BCG has been used to treat patients with CIS and high-grade T1 since 1990. Thiotepa and Valstar are rarely used, MMC is
used <FONT STYLE="white-space:nowrap">off-label</FONT> as the standard adjuvant treatment in the post-TURBT setting for <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC patients and Tecentriq is used to treat locally advanced or metastic
urothelial carcinoma only. <FONT STYLE="white-space:nowrap">Off-label</FONT> means that while the FDA has not approved MMC as adjuvant treatment in the post-TURBT setting for <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC patients,
physicians are permitted to utilize it as standard of care for this indication as part of medical practice. However, <FONT STYLE="white-space:nowrap">off-label</FONT> usage as a standard of care does not change the FDA&#146;s approval criteria and
does not suggest that FDA approval is more likely than for other investigational drugs. In the UTUC space, there are no approved drugs used to treat the disease. Tumor resection surgeries are conducted in some cases of
<FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC; however, complete kidney and upper urinary tract removal is the standard of care for frequently recurring UTUC. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are several products in the development pipeline, most of which are second- or third line-treatments mainly targeted for high-grade NMIBC patients who have failed
BCG treatment. All are targeted to reduce recurrence, but none are developed to reduce the need for TURBT and other tumor resection therapies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are aware that
other companies, such as Merck Sharp&nbsp;&amp; Dohme Corp., Viventia Bio Inc., Telesta Therapeutics Inc., Heat Biologics, Inc., Viralytics Limited, AADi, LLC, Biocancell Ltd., Halozyme Therapeutics, Inc., Astellas Pharma Inc., Cold Genesys, Inc.,
Altor BioScience Corporation, FKD Therapies Oy, Nippon Kayaku Co., Ltd, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Spectrum Pharmaceuticals, Inc., Taris Biomedical LLC and Handok Inc., are conducting or have recently conducted clinical trials for product candidates for the treatment of <FONT
STYLE="white-space:nowrap">low-grade</FONT> and high-grade NMIBC, including CIS. In addition, we are aware of several pharmaceutical companies that are developing drug candidates for muscle-invasive bladder cancer. The FDA approved Tecentriq
(atezolizumab) for the treatment of locally advanced or metastic urothelial carcinoma, a form muscle invasive bladder cancer, on May&nbsp;18, 2016. We do not know whether these potential competitors are already developing, or plan to develop, <FONT
STYLE="white-space:nowrap">low-grade</FONT> UTUC or high-grade UTUC treatments or other indications that we are pursuing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we face competition from
existing standards of treatment, including TURBT, which is surgery for bladder cancer. If we are not able to demonstrate that our product candidates are at least as safe and effective as such courses of treatment, medical professionals may not adopt
our product candidates to replace the existing standard of care, which is a first-line tumor surgical procedure for both bladder cancer and UTUC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
biopharmaceutical industry is intensely competitive and subject to rapid and significant technological change. Our potential competitors include large and experienced companies that enjoy significant competitive advantages over us, such as greater
financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition, and more experience and expertise in obtaining marketing approvals from the FDA and foreign regulatory authorities. These companies may
develop new drugs to treat the indications that we target, or seek to have existing drugs approved for use for the treatment of the indications that we target. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These potential competitors may therefore introduce competing products without our prior knowledge and without our ability to take preemptive measures in anticipation
of their commercial launch. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in this industry. Our competitors may succeed in developing,
acquiring or licensing on an exclusive basis products that are more effective, easier to administer or less costly than our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Government
Regulation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the
clinical development, manufacture and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate research and development activities and the testing, manufacture, quality control, safety, effectiveness,
labeling, storage, packaging, recordkeeping, tracking, approval, import, export, distribution, advertising and promotion of our products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The process required by
the FDA before product candidates may be marketed in the United States generally involves the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">nonclinical laboratory and animal tests that must be conducted in accordance with good laboratory practices, or GLPs; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission of an IND, which must become effective before clinical trials may begin; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval by an independent institutional review board, or IRB, for each clinical site or centrally before each trial may be initiated; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed product candidate for its intended use, performed in accordance with good clinical practices, or GCPs;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of an NDA; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of an FDA advisory committee review, if applicable; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of manufacturing facilities and selected clinical investigators for their compliance with cGMP and GCPs; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FDA approval of an NDA to permit commercial marketing for particular indications for use. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the commencement of
marketing of controlled substances, the DEA must also determine the controlled substance schedule, taking into account the recommendation of the FDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The testing
and approval process requires substantial time, effort and financial resources. Preclinical studies include laboratory evaluation of drug substance chemistry, pharmacology, toxicity and drug product formulation, as well as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
animal studies to assess potential safety and efficacy. Prior to commencing the first clinical trial with a product candidate, we must submit the results of the preclinical tests and preclinical
literature, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical studies may continue even after the IND is submitted. The IND
automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, raises safety concerns or questions about the conduct of the clinical trial by imposing a
clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Submission of an IND may not result in FDA authorization to commence a clinical trial. A separate submission to the
existing IND must be made for each successive clinical trial conducted during product development, as well as amendments to previously submitted clinical trials. Further, an independent IRB for each study site proposing to conduct the clinical trial
must review and approve the plan for any clinical trial, its informed consent form and other communications to study subjects before the clinical trial commences at that site. The IRB must continue to oversee the clinical trial while it is being
conducted, including any changes to the study plans. Regulatory authorities, an IRB or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable
health risk, the clinical trial is not being conducted in accordance with the FDA&#146;s or the IRB&#146;s requirements, if the drug has been associated with unexpected serious harm to subjects, or based on evolving business objectives or
competitive climate. Some studies also include a data safety monitoring board, which receives special access to unblinded data during the clinical trial and may advise us to halt the clinical trial if it determines that there is an unacceptable
safety risk for subjects or other grounds, such as no demonstration of efficacy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, for purposes of NDA approval, human clinical trials are typically
conducted in three sequential phases that may overlap. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 1&#151;Studies are initially conducted to test the product candidate for safety, dosage tolerance, structure-activity relationships, mechanism of action, absorption, metabolism, distribution and excretion in
healthy volunteers or subjects with the target disease or condition. If possible, Phase 1 trials may also be used to gain an initial indication of product effectiveness. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2&#151;Controlled studies are conducted with groups of subjects with a specified disease or condition to provide enough data to evaluate the preliminary efficacy, optimal dosages and dosing schedule and expanded
evidence of safety. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 3&#151;These clinical trials are undertaken in larger subject populations to provide statistically significant evidence of clinical efficacy and to further test for safety in an expanded subject population at
multiple clinical trial sites. Evidence is considered to be statistically significant when the probability of the result occurring by random chance, rather than from the efficacy of the treatment, is sufficiently low. These clinical trials are
intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. These trials may be done globally to support global registrations so long as the global sites are also representative of the U.S.
population and the conduct of the study at global sites comports with FDA regulations and guidance, such as compliance with GCPs. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may
require, or companies may pursue, additional clinical trials after a product is approved. These <FONT STYLE="white-space:nowrap">so-called</FONT> Phase 4 studies may be made a condition to be satisfied after approval. The results of Phase 4 studies
can confirm the effectiveness of a product candidate and can provide important safety information. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials must be conducted under the supervision of
qualified investigators in accordance with GCP requirements, which includes the requirements that all research subjects provide their informed consent in writing for their participation in any clinical trial, and the review and approval of the study
by an IRB. Investigators must also provide information to the clinical trial sponsors to allow the sponsors to make specified financial disclosures to the FDA. Clinical trials are conducted under protocols detailing, among other things, the
objectives of the trial, the trial procedures, the parameters to be used in monitoring safety and the efficacy criteria to be evaluated and a statistical analysis plan. Information about some clinical trials, including a description of the trial and
trial results, must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their ClinicalTrials.gov website. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The manufacture of investigational drugs for the conduct of human clinical trials is subject to cGMP requirements.
Investigational drugs and active pharmaceutical ingredients imported into the United States are also subject to regulation by the FDA relating to their labeling and distribution. Further, the export of investigational drug products outside of the
United States is subject to regulatory requirements of the receiving country as well as U.S. export requirements under the Federal Food, Drug and Cosmetic Act, or the FDCA. Progress reports detailing the results of the clinical trials must be
submitted at least annually to the FDA and the IRB and more frequently if SAEs occur. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrent with clinical trials, companies usually complete additional animal
studies and must also develop additional information about the chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements.
The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally,
appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>505(b)(2) Regulatory Approval Process </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;505(b)(2) of the
FDCA, or 505(b)(2), provides an alternate regulatory pathway to FDA approval for new or improved formulations or new uses of previously approved drug products. Specifically, 505(b)(2) permits the filing of an NDA where at least some of the
information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. The applicant may
rely upon the FDA&#146;s prior findings of safety and efficacy for an approved product that acts as the reference listed drug for purposes of a 505(b)(2) NDA. The FDA may also require 505(b)(2) applicants to perform additional studies or
measurements to support any changes from the reference listed drug. The FDA may then approve the new product candidate for all or some of the labeled indications for which the referenced product has been approved, as well as for any new indication
sought by the 505(b)(2) applicant. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Orange Book Listing </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;505 of the FFDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A
Section&nbsp;505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy, but where at least some of the
information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted.
This regulatory pathway enables the applicant to rely, in part, on the FDA&#146;s prior findings of safety and efficacy for an existing product, or published literature, in support of its application. Section&nbsp;505(j) establishes an abbreviated
approval process for a generic version of approved drug products through the submission of an abbreviated new drug application, or ANDA. An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form,
strength, route of administration, labeling, performance characteristics and intended use, among other things, to a previously approved product. ANDAs are termed &#147;abbreviated&#148; because they are generally not required to include preclinical
and clinical data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator drug through in vitro, in vivo or other testing.
The generic version must deliver the same amount of active ingredients into a subject&#146;s bloodstream in the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written for the reference
listed drug. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA patents whose claims cover the
applicant&#146;s product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book. These products may be
cited by potential competitors in support of approval of an ANDA or 505(b)(2) NDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any applicant who files an ANDA seeking approval of a generic equivalent version
of a drug listed in the Orange Book or a 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA that (1)&nbsp;no patent information on the drug product that is the subject of the application has been submitted to the FDA;
(2)&nbsp;such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
patent has expired; (3)&nbsp;the date on which such patent expires; or (4)&nbsp;such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which
the application is submitted. This last certification is known as a Paragraph IV certification. Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant
challenges a listed patent through a Paragraph IV certification. If the applicant does not challenge the listed patents or does not indicate that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not
be approved until all of the listed patents claiming the referenced product have expired. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the competitor has provided a Paragraph IV certification to the FDA,
the competitor must also send notice of the Paragraph IV certification to the holder of the NDA for the reference listed drug and the patent owner once the application has been accepted for filing by the FDA. The NDA holder or patent owner may then
initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification prevents the FDA from approving the
application until the earlier of 30 months from the date of the lawsuit, expiration of the patent, settlement of the lawsuit, a decision in the infringement case that is favorable to the applicant or such shorter or longer period as may be ordered
by a court. This prohibition is generally referred to as the <FONT STYLE="white-space:nowrap">30-month</FONT> stay. In instances where an ANDA or 505(b)(2) NDA applicant files a Paragraph IV certification, the NDA holder or patent owner regularly
take action to trigger the <FONT STYLE="white-space:nowrap">30-month</FONT> stay, recognizing that the related patent litigation may take many months or years to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant
period of time depending on the patent certification the applicant makes and the reference drug sponsor&#146;s decision to initiate patent litigation. The applicant may also elect to submit a statement certifying that its proposed label does not
contain, or carves out, any language regarding the patented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> rather than certify to a listed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> patent. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Exclusivity </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA provides periods of regulatory exclusivity, which provides the holder of an approved NDA limited protection from new competition in the marketplace for the
innovation represented by its approved drug for a period of three or five years following the FDA&#146;s approval of the NDA. Five years of exclusivity are available to NCEs. An NCE is a drug that contains no active moiety that has been approved by
the FDA in any other NDA. An active moiety is the molecule or ion, excluding those appended portions of the molecule that cause the drug to be an ester, salt, including a salt with hydrogen or coordination bonds, or other noncovalent, or not
involving the sharing of electron pairs between atoms, derivatives, such as a complex (<I>i.e.</I>, formed by the chemical interaction of two compounds), chelate (<I>i.e.</I>, a chemical compound), or clathrate (<I>i.e.</I>, a polymer framework that
traps molecules), of the molecule, responsible for the therapeutic activity of the drug substance. During the exclusivity period, the FDA may not accept for review or approve an ANDA or a 505(b)(2) NDA submitted by another company that contains the
previously approved active moiety. An ANDA or 505(b)(2) application, however, may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a product is not eligible for the NCE exclusivity, it may be eligible for three years of exclusivity. Three-year exclusivity is available to the holder of an NDA,
including a 505(b)(2) NDA, for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials, other than bioavailability or bioequivalence trials,
was essential to the approval of the application and was conducted or sponsored by the applicant. This three-year exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDAs for the condition of the new drug&#146;s approval. As a
general matter, three-year exclusivity does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year and three-year exclusivity will not delay the submission or approval of
a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and efficacy. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The Orphan Drug Act </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Orphan Drug Act, the FDA may grant
Orphan Drug Designation to drugs intended to treat a rare disease or condition&#151;generally a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan Drug Designation must be requested before submitting an
NDA. After the FDA grants Orphan Drug Designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the regulatory
review and approval process. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Orphan Drug Designation is entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year exclusivity period, the FDA may
not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA
from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of Orphan Drug Designation are tax credits for certain research and a waiver of the NDA application
user fee. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fast Track Designation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA is required to
facilitate the development and expedite the review of drugs that are intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs
for the condition. Under the Fast Track program, the sponsor of a new product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the submission of the IND for the product
candidate. The FDA must determine if the product candidate qualifies for Fast Track designation within 60 days after receipt of the sponsor&#146;s request. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For
Fast Track products, the sponsor may have more frequent interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#146;s NDA before the application is complete. This rolling review is available if the applicant
provides and the FDA approves a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA&#146;s time period goal for reviewing a Fast Track application does not begin until the last
section of the NDA is submitted. In addition, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. A Fast Track designated product
candidate would ordinarily meet the FDA&#146;s criteria for priority review. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>NDA Submission and Review by the FDA </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Assuming successful completion of the required clinical and preclinical testing, among other items, the results of product development, including chemistry, manufacture
and controls, nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling, as part of an NDA. The submission of an NDA requires payment of a substantial user fee to the FDA. These user fees must be filed at the
time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in some circumstances. One basis for a waiver of the application user fee is if the applicant
employs fewer than 500 employees, including employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced or delivered for introduction into interstate commerce, and the applicant,
including its affiliates, is submitting its first marketing application. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, under the Pediatric Research Equity Act, or PREA, an NDA or supplement to an
NDA for a new active ingredient, indication, dosage form, dosage regimen or route of administration must contain data that are adequate to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric
subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or
all pediatric data until after approval of the product for use in adults or full or partial waivers from the pediatric data requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA must refer
applications for drugs that contain active ingredients, including any ester or salt of the active ingredients, that have not previously been approved by the FDA to an advisory committee or provide in an action letter a summary of the reasons for not
referring it to an advisory committee. The FDA may also refer drugs which present difficult questions of safety, purity or potency to an advisory committee. An advisory committee is typically a panel that includes clinicians and other experts who
review, evaluate and make a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making
decisions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA reviews applications to determine, among other things, whether a product is safe and effective for its intended use and whether the
manufacturing controls are adequate to assure and preserve the product&#146;s identity, strength, quality and purity. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not
approve an application unless it determines that the manufacturing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
processes and facilities, including contract manufacturers and subcontracts, are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCPs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once the FDA
receives an application, it has 60 days to review the NDA to determine if it is substantially complete to permit a substantive review, before it accepts the application for filing. Once the submission is accepted for filing, the FDA begins an <FONT
STYLE="white-space:nowrap">in-depth</FONT> review of the NDA. The FDA&#146;s NDA review times may differ based on whether the application is a standard review or priority review application. The FDA may give a priority review designation to drugs
that are intended to treat serious conditions and provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. Under the goals and policies agreed to by the FDA under the
Prescription Drug User Fee Act, or PDUFA, the FDA has set the review goal of 10 months from the <FONT STYLE="white-space:nowrap">60-day</FONT> filing date to complete its initial review of a standard NDA for an NME and make a decision on the
application. For <FONT STYLE="white-space:nowrap">non-NME</FONT> standard applications, the FDA has set the review goal of 10 months from the submission date to complete its initial review and to make a decision on the application. For priority
review applications, the FDA has set the review goal of reviewing NME NDAs within six months of the <FONT STYLE="white-space:nowrap">60-day</FONT> filing date and <FONT STYLE="white-space:nowrap">non-NME</FONT> applications within six months of the
submission date. Such deadlines are referred to as the PDUFA date. The PDUFA date is only a goal and the FDA does not always meet its PDUFA dates. The review process and the PDUFA date may also be extended if the FDA requests or the NDA sponsor
otherwise provides additional information or clarification regarding the submission. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once the FDA&#146;s review of the application is complete, the FDA will issue
either a Complete Response Letter, or CRL, or approval letter. A CRL indicates that the review cycle of the application is complete and the application is not ready for approval. A CRL generally contains a statement of specific conditions that must
be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing, or other information or analyses in order for the FDA to reconsider the application. The FDA has the goal of reviewing 90% of application
resubmissions in either two or six months of the resubmission date, depending on the kind of resubmission. Even with the submission of additional information, the FDA ultimately may decide that the application does not satisfy the regulatory
criteria for approval. If and when those conditions have been met to the FDA&#146;s satisfaction, the FDA may issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific
indications. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may delay or refuse approval of an NDA if applicable regulatory criteria are not satisfied, require additional testing or information and/or
require post-marketing testing and surveillance to monitor safety or efficacy of a product, or impose other conditions, including distribution restrictions or other risk management mechanisms. For example, the FDA may require a risk evaluation and
mitigation strategy, or REMS, as a condition of approval or following approval to mitigate any identified or suspected serious risks and ensure safe use of the drug. The FDA may prevent or limit further marketing of a product, or impose additional
post-marketing requirements, based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling
claims, are subject to further testing requirements, FDA notification and FDA review and approval. Further, should new safety information arise, additional testing, product labeling or FDA notification may be required. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which such product may be marketed or may include
contraindications, warnings or precautions in the product labeling, which has resulted in a Black Box warning. The FDA also may not approve the inclusion of labeling claims necessary for successful marketing. Once approved, the FDA may withdraw the
product approval if compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, the FDA may require Phase 4
post-marketing studies to monitor the effect of approved products, and may limit further marketing of the product based on the results of these post-marketing studies. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Post-approval Requirements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any products manufactured or distributed
by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including manufacturing, periodic reporting, product sampling and distribution, advertising, promotion, drug shortage reporting, compliance with any post-approval
requirements imposed as a conditional of approval such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
as Phase 4 clinical trials, REMS and surveillance, recordkeeping and reporting requirements, including adverse experiences. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also
are continuing, annual program user fee requirements for any approved products, as well as new application fees for supplemental applications with clinical data. Drug manufacturers and their subcontractors are required to register their
establishments with the FDA and certain state agencies and to list their drug products, and are subject to periodic announced and unannounced inspections by the FDA and these state agencies for compliance with cGMPs and other requirements, which
impose procedural and documentation requirements upon us and our third-party manufacturers. We cannot be certain that we or our present or future suppliers will be able to comply with the cGMP regulations and other FDA regulatory requirements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented, or FDA notification. FDA regulations also
require investigation and correction of any deviations from cGMPs and specifications, and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly,
manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Later discovery of
previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in withdrawal of marketing approval, mandatory revisions
to the approved labeling to add new safety information or other limitations, imposition of post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a REMS program, among other
consequences. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA closely regulates the marketing and promotion of drugs. A company can make only those claims relating to safety and efficacy, purity and
potency that are approved by the FDA. Physicians, in their independent professional medical judgement, may prescribe legally available products for uses that are not described in the product&#146;s labeling and that differ from those tested by us
and approved by the FDA. We, however, are prohibited from marketing or promoting drugs for uses outside of the approved labeling. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the distribution of
prescription pharmaceutical products, including samples, is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and
regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. The Drug Supply Chain Security Act
also imposes obligations on manufacturers of pharmaceutical products related to product and tracking and tracing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Failure to comply with any of the FDA&#146;s
requirements could result in significant adverse enforcement actions. These include a variety of administrative or judicial sanctions, such as refusal to approve pending applications, license suspension or revocation, withdrawal of an approval,
imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, cyber letters, modification of promotional materials or labeling, product recalls, product seizures or detentions, refusal to allow imports or
exports, total or partial suspension of production or distribution, debarment, injunctions, fines, consent decrees, corporate integrity agreements, refusals of government contracts and new orders under existing contracts, exclusion from
participation in federal and state healthcare programs, restitution, disgorgement or civil or criminal penalties, including fines and imprisonment. Any of these sanctions could result in adverse publicity, among other adverse consequences. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Healthcare Regulations </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business activities, including but
not limited to, research, sales, promotion, distribution, medical education and other activities following product approval will be subject to regulation by numerous regulatory and law enforcement authorities in the United States in addition to the
FDA, including potentially the Department of Justice, the Department of Health and Human Services and its various divisions, including the CMS and the Health Resources and Services Administration, the Department of Veterans Affairs, the Department
of Defense and state and local governments. Our business activities must comply with numerous healthcare laws and regulations, including those described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully
offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, the referral of an individual for, or purchasing, leasing, ordering, or arranging for
the purchase, lease or order of, any good, facility, item or service reimbursable, in whole or in part, by Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value,
including unlawful financial inducements paid to prescribers and beneficiaries, as well as impermissible promotional practices. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from
prosecution, but the exceptions and safe harbors are drawn narrowly. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal
Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a cumulative review of all of its facts and
circumstances. Additionally, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, amended the intent requirement of the federal Anti-Kickback Statute
so that a person or entity no longer needs to have actual knowledge of the federal Anti-Kickback Statute, or the specific intent to violate it, to have violated the statute. The ACA also provided that a violation of the federal Anti-Kickback Statute
is grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal civil and criminal false claims laws, including the federal False Claims Act, prohibit, among other things, any person or entity from knowingly presenting,
or causing to be presented, a false claim for payment to, or for approval by, the federal government, including the Medicare and Medicaid programs, or knowingly making, using, or causing to be made or used a false record or statement material to a
false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The civil monetary penalties statute imposes
penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as
claimed or is false or fraudulent. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a condition of receiving Medicaid coverage for prescription drugs, the Medicaid Drug Rebate Program requires manufacturers to
calculate and report to CMS their Average Manufacturer Price, or AMP, which is used to determine rebate payments shared between the states and the federal government and, for some multiple source drugs, Medicaid payment rates for the drug, and for
drugs paid under Medicare Part B, to also calculate and report their average sales price, which is used to determine the Medicare Part B payment rate for the drug. In January 2016, CMS issued a final rule regarding the Medicaid Drug Rebate Program,
effective April&nbsp;1, 2016, that, among other things, revises the manner in which the AMP is to be calculated by manufacturers participating in the program and implements certain amendments to the Medicaid rebate statute created under the ACA.
Drugs that are approved under a biologics license application, or BLA, or an NDA, including a 505(b)(2) NDA, are subject to an additional requirement to calculate and report the manufacturer&#146;s best price for the drug and inflation penalties
which can substantially increase rebate payments. For BLA and NDA drugs, the Veterans Health Care Act requires manufacturers to calculate and report to the Department of Veterans Affairs a different price called the
<FONT STYLE="white-space:nowrap">Non-Federal</FONT> AMP, offer the drugs for sale on the Federal Supply Schedule, and charge the government no more than a statutory price referred to as the Federal Ceiling Price, which includes an inflation penalty.
A separate law requires manufacturers to pay rebates on these drugs when paid by the Department of Defense under its TRICARE Retail Pharmacy Program. Knowingly submitting false pricing information to the government creates potential federal False
Claims Act liability. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit
knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including public and private payors, or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money
or property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the payor is public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing
a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. The ACA amended the federal
health care fraud criminal statute implemented under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have violated the statute. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, the federal Open Payments program pursuant to the Physician Payments Sunshine Act, created under Section&nbsp;6002 of the ACA and its implementing
regulations, require some manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with specified exceptions) to report annually
information related to specified payments or other transfers of value provided to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report
annually specified ownership and investment interests held by physicians and their immediate family members. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we may be subject to data privacy and
security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, impose
requirements relating to the privacy, security and transmission of individually identifiable health information on HIPAA covered entities and their business associates, including mandatory contractual terms and the implementation of certain
safeguards of such information. Among other things, HITECH makes HIPAA&#146;s security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in
connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state
attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. In addition, state laws
govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways, may not have the same effect and may not be preempted by HIPAA, thus complicating compliance efforts. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any payor,
including commercial insurers. We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the
federal government, and/or state laws that require drug manufacturers to report information related to marketing expenditures or payments and other transfers of value to physicians and other healthcare providers. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Enforcement actions can be brought by federal or state governments or, in some cases, as &#147;qui tam&#148; actions brought by individual whistleblowers in the name of
the government. Depending on the circumstances, failure to comply with these laws can result in penalties, including criminal, civil and/or administrative criminal penalties, damages, fines, disgorgement, debarment from government contracts,
individual imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws,
exclusion from government programs, refusal to allow us to enter into supply contracts, including government contracts, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations, any of which
could adversely affect our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to commercialize any products successfully also will depend in part on the extent to which coverage and adequate reimbursement for our products, once
approved, and related treatments will be available from third-party payors, such as government health administration authorities, private health insurers and health maintenance organizations. Third-party payors determine which medications they will
cover and separately establish reimbursement levels. Even if we obtain coverage for a given product by a third-party payor, the third-party payor&#146;s reimbursement rates may not be adequate to make the product affordable to patients or profitable
to us, or the third-party payors may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians,
generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant
portion of the cost of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products
when more established or lower cost therapeutic alternatives are already available or subsequently become available. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Government authorities and other third-party
payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies
provide them with predetermined discounts from list prices as a condition of coverage, are using restrictive formularies and preferred drug lists to leverage greater discounts in competitive classes, and are challenging the prices charged for
medical products. Further, no uniform policy for determining coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from
payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that
coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot be sure that coverage and reimbursement will be
available for any product that we commercialize and, if reimbursement is available, that the level of reimbursement will be adequate. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain
marketing approval. If coverage and reimbursement are not available, or if reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Healthcare Reform Measures </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The United States and some foreign
jurisdictions are considering or have enacted a number of legislative and regulatory proposals designed to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the
United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry
has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, in March 2010, the ACA was passed,
which is changing health care financing by both governmental and private insurers and significantly affecting the U.S. pharmaceutical industry. The ACA, among other things, subjected manufacturers to new annual fees and taxes for specified branded
prescription drugs, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, expanded health care fraud and abuse laws, revised the methodology by which rebates owed by manufacturers to the state and
federal government for covered outpatient drugs under the Medicaid Drug Rebate Program are calculated, imposed an additional rebate similar to an inflation penalty on new formulations of drugs, extended the Medicaid Drug Rebate Program to Medicaid
managed care organizations, expanded the 340B program, which caps the price at which manufacturers can sell covered outpatient pharmaceuticals to specified hospitals, clinics and community health centers, and provided incentives to programs that
increase the federal government&#146;s comparative effectiveness research. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">However, some provisions of the ACA have yet to be fully implemented and certain
provisions have been subject to judicial and Congressional challenges, as well as efforts by the Trump Administration to repeal or replace certain aspects of the ACA. For example, since January 2017, President Trump has signed two executive orders
and other directives designed to delay, circumvent, or loosen certain requirements mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. The recently enacted Tax Cuts
and Jobs Act includes a provision that repeals, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health
coverage for all or part of a year. We continue to evaluate how the ACA and recent efforts to repeal and replace or limit the implementation of the ACA will impact our business. We continue to evaluate how the ACA and recent efforts to repeal and
replace or limit the implementation of the ACA will impact our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other legislative changes have been proposed and adopted in the United States since the
ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This
includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect in April 2013, following passage of the Bipartisan Budget Act of 2015, and will remain in effect through 2025 unless additional U.S.
Congressional action is taken. In addition, in January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased
the statute of limitations period for the government to recover overpayments to providers from three to five years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, there has been increasing legislative
and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted legislation at the federal and state levels designed
to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs.
Additional health reform measures may continue and affect our business in unknown ways. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The Foreign Corrupt Practices Act </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering or authorizing payment or offering of anything of value,
directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also
obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the companies to maintain books and records that accurately and fairly reflect all transactions of the companies, including
international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Foreign Regulation
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and
distribution of our products to the extent we choose to develop or sell any products outside of the United States. The approval process varies from country to country and the time may be longer or shorter than that required to obtain FDA approval.
The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Manufacturing,
Supply and Production </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not own or operate manufacturing facilities for the production of our product candidates, nor do we have plans to develop our own
manufacturing operations in the foreseeable future. We currently rely on third-party contract manufacturers for all of our required raw materials, active ingredients and finished products for our preclinical research and clinical trials, including
the single pivotal Phase 3 clinical trial for MitoGel. We do not have long-term agreements with any of these third parties. We also do not have any current contractual relationships for the manufacture of commercial supplies of our product
candidates if they are approved. If product candidates are approved by any regulatory agency, we intend to enter into agreements with a third-party contract manufacturer and one or more <FONT STYLE="white-space:nowrap">back-up</FONT> manufacturers
for the commercial production of those products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Development and commercial quantities of any products that we develop will need to be manufactured in facilities,
and by processes, that comply with the requirements of the FDA and the regulatory agencies of other jurisdictions in which we are seeking approval. We currently employ internal resources to manage our manufacturing contractors. The relevant
manufacturers of our drug products for our current preclinical and clinical trials have advised us that they are compliant with both cGLP and cGMP. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our product
candidates, if approved, may not be producible in sufficient commercial quantities, in compliance with regulatory requirements or at an acceptable cost. We and our contract manufacturers are, and will be, subject to extensive governmental regulation
in connection with the manufacture of any pharmaceutical products or medical devices. We and our contract manufacturers must ensure that all of the processes, methods and equipment are compliant with cGMP and cGLP for drugs on an ongoing basis, as
mandated by the FDA and foreign regulatory authorities, and conduct extensive audits of vendors, contract laboratories and suppliers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Marketing, Sales and Distribution </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Given our stage of development, we do not have any internal sales, marketing or distribution infrastructure or capabilities, and our marketing department currently
consists only of a marketing director, whose main responsibility is to produce marketing and communication materials, exhibitions, website content and to identify unmet needs in the urology market, assess their commercial potential and advise on the
prioritization of the development of our future product candidates accordingly. We have recently formed a U.S. subsidiary, Urogen Pharma, Inc., to support our U.S. development and potential commercialization efforts. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event that we receive regulatory approvals for our products in markets outside of the United States, we intend, where appropriate, to pursue commercialization
relationships, including strategic alliances and licensing, with pharmaceutical companies and other strategic partners, which are equipped to market or sell our products through their well-developed sales, marketing and distribution organizations in
such countries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we may <FONT STYLE="white-space:nowrap">out-license</FONT> some or all of our worldwide patent rights to more than one party to
achieve </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">the fullest development, marketing and distribution of any products we develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2017, we had 43 full-time employees and
four part-time employees, 36 based in Israel and 11 based in the United States. Of these employees, 35 are primarily engaged in research and development activities and 12 are primarily engaged in general and administrative matters. A total of 13
employees have an M.D. or Ph.D. degree. None of our employees is represented by a labor union. We have never experienced any employment-related work stoppages and believe our relationships with our employees are good. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Israeli labor laws govern the length of the workday and workweek, minimum wages for employees, procedures for hiring and dismissing employees, determination of
severance pay, annual leave, sick days, advance notice of termination, payments to the National Insurance Institute, and other conditions of employment and include equal opportunity and anti-discrimination laws. While none of our employees is party
to any collective bargaining agreements, certain provisions of the collective bargaining agreements between the Histadrut (General Federation of Labor in Israel) and the Coordination Bureau of Economic Organizations (including the
Industrialists&#146; Associations) are applicable to our employees in Israel by order of the Israeli Ministry of Economy and Industry. These provisions primarily concern pension fund benefits for all employees, insurance for work-related accidents,
recuperation pay and travel expenses. We generally provide our employees with benefits and working conditions beyond the required minimums. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Facilities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our principal executive offices are located at 9 HaTa&#146;asiya St., Ra&#146;anana 4365007, Israel, where we lease an approximately 11,180 square foot facility. This
Israeli facility houses our administrative headquarters and our research and development laboratories. We also maintain an office at 499 Park Avenue, New York, New York, where we lease approximately 9,336 square feet of space, which serves as the
headquarters for our U.S. subsidiary. We believe that our existing facilities are adequate to meet our current needs, and that suitable additional or alternative spaces will be available in the future on commercially reasonable terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Environmental, Health and Safety Matters </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are subject to extensive
environmental, health and safety laws and regulations in a number of jurisdictions, primarily Israel, governing, among other things: the use, storage, registration, handling, emission and disposal of chemicals, waste materials and sewage; chemicals,
air, water and ground contamination; air emissions and the cleanup of contaminated sites, including any contamination that results from spills due to our failure to properly dispose of chemicals, waste materials and sewage. Our operations use
chemicals and produce waste materials and sewage and require permits from various governmental authorities including, local municipal authorities, the Ministry of Environmental Protection and the Ministry of Health. The Ministry of Environmental
Protection and the Ministry of Health, local authorities and the municipal water and sewage company conduct periodic inspections in order to review and ensure our compliance with the various regulations. These laws, regulations and permits could
potentially require the expenditure by us of significant amounts for compliance or remediation. If we fail to comply with such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
laws, regulations or permits, we may be subject to fines and other civil, administrative or criminal sanctions, including the revocation of permits and licenses necessary to continue our business
activities. In addition, we may be required to pay damages or civil judgments in respect of third-party claims, including those relating to personal injury (including exposure to hazardous substances we use, store, handle, transport, manufacture or
dispose of), property damage or contribution claims. Some environmental, health and safety laws allow for strict, joint and several liability for remediation costs, regardless of comparative fault. We may be identified as a responsible party under
such laws. Such developments could have a material adverse effect on our business, financial condition and results of operations. In addition, laws and regulations relating to environmental, health and safety matters are often subject to change. In
the event of any changes or new laws or regulations, we could be subject to new compliance measures or to penalties for activities which were previously permitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal and Corporate Structure </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our legal and commercial name is UroGen
Pharma Ltd. We were formed as a company in the State of Israel in April 2004. Urogen Pharma, Inc., our wholly owned subsidiary, was incorporated under the laws of the State of Delaware in October 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal Proceedings </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, we may become party to litigation or
other legal proceedings that we consider to be a part of the ordinary course of our business. We are not currently involved in any legal proceedings that could reasonably be expected to have a material adverse effect on our business, financial
condition or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Scientific Advisory Board </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
maintain a Scientific Advisory Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_13"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers, Key Personnel and Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets
forth information relating to our executive officers and directors as of December&nbsp;15, 2017. Unless otherwise stated, the address for our executive officers and directors is c/o UroGen Pharma Ltd., 9 Ha&#146;Ta&#146;asiya Street, Ra&#146;anana
4365007, Israel. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:22.25pt; font-size:8pt; font-family:ARIAL"><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>POSITION</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Executive Officers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ron Bentsur</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chief Executive Officer and Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gil Hakim</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">President, Israeli Operation</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gary Titus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chief Financial Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Mark Schoenberg, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chief Medical Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Arie Belldegrun, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chairman of the Board of Directors</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cynthia Butitta</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fred Cohen, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kathryn Falberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stuart Holden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ran Nussbaum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pini Orbach, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Executive Officers </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Ron Bentsur </I>has served as our Chief
Executive Officer since August 2015, and as a member of our board of directors since October 2015. Mr.&nbsp;Bentsur has more than 15 years of experience in the biotech industry. Until 2015, Mr.&nbsp;Bentsur served for more than five years as the
Chief Executive Officer of Keryx Biopharmaceuticals, Inc., and during his tenure, Keryx received FDA approval pursuant to the FDA&#146;s 505(b)(2) regulatory pathway for Auryxia (ferric citrate) and launched it commercially in the United States.
Prior to that Mr.&nbsp;Bentsur served as Chief Executive Officer of XTL Biopharmaceuticals Ltd., a position he held from January 2006 until April 2009. From October 2000 Mr.&nbsp;Bentsur was with Keryx and served as its Chief Financial Officer from
June 2003 until his departure in January 2006. From July 1998 to October 2000, Mr.&nbsp;Bentsur served as Director of Technology Investment Banking at Leumi Underwriters, where he was responsible for all technology/biotechnology private placement
and advisory transactions. From June 1994 to July 1998, Mr.&nbsp;Bentsur worked as an investment banker in New York City, spending most of this period at ING Barings Furman Selz. Mr.&nbsp;Bentsur also serves as a member of the board of directors of
Stemline Therapeutics, Inc. since 2009, and of Advanced Inhalation Technologies, Ltd. since August 2015. Mr.&nbsp;Bentsur holds a B.A. in Economics and Business Administration with distinction from the Hebrew University of Jerusalem, Israel and an
M.B.A. (Magna Cum Laude), from New York University&#146;s Stern School of Business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Gil Hakim</I> has served as our President, Israeli Operation, since August
2015 and, prior to that, served as our Chief Executive Officer since August 2010. Mr.&nbsp;Hakim has more than 20 years of experience in the biotech industry. Prior to joining us, Mr.&nbsp;Hakim served as Director of New Product Development at
Medispec Ltd. from 2004 to 2010, and was in charge of product development in fields such as cardiology, urology and dermatology. Prior to Medispec, from 2002 to 2004, Mr.&nbsp;Hakim was Director of Marketing and Clinical Research at MTRE Advanced
Technologies Ltd., a wholly owned subsidiary of Mennen Medical Ltd. that develops thermoregulation devices. Prior to that, from 2000 to 2002, he was Business Development Manager at Omrix Biopharmaceuticals, Inc. (acquired by Johnson&nbsp;&amp;
Johnson in 2008), which develops biological glue and blood derivative products. Before that, from 1998 to 2000, he served as European Product Manager at Biosense-Webster (Johnson&nbsp;&amp; Johnson) in Belgium, following Johnson&nbsp;&amp;
Johnson&#146;s acquisition of Biosense Israel, where he was also part of the Research and Development team. Mr.&nbsp;Hakim holds a B.Sc. in Life Sciences from <FONT STYLE="white-space:nowrap">Ben-Gurion</FONT> University, Israel. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Gary Titus</I> has served as our Chief Financial Officer since July 2015. Mr.&nbsp;Titus has been a member of the board of directors of ImmunoCellular Therapeutics,
Ltd. since January 2013. Mr.&nbsp;Titus has more than 20 years of business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
experience in the healthcare and biopharmaceutical industries, primarily in senior management roles. Prior to his appointment as our Chief Financial Officer, from 2014 to 2015, Mr.&nbsp;Titus
held the position of Chief Financial Officer of BioCardia, Inc. Prior to that, from 2008 to 2013, Mr.&nbsp;Titus was Senior Vice President and Chief Financial Officer at SciClone Pharmaceuticals, Inc. From 2006 to 2008, Mr.&nbsp;Titus was Senior
Vice President of Finance and Chief Financial Officer at Kosan Biosciences, Inc. From 2003 to 2006, he was Chief Financial Officer and Vice President at Nuvelo, Inc. Earlier in his career, Mr.&nbsp;Titus held a variety of positions at other
companies, including Metabolex, Inc., Intrabiotics Pharmaceuticals, Inc. and Johnson&nbsp;&amp; Johnson&#146;s healthcare division, LifeScan, Inc. Mr.&nbsp;Titus holds a B.Sc. in Accounting from the University of South Florida and a B.Sc. in Finance
from the University of Florida. Mr.&nbsp;Titus also completed the Global BioExecutive Program at the University of California Berkeley&#146;s Haas School of Business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Mark Schoenberg, M.D.</I> has served as our Chief Medical Officer since December 2017 and, prior to that, served as our Medical Director since February 2016.
Dr.&nbsp;Schoenberg has over 20 years of experience in clinical practice and research focused on the care of patients with all forms of bladder cancer. Since April 2014, Dr.&nbsp;Schoenberg has been University Professor and Chairman of the Urology
Department at The Montefiore Medical Center for The Albert Einstein College of Medicine of Yeshiva University. Prior to joining Montefiore, from 2005 to 2014, Dr.&nbsp;Schoenberg served as Director of Urologic Oncology and Bernard L. Schwartz
Distinguished Professor of Urologic Oncology at Johns Hopkins Hospital. Dr.&nbsp;Schoenberg is also the past chair of the Medical Advisory Board of the Bladder Cancer Advocacy Network, the author of The Guide to Living with Bladder Cancer, <FONT
STYLE="white-space:nowrap">co-editor</FONT> of The Textbook of Bladder Cancer, a contributor to Campbell&#146;s Urology and a past Senior Editor of the journal Seminars in Urologic Oncology. Dr.&nbsp;Schoenberg received his M.D. (Alpha Omega Alpha)
from the University of Texas Health Sciences Center and completed his residency in General Surgery and Urology at the Hospital of The University of Pennsylvania, where he served as chief resident and urology instructor, before completing basic
research and clinical urologic oncology fellowships at Johns Hopkins under the auspices of The American Cancer Society. Dr.&nbsp;Schoenberg is a fellow of the American College of Surgeons, as well as a member of the American Association of Cancer
Research, the Society of Urologic Oncology and the American Urological Association. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Directors </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Arie Belldegrun, M.D.</I> has served as our Chairman since December 2012. Dr.&nbsp;Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in
Urologic Oncology, and Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, he was a research fellow at the National Cancer Institute/National Institute of Health in surgical
oncology and immunotherapy under Dr.&nbsp;Steven&nbsp;A. Rosenberg. Dr.&nbsp;Belldegrun has more than 20 years of experience in the life science and biotech industry. In 1996 he founded Agensys, Inc., a biotechnology company, and served as its
founding Chairman of the board of directors and as a board member until 2007, when it was acquired by Astellas Pharma Inc. Dr.&nbsp;Belldegrun was also a founder and the Vice-Chairman of the board of directors and Chairman of the scientific advisory
board of Cougar Biotechnology, Inc., a biotechnology company, from 2003 to 2009, when it was acquired by Johnson&nbsp;&amp; Johnson. He served as Chairman and Chief Executive Officer of Kite Pharma, Inc., until October 2017, when it was acquired by
Gilead Sciences, Inc. He currently also serves as the Chairman of Arno Therapeutics, Inc., and Two River Group, and until January 2017 served as a board member of Teva Pharmaceutical Industries Ltd. Dr.&nbsp;Belldegrun completed his M.D. at the
Hebrew University Hadassah Medical School in Jerusalem, Israel, his post graduate studies in Immunology at the Weizmann Institute of Science, Israel, and his residency in Urologic Surgery at Harvard Medical School. Dr.&nbsp;Belldegrun has authored
several books in oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy, and cancer vaccines. Dr.&nbsp;Belldegrun is certified by the American Board of Urology and is a Fellow of the
American College of Surgeons and the American Association of Genitourinary Surgeons. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Cynthia Butitta</I> has served as our director since October 2017.
Ms.&nbsp;Butitta served as Chief Financial Officer of Kite Pharma Inc. from January 2014 to May 2016 and as Chief Operating Officer from March 2014 to September 2017. From May 2011 to December 2012, she was Senior Vice President and Chief Financial
Officer at NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company. Prior to that, Ms.&nbsp;Butitta served as Chief Operating Officer of Telik, Inc., a biopharmaceutical company, from March 2001 to December 2010 and as its Chief Financial
Officer from August 1998 to December 2010. Ms.&nbsp;Butitta also served as Principal Accounting Officer of Telik, Inc. until December 2010. She served as a Director of Catalyst Semiconductor Inc., a semiconductor products company,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
from June 2000 to February 2003. Ms.&nbsp;Butitta received her B.S. degree with honors in Business and Accounting from Edgewood College in Madison, Wisconsin, and an M.B.A. degree in Finance from
the University of Wisconsin, Madison. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Fred Cohen, M.D.</I> has served as our director since May 2017. Dr.&nbsp;Cohen is a Senior Advisor to TPG Capital, where
he served for over 15 years as a Partner, and founder of TPG Biotechnology, a life science focused venture capital fund.&nbsp;Beginning in 2017, Dr. Cohen has served as a co-founder and managing partner of Vida Ventures, a biotechnology venture
capital fund. In addition, for over two decades throughout his career, Dr.&nbsp;Cohen has been affiliated with University of California, San Francisco where he held various clinical responsibilities, including as a research scientist, an internist
for hospitalized patients, a consulting endocrinologist, and the Chief of the Division of Endocrinology and Metabolism. Dr.&nbsp;Cohen received his B.S. degree in Molecular Biophysics and Biochemistry from Yale University, his D.Phil. in Molecular
Biophysics from Oxford on a Rhodes Scholarship, and his M.D. from Stanford. Dr.&nbsp;Cohen currently serves on the Board of Directors of several other biotechnology and pharmaceutical companies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Kathryn Falberg</I> has served as our director since April 2017. She previously served as Executive Vice President and Chief Financial Officer of Jazz
Pharmaceuticals plc, a multi-national specialty biopharmaceutical company, from March 2012 to March 2014 after serving as Senior Vice President and Chief Financial Officer since December 2009. Her responsibilities at Jazz Pharmaceuticals included
strategy, corporate development, corporate communications and information technology. From 2001 through 2009, Ms.&nbsp;Falberg served as a corporate director and audit committee chair for several companies. From 1995 to 2001, Ms.&nbsp;Falberg was
with Amgen Inc., a biotechnology company, where she served as Senior Vice President, Strategy and Chief Financial Officer and prior to that as Vice President, Corporate Controller and Chief Accounting Officer, and Vice President, Treasurer.
Ms.&nbsp;Falberg also serves as a member of the board of directors for the public biopharmaceutical companies Aimmune Therapeutics, Inc., Axovant Sciences Ltd. and The Trade Desk, Inc., a publicly held technology company. Ms.&nbsp;Falberg also
served on the board of directors of Medivation, Inc. from 2013 to 2016 and Halozyme Therapeutics, Inc. from 2007 to 2016. Ms.&nbsp;Falberg received an M.B.A. in Finance and B.A., in Economics from the University of California, Los Angeles and is a
certified public accountant (inactive). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stuart Holden, M.D.</I> has served as our director since December 2015. Dr.&nbsp;Holden has been the Chairman of
ProQuest Investments&#146; Scientific Advisory Board since it was founded in 1998. Since May 2014, Dr.&nbsp;Holden has served as a member of the UCLA faculty as a Health Sciences Clinical Professor of Urology, Spielberg Family Chair in Urologic
Oncology, in the Department of Urology at the UCLA David Geffen School of Medicine and Associate Director of the UCLA Institute of Urologic Oncology. Dr.&nbsp;Holden has worked in the field of prostate cancer for more than 36 years. Dr.&nbsp;Holden
also serves as Medical Director of the Prostate Cancer Foundation since the foundation&#146;s inception in 1993. Dr.&nbsp;Holden was the director of the Louis Warschaw Prostate Cancer Center at Cedars-Sinai Medical Center and the first holder of the
Warschaw, Robertson, Law Families Chair in Prostate Cancer. Dr.&nbsp;Holden has served as a member of the board of directors of Telormedix SA from 2008 to 2017, and served as a member of the board of directors of Acurian, Inc. from 1999 through
2014. In addition, he was a founding partner at Tower Urology in Los Angeles. Dr.&nbsp;Holden received a B.A. degree from the University of Wisconsin-Madison and completed his medical degree and received his surgical training at Weill Cornell
Medical College and the New York Hospital&#151;Cornell University Medical College. He completed his urology residency at Emory University School of Medicine and fellowships in urology and developmental genetics at Memorial Sloan-Kettering Cancer
Center. He also was awarded a clinical fellowship from the American Cancer Society. Dr.&nbsp;Holden was appointed to serve on our board by ProQuest Investments IV, L.P., one of our shareholders, pursuant to rights granted to such shareholder under
our articles of association as in effect prior to our initial public offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Ran Nussbaum</I> has served as our director since May 2013. Mr.&nbsp;Nussbaum is
a managing partner and the <FONT STYLE="white-space:nowrap">co-founder</FONT> of The Pontifax Group, a group of Israeli-based life sciences venture funds focusing on investments in development stage
<FONT STYLE="white-space:nowrap">bio-pharmaceutical</FONT> and <FONT STYLE="white-space:nowrap">med-tech</FONT> technologies and a shareholder of our company. He also serves as a board member on many of Pontifax&#146;s portfolio companies, including
BioBlast Pharma Ltd., Eloxx Pharmaceuticals Ltd., and Quiet Therapeutics Ltd. Mr.&nbsp;Nussbaum was appointed to serve on our board by Pontifax (Israel) III Limited Partnership and Pontifax Cayman III Limited, two of our shareholders, pursuant to
rights granted to such shareholders under our articles of association as in effect prior to our initial public offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Pini Orbach, Ph.D.</I> has served as our director since October 2014. Dr.&nbsp;Orbach has served as a director of
Quiet Therapeutics Ltd. since January 2013. Dr.&nbsp;Orbach has 10 years of experience in executive positions. Since February 2010, Dr.&nbsp;Orbach has been the head of Pharma and Life Science at Arkin Holdings. Dr.&nbsp;Orbach was the Chief
Executive Officer of NanoDoc Technology, Inc. from 2010 to 2015, Chairman of the board of directors of cCAM Biotherapeutics Ltd. from 2014 to 2015, and served as a Director of Quiet Therapeutics Ltd. since January 2013, FusiMab Ltd. from 2011 to
2014, HealOr Ltd. from 2010 to 2013, Metallo-Therapy Ltd. from 2011 to 2015, Insuline Medical Ltd. from December 2013 to January 2015, and CollPlant Holdings Ltd. from May 2013 to August 2014. Prior to joining Arkin Holdings, Dr.&nbsp;Orbach served
as Chief Executive Officer of several healthcare companies in Israel. Dr.&nbsp;Orbach received his Ph.D. from the Department of Physiology and Functional Genomics at the University of Florida, and was a postdoctoral fellow at the Cardiovascular
Research Center at Harvard Medical School. Dr.&nbsp;Orbach was appointed to serve on our board by Arkin Communications Ltd., one of our shareholders, pursuant to rights granted to such shareholder under our articles of association as in effect prior
to this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Arrangements Concerning Election of Directors; Family Relationships </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors consists of eight directors. Currently serving directors will continue to serve pursuant to their appointment until the first annual general
meeting of shareholders held after our initial public offering.<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;We are not a party to, and are not aware of, any voting agreements among our shareholders. In addition, there are no family
relationships among our executive officers and directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate Governance Practices </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Companies incorporated under the laws of the State of Israel, whose shares are publicly traded, including companies with shares listed on the NASDAQ Global Market, are
considered public companies under Israeli law and are required to comply with various corporate governance requirements under Israeli law relating to such matters as the composition and responsibilities of the audit committee and the compensation
committee (subject to certain exceptions that we intend to continue to utilize), and a requirement to have an internal auditor. This is the case even if our shares are not listed on the Tel Aviv Stock Exchange, or TASE, which our shares are not
expected to be. These requirements are in addition to the corporate governance requirements imposed by the NASDAQ Rules and other applicable provisions of U.S. securities laws to which we are subject (as a foreign private issuer). Under the NASDAQ
Rules, a foreign private issuer may generally follow its home country rules of corporate governance in lieu of the comparable requirements of the NASDAQ Rules, except for certain matters including the composition and responsibilities of the audit
committee and the independence of its members within the meaning of the rules and regulations of the SEC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have elected to rely on this &#147;home country
practice exemption&#148; with respect to the following NASDAQ requirements: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Quorum</I>. As permitted under the Israeli Companies Law and pursuant to our amended and restated articles of association, the quorum required for an ordinary meeting of shareholders consists of at least two
shareholders present in person, by proxy or by other voting instrument in accordance with the Israeli Companies Law, who hold at least
33<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>/<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>% of the voting power of our shares (and in an adjourned meeting, with some exceptions, at least two shareholders), instead of 33<SUP
STYLE="font-size:85%; vertical-align:top">1</SUP>/<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>% of the issued share capital required under the NASDAQ Rules. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Nomination of Directors</I>. With the exception of directors elected by our board of directors due to a vacancy, our directors are elected at an annual general meeting of our shareholders and hold office until the
next annual general meeting following his or her election. See &#147;Board Practices&#151;Board of Directors.&#148; The nominations for directors, which are presented to our shareholders by our board of directors, are generally made by the board of
directors itself or a duly authorized committee thereof, in accordance with the provisions of our amended and restated articles of association and the Israeli Companies Law. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Proxy Statements.</I> We are not required to and, in reliance on home country practice, we do not comply with certain NASDAQ Rules regarding the provision of proxy statements for general meetings of shareholders.
Israeli corporate law does not have a regulatory regime for the solicitation of proxies. We intend to provide notice convening an annual general meeting, including an agenda and other relevant documents. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Shareholder Approval.</I> We are not required to and, in reliance on home country practice, we do not comply with certain NASDAQ Rules regarding shareholder approval for certain issuances of securities under NASDAQ
Rule 5635. In accordance with the provisions of our amended and restated articles of association and the Israeli Companies Law, our board of directors is authorized to issue securities, including shares, warrants and convertible notes.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Executive Sessions</I>. We are not required to and, in reliance on home country practice, we do not comply with certain NASDAQ Rules regarding regularly scheduled meetings at which only independent directors are
present. In accordance with the provisions of our amended and restated articles and the Israeli Companies Law, such regularly scheduled meetings at which only independent directors are present are not required. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other than as stated above, we currently take all actions necessary to maintain compliance as a foreign private issuer under the applicable corporate governance
requirements of the Sarbanes-Oxley Act, the rules adopted by the SEC and the NASDAQ Rules. We may in the future elect to use the home country practice exemption with respect to some or all of the other NASDAQ Rules. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Practices </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Board of Directors </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, our board of directors is responsible for setting our general policies and supervising the performance of management. Our board of
directors may exercise all powers and may take all actions that are not specifically granted to our shareholders or to management. Our executive officers are responsible for our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management and have individual responsibilities established by our board of directors. Our Chief Executive Officer is appointed by, and serves at the
discretion of, our board of directors, subject to the terms of the employment agreement that we have entered into with him. All other executive officers are also appointed by our board of directors, and are subject to the terms of any applicable
employment agreements that we may enter into with them. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under our amended and restated articles of association, our board of directors must consist of at least
five directors and not more than nine directors. Our board of directors currently consists of eight directors. Other than vacancies to be filled through selection by the remaining members of our board, the Israeli Companies Law and our amended and
restated articles of association provide that directors are elected annually at the general meeting of our shareholders by a vote of the holders of a majority of the voting power represented present and voting in person, by proxy or by other voting
instrument at that meeting. We have only one class of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, our board of directors is required to employ independent judgment
and discretion when voting, and is prohibited from entering into any voting arrangements with respect to actions taken at meetings of the board. Further, the Israeli Companies Law provides that in the event a director learns about an alleged breach
of law or improper conduct of business relating to a company matter, said director must promptly take action to summon a meeting of the board of directors to address any such breach. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with the exemptions available to foreign private issuers under NASDAQ rules, we do not follow the requirements of the NASDAQ rules with regard to the
process of nominating directors. Instead, we follow Israeli law and practice, in accordance with which our board of directors (or a committee thereof) is authorized to recommend to our shareholders director nominees for election. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our amended and restated articles of association allow our board of directors to appoint directors to fill vacancies on our board of directors, including
filling empty board seats up to the maximum number of directors permitted under our articles of association, for a term of office equal to the remaining period of the term of office of each director whose office has been vacated. Vacancies on our
board of directors may be filled by a vote of a simple majority of the directors then in office. A director so appointed will hold office until the next annual general meeting of our shareholders in which the other directors then in office are
proposed to be replaced or reappointed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Directors may be removed from office by a resolution at a general meeting of shareholders adopted by a majority of the
voting power of our company or under other circumstances set forth in our amended and restated articles of association. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, we would be required to include on our board of directors at least two members, each
of whom qualifies as an external director, and as to whom special qualifications, voting requirements and other provisions would be applicable. We would also be required to include one such external director on each of our board committees. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under regulations promulgated under the Israeli Companies Law, Israeli companies whose shares are traded on stock exchanges such as the NASDAQ Stock Market that do not
have a controlling shareholder (as defined therein) and which comply with the requirements of the jurisdiction where the company&#146;s shares are traded with respect to the appointment of independent directors and the composition of an audit
committee and compensation committee, may elect not to follow the Israeli Companies Law requirements with respect to the composition of its audit committee and compensation committee and the appointment of external directors. As we do not have a
controlling shareholder, we have elected to comply with the requirements of the NASDAQ Stock Market with respect to the composition of our board and such committees, and therefore we are exempt from the Israeli Companies Law requirements with
respect thereto, including the appointment of external directors. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Leadership Structure of the Board </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with the Israeli Companies Law and our amended and restated articles of association, our board of directors is required to appoint one of its members to
serve as chairman of the board of directors. Our board of directors has appointed Arie Belldegrun, M.D. to serve as chairman of the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board
Committees </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law and our amended and restated articles of association, our board of directors is permitted to form committees, and to
delegate to any such committee powers allotted to the board of directors, subject to certain exceptions. In general, the board of directors may overturn a resolution adopted by a committee it has formed; provided, however, that the board&#146;s
decision shall not affect the ability of third parties, who were not aware of such decision, to rely on the committee&#146;s resolution prior to the time it is overturned. Only members of the board of directors can be members of a board committee,
unless the committee is solely advisory. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
audit committee consists of Kathryn Falberg, Pini Orbach and Stuart Holden. Kathryn Falberg serves as chairperson of the audit committee. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Israeli Companies Law
Requirements </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, we are required to maintain an audit committee. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>NASDAQ Listing Requirements </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the NASDAQ Rules, we are required to
maintain an audit committee consisting of at least three independent directors, each of whom is financially literate and one of whom has accounting or related financial management expertise. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the NASDAQ Stock Market. Our
board of directors has determined that Kathryn E. Falberg is an audit committee financial expert as such term is defined by the SEC rules and has the requisite financial experience as defined by the NASDAQ Rules. Each of the members of our audit
committee is &#147;independent&#148; as such term is defined in Rule <FONT STYLE="white-space:nowrap">10A-3(b)(1)</FONT> under the Exchange Act and satisfies the independent director requirements under the NASDAQ Rules. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Audit Committee Role </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audit committee charter sets forth the
responsibilities of the audit committee consistent with the rules and regulations of the SEC and the NASDAQ Rules, as well as the requirements for such committee under the Israeli Companies Law, including the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the board of directors in
accordance with Israeli law; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending the engagement or termination of the person filling the office of our internal auditor; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending the terms of audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services provided by the independent registered public accounting firm for <FONT STYLE="white-space:nowrap">pre-approval</FONT> by
our board of directors. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audit committee provides assistance to our board of directors in fulfilling its legal and fiduciary obligations in
matters involving our accounting, auditing, financial reporting, internal control and legal compliance functions by <FONT STYLE="white-space:nowrap">pre-approving</FONT> the services performed by our independent accountants and reviewing their
reports regarding our accounting practices and systems of internal control over financial reporting. Our audit committee also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary to satisfy itself
that the auditors are independent of management. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, our audit committee is responsible for: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">determining whether there are deficiencies in the business management practices of our company, including in consultation with our internal auditor or the independent auditor, and making recommendations to the board of
directors to improve such practices; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under the Israeli
Companies Law) (see &#147;Approval of Related Party Transactions under Israeli Law&#151;Fiduciary Duties of Directors and Executive Officers&#148;); </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">establishing the approval process for certain transactions with a controlling shareholder or in which a controlling shareholder has a personal interest; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">where the board of directors approves the working plan of the internal auditor, examining such working plan before its submission to the board of directors and proposing amendments thereto; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">examining our internal audit controls and internal auditor&#146;s performance, including whether the internal auditor has sufficient resources and tools to fulfill his responsibilities; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top">examining the scope of our auditor&#146;s work and compensation and submitting a recommendation with respect thereto to our board of directors or shareholders, depending on which of them is considering the appointment
of our auditor; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top">establishing procedures for the handling of employees&#146; complaints as to the management of our business and the protection to be provided to such employees. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Compensation, Nominating and Corporate Governance Committee and Compensation Policy </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have a compensation, nominating and corporate governance committee. The members of this committee are Arie Belldegrun, Ran Nussbaum, Fred Cohen and Cynthia Butitta.
Cynthia Butitta serves as chairperson of the committee. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Israeli Companies Law Requirements </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, the board of directors of a public company must maintain a compensation committee. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The duties of the compensation, nominating and corporate governance committee include the recommendation to the company&#146;s board of directors of a policy regarding
the terms of engagement of office holders, to which we refer as a compensation policy. Such policy must be adopted by the company&#146;s board of directors, after considering the recommendations of the compensation, nominating and corporate
governance committee, and will need to be approved by the company&#146;s shareholders, which we refer to as a Special Majority Approval for Compensation. A Special Majority Approval for Compensation requires shareholder approval by a majority vote
of the shares present and voting at a meeting of shareholders called for such purpose, provided that either: (i)&nbsp;such majority includes at least a majority of the shares held by all shareholders who are not controlling shareholders and do not
have a personal interest in such compensation arrangement, excluding abstentions; or (ii)&nbsp;the total number of shares of <FONT STYLE="white-space:nowrap">non-controlling</FONT> shareholders and shareholders who do not have a personal interest in
the compensation arrangement and who vote against the arrangement does not exceed 2% of the company&#146;s aggregate voting rights. We have adopted a compensation policy, which remains subject to shareholder approval. Even if the company&#146;s
shareholders do not approve the compensation policy, the board of directors may resolve to approve the compensation policy if and to the extent the board determines, in its judgment following internal discussions, that approval of the compensation
policy is in the best interests of the company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The compensation policy serves as the basis for decisions concerning the financial terms of employment or engagement
of office holders, including exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy relates to certain factors, including advancement of the
company&#146;s long-term objectives, business plan and policies, and creation of appropriate incentives for office holders. It also considers, among other things, the company&#146;s risk management, size and the nature of its operations. The
compensation policy furthermore considers the following additional factors: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the education, skills, expertise and accomplishments of the relevant office holder; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the office holder&#146;s roles and responsibilities and prior compensation agreements with him or her; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relationship between the terms offered and the average compensation of the company&#146;s personnel; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the impact of disparities in salary upon work relationships in the company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility of reducing variable compensation at the discretion of the board of directors; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility of setting a limit on the exercise value of <FONT STYLE="white-space:nowrap">non-cash</FONT> variable equity-based compensation; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as to severance compensation, the period of service of the office holder, the terms of his or her compensation during such service period, the company&#146;s performance during that period of service, the person&#146;s
contribution towards the company&#146;s achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The compensation policy also includes the following principles: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the link between variable compensation and long-term performance and measurable criteria; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conditions under which an office holder would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was restated in the
company&#146;s financial statements; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the minimum holding or vesting period for variable, equity-based compensation; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maximum limits for severance compensation. </TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Compensation, Nominating and Corporate Governance Committee Roles
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The compensation, nominating and corporate governance committee is responsible for (i)&nbsp;recommending the compensation policy to our board of directors for
its approval (and subsequent approval by our shareholders) and (ii)&nbsp;duties related to the compensation policy and to the compensation of our office holders, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending whether a compensation policy should continue in effect, if the then-current policy has a term of greater than five years from a company&#146;s initial public offering, or otherwise three years (approval of
either a new compensation policy or the continuation of an existing compensation policy must in any case occur five years from a company&#146;s initial public offering, or otherwise every three years); </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending to the board of directors periodic updates to the compensation policy; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assessing implementation of the compensation policy; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">determining whether to approve the terms of compensation of certain office holders which, according to the Israeli Companies Law, require the committee&#146;s approval; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">determining whether the compensation terms of a candidate for the position of the chief executive officer of the company needs to be brought to approval of the shareholders. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our compensation, nominating and corporate governance charter sets forth the responsibilities of the compensation, nominating and corporate committee, which include:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the responsibilities set forth in the compensation policy; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving the granting of options and other incentive awards to the extent such authority is delegated by our board of directors; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing, evaluating and making recommendations regarding the compensation and benefits for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our compensation, nominating and corporate governance committee is responsible for: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing our corporate governance functions on behalf of the board; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">making recommendations to the board regarding corporate governance issues; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying and evaluating candidates to serve as our directors consistent with the criteria approved by the board; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and evaluating the performance of the board; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">serving as a focal point for communication between director candidates, <FONT STYLE="white-space:nowrap">non-committee</FONT> directors and our management; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selecting or recommending to the board for selection candidates to the board; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">making other recommendations to the board regarding affairs relating to our directors. </TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Disclosure of Compensation
of Executive Officers </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For so long as we qualify as a foreign private issuer, we are not required to comply with the proxy rules applicable to U.S. domestic
companies, including the requirement applicable to emerging growth companies to disclose the compensation of our Chief Executive Officer, Chief Financial Officer, President, Israeli Operation and other two most highly compensated executive officers
on an individual, rather than on an aggregate, basis. Nevertheless, under regulations promulgated under the Israeli Companies Law, we are required to disclose the annual compensation of our five most highly compensated office holders (as defined
under the Israeli Companies Law) on an individual basis, rather than on an aggregate basis. This disclosure will not be as extensive as that required of a U.S. domestic issuer. We intend to commence providing such disclosure, at the latest, in the
notice (which is generally part of the proxy statement) for our 2018 annual general meeting of shareholders, which will be filed under cover of a Report of Foreign Private Issuer on <FONT STYLE="white-space:nowrap">Form&nbsp;6-K</FONT> and we may
elect to provide such information at an earlier date. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Internal Auditor </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, the board of directors of an Israeli public company must appoint an internal auditor recommended by the audit committee. An internal
auditor may not be: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a person (or a relative of a person) who holds more than 5% of the company&#146;s outstanding shares or voting rights; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a person (or a relative of a person) who has the power to appoint a director or the general manager of the company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an office holder (including a director) of the company (or a relative thereof); or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a member of the company&#146;s independent accounting firm, or anyone on its behalf. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The role of the internal auditor
is to examine, among other things, our compliance with applicable law and orderly business procedures, and to report to the chief executive officer, the chairman of the board and the chairman of the audit committee. The internal auditor is entitled
to receive notice of audit committee meetings and to participate in them. In addition, the internal auditor may request that the chairman of the audit committee convene a meeting within a reasonable time to discuss an issue raised by the internal
auditor. The internal auditor is responsible for preparing a proposal for an annual or periodical audit plan and submit such plan to the board of directors or the audit committee for their approval. We intend to appoint an internal auditor following
the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Approval of Related Party Transactions under Israeli Law </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fiduciary Duties of Directors and Executive Officers </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli
Companies Law codifies the fiduciary duties that office holders owe to a company. Each person listed in the table under &#147;Executive Officers and Directors&#148; is an office holder under the Israeli Companies Law. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An office holder&#146;s fiduciary duties consist of a duty of care and a duty of loyalty. The duty of care requires an office holder to act with the level of care with
which a reasonable office holder in the same position would have acted under the same circumstances. The duty of loyalty includes an obligation that an office holder act in good faith and in the best interests of the company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The duty of care includes a duty to use reasonable means to obtain: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">information on the advisability of a given action brought for his or her approval or performed by virtue of his or her position; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all other important information pertaining to any such action. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The duty of loyalty includes a duty to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refrain from any conflict of interest between the performance of his or her duties to the company and his or her other duties or personal affairs; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refrain from any activity that is competitive with the company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refrain from exploiting any business opportunity of the company to receive a personal gain for himself or herself or others; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disclose to the company any information or documents relating to the company&#146;s affairs which the office holder received as a result of his or her position as an office holder. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli Companies Law requires that an office holder promptly disclose to the board of directors any personal interest that he or she may be aware of and all
related material information or documents concerning any existing or proposed transaction with the company. An interested office holder&#146;s disclosure must be made promptly and in any event no later than the first meeting of the board of
directors at which the transaction is considered. A personal interest includes an interest of any person in an action or transaction of a company, including a personal interest of such person&#146;s relative or of a corporate body in which such
person or a relative of such person is a 5% or greater shareholder, director or general manager or in which he or she has the right to appoint at least one director or the general manager, but excluding a personal interest stemming from one&#146;s
ownership of shares in the company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A personal interest also includes the personal interest of a person for whom the office holder holds a voting proxy or the
personal interest of the office holder with respect to his or her vote on behalf of a person for whom he or she holds a proxy even if such person has no personal interest in the matter. An office holder is not, however, required to disclose a
personal interest if it derives solely from the personal interest of his or her relative in a transaction that is not considered an extraordinary transaction. Under the Israeli Companies Law, an &#147;extraordinary transaction&#148; is defined as
any of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a transaction other than in the ordinary course of business; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a transaction that is not on market terms; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a transaction that may have a material impact on a company&#146;s profitability, assets or liabilities. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If it is
determined that an office holder has a personal interest in a transaction, which is not an extraordinary transaction, approval by the board of directors is required for the transaction, unless the company&#146;s articles of association provide for a
different method of approval. Further, so long as an office holder has disclosed his or her personal interest in a transaction, the board of directors may approve an action by the office holder that would otherwise be deemed a breach of his or her
duty of loyalty. However, a company may not approve a transaction or action that is not in the company&#146;s interest or that is not performed by the office holder in good faith. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An extraordinary transaction in which an office holder has a personal interest requires approval first by the company&#146;s audit committee and subsequently by the
board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The compensation of, or an undertaking to indemnify or insure, an office holder who is not a director generally requires approval first by the
company&#146;s compensation committee, then by the company&#146;s board of directors. If such compensation arrangement or an undertaking to indemnify or insure is inconsistent with the company&#146;s stated compensation policy, or if the office
holder is the chief executive officer (apart from a number of specific exceptions), then such arrangement is further subject to a Special Majority Approval for Compensation. If the shareholders of a company do not approve the compensation terms of
office holders at a meeting of the shareholders, other than directors, the compensation committee and board of directors may override the shareholders&#146; decision, subject to certain conditions. Arrangements regarding the compensation,
indemnification or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
insurance of a director require the approval of the compensation committee, board of directors and shareholders by simple majority, in that order, and under certain circumstances, a Special
Majority Approval for Compensation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Generally, a person who has a personal interest in a matter which is considered at a meeting of the board of directors or the
audit committee may not be present at such a meeting or vote on that matter unless the chairman of the audit committee or board of directors (as applicable) determines that he or she should be present in order to present the transaction that is
subject to approval. If a majority of the members of the audit committee or the board of directors (as applicable) has a personal interest in the approval of a transaction, then all directors may participate in discussions of the audit committee or
the board of directors (as applicable) on such transaction and the voting on approval thereof, but shareholder approval is also required for such transaction. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to Israeli law, the disclosure requirements regarding personal interests that apply to directors and executive officers also apply to a controlling shareholder
of a public company. In the context of a transaction involving a shareholder of the company, a controlling shareholder also includes a shareholder who holds 25% or more of the voting rights in the company if no other shareholder holds more than 50%
of the voting rights in the company. For this purpose, the holdings of all shareholders who have a personal interest in the same transaction will be aggregated. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The approval of the audit committee, the board of directors and the shareholders of the company, in that order, is required for (i)&nbsp;extraordinary transactions with
a controlling shareholder or in which a controlling shareholder has a personal interest, (ii)&nbsp;the engagement with a controlling shareholder or his or her relative, directly or indirectly, for the provision of services to the company,
(iii)&nbsp;the terms of engagement and compensation of a controlling shareholder or his or her relative who is not an office holder or (iv)&nbsp;the employment of a controlling shareholder or his or her relative by the company, other than as an
office holder. In addition, the shareholder approval requires one of the following, which we refer to as a Special Majority: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at least a majority of the shares held by all shareholders who do not have a personal interest in the transaction and who are present and voting at the meeting approves the transaction, excluding abstentions; or
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the shares voted against the transaction by shareholders who have no personal interest in the transaction and who are present and voting at the meeting do not exceed 2% of the aggregate voting rights in the company.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that any such transaction with a controlling shareholder is for a period extending beyond three years and under certain conditions,
five years from a company&#146;s initial public offering, approval is required at the end of such period unless, with respect to certain transactions, the audit committee determines that the duration of the transaction is reasonable given the
circumstances related thereto. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Arrangements regarding the compensation, indemnification or insurance of a controlling shareholder in his or her capacity as an
office holder require the approval of the compensation committee, board of directors and shareholders by a Special Majority. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to regulations promulgated
under the Israeli Companies Law, certain transactions with a controlling shareholder or his or her relative, or with directors or other office holders, that would otherwise require approval of a company&#146;s shareholders may be exempt from
shareholder approval under certain conditions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Shareholder Duties </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Israeli Companies Law, a shareholder has a duty to act in good faith and in a customary manner toward the company and other shareholders and to refrain
from abusing his or her power in the company, including, among other things, in voting at a general meeting and at shareholder class meetings with respect to the following matters: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an amendment to the company&#146;s articles of association; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase of the company&#146;s authorized share capital; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a merger; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the approval of related party transactions and acts of office holders that require shareholder approval. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A shareholder
also has a general duty to refrain from discriminating against other shareholders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, certain shareholders have a duty of fairness toward the company.
These shareholders include a controlling shareholder, a shareholder who knows that he or she has the power to determine the outcome of a shareholder vote and a shareholder who has the power to appoint or to prevent the appointment of an office
holder of the company or other power towards the company. The Israeli Companies Law does not define the substance of the duty of fairness, except to state that the remedies generally available upon a breach of contract will also apply in the event
of a breach of the duty to act with fairness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Exculpation, Insurance and Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an
office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association.
Our amended and restated articles of association include such a provision. A company may not exculpate in advance a director from liability arising out of a breach of the duty of care with respect to a distribution. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may indemnify an office holder in respect of the following liabilities and expenses incurred for acts performed by him or her
as an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#146;s award approved by a court. However, if an undertaking to indemnify an office
holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#146;s activities when the undertaking to
indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reasonable litigation expenses, including attorneys&#146; fees, incurred by the office holder (1)&nbsp;as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct
such investigation or proceeding, provided that (i)&nbsp;no indictment was filed against such office holder as a result of such investigation or proceeding, and (ii)&nbsp;no financial liability was imposed upon him or her as a substitute for the
criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2)&nbsp;in connection with a monetary
sanction; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reasonable litigation expenses, including attorneys&#146; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in
connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder,
if and to the extent provided in the company&#146;s articles of association: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a financial liability imposed on the office holder in favor of a third party. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the
following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe
that the act would not harm the company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an act or omission committed with intent to derive illegal personal benefit; or </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a fine, civil fine, monetary sanction or forfeit levied against the office holder. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law,
exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the
shareholders. See &#147;Approval of Related Party Transactions under Israeli Law&#151;Fiduciary Duties of Directors and Executive Officers.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and
restated articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by the Israeli Companies Law. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We maintain directors and officers liability insurance for the benefit of our office holders to the fullest extent permitted by the Israeli Companies Law. In addition,
we have entered into agreements with each of our directors and executive officers exculpating them from liability to us for damages caused to us as a result of a breach of duty of care and undertaking to indemnify them, in each case, to the fullest
extent permitted by our amended and restated articles of association and Israeli law, including with respect to liabilities resulting from this offering to the extent that these liabilities are not covered by insurance. In the opinion of the SEC,
however, indemnification of directors and office holders for liabilities arising under the Securities Act is against public policy and therefore unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have adopted a Code of Business
Conduct and Ethics applicable to all of our directors and employees, including our Chief Executive Officer, Chief Financial Officer, controller or principal accounting officer, or other persons performing similar functions, which is a &#147;code of
ethics&#148; as defined in Item 16B of Form <FONT STYLE="white-space:nowrap">20-F</FONT> promulgated by the SEC. The full text of the Code of Ethics is posted on our website at www.urogen.com. Information contained on, or that can be accessed
through, our website does not constitute a part of this prospectus and is not incorporated by reference herein. If we make any amendment to the Code of Business Conduct and Ethics or grant any waivers, including any implicit waiver, from a provision
of the code of ethics, we will disclose the nature of such amendment or waiver on our website to the extent required by the rules and regulations of the SEC. Under Item 16B of <FONT STYLE="white-space:nowrap">Form&nbsp;20-F,</FONT> if a waiver or
amendment of the Code of Business Conduct and Ethics applies to our principal executive officer, principal financial officer, principal accounting officer or controller and relates to standards promoting any of the values described in Item 16B(b) of
Form <FONT STYLE="white-space:nowrap">20-F,</FONT> we are required to disclose such waiver or amendment on our website in accordance with the requirements of Instruction 4 to such Item 16B. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation of Executive Officers and Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The aggregate compensation
paid and equity-based compensation and other payments expensed by us to our directors and executive officers with respect to the year ended December&nbsp;31, 2016 was $1.8&nbsp;million. This amount does not include business travel, relocation,
professional and business association dues and expenses reimbursed to office holders, and other benefits commonly reimbursed or paid by companies in our industry. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the year ended December 31, 2017, our directors and executive officers were granted options to purchase 355,000&nbsp;ordinary shares, at a weighted-average
exercise price of $20.71 per share under our 2010 Israeli Share Option Plan. As of December 31, 2017, options to purchase 1,141,106 ordinary shares and restricted share units covering 194,560 ordinary shares, granted to our directors and executive
officers, remained outstanding. Since our initial public offering, our board of directors has approved certain modifications and new terms of compensation for our directors and office holders (as such term is used under Israeli law). Under Israeli
law, modifications or new compensation to directors and other office holders that was approved by the board prior to adoption of a compensation policy, or which is inconsistent with the company&#146;s stated compensation policy,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
would generally be subject to shareholder approval. We have called a shareholders&#146; meeting to approve such matters. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have adopted a compensation policy in accordance with the Israeli Companies Law, which remains subject to shareholder approval. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not have any written agreements with any director providing for benefits upon the termination of such director&#146;s relationship with our company, other than
our employment agreement with our Chief Executive Officer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board has approved the following components of officer and director compensation, and we have filed
a proxy statement in connection with an extraordinary meeting of shareholders to be held on February 14, 2018 to obtain shareholder approval for these matters: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our 2018 Officers&#146; Compensation Policy provides for, among other things, the following: </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the base salary for the chief executive officer shall be $535,000 per year, subject to annual updating at a rate not to exceed 10% per year; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the base salary for any officer reporting directly to the chief executive officer shall be between $300,000 per year and $500,000 per year; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the aggregate amount of all annual bonuses paid to each officer shall not exceed the gross sum equal to 50% of the base salary with respect to such officers; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount of annual share based compensation granted to the officers shall not exceed 150,000 options or restricted stock units in the case of the chief executive officer and 80,000 in the case of any officer reporting
directly to the chief executive officer; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the additional annual cash compensation payable to the chairman of the board is $75,000 and $40,000 for each director; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the additional annual cash compensation payable to the chairman of the audit committee is $20,000 and $7,500 for each member of the audit committee; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the annual cash compensation payable to the chairman of the compensation and nominating and corporate governance committees is $15,000 and $5,000 for each member of such committee; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each director shall be eligible for an initial grant of 20,000 options upon joining the board of directors; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each non-employee director shall be eligible for an annual grant of 10,000 options. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The following director options: </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a grant of options to each of Prof. Arie Belldegrun, Dr.&nbsp;Stuart Holden, Dr.&nbsp;Pini Orbach and Mr.&nbsp;Ran Nussbaum, to purchase 10,000 of our ordinary shares at an exercise price of $17.67; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a grant of options to Prof. Arie Belldegrun, as Chairman of our board of directors, to purchase an additional 40,000 of our ordinary shares at an exercise price of $43.67; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a grant of options to each of Ms.&nbsp;Kathryn Falberg and Dr.&nbsp;Fred Cohen, to purchase 40,000 of our ordinary shares, and a grant of options to Ms.&nbsp;Cynthia Butitta to purchase 50,000 of our ordinary shares at
exercise prices of $13.00, $16.99 and $30.66, respectively. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The following officer compensation: </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual base salary of $535,000 and a 50% annual target bonus to&nbsp;Ron Bentsur; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual base salary of $360,000, a 40% annual target bonus, and an additional $100,000 bonus in connection with the our initial public offering to Gil Hakim; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual base salary of $360,000 and a 40% annual target bonus to Gary Titus; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual base salary of $200,000 until December&nbsp;7, 2018 and thereafter an annual base salary of $450,000, a 50% annual target bonus and a $75,000 signing bonus to Prof. Mark Schoenberg; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a grant of options to Ron Bentsur to purchase 80,000 of our ordinary shares at an exercise price of $19.55 and 50,000 of our ordinary shares at an exercise price of $43.67; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a grant of options to Gil Hakim to purchase 50,000 of our ordinary shares at an exercise price of $19.55 and 30,000 of our ordinary shares at an exercise price of $43.67; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a grant of options to Gary Titus to purchase 40,000 of our ordinary shares at an exercise price of $19.55 and 25,000 of our ordinary shares at an exercise price of $43.67; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a grant of options to Prof. Mark Schoenberg to purchase 15,000 of our ordinary shares at an exercise price of $39.26 and 12,500 restricted stock units; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a 2017 bonus in the amount of $247,500 to Ron Bentsur; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a 2017 bonus in the amount of $125,125 to Gil Hakim; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a 2017 bonus in the amount of $125,125 to Gary Titus. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Agreements with Executive Officers; Consulting and
Directorship Services Provided by Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into written employment agreements with all of our executive officers. These agreements contain
standard provisions for a company in our industry regarding <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality of information, <FONT STYLE="white-space:nowrap">non-competition</FONT> and assignment of inventions. Our executive
officers will not receive benefits upon the termination of their respective employment with us, other than payment of salary and benefits (and limited accrual of vacation days) during the required notice period for termination of their employment,
which varies for each individual. In addition, we have entered into an agreement for management services with the chairman of our board of directors. See &#147;Certain Relationships and Related Party Transactions&#151;Agreements and Arrangements
with, and Compensation of, Directors and Executive Officers&#148; for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Incentive Plans </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2017 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors adopted our 2017
Equity Incentive Plan, or our 2017 Plan, in March 2017 and our shareholders approved our 2017 Plan in April 2017. Our 2017 Plan provides for the grant of incentive stock options to our employees and for the grant of nonstatutory stock options, stock
appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards, and other forms of stock awards to our employees, directors and consultants. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Authorized Shares.</I> The maximum number of ordinary shares that may be issued under our 2017 Plan as of the date of this prospectus is 1,400,000. In addition, the
number of ordinary shares reserved for issuance under our 2017 Plan will automatically increase on January 1st of each calendar year, from January&nbsp;1, 2018 through January&nbsp;1, 2026, so that the number of such shares reserved for issuance
will equal 12% of the total number of ordinary shares outstanding on the last day of the calendar month prior to the date of each automatic increase, or a lesser number of shares determined by our board of directors. The maximum number of ordinary
shares that may be issued upon the exercise of incentive stock options under our 2017 Plan is 5,600,000. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Ordinary Shares subject to stock awards granted under our
2017 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, do not reduce the number of shares available for issuance under our 2017 Plan. Additionally, shares issued pursuant to stock
awards under our 2017 Plan that we repurchase or that are forfeited, as well as shares used to pay the exercise price of a stock award or to satisfy the tax withholding obligations related to a stock award, become available for future grant under
our 2017 Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan Administration.</I> Our board of directors, or a duly authorized committee of our board of directors, administers our 2017 Plan. Our board
of directors may also delegate to one or more of our officers the authority to (1)&nbsp;designate employees (other than officers) to receive specified stock awards and (2)&nbsp;determine the number of shares subject to such stock awards. Under the
2017 Plan, our board of directors has the authority to determine the terms of awards, including recipients, the exercise, purchase or strike price of stock awards, if any, the number of shares subject to each stock award, the fair market value of an
Ordinary Share, the vesting schedule applicable to the awards, together with any vesting acceleration, the form of consideration, if any, payable upon exercise or settlement of the award and the terms of the award agreements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Section</I><I></I><I>&nbsp;162(m) Limits.</I> At such time as necessary for compliance with Section&nbsp;162(m) of the Code, no participant may be granted stock
awards covering more than 230,000 of our ordinary shares under the 2017 Plan during any calendar year pursuant to stock options, stock appreciation rights and other stock awards whose value is determined by reference to an increase over an exercise
price or strike price of at least 100% of the fair market value of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
ordinary shares on the date of grant. Additionally, no participant may be granted in a calendar year a performance stock award covering more than 230,000 of our ordinary shares or a performance
cash award having a maximum value in excess of $3.0&nbsp;million under our 2017 Plan. The limitations are designed to allow us to grant compensation that will not be subject to the $1,000,000 annual limitation on the income tax deductibility of
compensation paid to a covered executive officer imposed by Section&nbsp;162(m) of the Code. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock Options.</I> Incentive stock options and nonstatutory stock
options are granted pursuant to stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for stock options, within the terms and conditions of the 2017 Plan, provided that the exercise price of
a stock option generally cannot be less than 100% of the fair market value of our Ordinary Shares on the date of grant. Options granted under the 2017 Plan vest at the rate specified in the stock option agreement as determined by the plan
administrator. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted Stock Unit Awards.</I> Restricted stock unit awards are granted pursuant to restricted stock unit award agreements adopted by the plan
administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our board of directors, or a duly authorized committee of our board of directors, and permissible under
applicable law. A restricted stock unit award may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator or in any other form of consideration set forth in the restricted stock unit
award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, restricted stock units that have not vested will be
forfeited upon the participant&#146;s cessation of continuous service for any reason. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted Stock Awards.</I> Restricted stock awards are granted pursuant
to restricted stock award agreements adopted by the plan administrator. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past services to us or any other form of legal consideration that may be
acceptable to our board of directors, or a duly authorized committee of our board of directors, and permissible under applicable law. The plan administrator determines the terms and conditions of restricted stock awards, including vesting and
forfeiture terms. If a participant&#146;s service relationship with us ceases for any reason, we may receive through a forfeiture condition or a repurchase right any or all of the Ordinary Shares held by the participant that have not vested as of
the date the participant terminates service with us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock Appreciation Rights.</I> Stock appreciation rights are granted pursuant to stock appreciation grant
agreements adopted by the plan administrator. The plan administrator determines the purchase price or strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of our Ordinary Shares on the date
of grant. A stock appreciation right granted under the 2017 Plan vests at the rate specified in the stock appreciation right agreement as determined by the plan administrator. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Performance Awards.</I> The 2017 Plan permits the grant of performance-based stock and cash awards that may qualify as performance-based compensation that is not
subject to the $1,000,000 limitation on the income tax deductibility imposed by Section&nbsp;162(m) of the Code. Our compensation committee may structure awards so that the stock or cash will be issued or paid only following the achievement of
certain <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals during a designated performance period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Other Stock Awards.</I> The plan
administrator may grant other awards based in whole or in part by reference to our Ordinary Shares. The plan administrator will set the number of shares under the stock award and all other terms and conditions of such awards. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Changes to Capital Structure.</I> In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split or
recapitalization, appropriate adjustments will be made to (1)&nbsp;the class and maximum number of shares reserved for issuance under the 2017 Plan, (2)&nbsp;the class and maximum number of shares by which the share reserve may increase
automatically each year, (3)&nbsp;the class and maximum number of shares that may be issued upon the exercise of incentive stock options, (4)&nbsp;the class and maximum number of shares subject to stock awards that can be granted in a calendar year
(as established under the 2017 Plan pursuant to Section&nbsp;162(m) of the Code) and (5)&nbsp;the class and number of shares and exercise price, strike price or purchase price, if applicable, of all outstanding stock awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Transactions.</I> Our 2017 Plan provides that in the event of certain specified significant transactions,
including: (1)&nbsp;a sale of all or substantially all of our assets, (2)&nbsp;the sale or disposition of more than 50% of our outstanding securities, (3)&nbsp;the consummation of a merger or consolidation where we do not survive the transaction and
(4)&nbsp;the consummation of a merger or consolidation where we do survive the transaction but our Ordinary Shares outstanding prior to such transaction are converted or exchanged into other property by virtue of the transaction, unless otherwise
provided in an award agreement or other written agreement between us and the award holder, the administrator may take one or more of the following actions with respect to such stock awards: (1)&nbsp;arrange for the assumption, continuation or
substitution of a stock award by a successor corporation, (2)&nbsp;arrange for the assignment of any reacquisition or repurchase rights held by us to a successor corporation, (3)&nbsp;accelerate the vesting, in whole or in part, of the stock award
and provide for its termination prior to the transaction, (4)&nbsp;arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by us, (5)&nbsp;cancel or arrange for the cancellation of the stock award prior to the
transaction in exchange for a cash payment, if any, determined by the board or (6)&nbsp;make a payment, in the form determined by the board, equal to the excess, if any, of the value of the property the participant would have received upon exercise
of the awards prior to the transaction over any exercise price payable by the participant in connection with the exercise. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of a change in control,
awards granted under the 2017 Plan will not receive automatic acceleration of vesting and exercisability, although this treatment may be provided for in an award agreement. Under the 2017 Plan, a change in control is defined to include (1)&nbsp;the
acquisition by any person or company of more than 50% of the combined voting power of our then outstanding stock, (2)&nbsp;a merger, consolidation or similar transaction in which our stockholders immediately prior to the transaction do not own,
directly or indirectly, more than 50% of the combined voting power of the surviving entity (or the parent of the surviving entity), (3) a sale, lease, exclusive license or other disposition of all or substantially all of our assets other than to an
entity more than 50% of the combined voting power of which is owned by our stockholders, (4)&nbsp;our stockholders approve and the board approves a plan of complete dissolution or liquidation or a complete dissolution or liquidation of the Company
otherwise occurs except for a liquidation into a parent corporation and (5)&nbsp;a circumstance in which the members of the Incumbent Board (as defined in the 2017 Plan) no longer constitute a majority of the members of the board. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Transferability.</I> A participant may not transfer stock awards under our 2017 Plan other than by will, the laws of descent and distribution or as otherwise
provided under our 2017 Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan Amendment or Termination.</I> Our board of directors has the authority to amend, suspend or terminate our 2017 Plan, provided
that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. Certain material amendments also require the approval of our stockholders. No incentive stock options may be granted
after the tenth anniversary of the date our board of directors adopted our 2017 Plan. No stock awards may be granted under our 2017 Plan while it is suspended or after it is terminated. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Acceleration Upon Death</I>. Our 2017 Plan provides that if a participant dies while in a service relationship with us, all vested options and stock appreciation
rights held by the participant as of the date of death shall be exercisable by the participant&#146;s estate, by a person who acquired the right to exercise the option or stock appreciation right by bequest or inheritance, or by a person designated
to exercise the option or stock appreciation right upon the participant&#146;s death, but only within the period ending on the earlier of (i)&nbsp;the date 18 months following the date of death (or such longer or shorter period specified in the
participant&#146;s award agreement), and (ii)&nbsp;the expiration of the term of such option or stock appreciation right as set forth in the award agreement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2017 Israeli Equity Incentive Sub Plan </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our 2017 Israeli Equity Incentive
Sub Plan governs equity awards granted to our Israeli employees, directors and service providers. The 2017 Israeli Equity Incentive Sub Plan was adopted under our 2017 Equity Incentive Plan. The 2017 Israeli Equity Incentive Sub Plan provides for
the grant by us of awards pursuant to Sections 102 and 3(i) of the Israeli Income Tax Ordinance New Version, 5721&#151;1961, or the Ordinance, and the rules and regulations promulgated thereunder. in June 2017, we submitted the 2017 Israeli Equity
Incentive Sub Plan to the Israeli Tax Authority, or the ITA, and it is effective with respect to awards granted from 30 days thereafter. The 2017 Israeli Equity Incentive Sub Plan provides for awards to be granted to those of our or our
affiliates&#146; employees, directors and officers who are not Controlling Shareholders, as defined in the Ordinance, and who are considered Israeli residents, to the extent that such awards either are (i)&nbsp;intended to qualify for special tax
treatment under the &#147;capital gains track&#148; provisions of Section&nbsp;102(b)(2) of the Ordinance or (ii)&nbsp;not intended to qualify for such special tax treatment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
For more information regarding the &#147;capital gains track,&#148; see &#147;&#151;2010 Israeli Share Option Plan.&#148; The 2017 Israeli Equity Incentive Sub Plan also provides for the grant of
awards under Section&nbsp;3(i) of the Ordinance to our Israeli <FONT STYLE="white-space:nowrap">non-employee</FONT> service providers and Controlling Shareholders, who are not eligible for such special tax treatment. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2010 Israeli Share Option Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In September 2010, we adopted our
2010 Israeli Share Option Plan, or the 2010 Plan. The 2010 Plan provides for the grant of share options and restricted share units to our company&#146;s employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants. The
reserved pool of shares under the 2010 Plan is 2,701,579 shares. On March&nbsp;29, 2017, our board resolved that as of the consummation of our initial public offering, shares that are forfeited, cancelled, terminated or expire unexercised under the
2010 Plan shall not be available for issuance under new awards. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2010 Plan provides for the grant by us of awards pursuant to Sections 102 and 3(i) of the
Ordinance and the rules and regulations promulgated thereunder. Section&nbsp;102 of the Ordinance allows employees, directors and officers who are not controlling shareholders and who are Israeli residents, to receive favorable tax treatment for
compensation in the form of shares or options. Section&nbsp;102 of the Ordinance includes two alternatives for tax treatment involving the issuance of options or shares to a trustee for the benefit of the grantees and also includes an additional
alternative for the issuance of options or shares directly to the grantee. Section&nbsp;102(b)(2) of the Ordinance, which provides the most favorable tax treatment for grantees, permits the issuance to a trustee under the &#147;capital gains
track.&#148; In order to comply with the terms of the capital gains track, all options granted under a specific plan and subject to the provisions of Section&nbsp;102 of the Ordinance, as well as the shares issued upon exercise of such options and
other shares received following any realization of rights with respect to such options, such as share dividends and share splits, must be registered in the name of a trustee selected by the board of directors and held in trust for the benefit of the
relevant employee, director or officer. The trustee may not release these options or shares to the relevant grantee before the second anniversary of the registration of the options in the name of the trustee. However, under this track, we are not
allowed to deduct an expense with respect to the issuance of the options or shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2010 Plan provides for awards to be granted to our employees or those of
our affiliates, directors and officers who are not controlling shareholders, as defined in the Ordinance, and who are considered Israeli residents, to the extent that such awards either are (i)&nbsp;intended to qualify for special tax treatment
under the &#147;capital gains track&#148; provisions of Section&nbsp;102(b)(2) of the Ordinance or (ii)&nbsp;not intended to qualify for such special tax treatment. The 2010 Plan also provides for the grant of awards under Section&nbsp;3(i) of the
Ordinance to our Israeli <FONT STYLE="white-space:nowrap">non-employee</FONT> service providers and controlling shareholders, who are not eligible for such special tax treatment. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2010 Plan is administered by our board of directors. Although awards under the 2010 Plan may be granted until 10 years after the effective date of the 2010 Plan, as
of the consummation of our initial public offering, we stopped granting additional awards under the 2010 Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The terms of options granted under the 2010 Plan,
including the exercise price, vesting provisions and the duration are determined by our board of directors and set forth in an award agreement. Except as provided in the applicable award agreement, or in the discretion of the compensation committee,
an option may be exercised only to the extent that it is then exercisable and, generally, shall expire for employees 90 days following termination of the service of the grantee, and in the case of retiring directors, not later than nine months
following our listing on the NASDAQ Global Market. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Restricted share units are awards covering a number of hypothetical units with respect to shares that are
granted subject to such vesting and transfer restrictions and conditions of payment as our board of directors may determine in an award agreement. Restricted share units are payable in cash, ordinary shares of equivalent value or a combination
thereof. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of any dividend (excluding any ordinary dividend) or other distribution, recapitalization, share split, reverse share split, reorganization,
merger, consolidation, <FONT STYLE="white-space:nowrap">split-up,</FONT> <FONT STYLE="white-space:nowrap">split-off,</FONT> combination, repurchase or exchange of shares or similar event (including a change in control) that affects the ordinary
shares, the board of directors will make any such adjustments in such manner as it may deem equitable, including any or all of the following: (i)&nbsp;adjusting the number of shares available for grant under the 2010 Plan, and (ii)&nbsp;providing
for a substitution or assumption of awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All unvested options shall vest in their entirety upon (i)&nbsp;the sale of all or substantially all of the shares of
the Company, (ii)&nbsp;a merger, consolidation or reorganization in which the Company is not the surviving entity, or (iii)&nbsp;the sale, transfer or disposition of all or substantially all of the assets of the Company. Further, in such event the
optionholders may elect to exchange the options for ordinary shares on a cashless exercise basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_14"></A>PRINCIPAL SHAREHOLDERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth information with respect to the beneficial ownership of our ordinary shares as of December&nbsp;31, 2017 by: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person or entity known by us to own beneficially 5% or more of our outstanding ordinary shares; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our directors and executive officers individually; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our executive officers and directors as a group. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The beneficial ownership of our ordinary shares is determined
in accordance with the rules of the SEC and generally includes any shares over which a person exercises sole or shared voting or investment power, or the right to receive the economic benefit of ownership. For purposes of the table below, we deem
ordinary shares issuable pursuant to options that are currently exercisable or exercisable within 60 days of December 31, 2017 to be outstanding and to be beneficially owned by the person holding the options for the purposes of computing the
percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
percentage of shares beneficially owned has been computed on the basis of 13,751,390&nbsp;ordinary shares outstanding as of December 31, 2017. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of
December&nbsp;31, 2017 and based on their reported registered office, there are 11 record holders in the United States, holding in aggregate approximately 1.2% of our outstanding ordinary shares immediately prior to this offering. These do not
include outstanding ordinary shares held in street name. Except where otherwise indicated, we believe, based on information furnished to us by such owners, that the beneficial owners of the ordinary shares listed below have sole investment and
voting power with respect to such shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our shareholders, including the shareholders listed below, have the same voting rights attached to their ordinary
shares, and neither our principal shareholders nor our directors and executive officers have different or special voting rights with respect to their ordinary shares. See &#147;Description of Share Capital&#151;Voting Rights.&#148; A description of
any material relationship that our principal shareholders have had with us or any of our predecessors or affiliates within the past three years is included under &#147;Certain Relationships and Related Party Transactions.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise noted below, the address of each shareholder, director and executive officer is c/o UroGen Pharma
Ltd., 9 Ha&#146;Ta&#146;asiya St., Ra&#146;anana 4365007, Israel. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER AND</B><br><B>PERCENTAGE</B><br><B>OF ORDINARY SHARES</B><br><B>BENEFICIALLY OWNED </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE&nbsp;OF&nbsp;ORDINARY<BR>SHARES BENEFICIALLY<BR>OWNED AFTER THE<BR>OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ASSUMING<BR>NO<BR>EXERCISE<BR>OF&nbsp;OPTION<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(17)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ASSUMING<BR>FULL<BR>EXERCISE<BR>OF<BR>OPTION<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(17)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:112.40pt; font-size:8pt; font-family:ARIAL"><B>NAME OF BENEFICIAL OWNER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>5% or Greater Shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Arkin Communication Ltd. <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,643,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Menora Mivtachim Holdings Ltd. <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,338,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pontifax (Israel) III Limited Partnership <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">998,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pontifax Cayman III Limited Partnership <SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">ProQuest Investments IV, L.P. <SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,451,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Directors and Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Arie Belldegrun, M.D. <SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ron Bentsur <SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fred Cohen, M.D. <SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kathryn Falberg <SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cynthia Butitta<SUP STYLE="font-size:85%; vertical-align:top"> (10)&nbsp;</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pini Orbach, Ph.D. <SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stuart Holden, M.D. <SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gil Hakim <SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gary Titus <SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ran Nussbaum <SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,464,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Mark Schoenberg, M.D. <SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">All directors and executive officers as a group (11 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,179,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Indicates beneficial ownership of less than 1% of the total ordinary shares outstanding. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,643,658 ordinary shares. Mr.&nbsp;Moshe Arkin is the sole beneficial owner of Arkin Communication Ltd. The percentage ownership of Arkin Communication Ltd. decreased from 21.0% as of March&nbsp;31, 2017.
The address of Arkin Communication Ltd. is 6 HaChoshlim St., Bldg. C, Herzliya 46724, Israel. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents ordinary shares beneficially owned as of December&nbsp;31, 2016, based on a Schedule 13G/A filed on December&nbsp;6, 2017, by Menora Mivtachim Holdings Ltd. In such filing, Menora Mivtachim Holdings Ltd.
lists its address as Menora House, 115 Allenby St., Tel Aviv 61008, Israel, and indicates that it has shared voting power with respect to 1,338,762 ordinary shares and shared dispositive power with respect to 1,338,762 ordinary shares.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 968,525 ordinary shares and 29,646 ordinary shares issuable upon exercise of outstanding options. Does not include 14,316 ordinary shares issuable upon exercise of outstanding options which have not vested.
Pontifax Management Fund III L.P. is the general partner of Pontifax (Israel) III Limited Partnership, and Pontifax Management III G.P. (2011)&nbsp;Ltd. is the general partner of Pontifax Management Fund III L.P. Tomer Kariv and Ran Nussbaum are
directors of Pontifax Management GP and, as such, hold voting and/or dispositive power over the shares held by Pontifax (Israel) III Limited Partnership. The percentage ownership of Pontifax (Israel) III Limited Partnership decreased from 11.4% as
of March&nbsp;31, 2017. The address of Pontifax (Israel) III Limited Partnership is 14 Shenkar St., Herzliya 4672514, Israel. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 452,162 ordinary shares and 13,836 ordinary shares issuable upon exercise of outstanding options. Does not include 6,683 ordinary shares issuable upon exercise of outstanding options which have not vested.
Pontifax Management Fund III L.P. is the general partner of Pontifax Cayman III Limited Partnership, and Pontifax Management III G.P. (2011)&nbsp;Ltd. is the general partner of Pontifax Management Fund III L.P. Tomer Kariv and Ran Nussbaum are
directors of Pontifax Management GP and, as such, hold voting and/or dispositive power over the shares held by Pontifax Cayman III Limited Partnership. The percentage ownership of Pontifax (Israel) III Limited Partnership decreased from 5.3% as of
March&nbsp;31, 2017. The address of Pontifax Cayman III Limited Partnership is 14 Shenkar St., Herzliya 4672514, Israel. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Consists of 1,451,329 ordinary shares. ProQuest Associates IV LLC is the managing member and sole general partner of
ProQuest Investments VI, L.P. Jay Moorin and Alain Schreiber are the managing members of ProQuest Associates IV LLC and, as such, hold voting and/or dispositive power over the shares held by ProQuest Investments IV, L.P. The percentage ownership of
ProQuest </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Investments IV, L.P. increased from 10.2% as of March&nbsp;31, 2017. The address of ProQuest Investments IV, L.P. is 2430 Vanderbilt Beach Road, 108-190, Naples, FL 34109, USA. </TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 84,211 ordinary shares and 219,482 ordinary shares issuable upon exercise of outstanding options. Does not include 85,000 ordinary shares issuable upon exercise of outstanding options which have not vested.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 33,683 ordinary shares and 13,334 ordinary shares issuable upon exercise of outstanding options. Does not include 66,666 ordinary shares issuable upon exercise of outstanding options which have not vested.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 7,500 ordinary shares issuable upon exercise of outstanding options. Does not include 32,500 ordinary shares issuable upon exercise of outstanding options which have not vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 10,000 ordinary shares issuable upon exercise of outstanding options. Does not include 30,000 ordinary shares issuable upon exercise of outstanding options which have not vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 4,167 ordinary shares issuable upon exercise of outstanding options. Does not include 45,833 ordinary shares issuable upon exercise of outstanding options which have not vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 40,241 ordinary shares issuable upon exercise of outstanding options. Does not include 21,000 ordinary shares issuable upon exercise of outstanding options which have not vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 37,000 ordinary shares issuable upon exercise of outstanding options. Does not include 21,000 ordinary shares issuable upon exercise of outstanding options which have not vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 23,033 ordinary shares and 136,569 ordinary shares issuable upon exercise of outstanding options. Does not include 74,333 ordinary shares issuable upon exercise of outstanding options which have not vested.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 17,467 ordinary shares issuable upon exercise of outstanding options. Does not include 67,733 ordinary shares issuable upon exercise of outstanding options which have not vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of beneficial ownership of securities held by Pontifax (Israel) III Limited Partnership and Pontifax Cayman III Limited Partnership described in notes 3 and 4 above. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 88,600 ordinary shares issuable upon exercise of outstanding options. Does not include 43,200 ordinary shares issuable upon exercise of outstanding options which have not vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(17)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Underwriters&#146; option to purchase additional ordinary shares, as set out on the cover page of this prospectus. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_15"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Agreements with Shareholders </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Registration rights agreement
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into an investors&#146; rights agreement dated September&nbsp;18, 2014, as amended on October&nbsp;1, 2015 and on April&nbsp;12, 2016, or
the Registration Rights Agreement, with certain of our shareholders. The Registration Rights Agreement provides that certain holders of our ordinary shares have the right to demand that we file a registration statement or request that their ordinary
shares be covered by a registration statement that we are otherwise filing. Any registration rights with respect to this offering have been waived. The registration rights are described in more detail under &#147;Description of Share
Capital&#151;Registration Rights.&#148; All rights under the Registration Rights Agreement, other than the registration rights, terminated upon the closing of our initial public offering. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Telormedix SA agreement </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into an asset purchase
agreement, or the agreement, dated as of October&nbsp;1, 2015, with Telormedix SA. Also on October&nbsp;1, 2015, we entered into the 2015 Share Purchase Agreement, as further described below, pursuant to which ProQuest, which beneficially owns 62.6%
of Telormedix, became a 10% beneficial owner of the company. Pursuant to the 2015 Share Purchase Agreement, ProQuest appointed Stuart Holden, M.D., who was a member of the board of directors of Telormedix, to our board of directors. Pursuant to the
agreement, we purchased all of the intellectual property assets of Telormedix in consideration for an aggregate amount of 691,200 Series A preferred shares, which converted to ordinary shares in connection with our initial public offering. Upon the
occurrence of each of three specified regulatory milestones, we are required to issue an additional 92,800 ordinary shares to Telormedix, for an aggregate potential maximum amount of 278,400 ordinary shares. In April 2017, Telormedix transferred
135,200 Series A preferred shares and the right to receive an additional aggregate of 54,462&nbsp;Series A preferred shares upon the occurrence of the milestones to ProQuest, and 80,800 Series A preferred shares and the right to receive an
additional 32,538 Series A preferred shares upon the occurrence of the milestones to Aravis Venture I L.P. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Agreements and Arrangements with, and Compensation
of, Directors and Executive Officers </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Employment agreements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into written employment agreements with each of our executive officers. These agreements contain customary provisions and representations, including
confidentiality, <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation</FONT> and inventions assignment undertakings by the executive officers. However, the enforceability of the <FONT
STYLE="white-space:nowrap">non-competition</FONT> provisions may be limited under applicable law. The agreements are terminable by us at will, subject to prior notice, which varies for each individual. Our executive officers will not receive
benefits upon termination of their respective employment with us, other than payment of salary and benefits (and limited accrual of vacation days) during the required notice period for termination of their employment. However, Ron Bentsur, our Chief
Executive Officer, Gary Titus, our Chief Financial Officer, and Mark Schoenberg, our Chief Medical Officer will be entitled to accelerated vesting of their restricted stock units and stock options, respectively, in the event of termination without
cause. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Consulting and option agreements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We entered into an
agreement with our chairman of the board of directors, Arie Belldegrun, M.D., for management services pertaining to the development of our business. These services included serving as chairman of the board of directors, assisting us in our financing
activities and overseeing our clinical development activities. In consideration of these services, as of December&nbsp;31, 2016, we had issued Dr.&nbsp;Belldegrun options under our 2010 Israeli Share Option Plan to purchase 128,000 ordinary shares
at $4.02 per share and 166,482 ordinary shares at $5.00 per share. The agreement had no fixed term and was terminable at will (i)&nbsp;by Dr.&nbsp;Belldegrun upon 30 days&#146; prior written notice and (ii)&nbsp;by us at any time pursuant to the
directions of our board of directors or shareholders. The agreement contained customary provisions and representations, including confidentiality and inventions assignment undertakings by Dr.&nbsp;Belldegrun. On March&nbsp;29, 2017, our board
resolved to terminate the agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have also entered into an option agreement with our <FONT STYLE="white-space:nowrap">non-executive</FONT> directors Pini
Orbach and Stuart Holden and option agreements with Pontifax (Israel) III Limited Partnership and Pontifax Cayman III Limited Partnership, which are represented by our <FONT STYLE="white-space:nowrap">non-executive</FONT> director Ran Nussbaum,
according to which each was granted options under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
our 2010 Israeli Share Option Plan in the number and on the terms set out in the section above titled &#147;Principal Shareholders.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have also entered into an option agreement with our <FONT STYLE="white-space:nowrap">non-executive</FONT> directors Pini Orbach, Kathryn E. Falberg, Fred Cohen,
Cynthia Butitta and Stuart Holden and option agreements with Pontifax (Israel) III Limited Partnership and Pontifax Cayman III Limited Partnership, which are represented by our <FONT STYLE="white-space:nowrap">non-executive</FONT> director Ran
Nussbaum, pursuant to which each was granted options under our 2017 Equity Incentive Plan in the amount and on the terms set out in the &#147;Principal Shareholders&#148; table above. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Financing agreements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Between 2012 and 2015, Arkin Communications
Ltd. or Arkin, which appointed Pini Orbach, Ph.D., to our board of directors, Pontifax (Israel) III Limited Partnership, or Pontifax IL, and Pontifax Cayman III Limited Partnership, or Pontifax CM, which appointed Ran Nussbaum to our board of
directors, Shirat HaChaim Ltd., or Shirat HaChaim, a company controlled by Chaim Hurvitz, who served as our director until December 2017, Bellco Capital LLC, or Bellco, through several entities controlled by it (the beneficial owners of Bellco
Capital are Rebecka Belldegrun, M.D. and our chairman Arie Belldegrun, M.D.) and ProQuest Investments IV, L.P., or ProQuest, which appointed Stuart Holden, M.D. to our board of directors, invested in the company an aggregate amount of approximately
$22.4&nbsp;million in consideration of the securities described below: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From January 2012 through July 2013, we entered into share purchase agreements with Pontifax
IL, Pontifax CM, Shirat HaChaim and other investors, pursuant to which the company issued to the investors 1,375,233 ordinary shares at $5.00 per share, of which 272,691, 127,308 and 100,000 ordinary shares were issued to Pontifax IL, Pontifax CM
and Shirat HaChaim, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September&nbsp;18, 2014, we entered into the 2014 Share Purchase Agreement with Arkin, Pontifax IL, Pontifax CM, Shirat
HaChaim and other investors, pursuant to which the company issued to the investors 1,456,573 Series A preferred shares at $5.94 per share and 728,312 warrants exercisable into shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred
shares at $7.81 per share, of which 757,894, 172,224, 80,402 and 84,210 shares and 378,950, 86,112, 40,204 and 42,105 warrants were issued to Arkin, Pontifax IL, Pontifax CM and Shirat HaChaim, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October&nbsp;1, 2015, we entered into the 2015 Share Purchase Agreement with ProQuest, Arkin, Pontifax IL, Pontifax CM, Shirat HaChaim, Bellco and other investors,
pursuant to which the company issued to the investors 3,045,654 Series A preferred shares at $5.94 per share, of which 842,105, 589,475, 390,380, 182,252, 168,422 and 84,211 shares were issued to ProQuest, Arkin, Pontifax IL, Pontifax CM, Shirat
HaChaim and Bellco, respectively. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Lease agreement </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our U.S.
subsidiary, UroGen Pharma, Inc., entered into a lease agreement, dated as of September&nbsp;15, 2017 and commencing as of October 2017, for office space in New York, which serves as the headquarters for our U.S. subsidiary. Prior to that, our U.S.
subsidiary entered into a lease agreement, dated as of November 2015 and commencing as of May 2016, for office space in New York, which served as the headquarters for our U.S. subsidiary. Our U.S. subsidiary shared the office space equitably with
Kite Pharma, Inc., a Delaware corporation, who was&nbsp;a <FONT STYLE="white-space:nowrap">co-signatory</FONT> to such lease agreement. Arie Belldegrun, M.D., our chairman, served until November 2017 as the Chairman and Chief Executive Officer of
Kite Pharma until its acquisition in November 2017 by Gilead Sciences, Inc. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Indemnification agreements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated articles of association permit us to exculpate, indemnify and insure each of our directors and office holders to the fullest extent permitted
by the Israeli Companies Law. We have entered into indemnification agreements with each of our directors and executive officers, undertaking to indemnify them to the fullest extent permitted by Israeli law, including with respect to liabilities
resulting from a public offering of our shares, to the extent that these liabilities are not covered by insurance. We have also obtained Directors and Officers insurance for each of our executive officers and directors. For further information, see
&#147;Management&#151;Exculpation, Insurance and Indemnification of Directors and Officers.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Relationships </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Family members of Chaim Hurvitz, our former director, beneficially own more than 10% of Pontifax IL and Pontifax CM. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_16"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following descriptions of our share capital and provisions of our amended and restated articles of association are summaries and do not purport to be complete. Our
amended and restated articles of incorporation are filed with the SEC as an exhibit to our registration statement, of which this prospectus forms a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our authorized share capital consists of 100,000,000 ordinary
shares, par value NIS 0.01 per share, of which 13,751,390&nbsp;shares are issued and outstanding as of December 31, 2017. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our outstanding ordinary shares
are validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> Our ordinary shares are not redeemable and do not have any preemptive rights. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All ordinary shares have identical voting and other rights in all respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Number and Purpose of the Company </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our registration number with
the Israeli Registrar of Companies is 513537621. Our purpose as set forth in our amended and restated articles of association is to engage in any lawful activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer of Shares </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our fully paid ordinary shares are issued in registered
form and may be freely transferred under our amended and restated articles of association, unless the transfer is restricted or prohibited by another instrument, applicable law or the rules of a stock exchange on which the shares are listed for
trade. The ownership or voting of our ordinary shares by <FONT STYLE="white-space:nowrap">non-residents</FONT> of Israel is not restricted in any way by our amended and restated articles of association or the laws of the State of Israel, except for
ownership by nationals of some countries that are, or have been, in a state of war with Israel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Election of Directors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ordinary shares do not have cumulative voting rights for the election of directors. As a result, the holders of a majority of the voting power represented at a
meeting of shareholders have the power to elect all of our directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under our amended and restated articles of association, our board of directors must consist
of at least five and not more than nine directors. Our board of directors consists of eight directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to our amended and restated articles of
association, each of our directors is appointed by a simple majority vote of holders of our ordinary shares, participating and voting at an annual general meeting of our shareholders. Each director serves until the next annual general meeting
following his or her election and his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal by a vote of the majority of the aggregate voting power of our company at a general meeting of our
shareholders or until his or her office expires by operation of law. In addition, our amended and restated articles of association allow our board of directors to appoint directors to fill vacancies on the board of directors, including filling empty
board seats up to the maximum number of directors permitted under our articles of association, to serve until the next annual general meeting of shareholders. Our amended and restated articles of association do not have a retirement age requirement
for our directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Dividend and Liquidation Rights </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may declare a
dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Israeli Companies Law, dividend distributions are determined by the board of directors and do not require the approval of the
shareholders of a company unless the company&#146;s articles of association provide otherwise. Our amended and restated articles of association do not require shareholder approval of a dividend distribution and provide that dividend distributions
may be determined by our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Israeli Companies Law, the distribution amount is limited to the greater of retained earnings or
earnings generated over the previous two years, according to our then last reviewed or audited financial statements, provided that the end of the period to which the financial statements relate is not more than six months prior to the date of the
distribution. If we do not meet such criteria, then we may distribute dividends only with court approval. In each case, we are only permitted to distribute a dividend if our board of directors and the court, if applicable, determines that there is
no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations as they become due. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of our
liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by the
grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Exchange Controls </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are currently no Israeli currency control
restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the shares or interest or other payments to <FONT STYLE="white-space:nowrap">non-residents</FONT> of Israel, except for shareholders who are subjects of
countries that are, or have been, in a state of war with Israel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Shareholder Meetings </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months after the
date of the previous annual general meeting. All meetings other than the annual general meeting of shareholders are referred to in our amended and restated articles of association as extraordinary meetings. Our board of directors may call
extraordinary meetings whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Israeli Companies Law provides that our board of directors is required to convene an extraordinary meeting upon
the written request of (i)&nbsp;any two or more of our directors or <FONT STYLE="white-space:nowrap">one-quarter</FONT> or more of the members of our board of directors, or (ii)&nbsp;one or more shareholders holding, in the aggregate, either (a) 5%
or more of our outstanding issued shares and 1% of our outstanding voting power, or (b) 5% or more of our outstanding voting power. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the provisions of
the Israeli Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are the shareholders of record on a date to be decided by the board of directors, which may be between four and
40 days prior to the date of the meeting. Furthermore, the Israeli Companies Law requires that resolutions regarding the following matters must be passed at a general meeting of our shareholders: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">amendments to our articles of association; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appointment or termination of our auditors; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appointment of external directors (if applicable); </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval of certain related party transactions; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increases or reductions of our authorized share capital; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a merger; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the exercise of our board of director&#146;s powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli Companies Law requires that a notice of any annual general meeting or extraordinary meeting be provided to shareholders at least 21 days
prior to the meeting and if the agenda of the meeting includes the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, or an approval of a merger, notice must be provided at least
35 days prior to the meeting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, shareholders of a public company are not permitted to take action by way of written consent in lieu
of a meeting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Israeli Companies Law, whenever we cannot convene or conduct a general meeting in the manner prescribed under the law or our articles of
association, the court may, upon our, shareholders&#146; or directors&#146; request, order that we convene and conduct a general meeting in the manner the court deems appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Voting Rights </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Quorum Requirements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to our amended and restated articles of
association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders at a general meeting. As a foreign private issuer, the quorum required for our general meetings of
shareholders consists of at least two shareholders present in person, by proxy or by other voting instrument in accordance with the Israeli Companies Law who hold or represent between them at least
33<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>/<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>% of the total outstanding voting rights. A meeting adjourned for lack of a quorum is generally adjourned to the same day in the
following week at the same time and place or to a later time or date if so specified in the notice of the meeting. At the reconvened meeting, any two or more shareholders present in person or by proxy shall constitute a lawful quorum. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Vote Requirements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated articles of association
provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Israeli Companies Law or by our amended and restated articles of association. Under the Israeli Companies Law, each of (i)&nbsp;the
approval of an extraordinary transaction with a controlling shareholder, and (ii)&nbsp;the terms of employment or other engagement of the controlling shareholder of the company or such controlling shareholder&#146;s relative (even if such terms are
not extraordinary) requires the approval described above under &#147;Management&#151;Approval of Related Party Transactions under Israeli Law&#151;Fiduciary Duties of Directors and Executive Officers&#151;Disclosure of Personal Interests of
Controlling Shareholders and Approval of Certain Transactions.&#148; Additionally, (i)&nbsp;the approval and extension of a compensation policy and certain deviations therefrom require the approvals described above under
&#147;Management&#151;Compensation, Nominating and Corporate Governance Committee and Compensation Policy&#151;Israeli Companies Law Requirements,&#148; and (ii)&nbsp;the terms of employment or other engagement of the chief executive officer of the
company require the approvals described above under &#147;Management&#151;Approval of Related Party Transactions under Israeli Law&#151;Fiduciary Duties of Directors and Executive Officers&#151;Disclosure of Personal Interests of an Office Holder
and Approval of Certain Transactions.&#148; Under our amended and restated articles of association, (i)&nbsp;the removal of a director from office requires the adoption of a resolution at a general meeting of shareholders by a majority of the
aggregate voting rights of our company, and (ii)&nbsp;the alteration of the rights, privileges, preferences or obligations of any class of our shares requires a simple majority of the class so affected (or such other percentage of the relevant class
that may be set forth in the governing documents relevant to such class), in addition to the ordinary majority vote of all classes of shares voting together as a single class at a shareholder meeting. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further exceptions to the simple majority vote requirement are a resolution for the voluntary winding up, or an approval of a scheme of arrangement or reorganization,
of the company pursuant to Section&nbsp;350 of the Israeli Companies Law, that governs the settlement of debts and reorganization of a company, which requires the approval of holders of 75% of the voting rights represented at the meeting and voting
on the resolution. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Access to Corporate Records </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the
Israeli Companies Law, shareholders are provided access to: minutes of our general meetings; our shareholders register and principal shareholders register, articles of association and annual audited financial statements; and any document that we are
required by law to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. In addition, shareholders may request to be provided with any document related to an action or transaction requiring shareholder approval under
the related party transaction provisions of the Israeli Companies Law. We may deny this request if we believe it has not been made in good faith or if such denial is necessary to protect our interest or protect a trade secret or patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Modification of Class&nbsp;Rights </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law and our
amended and restated articles of association, the rights attached to any class of shares, such as voting, liquidation and dividend rights, may be amended by adoption of a resolution by the holders of a majority of the shares of that class present at
a separate class meeting, or otherwise in accordance with the rights attached to such class of shares, as set forth in our amended and restated articles of association. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
have entered into the Registration Rights Agreement with certain of our shareholders as part of the 2014 Share Purchase Agreement. As of the date of this prospectus, holders of a total of 4,515,674 of our ordinary shares have the right to require us
to register these shares under the Securities Act under specified circumstances and have incidental registration rights as described below. After registration pursuant to these rights, these shares will become freely tradable without restriction
under the Securities Act. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Demand Registration Rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If at any
time after 180 days after the effective date of our initial public offering registration statement, we receive a request from holders of at least 30% of the registrable securities then outstanding that we file a Form
<FONT STYLE="white-space:nowrap">F-1</FONT> registration statement with respect to registrable securities then outstanding having an anticipated aggregate offering price of at least $5.0&nbsp;million, then we shall (a)&nbsp;within 10 days after the
date such request is given, give demand notice to all holders other than the initiating holders; and (b)&nbsp;as soon as practicable, and in any event within 60 days after the date such request is given by the initiating holders, file a Form <FONT
STYLE="white-space:nowrap">F-1</FONT> registration statement under the Securities Act covering all registrable securities that the initiating holders requested to be registered and any additional registrable securities requested to be included in
such registration by any other holders, as specified by notice given by each such holder to us within 20 days of the date the demand notice is given. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will not
be obligated to file a registration statement at such time if in the good faith judgment of our board of directors, such registration would be materially detrimental to us and our shareholders, because such action would (a)&nbsp;materially interfere
with a significant acquisition, corporate reorganization, or other similar transaction involving us; (b)&nbsp;require premature disclosure of material information that we have a bona fide business purpose for preserving as confidential; or
(c)&nbsp;render us unable to comply with requirements under the Securities Act or Exchange Act. In such event we may defer the requested filing for a period of not more than 60 days. We may not invoke this right more than once in any <FONT
STYLE="white-space:nowrap">12-month</FONT> period and, during such 60 day period, we shall not register any securities for our own account or that of any other shareholder other than in an &#147;Excluded Registration&#148;: (i) a registration
relating to the sale of securities to our or a subsidiary&#146;s employees pursuant to a stock option, stock purchase, or similar plan; (ii)&nbsp;a registration relating to an SEC Rule 145 transaction; (iii)&nbsp;a registration on any form that does
not include substantially the same information as would be required to be included in a registration statement covering the sale of the registrable securities; or (iv)&nbsp;a registration in which the only ordinary shares being registered are
ordinary shares issuable upon conversion of debt securities that are also being registered. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition we shall not be obligated to effect, or to take any action
to effect, any demand registration (a)&nbsp;during the period that is 60 days before our good faith estimate of the date of filing of, and ending on a date that is 180 days after the effective date of, our initiated registration, provided that we
are actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (b)&nbsp;after we have effected two demand registrations; or (c)&nbsp;if the initiating holders propose to dispose of
shares of registrable securities that may be immediately registered on Form <FONT STYLE="white-space:nowrap">F-3.</FONT> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Form
<FONT STYLE="white-space:nowrap">F-3</FONT> Registration Rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If at any time when we are eligible to use a Form
<FONT STYLE="white-space:nowrap">F-3</FONT> registration statement, we receive a request from holders of the registrable securities then outstanding that we file a Form <FONT STYLE="white-space:nowrap">F-3</FONT> registration statement with respect
to outstanding registrable securities of such holders having an anticipated aggregate offering price of at least $3.0&nbsp;million, then we shall (a)&nbsp;within 10 days after the date such request is given, give a demand notice to all holders other
than the initiating holders; and (b)&nbsp;as soon as practicable, and in any event within 45 days after the date such request is given by the initiating holders, file a Form <FONT STYLE="white-space:nowrap">F-3</FONT> registration statement under
the Securities Act covering all registrable securities requested to be included in such registration by any other holders, as specified by notice given by each such holder to us within 20 days of the date the demand notice is given. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We shall not be obligated to effect, or to take any action to effect, any Form <FONT STYLE="white-space:nowrap">F-3</FONT> registration (a)&nbsp;during the period that
is 30 days before our good faith estimate of the date of filing of, and ending on a date that is 90 days after the effective date of, our initiated registration, provided that we are actively employing in good faith commercially reasonable efforts
to cause such registration statement to become effective; or (b)&nbsp;if we have effected two Form <FONT STYLE="white-space:nowrap">F-3</FONT> demand registrations within the <FONT STYLE="white-space:nowrap">12-month</FONT> period immediately
preceding the date of such request. A Form <FONT STYLE="white-space:nowrap">F-3</FONT> registration shall not be counted as &#147;effected&#148; until such time as the applicable registration statement has been
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
declared effective by the SEC, unless the initiating holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one
demand registration statement, in which case such withdrawn registration statement shall be counted as &#147;effected.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Piggyback Registration Rights
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, if we propose to register (including, for this purpose, a registration effected by us for shareholders other than the holders) any of our
securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), we shall, at such time, promptly give each holder notice of such registration. Upon the request
of each holder given within 20 days after such notice is given by us, we shall, subject to underwriter requirements, cause to be registered all of the registrable securities that each such holder has requested to be included in such registration. We
shall have the right to terminate or withdraw any registration initiated by us before the effectiveness of such registration, whether or not any holder has elected to include registrable securities in such registration. The expenses of such
withdrawn registration shall be borne by us. Any piggyback registration rights with respect to this offering have been waived. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Provisions </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will pay all registration expenses (other than underwriting discounts and selling commissions) and the reasonable fees and expenses of a single counsel for the
selling shareholders, related to any demand or piggyback registration. The demand, Form <FONT STYLE="white-space:nowrap">F-3</FONT> and piggyback registration rights described above will expire with respect to each holder of registrable securities
upon such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such holder&#146;s shares without limitation during a three-month period without registration. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Termination of Registration Rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No holder shall be entitled to
exercise any registration rights after, and all such rights shall terminate upon the earlier to occur of (a)&nbsp;(i) any dissolution or liquidation of us; (ii)&nbsp;the proper commencement, by or against us, of any bankruptcy or insolvency
proceeding under any bankruptcy or insolvency or similar law, whether voluntary or involuntary and (iii)&nbsp;the appointment of a receiver or liquidator to all or substantially all of our assets, and (b)&nbsp;the fifth anniversary of the completion
of our initial public offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the registration rights shall terminate as to any shares of registrable securities when such shares have been
(i)&nbsp;registered under the Securities Act pursuant to an effective registration statement filed thereunder and disposed of in accordance with the registration statement covering them, or (ii)&nbsp;publicly sold pursuant to Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Acquisitions under Israeli Law </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Full Tender Offer </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A person wishing to acquire shares of an Israeli public company and who would as a result hold over 90% of the target company&#146;s issued and outstanding share
capital is required by the Israeli Companies Law to make a tender offer to all of the company&#146;s shareholders for the purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli
company and who would as a result hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the shareholders who hold shares of the relevant class for the purchase of all of
the issued and outstanding shares of that class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class, and more than half of the shareholders who do
not have a personal interest in the offer accept the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will also be accepted if the shareholders who do not
accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the applicable class of shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon a successful completion of
such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to
determine whether the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions, the offeror may include in the terms of the tender offer that an offeree who
accepted the offer will not be entitled to petition the Israeli court as described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If (i)&nbsp;the shareholders who did not respond to or accept the tender offer hold at least 5% of the issued and
outstanding share capital of the company or of the applicable class or the shareholders who accept the offer constitute less than a majority of the offerees that do not have a personal interest in the acceptance of the tender offer, or (ii)&nbsp;the
shareholders who did not accept the tender offer hold 2% or more of the issued and outstanding share capital of the company (or of the applicable class), the acquirer may not acquire shares from shareholders who accepted the tender offer that will
increase its holdings to more than 90% of the company&#146;s issued and outstanding share capital or of the applicable class. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Special Tender Offer
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli Companies Law provides that, subject to certain exceptions, an acquisition of shares of an Israeli public company must be made by means of a
special tender offer if as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does not apply if there is already another holder of at least 25% of the voting rights in
the company. Similarly, the Israeli Companies Law provides that, subject to certain exceptions, an acquisition of shares in a public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become
a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A special tender offer must be extended to all shareholders of a company. A special tender offer may be consummated only if (i)&nbsp;the offeror acquired shares
representing at least 5% of the voting power in the company and (ii)&nbsp;the number of shares tendered by shareholders who accept the offer exceeds the number of shares held by shareholders who object to the offer (excluding the offeror,
controlling shareholders, holders of 25% or more of the voting rights in the company or any person having a personal interest in the acceptance of the tender offer or any of their relatives or any entity controlled by them). If a special tender
offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the target company and
may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer. Shares purchased
in contradiction to the tender offer rules under the Israeli Companies Law, will have no rights and will become dormant shares. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Merger </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli Companies Law permits merger transactions if approved by each party&#146;s board of directors and, unless certain requirements described under the Israeli
Companies Law are met, by a majority vote of each party&#146;s shareholders. In the case of the target company, approval of the merger further requires a majority vote of each class of its shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of shares represented at the
meeting of shareholders that are held by parties other than the other party to the merger, or by any person (or group of persons acting in concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25%
or more of the directors of the other party, vote against the merger. If, however, the merger involves a merger with a company&#146;s own controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the
merger is instead subject to the same Special Majority approval that governs all extraordinary transactions with controlling shareholders (as described under &#147;Management&#151;Approval of Related Party Transactions under Israeli
Law&#151;Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions&#148;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the transaction would have been approved by
the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the petition of holders of at least 25% of the
voting rights of a company. For such petition to be granted, the court must find that the merger is fair and reasonable, taking into account the respective values assigned to each of the parties to the merger and the consideration offered to the
shareholders of the target company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it
concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
unable to satisfy the obligations of the merging entities, and may further give instructions to secure the rights of creditors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, a merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger is filed with the Israeli
Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders of each party. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Anti-Takeover
Measures under Israeli Law </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli Companies Law allows us to create and issue shares having rights different from those attached to our ordinary
shares, including shares providing certain preferred rights with respect to voting, distributions or other matters and shares having preemptive rights. As of the closing of this offering, no preferred shares will be authorized under our amended and
restated articles of association. In the future, if we do authorize, create and issue a specific class of preferred shares, such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or
prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization and designation of a class of preferred shares will require an amendment to our amended and
restated articles of association, which requires the prior approval of the holders of a majority of the voting power attaching to our issued and outstanding shares and voting at a general meeting. The convening of the meeting, the shareholders
entitled to participate and the majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Israeli Companies Law as described above in &#147;&#151;Voting Rights.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Borrowing Powers </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Israeli Companies Law and our amended and
restated articles of association, our board of directors may exercise all powers and take all actions that are not required under law or under our amended and restated articles of association to be exercised or taken by our shareholders, including
the power to borrow money for company purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Changes in Capital </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
amended and restated articles of association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Israeli Companies Law and must be approved by a resolution duly passed by our shareholders at a
general meeting by voting on such change in the capital. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the
approval of both our board of directors and an Israeli court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The transfer agent and registrar for our ordinary shares is Computershare Trust Company, N.A. Its address is 250 Royall Street, Canton, MA 02021. Its telephone number
is +1 (201) <FONT STYLE="white-space:nowrap">680-4503.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ordinary shares are listed on the NASDAQ Global Market under the symbol &#147;URGN.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Sales of substantial amounts of our ordinary shares, or the perception that these sales could occur, could adversely affect prevailing market prices of our ordinary
shares and could impair our future ability to obtain capital, especially through an offering of equity securities. Assuming that the underwriters do not exercise their option to purchase additional ordinary shares with respect to this offering and
assuming no exercise of options outstanding following this offering, we will have an aggregate of 14,887,237 ordinary shares outstanding upon the closing of this offering based upon the number of outstanding shares as of December&nbsp;31, 2017. Of
these shares, 11,681,965 ordinary shares will be freely tradable without restriction or further registration under the Securities Act, unless owned by &#147;affiliates&#148; (as that term is defined under Rule 144 of the Securities Act, or Rule
144), who may sell only the volume of shares described below and whose sales would be subject to additional restrictions described below, or purchased by certain existing investors and their affiliated entities who are subject to <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">3,205,272 ordinary shares will be held by our existing affiliates and will be deemed to be &#147;restricted
securities&#148; under Rule 144. Subject to certain contractual restrictions, including the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below, restricted securities may only be sold in the public market pursuant to an
effective registration statement under the Securities Act or pursuant to an exemption from registration under Rule 144, Rule 701 or Rule 904 under the Securities Act. These rules are summarized below. Sales of these shares in the public market after
the restrictions under the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements lapse, or the perception that those sales may occur, could cause the prevailing market price of our ordinary shares to decrease or to be lower than it might be in
the absence of those sales or perceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Eligibility of Restricted Shares for Sale in the Public Market </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Approximately 3,205,272 of our ordinary shares will be eligible for resale pursuant to Rule 144 after 90 days following the pricing of this offering with respect to
affiliates of our company who will hold an aggregate of 3,205,272 ordinary shares upon the consummation of this offering, following the expiration of an affiliate&#146;s <FONT STYLE="white-space:nowrap">six-month</FONT> holding period and subject to
our compliance with the current public information requirements under Rule 144, and subject to the volume, manner of sale and other limitations under Rule 144 applicable to securities held by affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our
directors and executive officers and certain shareholders affiliated with our directors have signed <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. Pursuant to such <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, such persons
have agreed, subject to certain exceptions, not to sell or otherwise dispose of ordinary shares or any securities convertible into or exchangeable for ordinary shares for a period of 90 days after the date of this prospectus without the prior
written consent of Jefferies LLC. Jefferies LLC may, in its sole discretion, at any time without prior notice, release all or any portion of the ordinary shares from the restrictions in any such agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 144 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Shares Held for Six Months </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, under Rule 144 as currently in effect, and subject to the terms of any <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, commencing 90 days after
the closing of this offering, a person (or persons whose shares are aggregated), including an affiliate, who has beneficially owned our ordinary shares for six months or more, including the holding period of any prior owner other than one of our
affiliates (<I>i.e.</I>, commencing when the shares were acquired from our company or from an affiliate of our company as restricted securities), is entitled to sell our shares, subject to the availability of current public information about us. In
the case of an affiliate shareholder, the right to sell is also subject to the fulfillment of certain additional conditions, including manner of sale provisions and notice requirements, and to a volume limitation that limits the number of shares to
be sold thereby, within any three-month period, to the greater of: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1% of the number of ordinary shares then outstanding; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the average weekly trading volume of our ordinary shares on the NASDAQ Global Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The six month holding period of Rule 144 does not apply to sales of unrestricted securities. Accordingly, persons who hold unrestricted securities may sell them under
the requirements of Rule 144 described above without regard </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
to the <FONT STYLE="white-space:nowrap">six-month</FONT> holding period, even if they were considered our affiliates at the time of the sale or at any time during the ninety days preceding such
date. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Shares Held by <FONT STYLE="white-space:nowrap">Non-Affiliates</FONT> for One Year </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Rule 144 as currently in effect, a person (or persons whose shares are aggregated) who is not considered to have been one of our affiliates at any time during the
90 days preceding a sale and who has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than one of our affiliates, is entitled to sell his, her or its shares under Rule 144
without complying with the provisions relating to the availability of current public information or with any other conditions under Rule 144. Therefore, unless subject to a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement or otherwise
restricted, such shares may be sold immediately upon the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 701 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, under Rule 701, any of our employees, directors, officers, consultants or advisors who received or purchased ordinary shares from us under our 2010 Israeli
Share Option Plan or other written agreement before the closing of our initial public offering is entitled to resell these shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The SEC has indicated that Rule
701 will apply to typical share options granted by an issuer before it becomes subject to the reporting requirements of the Exchange Act, along with the shares acquired upon exercise of these options, including exercises after the closing of this
offering. Securities issued in reliance on Rule 701 are restricted securities and, subject to the contractual restrictions described in <FONT STYLE="white-space:nowrap">&#147;Underwriting&#151;Lock-up</FONT> Agreements,&#148; may be sold beginning
90 days after the closing of our initial public offering in reliance on Rule 144 by: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons other than affiliates, without restriction; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">affiliates, subject to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale,</FONT></FONT> current public information and filing requirements of Rule 144, in each case, without compliance
with the <FONT STYLE="white-space:nowrap">six-month</FONT> holding period requirement of Rule 144. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Options and RSUs </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2017, restricted share units and options to purchase a total of 2,560,091 ordinary shares were issued and outstanding. Substantially all of our
ordinary shares issuable under these options or restricted share units are subject to contractual <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with us or the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Form <FONT STYLE="white-space:nowrap">S-8</FONT> Registration Statement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
have filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register up to 1,400,000 ordinary shares, in the aggregate, issued or reserved for issuance under the 2017 Equity Incentive Plan.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register up to 2,486,858 ordinary shares, in
the aggregate, issued or reserved for issuance under the 2010 Israeli Share Option Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Ordinary shares issued upon exercise of a share option and registered
pursuant to the Form <FONT STYLE="white-space:nowrap">S-8</FONT> registration statement are, subject to vesting provisions and Rule 144 volume limitations applicable to our affiliates, available for sale in the open market immediately unless they
are subject to a <FONT STYLE="white-space:nowrap">lock-up</FONT> period or, if subject to the <FONT STYLE="white-space:nowrap">lock-up,</FONT> immediately after the <FONT STYLE="white-space:nowrap">lock-up</FONT> period expires. See
&#147;Management&#151;Equity Incentive Plans&#151;2017 Equity Incentive Plan&#148; and &#147;Management&#151;Equity Incentive Plans&#151;2010 Israeli Share Option Plan.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Holders of a total of 4,515,674 ordinary shares have
the right to require us to register these shares under the Securities Act under specified circumstances and will have incidental registration rights. After registration pursuant to these rights, these shares will become freely tradable without
restriction under the Securities Act. For more information on these registration rights, see &#147;Description of Share Capital&#151;Registration Rights.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_18"></A>TAXATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following description is not intended to constitute a complete analysis of all tax consequences relating to the acquisition, ownership and disposition of our
ordinary shares. You should consult your own tax advisor concerning the tax consequences in your particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Israeli Tax Considerations and Government Programs </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a brief
summary of the material Israeli tax laws applicable to us. This section also contains a discussion of material Israeli tax consequences concerning the ownership and disposition of our ordinary shares purchased by investors in this offering. This
summary does not discuss certain tax benefits, including under the Law for Encouragement of Capital Investments, 5719-1959, to which we may become eligible in the future if we establish a manufacturing facility for our products in Israel. This
summary also does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors subject to special treatment under Israeli law.
Examples of such investors include residents of Israel or traders in securities who are subject to special tax regimes not covered in this discussion. Because parts of this discussion are based on new tax legislation that has not yet been subject to
judicial or administrative interpretation, the appropriate tax authorities or the courts may not accept the views expressed in this discussion. The discussion below is subject to change, including due to amendments under Israeli law or changes to
the applicable judicial or administrative interpretations of Israeli law, which change could affect the tax consequences described below. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>General Corporate
Tax Structure in Israel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of 2018, Israeli companies are generally subject to corporate tax at the rate of 23% of a company&#146;s taxable income (reduced
from 24% in 2017). In addition, capital gains realized by Israeli companies are subject to tax at the regular corporate tax rate. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Taxation of our
Shareholders </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Capital gains taxes applicable to <FONT STYLE="white-space:nowrap">non-Israeli</FONT> resident shareholders.</I> As of 2018, capital gain
is generally subject to tax at the corporate tax rate of 23% (reduced from 24% in 2017) if generated by a company, or at the rate of 25% if generated by an individual, or 30% in the case of sale of shares by a substantial shareholder at the time of
sale or at any time during the preceding <FONT STYLE="white-space:nowrap">12-month</FONT> period. A person is considered to be a substantial shareholder if it holds, directly or indirectly, alone or together with another affiliated party, 10% or
more of a company&#146;s means of control, which include, among other things, voting rights, the right to receive profits of the company, the right to receive proceeds upon liquidation and the right to appoint a director. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Notwithstanding the foregoing, a <FONT STYLE="white-space:nowrap">non-Israeli</FONT> resident who derives capital gains from the sale of our shares that were purchased
after the shares were listed for trading on the NASDAQ is exempt from Israeli tax on such capital gains so long as they were not attributable to a permanent establishment that the <FONT STYLE="white-space:nowrap">non-resident</FONT> maintains in
Israel. In the case of a shareholder that is a corporation, in order for it to qualify as a <FONT STYLE="white-space:nowrap">non-Israeli</FONT> resident for these purposes, it must be incorporated in, as well as managed and controlled from, a
jurisdiction other than the State of Israel, and persons who are Israeli residents may not either: (i)&nbsp;have a controlling interest (directly or indirectly, alone or together with another, or together with another Israeli resident) exceeding 25%
in one or more of the means of control in such corporation or (ii)&nbsp;be the beneficiaries of, or entitled to, 25% or more of the revenues or profits of such corporation, whether directly or indirectly. Such exemption is not applicable to a person
whose gains from selling or otherwise disposing of the shares are deemed to be business income. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, a sale of shares by a
<FONT STYLE="white-space:nowrap">non-Israeli</FONT> resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shareholders may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale. In
transactions involving a sale of all of the shares of an Israeli resident company, such as a merger or other transaction, the Israel Tax Authority may, among other things, require from shareholders who are not liable for Israeli tax the execution of
a declaration in the form specified by that authority or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
a specific exemption from the Israeli Tax Authority to confirm their status as <FONT STYLE="white-space:nowrap">non-Israeli</FONT> residents may be required to be presented, and, in the absence
of such declaration or exemption, may require the purchaser of the shares to withhold taxes. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, with respect to mergers involving an exchange of shares,
Israeli tax law allows for tax deferral in certain circumstances, but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years from the date of the transaction during which
sales and dispositions of shares of the participating companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions in which the sellers receive shares in the acquiring entity that are publicly traded on a
stock exchange, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no disposition of such shares has occurred. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Taxation of <FONT STYLE="white-space:nowrap">non-Israeli</FONT> shareholders on receipt of dividends.</I> <FONT STYLE="white-space:nowrap">Non-Israeli</FONT>
residents are generally subject to Israeli withholding tax on the receipt of dividends paid on our ordinary shares at the rate of 25%, unless relief is provided in a treaty between Israel and the shareholder&#146;s country of residence (subject to
the receipt of a valid certificate from the Israel Tax Authority, allowing for such reduced withholding tax rate). With respect to a person who is considered a substantial shareholder at the time of receiving the dividend or at any time during the
preceding 12 months, subject to the terms of an applicable tax treaty, the applicable withholding tax rate is 30%. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Convention between the Government of
the United States of America and the Government of the State of Israel with respect to Taxes on Income, or the U.S.-Israel Tax Treaty, the maximum rate of tax withheld at source in Israel on dividends paid to a holder of our ordinary shares who is a
U.S. resident (for the purposes of the U.S.-Israel Tax Treaty) is 25%. However, with regard to dividends paid to a U.S. resident corporation which held 10% or more of our outstanding voting rights throughout the taxable year in which the dividend
was distributed and which maintained its shareholdings at or above such threshold during the entire previous taxable year, the maximum rate of withholding tax is generally 12.5%, provided that no more than 25% of our gross income for such preceding
year consists of certain types of dividends and interest. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">U.S. residents who are subject to Israeli withholding tax on a dividend may be entitled to a credit or
deduction for U.S. federal income tax purposes in the amount of the taxes withheld, subject to detailed limitations under U.S. laws applicable to foreign tax credits. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Excess Tax.</I><B><I></I></B>&nbsp;Individuals who are subject to tax in Israel, whether an Israeli resident or a <FONT STYLE="white-space:nowrap">non-Israeli</FONT>
resident, are also subject to an additional tax on annual income exceeding NIS 640,000 in 2017 and thereafter (linked to the Israeli consumer price index) at a rate of 3%, including, but not limited to, dividends, interest and capital gain, subject
to the provisions of an applicable tax treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Material U.S. Federal Income Tax Consequences to U.S. Holders </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following discussion describes the material U.S. federal income tax consequences to U.S. Holders (as defined below) under present law of an investment in our
ordinary shares. The effects of any applicable state or local laws, or other U.S. federal tax laws such as estate and gift tax laws are not discussed. This summary applies only to investors who hold the ordinary shares as capital assets (generally,
property held for investment) and who have the U.S. dollar as their functional currency. This discussion is based on the Internal Revenue Code of 1986, as amended, or the Code, U.S. Treasury regulations promulgated thereunder, judicial decisions,
published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, and the U.S.-Israel Tax Treaty, all as in effect as of the date of this offering. All of the foregoing authorities are subject to change, which
change could apply retroactively and could affect the tax consequences described below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following discussion does not address all U.S. federal income tax
consequences relevant to a holder&#146;s particular circumstances or to holders subject to particular rules, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">U.S. expatriates and certain former citizens or long-term residents of the United States; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons subject to the alternative minimum tax; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons holding our ordinary shares as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment for U.S. federal income tax purposes;
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">banks, insurance companies, and other financial institutions; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">real estate investment trusts and regulated investment companies; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">brokers, dealers, and traders in securities, commodities or currencies; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnerships, S corporations, and other entities or arrangements treated as partnerships for U.S. federal income tax purposes; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations and governmental organizations; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who acquired our ordinary shares pursuant to the exercise of any employee share option or otherwise as compensation; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that own, directly, indirectly or constructively 10% or more of our stock; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that hold their shares through a permanent establishment or fixed base outside the United States; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons deemed to sell our ordinary shares under the constructive sale provisions of the Code. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>U.S. HOLDERS ARE
URGED TO CONSULT THEIR TAX ADVISORS REGARDING THE APPLICATION OF THE U.S. FEDERAL TAX RULES TO THEIR PARTICULAR CIRCUMSTANCES AS WELL AS THE U.S. STATE AND LOCAL AND <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX CONSEQUENCES TO THEM OF THE
PURCHASE, OWNERSHIP AND DISPOSITION OF THE ORDINARY SHARES. </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For purposes of this discussion, a &#147;U.S. Holder&#148; is a beneficial owner of our ordinary
shares that, for U.S. federal income tax purposes, is or is treated as any of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an individual who is a citizen or resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation, or entity treated as a corporation for U.S. federal income tax purposes, created or organized under the laws of the United States, any state thereof, or the District of Columbia; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust that (1)&nbsp;is subject to the supervision of a U.S. court and the control of one or more &#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (2)&nbsp;has a valid
election in effect to be treated as a United States person for U.S. federal income tax purposes. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you are a partner in a partnership (or other
entity taxable as a partnership for U.S. federal income tax purposes) that holds our ordinary shares, your tax treatment generally will depend on your status and the activities of the partnership. Partnerships holding our ordinary shares and the
partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences applicable to them. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As indicated below, this
entire discussion is subject to the discussion of the U.S. federal income tax rules applicable to a &#147;passive foreign investment company,&#148; or a PFIC. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Passive Foreign Investment Company Considerations </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are
classified as a PFIC in any taxable year, a U.S. Holder will be subject to special rules generally intended to reduce or eliminate any benefits from the deferral of U.S. federal income tax that a U.S. Holder could derive from investing in a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> company that does not distribute all of its earnings on a current basis. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We must determine our PFIC status annually
based on tests (described below) which are factual in nature, and our status will depend on our income, assets and activities each year. In addition, our status as a PFIC may depend on how quickly we use the cash proceeds from this offering in our
business. We do not believe that we were classified as a PFIC for the taxable year ended December&nbsp;31, 2017. However, based upon the expected nature and composition of our income and assets, we presently anticipate that we will be classified as
a PFIC for the taxable year ending December&nbsp;31, 2018. We cannot provide any assurances regarding our PFIC status for the current or future taxable years, and our U.S. tax counsel has not provided any opinion regarding our PFIC status. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation is classified as a PFIC for U.S. federal income tax purposes in any taxable year in which, after applying
certain look-through rules with respect to the income and assets of subsidiaries, either (i)&nbsp;at least 75% of its gross income is &#147;passive income&#148; or (ii)&nbsp;at least 50% of the average quarterly value of its total gross assets
(which, assuming we are not a CFC for the year being tested, would be measured by fair market value of the assets, and for which purpose the total value of our assets may be determined in part by the market value of our ordinary
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
shares, which is subject to change) is attributable to assets that produce &#147;passive income&#148; or are held for the production of passive income. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Passive income for this purpose generally includes dividends, interest, royalties, rents, gains from commodities and securities transactions, the excess of gains over
losses from the disposition of assets which produce passive income, and generally includes amounts derived by reason of the temporary investment of funds raised in offerings of our ordinary shares. However, rents and royalties received from
unrelated parties in connection with the active conduct of a trade or business are not considered passive income for purposes of the PFIC test. If a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation owns directly or indirectly at least
25% by value of the stock of another corporation, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation is treated for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation and as receiving
directly its proportionate share of the other corporation&#146;s income. If we are classified as a PFIC in any year with respect to which a U.S. Holder owns our ordinary shares, we will continue to be treated as a PFIC with respect to such U.S.
Holder in all succeeding years during which the U.S. Holder owns our ordinary shares, regardless of whether we continue to meet the tests described above unless the holder makes a <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;purging
election&#148; with respect to our ordinary shares. <B>U.S. Holders should consult with their tax advisors regarding the availability and consequences of any PFIC purging elections.</B> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are a PFIC, and you are a U.S. Holder, then unless you make one of the elections described below, a special tax regime will apply to both (a)&nbsp;any
&#147;excess distribution&#148; by us to you (generally, your ratable portion of aggregate distributions in any year which are greater than 125% of the average annual distribution received by you in the shorter of the three preceding years or your
holding period for our ordinary shares) and (b)&nbsp;any gain realized on the sale or other disposition of the ordinary shares. Under this regime, any excess distribution and realized gain will be treated as ordinary income and will be subject to
tax as if (a)&nbsp;the excess distribution or gain had been realized ratably over your holding period, (b)&nbsp;the amount deemed realized in each year had been subject to tax in each year of that holding period at the highest marginal rate for such
year (other than income allocated to the current period or any taxable period before we became a PFIC, which would be subject to tax at the U.S. Holder&#146;s regular ordinary income rate for the current year and would not be subject to the interest
charge discussed below), and (c)&nbsp;the interest charge generally applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those years. In addition, dividend distributions made to you will not qualify for the
lower rates of taxation applicable to long-term capital gains discussed under &#147;Taxation of Dividends and Other Distributions on our Ordinary Shares.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain elections exist that may alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment (such as <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> treatment) of our ordinary shares. If a U.S. Holder makes the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT>
election, then in lieu of being subject to the tax and interest change rules disclosed above, the U.S. Holder generally will recognize as ordinary income any excess of the fair market value of the ordinary shares at the end of each taxable year over
their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ordinary shares over their fair market value at the end of the taxable year (but only to the extent of the net amount of income
previously included as a result of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election). If a U.S. Holder makes the election, the U.S. Holder&#146;s tax basis in the ordinary shares will be
adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition of ordinary shares in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to
the extent of the net amount of income previously included as a result of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election). The <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is available only if we are a PFIC and our ordinary shares are &#147;regularly traded&#148; on a &#147;qualified exchange.&#148; Our ordinary shares will be treated as &#147;regularly
traded&#148; in any calendar year in which more than a <I>de minimis</I> quantity of the ordinary shares are traded on a qualified exchange on at least 15 days during each calendar quarter (subject to the rule that trades that have as one of their
principle purposes the meeting of the trading requirement are disregarded). The NASDAQ Global Market is a qualified exchange for this purpose and, consequently, if the ordinary shares are regularly traded, the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election will be available to a U.S. Holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We do not currently intend to provide the information necessary for U.S. Holders to make QEF elections. U.S.
Holders should consult their tax advisors to determine whether any of these elections would be available and if so, what the consequences of the alternative treatments would be in their particular circumstances. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are determined to be a PFIC, the general tax treatment for U.S. Holders described in this section will apply to indirect distributions and gains deemed to be
realized by U.S. Holders in respect of any of our subsidiaries that also may be determined to be PFICs. A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election cannot be made with respect to the
stock of any of our subsidiaries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each U.S. Holder that is an investor of a PFIC is generally required to file an annual information return on IRS Form 8621
(Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund) containing such information as the U.S. Treasury Department may require. The failure to file IRS Form 8621 could result in the imposition of
penalties and the extension of the statute of limitations with respect to U.S. federal income tax. U.S. Holders should consult their tax advisors regarding whether we are a PFIC and the potential application of the PFIC rules. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Taxation of Dividends and Other Distributions on our Ordinary Shares </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussion under &#147;&#151;Passive Foreign Investment Company Considerations,&#148; above, the gross amount of any distribution to you with respect to
our ordinary shares will be included in your gross income as dividend income when actually or constructively received to the extent that the distribution is paid out of our current or accumulated earnings and profits (as determined under U.S.
federal income tax principles). To the extent the amount of the distribution exceeds our current and accumulated earnings and profits, it will be treated first as a return of your tax basis in our ordinary shares, and to the extent the amount of the
distribution exceeds your tax basis, the excess will be taxed as capital gain. We do not intend to calculate our earnings and profits under U.S. federal income tax principles. Therefore, a U.S. Holder should expect that the entire amount of any
distribution will generally be reported as dividend income. Any dividends will not be eligible for the dividends-received deduction allowed to corporations in respect of dividends received from other U.S. corporations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are not a PFIC for a given year in which a dividend is paid and the taxable year preceding the dividend, <FONT STYLE="white-space:nowrap">non-corporate</FONT>
U.S. Holders may qualify for the preferential rates of taxation with respect to dividends on ordinary shares applicable to long-term capital gains (i.e., gains from the sale of capital assets held for more than one year) applicable to qualified
dividend income (as discussed below). We believe that we qualify as a resident of Israel for purposes of, and are eligible for the benefits of, the U.S.-Israel Tax Treaty, although there can be no assurance in this regard. Further, the IRS has
determined that the U.S.-Israel Tax Treaty is satisfactory for purposes of the qualified dividend rules and that it includes an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">exchange-of-information</FONT></FONT> program.
Therefore, subject to the discussion under &#147;&#151;Passive Foreign Investment Company Considerations&#148; above, if the U.S.-Israel Tax Treaty is applicable, such dividends will generally be &#147;qualified dividend income&#148; in the hands of
individual U.S. Holders, provided that certain conditions are met, including holding period and the absence of certain risk reduction transaction requirements. The dividends will not be eligible for the dividends received deduction generally allowed
to corporate U.S. Holders. As discussed in &#147;Taxation&#151;Israeli Tax Considerations and Government Programs,&#148; payments of dividends by us may be subject to Israeli withholding tax. For U.S. federal income tax purposes, U.S. Holders will
be treated as having received the amount of Israeli taxes withheld by us, and as then having paid over the withheld taxes to the Israeli taxing authorities. As a result of this rule, the amount of dividend income included in gross income for U.S.
federal income tax purposes by a U.S. Holder with respect to a payment of dividends may be greater than the amount of cash actually received (or receivable) by the U.S. Holder from us with respect to the payment. Dividends will generally constitute
foreign source income for foreign tax credit limitation purposes. Any tax withheld with respect to distributions on our ordinary shares at the rate applicable to a U.S. Holder may, subject to a number of complex limitations, be claimed as a foreign
tax credit against such U.S. Holder&#146;s U.S. federal income tax liability or may be claimed as a deduction for U.S. federal income tax purposes. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific
classes of income. For this purpose, dividends distributed by us with respect to our ordinary shares generally will constitute &#147;passive category income&#148; or &#147;general category income.&#148; The rules with respect to the foreign tax
credit are complex and involve the application of rules that depend upon a U.S. Holder&#146;s particular circumstances. You are urged to consult your tax advisor regarding the availability of the foreign tax credit under your particular
circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Taxation of Disposition of the Ordinary Shares </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussion above under &#147;&#151;Passive Foreign Investment Company Considerations,&#148; you will recognize gain or loss on any sale, exchange or
other taxable disposition of an ordinary share equal to the difference between the amount realized on the disposition of the ordinary share and your adjusted tax basis in the ordinary share. The tax basis in an ordinary share generally will be the
cost of such ordinary share. Any such gain or loss will be capital gain or loss, and will be long-term capital gain or loss if you have held the ordinary share for more than one year at the time of sale, exchange or other taxable disposition.
Otherwise, such gain or loss will be short-term capital gain or loss. Long-term capital gains recognized by certain <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders, including individuals, generally will be taxable at a reduced
rate. The deductibility of capital losses is subject to limitations. Any such gain or loss you recognize generally will be treated as U.S. source income or loss for foreign tax credit limitation purposes. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Additional Medicare Tax </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain U.S. Holders that are individuals,
estates or trusts are subject to a 3.8% tax on all or a portion of their &#147;net investment income,&#148; which may include all or a portion of their dividend income and net gains from the disposition of ordinary shares. Each U.S. Holder that is
an individual, estate or trust is urged to consult its tax advisors regarding the applicability of the Medicare tax to its income and gains in respect of its investment in our ordinary shares. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Information Reporting and Backup Withholding </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">U.S. backup withholding
tax and information reporting requirements may apply to certain payments to certain holders of our ordinary shares. Information reporting will generally apply to payments of dividends on, and to proceeds from the sale or redemption of, our ordinary
shares made within the United States, or by a U.S. payer or U.S. middleman, to a holder of our shares, other than an exempt recipient (including a payee that is not a U.S. person that provides an appropriate certification and certain other persons).
Certain U.S. Holders are exempt from backup withholding, including corporations and certain <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations. A U.S. Holder will be subject to backup withholding if such holder is not otherwise exempt
and such holder: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fails to furnish the holder&#146;s taxpayer identification number, which for an individual is ordinarily his or her social security number; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">furnishes an incorrect taxpayer identification number; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">is notified by the IRS that the holder previously failed to properly report payments of interest or dividends; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fails to certify under penalties of perjury that the holder has furnished a correct taxpayer identification number and that the IRS has not notified the holder that the holder is subject to backup withholding.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against
the U.S. Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. U.S. Holders should consult their tax advisors regarding their qualification for an exemption from backup withholding and the
procedures for obtaining such an exemption. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Additional Reporting Requirements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain U.S. Holders who are individuals (and under proposed regulations, certain entities) are required to report information relating to an interest in our ordinary
shares, subject to certain exceptions (including an exception for ordinary shares held in accounts maintained by financial institutions) by filing IRS Form 8938 (Statement of Specified Foreign Financial Assets) with their federal income tax return.
U.S. Holders should consult their tax advisors regarding the possible implications of these tax return disclosure obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the terms and conditions set forth in the underwriting agreement,
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, Jefferies LLC, 520 Madison Avenue, New York, New York 10022, and&nbsp;Cowen and Company, LLC, 599 Lexington
Ave, 27<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, New York, New York 10022, are serving as the representatives of the underwriters named below and the joint book-running managers for this offering. Pursuant to such agreement, we
have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the respective number of ordinary shares shown opposite its name below: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:56.55pt; font-size:8pt; font-family:ARIAL"><B>UNDERWRITER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>ORDINARY&nbsp;SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Oppenheimer &amp; Co. Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">National Securities Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,135,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters
of officers&#146; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the ordinary shares if any of them are purchased. If an
underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated. We have agreed to indemnify the underwriters and certain of
their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the ordinary shares as permitted by
applicable laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can be given as
to the liquidity of the trading market for the ordinary shares, that you will be able to sell any of the ordinary shares held by you at a particular time or that the prices that you receive when you sell will be favorable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters are offering the ordinary shares subject to their acceptance of the ordinary shares from us and subject to prior sale. The underwriters reserve the
right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which they exercise discretionary
authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commission and Expenses </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us
that they propose to offer the ordinary shares to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less a concession not in
excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share. The underwriters may allow, and certain dealers may reallow, a discount from the concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary
share to certain brokers and dealers. After the offering, the initial public offering price, concession and reallowance to dealers may be reduced by the representatives. No such reduction will change the amount of proceeds to be received by us as
set forth on the cover page of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table shows the public offering price, the underwriting discounts and commissions that we are to pay
the underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional ordinary shares. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER ORDINARY SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>ORDINARY<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>ORDINARY<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>ORDINARY<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>ORDINARY<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Underwriting discounts and commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately
$0.7&nbsp;million. We also have agreed to reimburse the underwriters for up to $20,000 for certain expenses incurred in connection with this offering, including for their FINRA counsel fee. In accordance with FINRA Rule 5110, these reimbursed
expenses are deemed underwriting compensation for this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ordinary shares are listed on the NASDAQ Global Market under the trading symbol &#147;URGN&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stamp Taxes </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you purchase ordinary shares offered in this prospectus, you
may be required to pay stamp taxes and other charges under the laws and practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus. However, no stamp taxes will be payable to the State of
Israel in connection with the sale of shares offered hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Option to Purchase Additional Ordinary Shares </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to an
aggregate of 170,377 ordinary shares from us at the public offering price set forth on the cover page of this prospectus, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated,
subject to specified conditions, to purchase a number of additional ordinary shares proportionate to that underwriter&#146;s initial purchase commitment as indicated in the table above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>No Sales of Similar Securities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, our officers and directors and certain
entities affiliated with them have agreed, subject to specified exceptions, not to directly or indirectly: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open &#147;put equivalent position&#148; within the meaning of Rule
<FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">otherwise dispose of any share capital, options or warrants to acquire share capital or securities exchangeable or exercisable for or convertible into share capital currently or hereafter owned either of record or
beneficially, or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">publicly announce an intention to do any of the foregoing for a period of 90 days after the date of this prospectus without the prior written consent of Jefferies LLC. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This restriction terminates after the close of trading of the ordinary shares on and including the 90th day after the date of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Jefferies LLC may, in its sole discretion and at any time or from time to time before the termination of the <FONT
STYLE="white-space:nowrap">90-day</FONT> period release all or any portion of the securities subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stabilization </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, pursuant to Regulation
M under the Exchange Act, certain persons participating in the offering may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These
activities may have the effect of stabilizing or maintaining the market price of the ordinary shares at a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either &#147;covered&#148;
short sales or &#147;naked&#148; short sales. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to
purchase additional ordinary shares in this offering. The underwriters may close out any covered short position by either exercising their option to purchase additional ordinary shares or purchasing our ordinary shares in the open market. In
determining the source of ordinary shares to close out the covered short position, the underwriters will consider, among other things, the price of ordinary shares available for purchase in the open market as compared to the price at which they may
purchase ordinary shares through the option to purchase additional ordinary shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Naked&#148; short sales are sales in excess of the option to purchase
additional ordinary shares. The underwriters must close out any naked short position by purchasing ordinary shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward
pressure on the price of our ordinary shares in the open market after pricing that could adversely affect investors who purchase in this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A stabilizing
bid is a bid for the purchase of ordinary shares on behalf of the underwriters for the purpose of fixing or maintaining the price of the ordinary shares. A syndicate covering transaction is the bid for or the purchase of ordinary shares on behalf of
the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our ordinary shares or preventing or retarding a decline in the market price of our ordinary shares. As a result, the price of our ordinary shares may be higher than the price that might otherwise exist in the open
market. A penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the ordinary shares originally sold by such syndicate member are
purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we, nor any of the underwriters make
any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our ordinary shares. The underwriters are not obligated to engage in these activities and, if commenced,
any of the activities may be discontinued at any time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters may also engage in passive market making transactions in our ordinary shares on the NASDAQ
Global Market in accordance with Rule&nbsp;103 of Regulation&nbsp;M during a period before the commencement of offers or sales of our ordinary shares in this offering and extending through the completion of distribution. A passive market maker must
display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits are
exceeded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Electronic Distribution </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A prospectus in electronic format
may be made available by <FONT STYLE="white-space:nowrap">e-mail</FONT> or on the web sites or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may view offering terms
online and may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of ordinary shares for sale to online brokerage account holders. Any such allocation for online distributions will be made by the
underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#146; web sites and any information contained in any other web site maintained by any of the underwriters is not
part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Activities and Relationships </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial
and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriters and certain of their affiliates have, from time to time, performed, and may
in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the ordinary course of their various business activities, the underwriters and certain of their affiliates may make or hold a broad array of investments and actively
trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities
and/or instruments issued by us and our affiliates. If the underwriters or their respective affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies.
The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our
affiliates, including potentially the ordinary shares offered hereby. Any such short positions could adversely affect future trading prices of the ordinary shares offered hereby. The underwriters and certain of their respective affiliates may also
communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire,
long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Disclaimers About <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Jurisdictions </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Australia </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus is not a disclosure document for the
purposes of Australia&#146;s Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been lodged with the Australian Securities&nbsp;&amp; Investments Commission and is only directed to the categories of exempt persons set out below.
Accordingly, if you receive this prospectus in Australia: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You confirm and warrant that you are either: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a &#147;sophisticated investor&#148; under section 708(8)(a) or (b)&nbsp;of the Corporations Act; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a &#147;sophisticated investor&#148; under section 708(8)(c) or (d)&nbsp;of the Corporations Act and that you have provided an accountant&#146;s certificate to the company which complies with the requirements of section
708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a person associated with the Company under Section&nbsp;708(12) of the Corporations Act; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b)&nbsp;of the Corporations Act. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To
the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the Corporations Act any offer made to you under this prospectus is void and incapable of
acceptance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You warrant and agree that you will not offer any of the shares issued to you pursuant to this prospectus for resale in Australia within 12 months of
those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708 of the Corporations Act. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>European Economic Area </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In relation to each member state of the
European Economic Area which has implemented the Prospectus Directive, each referred to herein as a Relevant Member State, an offer to the public of any ordinary shares which are the subject of the offering contemplated by this prospectus may not be
made in that Relevant Member State, except that an offer to the public in that Relevant Member State of any ordinary shares may be made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that
Relevant Member State: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a &#147;qualified investor&#148; as defined in the Prospectus Directive; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the
representatives of the underwriters for any such offer; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided that no such offer of
securities shall require the company or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the purposes of this provision, the expression &#147;offer to the public&#148; in relation to the securities in any Relevant Member State means the communication in
any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe the securities, as the same may be varied in that Relevant Member State by
any measure implementing the Prospectus Directive in that Relevant Member State, and the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, the &#147;2010 PD Amending
Directive&#148;), and includes any relevant implementing measure in the Relevant Member State, and the expression &#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Hong Kong </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No securities have been offered or sold, and no securities
may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to &#147;professional investors&#148; as defined in the
Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong
Kong or which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32) or the Securities and Futures Ordinance (Cap. 571) of Hong Kong. No document, invitation or advertisement relating to the securities has
been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong
Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the
Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been registered with the Registrar of
Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the securities will
be required, and is deemed by the acquisition of the securities, to confirm that he is aware of the restriction on offers of the securities described in this prospectus and the relevant offering documents and that he is not acquiring, and has not
been offered any securities in circumstances that contravene any such restrictions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Japan </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offering has not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948 of Japan, as amended), or FIEL,
and the underwriters will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means, unless otherwise provided herein, any person resident in Japan,
including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except
pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and ministerial guidelines of Japan. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Singapore </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been and will not be lodged or
registered with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or the invitation for subscription or purchase of the securities may not be issued, circulated
or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under
Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii)&nbsp;to a relevant person as defined under Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the
conditions, specified in Section&nbsp;275 of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of any other applicable provision of the SFA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Where the securities are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor as defined under Section&nbsp;4A of the SFA) the sole business of which is to hold investments and the entire share capital of which is owned by one or more
individuals, each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an individual who is an accredited investor, </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall
not be transferred for six months after that corporation or that trust has acquired the securities pursuant to an offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person pursuant to an offer referred to in Section&nbsp;275(1A) or
Section&nbsp;276(4)(i)(B) of the SFA; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Switzerland </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The securities may not be publicly offered in
Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses
under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in
Switzerland. Neither this prospectus nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither this prospectus nor any other offering or marketing material relating to the offering, the company or the securities have been or will be filed with or approved
by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of securities has not been and
will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>United Kingdom </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus is only being distributed to, and is
only directed at, persons in the United Kingdom that are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive that are also (i)&nbsp;investment professionals falling within Article 19(5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005, as amended, referred to herein as the Order, and/or (ii)&nbsp;high net worth entities falling within Article 49(2)(a) to (d)&nbsp;of the Order and other persons to whom it may lawfully be
communicated. Each such person is referred to herein as a Relevant Person. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus and its contents are confidential and should not be distributed,
published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom. Any person in the United Kingdom that is not a Relevant Person should not act or rely on this document or any of its contents. Any
investment or investment activity to which this prospectus relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Israel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This document does not constitute a prospectus under the
Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In the State of Israel, this document is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
being distributed only to, and is directed only at, and any offer of the ordinary shares is directed only at, (i)&nbsp;a limited number of persons in accordance with the Securities Law and
(ii)&nbsp;investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members
of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and &#147;qualified individuals&#148;, each as defined in the Addendum (as it may be amended from time to time), collectively
referred to as qualified investors (in each case purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors will be required to submit
written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Canada </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Resale Restrictions </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The distribution of ordinary shares in Canada is being
made only in the provinces of Ontario, Quebec, Alberta and British Columbia on a private placement basis exempt from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades of
these securities are made. Any resale of the ordinary shares in Canada must be made under applicable securities laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions
or under a discretionary exemption granted by the applicable Canadian securities regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the securities. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Representations of Canadian Purchasers </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">By purchasing ordinary shares in
Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the purchase confirmation is received that: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser is entitled under applicable provincial securities laws to purchase the ordinary shares without the benefit of a prospectus qualified under those securities laws as it is an &#147;accredited investor&#148;
as defined under National Instrument <FONT STYLE="white-space:nowrap">45-106&#151;</FONT><I>Prospectus Exemptions</I>, </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser is a &#147;permitted client&#148; as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103&#151;</FONT><I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>,
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where required by law, the purchaser is purchasing as principal and not as agent, and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser has reviewed the text above under Resale Restrictions. </TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Conflicts of Interest </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers are hereby notified that each of the underwriters are relying on the exemption set out in section 3A.3 or 3A.4, if applicable, of National
Instrument <FONT STYLE="white-space:nowrap">33-105&#151;</FONT><I>Underwriting Conflicts</I> from having to provide certain conflict of interest disclosure in this document. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Statutory Rights of Action </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securities legislation in certain provinces or
territories of Canada may provide a purchaser with remedies for rescission or damages if the prospectus (including any amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages are
exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities
legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Enforcement of Legal Rights </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our directors and officers as well as the experts named herein may be located outside of Canada and, as a result, it may not be possible for Canadian purchasers
to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the assets of those persons may be located outside of Canada and, as a result, it may not be possible to satisfy a judgment against
us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Taxation and Eligibility for
Investment </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers of ordinary shares should consult their own legal and tax advisors with respect to the tax consequences of an investment in the
ordinary shares in their particular circumstances and about the eligibility of the ordinary shares for investment by the purchaser under relevant Canadian legislation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_20"></A>EXPENSES OF THIS OFFERING </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the costs and expenses, other than the underwriting discounts and commissions, payable by us in connection with the sale of our ordinary
shares being registered. All amounts are estimates except for the SEC registration fee and the FINRA filing fee. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:18.65pt; font-size:8pt; font-family:ARIAL"><B>ITEM</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT&nbsp;TO<BR>BE PAID</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">475,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The validity of the issuance of our ordinary shares offered in this prospectus and certain other matters of Israeli law will be passed upon for us by Hamburger
Evron&nbsp;&amp; Co., Tel Aviv, Israel. As of the date of this prospectus, Hamburger Evron&nbsp;&amp; Co. beneficially owns an aggregate of 83,928 of our ordinary shares issuable upon the exercise of options. Certain matters of U.S. law will be
passed upon for us by Cooley LLP, New York, New York. Legal counsel to the underwriters are Gornitzky&nbsp;&amp; Co., Tel Aviv, Israel, with respect to Israeli law, and Covington&nbsp;&amp; Burling LLP, New York, New York, with respect to U.S. law.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_22"></A>EXPERTS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The financial
statements as of December&nbsp;31, 2016 and 2015 and for each of the two years in the period ended December&nbsp;31, 2016 included in this prospectus<B><SUP STYLE="font-size:85%; vertical-align:top"></SUP></B>&nbsp;have been so included in reliance
on the report of Kesselman&nbsp;&amp; Kesselman, Certified Public Accountants (Israel), an independent registered public accounting firm and a member firm of PricewaterhouseCoopers International Limited, given on the authority of said firm as
experts in auditing and accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_23"></A>ENFORCEMENT OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in this
registration statement, most of whom reside outside of the United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets and substantially all of our directors and officers are located
outside of the United States, any judgment obtained in the United States against us or any of our directors and officers may not be collectible within the United States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have been informed by our legal counsel in Israel, Hamburger Evron&nbsp;&amp; Co., that it may be difficult to assert U.S. securities law claims in original actions
instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear
a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain
matters of procedure will also be governed by Israeli law. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have irrevocably appointed Urogen Pharma, Inc. as our agent to receive service of process in any
action against us in any U.S. federal or state court arising out of this offering or any purchase or sale of securities in connection with this offering. Subject to specified time limitations and legal procedures, Israeli courts may enforce a U.S.
judgment in a civil matter which, subject to certain exceptions, is <FONT STYLE="white-space:nowrap">non-appealable,</FONT> including a judgment based upon the civil liability provisions of the Securities Act and the Exchange Act and including a
monetary or compensatory judgment in a <FONT STYLE="white-space:nowrap">non-civil</FONT> matter, provided that among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment was obtained after due process before a court of competent jurisdiction, according to the laws of the state in which the judgment was given and the rules of private international law currently prevailing in
Israel; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevailing law of the foreign state in which the judgment was rendered allows for the enforcement of judgments of Israeli courts; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adequate service of process has been effected and the defendant has had a reasonable opportunity to be heard and to present his or her evidence; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment is not contrary to public policy of Israel, and the enforcement of the civil liabilities set forth in the judgment is not likely to impair the security or sovereignty of Israel; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment was not obtained by fraud and does not conflict with any other valid judgments in the same matter between the same parties; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an action between the same parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment is enforceable according to the laws of Israel and according to the law of the foreign state in which the relief was granted. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into
<FONT STYLE="white-space:nowrap">non-Israeli</FONT> currency and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a <FONT STYLE="white-space:nowrap">non-Israeli</FONT> currency is for the
Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the
judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk
of unfavorable exchange rates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_24"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> under the Securities Act relating to this offering of our
ordinary shares. This prospectus does not contain all of the information contained in the registration statement. The rules and regulations of the SEC allow us to omit certain information from this prospectus that is included in the registration
statement. Statements made in this prospectus concerning the contents of any contract, agreement or other document are summaries of all material information about the documents summarized, but are not complete descriptions of all terms of these
documents. If we filed any of these documents as an exhibit to the registration statement, you may read the document itself for a complete description of its terms. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You may read and copy the registration statement, including the related exhibits and schedules, and any document we file with the SEC without charge at the SEC&#146;s
public reference room at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Room 1580, Washington, D.C.
20549. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information on the public reference room. The SEC also maintains a
website that contains reports and other information regarding issuers that file electronically with the SEC. Our filings with the SEC are also available to the public through the SEC&#146;s website at <I>http://www.sec.gov</I>. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are currently subject to the information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements file
reports with the SEC. These other reports or other information may be inspected without charge at the locations described above. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content
of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. In addition, we are not required under the
Exchange Act to file reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We maintain a corporate website at <I>http://www.urogen.com</I>. Information contained on, or that can be accessed through, our website does not constitute a part of
this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc504802_25"></A>CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="index"></A>TABLE OF CONTENTS </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Audited Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin504802_2">Report of independent registered public accounting firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin504802_3">Consolidated Balance sheets as of December&nbsp;31, 2016 and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin504802_4">Consolidated Statements of operations for the years ended December&nbsp;
31, 2016 and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin504802_5">Consolidated Statements of changes in shareholders&#146; equity for the years ended December&nbsp;31,
 2016 and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin504802_6">Consolidated Statements of cash flows for the years ended December&nbsp;
31, 2016 and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin504802_7">Notes to the consolidated financial statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Unaudited Condensed Consolidated Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin504802_9">Condensed consolidated Balance sheets as of September&nbsp;
30, 2017 and December&nbsp;31, 2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin504802_10">Condensed consolidated Statements of operations for the nine months ended September&nbsp;30,
 2017 and 2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin504802_11">Condensed consolidated Statements of changes in shareholders&#146; equity for the nine
 months ended September&nbsp;30, 2017 and 2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin504802_12">Condensed consolidated Statements of cash flows for the nine months ended September&nbsp;30,
 2017 and 2016</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin504802_13">Notes to Condensed Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g504802g56i55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin504802_2"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">To the shareholders of </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations, changes in shareholders&#146; equity and cash flows
present fairly, in all material respects, the financial position of Urogen Pharma Ltd. (the Company) at December 31, 2016 and 2015, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2016
in conformity with accounting principles generally accepted in United States of America. These financial statements are the responsibility of the Company&#146;s management and Board of Directors. Our responsibility is to express an opinion on these
financial statements based on our audits. We conducted our audits of these statements in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting
principles used and significant estimates made by management and Board of Directors, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:145pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Tel-Aviv,&nbsp;Israel&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">/s/ Kesselman &amp; Kesselman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">March 8, 2017, except for the</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">effects of the share split
discussed</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">in note 1d to the consolidated</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">financial statements, as to which</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">the date is April 24, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certified Public Accountants (lsr.)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">A&nbsp;member&nbsp;firm&nbsp;of&nbsp;PricewaterhouseCoopers&nbsp;International Limited</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="68%"></TD></TR>

<TR STYLE="font-size:1px; font-family:ARIAL; font-size:9.5pt">
<TD COLSPAN="5" VALIGN="top" STYLE="BORDER-LEFT:1px dotted #000000; BORDER-TOP:1px dotted #000000; padding-left:8pt; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kesselman &amp; Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv 6812508,
Israel,</I></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;P.O Box 50005 Tel-Aviv 6150001 Telephone: +972-3-7954555, Fax: +972-3-7954556,
www.pwc.com/il</I></B></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin504802_3"></A>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in
thousands, except share and per share data) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><B>Assets</B></TD>
<TD VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CURRENT ASSETS:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL CURRENT ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">NON-CURRENT</FONT> ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><B>Liabilities and Shareholders&#146; equity</B></TD>
<TD VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CURRENT LIABILITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable, accrued expenses and advances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Employee related accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds&nbsp;from exercise of warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL CURRENT LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">NON-CURRENT</FONT> LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>COMMITMENTS AND CONTINGENCIES (Note 6)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>SHAREHOLDERS&#146; EQUITY:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares, NIS 0.01 par value: 17,600,000 shares authorized at December&nbsp;31, 2016 and 2015;
2,305,743 and 2,300,959 issued and outstanding as of December&nbsp;31, 2016 and 2015, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A and <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares, NIS 0.01 par
value:<BR>14,400,000 shares authorized at December&nbsp;31, 2016 and 2015; 5,193,427 shares issued and outstanding at December&nbsp;31, 2016 and 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin504802_4"></A>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands, except share and per share data) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>REVENUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>COST OF REVENUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>GROSS PROFIT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>OPERATING EXPENSES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>RESEARCH AND DEVELOPMENT EXPENSES, NET</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>GENERAL AND ADMINISTRATIVE EXPENSES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>OPERATING INCOME (LOSS)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>FINANCE EXPENSES, NET</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>NET LOSS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>LOSS PER ORDINARY SHARE BASIC AND DILUTED</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER ORDINARY
SHARE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin504802_5"></A>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share data) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ORDINARY</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PREFERRED</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADDITIONAL</B><br><B><FONT STYLE="white-space:nowrap">PAID-IN&nbsp;CAPITAL</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED</B><br><B>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>BALANCE AS OF JANUARY 1, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">862,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>CHANGES DURING 2015:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Issuance of preferred shares, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,635,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Purchase of IP R&amp;D in consideration for Preferred A Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>BALANCE AS OF DECEMBER&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,193,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>CHANGES DURING 2016:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Exercise of options into ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>BALANCE AS OF DECEMBER&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,193,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(*) Represents amount less than one thousand </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin504802_6"></A>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CASH FLOWS FROM OPERATING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adjustments required to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">In process R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Share based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exchange rates differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value adjustment of warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in operating asset and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Decrease (increase) in prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in accounts payable, accrued expenses and advances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in employee related accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CASH FLOWS FROM INVESTING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in restricted deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CASH FLOWS FROM FINANCING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise of options into ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds&nbsp;from exercise of warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of preferred shares from 2014 Share Purchase Agreement net of issuance cost</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>INCREASE IN CASH AND CASH EQUIVALENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>BALANCE OF CASH AND CASH EQUIVALENTS AT END OF THE YEAR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>SUPPLEMENTAL DISCLOSURES OF <FONT STYLE="white-space:nowrap">NON-CASH</FONT> INVESTING AND FINANCING
ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of IP R&amp;D in consideration for Preferred A Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Non cash issuance cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin504802_7"></A>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 1&#151;NATURE OF OPERATIONS </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">UroGen Pharma Ltd. (formerly TheraCoat Ltd.) is an Israeli company incorporated in April 2004 (&#147;UPL&#148;). </TD></TR></TABLE>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">UroGen Pharma Inc., a subsidiary of UPL, was incorporated in Delaware in October 2015 and began operating in February 2016 (&#147;UPI&#148;). </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">UPL and UPI (together the &#147;Company&#148;) is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change
the standard of care for urological pathologies. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">In August 2015 the Company entered into an agreement with Allergan Pharmaceuticals International Limited (&#147;Allergan&#148;), a wholly owned subsidiary of Allergan plc, pursuant to which the Company undertook to
supply its gel product and supporting services to Allergan for consideration of $750, to allow Allergan to conduct certain scientific investigations aimed at testing utility of the Company&#146;s gel product for the delivery of a certain proprietary
product of Allergan. Further, the Company granted Allergan a time limited option to negotiate an exclusive, worldwide right to research, develop, make and have made, use, sell, offer to sell and import the Company&#146;s product in combination with
Allergan&#146;s product. </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">Pursuant to the terms of the agreement from 2015, on October&nbsp;7, 2016, the Company entered into an
exclusive license agreement with Allergan to license worldwide rights to some of its products indicated for use with neurotoxins. As stipulated in the agreement, Allergan paid a <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront fee of
$17.5&nbsp;million in accordance with the terms of the license agreement. Allergan shall pay the Company additional milestone payments of up to $207.5&nbsp;million and tiered royalty payments as a percentage of net sales of the licensed product all
as stated in the agreement. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">As of the date of approval of the consolidated financial statements, the Company has the ability to fund its planned operations for at least the next 12 months. However, in order to complete the clinical trials aimed at
developing a product until obtaining its marketing approval, the Company will need to raise additional funds. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">As described in Note 12, in April 2017, the Company&#146;s board of directors and shareholders approved an aggregate 3.2-for-1 share split of the Company&#146;s ordinary, Preferred A and Preferred A-1 shares. All of the
share and per share amounts reflected in these financial statements and the notes thereto have been adjusted, on a retroactive basis, to reflect this share split. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 2&#151;SIGNIFICANT ACCOUNTING POLICIES: </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Basis of presentation
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America
(&#147;U.S. GAAP&#148;). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Use of estimates in the preparation of financial statements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. As applicable
to these consolidated financial statements, the most significant estimates and assumptions relate to the fair value of share-based compensation, the fair value of the warrants for preferred shares and timing of revenue recognition. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>c. Functional currency </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The U.S. dollar (&#147;Dollar&#148;) is the
currency of the primary economic environment in which the operations of the Company and subsidiary are conducted. Therefore, the functional currency of the Company is the Dollar. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accordingly, transactions in currencies other than the Dollar are measured and recorded in the functional currency using the exchange rate in effect at the date of the
transaction. At the balance sheet date, monetary assets and liabilities that are denominated in currencies other than the Dollar are measured using the official exchange rate at the balance sheet date. The effects of foreign currency <FONT
STYLE="white-space:nowrap">re-measurements</FONT> are recorded in the consolidated statements of operations as &#147;financial income (expenses).&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>d. Cash and cash equivalents </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or
less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>e. Property and
equipment </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">Property and equipment are stated at cost, net of accumulated depreciation. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s property and equipment are depreciated using the straight-line method on the basis of their estimated useful lives. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Annual rates of depreciation are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Computers and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">15-30</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">6-15</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Manufacturing equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Leasehold improvements are amortized using the straight-line method over the shorter of the expected lease term and the estimated useful life of the improvements. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>f. Impairment of long-lived assets </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company tests long-lived
assets, comprised solely of property and equipment, for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future undiscounted cash flows of the assets is less than the carrying amount of such
assets, an impairment loss would be recognized. The assets would be written down to their estimated fair values, calculated based on the present value of expected future discounted cash flows or some other fair value measure. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2016 and 2015, the Company did not recognize an impairment loss for its long-lived assets. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>g. Contingencies </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain conditions may exist as of the date of the
financial statements, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company&#146;s management assesses such contingent liabilities and such assessment inherently
involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company&#146;s management evaluates the perceived
merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Management applies
the guidance in ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">450-20-25</FONT></FONT> when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable that a loss has been
incurred and the amount of the liability can be estimated, then the estimated liability is recorded as accrued expenses in the Company&#146;s financial statements. If the assessment indicates that a potential loss contingency is not probable but is
reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable are disclosed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accruing a provision for loss, the Company recognizes an accrual for the amount within a range of loss that represents the best estimate within the range. When no
amount within the range is a better estimate than any other amount, the Company accrues for the minimum amount within the range. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>h. Financial instruments
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When the Company issues preferred shares, it considers the provisions of ASC 480 in order to determine whether the preferred share should be classified as
a liability. If the instrument is not within the scope of ASC 480, the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
further analyzes the instrument&#146;s characteristics in order to determine whether it should be classified within temporary equity (mezzanine) or within permanent equity in accordance with the
provisions of ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">480-10-S99.</FONT></FONT> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When the Company issues other freestanding
instruments, the Company first analyzes the provisions of ASC&nbsp;480 in order to determine whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in earnings in each period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the instrument is not within the scope of ASC 480, the Company further analyzes the provisions of <FONT STYLE="white-space:nowrap">ASC&nbsp;815-40</FONT> in order to
determine whether the instrument should be classified within equity or rather classified as an asset or liability, with subsequent changes in fair value recognized in earnings in each period. See note&nbsp;7 and note&nbsp;8. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>i. Share-based compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounts for employees&#146;
and directors&#146; share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period. As of
December&nbsp;31, 2016 the Company has early adopted the policy to account for forfeitures as they occur according to the FASB&#146;s Accounting Standards Update <FONT STYLE="white-space:nowrap">(ASU)&nbsp;2016-09,</FONT> Improvements to Employee
Share-Based Payment Accounting. The adjustment for the beginning of the period was not material ($30) and therefore it was not reflected in the consolidated statements of changes in shareholders&#146; equity. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the straight-line method
and to value the awards based on the single-option award approach. Performance based awards are expensed over the requisite service period when the achievement of performance criteria is probable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Equity awards granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> are <FONT STYLE="white-space:nowrap">re-measured</FONT> at each reporting period at fair
value until the commitment date had been reached which is usually the date the service is completed. The fair value of equity awards is charged to the statement of operations over the service period using the straight-line method. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>j. Revenue recognition </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Virtually all the Company&#146;s revenues are
derived from the license agreement with Allergan, to license worldwide rights to some of its products. Revenue is recognized only when all of the following conditions have been met: (i)&nbsp;there is persuasive evidence of an arrangement;
(ii)&nbsp;delivery has occurred: (iii)&nbsp;the fee is fixed or determinable: and (iv) collectability of the fee is reasonably assured. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The license agreement
contains two deliverables: (a)&nbsp;the license component and (b)&nbsp;Allergan&#146;s right to require supply services of RTGel vials from the Company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In an
arrangement with multiple deliverables, the delivered item or items shall be considered a separate unit of accounting if all of the following criteria are met: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(a)&nbsp;The delivered item or items have value to the customer on a standalone basis. The item or items have value on a standalone if they are sold separately by any
vendor or the customer could resell the delivered item(s) on a standalone basis. In the context of a customer&#146;s ability to resell the delivered item(s), this criterion does not require the existence of an observable market for the
deliverable(s), and </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(b)&nbsp;If the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered
item or items is considered probable and substantially in the control of the vendor. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When deliverables are separable, arrangement consideration is allocated to the
separate units of accounting based on the relative selling price of each deliverable (where the amount allocable to the delivered element is limited to the amount not contingent on the delivery of future products or services) and the appropriate
revenue recognition principles are applied to each unit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The license component has standalone value (and therefore is accounted for separately from the supply services) since
Allergan can use the license for its intended purposes without the Company&#146;s supply services. The four conditions of ASC&nbsp;605 were met as of December&nbsp;31, 2016: (1)&nbsp;persuasive evidence of an arrangement exists since the Company and
Allergan engaged with a binding agreement; (2)&nbsp;delivery has occurred or services have been rendered since all documents and data Allergan has requested relating to the Company&#146;s know-how were provided before December&nbsp;31, 2016 and
Allergan can use the license for its intended purposes without the supply services (except for immaterial support services); (3)&nbsp;the fee is fixed or determinable, as indicated in the license agreement; and (4)&nbsp;collectability is reasonably
assured. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Therefore, as of December&nbsp;31, 2016, the consideration received in an amount of $17.5 million represents arrangement consideration for both the
license of the intellectual property as well as Allergan&#146;s right to future supply services (which would be provided in consideration for future payments to the Company according to the pricing stipulated in the supply agreement). The Company
determined that the pricing of the supply services represents their standalone selling price. Accordingly, the Company allocated the entire upfront fee of $17.5 million to the license component. In addition, revenue from the supply services would be
recorded in an amount equal the consideration stipulated in the agreement for these services, when these services are provided. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As described in Note&nbsp;1, the
Company is also entitled to milestone payments and royalties based on Allergan&#146;s revenue from its product, which are not considered fixed or determinable until their occurrence. Therefore, these amounts would only be recognized when the
conditions for payment are met, and they become due and payable. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>k. Research and development costs </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other
employee benefits, subcontractors and materials used for research and development activities and professional services. Grants received from the Israel Innovation Authority, f/k/a the Office of the Chief Scientist of Israel&#146;s Ministry of
Industry, Trade and Labor (the &#147;IIA&#148;) are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the
grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred. In the year ended December&nbsp;31, 2015 the company deducted research and development expenses in the amount of $537. In
the year ended December&nbsp;31, 2016, the company had an increase of $175 to its research and development expenses as a result of its decision not to pursue one of its research programs that had been approved as a result of other financing
opportunities. The costs of services performed by others in connection with the research and development activities of an entity, including research and development conducted by others in behalf of the entity, shall be included in research and
development costs. The amount received from Allergan from the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> collaboration agreement signed in August 2015 was deducted from research and development expenses in the statements of operations as
the applicable costs were incurred. For the years ended December&nbsp;31, 2016 and 2015 an amount of $126 and $624, respectively, was deducted from research and development expenses. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The costs of intangibles that are purchased from others for a particular research and development project and that have no alternative future uses (in other research
and development projects or otherwise) and therefore no separate economic values are research and development costs at the time the costs are incurred. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
intellectual property costs totaling $4,103, as described in note&nbsp;8a(5), were expensed as incurred to research and development costs in accordance with ASC&nbsp;730, as the intellectual property was purchased from others for a particular
research and development project and has no alternative future use and therefore no separate economic value. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>l. Income taxes: </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>1) Deferred taxes </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Income taxes are computed using the asset and liability
method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the
deferred taxes will not be realized in the foreseeable future. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2) Uncertain income tax positions </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company follows a <FONT STYLE="white-space:nowrap">two-step</FONT> approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the
tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained based on technical merits. If this threshold is met, the second step is to measure the tax benefit as
the largest amount that is more likely than not of being realized upon ultimate settlement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>m. Loss per share </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic loss per share (&#147;LPS&#148;) is computed by dividing net loss for the year, after reducing cumulative dividends on preferred shares by the weighted average
number of ordinary shares of the Company outstanding for each period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The calculation of diluted net loss per share excludes potential share issuances of ordinary
shares upon the exercise of share options, warrants for preferred shares and convertible preferred share as each of their effect is anti-dilutive. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>n. Fair
value measurement </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an
orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable
inputs used to measure fair value into three broad levels, which are described as follows: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;1: Quoted prices (unadjusted) in active markets that are
accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&nbsp;1 inputs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;2: Observable
prices that are based on inputs not quoted on active markets, but corroborated by market data. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;3: Unobservable inputs are used when little or no market
data is available. The fair value hierarchy gives the lowest priority to Level&nbsp;3 inputs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In determining fair value, the Company utilizes valuation techniques
that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>o. Concentration of credit risks </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial instruments that
potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents. The Company deposits cash and cash equivalents with highly rated financial institutions, and, as a matter of policy, limits the amounts
of credit exposure to any single financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>p. Segment reporting </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Operating segments are reported in a manner
consistent with the internal reporting provided to the chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments. The Company operates in one operating segment. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>q. IPO Costs </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounts for IPO costs in accordance with
SEC Staff Accounting Bulletin Topic 5A. During the year ended December 31, 2016, the Company recorded $1.7 million in general and administrative expenses related to IPO costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>r. Newly issued and recently adopted accounting pronouncements </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">In August 2014, FASB issued ASU <FONT STYLE="white-space:nowrap">2014-15&#151;Presentation</FONT> of Financial Statements&#151;Going Concern (ASC Subtopic <FONT STYLE="white-space:nowrap">205-40):</FONT>
&#147;Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern&#148;. The update requires management to assess a company&#146;s ability to continue as a going concern and to provide related footnote disclosures in
certain circumstances. All entities are required to apply the new requirements in annual periods ending after December&nbsp;15, 2016, and interim periods thereafter. Early application is permitted. The Company adopted the provisions of these
pronouncement. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">In May 2014, the FASB issued Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">No.&nbsp;2014-09,</FONT> &#147;Revenue from Contracts with Customers&#148; (Topic 606), (&#147;ASU <FONT
STYLE="white-space:nowrap">2014-09&#148;).</FONT> ASU <FONT STYLE="white-space:nowrap">2014-09</FONT> requires entities to recognize revenue that represents the transfer of promised goods or services to customers in an amount equivalent to the
consideration to which the entity expects to be entitled to in exchange for those goods or services. The following steps should be applied to determine this amount: (1)&nbsp;identify the contract(s) with a customer; (2)&nbsp;identify the performance
obligations in the contract; (3)&nbsp;determine the transaction price; (4)&nbsp;allocate the transaction price to the performance obligations in the contract; and (5)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation.
ASU <FONT STYLE="white-space:nowrap">2014-09</FONT> supersedes the revenue recognition requirements in ASU 605, &#147;Revenue Recognition,&#148; and most industry-specific guidance in the Accounting Standards Codification. In August 2015, the FASB
issued ASU <FONT STYLE="white-space:nowrap">2015-14</FONT> on this same topic, which defers for one year the effective date of ASU <FONT STYLE="white-space:nowrap">2014-09,</FONT> therefore, the guidance is effective for the Company for annual
reporting periods, including interim periods therein, beginning January&nbsp;1, 2018. The new revenue standards may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of
adoption. The Company is currently evaluating the impact of adopting the guidance on its Consolidated Financial Statements. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> Leases (Topic 842) (&#147;ASU <FONT STYLE="white-space:nowrap">2016-02&#148;).</FONT> ASU
<FONT STYLE="white-space:nowrap">2016-02</FONT> supersedes existing guidance in Leases (Topic 840). The revised standard requires lessees to recognize the assets and liabilities arising from leases with lease terms greater than twelve months on the
balance sheet, including those currently classified as operating leases, and to disclose key information about leasing arrangements. Lessees will be required to recognize a lease liability and a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset on their balance sheets, while lessor accounting will remain largely unchanged. The guidance is effective for annual periods beginning after December&nbsp;15, 2018, with early adoption
permitted. The Company is currently evaluating the impact the adoption of ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> will have on its consolidated financial statements and related disclosures. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top">In March 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-09,</FONT> &#147;Improvements to Employee Share-Based Payment Accounting.&#148; ASU <FONT STYLE="white-space:nowrap">2016-09</FONT> is
aimed to simplifying the accounting for share-based payment transactions. Included in the update are modifications to the accounting for income taxes upon vesting or settlement of awards, employer tax withholding on share-based compensation and
financial statements presentation of excess tax benefits. The guidance also provides an accounting policy election to account for forfeitures as they occur. As permitted by ASU <FONT STYLE="white-space:nowrap">2016-09,</FONT> the Company
early-adopted this standard in the fourth quarter of 2016, using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of the beginning of the period in which the guidance is adopted. The impact of this
adoption is immaterial. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top">In August 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-15,</FONT> &#147;Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments,&#148; which addresses the presentation of
restricted cash and restricted cash equivalents (or amounts generally described as such) within the statement of cash flows under ASC 230, Statement of Cash Flows, with the intent to reduce diversity in practice. Among others, this ASU addresses
cash flow treatment such as debt prepayment or debt extinguishment costs and proceeds from the settlement of insurance claims. Entities are required to disclose how the statement of cash flows reconciles to the balance sheet if restricted cash is
shown separately from cash and cash equivalents on the balance sheet. Entities must also disclose information about the nature of the restrictions. The amendments are effective for public business entities for fiscal years beginning after
December&nbsp;15, 2017, and interim periods within those fiscal years. Early adoption is permitted. A retrospective basis adoption is required. The Company is currently evaluating the impact of the standard on its consolidated financial statements.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">6)</TD>
<TD ALIGN="left" VALIGN="top">In November 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-18,</FONT> &#147;Statement of Cash Flows (Topic 230): Restricted Cash&#148; (&#147;ASU
<FONT STYLE="white-space:nowrap">2016-18&#148;).</FONT> ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> amends the classification and presentation of changes in restricted cash or restricted cash equivalents in the statement of cash flows. The
ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> is effective for public business entities for fiscal years beginning after December&nbsp;15, 2017, and interim periods within those fiscal years. For all other entities, the amendments are
effective for fiscal years beginning after December&nbsp;15, 2018, and interim periods within fiscal years beginning after December&nbsp;15, 2019. Early adoption is permitted, including adoption in an interim period. The Company is currently
evaluating the impact the adoption of ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> will have on its consolidated financial statements. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE
3&#151;PROPERTY AND EQUIPMENT </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cost:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Computers and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Manufacturing equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less&#151;Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depreciation expense was $213 and $113 for the years ended December&nbsp;31, 2016 and 2015, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 4&#151;EMPLOYEE RIGHTS UPON RETIREMENT </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is required by law
to make severance payments upon dismissal of an employee or upon termination of employment in certain other circumstances. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company operates a number of
post-employment defined contribution plans. A defined contribution plan is a program that benefits an employee after termination of employment, under which the Company regularly makes fixed payments to a separate and independent entity so that the
Company has no legal or constructive obligation to pay additional contributions if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods. The fund assets are not
included in the Company&#146;s financial position. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company operates pension and severance compensation plans subject to Section&nbsp;14 of the Israeli
Severance Pay Law. The plans are funded through payments to insurance companies or pension funds administered by trustees. In accordance with its terms, the plans meet the definition of a defined contribution plan, as defined above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 5&#151;PROCEEDS FROM EXERCISE OF WARRANTS FOR PREFERRED SHARES </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Warrants for preferred shares are exercisable for Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares at an exercise price of $7.81 per share. As of
December&nbsp;31, 2016, the number of warrants for preferred shares that are exercisable for Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares is 728,312. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During 2016 the Company notified these warrant holders that it is ready to accept an exercise notice that is conditioned on the price per share that will be determined
in the anticipated IPO. As of December&nbsp;31, 2016 the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Company received a total amount of $570 as consideration for the conditional cash exercise of the warrants. The cash received for the warrant exercises was recorded among current liabilities as
Proceeds from exercise of warrants for preferred shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 6&#151;COMMITMENT AND CONTINGENCIES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Lease agreement </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2016, the Company signed an addendum to
its November 2014 lease agreement in order to increase the office space rented and to extend the rent period. The Company has a lease agreement effective until 2019. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The rent expenses for the years ending December&nbsp;31, 2016 and 2015 are approximately $218 and $121, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">UPI entered into a lease agreement for its office for a period of 7 years commencing on May&nbsp;1, 2016. As part of the agreement UPI provided the lessor with a letter
of credit which expires on December 2017 and shall be automatically annually renewed for approximately $75. The rent expenses for the year ended December&nbsp;31, 2016 are approximately $102. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The future minimum lease payments required in each of the next seven years under the lease agreements are $400 per year for the year 2017, $405 in 2018, $351 in 2019,
$192 per year for the years 2020 until 2022 and $80 in 2023. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Grants from the Israel Innovation Authority (&#147;IIA&#148;), formerly known as the Office
of the Chief Scientist of the State of Israel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has received grants from the IIA for research and development funding. Up until 2007, the IIA
participation in the funding of the Company&#146;s operations was as part of the Director General Directive 8.2 of Israel by grants provided to Granot Ventures. Since 2008, the funding was provided directly to Company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is committed to pay royalties to the Government of Israel on proceeds from sales of products in the research and development of which the IIA participates
by way of grants. At the time the grants were received, successful development of the related projects was not assured. In the case of failure of a project that was partly financed as above, the Company is not obligated to pay any such royalties.
Under the terms of the funding from the IIA, royalties of <FONT STYLE="white-space:nowrap">3%-4.5%</FONT> are payable on sales of products developed from a project so funded, up to 100% of the amount of the grant received by the Company (dollar
linked); with the addition of annual interest at a rate based on <FONT STYLE="white-space:nowrap">12-month</FONT> LIBOR. The Company is subject to several conditions, including restrictions on its intellectual property. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2016, the maximum royalty amount payable by the Company under these funding arrangements is $2,105 (excluding interest). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>c. Financing success fees </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company entered into agreements with
third parties and shareholders in connection with fundraising efforts. In consideration of the services rendered, the Company undertook to pay those third parties and shareholders certain success fees from funds actually received by the Company
and/or options to purchase equity of the Company, at a rate agreed between the parties. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Total success fees to third parties for the year ended December&nbsp;31,
2016 consisted of 5,726 options to third parties to purchase ordinary shares with a fair value of $9. For the year ended December&nbsp;31, 2015, total success fees to third parties were $108, and were payable in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 7&#151;FINANCIAL INSTRUMENTS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Warrants for preferred shares
</I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">In 2014, as part of a share purchase agreement (the&#147;2014 SPA&#148;), the Company issued warrants (the <FONT STYLE="white-space:nowrap">&#147;A-1</FONT> warrants&#148;) for preferred shares, see note 8a2.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">The <FONT STYLE="white-space:nowrap">A-1</FONT> warrants are exercisable into Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares of the Company, nominal value NIS 0.01 per share, for an exercise price
of $7.81 per share commencing on the date of the issuance and until the earlier of an IPO, M&amp;A event or four years. </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">The warrants
are exercisable for Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares, in consideration for cash representing the exercise price. In the event that the warrant is exercised in connection with an IPO or M&amp;A event, the holder may
elect to convert the warrant on a net share basis. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">A-1</FONT> warrants are classified as liabilities in
accordance with ASC 480, as they are freestanding instruments, exercisable into Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares, which are redeemable upon certain events that represent &#147;Deemed Liquidation&#148; events (see
also Note 8c3). Accordingly, the <FONT STYLE="white-space:nowrap">A-1</FONT> warrants are measured at fair value in every reporting period, and changes in their fair value are recognized in earnings within financial income (expense). </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2015 the fair value of the warrants for preferred shares was measured in accordance with the Hybrid Method. The Hybrid Method
combines the probabilities of an IPO scenario which was estimated at 15% and a liquidation event scenario which was estimated at 85%. The fair value was determined mainly based on the SPA price per share of $5.94 of Series A preferred shares and
assumptions related to achieving the required milestone for additional investment that was determined in the 2014 SPA, and expected volatility at a rate of 75.4%. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">The fair value of the preferred share warrants as of December&nbsp;31, 2016 was measured in accordance with the Hybrid Method. The Hybrid Method
combines the probabilities of an IPO scenario which was estimated at 20% and a liquidation event scenario which was estimated at 80%. As of December&nbsp;31, 2016 the fair value of the warrants for preferred shares was determined mainly based on
estimation of the company&#146;s equity value derived from DCF calculation and on assumption relating to the future revenue forecast, clinical success probabilities, relevant discount rates between <FONT STYLE="white-space:nowrap">10.5%-19%</FONT>
(10.5% for the cash flow expected to be derived from the license agreement with Allergan and 19% for the cash flows expected to be derived from the company&#146;s internal development) and expected volatility at a rate of 73.93%. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. The Company financial instruments measured in fair value and classified as Level&nbsp;3. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The table below sets forth a summary of the changes in the fair value of the warrants for preferred shares classified as Level&nbsp;3: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in fair value of warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>c.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>As of December&nbsp;31, 2016 and 2015 the fair value of all financial assets and liabilities, approximate their carrying amounts. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 8&#151;SHARE CAPITAL: </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Share capital </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2016 and 2015 the share capital of the Company was as follows: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AUTHORIZED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ISSUED&nbsp;AND&nbsp;OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares of NIS 0.01 par value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A and <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares of NIS 0.01 par value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,193,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,193,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">In September 2014 (closing in October 2014), the Company signed the 2014 SPA with shareholders and new investors for an aggregate amount of up to $8,000 in exchange for Series A preferred shares at a price per share of
$5.94 and warrants to purchase Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares at a per share of $7.81. According to the 2014 SPA, each investor that invested more than $500 was required to transfer 50% of its investment at the
initial closing in October 2014 (the &#147;Initial Closing&#148;) and an additional 50% once the Company meets certain milestones the (&#147;Milestone Closing&#148;) or upon an investors&#146; waiver of attainment of the milestone.
</TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">During 2014, the Company received $4,304 and an additional amount of $130 in January 2015, net of issuance costs of $67, in exchange
for 758,118 Series A preferred shares and 379,088 <FONT STYLE="white-space:nowrap">A-1</FONT> warrants. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">In July 2015, at the Milestone Closing the
Company issued for total consideration of $3,500, 589,472 Series A preferred shares and 294,739 <FONT STYLE="white-space:nowrap">A-1</FONT> warrants at $7.81 price per Series A preferred share. </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">In October 2015, the Company reclassified 8,000,000 ordinary shares from the authorized but unissued share capital of the Company, into 8,000,000 Series A preferred shares NIS 0.01 each, so that the authorized share
capital of the Company, after giving effect to the additional Series A preferred shares, shall be follows: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:69.50pt; font-size:8pt; font-family:ARIAL"><B>CLASS&nbsp;OF SHARES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAR<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares NIS 0.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A preferred shares NIS 0.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares NIS 0.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top">In October 2015 (closing in November 2015), the Company signed a share purchase agreement (the &#147;2015 SPA&#148;) with shareholders and new investors for an aggregate amount of up to $18,084 in exchange for 3,045,652
Series A preferred shares of the Company at a price per share of $5.94. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top">In October 2015 the Company entered into an asset purchase agreement with Telormedix SA (&#147;TMX&#148;) pursuant to which the Company purchased all of the intellectual property assets of TMX (in process R&amp;D) in
consideration for 691,200 Series A preferred shares of the Company at a price per share of $5.94 (this includes 172,800 Series A preferred shares, which are being held in escrow and will be automatically released to TMX on the earlier of (i) 12
months from the date of initial closing, as set forth in the asset purchase agreement, and (ii)&nbsp;consummation of an IPO). The Company will issue an additional 92,800 Series A preferred shares upon occurrence of each of three milestones, for a
maximum potential of 278,400 Series A preferred shares. The intellectual property costs totaling $4,103 were expensed as incurred to research and development costs as there is no alternative future use and therefore no separate economic value.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Terms of the Company&#146;s ordinary shares </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each ordinary share is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available, when and if
declared by the Board of Directors. Since its inception, the Company has not declared any dividends. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>c. Terms of the Company&#146;s convertible preferred
shares: </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Preferred shares of the Company include Series A and <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares. The exercise price of Series A
preferred shares is $5.94 and the exercise price of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares is $7.81. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">The holder of each preferred share shall: (i)&nbsp;be entitled to the number of votes which is equal to the number of ordinary shares into which such preferred share is then convertible, (ii)&nbsp;have voting rights and
powers equal to the voting rights and powers of any holder of ordinary shares and shall vote as a single class with the holders of ordinary shares, and (iii)&nbsp;be entitled to notice of any meeting of the shareholders. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">From and after the date of the issuance of any preferred shares, dividends at the rate per annum of 8% of the Original Purchase Price (as defined) per share shall accrue on such preferred shares (subject to appropriate
adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the preferred shares). </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">In the event of: (i)&nbsp;any dissolution or liquidation of the Company, (ii)&nbsp;the proper commencement by or against the Company of any bankruptcy or insolvency proceeding under any bankruptcy or insolvency or
similar law, whether voluntary or involuntary, (iii)&nbsp;the appointment of a receiver or liquidator to all or substantially all of the Company&#146;s assets, (iv)&nbsp;a Deemed Liquidation (as defined below) event (each of the foregoing, a
&#147;Liquidation Event&#148;), or (v)&nbsp;distribution of Dividends, then any Dividends, assets or proceeds of the Company available for distribution to the shareholders (&#147;Distributable Proceeds&#148;), shall be distributed among the
shareholders pursuant to the following order of preference: </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">First, the holders of the preferred shares shall be entitled to receive out of the Distributable Proceeds, prior to and in preference to any distribution to any of the holders of the ordinary shares an amount per
preferred share equal to the higher of: (i)&nbsp;the Original Purchase Price plus any Accruing Dividends (as defined), accrued but unpaid thereon, whether or not declared, together with any other dividends declared but unpaid thereon less any amount
of Distributable Proceeds previously paid with regard to such shares (collectively, the &#147;Preferential A Amount&#148;) and (ii)&nbsp;such amount per share as would have been payable had all preferred shares been converted into ordinary shares
immediately prior to such Liquidation Event. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">If the assets (or securities) available for distribution shall be insufficient to permit the payment to holders of the preferred shares of the full Preferential A Amount, then the entire assets (or securities) available
for distribution shall be distributed <FONT STYLE="white-space:nowrap">pro-rata</FONT> among the holders of the preferred shares in proportion to the Preferential A Amount each such holder is otherwise entitled to receive. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Second, after payment in full of the Series A Liquidation Amount, the remaining assets of the Company available for distribution to the Company&#146;s shareholders shall be distributed among the holders of ordinary
shares, pro rata based on the number of shares held by each such holder. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Any of the following events shall be deemed a Liquidation Event (each a &#147;Deemed Liquidation&#148;): a transaction or
a series of related transactions which entails (i)&nbsp;any sale of all, or substantially all, of the Company&#146;s assets or technology, including by way of granting an exclusive license that is equivalent to the sale of all, or substantially all
of the Company&#146;s intellectual property; (ii)&nbsp;the consolidation, merger, or reorganization of the Company into any other entity, in which the Company is not the surviving entity; except, in each case, any transaction in which the
shareholders of the Company prior to the transaction hold more than fifty percent (50%) of the outstanding share capital of the Company or the surviving company, as applicable, immediately following such transaction; provided, however, that shares
of the surviving entity held by shareholders of the Company acquired by means other than the exchange or conversion of the shares of this Company shall not be used in determining if the shareholders of the Company own more than fifty percent (50%)
of the outstanding share capital of the surviving entity (or its parent), but shall be used </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
for determining the total outstanding share capital of the surviving entity; and (iii)&nbsp;any sale of all, or substantially all, of the Company&#146;s issued and outstanding share capital.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top">The holders of preferred shares shall have the following conversion rights: </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Optional conversion&nbsp;- each preferred share shall be convertible, at the option of the holder thereof, at any time after the date of issuance of such share into such number of fully paid shares of ordinary shares as
is determined by dividing the Original Purchase Price by the conversion price applicable to such share, in effect on the date that the certificate is surrendered for conversion. The initial conversion price of the preferred shares shall be the
Original Purchase Price; provided, however, that the conversion price for the preferred shares shall be subject to certain adjustments. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Automatic conversion&nbsp;- Each preferred share shall automatically be converted into ordinary shares at the Conversion Price at the time in effect for such preferred share, on the consummation of any one of the
following events: </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top">Upon the closing of an IPO, where the Company&#146;s <FONT STYLE="white-space:nowrap">pre-money</FONT> valuation is $75,000 or more with net proceeds to the Company of $25,000 or more (a &#147;Qualified Public
Offering&#148;); or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii)</TD>
<TD ALIGN="left" VALIGN="top">In the event that holders of a majority of sixty percent (60%) of the then outstanding preferred shares, voting as a single class, consent to such. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top">The preferred shares also confer on their holders certain anti-dilution rights that adjust the conversion ratio in the event that the Company issues new shares at a price lower than the original issue price to the
respective preferred shareholders. </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">The Series A preferred shares are classified within permanent equity as they are not subject to
liability classification under the scope of ASC 480, and meet all the requirements of equity classification under ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">480-10-S99.</FONT></FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>d. Share-based compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2010, the Company&#146;s
board of directors approved a share option plan (the &#147;Plan&#148;) for grants to Company employees, consultants, directors, and other service providers. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
grant of options to Israeli employees under the Plan is subject to the terms stipulated by Section&nbsp;102 of the Israeli Income Tax Ordinance (&#147;Section&nbsp;102&#148;). The option grants are subject to the track chosen by the Company, either
the &#147;regular income&#148; track or the &#147;capital gains&#148; track, as set out in Section&nbsp;102. The Company registered the Plan under the capital gains track, which offers more favorable tax rates to the employees. As a result, and
pursuant to the terms of Section&nbsp;102, the Company is not allowed to claim as an expense for tax purposes the amounts credited to the employees in respect of options granted to them under the Plan, including amounts recorded as salary benefits
in the Company&#146;s accounts, with the exception of the work-income benefit component, if any, determined on grant date. For <FONT STYLE="white-space:nowrap">non-employees</FONT> and for <FONT STYLE="white-space:nowrap">non-Israeli</FONT>
employees, the Plan is subject to Section 3(i) of the Israeli Income Tax Ordinance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The expected volatility is based on the historical volatility of comparable
companies. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the options granted in dollar terms. The expected term is the length of time until the expected dates of exercising the
options, and is estimated for employees (except senior management) using the simplified method due to insufficient specific historical information of employees&#146; exercise behavior, and for <FONT STYLE="white-space:nowrap">non-employees,</FONT>
directors and senior management using the contractual term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the years ended December&nbsp;31, 2016 and 2015, the Company granted options to certain employees and <FONT
STYLE="white-space:nowrap">non-employees</FONT> as follows: </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>1) Options granted to employees and directors: </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Set forth below are grants made by the Company to employees as of December&nbsp;31, 2016. The majority of the options vest over a period of four years and expire on the
seventh anniversary of the date of grant. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">During 2015, the Company granted 1,098,777 options to employees and directors with exercise prices ranging from $0 to $5.94 per share. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">During 2016, the Company granted 404,813 options to employees and directors with exercise prices ranging from $5 to $5.94 per share. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of options granted to employees and directors during 2016 and 2015 was $906 and $2,334, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The total unrecognized compensation cost of employee options at December&nbsp;31, 2016 is $1,776, which is expected to be recognized over a weighted average period of
2.44 years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of options granted to employees and directors on the date of grant was computed using the Black-Scholes model. The underlying data used
for computing the fair value of the options are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Value of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">$2.98-5.54</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">$2.98-3.01</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">74.8%-80%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">69.78%-76.68%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">1.4%-2.13%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.38%&#150;2.08%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">7 years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">1-7</FONT> years</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2) Options granted to consultants and other service providers: </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During 2016
and 2015, the Company granted 132,032 and 203,820 options, respectively, to consultants and service providers with an exercise price ranging from $0 to $5.94 per share. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value as of December&nbsp;31, 2016 and 2015 of options granted to consultants and other service providers during 2016 and 2015 was $671 and $57, respectively.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of options granted to consultants and other service providers as of December&nbsp;31, 2016 and 2015 was computed using the Black-Scholes model. The
underlying data used for computing the fair value of the options are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Value of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">$1.58-7.96</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$2.98</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">72.72%-80%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">73.31%-76.3%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">1.56%-2.27%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1.88%&#150;2.07%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">5.8-8.5&nbsp;years</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">6.8-7</FONT> years</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">The following table summarizes the number of options outstanding under the Plan for the years ended December&nbsp;31, 2016 and 2015, and related information: </TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EMPLOYEES AND</B><br><B>DIRECTORS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CONSULTANTS AND</B><br><B>SERVICE PROVIDERS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>OPTIONS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED<BR>AVERAGE&nbsp;PRICE<BR>PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>OPTIONS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED<BR>AVERAGE&nbsp;PRICE<BR>PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Outstanding at January&nbsp;1, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">595,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Canceled/Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,088</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Outstanding at December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,686,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Canceled/Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,784</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Outstanding at December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,030,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">634,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top">The following tables summarize the outstanding and exercisable options as of December&nbsp;31, 2016: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="16" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="8" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTIONS OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTIONS EXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>EXERCISE</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PRICE&nbsp;PER&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:72.30pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>SHARE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF&nbsp;OPTIONS<BR>OUTSTANDING&nbsp;AT&nbsp;END<BR>OF YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED&nbsp;AVERAGE<BR>REMAINING<BR>CONTRACTUAL LIFE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF&nbsp;OPTIONS</B><br><B>EXERCISABLE&nbsp;AT&nbsp;END</B><br><B>OF YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED&nbsp;AVERAGE<BR>REMAINING&nbsp;CONTRACTUAL<BR>LIFE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">$0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">$1.56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">$1.78</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">$2.45</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">$4.02</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">$5.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,357,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">765,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">$5.94</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">$6.73</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,665,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,430,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The aggregate intrinsic value of the total vested and exercisable options as of December&nbsp;31, 2016 is $5,683. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top">The following table illustrates the effect of share-based compensation on the statements of operations: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">6)</TD>
<TD ALIGN="left" VALIGN="top">In February, March, April, June and November 2016, the Company increased the number of ordinary shares reserved for issuance under the Company&#146;s share option/incentive plans and arrangements by 320,000, 208,000,
137,600, 131,200 and 90,220 ordinary shares, respectively, to a total amount of 2,703,499 ordinary shares. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 9&#151;TAXES ON INCOME </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is taxed under Israeli tax laws: </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Tax rates </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The income of the Company is taxed at the regular rate. The corporate tax rate for 2016 was 25% and for 2015 was 26.5%. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2016, the Economic Efficiency Law (Legislative Amendments for Implementing the Economic Policy for the 2017 and 2018 Budget Year), 2016 was published,
introducing a gradual reduction in corporate tax rate from 25% to 23%. However, the law also included a temporary provision setting the corporate tax rate in 2017 at 24%. As a result, the corporate tax rate will be 24% in 2017 and 23% in 2018 and
thereafter. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The change in tax rate as mentioned above has not affected the Company since the Company has not recognized taxes to date. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Tax assessments </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All the tax assessments filed by 2013 are
considered final. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>c. Losses for tax purposes carried forward to future years </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2016, the Company had approximately $14,260 of net carry forward tax losses available to reduce future taxable income without limitation of use.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>d. Deferred income taxes: </I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">In respect of:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net operating loss carry forward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and Development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">In-Process R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less&#151;valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The change in valuation allowance for the years ended December&nbsp;31, 2016 and 2015 were as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,948</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at the end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The main reconciling item between the statutory tax rate of the Company and the effective rate is the share based
compensation and provision for full valuation allowance in respect of tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>e.</B></TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2016 and 2015, the Company had not accrued a provision for uncertain tax positions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE
10&#151;LOSS PER ORDINARY SHARE: </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the calculation of basic and diluted loss per share for the periods indicated: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Basic and diluted:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss attributable to equity holders of the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dividend accumulated for preferred shares during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss attributable to equity holders of the Company, after deducting dividend accumulated for preferred
shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average number of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss per ordinary share (LPS)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the years ended December&nbsp;31, 2016 and 2015, all ordinary shares underlying outstanding options, <FONT STYLE="white-space:nowrap">A-1</FONT> warrants and
convertible preferred shares have been excluded from the calculation of the diluted loss per share since their effect was anti-dilutive. Diluted LPS does not include 2,665,099 and 2,199,838 ordinary shares underlying outstanding options for the
years ended December&nbsp;31, 2016 and 2015, respectively, 728,312 shares issuable upon exercise of the <FONT STYLE="white-space:nowrap">A-1</FONT> warrants for series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares for the years ended
December&nbsp;31, 2016 and 2015, and 5,193,427 shares issuable upon conversion of preferred shares for the years ended December&nbsp;31, 2016 and 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE
11&#151;RELATED PARTIES-TRANSACTIONS AND BALANCES: </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Related parties include the Chairman of the Board of Directors, the board members and the Chief Executive
Officer of the Company. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Transactions with related parties </I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Payroll and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Management fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Balances with related parties: </I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>c.
Related parties: </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">UPI entered into a lease agreement, dated as of November 2015 and commencing as of May 2016, for office space in New York, which serves as
the headquarters for UPI (see note 6). UPI shares the office space equitably with Kite Pharma, Inc., a Delaware corporation, who is a cosignatory to such lease agreement. Arie Belldegrun, M.D., UPL&#146;s chairman, serves as the Chairman and Chief
Executive Officer of Kite Pharma, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 12&#151;SUBSEQUENT EVENTS: </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On April 19, 2017, the Company&#146;s board of directors and shareholders approved an aggregate 3.2-for-1 share split of the Company&#146;s ordinary, Preferred A and
Preferred A-1 shares. The share split was effected on April 19, 2017 by the issuance of 2.2&nbsp;ordinary shares for each outstanding ordinary, Preferred A and Preferred A-1 share held immediately prior to the share split. The Company has evaluated
subsequent events through March 8, 2017, the date the financial statements were available to be issued. In connection with the reissuance of the financial statements, the Company has evaluated subsequent events through April 24, 2017, the date the
financial statements were available to be reissued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin504802_9"></A>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands, except share and per share data) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SEPTEMBER&nbsp;30,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><B>Assets</B></TD>
<TD VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CURRENT ASSETS:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL CURRENT ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">NON-CURRENT</FONT> ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><B>Liabilities and shareholders&#146; equity</B></TD>
<TD VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CURRENT LIABILITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Employee related accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from exercise of warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL CURRENT LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">NON-CURRENT</FONT> LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>SHAREHOLDERS&#146; EQUITY:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares, NIS 0.01 par value: 100,000,000 shares and 17,600,000 shares authorized at
September&nbsp;30, 2017 and December&nbsp;31, 2016, respectively; 13,178,400 and 2,305,743 issued and outstanding at September&nbsp;30, 2017 and December&nbsp;31, 2016, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Preferred A and Preferred <FONT STYLE="white-space:nowrap">A-1</FONT> shares, NIS 0.01 par
value:<BR>14,400,000 shares authorized at December&nbsp;31, 2016, 5,193,427 shares issued and outstanding at December&nbsp;31, 2016.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin504802_10"></A>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED</B><br><B>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>REVENUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>COST OF REVENUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>GROSS PROFIT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>OPERATING EXPENSES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">RESEARCH AND DEVELOPMENT EXPENSES, NET</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">GENERAL AND ADMINISTRATIVE EXPENSES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>OPERATING LOSS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>FINANCE EXPENSES, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>NET LOSS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>LOSS PER ORDINARY SHARE BASIC AND DILUTED</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATING BASIC AND DILUTED LOSS PER
ORDINARY SHARE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,223,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin504802_11"></A>UROGEN PHARMA LTD. 7 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#146; EQUITY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share data) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ORDINARY</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PREFERRED</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADDITIONAL<BR><FONT STYLE="white-space:nowrap">PAID-IN</FONT><BR>CAPITAL</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED<BR>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>AMOUNTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>BALANCE AS OF JANUARY&nbsp;1, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,193,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>CHANGES DURING THE NINE MONTHS ENDED SEPTEMBER&nbsp;30, 2017:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Exercise of options into ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,816</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Exercise of warrants into preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">364,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Conversion of preferred shares into ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,557,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,557,463</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Issuance of ordinary shares, net of issuance expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,144,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>BALANCE AS OF SEPTEMBER&nbsp;30, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,178,4000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">113,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(37,128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>BALANCE AS OF JANUARY&nbsp;1, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,193,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>CHANGES DURING THE NINE MONTHS ENDED SEPTEMBER&nbsp;30, 2016:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Exercise of options into ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>BALANCE AS OF SEPTEMBER&nbsp;30, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,193,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(40,137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(*) Represents less than one thousand </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The
accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin504802_12"></A>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED</B><br><B>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CASH FLOWS FROM OPERATING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adjustments required to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exchange rates differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value adjustment of warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in operating asset and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Decrease (increase) in inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Decrease (increase) in accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Decrease (increase) in prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase (decrease) in deferred revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase (decrease) in employee related accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,609</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CASH FLOWS FROM INVESTING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(578</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in restricted deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(672</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CASH FLOWS FROM FINANCING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise of options into ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of ordinary shares, net of issuance expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Payment of deferred equity offering cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(510</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from exercise of warrants to preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>BALANCE OF CASH AND CASH EQUIVALENTS AT END OF THE PERIOD</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>SUPPLEMENTAL DISCLOSURES OF <FONT STYLE="white-space:nowrap">NON-CASH</FONT> INVESTING AND FINANCING
ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise of warrants into preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin504802_13"></A>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share data) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE <FONT STYLE="white-space:nowrap">1-</FONT>
NATURE OF OPERATIONS </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">UroGen Pharma Ltd. is an Israeli-domiciled company incorporated in April 2004 (&#147;UPL&#148;). UroGen Pharma, Inc. a subsidiary of UPL, was incorporated in Delaware in October 2015 and began operating in February 2016
(&#147;UPI&#148;). UPL and UPI are referred to herein together as the &#147;Company.&#148; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Company is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">In May 2017, the Company raised $60.8&nbsp;million, net of issuance costs and underwriting discounts, in an Initial Public Offering (&#147;IPO&#148;) on the NASDAQ Stock Market (&#147;NASDAQ&#148;) (see Note 6a2).
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">As of the date of approval of the consolidated financial statements, the Company has the ability to fund its planned operations for at least the next 12 months. However, the Company&#146;s product candidates may never
achieve commercialization and it will continue to incur losses for the foreseeable future. Therefore, in order to fund the Company&#146;s research and development expenses, general and administrative expenses and capital expenditures until such time
that the Company can generate substantial revenues, the Company may need to raise additional funds. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">As described in Note 6a1, in April 2017, the Company&#146;s board of directors and shareholders approved a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3.2-for-1</FONT></FONT> split of the
Company&#146;s ordinary, Preferred A and Preferred <FONT STYLE="white-space:nowrap">A-1</FONT> shares. All of the share and per share amounts reflected in these financial statements and the notes thereto have been adjusted, on a retroactive basis,
to reflect this share split. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top">During July 2017, the Company announced that it had earned a milestone payment of $7.5&nbsp;million under its exclusive worldwide licensing agreement with Allergan Pharmaceuticals International Limited
(&#147;Allergan&#148;) resulting from Allergan&#146;s submission of an Investigational New Drug (&#147;IND&#148;) application for the Company&#146;s RTGel in combination with Allergan&#146;s BOTOX for the treatment of overactive bladder to the U.S.
Food and Drug Administration (&#147;FDA&#148;). The Company received the milestone payment in August 2017. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 2&#151;BASIS OF PRESENTATION
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted
in the United States of America (&#147;U.S. GAAP&#148;) for interim financial statements. Accordingly, they do not contain all information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited
condensed consolidated interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company&#146;s financial position as of September&nbsp;30, 2017, the results of operations
and cash flows for the nine month period ended September&nbsp;30, 2017 and 2016. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These unaudited condensed consolidated interim financial statements should be read
in conjunction with the audited financial statements for the year ended December&nbsp;31, 2016 and notes thereto included in the Company&#146;s annual financial statements for the year ended December&nbsp;31, 2016. The condensed balance sheet data
as of December&nbsp;31, 2016 included in these unaudited condensed consolidated financial statements was derived from the audited financial statements for the year ended December&nbsp;31, 2016, but does not include all disclosures required by U.S.
GAAP. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The results for the nine month period ended September&nbsp;30, 2017 are not necessarily indicative of the results to be expected for the year ending
December&nbsp;31, 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 3&#151;RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS: </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2014, the FASB issued Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">No.&nbsp;2014-09,</FONT> &#147;Revenue from Contracts with
Customers&#148; (Topic 606), (&#147;ASU <FONT STYLE="white-space:nowrap">2014-09&#148;).</FONT> ASU <FONT STYLE="white-space:nowrap">2014-09</FONT> requires entities to recognize revenue that represents the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share data) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
transfer of promised goods or services to customers in an amount equivalent to the consideration to which the entity expects to be entitled to in exchange for those goods or services. The
following steps should be applied to determine this amount: (1)&nbsp;identify the contract(s) with a customer; (2)&nbsp;identify the performance obligations in the contract; (3)&nbsp;determine the transaction price; (4)&nbsp;allocate the transaction
price to the performance obligations in the contract; and (5)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. ASU <FONT STYLE="white-space:nowrap">2014-09</FONT> supersedes the revenue recognition requirements in
ASU 605, &#147;Revenue Recognition,&#148; and most industry-specific guidance in the Accounting Standards Codification. In August 2015, the FASB issued ASU <FONT STYLE="white-space:nowrap">2015-14</FONT> on this same topic, which defers for one year
the effective date of ASU <FONT STYLE="white-space:nowrap">2014-09,</FONT> therefore, the guidance is effective for the Company for annual reporting periods, including interim periods therein, beginning January&nbsp;1, 2018. The new revenue
standards may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The Company is currently evaluating the impact of adopting the guidance on its Consolidated
Financial Statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 4&#151;FAIR VALUE MEASUREMENT </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Fair value is
based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in
fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the
highest priority to Level&nbsp;1 inputs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&nbsp;3 inputs.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the
extent possible and considers counterparty credit risk in its assessment of fair value. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s assets and liabilities that are measured at fair value
as of September&nbsp;30, 2017 and December&nbsp;31, 2016 are classified in the tables below in one of the three categories described above: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SEPTEMBER&nbsp;30,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrants for preferred shares&#151;Level&nbsp;3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of the preferred share warrants as of December&nbsp;31, 2016 was measured in accordance with the Hybrid Method. The Company utilized the Hybrid Method to
combine the probability of an IPO scenario at such date, which was estimated at 20%, with the probability of a liquidation event at such date, which was estimated at 80%. As of December&nbsp;31, 2016, the fair value of the warrants for preferred
shares was determined mainly based on estimation of the Company&#146;s equity value derived from a discounted cash flow, or DCF, calculation and based on assumptions relating to the Company&#146;s revenue forecast, clinical success probabilities,
relevant discount rates between <FONT STYLE="white-space:nowrap">10.5%-19&nbsp;%</FONT> (10.5% for the cash flow expected to be derived from the license agreement with Allergan and 19% for the cash flow expected to be derived from the Company&#146;s
internal development), and expected volatility at a rate of 73.93%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share data) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The table below sets forth a summary of the changes in the fair value of the warrants for preferred shares classified
as Level&nbsp;3: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at the beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in fair value during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise of warrants to preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the completion of the IPO, the Company converted all outstanding warrants into 364,036 Preferred <FONT STYLE="white-space:nowrap">A-1</FONT> shares
of the Company and subsequently converted all of its preferred shares, including the Preferred <FONT STYLE="white-space:nowrap">A-1</FONT> shares, into ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 5&#151;PROCEEDS FROM EXERCISE OF WARRANTS FOR PREFERRED <FONT STYLE="white-space:nowrap">A-1</FONT> SHARES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s warrants outstanding prior to the IPO were exercisable for Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares at an exercise price
of $7.81 per share. Prior to the IPO, such warrants were exercisable for 728,312 Preferred <FONT STYLE="white-space:nowrap">A-1</FONT> shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During 2017 and
2016, the Company notified holders of these warrants that it was ready to accept an exercise notice that was conditioned on the price per share at which the Company&#146;s shares would be sold in an anticipated IPO. Prior to the IPO, the Company
received a total amount of $952 as consideration for the conditional cash exercise of these warrants. The cash received was recorded among current liabilities as proceeds from exercise of warrants for preferred shares. As of September&nbsp;30, 2017,
following the exercise of the warrants, the cash received was <FONT STYLE="white-space:nowrap">re-classified</FONT> to additional paid in capital. See also note 6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 6&#151;SHARE CAPITAL </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Share capital </I></B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">On April&nbsp;19, 2017, the Company&#146;s board of directors and shareholders approved an aggregate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3.2-for-1</FONT></FONT> share split of the
Company&#146;s ordinary, Preferred A and Preferred <FONT STYLE="white-space:nowrap">A-1</FONT> shares. The share split was effected on April&nbsp;19, 2017 by the issuance of 2.2 ordinary shares for each outstanding ordinary, Preferred A and
Preferred <FONT STYLE="white-space:nowrap">A-1</FONT> share held immediately prior to the share split. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">In May 2017, the Company completed an IPO on the NASDAQ Stock Market, in which it issued 5,144,378 ordinary shares in consideration for $60.8&nbsp;million, net of issuance costs and underwriting discounts. In addition,
during the year ended December&nbsp;31, 2016, the Company recorded $1.7&nbsp;million in general and administrative expenses related to IPO costs, in accordance with SEC staff Bulletin Topic 5A. </TD></TR></TABLE>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">Upon the completion of the IPO, the Company converted all outstanding warrants for Preferred <FONT STYLE="white-space:nowrap">A-1</FONT> shares into
364,036 Preferred <FONT STYLE="white-space:nowrap">A-1</FONT> shares of the Company. Subsequently, the Company converted all outstanding Preferred A and Preferred <FONT STYLE="white-space:nowrap">A-1</FONT> shares into ordinary shares at a ratio of
1:1. As of September&nbsp;30, 2017, the Company&#146;s share capital was composed entirely of ordinary shares. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">During the nine months ended September&nbsp;30, 2017, the Company received $333 from the exercise of 170,816 options into ordinary shares. </TD></TR></TABLE>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share data) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Share-based compensation </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The following table illustrates the effect of share-based compensation on the statements of operations: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">2017 Equity Incentive Plan </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">In March 2017, the Company&#146;s board of directors adopted the 2017 Equity
Incentive Plan (&#147;2017 Plan&#148;), which was approved by the shareholders in April 2017. The 2017 Plan provides for the grant of incentive stock options to the Company&#146;s employees and for the grant of nonstatutory stock options, stock
appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards, and other forms of stock awards to the Company&#146;s employees, directors and consultants. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">The maximum number of ordinary shares that may initially be issued under the 2017 Plan is 1,400,000. In addition, the number of ordinary shares reserved
for issuance under the 2017 Plan will automatically increase on January 1st of each calendar year, from January&nbsp;1, 2018 through January&nbsp;1, 2026, so that the number of such shares reserved for issuance will equal 12% of the total number of
ordinary shares outstanding on the last day of the calendar month prior to the date of each automatic increase, or a lesser number of shares determined by our board of directors. The maximum number of ordinary shares that may be issued upon the
exercise of incentive stock options under the 2017 Plan is 5,600,000. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">The plan administrator determines the exercise price for stock options,
within the terms and conditions of the 2017 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our Ordinary Shares on the date of grant. Options granted under the 2017 Plan vest at
the rate specified in the stock option agreement as determined by the plan administrator. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">In April 2017, the Company&#146;s board of directors approved modifications of performance conditions for 67,200 restricted stock units and contingent options for executive management. The Company recorded an expense of
$527 under general and administrative expenses with respect to these modifications. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">During the nine months ended September&nbsp;30, 2017, the Company&#146;s board of directors approved grants of 130,000 options to directors of the Company. Each option is exercisable into one ordinary share of the
Company at an exercise price between $13.00 and $17.67. The options vest in several installments over a one or a three-year period. As of the grant date, the fair value of these options was estimated at $1,657. The options expire ten years from the
date of the grant. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">During the nine months ended September&nbsp;30, 2017, the Company&#146;s board of directors approved grants of 170,000 options to executive management of the Company. Each option is exercisable into one ordinary share
of the Company at an exercise price of $19.55. The options vest in several installments over a three-year period. As of the grant date, the fair value of these options was estimated at $2,645. The options expire ten years after their grant date.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">During the nine months ended September&nbsp;30, 2017, the Company&#146;s board of directors approved grants of 75,000 options and 25,000 restricted stocks to employees of the Company. Each option is exercisable into one
ordinary share of the Company at an exercise price of $30.59. The options and restricted stock vest in several installments over a three-year period. As of the grant date, the fair value of these options and restricted stock was estimated at $2,234.
The options expire ten years after their grant date. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share data) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 7&#151;RELATED PARTIES </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">UPI entered into a lease agreement in November 2015, which commenced in May 2016, for office space in New York, which serves as the headquarters for our U.S.
subsidiary. UPI shares the office space equitably with Kite Pharma, Inc., a Delaware corporation that is a <FONT STYLE="white-space:nowrap">co-signatory</FONT> to such lease. Arie Belldegrun, M.D., UPL&#146;s Chairman, served as the Chairman and
Chief Executive Officer of Kite Pharma, Inc. until his resignation effective as of October&nbsp;3, 2017, in connection with the acquisition of Kite Pharma, Inc. by Gilead Sciences, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 8&#151;LOSS PER SHARE: </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the calculation
of basic and diluted loss per share (&#147;LPS&#148;) for the periods indicated: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Basic and diluted:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net Loss attributable to equity holder of the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dividend accumulated on preferred shares during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net Loss attributable to equity holders of the Company, after reducing dividend accumulated on preferred
shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average number of ordinary shares outstanding used in computing basic and diluted net loss per
ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,223,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Basic and diluted net loss per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the nine month periods ended September&nbsp;30, 2017 and 2016, all ordinary shares underlying outstanding options, <FONT STYLE="white-space:nowrap">A-1</FONT>
warrants and convertible preferred shares have been excluded from the calculation of the diluted loss per share since their effect was anti-dilutive. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The shares
accounted for in diluted loss per ordinary share do not include 2,918,349 and 2,594,698 ordinary shares underlying outstanding options for the nine month period ended September&nbsp;30, 2017 and 2016, respectively, and 728,312 shares issuable upon
exercise of the Preferred <FONT STYLE="white-space:nowrap">A-1</FONT> warrants, which were converted to ordinary shares upon the IPO, for the nine month period ended September&nbsp;30, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 9&#151;SUBSEQUENT EVENTS: </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has evaluated subsequent events
through November&nbsp;14, 2017. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the fourth quarter, UPI entered into a new lease agreement for its New York headquarters. The lease agreement commenced in
October 2017, and shall terminate in February 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>1,135,847 Ordinary Shares </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g504802g15c64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>UroGen Pharma Ltd. </B></P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center> <P STYLE="margin-top:13pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>PRELIMINARY PROSPECTUS
</B></P> <P STYLE="font-size:13pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:110pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Jefferies </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Cowen </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Oppenheimer &amp; Co. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>National Securities Corporation </B></P>
<P STYLE="margin-top:110pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;6.
Indemnification of Directors, Officers and Employees. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may not exculpate an office holder from liability for a breach
of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care, but only if a provision authorizing
such exculpation is included in its articles of association. Our amended and restated articles of association include such a provision. A company may not exculpate in advance a director from liability arising out of a breach of the duty of care with
respect to a distribution. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may indemnify an office holder with respect to the following liabilities and expenses
incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#146;s award approved by a court. However, if an undertaking to indemnify an office
holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#146;s activities when the undertaking to
indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reasonable litigation expenses, including attorneys&#146; fees, incurred by the office holder (1)&nbsp;as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct
such investigation or proceeding, provided that (i)&nbsp;no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii)&nbsp;no financial liability was imposed upon him or her as a substitute for the
criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2)&nbsp;in connection with a monetary
sanction; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reasonable litigation expenses, including attorneys&#146; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in
connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder,
if and to the extent provided in the company&#146;s articles of association: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a financial liability imposed on the office holder in favor of a third party. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a
company may not indemnify, exculpate or insure an office holder against any of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe
that the act would not harm the company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an act or omission committed with intent to derive illegal personal benefit; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a fine, civil fine, monetary sanction or forfeit levied against the office holder. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law,
exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the
shareholders. See &#147;Management&#151;Approval of Related Party Transactions under Israeli Law&#151;Fiduciary Duties of Directors and Executive Officers.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated articles of association permits us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by
the Israeli Companies Law. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We maintain directors and officers liability insurance for the benefit of our office holders to the fullest extent permitted by the
Israeli Companies Law. In addition, we have entered into agreements with each of our directors and executive officers exculpating them from liability to us for damages caused to us as a result of a breach of duty of care and undertaking to indemnify
them, in each case, to the fullest extent permitted by our amended and restated articles of association and Israeli law, including with respect to liabilities resulting from this offering to the extent that these liabilities are not covered by
insurance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Insofar as the indemnification for liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, may be permitted to
directors, officers or persons controlling the registrant, we have been informed that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;7. Recent Sales of Unregistered Securities. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following list
sets forth information as to all securities we have sold since January&nbsp;1, 2014, which were not registered under the Securities Act. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In February 2014, we issued a series of unsecured subordinated convertible promissory notes to new investors and several of our existing shareholders These notes were amended in July 2014 and are referred to as the 2014
notes, as amended. Pursuant to the 2014 notes, we initially received an aggregate principal amount of $647,112, bearing interest at 6% per annum. The principal and all accrued interest on the 2014 notes was to be, on the consummation of the
investment of a specified amount, automatically converted into either: (i)&nbsp;Series A preferred shares at a five percent (5%) discount on the price per share; or (ii)&nbsp;into ordinary shares at a fifteen percent (15%) discount on the price per
share, on the date of conversion, as determined by our board of directors, all at the election of the 2014 note holders. On October&nbsp;20, 2014, in lieu of such automatic conversion, we offered the holders of the 2014 notes the right to convert
the 2014 notes into Series A preferred shares at a price per share of $5.94 and to receive warrants for no additional consideration, all as if they were subscribing to purchase securities pursuant to the 2014 Share Purchase Agreement. All of the
2014 note holders elected to convert the principal amounts of their notes on these terms immediately prior to the initial closing of the 2014 Share Purchase Agreement and waived their right to interest due or payable on the principal amount. All
2014 notes were cancelled. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On October&nbsp;20, 2014, June&nbsp;28, 2015 and July&nbsp;7 and 28, 2015, (i) we issued to certain investors and existing shareholders, 1,347,590 preferred shares for approximately $8.0&nbsp;million, which will be
converted into ordinary shares prior to this offering. We further granted such investors and existing shareholders 673,827 warrants to purchase preferred shares (to be converted into warrants to purchase ordinary shares prior to this offering) at an
exercise price of $7.81 per share; and (ii)&nbsp;we issued to the 2014 notes holders 108,983 preferred shares and 54,485 warrants to purchase preferred shares (to be converted into ordinary shares and warrants prior to this offering) at an exercise
price of $7.81 in exchange for their conversion of all principal and accrued interest due on the notes in an aggregate amount of $647,112. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On November&nbsp;12, 2015, we issued to Telormedix SA, or TMX, 691,200 preferred shares in consideration of any and all owned knowledge or data of TMX, whether registered or unregistered, including, but not limited to,
intellectual property, goodwill, clinical studies, and licenses. These shares will be converted into ordinary shares prior to this offering. We also undertook to issue to TMX 278,400 additional preferred shares upon the achievement of certain
milestones, which may be met in the future. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On December&nbsp;10, 2015, we issued to certain investors and existing shareholders 3,045,652 preferred shares, which will be converted into ordinary shares prior to this offering for $18.1&nbsp;million.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The sales of the above securities were deemed to be exempt from registration under the Securities Act because they were made outside of the U.S. to
certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> individuals or entities pursuant to Regulation S or, in reliance upon the exemption from registration provided under Section&nbsp;4(a)(2) of the Securities Act and the regulations promulgated
thereunder. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, we granted share options and restricted share units to employees, directors, consultants and service providers under our 2010 Israeli
Share Option Plan covering an aggregate of 2,665,099 ordinary shares, with a weighted-average exercise price of $4.85. We also granted an aggregate of 674,500 share options and restricted share units to employees, directors, consultants and service
providers under our 2017 Equity Incentive Plan, with a weighted-average exercise price of $22.89. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We claimed exemption from registration under the Securities Act
for these option grants described above under Section&nbsp;4(a)(2), Regulation S, or under Rule 701 of the Securities Act as transactions pursuant to written compensatory plans or pursuant to a written contract relating to compensation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No underwriters were employed in connection with the securities issuances set forth in this Item. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;8. Exhibits and Financial Statement Schedules. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>(a) Exhibits.
</B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>EXHIBIT</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:33.85pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:83.90pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>EXHIBIT DESCRIPTION</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;1.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d504802dex11.htm">Form of Underwriting Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;3.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1668243/000119312517175069/d401998dex31.htm">Articles of Association of the Registrant (incorporated by reference to Exhibit 3.1 to the Form <FONT STYLE="white-space:nowrap">6-K</FONT> filed
on May&nbsp;18, 2017) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;5.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d504802dex51.htm">Opinion of Hamburger Evron&nbsp;&amp; Co., Israeli counsel to the Registrant, as to the validity of the ordinary shares</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1668243/000119312517116003/d142578dex101.htm">Form of Officer Indemnity and Exculpation Agreement (incorporated by reference to Exhibit 10.1 to the Registrant&#146;s Registration Statement
 on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-217201))</FONT> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.2</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1668243/000119312517116003/d142578dex102.htm">2010 Israeli Share Option Plan (incorporated by reference to Exhibit 10.2 to the Registrant&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-217201))</FONT> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.3</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1668243/000119312517116003/d142578dex103.htm">Investors&#146; Rights Agreement, dated September&nbsp;18, 2014, as amended on October&nbsp;1, 2015 and April&nbsp;
12, 2016, among the Registrant and the Registrant&#146;s shareholders (incorporated by reference to Exhibit 10.3 to the Registrant&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-217201))
</FONT> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.4</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1668243/000119312517116003/d142578dex104.htm">Asset Purchase Agreement, dated October&nbsp;
1, 2015, between the Registrant and Telormedix SA (incorporated by reference to Exhibit 10.4 to the Registrant&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
333-217201))</FONT> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.5&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1668243/000119312517116003/d142578dex105.htm">License Agreement, dated as of October&nbsp;
7, 2016, by and between the Registrant and Allergan Pharmaceuticals International Limited (incorporated by reference to Exhibit 10.5 to the Registrant&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-217201))</FONT> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.6</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1668243/000119312517116003/d142578dex106.htm">2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-217201))</FONT> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.7</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1668243/000119312517116003/d142578dex107.htm">2017 Israeli Equity Incentive Sub Plan to the 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registrant&#146;s
 Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-217201))</FONT> </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">21.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1668243/000119312517116003/d142578dex211.htm">Subsidiary of the Registrant (incorporated by reference to Exhibit 21.1 to the Registrant&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-217201))</FONT> </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>EXHIBIT</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:33.85pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:83.90pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>EXHIBIT DESCRIPTION</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">23.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d504802dex231.htm">Consent of Kesselman&nbsp;&amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">23.2</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d504802dex51.htm">Consent of Hamburger Evron&nbsp;&amp; Co. (included in Exhibit 5.1) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">24.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#sig">Power of Attorney (included in signature pages of Registration Statement)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">99.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1668243/000119312517116003/d142578dex991.htm">Consent of Dr.&nbsp;J. Gregory Wirth (incorporated by reference to Exhibit 99.1 to the Registrant&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-217201))</FONT> </A></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">&#134;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Registrant has been granted confidential treatment for certain portions of this exhibit. This exhibit omits the information subject to this confidentiality treatment. Omitted portions have been filed separately with the
SEC. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>(b) Financial Statement Schedules.</B> Schedules not listed above have been omitted because the information required to be set forth therein
is not applicable or is shown in the financial statements or notes thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;9. Undertakings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant
to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim
for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of
appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The undersigned Registrant hereby undertakes that: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">for purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form of
prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared effective; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form <FONT STYLE="white-space:nowrap">F-1</FONT> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Ra&#146;anana, Israel on this 16th day
of&nbsp;January, 2018. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="3"><B>UROGEN PHARMA LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">/s/ Ron Bentsur</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Ron Bentsur</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>Chief Executive Officer</I></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="sig"></A>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ron Bentsur and Gary Titus, and each of them acting
individually, as his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, each with full power of substitution, for him or her in any and all capacities, to sign any and
all amendments to this Registration Statement, including&nbsp;post-effective&nbsp;amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule&nbsp;462(b) increasing the number of securities for which
registration is sought, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be
done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:49.50pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:23.50pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:22.00pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>DATE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL" ALIGN="center">/s/ Ron Bentsur</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Ron Bentsur</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Chief Executive Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>(Principal Executive Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">January&nbsp;16, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL" ALIGN="center">/s/ Gary Titus</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Gary Titus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>(Principal Financial Officer and Principal Accounting Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">January&nbsp;16, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL" ALIGN="center">/s/ Arie Belldegrun, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Arie Belldegrun, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chairman</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">January&nbsp;16, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL" ALIGN="center">/s/ Fred E. Cohen M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Fred E. Cohen M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">January&nbsp;16, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL" ALIGN="center">/s/ Kathryn E. Falberg</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Kathryn E. Falberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">January&nbsp;16, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL" ALIGN="center">/s/ Stuart Holden, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Stuart Holden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">January&nbsp;16, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL" ALIGN="center">/s/ Cynthia M. Butitta</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Cynthia M. Butitta</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">January&nbsp;16, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL" ALIGN="center">/s/ Ran Nussbaum</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Ran Nussbaum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">January&nbsp;16, 2018</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL" ALIGN="center">/s/ Pini Orbach, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Pini Orbach, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">January&nbsp;16, 2018</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" COLSPAN="3"><B>Urogen Pharma, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL">/s/ Ron Bentsur</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">A<SMALL>UTHORIZED</SMALL> U.S. R<SMALL>EPRESENTATIVE</SMALL></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">January&nbsp;16,&nbsp;2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top">Name:&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ron Bentsur</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and CEO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d504802dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UroGen Pharma Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[</B>&#9679;<B></B><B>] Ordinary Shares </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Par Value NIS 0.01 Per Share) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>UNDERWRITING AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#9679;], 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">COWEN AND COMPANY, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the several
Underwriters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o JEFFERIES LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o COWEN AND COMPANY, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">599 Lexington Avenue, 27th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Introductory.</B> UroGen Pharma Ltd.,
a company organized under the laws of the State of Israel (the &#147;<B>Company</B>&#148;), proposes to issue and sell to the several underwriters named in <U>Schedule A</U> (the &#147;<B>Underwriters</B>&#148;) an aggregate of [&#9679;] ordinary
shares, par value NIS 0.01 per share (the &#147;<B>Ordinary Shares</B>&#148;). The [&#9679;] Ordinary Shares to be sold by the Company are called the &#147;<B>Firm Shares</B>.&#148; In addition, the Company has granted to the Underwriters an option
to purchase up to an additional [&#9679;] Ordinary Shares as provided in Section&nbsp;2. The additional [&#9679;] Ordinary Shares to be sold pursuant to such option are called the &#147;<B>Optional Shares</B>.&#148; The Firm Shares and, if and to
the extent such option is exercised, the Optional Shares are collectively called the &#147;<B>Offered Shares</B>.&#148; Jefferies LLC (&#147;<B>Jefferies</B>&#148;) and Cowen and Company, LLC (&#147;<B>Cowen</B>&#148;) have agreed to act as
representatives of the several Underwriters (in such capacity, the &#147;<B>Representatives</B>&#148;) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on <U>Schedule A</U>,
the term &#147;Representatives&#148; as used herein shall mean you, as Underwriters, and the term &#147;Underwriters&#148; shall mean either the singular or the plural, as the context requires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has prepared and filed with the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) a registration statement on
Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-[&#9679;])</FONT> which contains a form of prospectus to be used in connection with the public offering and sale of the Offered Shares. Such
registration statement, as amended, including the financial statements, exhibits and schedules thereto, in the form in which it became effective under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder
(collectively, the &#147;<B>Securities Act</B>&#148;), including any information deemed to be a part thereof at the time of effectiveness pursuant to Rule&nbsp;430A under the Securities Act, is called the &#147;<B>Registration Statement</B>.&#148;
Any registration statement filed by the Company pursuant to Rule 462(b) under the Securities Act in connection with the offer and sale of the Offered Shares is called the &#147;<B>Rule 462(b) Registration Statement</B>,&#148; and from and after the
date and time of filing of any such Rule 462(b) Registration Statement the term &#147;Registration Statement&#148; shall include the Rule 462(b) Registration Statement. The prospectus, in the form first used by the Underwriters to confirm sales of
the Offered Shares<B> </B>or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act is called the &#147;<B>Prospectus.</B>&#148; The preliminary
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospectus, dated [&#9679;], 2018, describing the Offered Shares and the offering thereof is called the &#147;<B>Preliminary Prospectus</B>,&#148; and the Preliminary Prospectus and any other
prospectus in preliminary form that describes the Offered Shares and the offering thereof and is used prior to the filing of the Prospectus is called a &#147;<B>preliminary prospectus.</B>&#148; As used herein, &#147;<B>Applicable Time</B>&#148; is
[&#9679;] [a.m./p.m.] (New York City time) on [&#9679;], 2018. As used herein, &#147;<B>free writing prospectus</B>&#148; has the meaning set forth in Rule 405 under the Securities Act, and &#147;<B>Time of Sale Prospectus</B>&#148; means the
Preliminary Prospectus, together with the free writing prospectuses, if any, identified in <U>Schedule B</U> hereto and the pricing information set forth on <U>Schedule B</U> hereto. As used herein, <B>&#147;Road Show&#148;</B> means a &#147;road
show&#148; (as defined in Rule 433 under the Securities Act) relating to the offering of the Offered Shares contemplated hereby that is a &#147;written communication&#148; (as defined in Rule 405 under the Securities Act). As used herein,
&#147;<B>Section</B><B></B><B>&nbsp;5(d) Written Communication</B>&#148; means each written communication (within the meaning of Rule 405 under the Securities Act) that is made in reliance on Section&nbsp;5(d) of the Securities Act by the Company or
any person authorized to act on behalf of the Company to one or more potential investors that are qualified institutional buyers (&#147;<B>QIBs</B>&#148;) and/or institutions that are accredited investors (&#147;<B>IAIs</B>&#148;), as such terms are
respectively defined in Rule 144A and Rule 501(a) under the Securities Act, to determine whether such investors might have an interest in the offering of the Offered Shares; &#147;<B>Section</B><B></B><B>&nbsp;5(d) Oral Communication</B>&#148; means
each oral communication, if any, made in reliance on Section&nbsp;5(d) of the Securities Act by the Company or any person authorized to act on behalf of the Company made to one or more QIBs and/or one or more IAIs to determine whether such investors
might have an interest in the offering of the Offered Shares; &#147;<B>Marketing Materials</B>&#148; means any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering
of the Offered Shares, including any roadshow or investor presentations made to investors by the Company (whether in person or electronically); and &#147;<B>Permitted Section</B><B></B><B>&nbsp;5(d) Communication</B>&#148; means the
Section&nbsp;5(d) Written Communication(s) and Marketing Materials listed on Schedule C attached hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement
to (i)&nbsp;the Registration Statement, any preliminary prospectus (including the Preliminary Prospectus) or the Prospectus, or any amendments or supplements to the foregoing, or any free writing prospectus, shall include any copy thereof filed with
the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval system (&#147;<B>EDGAR</B>&#148;) and (ii)&nbsp;the Prospectus shall be deemed to include any &#147;electronic Prospectus&#148; provided for use in connection with the
offering of the Offered Shares as contemplated by Section&nbsp;3(o) of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Company has only one
subsidiary, then all references herein to &#147;subsidiaries&#148; of the Company shall be deemed to refer to such single subsidiary, <U>mutatis</U> <U>mutandis</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreements with the Underwriters as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.</B>&nbsp;&nbsp;&nbsp;&nbsp;Representations and Warranties of the Company. The Company hereby represents,
warrants and covenants to each Underwriter, as of the date of this Agreement, as of the First Closing Date (as hereinafter defined) and as of each Option Closing Date (as hereinafter defined), if any, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Compliance with Registration Requirements</I></B><B>.</B> The Registration Statement has become
effective under the Securities Act. The Company has complied, to the Commission&#146;s satisfaction, with all requests of the Commission for additional or supplemental information, if any. No stop order suspending the effectiveness of the
Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company, are contemplated or threatened by the Commission. The Company is a &#147;foreign private issuer&#148;
within the meaning of Rule 405 under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Disclosure</I></B><B>.</B> The Preliminary Prospectus and
the Prospectus when filed complied, in all material respects, with the Securities Act and, if filed by electronic transmission pursuant to EDGAR, was identical (except as may be permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT>
under the Securities Act) to the copy thereof delivered to the Underwriters for use in connection with the offer and sale of the Offered Shares. Each of the Registration Statement and any post-effective amendment thereto, at the time it became or
becomes effective, complied and will comply, in all material respects, with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to
make the statements therein not misleading. As of the Applicable Time, the Time of Sale Prospectus (including any preliminary prospectus wrapper)<B> </B>did not, and at the First Closing Date (as defined in Section&nbsp;2) and at each applicable
Option Closing Date (as defined in Section&nbsp;2), will not, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made,
not misleading. The Prospectus (including any Prospectus wrapper), as of its date, did not, and at the First Closing Date and at each applicable Option Closing Date, will not, contain any untrue statement of a material fact or omit to state a
material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the three immediately preceding sentences do not apply to
statements in or omissions from the Registration Statement or any post-effective amendment thereto, or the Prospectus or the Time of Sale Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with written
information relating to any Underwriter furnished to the Company in writing by the Representatives expressly for use therein, it being understood and agreed that the only such information consists of the information described in Section&nbsp;9(b)
below. There are no contracts or other documents required to be described in the Time of Sale Prospectus or the Prospectus or to be filed as an exhibit to the Registration Statement which have not been described or filed as required. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Free Writing Prospectuses; Road Show</I></B><B>.</B> As of the determination date referenced in Rule
164(h) under the Securities Act, the Company was not, is not or will not be (as applicable) an &#147;ineligible issuer&#148; in connection with the offering of the Offered Shares pursuant to Rules 164, 405 and 433 under the Securities Act. Each free
writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act. Each free writing prospectus that the
Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply, in all material respects, with the requirements of
Rule 433 under the Securities Act, including timely filing with the Commission or retention where required and legending, and each such free writing prospectus, as of its issue date and at all subsequent times through the completion of the public
offer and sale of the Offered Shares did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Prospectus or any preliminary prospectus and
not superseded or modified. Except for the free writing prospectuses, if any, identified in <U>Schedule B</U>, and electronic road shows, if any, furnished to you before first use, the Company has not prepared, used or referred to, and will not,
without your prior written consent, which will not be unreasonably withheld, prepare, use or refer to, any free writing prospectus. Each Road Show, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time,
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I>[Intentionally Omitted.]</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Distribution of Offering Material by the Company</I></B><B>.</B> Prior to the later of (i)&nbsp;the
expiration or termination of the option granted to the several Underwriters in Section&nbsp;2 and (ii)&nbsp;the completion of the Underwriters&#146; distribution of the Offered Shares, the Company has not distributed and will not distribute
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any offering material in connection with the offering and sale of the Offered Shares other than the Registration Statement, the Time of Sale Prospectus, the Prospectus or any free writing
prospectus reviewed and consented to by the Representatives, the free writing prospectuses, if any, identified on <U>Schedule B</U> hereto and any Permitted Section&nbsp;5(d) Communications. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>The Underwriting Agreement</I></B><B>.</B> This Agreement has been duly authorized, executed and
delivered by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Authorization of the Offered Shares</I></B><B>.</B> The Offered Shares
have been duly authorized for issuance and sale pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and the issuance and
sale of the Offered Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase any securities of the Company that have not been duly waived or satisfied. Upon the sale and delivery to
the Underwriters of the Offered Shares, and payment therefor, the Underwriters will acquire good, marketable and valid title to such Offered Shares, free and clear of all pledges, liens, security interests, charges, claims or encumbrances. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>No Applicable Registration or Other Similar Rights</I></B><B>.</B> There are no persons with
registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been duly waived. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>No Material Adverse Change</I></B><B>.</B> Except as otherwise disclosed in the Registration Statement,
the Time of Sale Prospectus and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the Prospectus: (i)&nbsp;there has been no material adverse change, or
any development that would reasonably be expected to result in a material adverse change, in the condition, financial or otherwise, or in the earnings, business, properties, operations, assets, liabilities or prospects, whether or not arising from
transactions in the ordinary course of business, of the Company and its subsidiaries, considered as one entity (any such change being referred to herein as a &#147;<B>Material Adverse Change</B>&#148;); (ii) the Company and its subsidiaries,
considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including, without limitation, any losses or interference with its business from fire, explosion, flood, earthquakes, accident or other
calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, or
have entered into any material transactions not in the ordinary course of business; and (iii)&nbsp;there has not been any material decrease in the share capital or any material increase in any short-term or long-term indebtedness of the Company or
its subsidiaries and there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company, by any of the Company&#146;s subsidiaries on any class of share capital, or any
repurchase or redemption by the Company or any of its subsidiaries of any class of share capital. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Independent Accountants</I></B><B>.</B> Kesselman&nbsp;&amp; Kesselman, a member firm of
PricewaterhouseCoopers International Limited, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration
Statement, the Time of Sale Prospectus and the Prospectus, is (i)&nbsp;an independent registered public accounting firm as required by the Securities Act and the rules of the Public Company Accounting Oversight Board (&#147;<B>PCAOB</B>&#148;), (ii)
in compliance with the applicable requirements relating to the qualification of accountants under Rule <FONT STYLE="white-space:nowrap">2-01</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Securities Act and (iii)&nbsp;a
registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Financial Statements</I></B><B>.</B> The financial
statements filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus present fairly, in all material respects, the consolidated financial position of the Company and its subsidiaries as of the
dates indicated and the results of their operations, changes in shareholders&#146; equity and cash flows for the periods specified. Such financial statements have been prepared in conformity with U.S. generally accepted accounting principles
(&#147;<B>GAAP</B>&#148;) applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto and except in the case of unaudited financial statements, which are subject to normal and
recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and do not contain certain footnotes as permitted by the applicable rules of the Commission. No other financial statements or supporting schedules are required to be included in
the Registration Statement, the Time of Sale Prospectus or the Prospectus. The financial data set forth in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus under the captions &#147;Prospectus Summary&#151;Summary
Consolidated Financial Data,&#148; &#147;Selected Consolidated Financial Data&#148; and &#147;Capitalization&#148; fairly present, in all material respects, the information set forth therein on a basis consistent with that of the audited and, if
applicable, unaudited financial statements contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus. All disclosures contained in the Registration Statement, any preliminary prospectus or the Prospectus and any free
writing prospectus that constitute <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures (as defined by the rules and regulations under the Securities Act and the Securities Exchange Act of 1934, as amended, and the rules and
regulations thereunder (collectively, the &#147;<B>Exchange Act</B>&#148;)) comply with Regulation G under the Exchange Act and Item 10 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act, as applicable. To the
Company&#146;s knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated in or
otherwise aided the preparation of, or audited, the financial statements, or other financial data filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Company&#146;s Accounting System</I></B><B>.</B> The Company makes and keeps accurate books and records
and maintains a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization; (ii)&nbsp;transactions are recorded as
necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; and
(iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial
Reporting</I></B><B>.</B> The Company has established and maintains disclosure controls and procedures (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act),
which (i)&nbsp;are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&#146;s principal executive officer and its principal financial officer by others within
those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared; (ii)&nbsp;have been evaluated by management of the Company for effectiveness as of the end of the Company&#146;s most
recent fiscal quarter; and (iii)&nbsp;are effective, in all material respects, to perform the functions for which they were established. Since the end of the Company&#146;s most recent audited fiscal year, there have been no significant deficiencies
or material weakness in the Company&#146;s internal control over financial reporting (whether or not remediated) and no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely to
materially affect, the Company&#146;s internal control over financial reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially
affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Incorporation and Good Standing of the
Company</I></B><B>.</B> The Company has been duly organized and is validly existing as a company under the laws of the State of Israel and has the corporate power and authority to own, lease and operate its properties and to conduct its business as
described in the Registration Statement, the Time of Sale Prospectus and the Prospectus and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good
standing in each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or in good standing would not reasonably
be expected to have, individually or in the aggregate, a material adverse effect on the condition (financial or other), earnings, business, properties, operation, assets, liabilities, or prospects of the Company and its subsidiaries, considered as
one entity (any such effect being referred to herein as a &#147;<B>Material Adverse Effect</B>&#148;). The Company has not been designated as a &#147;breaching company&#148; (within the meaning of the Israeli Companies Law 5759-1999) by the
Registrar of Companies of the State of Israel. The certificate of incorporation, articles of association and other organizational documents of the Company comply with the requirements of applicable Israeli law and are in full force and effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Subsidiaries</I></B><B>.</B> Each of the Company&#146;s &#147;subsidiaries&#148; (for purposes of this
Agreement, as defined in Rule 405 under the Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing (where such
qualification is required) under the laws of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the
Registration Statement, the Time of Sale Prospectus and the Prospectus. Each of the Company&#146;s subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact business and is in good
standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified would not reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect. All of the issued and outstanding capital stock or other equity or ownership interests of each of the Company&#146;s subsidiaries has been duly authorized and validly issued, is fully paid
and nonassessable and is owned by the Company, directly or through subsidiaries, free and clear of any material security interest, mortgage, pledge, lien, encumbrance or adverse claim. The Company does not own or control, directly or indirectly, any
corporation, association or other entity other than the subsidiaries listed in or included as an exhibit to the Registration Statement. None of the outstanding shares of capital stock of any of the Company&#146;s subsidiaries were issued in
violation of any preemptive rights or rights of first refusal or other similar rights to subscribe for or purchase securities of any such subsidiary. None of the subsidiaries of the Company is a &#147;significant subsidiary&#148; (as defined in Rule
405 under the Securities Act). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Capitalization and Other Share Capital Matters</I></B><B>.</B> The
authorized, issued and outstanding share capital of the Company is as set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus under the caption &#147;Capitalization&#148; (other than for subsequent issuances, if any,
pursuant to employee benefit plans, or upon the exercise of outstanding options or warrants, in each case described in the Registration Statement, the Time of Sale Prospectus and the Prospectus). The share capital of the Company, including the
Ordinary Shares and the Offered Shares, conforms, in all material respects, to each description thereof contained in the Time of Sale Prospectus. All of the issued and outstanding Ordinary Shares have been duly authorized and validly issued, are
fully paid and nonassessable and have been issued in compliance with all federal, state and local, including Israeli, securities laws. None of the outstanding Ordinary Shares was issued in violation of any preemptive rights, rights of first refusal
or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities
convertible into or exchangeable or exercisable for, any share capital of the Company or any of its subsidiaries other than those described in the Registration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Statement, the Time of Sale Prospectus and the Prospectus. The descriptions of the Company&#146;s equity compensation plans or arrangements, and the options or other rights granted thereunder,
set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus accurately and fairly present, in all material respects, the information required to be shown with respect to such plans, arrangements, options and rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Stock Exchange Listing</I></B><B>.</B> The Ordinary Shares are registered pursuant to
Section&nbsp;12(b) of the Exchange Act and are listed on the Nasdaq Global Market (&#147;<B>Nasdaq</B>&#148;), and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Ordinary Shares
under the Exchange Act or delisting the Ordinary Shares from Nasdaq, nor has the Company received any notification that the Commission or Nasdaq is contemplating terminating such registration or listing. To the Company&#146;s knowledge, it is in
compliance with all applicable listing requirements of Nasdaq. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I><FONT STYLE="white-space:nowrap">Non-Contravention</FONT> of Existing Instruments; No Further
Authorizations or Approvals Required</I></B><B>.</B> Neither the Company nor any of its subsidiaries is in violation of its articles of association or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents, as
applicable, or is in default (or, with the giving of notice or lapse of time, would be in default) (&#147;<B>Default</B>&#148;) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument
(including, without limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by
which any of them may be bound, or to which any of their respective properties or assets are subject, including (A)&nbsp;any instrument of approval granted to any of them by the Israel Innovation Authority of the Israeli Ministry of Economy and
Industry (the &#147;<B>IIA</B>&#148;) or (B)&nbsp;any instrument of approval granted to any of them by the Authority for Investment and Development of Industry and the Economy of the Israeli Ministry of Economy and Industry (the &#147;<B>Investment
Center</B>&#148;) (each, an &#147;<B>Existing Instrument</B>&#148;), except for such Defaults as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. The Company&#146;s execution, delivery and
performance of this Agreement, consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus, including the issuance and sale of the Offered Shares (including the use of
proceeds from the sale of the Offered Shares as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus under the caption &#147;Use of Proceeds&#148;) (i) have been duly authorized by all necessary corporate action
and will not result in any violation of the provisions of the articles of association or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents, as applicable, of the Company or any of its subsidiaries (ii)&nbsp;will not
conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its
subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument, except as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, and (iii)&nbsp;will not result in any
violation of any law, administrative regulation or administrative or court decree applicable to the Company or any of its subsidiaries, except as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.
No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for, or in connection with, the Company&#146;s execution, delivery and performance
of this Agreement and consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus, except (A)&nbsp;such as have been obtained or made by the Company and are in full force and
effect under the Securities Act and such as may be required under applicable state securities or blue sky laws, the Financial Industry Regulatory Authority, Inc. (&#147;<B>FINRA</B>&#148;), or Nasdaq and (B)&nbsp;the filing of certain notices with
the Registrar of Companies of the State of Israel regarding the issuance of the Offered Shares or the filing of certain information following the First Closing Date (and, if applicable, at each Option Closing Date) with the Investment Center and the
IIA. Subject to the Underwriters&#146; compliance with their obligations under Section&nbsp;5(b) hereof, the Company is not required to publish a prospectus in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the State of Israel under the laws of the State of Israel with respect to the offer or sale of the Offered Shares. As used herein, a &#147;<B>Debt Repayment Triggering Event</B>&#148; means any
event or condition which gives, or with the giving of notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#146;s behalf) the right to require the repurchase,
redemption or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Compliance with Laws.</I></B> The Company and its subsidiaries have been and are in compliance with all
applicable laws, rules and regulations, except where failure to be so in compliance would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>No Material Actions or Proceedings</I></B><B>.</B> There is no action, suit, proceeding, inquiry or
investigation brought by or before any governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which would be reasonably expected, individually or in the
aggregate, to have a Material Adverse Effect or materially and adversely affect the consummation of the transactions contemplated by this Agreement or the performance by the Company of its obligations hereunder; and the aggregate of all pending
legal or governmental proceedings to which the Company or any such subsidiary is a party or of which any of their respective properties or assets is the subject, including ordinary routine litigation incidental to their business, if determined
adversely to the Company or such subsidiary, would not reasonably be expected to have a Material Adverse Effect. No labor dispute with the employees of the Company or any of its subsidiaries, or with the employees of any principal supplier,
manufacturer, customer or contractor of the Company, exists or, to the knowledge of the Company, is threatened or imminent, which could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Intellectual Property Rights</I></B><B>.</B> The Company and its subsidiaries own, or have obtained
valid and enforceable licenses for, the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property (1)&nbsp;described in the Registration Statement, the Time of Sale
Prospectus and the Prospectus as being owned or licensed by them or (2)&nbsp;which are necessary for the conduct of their respective businesses as currently conducted or as currently proposed in the Registration Statement, the Time of Sale
Prospectus or the Prospectus to be conducted (collectively, &#147;<B>Intellectual Property</B>&#148;) except in the case of clause (2)&nbsp;where the failure to own, possess or acquire such rights would not reasonably be expected, individually or in
the aggregate, to have a Material Adverse Effect. Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, to the Company&#146;s knowledge: (i)&nbsp;there are no third parties who have rights
to any Intellectual Property; and (ii)&nbsp;there is no infringement by third parties of any Intellectual Property. Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, there is no pending
or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others: (A)&nbsp;challenging the Company&#146;s or its subsidiaries&#146; rights in or to any Intellectual Property, and the Company is unaware of any facts which
would form a reasonable basis for any such action, suit, proceeding or claim; (B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for
any such action, suit, proceeding or claim; or (C)&nbsp;asserting that the Company or any of its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described in the Registration Statement,
the Time of Sale Prospectus or the Prospectus as under development, infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others, and the Company is unaware of any facts which
would form a reasonable basis for any such action, suit, proceeding or claim. Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, the Company and its subsidiaries have complied with the
terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or its subsidiaries, and all such agreements are in full force and effect. The product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates described in the Registration Statement, the Time of Sale Prospectus and the Prospectus as under development by the Company or its subsidiary fall within the scope of the claims of one
or more patents or patent applications owned by, or exclusively licensed to, the Company or any such subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>All Necessary Permits, etc</I></B><B>.</B> The Company and its subsidiaries possess such valid and
current certificates, authorizations or permits required by state, federal or foreign, including Israeli, regulatory agencies or bodies to conduct their respective businesses as currently conducted and as described in the Registration Statement, the
Time of Sale Prospectus or the Prospectus (&#147;<B>Permits</B>&#148;), except where the failure to so possess would not reasonably be expected to, individually or in the aggregate, result in a Material Adverse Effect. Neither the Company nor any of
its subsidiaries is in violation of, or in default under, any of the Permits or has received any notice of proceedings relating to the revocation or modification of, or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with, any Permit, except
as would not reasonably be expected to have a Material Adverse Effect. All information supplied by the Company with respect to the applications or notifications relating to grants and benefits from the IIA was true, correct and complete in all
material respects when supplied to the appropriate authorities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Title to
Properties</I></B><B>.</B> The Company and its subsidiaries have good and marketable title to all of the real and personal property and other assets reflected as owned in the financial statements referred to in Section&nbsp;1(k) above (or elsewhere
in the Registration Statement, the Time of Sale Prospectus or the Prospectus), in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects, except as do not materially interfere
with the use made or proposed to be made of such property and other assets by the Company. Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the real property, improvements, equipment and personal
property held under lease by the Company or any of its subsidiaries are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property,
improvements, equipment or personal property by the Company or such subsidiary. The preceding sentence does not apply to any intellectual property rights, which are covered by the representations and warranties contained in Section&nbsp;1(u) hereof.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Tax Law Compliance</I></B><B>.</B> The Company and its subsidiaries have filed all material United
States (federal, state and local), Israeli and foreign (state and local) income and franchise tax returns or have properly requested extensions thereof and have paid all taxes required to be paid by any of them and, if due and payable, any related
or similar assessment, fine or penalty levied against any of them except as may be being contested in good faith and by appropriate proceedings or except where the failure to pay such taxes could not reasonably be expected to result in a Material
Adverse Effect. The Company has made adequate charges, accruals and reserves in the applicable financial statements referred to in Section&nbsp;1(k) above in respect of all federal, state, Israeli and foreign income and franchise taxes for all
periods as to which the tax liability of the Company or any of its subsidiaries has not been finally determined. No transaction, stamp or other issuance or transfer taxes or duties, and assuming that the Underwriters are not otherwise subject to
taxation in Israel due to Israeli tax residence or the existence of a permanent establishment in Israel, no capital gain, income, transfer, withholding or other tax or duty is payable in the State of Israel by or on behalf of the Underwriters to any
taxing authority thereof or therein in connection with (i)&nbsp;the issuance, sale and delivery of the Offered Shares by the Company; (ii)&nbsp;the purchase from the Company, and the initial sale and delivery by the Underwriters of the Offered
Shares to purchasers thereof; (iii)&nbsp;the holding or transfer of the Offered Shares; or (iv)&nbsp;the execution and delivery of this Agreement or any other document to be furnished hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Insurance</I></B><B>.</B> Each of the Company and its subsidiaries are insured by recognized and
reputable institutions with policies in such amounts and with such deductibles and covering such risks as the Company reasonably believes are generally deemed customary for their businesses including, but not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limited to, policies covering real and personal property owned or leased by the Company and its subsidiaries against theft, damage, destruction, acts of vandalism and earthquakes and policies
covering the Company and its subsidiaries for clinical trial liability claims. The Company has no reasonable basis to believe that it or any of its subsidiaries will not be able (i)&nbsp;to renew its existing insurance coverage as and when such
policies expire or (ii)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not reasonably be expected to have a Material Adverse Effect.
Neither the Company nor any of its subsidiaries has been denied any material insurance coverage which it has sought or for which it has applied. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Compliance with Environmental Laws</I></B><B>. </B>Except as would not reasonably be expected,
individually or in the aggregate, to have a Material Adverse Effect: (i)&nbsp;neither the Company nor any of its subsidiaries is in violation of any Israeli or United States (federal, state or local) or foreign statute, law, rule, regulation,
ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment
(including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants,
contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, &#147;<B>Hazardous Materials</B>&#148;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or
handling of Hazardous Materials (collectively, &#147;<B>Environmental Laws</B>&#148;); (ii) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance
with their requirements; (iii)&nbsp;there are no pending, or to the knowledge of the Company, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation,
investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries; and (iv)&nbsp;to the knowledge of the Company, there are no events or circumstances existing as of the date hereof that would reasonably
be expected to form the basis of an order for <FONT STYLE="white-space:nowrap">clean-up</FONT> or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its
subsidiaries relating to Hazardous Materials or any Environmental Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Benefit Plan Compliance.
</I></B>Each benefit, pension and compensation plan, agreement policy and arrangement that is maintained, administered or contributed to by the Company or any of its subsidiaries for current or former employees or directors of the Company or any of
its subsidiaries, or with respect to which any of such entities would reasonably be expected to have any current, future or contingent liability or responsibility, has been maintained in compliance with its terms and the requirements of any
applicable statutes, orders, rules and regulations, except as would not, individually or in the aggregate, be expected to have a Material Adverse Effect and except with respect to matters over which none of the Company or its subsidiaries have
control; the Company and each of its subsidiaries have complied with all applicable statutes, orders, rules and regulations in regard to such plans, agreements, policies and arrangements, except as would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect; the fair market value of the assets of each such plan, agreement, policy and arrangement which is required or intended to be funded (excluding for these purposes accrued but unpaid
contributions) exceeds the present value of all benefits accrued or earned or payments due under such plan, agreement, policy or arrangement determined using reasonable actuarial assumptions. The liabilities reflected on the relevant entity&#146;s
financial statements with respect to each such plan, agreement, policy and arrangement which is not required or intended to be funded accurately reflects the present value of all benefits earned or accrued or payments due under such plan, agreement,
policy or arrangement determined using reasonable actuarial assumptions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Compliance with the
Sarbanes-Oxley Act.</I></B> The Company is in compliance, in all material respects, with (i)&nbsp;all provisions of the Sarbanes-Oxley Act of 2002 and all rules and regulations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
promulgated thereunder or implementing the provisions thereof (collectively, the &#147;<B>Sarbanes-Oxley Act</B>&#148;) that are then in effect and with which the Company is required to comply,
and is or will be taking steps to ensure that it will be in compliance, in all material respects, with other provisions of the Sarbanes-Oxley Act not currently in effect, upon the effectiveness of such provisions and their becoming applicable to the
Company and (ii)&nbsp;with all corporate governance requirements under applicable Nasdaq regulations, and, in each case, has no reason to believe that it will not be able to comply with any of such provisions. There is and has been no failure on the
part of the Company or any of its directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act, including, without limitation, Section&nbsp;402 related to loans and, as applicable, Sections
302 and 906 related to certifications. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Company Not an &#147;Investment Company;&#148; Not a
&#147;Passive Foreign Investment Company.&#148;</I></B> The Company is not, and will not be, either after receipt of payment for the Offered Shares or after the application of the proceeds therefrom as described under &#147;Use of Proceeds&#148; in
the Registration Statement, the Time of Sale Prospectus or the Prospectus, required to register as an &#147;investment company&#148; under the Investment Company Act of 1940, as amended (the <B>&#147;Investment Company Act&#148;)</B>. Neither the
Company nor any subsidiary of the Company is, and, after giving effect to the offering and sale of the Offered Shares and the application of the proceeds thereof, neither of them will be, a &#147;controlled foreign corporation&#148; as defined by
the United States Internal Revenue Code of 1986, as amended (the &#147;<B>Code</B>&#148;). As of December&nbsp;31, 2017, the Company would not have been considered a &#147;passive foreign investment company,&#148; as such term is defined in the
Code, and immediately after the offering and sale of the Offered Shares and assuming the application of the proceeds as described in the Time of Sale Prospectus under &#147;Use of Proceeds,&#148; less than 50% of the Company&#146;s assets will be
classified as assets that produce, or are held for the production of, passive income for the purpose of Section&nbsp;1297 of the Code and the rules, regulations and administrative pronouncements relating thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I> No Price Stabilization or Manipulation; Compliance with Regulation M</I></B><B>.</B> Neither the
Company nor any of its subsidiaries has taken, directly or indirectly, without giving effect to activities by the Representatives, any action designed to or that would be reasonably expected to cause or result in stabilization or manipulation of the
price of the Offered Shares or of any &#147;reference security&#148; (as defined in Rule 100 of Regulation M under the Exchange Act (<B>&#147;Regulation M&#148;</B>)) with respect to the Offered Shares, whether to facilitate the sale or resale of
the Offered Shares or otherwise, and has taken no action which would directly or indirectly violate Regulation M. In addition, the Company has not engaged in any form of solicitation, advertising or other action constituting an offer or a sale under
the Israeli Securities Law 5728-1968, as amended (the &#147;<B>Israeli Securities Law</B>&#148;) and the regulations promulgated thereunder in connection with the transactions contemplated hereby which would require the Company to publish a
prospectus in the State of Israel under the laws of the State of Israel. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Related-Party
Transactions</I></B><B>.</B> There are no business relationships or related-party transactions involving the Company or any of its subsidiaries or any other person required to be described in the Registration Statement, the Time of Sale Prospectus
or the Prospectus that have not been described as required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>FINRA Matters</I></B><B>.</B> All of
the information provided to the Underwriters or to counsel for the Underwriters by or on behalf of the Company, or to its knowledge, by or on behalf of its officers, directors and the holders of any securities (debt or equity) or options to acquire
any securities of the Company in connection with the offering of the Offered Shares, is true, complete, correct, in all material respects, and compliant with FINRA&#146;s rules and any letters, filings or other supplemental information provided to
FINRA by such parties pursuant to FINRA Rules or NASD Conduct Rules is true, complete and correct in all material respects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Parties to
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I></B><B>.</B> The Company has furnished to the Underwriters a letter agreement substantially in the form attached hereto as <U>Exhibit A</U> (the
&#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement</B>&#148;) from each of the persons listed on <U>Exhibit B</U>. Such <U>Exhibit B</U> lists under an appropriate caption the directors, executive officers and certain additional
shareholders of the Company. If any additional persons shall become directors or executive officers of the Company prior to the end of the Company <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period (as defined below), the Company shall cause
each such person, prior to or contemporaneously with their appointment or election as a director or executive officer of the Company, to execute and deliver to the Representatives a <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement.<B> </B>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Statistical and Market-Related Data</I></B><B>.</B> All statistical, demographic and <FONT
STYLE="white-space:nowrap">market-related</FONT> data included in the Registration Statement, the Time of Sale Prospectus or the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate in all material
respects. To the extent required, the Company has obtained the written consent to the use of such data from such sources. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>No Unlawful Contributions or Other Payments</I></B><B>.</B> Neither the Company nor any of its
subsidiaries nor, to the Company&#146;s knowledge, any employee or agent of the Company or any of its subsidiaries, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of
any applicable law or of the character required to be disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Foreign Corrupt Practices Act</I></B><B>.</B> Neither the Company nor any of its subsidiaries nor, to
the knowledge of the Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its subsidiaries
(i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii)&nbsp;made any direct or indirect unlawful payment to any domestic government official, &#147;foreign
official&#148; (as defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (collectively, the &#147;<B>FCPA</B>&#148;)) or employee from corporate funds; (iii)&nbsp;violated or is in violation
of any provision of the FCPA or any applicable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> anti-bribery statute or regulation; or (iv)&nbsp;made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any
domestic government official, such foreign official or employee; and the Company and its subsidiaries and, to the knowledge of the Company, the Company&#146;s affiliates have conducted their respective businesses in compliance with the FCPA and have
instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. The foregoing representation and warranty shall also be deemed given regarding laws of <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions similar to the FCPA, including, without limitation, Sections&nbsp;291 and 291A of the Israel Penal Law 5737-1977 and the rules and regulations thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Money Laundering Laws</I></B><B>.</B> The operations of the Company and its subsidiaries are, and have
been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions,
the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<B>Money Laundering Laws</B>&#148;) and no action, suit
or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>OFAC</I></B><B>.</B> Neither the Company nor any of its subsidiaries nor, to the knowledge of the
Company, after due inquiry, any director, officer, agent, employee, affiliate or other person acting on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
behalf of the Company or any of its subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department
(&#147;<B>OFAC</B>&#148;), the United Nations Security Council (&#147;<B>UNSC</B>&#148;), the European Union, Her Majesty&#146;s Treasury (&#147;<B>HMT</B>&#148;), or other relevant sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;),
nor is the Company located, organized or resident in a country or territory that is the subject of Sanctions; and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such
proceeds to any subsidiary, or any joint venture partner or other person or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that currently is the subject to any Sanctions, or in any
other manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of such Sanctions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Brokers</I></B><B>. </B>Except pursuant to this Agreement, there is no broker, finder or other party
that is entitled to receive from the Company any brokerage or finder&#146;s fee or other fee or commission as a result of any transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Submission to Jurisdiction</I></B>. The Company has the power to submit, and pursuant to
Section&nbsp;18 of this Agreement, has legally, validly, effectively and irrevocably submitted, to the personal jurisdiction of each United States federal court and New York state court located in the Borough of Manhattan, in the City of New York,
New York, U.S.A. (each, a &#147;<B>New York Court</B>&#148;), and the Company has the power to designate, appoint and authorize, and pursuant to Section&nbsp;18 of this Agreement, has legally, validly, effectively and irrevocably designated,
appointed and authorized an agent for service of process in any action arising out of or relating to this Agreement or the Offered Shares in any New York Court, and service of process effected on such authorized agent will be effective to confer
valid personal jurisdiction over the Company as provided in Section&nbsp;18 hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>No Rights of
Immunity</I></B>. Except as provided by laws or statutes generally applicable to transactions of the type described in this Agreement, neither the Company nor any of its respective properties, assets or revenues has any right of immunity under the
laws of the State of Israel, New York or United States law, from any legal action, suit or proceeding, from the giving of any relief in any such legal action, suit or proceeding, from <FONT STYLE="white-space:nowrap">set-off</FONT> or counterclaim,
from the jurisdiction of any Israeli, New York or United States federal court, from service of process, attachment upon or prior judgment, or attachment in aid of execution of judgment, or from execution of a judgment, or other legal process or
proceeding for the giving of any relief or for the enforcement of a judgment, in any such court, with respect to its obligations, liabilities or any other matter under or arising out of or in connection with this Agreement. To the extent that the
Company or any of its respective properties, assets or revenues may have or may hereafter become entitled to any such right of immunity in any such court in which proceedings may at any time be commenced, the Company waives or will waive such right
to the extent permitted by law and has consented to such relief and enforcement as provided in Section&nbsp;18 of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Forward-Looking Statements.</I></B> Each financial or operational projection or other
&#147;forward-looking statement&#148; (as defined by Section&nbsp;27A of the Securities Act or Section&nbsp;21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Prospectus or the Prospectus (i)&nbsp;was so included by
the Company in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii)&nbsp;is accompanied by meaningful cautionary statements
identifying those factors that could cause actual results to differ materially from those in such forward-looking statement. No such statement was made with the knowledge of an executive officer or director of the Company that it was false or
misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Emerging Growth Company Status.</I></B> From the time of initial confidential
submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section&nbsp;5(d) Written Communication or any Section&nbsp;5(d) Oral Communication) through the date hereof, the Company
has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act (an &#147;<B>Emerging Growth Company</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Communications.</I></B> The Company (i)&nbsp;has not
alone engaged in communications with potential investors in reliance on Section&nbsp;5(d) of the Securities Act other than Permitted Section&nbsp;5(d) Communications with the consent of the Representatives with entities that are QIBs or IAIs and
(ii)&nbsp;has not authorized anyone other than the Representatives to engage in such communications; the Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking Marketing Materials, Section&nbsp;5(d) Oral
Communications and Section&nbsp;5(d) Written Communications; as of the Applicable Time, each Permitted Section&nbsp;5(d) Communication, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time, include an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each Permitted Section&nbsp;5(d) Communication, if
any, does not, as of the date hereof, conflict with the information contained in the Registration Statement, the Preliminary Prospectus and the Prospectus; and the Company has filed publicly on EDGAR at least forty-eight (48)&nbsp;hours prior to the
delivery of any request for the acceleration of the effective date of the Registration Statement in accordance with Rule 461 under the Securities Act, any confidentially submitted registration statement and registration statement amendments relating
to the offer and sale of the Offered Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ss)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Clinical Data and Regulatory Compliance.</I></B> The
preclinical studies and clinical trials being conducted or sponsored by the Company, and, to the knowledge of the Company, other studies (collectively, &#147;<B>studies</B>&#148;) that are described in, or the results of which are referred to in,
the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are being conducted, in all material respects, in accordance with the protocols, procedures and controls designed and approved for such studies and
with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete, in all material respects, and fairly presents the data derived from such studies, and the Company and its
subsidiaries have no knowledge as of the date hereof of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time of Sale Prospectuses
or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required for the conduct of the studies by the Israeli Ministry of Health, the Food and Drug Administration of the U.S.
Department of Health and Human Services or any committee thereof or from any other U.S., Israeli or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the
&#147;<B>Regulatory Agencies</B>&#148;), except where the failure to make such filing or obtain such approval would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect; neither the Company nor any of
its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring, and, to the knowledge of the Company, no Regulatory Agency has threatened to initiate, the termination, suspension or modification of any clinical
trials that are described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance, in all material respects, with all
applicable rules, regulations and policies of the Regulatory Agencies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>No Contract Terminations.
</I></B>Neither the Company nor any of its subsidiaries has sent or received any communication regarding termination of, or intent not to renew, any of the contracts or agreements referred to or described in any preliminary prospectus, the
Prospectus or any free writing prospectus, or referred to or described in, or filed as an exhibit to, the Registration Statement, and no such termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> has been threatened by the Company or
any of its subsidiaries or, to the Company&#146;s knowledge, any other party to any such contract or agreement, which threat of termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> has not been rescinded as of the date hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uu)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Compliance with Israeli Law.</I></B> All corporate
approvals on the part of the Company, including under Chapter 5 of Part&nbsp;VI of the Israeli Companies Law 5759-1999, for the offer or sale of Offered Shares and the transactions contemplated hereby have been obtained. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vv)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Dividend Restrictions</I></B><B>.</B> No subsidiary of the Company is prohibited or restricted,
directly or indirectly, from paying dividends to the Company, or from making any other distribution with respect to such subsidiary&#146;s equity securities or from repaying to the Company or any other subsidiary of the Company any amounts that may
from time to time become due under any loans or advances to such subsidiary from the Company or from transferring any property or assets to the Company or to any other subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any certificate signed by any officer of the Company or any of its subsidiaries and delivered to any Underwriter or to counsel for the
Underwriters in connection with the offering, or the purchase and sale, of the Offered Shares shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company acknowledges that the Underwriters and, for purposes of the opinions to be delivered pursuant to Section&nbsp;6 hereof, counsel to
the Company and counsel to the Underwriters, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.</B>&nbsp;&nbsp;&nbsp;&nbsp;Purchase, Sale and Delivery of the Offered Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>The Firm Shares</I></B><B>.</B> Upon the terms herein set forth, the Company agrees to issue and sell
to the several Underwriters an aggregate of [&#9679;] Firm Shares. On the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Underwriters agree, severally
and not jointly, to purchase from the Company the respective number of Firm Shares set forth opposite their names on <U>Schedule A</U>. The purchase price per Firm Share to be paid by the several Underwriters to the Company shall be $[&#9679;] per
share.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>The First Closing Date</I></B><B>.</B> Delivery of the book-entry positions for
the Firm Shares to be purchased by the Underwriters and payment therefor shall be made at the offices of Covington&nbsp;&amp; Burling LLP (or such other place as may be agreed to by the Company and the Representatives) at [9:00] a.m. New York City
time, on [&#9679;], 2018<B>,</B> or such other time and date not later than 1:30 p.m. New York City time, on [the date that is 10 business days following the initial contemplated closing date] as the Representatives shall designate by notice to the
Company (the time and date of such closing are called the &#147;<B>First Closing Date</B>&#148;). The Company hereby acknowledges that circumstances under which the Representatives may provide notice to postpone the First Closing Date as originally
scheduled include, but are not limited to, any determination by the Company or the Representatives to recirculate to the public copies of an amended or supplemented Prospectus or a delay as contemplated by the provisions of Section&nbsp;11. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>The Optional Shares; Option Closing Date</I></B><B>.</B> In addition, on the basis of the
representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Company hereby grants an option to the several Underwriters to purchase, severally and not jointly, up to an
aggregate of [&#9679;] Optional Shares from the Company at the purchase price per share to be paid by the Underwriters for the Firm Shares, less an amount per share equal to any dividend or distribution declared by the Company and payable on the
Firm Shares but not payable on the Optional Shares. The option granted hereunder may be exercised at any time and from time to time in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whole or in part upon notice by the Representatives to the Company, which notice may be given at any time within 30 days from the date of this Agreement. Such notice shall set forth (i)&nbsp;the
aggregate number of Optional Shares as to which the Underwriters are exercising the option and (ii)&nbsp;the time, date and place for the electronic settlement for the Optional Shares (which time and date may be simultaneous with, but not earlier
than, the First Closing Date; and in the event that such time and date are simultaneous with the First Closing Date, the term &#147;<B>First Closing Date</B>&#148; shall refer to the time and date of delivery of the book-entry positions for the Firm
Shares and such Optional Shares). Any such time and date of delivery, if subsequent to the First Closing Date, is called an &#147;<B>Option Closing Date</B>,&#148; shall be determined by the Representatives and shall not be earlier than three or
later than five full business days after delivery of such notice of exercise. If any Optional Shares are to be purchased, each Underwriter agrees, severally and not jointly, to purchase the number of Optional Shares (subject to such adjustments to
eliminate fractional shares as the Representatives may determine) that bears the same proportion to the total number of Optional Shares to be purchased as the number of Firm Shares set forth on <U>Schedule A</U> opposite the name of such Underwriter
bears to the total number of Firm Shares.<B> </B>The Representatives may cancel the option at any time prior to its expiration by giving written notice of such cancellation to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Public Offering of the Offered Shares</I></B><B>.</B> The Representatives hereby advise the Company
that the Underwriters intend to offer for sale to the public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, their respective portions of the Offered Shares as soon after this
Agreement has been executed and the Registration Statement has been declared effective as the Representatives, in their sole judgment, have determined is advisable and practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Payment for the Offered Shares</I></B><B>. </B>(i)<B></B>&nbsp;Payment for the Offered Shares shall be
made at the First Closing Date (and, if applicable, at each Option Closing Date) by wire transfer of immediately available funds to the order of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;It is understood that the Representatives have been authorized, for their own account and the accounts of the
several Underwriters, to accept delivery of and receipt for, and make payment of the purchase price for, the Firm Shares and any Optional Shares the Underwriters have agreed to purchase. Each of Jefferies and Cowen, individually and not as the
Representatives of the Underwriters, may (but shall not be obligated to) make payment for any Offered Shares to be purchased by any Underwriter whose funds shall not have been received by the Representatives by the First Closing Date or the
applicable Option Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Delivery of the Offered Shares</I></B><B>.</B> The Company shall deliver, or cause to be delivered,
through the facilities of The Depository Trust Company (&#147;<B>DTC</B>&#148;) unless the Representatives shall otherwise instruct, to the Representatives for the accounts of the several Underwriters the Firm Shares to be sold by them at the First
Closing Date, against release of a wire transfer of immediately available funds for the amount of the purchase price therefor. The Company shall also deliver, or cause to be delivered, through the facilities of DTC unless the Representatives shall
otherwise instruct, to the Representatives for the accounts of the several Underwriters, the Optional Shares the Underwriters have agreed to purchase from them at the First Closing Date or the applicable Option Closing Date, as the case may be,
against the release of a wire transfer of immediately available funds for the amount of the purchase price therefor. The Offered Shares shall be registered in such names and denominations as the Representatives shall have requested at least two full
business days prior to the First Closing Date (or the applicable Option Closing Date, as the case may be) and shall be made available for inspection on the business day preceding the First Closing Date (or the applicable Option Closing Date, as the
case may be). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.</B>&nbsp;&nbsp;&nbsp;&nbsp;Additional Covenants of the Company.
The Company further covenants and agrees with each Underwriter as follows: <B></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Delivery of
Registration Statement, Time of Sale Prospectus and Prospectus.</I></B><I> </I>The Company shall furnish to you in New York City, without charge, prior to 10:00 a.m. New York City time on the second business day succeeding the date of this Agreement
and during the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales
of the Offered Shares, as many copies of the Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the Registration Statement as you may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Representative&#146;s Review of Proposed Amendments and Supplements.</I></B><I> </I>During the period
when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), the Company (i)&nbsp;will furnish to the
Representatives for review, a reasonable period of time prior to the proposed time of filing of any proposed amendment or supplement to the Registration Statement, a copy of each such amendment or supplement and (ii)&nbsp;will not amend or
supplement the Registration Statement without the Representative&#146;s prior written consent, which consent shall not be unreasonably withheld. Prior to amending or supplementing any preliminary prospectus, the Time of Sale Prospectus or the
Prospectus, the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the time of filing or use of the proposed amendment or supplement, a copy of each such proposed amendment or supplement. The Company shall
not file or use any such proposed amendment or supplement without the Representative&#146;s prior written consent, which consent shall not be unreasonably withheld. The Company shall file with the Commission within the applicable period specified in
Rule&nbsp;424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Free Writing Prospectuses.</I></B><I> </I>The Company shall furnish to the Representatives for review,
a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto prepared by or on behalf of, used by, or referred to by the Company, and the
Company shall not file, use or refer to any proposed free writing prospectus or any amendment or supplement thereto without the Representatives&#146; prior written consent, which consent shall not be unreasonably withheld. The Company shall furnish
to each Underwriter, without charge, as many copies of any free writing prospectus prepared by or on behalf of, used by or referred to by the Company as such Underwriter may reasonably request. If at any time when a prospectus is required by the
Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares (but in any event if at any time through and including the First
Closing Date) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the
Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such
time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, as the case may be; <I>provided, however</I>, that prior to
amending or supplementing any such free writing prospectus, the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented
free writing prospectus, and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the Representative&#146;s prior written consent, which consent shall not be unreasonably withheld. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Filing of Underwriter Free Writing
Prospectuses.</I></B><I> </I>The Company shall not take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by
or on behalf of such Underwriter that such Underwriter otherwise would not have been required to file thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Amendments and Supplements to Time of Sale Prospectus.</I></B><I> </I>If the Time of Sale Prospectus is
being used to solicit offers to buy the Offered Shares at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of
Sale Prospectus so that the Time of Sale Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a
prospective purchaser, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement, or if, in the opinion of counsel for the
Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the Company shall (subject to Section&nbsp;3(b) and Section&nbsp;3(c) hereof) promptly prepare, file with the Commission and furnish, at
its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or supplemented will not include an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading or so that the Time of Sale Prospectus, as
amended or supplemented, will no longer conflict with the information contained in the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Certain Notifications and Required Actions</I></B><B>.</B> After the date of this Agreement, the
Company shall promptly advise the Representatives in writing of: (i)&nbsp;the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii)&nbsp;the time and date of any filing of any post-effective
amendment to the Registration Statement or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus; (iii)&nbsp;the time and date that any post-effective amendment to the
Registration Statement becomes effective; and (iv)&nbsp;the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or any amendment or supplement to any
preliminary prospectus, the Time of Sale Prospectus or the Prospectus or of any order preventing or suspending the use of any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus, or of any proceedings
to remove, suspend or terminate from listing or quotation the Offered Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any
of such purposes. If the Commission shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order as soon as practicable. Additionally, the Company agrees that it shall comply with all
applicable provisions of Rule&nbsp;424(b), Rule 433 and Rule 430A under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b) or Rule 433 were received in a timely manner by the
Commission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Amendments and Supplements to the Prospectus and Other Securities Act Matters.</I></B>
If any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or any similar rule) to a purchaser, not misleading, or if in the opinion of the Representatives or counsel for the Underwriters it is otherwise necessary to amend or supplement the Prospectus to
comply with applicable law, the Company agrees (subject to Section&nbsp;3(b) and Section&nbsp;3(c) hereof) to promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments
or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in
the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading or so that the Prospectus, as amended or
supplemented, will comply with applicable law. Neither the Representative&#146;s consent to, nor delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&#146;s obligations under Section&nbsp;3(b) or
Section&nbsp;3(c). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Blue Sky Compliance</I></B><B>.</B> The Company shall cooperate with the
Representatives and counsel for the Underwriters to qualify or register the Offered Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws (or other foreign
laws) of those jurisdictions reasonably requested by the Representatives, shall comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Offered Shares. The
Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a
foreign corporation. The Company will advise the Representatives promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Offered Shares for offering, sale or trading in any jurisdiction or any
initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its reasonable best efforts to obtain the withdrawal thereof
at the earliest possible moment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Use of Proceeds</I></B><B>.</B> The Company shall apply the net
proceeds from the sale of the Offered Shares sold by it in the manner described under the caption &#147;Use of Proceeds&#148; in the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Earnings Statement</I></B><B>.</B> The Company will make generally available to its security holders
and to the Representatives as soon as practicable an earnings statement (which need not be audited) covering a period of at least twelve (12)&nbsp;months beginning with the first fiscal quarter of the Company commencing after the date of this
Agreement that will satisfy the provisions of Section&nbsp;11(a) of the Securities Act and the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Continued Compliance with Securities Laws</I></B><B>.</B> The Company will comply with the Securities
Act and the Exchange Act so as to permit the completion of the distribution of the Offered Shares as contemplated by this Agreement<B>, </B>the Registration Statement, the Time of Sale Prospectus and the Prospectus. Without limiting the generality
of the foregoing, the Company will, during the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar
rule), file on a timely basis with the Commission and Nasdaq all reports and documents required to be filed under the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Compliance with Israeli Securities Laws.</I></B> The Company acknowledges, understands and agrees that
the Offered Shares may be offered and sold in Israel only by the Underwriters and only to such Israeli investors listed in the First Addendum to the Israeli Securities Law (the &#147;<B>Addendum</B>&#148;) and who submit written confirmation to the
Underwriters and the Company that such investor (A)&nbsp;falls within the scope of the Addendum, is aware of the meaning of same and agrees to it and (B)&nbsp;is acquiring the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Offered Shares for investment for its own account or, if applicable, for investment for clients who are investors listed in the Addendum and in any event not as a nominee, market maker or agent
and not with a view to, or for the resale in connection with, any distribution thereof (&#147;<B>Israeli Accredited Investors</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I>[Intentionally Omitted.]</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Listing</I></B><B>.</B> The Company will use its reasonable best efforts to list, subject to notice of
issuance, the Offered Shares on Nasdaq. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Company to Provide Copy of the Prospectus in Form That May
be Downloaded from the Internet</I></B><B>.</B> If requested by the Representatives, the Company shall cause to be prepared and delivered, at its expense, within one business day from the effective date of this Agreement, to the Representatives an
&#147;<B>electronic Prospectus</B>&#148; to be used by the Underwriters in connection with the offering and sale of the Offered Shares. As used herein, the term &#147;<B>electronic Prospectus</B>&#148; means a form of Prospectus, and any amendment
or supplement thereto, that meets each of the following conditions: (i)&nbsp;it shall be encoded in an electronic format, satisfactory to the Representatives, that may be transmitted electronically by the Representatives and the other Underwriters
to offerees and purchasers of the Offered Shares; (ii)&nbsp;it shall disclose the same information as the paper Prospectus, except to the extent that graphic and image material cannot be disseminated electronically, in which case such graphic and
image material shall be replaced in the electronic Prospectus with a fair and accurate narrative description or tabular representation of such material, as appropriate; and (iii)&nbsp;it shall be in or convertible into a paper format or an
electronic format, satisfactory to the Representatives, that will allow investors to store and have continuously ready access to the Prospectus at any future time, without charge to investors (other than any fee charged for subscription to the
Internet as a whole and for <FONT STYLE="white-space:nowrap">on-line</FONT> time). The Company hereby confirms that it has included or will include in the Prospectus filed pursuant to EDGAR or otherwise with the Commission and in the Registration
Statement at the time it was declared effective an undertaking that, upon receipt of a request by an investor or his or her representative, the Company shall transmit or cause to be transmitted promptly, without charge, a paper copy of the
Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Agreement Not to Offer or Sell Additional Shares</I></B><B>. </B>During the period
commencing on and including the date hereof and continuing through and including the 90th day following the date of the Prospectus (such period being referred to herein as the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT>
Period</B>&#148;), the Company will not, without the prior written consent of Jefferies (which consent may be withheld in its sole discretion), directly or indirectly: (i)&nbsp;sell, offer to sell, contract to sell or lend any share capital of the
Company, whether in the form of ordinary shares, preferred shares or otherwise (&#147;<B>Share Capital</B>&#148;) or Related Securities (as defined below); (ii) effect any short sale, or establish or increase any &#147;put equivalent position&#148;
(as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act) or liquidate or decrease any &#147;call equivalent position&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(b)</FONT> under the Exchange
Act) of any Share Capital or Related Securities; (iii)&nbsp;pledge, hypothecate or grant any security interest in any Share Capital or Related Securities; (iv)&nbsp;in any other way transfer or dispose of any Share Capital or Related Securities;
(v)&nbsp;enter into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of any Share Capital or Related Securities, regardless of whether any such transaction is to be settled in
securities, in cash or otherwise; (vi)&nbsp;announce the offering of any Share Capital or Related Securities; (vii)&nbsp;file any registration statement under the Securities Act in respect of any Share Capital or Related Securities (other than as
contemplated by this Agreement with respect to the Offered Shares); or (viii)&nbsp;publicly announce the intention to do any of the foregoing; <I>provided, however</I>, that the Company may (A)&nbsp;effect the transactions contemplated hereby,
(B)&nbsp;issue Share Capital of the Company or options to purchase Share Capital of the Company, or issue Share Capital of the Company upon exercise of warrants, options, pursuant to any share option, share bonus or other equity incentive or
employee share purchase plan or arrangement described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, (C)&nbsp;file a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to the Share
Capital granted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to or reserved for issuance under any share-based compensation plans of the Company described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, and
(D)&nbsp;issue Share Capital or Related Securities (assuming the conversion, exercise or exchange thereof into Share Capital) in an aggregate amount not to exceed 5.0% of the Company&#146;s outstanding Share Capital immediately following the
completion of the offering of Offered Shares contemplated herein in connection with the acquisition by the Company of the securities, businesses, property or other assets of another person or entity or in connection with strategic partnering
transactions; provided that, in the case of subclause (D), each recipient of such Share Capital or Related Securities shall have entered into a <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement with the Underwriters substantially in the form
of <U>Exhibit A</U> hereto. For purposes of the foregoing, &#147;<B>Related Securities</B>&#148; shall mean any options or warrants evidencing Share Capital of the Company or other rights to acquire Share Capital of the Company or any securities
exchangeable or exercisable for or convertible into Share Capital of the Company, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible into, Share Capital of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Future Reports to the Representatives. </I></B>During the period of five years hereafter, the Company
will furnish to the Representatives, c/o Jefferies, at 520 Madison Avenue, New York, New York 10022, Attention: Global Head of Syndicate and c/o Cowen, at 599 Lexington Avenue, 27th Floor, New York, New York 10022, Attention: General Counsel:
(i)&nbsp;as soon as practicable after the end of each fiscal year, copies of the Annual Report of the Company containing the balance sheet of the Company as of the close of such fiscal year and statements of income, shareholders&#146;<I> </I>equity
and cash flows for the year then ended and the opinion thereon of the Company&#146;s independent public or certified public accountants; (ii)&nbsp;as soon as practicable after the filing thereof, copies of each Annual Report on Form <FONT
STYLE="white-space:nowrap">20-F,</FONT> Report on Form <FONT STYLE="white-space:nowrap">6-K</FONT> or other report filed by the Company with the Commission or any securities exchange; and (iii)&nbsp;as soon as available, copies of any report or
communication of the Company furnished or made available generally to holders of its Ordinary Shares; <I>provided, however,</I> that the requirements of this Section&nbsp;3(q) shall be satisfied to the extent that such reports, statements,
communications, financial statements or other documents are available on EDGAR. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Investment
Limitation</I></B><B>.</B> The Company shall not invest or otherwise use the proceeds received by the Company from its sale of the Offered Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment
company under the Investment Company Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>No Stabilization or Manipulation; Compliance with
Regulation M</I></B><B>. </B>The Company will not take, and will ensure that no controlled affiliate of the Company will take, directly or indirectly, without giving effect to activities by the Representatives any action designed to or that might
cause or result in stabilization or manipulation of the price of the Offered Shares or any reference security with respect to the Offered Shares, whether to facilitate the sale or resale of the Offered Shares or otherwise, and the Company will, and
shall cause each of its controlled affiliates to, comply with all applicable provisions of Regulation M. In addition, the Company will not engage in any form of solicitation, advertising or other action constituting an offer or a sale under the
Israeli Securities Law and the regulations promulgated thereunder in connection with the transactions contemplated hereby, which would require the Company to publish a prospectus in the State of Israel under the laws of the State of Israel. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Enforce <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I></B><B>.</B> During the <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Period, the Company will use commercially reasonable efforts to enforce all agreements between the Company and any of its security holders that restrict or prohibit, expressly or in operation, the offer,
sale or transfer of Ordinary Shares or Related Securities or any of the other actions restricted or prohibited under the terms of the form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement. In addition, the Company will direct the
transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements for the duration of the periods contemplated in such agreements,
including, without limitation, <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements entered into by the Company&#146;s officers and directors and security holders pursuant to Section&nbsp;6(k) hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Company to Provide Interim Financial
Statements</I></B><B>.</B> Prior to the First Closing Date and each applicable Option Closing Date, the Company will furnish the Underwriters, as soon as practicable after they have been prepared by or are available to the Company, a copy of any
unaudited interim financial statements of the Company for any period subsequent to the period covered by the most recent financial statements appearing in the Registration Statement and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Tax Indemnity</I></B>. The Company will indemnify and hold harmless the Underwriters against any
documentary, stamp or similar issue tax, including any interest and penalties, on the creation, issue and sale of the Offered Shares and on the execution and delivery of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Transfer Agent</I></B>. The Company agrees to maintain a transfer agent and, if necessary under the
jurisdiction of organization of the Company, a registrar for the Ordinary Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Amendments and
Supplements to Permitted Section</I></B><B><I></I></B><B><I>&nbsp;5(d) Communications. </I></B><I></I>If at any time following the distribution of any Permitted Section&nbsp;5(d) Communication, there occurred or occurs an event or development as a
result of which such Permitted Section&nbsp;5(d) Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and, upon the reasonable request of the Representatives, will promptly amend or supplement, at its own expense, such Permitted
Section&nbsp;5(d) Communication to eliminate or correct such untrue statement or omission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Emerging Growth Company Status.</I></B> The Company will promptly notify the Representatives if the
Company ceases to be an Emerging Growth Company at any time prior to the later of (i)&nbsp;the time when a prospectus relating to the Offered Shares is not required by the Securities Act to be delivered (whether physically or through compliance with
Rule 172 under the Securities Act or any similar rule) and (ii)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period (as defined herein). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Representatives, on behalf of the several Underwriters, may, in their sole discretion, waive in writing the performance by the Company of
any one or more of the foregoing covenants or extend the time for their performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Payment of Expenses</B>. The Company agrees to pay all costs, fees and expenses
incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i)&nbsp;all expenses incident to the issuance and delivery of the Offered Shares
(including all printing and engraving costs), (ii) all fees and expenses of the registrar and transfer agent of the Ordinary Shares, (iii)&nbsp;all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the
Offered Shares to the Underwriters, (iv)&nbsp;all fees and expenses of the Company&#146;s counsel, independent public or certified public accountants and other advisors, (v)&nbsp;all costs and expenses incurred in connection with the preparation,
printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Time of Sale Prospectus, the Prospectus, each free writing prospectus prepared
by or on behalf of, used by, or referred to by the Company, and each preliminary prospectus, each Permitted Section&nbsp;5(d) Communication, and all amendments and supplements thereto, and this Agreement, (vi)&nbsp;all filing fees, reasonable
attorneys&#146; fees and expenses incurred by the Company or the Underwriters in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Offered Shares for offer and sale
under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Representatives, preparing and printing a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;Blue Sky Survey&#148; or memorandum and a &#147;Canadian wrapper&#148;, and any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions,
(vii)&nbsp;the costs, fees and expenses incurred by the Underwriters in connection with determining their compliance with the rules and regulations of FINRA related to the Underwriters&#146; participation in the offering and distribution of the
Offered Shares, including any related filing fees and the legal fees of, and disbursements by, counsel to the Underwriters, in an amount not to exceed $20,000 (including the fees and expenses in clause (vi)&nbsp;above and excluding all filing fees),
(viii) the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148;, any Permitted Section&nbsp;5(d) Communication or any Section&nbsp;5(d) Oral Communication undertaken in connection with the offering of the
Offered Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants
engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and any such consultants, and the cost of any aircraft chartered
in connection with the road show, provided, however, that the Underwriters shall be responsible for the payment of fifty percent (50%) of the cost of any aircraft and other transportation chartered in connection with the road show and (ix)&nbsp;the
fees and expenses associated with the inclusion of the Offered Shares for listing on Nasdaq. Except as provided in this Section&nbsp;4 or in Section&nbsp;7, Section&nbsp;9 or Section&nbsp;10 hereof, the Underwriters shall pay their own expenses,
including the fees and disbursements of their counsel and their own travel and lodging expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;Covenant of the Underwriters. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Each Underwriter severally and not jointly covenants with the Company not to take any action that would
result in the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would not, but for such actions, be required to
be filed by the Company under Rule 433(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Compliance with Israeli Securities Laws.</B> The
Underwriters, severally and not jointly, acknowledge, understand and agree that the Offered Shares may be sold in Israel by the Underwriters only to Israeli Accredited Investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Conditions of the Obligations of the Underwriters.</B> The respective
obligations of the several Underwriters hereunder to purchase and pay for the Offered Shares as provided herein on the First Closing Date and, with respect to the Optional Shares, each Option Closing Date, shall be subject to the accuracy of the
representations and warranties on the part of the Company set forth in Section&nbsp;1 hereof as of the date hereof and as of the First Closing Date as though then made and, with respect to the Optional Shares, as of each Option Closing Date as
though then made, to the timely performance by the Company of its covenants and other obligations hereunder, and to each of the following additional conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Comfort Letter</I></B><B>.</B> On the date hereof, the Representatives shall have received from
Kesselman&nbsp;&amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited, independent registered public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance
satisfactory to the Representatives, containing statements and information of the type ordinarily included in accountant&#146;s &#147;comfort letters&#148; to underwriters, delivered according to Statement of Auditing Standards No.&nbsp;72 (or any
successor bulletin), with respect to the audited and unaudited financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus, and each free writing prospectus, if any. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;</B><B><I>Compliance with Registration Requirements; No Stop Order; No Objection from FINRA.</I></B><B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have filed the Prospectus with the Commission
(including the information required by Rule 430A under the Securities Act) in the manner and within the time period required by Rule 424(b) under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment to the
Registration Statement shall be in effect, and no proceedings for such purpose shall have been instituted or threatened by the Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and
arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>No Material Adverse Change or Ratings Agency Change</I></B><B>.</B> For the period
from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;in the judgment of the Representatives there shall not have occurred any Material Adverse Change; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential
downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#147;nationally recognized statistical rating
organization&#148; as that term is used in Rule <FONT STYLE="white-space:nowrap">15c3-1(c)(2)(vi)(F)</FONT> under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Opinion of U.S. Counsel for the Company</I></B><B>.</B> On each of the First Closing Date and each
Option Closing Date, the Representatives shall have received the opinion of Cooley LLP, U.S. counsel for the Company, dated as of such date, in form and substance reasonably satisfactory to the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Opinion of Israeli Counsel for the Company</I></B><B>.</B> On each of the First Closing Date and each
Option Closing Date, the Representatives shall have received the opinion of Hamburger Evron&nbsp;&amp; Co., Israeli counsel for the Company, dated as of such date, in form and substance reasonably satisfactory to the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Opinion of IP Counsel for the Company.</I></B> On each of the First Closing Date and each Option
Closing Date, the Representatives shall have received the opinion of Greenberg Traurig LLP, counsel for the Company with respect to intellectual property, dated as of such date, in form and substance reasonably satisfactory to the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Opinion of U.S. Counsel for the Underwriters</I></B><B>.</B> On each of the First Closing Date and
each Option Closing Date, the Representatives shall have received the opinion of Covington&nbsp;&amp; Burling LLP, U.S. counsel for the Underwriters in connection with the offer and sale of the Offered Shares, in form and substance satisfactory to
the Underwriters, dated as of such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Opinion of Israeli Counsel for the
Underwriters</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date, the Representatives shall have received the opinion of Gornitzky&nbsp;&amp; Co., Israeli counsel for the Underwriters in connection with the offer and sale
of the Offered Shares, in form and substance satisfactory to the Underwriters, dated as of such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Officers&#146; Certificate</I></B><B>.</B> On each of the First Closing Date and each Option Closing
Date, the Representatives shall have received a certificate executed by the Chief Executive Officer of the Company and the Chief Financial Officer of the Company, dated as of such date, to the effect set forth in Section&nbsp;6(b)(ii) and further to
the effect that: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;for the period from and including the date of this Agreement through
and including such date, there has not occurred any Material Adverse Change; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the representations, warranties
and covenants of the Company set forth in Section&nbsp;1 of this Agreement are true and correct with the same force and effect as though expressly made on and as of such date; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the Company has complied with all the agreements hereunder and satisfied all the conditions on its part to be
performed or satisfied hereunder at or prior to such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Bring-down Comfort
Letter</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date the Representatives shall have received from Kesselman&nbsp;&amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited, independent registered
public accountants for the Company, a letter dated such date, in form and substance satisfactory to the Representatives, which letter shall: (i)&nbsp;reaffirm the statements made in the letter furnished by them pursuant to Section&nbsp;6(a), except
that the specified date referred to therein for the carrying out of procedures shall be no more than three business days prior to the First Closing Date or the applicable Option Closing Date, as the case may be; and (ii)&nbsp;cover certain financial
information contained in the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreements.</I></B> On or prior to the date hereof, the Company shall have furnished to the Representatives an agreement in the form of <U>Exhibit A</U> hereto from each of the persons listed on <U>Exhibit B</U> hereto, and each such agreement shall
be in full force and effect on each of the First Closing Date and each Option Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Rule
462(b) Registration Statement</I></B>. In the event that a Rule 462(b) Registration Statement is filed in connection with the offering contemplated by this Agreement, such Rule 462(b) Registration Statement shall have been filed with the Commission
on the date of this Agreement and shall have become effective automatically upon such filing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Additional Documents</I></B>. On or before each of the First Closing Date and each Option Closing
Date, the Representatives and counsel for the Underwriters shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling them to pass upon the issuance and sale of the Offered Shares as
contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all proceedings taken by the Company in connection with the
issuance and sale of the Offered Shares as contemplated herein and in connection with the other transactions contemplated by this Agreement shall be satisfactory in form and substance to the Representatives and counsel for the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any condition specified in this Section&nbsp;6 is not satisfied when and as required to be satisfied, this Agreement may be terminated by
the Representatives by notice from the Representatives to the Company at any time on or prior to the First Closing Date and, with respect to the Optional Shares, at any time on or prior to the applicable Option Closing Date, which termination shall
be without liability on the part of any party to any other party, except that Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Reimbursement of Underwriters&#146; Expenses.</B> If this Agreement is
terminated by the Representatives pursuant to Section&nbsp;6, Section&nbsp;11 or Section&nbsp;12(i), (iv) or (v), or if the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sale to the Underwriters of the Offered Shares on the First Closing Date is not consummated because of any refusal, inability or failure on the part of the Company to perform any agreement herein
or to comply with any provision hereof, the Company agrees to reimburse the Representatives and the other Underwriters (or such Underwriters as have terminated this Agreement with respect to themselves), severally, upon demand for all <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses that shall have been documented and reasonably incurred by the Representatives and the Underwriters in connection with the proposed purchase and the
offering and sale of the Offered Shares, including, but not limited to, fees and disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Effectiveness of this Agreement.</B> This Agreement shall become effective upon
the execution and delivery hereof by the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Indemnification of the Underwriters</I></B><B>.</B> The Company agrees to indemnify and hold harmless
each Underwriter, its affiliates, directors, officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as
incurred, to which such Underwriter or such affiliate, director, officer, employee, agent or controlling person may become subject, under Section&nbsp;15 of the Securities Act, Section&nbsp;20 of the Exchange Act, other federal or state statutory
law or regulation, or the laws or regulations of foreign jurisdictions where Offered Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent
of the Company), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in
the Registration Statement, or any amendment thereto, or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or
alleged untrue statement of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the
Securities Act, any Marketing Material, any Section&nbsp;5(d) Written Communication or the Prospectus (or any amendment or supplement to the foregoing), or the omission or alleged omission to state therein a material fact necessary in order to make
the statements, in the light of the circumstances under which they were made, not misleading; and to reimburse each Underwriter and each such affiliate, director, officer, employee, agent and controlling person for any and all documented expenses
that are reasonably incurred (including the counsel fees and disbursements reasonably incurred) as such expenses are incurred by such Underwriter or such affiliate, director, officer, employee, agent or controlling person in connection with
investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; <I>provided, however</I>, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense
to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information relating to any Underwriter furnished to
the Company by the Representatives in writing expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any such free writing prospectus, any Marketing Material, any Section&nbsp;5(d) Written
Communication or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information consists of the information described in Section&nbsp;9(b) below. The indemnity agreement set forth in this
Section&nbsp;9(a) shall be in addition to any liabilities that the Company may otherwise have. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Indemnification of the Company, its Directors and Officers</I></B>. Each Underwriter agrees, severally
and not jointly, to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement, and each person, if any, who controls the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, against any loss, claim, damage, liability or expense, as incurred, to which the Company, or
any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, if such
settlement is effected with the written consent of such Underwriter), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or
alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements
therein not misleading or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed,
or is required to file, pursuant to Rule 433 of the Securities Act, any Section&nbsp;5(d) Written Communication or the Prospectus (or any such amendment or supplement) or the omission or alleged omission to state therein a material fact necessary in
order to make the statements, in the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission
was made in the Registration Statement, such preliminary prospectus, the Time of Sale Prospectus, such free writing prospectus, such Section&nbsp;5(d) Written Communication or the Prospectus (or any such amendment or supplement), in reliance upon
and in conformity with information relating to such Underwriter furnished to the Company by the Representatives in writing expressly for use therein; and to reimburse the Company, or any such director, officer or controlling person for any and all
expenses (including the fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer or controlling person in connection with investigating, defending, settling, compromising or paying any such loss,
claim, damage, liability, expense or action. The Company hereby acknowledges that the only information that the Representatives have furnished to the Company expressly for use in the Registration Statement, any preliminary prospectus, the Time of
Sale Prospectus, any free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, any Section&nbsp;5(d) Written Communication or the Prospectus (or any amendment or supplement to the
foregoing) are the statements set forth in the first sentence of the third paragraph and the first and third sentences of the fourth paragraph under the caption &#147;Underwriting,&#148; the first two sentences of the first paragraph below the title
&#147;Commission and Expenses,&#148; the first sentence of the first paragraph, the third sentence of the second paragraph and the first sentence of the sixth paragraph below the title &#147;Stabilization&#148; and the first sentence of the
paragraph below the title &#147;Electronic Distribution,&#148; in each case under the caption &#147;Underwriting&#148; in the Preliminary Prospectus and the Prospectus. The indemnity agreement set forth in this Section&nbsp;9(b) shall be in addition
to any liabilities that each Underwriter may otherwise have. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Notifications and Other
Indemnification Procedures</I></B><B>.</B> Promptly after receipt by an indemnified party under this Section&nbsp;9 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an
indemnifying party under this Section&nbsp;9, notify the indemnifying party in writing of the commencement thereof, but the omission to so notify the indemnifying party will not relieve the indemnifying party from any liability which it may have to
any indemnified party to the extent the indemnifying party is not materially prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying party from any liability that it may have otherwise than on account of
this indemnity agreement. In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to
the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense
thereof with counsel reasonably satisfactory to such indemnified party; <I>provided, however</I>, that if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably
concluded that a conflict may arise between the positions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are
different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on
behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party&#146;s election so to assume the defense of such action and approval by the indemnified party of
counsel, the indemnifying party will not be liable to such indemnified party under this Section&nbsp;9 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i)&nbsp;the
indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate
counsel (together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by the Representatives (in the case of counsel
for the indemnified parties referred to in Section&nbsp;9(a) above) or by the Company (in the case of counsel for the indemnified parties referred to in Section&nbsp;9(b) above)) or (ii)&nbsp;the indemnifying party shall not have employed counsel
satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action or (iii)&nbsp;the indemnifying party has authorized in writing the employment of counsel for the indemnified
party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Settlements</I></B><B>.</B> The indemnifying party under this Section&nbsp;9 shall not be liable for
any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim,
damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of
counsel as contemplated by Section&nbsp;9(c) hereof, the indemnifying party shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by such
indemnifying party of the aforesaid request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior
written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and
indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such
action, suit or proceeding and does not include an admission of fault or culpability or a failure to act by or on behalf of such indemnified party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Contribution.</B> If the indemnification provided for in Section&nbsp;9 is for
any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the
aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received
by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Offered Shares pursuant to this Agreement or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;above is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other hand, in connection with the statements or
omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the
Offered Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the offering of the Offered Shares pursuant to this Agreement (before deducting expenses) received by the Company, and the
total underwriting discounts and commissions received by the Underwriters, in each case as set forth on the front cover page of the Prospectus, bear to the aggregate initial public offering price of the Offered Shares as set forth on such cover. The
relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission
to state a material fact relates to information supplied by the Company, on the one hand, or the Underwriters, on the other hand, and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such
statement or omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses
referred to above shall be deemed to include, subject to the limitations set forth in Section&nbsp;9(c), any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The
provisions set forth in Section&nbsp;9(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section&nbsp;10; <I>provided, however,</I> that no additional notice shall be required
with respect to any action for which notice has been given under Section&nbsp;9(c) for purposes of indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the
Underwriters agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;10 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of
allocation which does not take account of the equitable considerations referred to in this Section&nbsp;10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the
provisions of this Section&nbsp;10, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions received by such Underwriter in connection with the Offered Shares underwritten by it and
distributed to the public. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
The Underwriters&#146; obligations to contribute pursuant to this Section&nbsp;10 are several, and not joint, in proportion to their respective underwriting commitments as set forth opposite their respective names on <U>Schedule A</U>. For purposes
of this Section&nbsp;10, each affiliate, director, officer, employee and agent of an Underwriter and each person, if any, who controls an Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act
shall have the same rights to contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of
Section&nbsp;15 of the Securities Act and Section&nbsp;20 of the Exchange Act shall have the same rights to contribution as the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Default of One or More of the Several Underwriters</B><I>.</I> If, on the
First Closing Date or any Option Closing Date any one or more of the several Underwriters shall fail or refuse to purchase Offered Shares that it or they have agreed to purchase hereunder on such date, and the aggregate number of Offered Shares
which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Offered Shares to be purchased on such date, the Representatives may make arrangements satisfactory to the
Company for the purchase of such Offered Shares by other persons, including any of the Underwriters, but if no such arrangements are made by such date, the other Underwriters shall be obligated, severally and not jointly, in the proportions that the
number of Firm Shares set forth opposite their respective names on <U>Schedule A</U> bears to the aggregate number of Firm Shares set forth opposite the names of all such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or in
such other proportions as may be specified by the Representatives with the consent of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Underwriters, to purchase the Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date. If, on the First Closing Date or any Option
Closing Date any one or more of the Underwriters shall fail or refuse to purchase Offered Shares and the aggregate number of Offered Shares with respect to which such default occurs exceeds 10% of the aggregate number of Offered Shares to be
purchased on such date, and arrangements satisfactory to the Representatives and the Company for the purchase of such Offered Shares are not made within 48 hours after such default, this Agreement shall terminate without liability of any party to
any other party except that the provisions of Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. In any such case either the Representatives or the Company shall
have the right to postpone the First Closing Date or the applicable Option Closing Date, as the case may be, but in no event for longer than seven days in order that the required changes, if any, to the Registration Statement and the Prospectus or
any other documents or arrangements may be effected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the term &#147;<B>Underwriter</B>&#148; shall be deemed
to include any person substituted for a defaulting Underwriter under this Section&nbsp;11. Any action taken under this Section&nbsp;11 shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination of this Agreement</B><B><I>.</I></B> Prior to
the purchase of the Firm Shares by the Underwriters on the First Closing Date, this Agreement may be terminated by the Representatives by notice given to the Company if at any time: (i)&nbsp;(a) trading or quotation in any of the Company&#146;s
securities shall have been suspended or limited by the Commission or by Nasdaq, or (b)&nbsp;trading in securities generally on either Nasdaq or the New York Stock Exchange shall have been suspended or limited, or minimum or maximum prices shall have
been generally established on any of such stock exchanges; (ii)&nbsp;a general banking moratorium shall have been declared by any of federal, New York or Israeli authorities; (iii)&nbsp;there shall have occurred any outbreak or escalation of
national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#146; or
international political, financial or economic conditions, as in the judgment of the Representatives is material and adverse and makes it impracticable to market the Offered Shares in the manner and on the terms described in the Time of Sale
Prospectus or the Prospectus or to enforce contracts for the sale of securities; (iv)&nbsp;in the judgment of the Representatives there shall have occurred any Material Adverse Change; or (v)&nbsp;the Company shall have sustained a loss by strike,
fire, flood, earthquake, accident or other calamity of such character as in the judgment of the Representatives may interfere materially with the conduct of the business and operations of the Company regardless of whether or not such loss shall have
been insured. Any termination pursuant to this Section&nbsp;12 shall be without liability on the part of (a)&nbsp;the Company to any Underwriter, except that the Company shall be obligated to reimburse the expenses of the Representatives and the
Underwriters pursuant to Section&nbsp;4 or Section&nbsp;7 hereof or (b)&nbsp;any Underwriter to the Company; <I>provided, however,</I> that the provisions of Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such
termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;13.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Advisory or Fiduciary Relationship. </B>The Company
acknowledges and agrees that (a)&nbsp;the purchase and sale of the Offered Shares pursuant to this Agreement, including the determination of the public offering price of the Offered Shares and any related discounts and commissions, is an <FONT
STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b)&nbsp;in connection with the offering contemplated hereby and the process leading to
such transaction, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its shareholders, or its creditors, employees or any other party, (c)&nbsp;no Underwriter has assumed or will assume
an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other
matters) and no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Underwriter has any obligation to the Company with respect to the offering contemplated hereby except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their
respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and (e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the
offering contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;14.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Representations and Indemnities to Survive Delivery</B><B><I>.</I></B> The
respective indemnities, agreements, representations, warranties and other statements of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of
any investigation made by or on behalf of any Underwriter or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive
delivery of and payment for the Offered Shares sold hereunder and any termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;15.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notices.</B> All communications hereunder shall be in writing and shall be
mailed, hand delivered or telecopied and confirmed to the parties hereto as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If&nbsp;to&nbsp;the&nbsp;Representatives:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jefferies LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">520 Madison Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, New York 10022</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: +1 646 <FONT STYLE="white-space:nowrap">619-4437</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">599 Lexington Avenue,
27th Floor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, NY 10022</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: (646) <FONT STYLE="white-space:nowrap">562-1269</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">with a copy to (which shall not constitute notice):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Covington&nbsp;&amp; Burling LLP</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">620 Eighth
Avenue</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, New York 10018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: +1 646 <FONT STYLE="white-space:nowrap">441-9111</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Eric W. Blanchard and Brian K. Rosenzweig</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Gornitzky&nbsp;&amp; Co.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Zion Building, 45 Rothschild Blvd</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tel Aviv, 6578403, Israel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: +972 3 <FONT STYLE="white-space:nowrap">560-6555</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Chaim Friedland and Ari Fried</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to the Company:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">UroGen Pharma Ltd.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9 Ha&#146;Ta&#146;asiya St.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ra&#146;anana 4365007, Israel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: +972 <FONT STYLE="white-space:nowrap">77-4171410</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Ron Bentsur and Gary Titus</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">with a copy to (which shall not constitute notice):</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="77%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cooley LLP</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">1114 Avenue of the
Americas</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, New York 10036</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: +1 212 <FONT STYLE="white-space:nowrap">479-6275</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Divakar Gupta</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hamburger Evron&nbsp;&amp; Co.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Museum Tower, 17th Floor</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">4 Berkowitz
Street</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Tel-Aviv</FONT> 6423806, Israel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: +972 3 <FONT STYLE="white-space:nowrap">607-4004</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Yaron Sobol</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party hereto may change the address for receipt of communications by giving written notice to the others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;16.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Successors</B><B><I>.</I></B> This Agreement will inure to the benefit of and
be binding upon the parties hereto, including any substitute Underwriters pursuant to Section&nbsp;11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling persons referred to in Section&nbsp;9 and
Section&nbsp;10, and in each case their respective successors, and no other person will have any right or obligation hereunder. The term &#147;successors&#148; shall not include any purchaser of the Offered Shares as such from any of the
Underwriters merely by reason of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;17.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Partial
Unenforceability.</B> The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or
provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;18.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Governing Law Provisions; Currency Provisions</B><B><I>.</I></B> This
Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this
Agreement or the transactions contemplated hereby (&#147;<B>Related Proceedings</B>&#148;) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State
of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the &#147;<B>Specified Courts</B>&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in
regard to the enforcement of a judgment of any such court (a &#147;<B>Related Judgment</B>&#148;), as to which such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service
of any process, summons, notice or document by mail to such party&#146;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally
waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding
brought in any such court has been brought in an inconvenient forum. The Company and each other party not located in the United States has irrevocably appointed Urogen Pharma, Inc., which currently maintains a New York City office at 499 Park
Avenue, 12th Floor, New York, NY 10022, United States of America, as its agent to receive service of process or other legal summons for purposes of any such suit, action or proceeding that may be instituted in any state or federal court in the
Borough of Manhattan in the City of New York, United States of America. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to any Related Proceeding, each party irrevocably waives, to the fullest extent
permitted by applicable law, all immunity (whether on the basis of sovereignty or otherwise) from jurisdiction, service of process, attachment (both before and after judgment) and execution to which it might otherwise be entitled in the Specified
Courts, and with respect to any Related Judgment, each party waives any such immunity in the Specified Courts or any other court of competent jurisdiction, and will not raise or claim or cause to be pleaded any such immunity at or in respect of any
such Related Proceeding or Related Judgment, including, without limitation, any immunity pursuant to the United States Foreign Sovereign Immunities Act of 1976, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of the Company pursuant to this Agreement in respect of any sum due to any Underwriter shall, notwithstanding any judgment in
a currency other than United States dollars, not be discharged until the first business day, following receipt by any Underwriter of any sum adjudged to be so due in such other currency, on which such Underwriter may in accordance with normal
banking procedures purchase United States dollars with such other currency. If the United States dollars so purchased are less than the sum originally due to such Underwriter in United States dollars hereunder, the Company agrees as a separate
obligation and notwithstanding any such judgment, to indemnify such Underwriter against such loss. If the United States dollars so purchased are greater than the sum originally due to such Underwriter hereunder, such Underwriter agrees to pay to the
Company an amount equal to the excess of the dollars so purchased over the sum originally due to such Underwriter hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All payments
made by the Company to the Underwriters, their respective affiliates, directors, officers, employees and agents or to any person controlling any Underwriter under this Agreement, if any, will be made without withholding or deduction for or on
account of any present or future taxes, duties, assessments or governmental charges of whatever nature (other than taxes on net income) imposed or levied by or on behalf of the State of Israel or any political subdivision or any taxing authority
thereof or therein unless the Company is or becomes required by law to withhold or deduct such taxes, duties, assessments or other governmental charges. In such event, the Company will pay such additional amounts as will result, after such
withholding or deduction, in the receipt by each Underwriter, their respective affiliates, directors, officers, employees and each person controlling any Underwriter, as the case may be, of the amounts that would otherwise have been receivable in
respect thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;19.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>General Provisions.</B> This Agreement constitutes the
entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two or
more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and
no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The section headings herein are for the convenience of the parties only and shall not affect the construction or
interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately
represented by counsel during negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of Section&nbsp;9 and the contribution provisions of Section&nbsp;10, and is fully informed regarding said
provisions. Each of the parties hereto further acknowledges that the provisions of Section&nbsp;9 and Section&nbsp;10 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and its business in
order to assure that adequate disclosure has been made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as
contemplated by the Securities Act and the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>UROGEN PHARMA LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representatives in New
York, New York as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COWEN AND COMPANY, LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acting individually and as Representatives of the several Underwriters named in the attached Schedule&nbsp;A.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COWEN AND COMPANY, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule A </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Underwriters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Number&nbsp;of<BR>Firm&nbsp;Shares<BR>to&nbsp;be&nbsp;Purchased</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oppenheimer&nbsp;&amp; Co. Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">National Securities Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Free Writing Prospectuses Included in the Time of Sale Prospectus </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[None.] </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Pricing Information </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Number of Firm Shares: <B>[</B><B></B>&#9679;<B></B><B></B><B>]</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Number of Optional Shares: <B>[</B><B></B>&#9679;<B></B><B></B><B>]</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Public offering price per Ordinary Share: $<B>[</B><B></B>&#9679;<B></B><B></B><B>]</B> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Permitted Section&nbsp;5(d) Communications </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[None.] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Representative of the Several
Underwriters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RE:&nbsp;&nbsp;&nbsp;&nbsp;UroGen
Pharma Ltd. (the &#147;<B>Company</B>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies&nbsp;&amp; Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned is an executive officer or director of the Company or an owner of ordinary shares of the Company (the &#147;<B>Shares</B>&#148;), or of
securities convertible into or exchangeable or exercisable for Shares. The Company proposes to conduct a public offering of ordinary shares of the Company (the &#147;<B>Offering</B>&#148;) for which Jefferies LLC (&#147;<B>Jefferies</B>&#148;) will
act as the representative of the underwriters. The undersigned recognizes that the Offering will benefit each of the Company and the undersigned. The undersigned acknowledges that the underwriters are relying on the representations and agreements of
the undersigned contained in this letter agreement in conducting the Offering and, at a subsequent date, in entering into an underwriting agreement (the &#147;<B>Underwriting Agreement</B>&#148;) and other underwriting arrangements with the Company
with respect to the Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annex A sets forth definitions for capitalized terms used in this letter agreement that are not defined in the body of this
agreement. Those definitions are a part of this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration of the foregoing, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the undersigned hereby agrees that, during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, the undersigned will not (and will cause any Family Member not to), without the prior written
consent of Jefferies, which may withhold its consent in their sole discretion: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Sell or Offer to Sell any Shares or Related Securities currently or hereafter owned either of record or beneficially (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) by the
undersigned or such Family Member, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enter into any Swap, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and sale of any Shares or Related Securities, or cause to be filed a registration statement, prospectus
or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">publicly announce any intention to do any of the foregoing. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing will not apply to the registration
of the offer and sale of Shares, and the sale of Shares to the underwriters, in each case as contemplated by the Underwriting Agreement. In addition, the </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
foregoing restrictions shall not apply to (i)&nbsp;the transfer of Shares or Related Securities by gift of the undersigned, (ii)&nbsp;the transfer of Shares or Related Securities by will, other
testamentary document, or by intestate succession to a legal representative, heir or beneficiary of the undersigned, (iii)&nbsp;the transfer of Shares or Related Securities to a trust whose beneficiaries consist exclusively of one or more of the
undersigned and/or a Family Member, (iv)&nbsp;transfers or dispositions of the undersigned&#146;s Shares or Related Securities to any corporation, partnership, limited liability company or other entity all of the beneficial ownership interests of
which are held by the undersigned or any Family Member, (v)&nbsp;distributions of the undersigned&#146;s Shares or Related Securities to partners, members, stockholders or trust beneficiaries of the undersigned, or (vi)&nbsp;if the undersigned is a
corporation, partnership, limited liability company, trust or other business entity, the transfer of Shares or Related Securities to another corporation, partnership, limited liability company, trust or other business entity that is a direct or
indirect affiliate (as defined in Rule 405 promulgated under the Securities Act), or one or more limited partners, general partners, limited liability company members or stockholders of the undersigned; provided, however, that in any such case, it
shall be a condition to such transfer that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each transferee executes and delivers to Jefferies an agreement in form and substance satisfactory to Jefferies stating that such transferee is receiving and holding such Shares and/or Related Securities subject to the
provisions of this letter agreement and agrees not to Sell or Offer to Sell such Shares and/or Related Securities, engage in any Swap or engage in any other activities restricted under this letter agreement except in accordance with this letter
agreement (as if such transferee had been an original signatory hereto), and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prior to the expiration of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, no public disclosure or filing under the Exchange Act by any party to the transfer (donor, donee, transferor or transferee) shall be
required, or made voluntarily, reporting a reduction in beneficial ownership of Shares or Related Securities in connection with such transfer. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, notwithstanding the restrictions imposed by this letter agreement, the undersigned may (i)&nbsp;exercise an option to purchase Shares granted
under any equity incentive plan or stock purchase plan of the Company, provided that the Shares issued upon such exercise shall continue to be subject to the restrictions on transfer set forth in this letter agreement, (ii)&nbsp;establish a trading
plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of Shares, provided that such plan does not provide for any transfers of Shares during the <FONT STYLE="white-space:nowrap">Lock-up</FONT>
Period and the entry into such plan is not publicly disclosed, including in any filing under the Exchange Act, during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period and (iii)&nbsp;transfer Shares or Related Securities (A)&nbsp;as
forfeitures to satisfy tax withholding obligations of the undersigned in connection with the vesting or exercise of equity awards by the undersigned pursuant to the Company&#146;s equity incentive, stock option, stock bonus or other stock plan or
arrangement described in the Prospectus, (B)&nbsp;pursuant to a net exercise or cashless exercise by the undersigned of outstanding equity awards pursuant to the Company&#146;s equity incentive, stock option, stock bonus or other stock plan or
arrangement described in the Prospectus; provided that any Shares acquired upon the net exercise or cashless exercise of equity awards described in this clause (B)&nbsp;shall be subject to the restrictions set forth in this letter agreement,
(C)&nbsp;pursuant to a bona fide third-party tender offer for all outstanding shares of the Company, merger, consolidation or other similar transaction made to all holders of the Company&#146;s securities involving a change of control of the Company
(including, without limitation, the entering into any lock-up, voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of common stock or other such securities in connection with such
transaction, or vote any common stock or other such securities in favor of any such transaction); provided that in the event that such tender offer, merger, consolidation or other such transaction is not completed, such securities </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
held by the undersigned shall remain subject to the provisions of this letter agreement, or (D)&nbsp;by operation of law, including pursuant to a domestic order or negotiated divorce settlement;
provided that, in the case of a transfer pursuant to clause (A)&nbsp;above, if the undersigned is required to make a filing under the Exchange Act reporting a reduction in beneficial ownership of Shares during the
<FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, the undersigned shall include a statement in such report to the effect that the purpose of such transfer was to cover tax obligations of the undersigned in connection with such exercise; and
further provided that, in the case of a transfer pursuant to clause (B)&nbsp;above, that no public disclosure or filing under the Exchange Act by any party to the transfer shall be required, or made voluntarily, during the <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned also agrees and consents to the entry of stop transfer instructions with the
Company&#146;s transfer agent and registrar against the transfer of Shares and/or Related Securities held by the undersigned and the undersigned&#146;s Family Members, if any, except in compliance with the foregoing restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the Offering only, the undersigned waives any registration rights relating to registration under the Securities Act of the offer and sale of
any Shares and/or any Related Securities owned either of record or beneficially by the undersigned, including any rights to receive notice of the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned confirms that the undersigned has not, and has no knowledge that any Family Member has, directly or indirectly, taken any action designed to
or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale of the Shares. The undersigned will not, and will cause any Family Member not to take,
directly or indirectly, any such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not the Offering occurs as currently contemplated or at all depends on market conditions and other
factors. The Offering will only be made pursuant to the Underwriting Agreement, the terms of which are subject to negotiation between the Company and the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power, capacity and authority to enter into this letter agreement. This letter
agreement is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
(i)&nbsp;the Company notifies Jefferies in writing that it does not intend to proceed with the Offering, (ii)&nbsp;the Underwriting Agreement is not executed before March&nbsp;31, 2018, (iii) the purchase of Firm Shares (as defined in the
Underwriting Agreement) does not occur by March&nbsp;31, 2018, or (iv)&nbsp;the Underwriting Agreement (other than the provisions thereof that survive termination) terminates or is terminated prior to payment for and delivery of the Firm Shares,
then in each case, this letter agreement shall automatically, and without any action on the part of any other party, terminate and be of no further force and effect, and the undersigned shall automatically be released from the obligations under this
letter agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter agreement shall be governed by, and construed in accordance with, the laws of the State of New York. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Printed Name of Person Signing</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><I>(Indicate capacity of person signing if signing as custodian or trustee, or on behalf of an entity)</I></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain Defined Terms </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Used in <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the letter agreement to which this Annex A is attached and of which it is made a part: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Call Equivalent Position</B>&#148;<B> </B>shall have the meaning set forth in Rule <FONT STYLE="white-space:nowrap">16a-1(b)</FONT> under the Exchange Act. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Exchange Act</B>&#148;<B> </B>shall mean the Securities Exchange Act of 1934, as amended. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Family Member</B>&#148; shall mean the spouse of the undersigned, an immediate family member of the undersigned or an immediate family member of the undersigned&#146;s spouse, in each case living in the
undersigned&#146;s household or whose principal residence is the undersigned&#146;s household (regardless of whether such spouse or family member may at the time be living elsewhere due to educational activities, health care treatment, military
service, temporary internship or employment or otherwise). &#147;<B>Immediate family member</B>&#148; as used above shall have the meaning set forth in Rule <FONT STYLE="white-space:nowrap">16a-1(e)</FONT> under the Exchange Act. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148; shall mean the period beginning on the date hereof and continuing through the close of trading on the date that is ninety (90)&nbsp;days after
the date of the Prospectus (as defined in the Underwriting Agreement). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Put Equivalent Position</B>&#148; shall have the meaning set forth in Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Related Securities</B>&#148; shall mean any options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or
rights ultimately exchangeable or exercisable for or convertible into Shares. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Securities Act</B>&#148; shall mean the Securities Act of 1933, as amended. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Sell or Offer to Sell</B>&#148; shall mean to: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell, offer to sell, contract to sell or lend, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effect any short sale or establish or increase a Put Equivalent Position or liquidate or decrease any Call Equivalent Position </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pledge, hypothecate or grant any security interest in, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other way transfer or dispose of, </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">in each case whether effected directly or
indirectly. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Swap</B>&#148; shall mean any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of Shares or Related Securities, regardless of whether any such
transaction is to be settled in securities, in cash or otherwise. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capitalized terms not defined in this Annex A shall have the meanings
given to them in the body of this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Directors, Executive Officers and Additional Shareholders </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Signing <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ron Bentsur </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gil Hakim </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gary S. Titus </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark P. Schoenberg </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors</B>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ron Bentsur </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Falberg </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cynthia Butitta </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fred Cohen </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stuart Holden </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ran Nussbaum </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pini Orbach </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arie Belldegrun </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Shareholders: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bellco Capital, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arie Belldegrun MD. Inc., Profit Sharing Plan and Trust </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pontifax
(Israel) III Limited Partnership </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pontifax Cayman III Limited Partnership </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arkin Communications Ltd. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d504802dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 5.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">January&nbsp;16, 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">UroGen Pharma Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9 Ha&#146;Ta&#146;asiya Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ra&#146;anana 4365007 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Israel </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Re: <B><U>Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT></U></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as Israeli counsel for
UroGen Pharma Ltd., an Israeli company (the &#147;<B>Company</B>&#148;), in connection with the underwritten public offering by the Company, contemplating (i)&nbsp;the issuance and sale by the Company of ordinary shares, nominal value NIS 0.01 per
share (&#147;<B>Ordinary Shares</B>&#148;) of the Company (the &#147;<B>Offering Shares</B>&#148;); and (ii)&nbsp;the potential issuance and sale by the Company of additional Ordinary Shares (the &#147;<B>Additional Shares</B>&#148; and collectively
with the Offering Shares, the &#147;<B>Shares</B>&#148;) that are subject to an option to purchase additional shares granted by the Company to the underwriters of the offering (the &#147;<B>Offering</B>&#148;). This opinion letter is rendered
pursuant to Item 8(a) of Form <FONT STYLE="white-space:nowrap">F-1</FONT> promulgated by the U.S. Securities and Exchange Commission (the &#147;<B>SEC</B>&#148;) and Items&nbsp;601(b)(5) and (b)(23) of the SEC&#146;s Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> promulgated under the United States Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection herewith, we have examined the originals, or photocopies or copies, certified or otherwise identified to our satisfaction, of: (i)&nbsp;the registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;F-1</FONT> filed by the
Company with the SEC (as amended through the date hereof, the &#147;<B>Registration Statement</B>&#148;) to which this opinion is attached as an exhibit; (ii)&nbsp;a copy of the articles of association of the Company incorporated by reference as
exhibit 3.1 into the Registration Statement (the &#147;<B>Articles</B>&#148;); (iii) resolutions of the board of directors (the &#147;<B>Board</B>&#148;) which relate to the Registration Statement and the actions to be taken in connection with the
Offering; and (iv)&nbsp;such other corporate records, agreements, documents and other instruments, and such certificates or comparable documents of public officials and of officers and representatives of the Company as we have deemed relevant and
necessary as a basis for the opinions hereafter set forth. We have also made inquiries of such officers and representatives as we have deemed relevant and necessary as a basis for the opinions hereafter set forth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted
to us as originals, the conformity to original documents of all documents submitted to us as certified, confirmed as photostatic copies and the authenticity of the originals of such latter documents. As to all questions of fact material to these
opinions that have not been independently established, we have relied upon certificates or comparable documents of officers and representatives of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing we are of the opinion that, upon payment to the Company of the consideration per Share in such amount and form as
shall be determined by the Board, the Shares, when issued and sold in the Offering as described in the Registration Statement, will be duly authorized, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of our firm are admitted to the Bar in the State of Israel, and we do not express any opinion as to the laws of any other jurisdiction. This opinion
is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the filing of
this opinion as an exhibit to the Registration Statement and to the reference to our firm appearing under the caption &#147;Legal Matters&#148; and &#147;Enforceability of Civil Liabilities&#148; in the prospectus forming part of the Registration
Statement. In giving this consent, we do not thereby admit that we are within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act, the rules and regulations of the SEC promulgated thereunder or Item 509 of
the SEC&#146;s Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter is rendered as of the date hereof and we disclaim any obligation to advise you of facts,
circumstances, events or developments that may be brought to our attention after the effective date of the Registration Statement that may alter, affect or modify the opinions expressed herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hamburger Evron&nbsp;&amp; Co. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Yaron Sobol</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Yaron Sobol, Adv.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d504802dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 23.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g504802pwc.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the&nbsp;use&nbsp;in<B> </B>this Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1&nbsp;of</FONT> our report dated
March&nbsp;8, 2017, except for the effects&nbsp;of the share split discussed in&nbsp;note 1d to the consolidated financial statements, as to which the date is April&nbsp;24, 2017 relating to the financial statements of Urogen Pharma Ltd., which
appears in such Registration Statement. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Tel-Aviv,</FONT> Israel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>/s/Kesselman&nbsp;&amp; Kesselman</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">January&nbsp;16, 2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certified Public Accountants (lsr.)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A&nbsp;member&nbsp;firm&nbsp;of&nbsp;PricewaterhouseCoopers&nbsp;International Limited</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g504802kesselman.jpg" ALT="LOGO">
 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g504802g03a96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g504802g03a96.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1L44&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 6#T.0         IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ /      0 " \     !  (X0DE-!"8       X
M    /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  $3   "8@         !                          $
M F(   $3                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   $3     %)G:'1L;VYG   "8@    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !$P    !29VAT
M;&]N9P   F(    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     0X0DE-! P     $(,    !    H    $@   '@  "'    $&<
M&  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)
M" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,
M# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( $@ H ,!
M(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)
M"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@%
M PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A
M\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!
M  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:B
MLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /0\;I6!;17;95N>
M\;G.+G22=7'Z2'U#'Z%TW'^TY=9;5O96-C;;'%]CFU55LIH]6VQ]ECVL]C%?
MPOZ)3_4"P_K+G_5W.Q7]-R>IX++*KZGVX]V377)IL9>['N_G+*]_I['_ *-)
M39Q_^:V375;1;0]N1L]+]+!<;6^K2S8YX?ZEM8WLK^FI;/JR++:G64MLQW.9
M:UUNTM+6-R;)W/'\W0_U7_R%REV-]7K<NO);U+I-8IR1DLH;FU>F &8E+<9C
M&T,V,9^S,?TK?\%^E_1?S?IDR,/I76,S-NKZCTZRS-:^649;7^FYXP6NM]1F
M/O?_ ,E4>QWI_P ]D,]1)+TUG_->N ^VB7&H "V3^G.S%,-?]'(=_-/_ #T[
M6?5AS'/;=CEC"UKG"X$ O)KJ:X^I_A;&^G7^^]<P.@XU;Z[OVA@@8[*F4M]:
MO8P4OQL@^S[/[FVVX7T?IU_:+?TMOITJB[H_U;-/V?\ :_3!MV"'9E7%;74'
MU*O0KW^I58_Z7Y_^D_FGI3VNSZM'*KPP^EV3:Y];*FV$N+ZAZEU>UK_YRIGO
M>Q6_V-TS_0#[W?\ DEPSL/H)N=<WJ_207FW<VS*HM81<<ASVNK?CMW[/MGMW
M?Z#_ (1=UB]8Z3F5VVXF;CY%6.)OLJM8]K!!=-KJW.;7[6_GI(<NW*^JE.?;
M@7D4W4 FQ]HL92-M;<JQGVNS;C>I7C6UWV,]7^:17/\ JHVZJ@W4&V][*ZV-
MMW$NM8Z_';['NV^O36Y]._\ G?S%A=1/U:R<W/S*.K],;=GNH>W*=DTFVHX_
MH/J;5+;&^AZ^)5=;2_V7H&%B]%Q\FAV'UKIY=CNQ[*Z1E4N!.-59B&RUK:OT
MEN33:[U,C^=J_1_Z.K8DO1MN^J1%LY&.ST'6,M#[=A::G_9[]PL>SVUW?H]_
MT$]K_JI3;Z-EU#;/4])S?5DM?L?D[+H?^A_04V6?I=BYZ_I'3,D9;']3P2[,
M?Z@/VBL^F[[19U+:UOI?IV?:,BYNV[_!?\6E?]7<)[K7OZGC-%K16T&^N&4B
MK*PVXU?Z!K?3;1GW-K]OZ/TZ?Y?J)5'Q>CK_ .:MH::K\:P/L;2PMO!FQXW5
MTMVV>ZU[?H5IL<_5;*R6XN+;3?<]CK&MJL+P6L+*[#OK<YGL?;7[5R]O3.@5
M955M_5>GML9=]H#+<JO:[WOO?5M?5]%UC_YSZ=7IJ>!C_5_#R,>UG7.F[:?3
M:\.R:+-S:_L.WVV5[6V_Y*J<VSZ;++K+*_3L92DI[+]C=-_T _SG?^22_8W3
M/] /O=_Y)'Q<O%S*&Y.'=7DX]D[+JG!['02QVVRLN8[:]NU&20TOV-TS_0#[
MW?\ DDOV-TS_ $ ^]W_DE=224TOV-TW_ $ ^]W_DE5ZGTW"Q\&VZFO9:P L>
M'.D$.;JWW+75+K7_ "9?\!_U34E/_]#T["_HE/\ 4"\%^MH;_P ZNL$C_M99
MV^"]ZPOZ)3_4"\=RNG_:/KGUG)>)KQ\RS8/&P\'_ *TWW)!2'H/U:P8&3U=G
MJ/YKP^&#^5DN;[K'_P# -]G^D71Y&<QE QZ&-IJ&@JJ:&,'P8P;57<!13O?J
M"=K6#4N<?HM:AOP+8W9+H<=?2:=&_P D_OID^6XSQRF1#I^E_B1]*./6HCBE
M]@']Z3&JQKF$$@.D[4'-P\7+9LRJF6CLXB'#^I8/>W_.1G58K&G]&T_$*N0!
MK3,#\T\?V?W5,(XR!&,B"/WQ4?\ &XO2O!F-3 &/]4\4O\7A]3S/4^DNP7![
M/TF,XPUY EI_<MC_ *#_ ,]=C_BU _YO_6C_ (H?^>+E2?77?4YMHWUO!:YA
M\/\ R35I?XOJ'XO1?K70\[C77$^(]"[8[^TU,(()!%$(-&C'6)U#P'3<%V9L
M8V&L:UOJ61,2.W[SW+J<3$QL:OT\>L,:-28ESCXV._.53IF,,;"HJ ]Q8'V'
MQ<X?]]^@M3&9#A/T9$_!-)MEA$1%]4N%CM-AM( #=>%8(ESGV.: 1)'GX!JG
M2U]E;RP!NX[1Y >U6<?#W.:S:"Z=3X#X),O%HU*^F8^7B^ADU,M8^3Z;A/\
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M#]:7V'<]]>YSO$FFXN7%9%?5<JWU;\;(<Z(:!38&M;^Y6W9[6KN/\7&-DU]
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J
M"  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P
M  $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD
M!     $   "\    Z  .RT0  "<0  [+1   )Q!!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$W.C$R.C(Q(#$W.C(Y.C(V %)2,3$W-3<R
M   #H $  P    '__P  H ( !     $   )BH , !     $   $3
M  8! P #     0 &   !&@ %     0   38!&P %     0   3X!*  #
M 0 "   " 0 $     0   48" @ $     0              2     $   !(
M     3A"24T#_0      "           _^$!2$U- "H    (  @!$@ #
M 0     !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P
M  #H   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3<Z,3(Z,C$@,3<Z,CDZ,C8 4E(Q,3<U-S(       .@ 0 #
M ?__  "@ @ $     0   F*@ P $     0   1,         !@$#  ,    !
M  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0
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M 0$! ?_  !$( 1 "7 ,!$0 "$0$#$0'_Q  ?   ! P0# 0
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M ]?O!])GTROV;_!U^2#FW\]&$'' >OWCCZ3/IEO+C?X.?R0<W#__ #0<(..
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M=*?ZJP,1X0\_%K^U?X@ON29^_J[/PA'QDIG_ $J7_P!J>_\ 6.80BGW*]O\
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MNF46XQMT4]!,!_2XDM2E,0]LNK !]A:YZZQ9Y#SR$.HDR4I?0V 8SJXB"A2
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M!X%WTYZ= ]SN01!8) 4+.U]+V)U?6^W/@8I9:E* CMDE:E!&X)W!-^Z@>@N
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M+KJ$+<0&@D%AP;!N5<E6[S]H&"=6#[Z-\6V/(N?*T2JZ>D4Z4C4,SLVC7/\
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MBIHT&2\XIY3)>;8)7OM=6ZWCL+6[6MUL">@'?&+*&<:C-ONW6XT<GR),407
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M'=EY$U*DRTHK*L )*5*6 E,LJ =)20[)(V?A&TIP?:>)H^7J.1'0V1%:65!
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M^OW?73@+W\VYB[[^OK#*9Z$>.Z^^O:K>O:$]22 W8+ O8E-@?9<"_4XFR[$
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MF/M;L9@\O!.S&$4DH !=$B9-"23F7,N27)9W-G &T?+_ +0,85C7:S&ZM9S
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MH=A/+]+)PZI[A3.=.MK=LJU+I[.@%OY<9HUT?4B<Z()M?M_+WPBAT/0Q@?\
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MIO\ ?J9$L#4+FH2KD"YU.O$\!&QH<*Q+$Y@E8=05M=,4X I*2?4  ,ZB925
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MTC/^SW:V(!4UA])>SGV3]G<***_M',178R.[,JDFI_\ 9U*P!:9*+"IFRE
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MZNBX)=0# J)6+2)86D(J$V:4&'!KI 5?K]8V$RLI"PJZ8I7?]U"7#O<-=/\
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M "?!]:/;[,9@3IQU'E^:?&,R)/A(-^7DS_)F+ZPM*=*86 2C8;@!"@1<_?\
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M:IZDBC4Q+K+:Z@\QM4>:_)D76XZLJ4JU@0$V$:N0JFE"6K():4NA"2P"E.Y
MT+[N-3L\>A=C4S,3_P#;%1,FU>)8Q-F+J*F>E)G3) 613I4<H\:9;!9 !(Z&
M+QIED9QI##"6C=26RI9MV4D= ;6!OTN+=;BYQR4R=WJB"2<KY=^>WH[V8Z7/
MT5A6')IY0F3@&E( 0DN0$D [F_%R^C[F)]Z4Z=-5>6VRH*3'BL[I2[]!L!)
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MI0%F20 I).;.!8OFT?4.1J=6BXP]'(\52'9;ZN<AP*198%E%6\]R3[?P >8
MW9PV2DI5,FY5@@AU:*VMQUVXQBG]LYT]"DHELA2<H4$YE\&-M+N6%RQXPZ5-
MICM/D,LQX+<MEI&WF*2@E"KW44GO;J>M_KNO3O,DRQ=*%!0#+L!J SFUK$[_
M  CEJJIESI2E+FKEJ6HN7;PW+'BYN.)&PCFO/SMWJJZ$%1'R"IW:FUR4CM?N
M>GSA)L;XHLK923+L0SGRL_0\O*T68?*IU$3A6K*Y8>ZM #HYL=!L]K1:FM'7
MZE3':C&AH:6ZGF-)0O:I!45 C:"/:#VZGKT\KD84N9*[U!3F-[G3R=G?1A$M
M?;)-+4IDSE*4E+)*SE)(ZD'CM\82U,K^;,@U,4:8>;37R&]JR5J0GH%$;K@!
M/?SMVN;6QA%14T2\DXZG*Y(N"=K</76QC9U&'X/C]-^MD,*A/[@8,26(8 6>
M^W#:%CF!,>IP%2$%M;+[:^<H(!* H6[=0%7-[CRZ^6,E4E%5),X*9?J^C<+.
M;6TC58<5TU4F653 I"F(42/"/=^8&AX1#;/=):ICJE-V*"IQ+84+703YW'E]
M;YD^>.=JQD4E(#YDW(^?F"?S7V;L_5?J967.72Q-[L2S _:WRAA,TQC3(D+-
M5(>3"S%ERITZLTFH)&Y4.;&FL!IP(O95]ZD+2; I)^2T>D09-3+5*)0<S.-0
M"3ROQ(+^5GR]KZ.DK^SN)TE7+*Y0H9Q0P%BE*E!*EGQ)"R+DG4QE/CNL.YD@
MY4R;GA+>=:S7H=8SQ2:S%3[D9@<K$*&9E,9DNL.H$E$5:TH22"A*^I]FU0A7
MZ@4M-634SU3!-GI4R@I"E!@,P+;BQ' ;1\XT9G579E..=H>SZIN!2<%71X+5
M4DXIJ<.ETYG9:A<E,Q!F2S4)!S92E1%QQ5? IG^31LRYJR=S>3'RQGC-.7&H
MOQ_5S1\PS(@:0M-@IMM*=J#>VT"W3H/<^R\U4W!:9!)4J4J:E:CJ2F84W.IL
MD#@WQ/Q![2*&GI>U5=.D)248A(I,1[^YF3S6R43RN9_"/?RY0!E(5&Q317_6
M*53WKW+D1A9^=2 ;]?:;XZ"."BZ80A':B?L?YZ_>=F;^A)V$5&HZCYQCV]#!
M]2PX'/N$Y=_G=1Q0:>9^9BZ9[QZ)_E$/OH%^V4X[?NIZ+_V:-*<7;#J?D(*]
MV7T5_,8F'BD6080@PA&E_P#1,EJKQK>CLRZ$[5?J5U+K:G5&X6W#S!0V%1^7
MY\PN)5N]@.,U.2F:DA.8OH0X-]XP5-I*^A^I_'B)&5840-1ML2,F[=T)6@J=
M!  6M"B#?Q=4BW8H]F-XLT\QA/ELS6 &C[&T<?-"+: G>YW_  &'[HACLL,@
MI<0M1"DI""KE 'NK:GKL58W(L4;A;&,RZ!08**+Z@L7LS'BS>?$$QAF2U@>"
M: /X2"WQO=RY&EF?DLW)DA"$,MR6V%WV(*D**FR@#Q.*+B1N;*=W:Q+ _P!<
M7E2:=,F65R*A)[RX=5[BWUWVMPC'(%4597"LM@2Q?[Z^M](B;Q;YK<C9=H.5
M$.?"U28NHRP'2M2F(2>2A=TK6=K\AU32K^$^K-FPV]?=_81A,^IQ+%,:JO'*
MHY<C#Z=2K@S9Q[V84:,4!"0>2H\=]M>+KD8?AN!E03-J:E59/ 8?L)1W<O1B
MV99(V=+V#Q;N"G)WK-0S1G>0PI?J"8M!@%#96\E^4/6Y[L=)0HEUEEJ,8ZTE
M)3.]4;Z!_KN?;WCZZ;#\*P*0@S#/G3:RI0"6[M*52J<+ US*[XLXL$%WC3^P
M[ I57.Q7%JA!!I9<NEDDC_UEK[^?,EWL9<I,H \#,'2=U?K](I*5H6PXU+<;
M4D\\G8X6TD+]7NR G>?6&81\S4:&2;MW'RR<0P^:C+/IS+66)*4D,>1U&C_!
M[1]/2:"GJ)LON)GCL&42 "V@N_YJ\,U5<YQ$MN*6XW+?<4IM,0,J9#H<<E!3
M;JTE'+$MZ=+,50_T<7,-%0"!!\&N_38;5*4)=;,2LDMG+!)?0%V8;6OJT=:G
M#9X"$"8DD(2"'W Y/P(UY\H8BO9G<G///N;)7K.\!Q+HW!#SKH0L-\Y*DHF/
MU@<TD;F&<\K00!2CR\$_ \2I4(K)6)2U!"R):3,NI#D)<.]TD'3<: QT>'_J
M:66E*9;^,I4PL6L;D7#L1Y0W<M+;R-JI,N4I.\(6[8+F /(<WR&E%1#4M<OU
MEY( *6JQ7!T]7(;C5.)X]3(,TRY<](<C+<ZVL'(8<>)O'1RILN:HIG4ZI;&Y
MR6<'4%CJ># CE"%-63%=]7;C("TI4HN23\(LIV%MZ<.5=3A26GYEP"'AF!)%
MTD8@RNT'Z@K568<M $MU&6A_$WB5IN7+@7U+1T$C#L)7*E+,Q<M2B'XZ GD?
MOMK'G&J[D=8<?#P*N6&RML.):*=FQ#VQ"2IQM"&1+OU]8AUA73F]8ZJCLY6W
M3+G29G\<Q:2G*O\ B+Z#Q9@=1;H]L[":>4F9^@JE J4HEU$?Q$DL;:W-[:VB
MN772\OE&2XTVAF[*#'4E2$BYY2EK?2%N,(:4XH_7+@J-OA4XD#"$+"308RI(
M+'NE3;*!#BQ^]V=XU*9>)(=2/WLECO<&^[[7Z0G93YDS>0MQS:M*ENAUQ-R$
MWVF_/6"I!;-K'J&D@=%6.5&&XY1K$^342YS/;,]P+:G\&O+.*ZIE)R5E&DN/
MX4N;A[;:'Z1T,"))D%AUS>2I8;5#62NP%DJ5;=M3WMTL0DBQQEEXKCE/-_UM
M#WTC-[OZ<*2J]W+ GCZOH(C)J</+A4A: 220$G=[N.' Z<WNGZRT_2UE18:2
MD-J1ZPI".7X3X"MOE'PMFY)MXD)4?;B!B.(8=,05JHS+?4"6S$NX'"_P^>TI
M:?#:D2335,R4I2B%%2FU(L_+SN&80B%U^&VLI 7SG4[)+Y0>0H DGE@I!0$F
MX-NY"C88A(E8)5#O4+RK6 )966R%@^6X8[:%N;&.@G89-1+S2JIU!O$%[,[B
M]^7#:+I3YB TX&Y+L$E>XMH>W;]H7UOS";)*G1\J0;7) QLIF'&G3(128NC,
MK4)4_P ;GX/QVC33S7TTMP L@O?*7'KS'3D\7VG4&)4742E++[>XI49 4XM3
MZ02D!6[XJ2IPGR5O=Z^/IM:.DQE,R4!-3,F+LI1()(V=_(_TC05O:"::>?(J
MJ8)6'RJ0&-N8)_-!#UTJG1X\-"%N#G(2AL( W#EW;=0DDI5=M;I4%B_Q'B#8
M'$J;43I<_N*FD5,EYRLJ4FV<C(22&VMP+Z:QP<Z=A\XK4OOD&876#F!400<W
MD=!9K$-I##Y[I":7F*3R4OIB2_UXSS@=UW;I?2I=@"4R% C:#9([ 8^YO8UV
MB7CW8FE3.)-3A$R?ADX*+DRJ1&>F47V_1SJ=.OO9[N(^!O;/@4G NW5>9"5?
MHL6DR,5ITH20A,ZK/<U*$LX!-3)J"1LDIT!$7NBUJ4NELD;5A@-L.!2!M;,0
MLF,L62+I6VW&>4+_ .EICI5_TM5_FKVPX+18)VVQ*1+'<)Q!4C%I2DC)X*^6
M/U1#,S5$F:A7-9W8#ZQ]C6,*[1>SW!Y_ZA:ZC!43\'FYE.O-0KSTJ2Y&M%/I
M9R=3WG>%R1'@_-2^L,O6C!! 90FZEH(#5R3<!18;BI5UO==/(Z\\[O+OTXEH
MM-*[L[_ N3;7SZ"_JE(NLE>\TSJSVWW.]QI8ML(:[5NE1:MI=J!38[89<D92
MKC"%NW6AHKITM*U)\162T&E!/7KZI%M_I$WJ)$]KJ2=2P]3K]/K%TX3)LF>"
M'&;ERU/#0Z<GCZ"WHP/J=G!7_LW:4_U4IV+(Y6)$\0]DZ$:P'V:<YM_BHLS&
M&?\ [2O_ !5_*8S4_P#ORO\ \Q.G6/F:QZ@TB?(4ZFZO67K$]2?A%=R>U^EO
MF\O+EB #X>%^+]?GU\H]-&=-A8>G+IRAPJ9/^%0ZA2MMA9)5N"+=[=;CV?YM
MBD79M!;@>+]'?DYWUB\2G55$HO=8"QYD63WM?V?(?+"+V>W&T=T1$R9S#:PI
M+3('@1U"E7]G2YO;M:P[]CA^:QF1X00;V8>=O+?KP$/CEM0BPU+N&E!)"24C
M<H@6%^O?R^;&0&Q#Z ,QY;->S7NWS@0& 5< AA^6ZVCBGQENU%"D-I==<?*E
M+<'^NJWB!Z;4W)ZV[7]IQ4*!#/?S?XG?^\; 92A*3[ILW'Y<./\ 5VZI5I48
ML0GV5-N)904J!24;-NRZ2GLD#I]\"W7%20 XON]V^._3J2VL14RTY2H*#YQ<
M7)N+?T^+@19*,WZS5$EQ5DEQ*P5=0 "%*M_$.N*(OPL#ZW^0/I;>*+?0&S#Z
MM^>EH=]:%I:CLL;7$I4@C9_Z114!XK&W4FQ)Z ?@$B6X+N0'!MO^6/PY11*@
MD7N6(?H'YV.O':+LW#2$)0&PETM;5["+E2CXC?R)!/7H+6-AB49F8$'G?3R?
MUN.L153%E>9*;$\+G74<^?(DF%'1:.FEAM]]Y*6]Y<#CQ +35P2IQ1LD^=NU
M[??. GQ#>_D6&YMM\;'C$Q!6M+9;FWF;-=N9?XP^>GLMZ;44/4Y*8U-N65RW
M@LNRE H*N4@64OJM6P6V$IZWZ'&#.25!V;^A#,Q/GS=GB69:9*4DG-FLH*+Y
M?(6M\N!!B54#+%(W^O.0R9*$H*Y,M0=D.@]2I*R=K*;GXJ$I/D;XO2H[W U/
MP_.=V<ZP%*4I:D@LG1@Y'+U+CIK#@44MA/)1&;Y2R$E]-MK?B!O:_4"Y)/MO
MBQ:VN+ML=[W^8!VZ"+@% @:M\>3DN.?.'HRS,CH4N.Z4K.U);\5]Q3W2GK8&
MWB!L>Q!-SBQ,XN $ZV>]APOPX;\P\1YLI9(4=!MK;FWWYZQYUNKAIE]QAA1>
M)6E2[7NT@V2D]R">]O;;OY9D@J?B[C7R;@S?>P:,7=CKP_IIT\V9XB#JQGI[
ME(CM.K96ZYLL004_!66+'I8CO?SZ8HOP).;5N;ZAM>M]-NL2*>6"2"+<3T)Y
M?VY1'(..U *0J]P%%#RR2D=";COXK_AQ%2HK"A=]!Y$<1K^&))2A%W<"S6:X
M8'A8[=&X0[V0\LU%Q#26'&G'"%%;DA/+2D&RKIN+*)2"/9U!]N+TRU&Q!<Z#
MZ]/G&LJ%H42&'JSG31M_6+OF;+[\J3ZJXPR6V %EQ;B5)*NERVV1YGH;=A<]
M ,2.Z)3?H1]V_.FD)2NZ"@]U,Q\PXU;1_K#,2X<B.KE-S'TI;D.$)+BBA"0K
MH&^OA'86%QM/LZ8MFHRD90$N'MKPN]N;?TC.LH6 Z0]@7W+#GRT9XM%4=DL*
M:4^OG!Q*D#9XEBR38J'?KM[^8)&(*RH'WBSOQ%@1K_31KQKURWOL-1Q?ART/
M]&AB,]NMN17^8C_6!)/6X)(Z'MY&V*=\H$,3?A];Z;<P(U\Q)!8,"X VUL[-
M?5G/'E%7Z.%MMSTC'#HK9XHN8\QN(-[A)=RG66"H?*4K4._8D=,;W#5J5J2;
M'5N'0:?6PUCG,3!"M=6MS=['ARVC<SUDER8FGN;G(Q6EW]3=:Y*FR YS?<^1
ML"">FXKV@7^>QQLYY(D3RG7N9K'4@]VJXZ:Q"H2@5U%G;+^KIQ=B \U !(-B
M [D;QK:Z,9?<F#3R1GVE4>OIETY$Y%3K,]R##RW$15IC1!=W(:DSI,Q0/(W*
M*5C<$BU\?.LV4A%=3KJ92)^91*9TRYEJ4H\&%RVM[7$?H>FN-/V3KZ? *ZJH
M)U++_23:>AE2ZF;B-:J0E2YG<@+,NGERP3G#!SJVF!76[)HR=Q;:J4!S,<7-
M:D9KJ$P5:.MQQLHFO*E-P[NK6I2HC3J6"O<4J".B;'JQ]*PI0=*DD A8+E :
MP!TV'/=X[?V9$XA*PZ:N4:4]R$KIEI&9,Q RKFJ_X%9OE&A+ZQ-+3AZ.U3V2
MH-E24MCI;<$A">YMT^0_\;GCZ9:765!U9@ESP)TUZ.P]&CZ(Q*G[N7+RE@M*
M$K%F5:SC?Y[\(E7D"K/1692*>ASGS4EI"DDC:I0M?IY];#OWQT-)-*$E2!JD
MI(#:$AR+%VMRO'FG:*DESILDU2OVJ=06_P#Q2+>$O9W_ #6'WRKDBLYHIK\2
ME0E2):G5>LOH0I:8:^:I)2XI(\MO8GIXNV-M2X<NH1^R@E"E>)5[=3?5PS\V
MC@<6QR@PN>)E7/,NE8]U+4K+-F)/\:!;-:[CB-8<*BY:5E2H-PIZF3.@V6^\
MZVK9?V(*@04CY">MK]L3Y-"BEFH*I:9I1<+4ERG_ +7(XC32WPYZMQ.7B].J
M?3!8IUVE("B)B@WO$.X9FTU+N(5>;*G6GZ5[H45IEQ(MS+!)%^B24] ;&UK'
MO[;BV,N,5E9W"5424JF!24Y2P 1E4[7&^4#1MM&C4813T<JH5*K.\0%!2L[N
M20I+!B_%1?;U%'E7+*\S-MN5R3R75K(4PVE25W("@D%.WIW[=+]+XUE'AM57
MRT3\0G=RZP A!\1(?6[D$._3A$C%\2&%S",/EIFIRD9B 2$DN27+"X2;:FU]
M(<"1DJ!14 TY;KJ@"' \5"R;75<DFZMP OU\/0XWZ</IZ4%4I16H) <WM8O_
M /Q ?[1SB,:J:Y^_3D3K;PW&HVUO"2JB)"VN4B$LI:6-RP"XGY?%Y>9]@]G;
M&,J>67 L;VTV/]@-3M&WI%2D!U35)$P%*4@Z*+%VY <X]H-2JT':46B1&D^-
M4E20V1:X-KDWZ= .MNMK8H*I2$,E.9C<:$!C<,[:L[/SBV?24DW.C),FS5BQ
M2"2ER/$XN!MK9^AAH<RU6B9IJ$UAQQ*Y3"' K:VH*201<I5;Q7)O=)%@3[<:
MJ=/E5<U2!+6%I&914DA+6%M+A]]O3L<*I*["Z>G6D9)*D^$K4?$<I.4 N'8<
M#H=&AM<X5*H98IT:/$#CL25MLZ@]&PE*3RU _76O>XZV(^0Q)Y5)0 D> FX&
MFY?KOKPCIL&IJ?$ZA:ZI2$S4#<-F=PSAM"SMQMO#>9KK-*S#E^,[L29K.Y#J
M5!)4JX!!%NNT$=/9U%^^(=0M&5)2 57?4D#GZGY<8Z+":6LP[$5RU%:I"E65
MME<V-KMNXY](WY\@0V<H5Q^4Z8R$QVGP4BQ6N/*8>:;2!W+SC:&@.Q*^QQ#H
MTK54I<LE*DOSN_IJ'V:\;['YB:C!\5IES4HE+I)Y,Q2\H&64K4C8.Y?X<<GU
M(GQ\WZEZ0S,EUR'E'.R,OY9J&=<HS8)<0^X6(WKRW7T,E!J#<5*0M3B0I*5)
M\0[XW$X)G8S(-!F$V7W2JDD$ R@H #FYS.#L!'S'ALJ?0>S_ !Q>/82O$L$F
MJJZ;!,4IZMER ZNXEIEJ4/V%3'4&205:0U_">YMUTU%E1E!,>H:HYTG"Q)0Z
M)699SA6!?J%GQ[A8$$=,>W=FD*E87+)2F6)LR>I.750,Y9OY^I:\?&'M'G)G
M]I9BI1)ERJ##:-8=\DZDI)4N9+(L 00"6&KO&T3E:QR[15>:J;$)_P#Y0/\
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M%)ES%RR$$KFW\3,0'V+FQ;3AIV=5V'_2]BZ3M)5XE3BM!654U"M*4]V9D[N
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MJ#:WY=#B5>QA2IDA"&GHKSDD\UU1WFQ!QP%$K]F91UO[(!RTB38+3OEV8"[
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M2#AM+V#[04=9V8_58A@^+8?+GU%!(3._54TV2CO)N(H6L&5-ES;E4G/F2"
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MVN0 ]M20^^PBD7%7M4ZW6W7>84I*RE\EX.$NDO)356@GGF4X7Q>R$U>J$_\
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MD+3S@E;:R+=7.8_*&Q-A8==Z Y?OB$J?A\^TVEF O<,$M?1@G1V_!&QES)2
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M<@K22% FX((!<?2,'U.T[@90T.XW\F.,@U++<O6F329*WBI=/RMGK*<;-$*
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M>/1/\HA]] OVRG';]U/1?^S1I3B[8=3\A!7NR^BOYC$P\4BR#"$&$(T//HQ
MCZ;/!:+=3I_J9U^3]4="Z8"Y XPC3)!N <2(&Q@9?=BR6Y,=U4>0RZV\R^TL
MI6TZVH+0XE7<.)4D*1M[* ((.*,. ^$5^'XX_+CY1F!X7.(.G9_R_%RQFNHQ
MT9WIB?5QSU(:<K4-H?K=]A);*77TL "590\75*>MQGE*4KP(=TVL3;R_!S$8
M%I4%I()9[@EF;JXW_M<Q-1#4&0C8A2$%?2WC)W'JFWQ; &WE]:!]=B6F95R0
MYEDLXNER>-SL1:YTUX1D,U,M220'&@9[ N]_1M"T)NO49;"4R6RE90.6\&^O
M+2?BGXR_"F^SL=NQ! \9Q]'^Q'MQF$_LMB$SNE)4:C"2LJR%R344[$L#?/*2
M +9@ ,J!'S;[=.R2J@R.UV'TZIJ[4N,2I88I0D!-+5L!P_;F+U RDDC/%#0I
MZHSZ8RE;67G$K0M:4_!K(2EPBZ%;2MO?M(2 '?5U 72JW1>VGL(G&\,5VAPR
M0N9B6'2PJJD2D_N55"@#,!E!,R;3 &9DNI:0M)%D1S/L3[>)P/$I?9W$ZE*,
M.Q68H4-0M;2J&KF/W8FDED2ZATRBH@!"S++LI;N.AU#"=BX[:G%-DN%*-KGQ
M=I4E;<5*02EQ2$$DJ D1!>S/A^/^Y6M:D*F(#*(8*=(+D%AH -+;1]>E2E#(
M"2FP# AP+)+:<[C6.'IT8K3\%N04J3O/0=>8>8GX%"@E0?>#*2?")B5=V\9Q
M35*5#NYH42Q "BQZNIFT!^HBPYDJ 8;<F  X:O\ 6!4V(]';3&E!L.-@D'=N
M62$ B_-1M2L**/8D5!72S%DXI\NK0H!:,Q!Y$;AP]]>'D-(E29B025G+=RWA
M)OH=R+DL-"':$^7'%+*_=!F1N4M1N0A2_$I0*]\OH7%*+CG3IZTXGL%8C3ED
MC*J0HD6TMP+#Y"_QUZ:1.I%(1GF*0 E%RZ,P;4E))8ZN1SM%OEO3T+2X4-E@
M]+-%E2UV6=A65K=L5A/,6%>$!^2.]KZZH&'"63W9[P^\,H++W'+Q/:R;,P,3
M)*94^8$HG)RZ#B0-"YN;,Y/6Y+&W!]M752%.K-O"ZW&!.T;DE8]67X[='+^$
ME#X'<8CRY5%, *9I!LX22X.X9.K;B]Q<1+"9TLE,E:52R5.2!8\GY^GE'9RH
M,*;"'(:G%)5=*TH2GXG8JM# N-HW6Z;D+5W7UF(HEI([JLEWN!F8C@/ANSO%
M$%:5>)*5#=V()'+0AO/76XBX-/L.MA24K0M"0G<IQ:@;)OL &S:4I(0" +[3
M:V"S64WN>)[D@D@F[GC>Y_'B29TLV7(;9PEG8ZLS=/F(J69<@+#S,E3@Z)+"
MW5!L 7'4EXCY.P(0IPV Z8NEE*T-44^11+A02USK<,;_  >XBU?Z90R!9"CH
MS@C1QKMIKQ8F*R!5:BU,+0C6;6/'MY3G, \6XJ4E>U+2@@+V]5 .A5P;8S4T
MC#D A4W+.8L+^6OJYN^D8)M/,,HRI$^Z]647.[$N'9M[0XM/JPDLM)>@N(<:
MVW=2&W+BX*5D& /]$$(#@-PXY'D$WW]9DR7*0I/=5*#H]V8_EFY\P(Y9='6R
MIF12DJ?3,'5:V][E]8XE2J<ZVZIQ?JR&[KNI3@+26@L(5<)0E?*#38L;[EP$
M="7SNS4DG$JB?+HZ*4:JLFSA34TM%^\6;,=03<7(/G$*KJ$X933*RN1(IJ>7
M3FIJ*J9, ERT!^/A2+'0"&+KM2359JO5+M0F2416#S5A*0 -PYJE$K<"$@V3
M<I2D&]AC[O\ 9UV2/8_LXBGJ5RQBM>M%7B\XA/AFA.3N$JL>XD(4922[(2I2
MPSJ,? ?M+[:3NW/:-=3(.7#Z *H\)IDDAY68JSJ0#E[^H4!,4MLRU(2@DVA6
M4BDKI4%4A]3;9>:$B2XMU+0CQD(W@K6XL;5MI4I9"P&N<IM9\8"L?,/M?[;R
M^U6/S*&C7FPG!%&32+2II=36*.6KGJ&BTLGNI2E LF6)@([R/ICV0=B/^E>S
MZ*VM3W6+8T$SJQ!;O*6C2 :6G2IB4J\7>3<K9C,4A0/=N,2_&'Q!KSO6WM/<
MHU0+RC2E\JN.P]HB5RN,/+6X&9""I<BFP%LLQF4@AIY;:'P"4((\>8; #R$>
MK%:U>\2VP<D#[EWB#O\ QO\ ?Z=?GZ#K\@]F)$6\MH,(1]@CT8/U.S@J_P!G
M'2G^JL#$>$//Q:_M7N(+[DF?OZNS\(1\99_=ZY*\71,E_I[?A'/XSV_R,(1R
M#:R@0E0%TD$ I)]A\NOR?>P.E].>G.*@D&Q(/+7TB:V@>KZY3+&4LP2[.(2&
MJ8_(6D!P-V"8Y-NBDCJ@W%QT]F-+B%*4H,R4 $EW8,UGLPY:^9WCJ,(KTS")
M$P^-) ?7-LV_]6)B;M%6V-KKAV>=P;A7FDA/0'IT*OGQI$. YNVY/F;DV<L#
MUMI'8(1=+#<7TW_/I#R4!UGHY'+CEU-=4@+6E1%U$*M<)'6X['Y<9 H$Z![;
M#R8<['3AO$E9R)(Y:MY;O?0DOY0XT^J-)C)0TCQEKQ+5T47$I\P0>M^]_P"7
ML)%]MV=N>T1DC.01?*02S;<?S^M'1&WZA+6TL+.^QW=VR;V"3>_M^]:_LQ'4
M'UUX[[-^?")Z"S:V =GV#\>8_+1+#(%0ATFE-(FI#4-KF>L@]5..(&Y(/F4D
M73UOT)]HQ5(=V+M9G(N;;E['GN!>(]0E2SX202+,6()=F8C?S.O!K;J/G%O,
M#D:-!<;:@1RIMJ."HW-K%93YGV#Y"+XOF^%"4BQ( 8#CL]@=2]OI&:E[R0DD
MI#WS/<LP=]].)):VT6*A1X4= 4XA*7%J"TK!L2L&X\C_ )'3MC&E(3S;CP=[
M_GJ2^.9/5,*AJX(Z>7QZ/9[0JG:PN8W'B-.J*&W-Z4BZEVZ)\/4] +@6^4=/
M.BE7  W TV#/\;/MO&%*6+D#3D^WY^"'=RJ51X#)3'3%994XIY;BBG>XJYW+
M1L\>[SO>_7K;&9!LX L^AWM;\X:0EJ_>U<.&#V&HMJ+-P:*&=F=F&^ZY[M*>
M*%K"HK2$(9L2=B@M!65$&WQ@D^SK:U^=9L1PNVQOPO\ +C:-M*964%(*OX2P
M)L]Q9_-^@:+Y3<RPX--:<=<2B3);4\=RBHJ6Z2=RE$*N;=#U'L^?(&(9KZ[7
MTU.OPV$8#XYC:Y3IMP O<VTZQYS\Y/14&6AU=RT V\RZD-)!(&T(;%U7'0BX
MO?KT[T4V0[68*!8ZL>'GNQUO&0J2!E/UL.3:<X24G-4^>XTZ$F,-P29+C:@5
M#ON2%J-P/8-H_P!V$2TMF=R"=W?XOKN+MSUB'-* [*>SV+ ]>/X\(^J5AQV>
MA:J@KF%12M]!W%00>B0$BR+#HFX-KGJ,7ACZ.+6Z\QSX;-$:9,&11;75_)[W
M/71XO,ROS8U-2J(M2D(;45*<>!+H((W%'?XQZ].H^7&=,MAU<; ,?QSPOI&O
M="E@* ;H_F]^'E:_&/V9,]R&'U7<1ZQXDI2";)W&QL!Y=SW[B_F3C*E)?1AI
MHVS:-&6=W24,FU@[69[[<+\=;V9XU9WS?RP^]4)20NZU@DV2H>77J![>_M(Q
M>PL -#P=M_+^MN6BJ)J X!<DB^^MSU LPC&+KGJ\7WY--I\P/*7O0I+:M_+!
M6!X+=3TZD7Z7))Z8V%/(S,HV V;4_5KL-FZ1I:FK 2I ]X__ .GU<%RUWV8<
M8A;.E.RUEY8<4XHW6M?4*)5?H3U[^72W?L,;$ )#"-02Y)XWBG-N2HCO?\'3
MR^]Y]+]O+%8I&<CZ')^JQ\//_9\Y'[YRI.N<(1]33"$&$(,(080@PA!A"#"$
M6:O,\^FOH/:Q)L;>'8H*Z_,2?O7\L44V53Z93\C^=(,^GQX<_*,#FO-)JK.9
M/2"TV"R[ZO,X?LIUJ,6T+^$G/T'4.!,;3M'5W;2XR 191ND7L,><XY+G3,5Q
M IEB^'TP):Y4'2'U=@5!).Q(Y1[[V'5(EX!V07-F90CM!BJU9BX"1/H5EA<@
MY_&#_P B5:DQB*TGI^9*WPJ:Y5;W/EMPLW<3&FB(,9;#K-J73,N&GR"$+2DV
M2_3U;AVZ)N"4@XY_!*.>*G#D*&4(Q&4H<&42,HU\))NGDY$>K^UG$:"HK\<F
M2IZ9B5]CJR62+^)4J0"_+(&/_(,.+9K^ _)TBF4>"5L%(6HK*2BY3X&6PDW!
M'Q&A?SM<8]IF%YJVLRYB3SRE+.>0+ ;"T?%*#90U&9QK9LR  79F2 .20+,&
MS;Q$I1&92GI9*"18CNJW;R['\'S8QJ_A_P#(1=TTB#?%C^S-P;?=S@?T=)QW
MO8__ .#=MO\ ]"F__P!LN.#[5_\ QCL7_P#KDO\ _J7$[$=OO_[ACA([R.^$
M(,(080@PA!A"#"$([43]C_/7[SLS?T).PBHU'4?.,>WH8/J6' Y]PG+O\[J.
M*#3S/S,73/>/1/\ *(??0+]LIQV_=3T7_LT:4XNV'4_(05[LOHK^8Q,/%(L@
MPA!A"-#/Z,1>1].+@O9W?"?2UU/<V=+E(S/E] 4//XY N!V)[WPA&FBGXH^;
M_P#'_'B1".UA[,(17T>LU*@56%6:/)>A5*G/IDPY#)\:'FEA78VNDGHM)N%H
MN.HQ4$IN"0>()'R@;B]QL_\ 7EPY1F@X<^)'*NJ=+C4BKE-.SU"BI$^&ZM"$
M5'D-IYDZGV/C;40E3C:D[VRV$[3?$^GF3Y[2A,39@,Q<^?Q9OP19H"#G5<.6
MW86##R=FW;:)@L,PIK02MP%E:5-J24A*@VM"@M1"EI2M2$A2PA2;*+:;]2#B
M7(K:S#*Q%33)5)J9$R2N7.22DDRE.5(4""D*8$D$/N;1#J*>FQ&1-HJF7WU)
M64\Z3.#. %)T((:P+!]-M8:VN49RE23RPLQ7#=AQ5D@@%5V5*!Z*3<J0I)/R
M'M;[:[ ]N:/M=A:<RT)Q6CERY5;2&Y)F(2#5 %PN5,2"5DV07#VCXB[>=C*K
MLEB4P4\I7^55:YD[#JK0$(4HJI5G^&=*%I>ZP 1RO5#S"75-QIK@<6VG8RMT
MDA>T!+(6#<E2MSHN>I/*O<I3;Q+VJ^RI6&S9^/=F*92Z%:ESJ^BEH&>D5,45
MKJ*="0"JG6HDJEI [FP0$I$>V^RCVIIQ%$GL]VCJDHKPE$K#JZ8K**M,L9$2
M*A9(RU"$I\,Q1_>U62LN;Q,G,$\@LMG:02I"3=71*2GJT0-S:W4('6S@:*>J
M$X\%11STD+$W*$,PSDY0-BI[L+/N?./HA*F.93K#:D97W=B'3>[$ IY&*8+C
MJ2M26E)*5<LE"%#;8E1Z<M(2-ZPY9(MLV#L,4G_J L?N@V!#EQ</Q;^O5XD2
MYJ"IE)&MG2"^[Z,]KV^\4\=,0D*+S94HK2H+Z  J3NW&Z>BAN2?;SKGXB;0I
MRY[']I1V!2X!<:@/H>G WWV2IDLRT9Y+#*&( #AK%MW&EMXHJ_',AII<66AL
M-$%P-.G<X47-RE+X!#A42 1V/;$6G2$]XF=3DYRHNI(.I=W(?AJ1>\;"CGTJ
M9B ,H\*=0 Q W8:V/W,)QL32HN*2V#V2ITA0-R >BG5>)0)NE1M=2S?H;VBC
MH4$K1+4ZE%13H 27VM8VMUYQLU397=J[E1W<9CST8\?/AL8J$E\72EI#I;"@
MDA12$*5V4KHM*P5 ;CV!WGN<6?IJ4KS%91,;PH#L0]G +<A;II$65-F*.>[)
M+,39O5M>+Q7P5L(;!?2(Y<)Z@73WM>Y1;>5)(5>P[GSOB5,1-"1D\3@ .Y8?
MT^$9369W2]P>)M8AOCUBM8;@A*FH\M)6XHK*%%=^MP?KD6N%@$#H$[O+IBQ4
MRM!!5*'<BQ4SD6X\O/T(BKL 2D/<OZZF_"YX><5RC4&F6E,K;*6?KD@$J22.
MA)=4?&DE3ER+%;HMTQA2)$Q3KE,I_?8!3/Q&G%W<O&66N1W@5G:: &1F-[!B
MSMS)9^!BH:S7(A7;<C.$MI 6ZE04D>8"DA+FZQ3UM<DI?)ON)-XPL5*Y:::H
MFSI\TM34R$$S)BCM9B=6&L*A"4!50N;([J53J545$^:)<N6-SF=@?EJ-XL-;
MS(Y4VA&B-\B/?X1/A*G=W*LE*N6BZ4H0TE0OU<2M7<DX^P/8_P"RQ?9V0CM#
MVB3WF,S"#04BDYO\OE$?[DQ)]^J7O,8A T:[?#'MH]JZ>T<R=V6[.S"C!*&>
M$U56%,G%9EB96;:D2;A)+3[%*4A@JFH$*,E9J51=;8BQ$EW>Z$A-V6W'"Z%W
M0A*8S;9=\0LI5D$VZ&[VU>TG_)*29V;P2>%8M5RC_FE2E3?HJ-8 -*@I4\N=
M.2^<I(*)7_>I.7![%_9NG%JV7VMQVGRX11S ,*IIB 4UE4AC^H6E0_=IZ=?N
M!0(7-3_P0I\?7%GQ7-UZ/4M,-.IJTTT.^JYES#%>4EJH(CJ0\JF4MQMPJ$(2
M$<J3()!>0REL%0=(Q\@CQ'Q-=R038EFU#W( #[L'CZUFK26R,PT+"PU %K7>
MVQ.F\8XCUN3U)ZF_6_4JZ^WQ$JZ^9)[XS,. ^$8(,5A!A"/L$>C!^IV<%7^S
MCI3_ %5@8CPAYN+;KPO<08]ND>?OZN3\(1\9.2=LV5TN!(>Z6[GF. =/X[8K
ME/ _"$=4+*U]0"+'R[??Q0AK$14@I,5D26]#=;E,+4RZRYS&G&U%"D*!LDA2
M2"#\MQ\N*$!0RD.-&-Q\#:*I6J6K.@D*%P06+BXN+ZQD;T"UKI&<&(^5LRO(
MBUY" S#EN+#<>8A"5 )*U]G;#K<W4?B_)SU=1=T<\H,@V+!F&]M/A<M'?X+B
MZ*@2Y,\M,"'_ /(C<FY+L[;!V<:3GIDP4UEE#!2E9(*RAN_0 6()(W!23T4+
MD?)B $MQMI<V;7IS&D;^8DSC:WV=^/YS:+F)LJJ2VVP+[N@ 04FW;M<W/EUQ
MC7Q\ASXGY?6\9I20@$,!8ZL>G+Y\(??*=/CLJ;:*0A:DILXK_7/0J/M"38^T
M$6QC(<%]&O\ GYQVBQ18VLS:6TV;?9OA"VG2T);++*TH8824KZ"SR[&ZS?I8
M^1\NA&,DM-G.NOGJYTOI;RC'G8N/X6.QTT9SI?3^D-:Q/'K:W-REI+RR/$%
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MBHU'4?.,>WH8/J6' Y]PG+O\[J.*#3S/S,73/>/1/\HA]] OVRG';]U/1?\
MLT:4XNV'4_(05[LOHK^8Q,/%(L@PA!A"-"#Z,3_9YX+/N1:J?UPRWA"-.4=O
MOG^4XD14_0?(1SA%(,(16TNKU*B5&+5*3-D4^H0G.;&F1G%M.M+"]UMZ2DE*
MK64F]E"X/3IBJ24ETDI/%-C\1>! (O?D;AHRA\/7&53*GZEE34]]NEU=QQJ/
M!S%L2W39BK(;93/L?UK(=6=BG".41U)"B1B2FM7F0B9X@D  JN3S<O<Z=(PJ
ME"^3P$ESE+7-B6'KO\HR"K<AUVGMO)?8GPWDI#3T=U#C3B%I2E+S#B%+;42-
MY"DGMM/;ICK>S_:&KP'%J7$\-GB1,EH2D&7[DQ)_WJ:I2" 9:@X&9VU CF,?
M[/89C]!/PO%:;OY:\RT'W33+8B342%:B8A_%E(4JX+C5OJC3)-,<W*39"@%M
M.I))220I 7TLA8LDFQL""!\7'V1V/[;X-VRH%]Q,0BN1+3*K<-G-G"R@":J1
M?]Z0LY@C*X"&=P\?&G;/L/B_8JOEA05.H5+5,H<4D@F6L)6.Z$PI_P#=ZA+)
M*G(!6"4G87&#6TI06)S(<N;B0;!7P93M05$$^0)4"3NZ]R3CR_M][&TU<R;B
MO9%"::H94RIP<L))"G4M=(S)2LEVD 93_P"FS!,>H=@/;1/H4RL)[7+F55(H
MIE2<9NN>E:<H3*K'=10 ;S7S'WYAU,>S\M*E$MMV;D)"@IM9-N8HA-^EE+3L
M+/\ UDI-[C'SC6X+544Y=/5HJ9,V2E2E2JF29?>$644$L2DD.G3:/IR@Q&DQ
M"FE5]%-D5$F:4!*J>:)Z$@@93--P%@$%5K$'>\>34>(V5A3:U*VKVE(*1=:]
MVQ5R";7M<=P+CV8TREU)#A0 /NH+>%+63OH&&D;K]8M@E0!RC+9BFUK<K6Y0
M.TUI(4MN0Z@DA6PJ(2VI5MP OU2@^%-QT%O*V**JIB@$]VDD !\H+Y;:M>]]
M-+QEE5,MW,AU6)('3>]O+<6:+3S.2\6E2[V4=H/UPN;?7V/0W\KW.(DU6_=%
M]2UK[\F_-WB?^H0F66)2[Z6;W>']-Q%S]?3'25 MF^VR6U(6K<>X-B>@591%
MNZB"";XCIE(G*"U'(4]0H:#4 $$?/J8QR:HY2,QZ@D\K^7RZ&/14V"H*)A]2
MGJ'+[;JZ%0)1:Y[V'RV]N+FF:2IXUW)T!8<QYW?3>,B9MSN7<;<WTOYWBB1#
MI[ZPA*UI<O?X,D<L'IU5T^-\0I'A%[^6)B36@!2EI5+:X4 4LPU!UMK\8O7B
M"U#NEI _A''@&;UO"H*FX%.<#CR=O+.PJ<(<<N"HW"3?<KP[DV'QECJ+XW&
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MYX+*3JODZKYER[2N$7-3M3IF8VJZ*.WF)>976F4UV,IQF*_5$15DQ6*H''T
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M_:##B/7[0>^<XJ?M;FOGX\N#/](;"_ ?$_:##B/7[0>^<XJ?M;FOGX\N#/\
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M_:##B/7[0>^<XJ?M;FOGX\N#/](;"_ ?$_:##B/7[0>^<XJ?M;FOGX\N#/\
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@H<R?2*@EM+S?ZXI\V3&420AU5B<!I?G\X'6W ?(1_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g504802g04e65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g504802g04e65.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[23^4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    '@X0DE-!!D       0    >.$))30/S       )           !
M #A"24T$"@       0  .$))32<0       *  $          3A"24T#]0
M    2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M 0!:    !@       0 U     0 M    !@       3A"24T#^       <
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #00    8
M!+    1J    !@!G #  - !E #8 -0    $
M 0             $:@  !+                       0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P  !+      4F=H=&QO;F<   1J    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    #CA"24T$#      :IP    $   "7    H
M <@  1T    :BP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ H "7 P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M+TOTC.1_\<'ZO_\ SG8'^=5_[P(C/KST6S5GU*PCY[JA^7 2]R.]#[$B,CH
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M/'YQ_P"^A'<V" /F5-M@?I6TN\^ IUUR27Z*,NCAC$:1%!$QFL!L^:(ZIYX
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M_2-=^BL^DU6&]=Z4\MK(LWO<VMK=K@[<X[&-VEGYSD>"7;\0L]['T)_Q9_\
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M?))2VD1&G@DG222__]D .$))300A      !5     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      2Y-30 J    "  '
M 1(  P    $  0   1H !0    $   !B 1L !0    $   !J 2@  P    $
M @   3$  @   !X   !R 3(  @   !0   "0AVD !     $   "D    T  M
MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R
M,#$V.C S.C$P(#(R.C(Q.C0P   #H $  P    '__P  H ( !     $   1J
MH , !     $   2P          8! P #     0 &   !&@ %     0   1X!
M&P %     0   28!*  #     0 "   " 0 $     0   2X" @ $     0
M            2     $   !(     3A"24T#_0      "           _^$!
M,$U- "H    (  <!$@ #     0     !&@ %     0   &(!&P %     0
M &H!*  #     0 "   !,0 "    '@   '(!,@ "    %    )"':0 $
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M 1$  A$! Q$!_\0 'P    8" P$             !08'" D*  0" PL!_\0
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M5([].;-(4N43DFC*KPJ ?*H))*2TF VQ@=HK7*D+F)GRT]XJ1/E+DS>Z)83
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MV&VILW9F*ERD_P"*+'Y7$RL1)FX:=*!!FS)4_.)9,M!?(HI424 #QI>"7MS
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M>[6F62".[04M$&S^T6%F[*&T,9,[HRU)EXG)(G9$3)BU"6F6,JBM.7*,R5+
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M_P#BC/SZ^.S_  $_#C_SF]\/]VZ/R_X?_P"H=I_[39_^^#O.TW^6V-_<8O\
MXHS\^OCL_P !/PX_\YO?#_=NC\O^'_\ J':?^TV?_O@[SM-_EMC?W&+_ .*,
M_/KX[/\  3\./_.;WP_W;H_+_A__ *AVG_M-G_[X.\[3?Y;8W]QB_P#BC/SZ
M^.S_  $_#C_SF]\/]VZ/R_X?_P"H=I_[39_^^#O.TW^6V-_<8O\ XHS\^OCL
M_P !/PX_\YO?#_=NC\O^'_\ J':?^TV?_O@[SM-_EMC?W&+_ .*,_/KX[/\
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M5+$QAG$LJ 449GRE0!9GK!_ZKQ)&=$$5(1],,\")SCPT^+C *C<;7V; )89
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MNS^'M[]#->G7!^O.#(>'O](UW^F+^ F/[?AM\7 //'Y)[.$G&/;'=G!]_O\
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M?#&>]"5+-;,5>%(L[6(>IK44M_;C29S(UAH65O;='(<*,@$'S"1QG!;!+?<
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M(F> T/\ 4?@WTA!-6>'_ +EZ59S5Z?EKJ>,$FIMKK5QE#M;=L1FG7&?8Q_Z
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MU.TTJK'(PVALY])*\%EPVT# & N0<DX*JV%O>(I(<$$DAFL;>UR_$;HR)>1
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M&D &XIMR=W)#J0Q./8CV.?YR/<](6<IT;<QO8?.]7K#Q4T>@J2'L'.]QI[-
MC14DU7+#%%#(\LK^D1[=SD$*!DA2Q.[  P0,X!]NH5N@%1\(:Y-_E3Z.U(GP
M\F9.6B6A*E*6KPY14FP#D5<F'O=H>U"6NEAO%TA#UTL:S01.BL*9< AQN0@,
M>2!D^Q)7!4]<QC<8N:L24N4$M4T:HK4OT^Z/H'L/V3DX.7+QV+2%SC^D$C-)
M6&((<5<4(=B]7H8=+1V]XP%C#,N00H7*X9]N[@#@#'#<#('68F02M0! "2H&
MK U(I?<U:&A:/7I67*@*8Y4) L3N=GYNS#6#=048=2O ,8 .0JG.>257.']/
M!]F&/8CJ52<B1J$W(U?XWMIOARYF514%D.0S*K4 :'KX[6\QQ!&X;.Y6VC!C
M(]0#98XY.XJ<MD9X8CH(HZM06S6#:E]-?I>+,J:@J)42?"7L27#,7/D0>4!5
MRE3RRJY667S P#,#NQZ2/FY (SD\>^!N)Z:I)2G-G27<!(+I ;04JW"-60E2
MB$I)0K0/E41Y$WW;Z@4> VV6]YB\I4F11(5#+ZBN\KNSG.[("KG@Y7'M@Y$P
MS$J5W=3_ $U*7&I'/@28[W9V9,F45Y@6+%55"X-:L3Z4@QV^RS2I)#M\UPLA
M;.PE#M*J$8A@H"_+(4@AFRC;.HTS5NXE*87\14*M8&@U^&^'8F>0QSD ^%TJ
M<\B'=J-NOP;Y:Z!@Q$XCD&_ ](VKM=2,%U4(S+YFU7W [B_!;>U^4Z@3^E#)
MRI4]&%6&@=Q2_#7*Q<HI1G27"FF'>"05$!MQWWN2YA08;6KQ)!"J$/M;D@,.
M5'!"OZ0X79CWR""HZL $.30/4 ,=>%-!O;E&3+QJ4K(7F*2X OI>[7I]:09K
M31A 8ZM51C_@V&W]+A-I&[];U*QV.2P.XD;T<=-H7<WI1QYN]G%J'6C!G3$J
MF$S$50 2Q_4&!)\(MN<4#,*1O5]N1H$E5=DB*1'[[PRLSECZ_2/LH6Y!3(<-
ME1TB4I0Y #/XG !=BQ)KNK"X<^-BIG>A/ZG/N6YGXP&T-":F$B<>=*[LJ;4?
M: 51DC+F-2VS?D%-B;V*QYQD*2X#!*15RD 6:H84X5&E83'H1+F([@+ENEBQ
M+%89S2FAJ:D&L!=5I\M,S!,.H8*,[E]F"E@#@@#:3@%AB,$\8 %:!0(W"_.U
M+MJSQ5F+\(!%Z*\-11R:U>G.K[HV(K2SPM')'RF%D] )=%!?> > &! ^?"$<
M#'5F5+4N60["ANVI]?C&7B4)SN 0EZ48N P?XW]-4]U-IJGJ$G@JJ.*IHIF>
M&6)PA66%L;DV8.Y#G&2!P WI7W):52IF<%@""6)#BHJS6+:^IC.Q6S\-C</,
MD3@E2)@5F2L!3$AE*"59AFRBXJ79VM&5WR[-/H2X&[VF&2?359((@1F0VNJ=
ME<4\KAA^B<$F&0G(7$6"VT-U. Q@Q1RK8$4%G;C5^+ORCY5[:=DU[#QDR;AD
MJF8*:ZTJ8_PQWC!VH'MPH"=(;?40,<*0"@?D$C;@+D')XS[KAC^& 1SJE!+$
M* &9C7< ?J(\_6"[;C8D,;V._3[0%L@0CW!99 QV_;VLH7AA[A?L'[_Y\!":
M&]RP'%]:CZO?2NK,@U#<""U#QLP:VK1:I^B#,A^)3WR"EO\ ZQWN,=I(.,=^
M?#3G.">03Z?;()(S[]!4DT!);0]-[/=XBG-E!!=R/1CIN!H(]'#I(KQ5&^F%
MJ&^&=V/#?9/CH[9;N<<?V!/$SSGY8.#_ #='1AZ+GD?E'FZQ%0J^4&X/I)^R
M23S@Y/L<YX^[CI'U8];N>D.RDER6TIN@32-I<;?<G@L,#:#R"5^?'&??\,].
M =@.N/#00X!J"%1[9=N+[W'U!2:>M$$DBLZM45)4[*6G#H)'9MN <'V)'.!\
M\BO/Q"9*0%&M<H9ZGH1?V?@9F.GIE)S!-U*9Z:LVOH]N(FI[4>'RP:,T_3VF
MWTRM5F-?KE<45YZBH*G<3* 6 'L.<<8SCV=L[''"3>^()F+4%6!2$@N+DD68
MM?C1^]&Q<-+PTN7D+*2?'<N[>*UPYWZ-I"NTG:^2EY,15$Q]K:-OWEB3PV/L
MC'\W..O4=C]HY,U21-R)4HAUDBIH26)-Z[O4O'(;7[. )6J0@E1\1 >Y(-P+
M5;A [;]$0ABNP, =IY!'N#SGD9]\#_X]>GX69@\0E(ES4GPI.4@%R:L"ZAY?
MM'"3\)B9!*9DE:2[.V^VNZM@>0@R4>A#(0R(H/OZ4&."PP<8/R]P&.,$GG U
M0$2TC('H#0:AZ:5I<TL+&*+*+YG %"]J#<[G7]H.5+H6)5!,>YFY/IR% &#R
M?8'CY#V^_GH*1,8K0;?TCW8Z^?E"(FI2^50 HX/G8,6ZOIO'1<4(4[ %!  9
M>!QR1R/^?_3U"G#ID$J2DN:'Q"U[>6@](D[W-1\WN:>5N)/-HTKAI*%X)$:-
M2"AX9?V^QW8'&?\ 1U%,E=ZE>9)R@YF#$DU;0!M*D$-YQ8E+5*5F20%4+\ ;
M;PX9M\(;3P5VD=42K3DI2^B5Q]I6!8$J%]O5[GV/.[V''CW:;!F1.5EEN%J)
M\09(H.#AO,N&M6/:.SV*.,V=+3=<LL U2X-:&NM&>'$T^M[#J.RI2^6$G@&Q
MS(H4C )X].X<>XW%?NZY.9*ERTA25YUEG<NW #<.(U:K1U,C"S0I*FHX<#CT
M_J(+>U WEQ!2H^R>,8]QSQP<_A^SJ'-4W'F7\M/+@T=%(D^).9VJ1R^HWVW"
M.OZC$C&50%(R1@$GY9S[@C_)S^/3:]=;NC%F;*%SZ"X-+[M6M6U(^2Q *QE1
MMF,!B#C)/I]\#GG&?\@^2%0'\P^+<^6L'=E"4@!W4DC+I>ATI8MI!7KJ6.HD
M;8NX8&YE&[''R(R.!D<X]OF.LG&%:E@#](:N\7N+>FM&-8MY"E#JN6I4M5.A
M85;S@ J+6D;>B(;F.2Q]*X;Y<XSQR<CV]P?;J67)2)9*B,Q!#=#IJ7BO.(4X
M.8%BQ#9A05 .O,:TWPUKQ =C;)W-M$Z/$M+?::.0VVYQ*ID23:WEPR28+/ Y
M5058E02#QZ=L*3W"RDN4+.93?J ;*&L+@D^E8X_M!L"7MB5_!ED8F6ETS7 *
MC6BRQ=SN<V'$0TZLTK=-(7NOT_>:>2EKK?*T4BN,+(N 5GB8@!XI5]2$ 9Y4
MX8'JZE0L+:&G&Y?A2/&L3AIV$G+D3T%$R66((]QO!T]ZP2 A0^IM@;TAL#'O
MC!)''_?Y]1A^(!H\5XTZFC60,R,I?=RV6.<G!]ACG\/\IXZ4I H]7U!&M[>;
MZ<8(#_J;_P#O(_\ *?\ JZ;!!O484['VG80P4*-JXX"B5&9<YVD< Y)]C@0@
MD?\ R]ZM?3IXL5%4J8LQ#..1<:VH3&W"""JXV'<"22"!^KC!^P1P=HR /45/
M#]*5I+N+#W^8B1!-$BCF^N[<2X_<:PY_L7H%;C61W^YC=3TI/DB0?;D 7:/V
M<G)S]D>Y+ #!VGCB )2%'P@O?+HP<AN;:W-C'K/8+L\)TV7M#%)4M$M0"$L'
M(8U(/#F=[P^B@-/#$J(JQX5< *QQA47:=H) ''LI](XYXZP#-9M7(H1KZ>5(
M]NE"4A@Q2E[(#:_S-PW#@\#U/5T\*;YY@@;*C<54 $C)R3EMWJ'(^S@8R#B:
M4E2VH0#\7=O(D\/A%M6(2A+A= P URBM33ZN'C;DU;8J"+:TX9U"@^6I)P#[
M<E0!A<>KU9^R <]6!)*595JH*M<VS7'K2*2]J2@_@*F-*W<U-]#2M:;[@+:T
M^O3M3VVVRS^HLDLN%4<9/IW,VX9R?1C(P0.!U'.5AP^?,6 L4L?)WTLS4ATK
M&SY\PB7+6A+ .X//4\*[XZV%YJZV$2+3HK[B%C];G*N<9VA>0"O"\$@@\=4I
M\R4I"D(0L+"? 6%*O9\I#;ZWK2.KV&C$JQ*<\PE/ZJM^D,;MSIONT*78K>E.
M_ED-M8A"VS!)8JH9L$,P.W)8\97V)ZJ2D34J)FE*@;Y>#W< U?3B^D>K$$R4
MI0+L^C\GKK[ZPH/U"*E@WN $>*5-Y8 KD, =JJV6 4-Z7]1Y8'<07YT2Y20A
M#$!U .7.]]7?K7/[M<V:$L<MS9G%-6@C"(TN^1T?:7+(R[&;R\NXCV\84LPW
M!LC?&'(*#'44I:YBDK4G*!0%Q5[%AO9ZZWW0[:"0B0$H++0"%F]$AD[PU"S5
M%'@T65H:T 13*C*4VJ3N\J3YJ#[D$Y).1AF7 (8-U?F(6^90.CJI6C.P/VCC
M/S$N:I(0 %@E*V>I"B=:!@UANJ#2#Q 90]/"S%5P0[YQE50,#GA,AE&,<[5<
MG (CZC=^%?M?[<FM&MAU 2YA!&8I4D:G]-*%]YJ?,P,K''("AY5VVQ'&&##
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M9XV!4^7(,'Y $G]GSQ@G(!&/;G=H(1B,Z6"DN "[#+0ZL;%VN6II&M@<1,D
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MMB?T!V?,+#3*>F;?HT>C'TL4XJF_3 BH^&EV0+ $#QR]M",@'D=A/$P1C/\
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M$4V85H+)T.6C?+BUZQT7/NHU8R&9I"NT*^YB1QCD?,DY^9'O[9/4R<5**:D
M\2D,3NW6W^<9REC5G'&U]*M737=9DWU+W ,@=+?*V&# J005R/;/MQ]^>"3G
MGIXF@W#O8@N?@7N/:(\^8L3\-19B^N[]T5KM55NV>,5#,LI._DMDDL3D@\??
MS^W'SZFEXA<KQ)4JP9B1\*.&WUC&GY5KJD%M-*4KO?GY07*;4MRHI1)354T)
M3U!HI67D9/J&XC\"0!SUHX?;>,D*="UJHS*)9F'$;F!!T,4IN$D3B53$()8V
M )J*4O<7TM"E6OO3J&&)8JFIDGAVX;S'8DC"$G)^USG/)S@DX]CO8?M/0">
M%!W(8FMFJRJ%HR)FR)()4G,*NQ30>;4WU/" VY:]I+O/YDLCPR'/#,V!\\@
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MI"A84E%,N4%+4J2QW#5Q3F#'73V]8*Y28\ ;5(8OC &<!1C9R23Z?F67)Z1
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M<):H4[Y@Q:K,3NYP89G\DR& <)LB<L",9PQB..'7TMDA@/4Q!!P6M(E)4!X
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M=76D2.7U/-\LP1%8@$0.O*X YSP">.2 ,Y./<8&'.)5+3F#J =5 DT46<AJ
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M;Z?!WOUIH3\%XFL ^@U9J%K"_O!-DTY4T\L=?1J6\IS(T1!)5"-Q  W>H*P
M YY^XG+<XF2P$/F.AWFNITM;ANC/ER%X7$IG2A_##@DFM=&!+M6K49H7CM_J
M2JI)8I%#-+'N\V,Y!7:"  "#N_$9SZ<;?FE12E25I HH%E<P:LWE0::O'4(6
MG$8=(425.EW>HW#=?3=!XU;>Q?:9%6 ><FUV>0 D-]MA@!,Y)&W.0!A1@9/5
MJ;.4N7E(W%P[U()=_2%$ALM62#0$<6WMKO\ I!7H8*V*#RF0R2/RC/@K'E.
M> 6.6.[+'UDGD<]5Y1R&8MOY4I3Q)=W^/M&FE* ,X2WA9N+%B[M^[7,=<%%,
MDSO(K"'+.P<OO<@\[<[@F,$#D%LG)4GBXDFB]69J6OP/G:*JS+<E7ZR[ .PX
M>U6UK'&_1Q34XI8>5D\J; &T+NY(.U@#Z=ONZ@'.1@8ZMRIF;*2+UH3\^7EZ
MQSVT9>>5.SIW-??S_?R:$Q-&\!E,VX!68#"A>< ,5(Y..6^9Y ]^I\R&\92
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MH&<9P>,8SQG.*>*1WDHB]M!ON2S^^ZMXVMEXU0:65!1=SFJ7 N+.*#=II4M
MK+0:>I(E22%P2O  _6.3[$?B#CV]O?KG)D@!9#E+$T')QI??Z4:.JF353)96
M:.D C2@ /P@#N0J(03EG7( *X. ,_=G& /UOGC\>E"<MC7+E<[N/K&>Z0&54
MNX/!J."&ON(X[X &H$J5+9VR.<YSZR?EN]A@GY$^V<9]NE&;^9O+WB@N4I:U
M>$"MKOZG[DWCK33T;-Y9V[BI]E'(^X$L^<Y]@<_+YXZ6*<W"*+E*0&NP:G"A
M>M*-Z-&VNBHV<E@H]R,!5&!^.Y<<X_;_ *".;O7?%;N2 [ CU?RW\;\8%J?0
M8F(=O;@?+!^S]QP<$XS^KTK5;?:A^GP>)$2@?*H8-Y,6;U@T4NCZ2UQ"5P%)
M P<''!QR#[\<DC[.?EGI0FCGC3U'QTAJI14" PJP=[[CIUZ[9M@J&01+N+9
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M=NMTJI=D5-22S,^0&;8APJ[\ ,3@8QR1Z<ENKDE&:854R 4S&CL-V_AO=Q'
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M42A(H*$L0WGJ_ 'GO+EYM,14O+3Y3=ECMWE2=S$@<\C>WH4AN2?PZ=-Q!8
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M@CKK]H+R35^[%Q<^O*P/D!\F3R6+&M'J&>@.O6^%DNFCO.H94DAC92"6W(W
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MK1@/)W=M+F +4W:^.L@58Z=<L"GI1>-Q.XDJO'VA@'YJ">< N6I*V(!#  N
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M-[D%2%)<@NY#BC4 (+ZAKGW#J[3[2PLOD90D;3@;5+,3D\ 9(4J3SP3P#EC
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M_30A(<L+-8!@":4BN;JS5-UU5=JZ]7FKDJ[C<)C/--([,><$*NXMM1 0JJ,
M*![DD]8<V:J:M2E5)-::_+@/VCC)DQ4U96HN5%SSU@JJQY8^O(V@8!YY.0<#
M!/M\^>A- "[O8#KUM\(9&I48< ;67:<D9]V/N>2?G_W^?0JHMEM3YEG;4^VZ
M".(. !YX&!C&U_\ H7'^3CI0"PJ+;C]8([X9MI(95((PHS@-CT@[,'.?8$?9
MS@AL';4&5)+OR-=U7][>]YDD_P P<7%174?7Z "-I,9))VD-D@*"5!!)(!4\
MDCT\J2<C:O"](2DDZ;FX/=]]/F;P\,>'D:=&W[/VQ,0%*L6&T?:]R-Q/!)/N
M3DCW!!(R. AY-=]>O4_*%!(-.@^D;\4GEH",DEP I52I.!SP =V !@ >P(R%
MZ0I2H:NFOD_M\/E,A>7Q#RXFC&FO"_*%P[4]XM2=N;E3RT=6]3;2^ZHMC.P0
MKO.3 78B)LG)P-I/!"Y9NH)DM) (N7S);P@W%1[6-=8ZC8/:7&['GI*)RS*S
MN4@D'_XEZ#_M-+<3$M79_P 3&G=7TD,:W#;.H@\VCF95J8#N V%6/()# %=Z
MM^J0"#UGSD A2,E2VO$-P,>^=G>V.&VC**C,(6% *!#D9A<M:M*7  >'CV/5
M=OKUADIY(&8JH4%D+* IW'@L1\C@9QC/'OU6$O*D^ :^)F;1Z4)!#WXVCMQC
M$$!2)F9P[TON<OUP@^"O@D0;2-H7+'("OC/('!(!.,8W<DX YZKA1,PR[^&[
M/5RFWW:I=R[.&-)_F8NS,GZ>WO'1-<=Q$3-ZMV[:I XV#;A?<YYP2/<CYDXK
MJ05)SGPK05!"G<,X=TV8[K,*7B9,U9#DFOM[!VW6TXQK5=7'#M9L1O\ ;8YR
M#Z<'*CG<O).!]H$'CVG$A,M*72+N] 7K6QL].% ]X#,$RA]NN-6]',=)F^L'
M!D120I4YR/4PY(/JC+#T@@;<9P1QT).8D 65E9["O5N9!I$$R8$.P<NP'/?>
MVO[P.1P1/&FX%@&W2' R#C&W#\Y!V@8Y!"C ZG[L5*/&S.X#"M=[[K#X1DXF
M><P3FM0)XENB=8Z9VAIU?RHUW*FY?2<< [1GG&2HXP/5@>_!OX=)<@L^4 4L
M]+ONW-&=BEJ"0HGG0-O9W+5#? 1J6NX%;C3SERJQSJ^XG< 0P(&!CC@E5.,D
MC(P<]=/LJ4I$Y) Z ;SK7TCEMKXA*L-,00_>(WTJYO86^!XQ8C\&G<.DFTG8
M9)ZP1"*&%")74 >6L:9S^JIP2 /P&>O:9Z!BL!AIR$DYY <$%W0,BK[RDM4,
M[<_C'M5AIJ,=/1D\"9BD%7_FM4RFYLQ !]HD.O7?K2&CK8;C=+O100P0B5FD
MJ8H@0.&R7=1C)+ $<\?(CKG4]GI^-FLE"B2[LX  !+DM\;"IX<Q)FSI3I262
M%!.9M"0"XS4&O'X0%_$;^/?HC26B=0=H>SE+0:IUM/YU,]UIW#V^T%=ZLU;5
MI.1(P)4?5Z8O,2PW^5E7"'9F#[.8L8H3TXC&JEN<.%9Y4E5@9Q20"IPX0#>Y
MW]KA9(GX5",2G.J5-[R6O*SAM!4E@15F-HI0]W>[FL.[>K[MK'6][J[W>[M4
MO43U%02R098LM+11%V6&FB5GCC">E>2P)8,V+M/'S\=.5/Q$U<W,&3F/A0MP
M2E""^5( .4"@%-*:\I,N4D!"4H%6"6&^JM];O<M""UE4?,.,?/)!)PS J ,*
M=X).T#<,D'(]LX"IBU+(-6)J=Q#-\1^T6V"DOKIUSTK\R7YYM[%@[!MK*Q48
M /V>=P .6.7SN (7. 0O5:826(.4E)MNKO(X5^ ,*D9;>]=.NJD/FDW;<*RJ
M&&S@;03@$$$!B>"<_9Q[ ]1&K-I:MWN2-31N?-H5R;MY #X=?*TK]$(!'Q(^
M^ \M4 \$/<E?2>,COWX;3]C/'OQA5  Q@'J!3Y!NS'UKI;[0Q=O/Y1Z-/4<1
M15 ^F(_O9?8_^73VR_V!>)KHAZ+^7S$>;0K%6##W'/\ /\L_S])NZZZJ(EC:
MADW3*TA51M;G.T'^<G&?^^.E%6>G,M5J/YP0(+(,_HF##C!4[BI.,^WS'W8^
M>>@L:7%G%>'7O!!ZT7K>^:,N]-=K+734E9!('!CD=(YMK M'(JLJD, % ;.3
M^/4<Q 6.(L=U^?PBUA,9.P<Y,V2HI(N'+$."06(W>T3+>'7QEV?5T%'8M4U,
M5LO@18@E0^(ZHKM :%V.-Y W,C'V)P3CJ DI2J6I+FF58%+_ ,VKG0T!\X]7
MV#VMDXA2)6(69:F8BC.!O)8@7=A3E$F6F]9T-5%3ST=6LT;J@*!@<YP">!ZU
M S^/(_#J#P@L ";ANJ7O;<8]#DXN7.2<LP*!#@BCBC:V%OA2D. TW=H:B-'4
M[7)]2<<CD_>2-I]L\9/O\^H$*\;S!E4  +I!34B_$EVIHS1%B)RI66A=LPI2
MI(<"FXVY7,+K8=1S4/EBG<^6Y7)8X]PN>1RI^1R/NXZLA64A3M0Z@/3G6@WQ
M0FS4S$!9;,7>H9W%JZ5%V\C"L4.I9A3[L[@ZJS)G<V00,<-ZC\N><9&.M"0F
M8N6Y6&JQ%B=P)/GN?TC-5,"%Y!4MF)HS6W&N]H[)[Q+4Q8R5W-G[*J1@E0,_
M<<< \^QYZLY)C-F<,1Y>NHINUI""=+2IUE+#B 'W,0/2!&VW::AA"RYVM@CD
M#D8Y)!V!?88]1)/)'SI3,\A2B"0QN78NS[NASB4XF7,*C+X/5W-!X=31GK=^
M4:]?KH4 GGDDVJ0=BEP%0KNY)SP!@X W9!XY(ZJSL5,*%%2D@!*C76A-"2Q^
M3\8T<)A^_H "30 !R"6:@JS^NZ"K8=?TUXDJCY[;DD90L;,<[N0PVG@8Q[\\
M^Q^5'#SA-44H4DDU?,X%J4/QK6D:N+E'!%*UIJ4I#,;L*&PMI3T$&*2KN+MN
M'F+'( P<G!R=J\G\ . H)SD$#VZUI.#F*8K&4$^+,"DG_P ;!QK2U3',XO:"
M%AD904DD-51<,UZUMN^&H(K7;9C<:S;+.<.V?401N(^URP/S&1[8P!DC3E2Y
M2:#*PU<%B*7L[1BS<5-F)R*4$@$'<6%&+G=0^[P3M7]X[)IVWU%96W.FH:6!
M3EGD6/9&JJ?4,J%'.!N/)X&<$G4PN'4LB82R*D&R!>ZF(8:%]*1@X[$RI04?
M"54?]+FH%[\_6U(@A\9WQ,((UN.B.V=:M;6/YD%1<DE<P4OH4-B1'0D\D #+
M,3ZBBX)MXG'R<&GNY!3,G,05."F62*$,0Y N"7IH1'(8S:.8E*>(!&@:]Z$/
M;6YB [4VJKQJFZU=YOEQGN-QK)6FFGGE+L2S%MJ9)"(H)547"CV"\=<S,FKG
M+4N8LE1+WYEA6@?=PX1C*6I9)))?>7@K,^?7P1[C)!;&.001_-_E^730&\1M
MH]_/HZ6AL:LTA2(B(Y.<\#?CG!W$'C'&2>0<<=.)8>'T9[U\M\$:TLR@ $-[
M*#CU<Y ^1X7Y_/ Z8I;@4Z\K:^581QO'K''ZR@XP>./^_OTF8]%7UB/.>'7G
M&RAV;-RMA5]6X+P"3G]4^IFR<$X(!Q@MQ7RFO /P/*+5"6>S4&NO!^-*,=\;
M2>EBS9W%]Q#<AF (&&&"/LG&,*<D*&4@]("Q'5(<[%S4;F/RZ^$;$;;LJR@%
MPI(&%!"LH (8CU9P=VT _,<8Z<?&: . 3^U(<.O41L12%6>('!.6)'!)P%!.
M1^M@$C)QG"@8/2%0(8@->GM=Q"H/\H/KOYLQ)H?7G&]',NP@L/2I&>?8/C+'
M' )PH!P6P1EADF+*H*! HHL^E:\^M!$H4&%;<;>9XG5M\&"TWNLMM4E;;JN>
MEJ(MI2>GF,+(RMR=ZX(574;D8%?U=K<X1:$N1, 79O\ MU#?<O?RM2,9.P\P
M392RE7 T.C<6 UAX7;3Q9ZCT[Y--J$&X4Z-Y1JZ=_P!*.%&9HN$9\ $F':Q]
M]@)#=5U2RQ!+BK ABQ%OEN^,=_L?MWB\/EESTA8_25L^X $6KHQ<!SI#\]!>
M*?35_IXQ37F)YE0>9 \OE31AF.]61]H!R%7/I'//N>J1POC*B6%K%_([NG>_
MI6R^VF"GA.>;+"C=*;^>YG;R-X7NU]T+;<-CBHC"E@01(>/22<%');D'Y,/G
MN'N6?EU)%% EOT[^5VT'WCK\/V@P4P =ZG@<R2"_ 5#,&K2E:"#+!KBW5(3=
M,LA#$1%7(;<OVB."#M(YR3\Q[9ZA7+FNV0OQ/E2GRB4X^0+3 2=![MNZ-8$H
M]14 ?.]2A12!R'XDR,MQ@'@E2H(0_JE@>I):%)22N6IGTWT]KZ1!-Q\L@C/E
M\5_+B0* BKC3E H=8TL>,3(2V -J@@<@?,8Q]VX$?>#QBW+EI(S92RM'8AJ6
M#;B;:QF3,3+\:C, %\V8;@*CC:^ZD =PU]0(?TM3&JJI5SN0%=J,<$$%@P.X
M>H8QC&"2#;DREDD(00_'AUP!TH8RI^T)*G::A1&A6D%5+7?5K0FU^[QV>RHT
M@K*==K*Q<R+AMO.0V1CY@^V0#ZER,='@P$MG4$E "CN#JL&JX-=_F8X_:>V,
M,'SK25 $,EJ7I<[M>>E%!T=\5"S=H=-FVT3SW*[1,XIJ:C_2!R#E/,D#;412
M3P?D<$$#*^N[*[4[*PFRT2<0C\Q-EYA+38U-7O<A_A6/G[M-@%;1QZILJ8E"
M5K*ELH*!9KAP0VE#K#%/$3\2KO[WYBJ;94:GJ]+Z;FD:,VRT5,D554PR ';5
M7"-Q(5+*-R4XA'#1R/(!NZR\?VMQD]*I>%1*P$A?AR8<?Q)@8@IF35N:C<PW
M!HR96R9$M25*3G4-%42#P NQ&KDB(YZV]R5;3&29G>1F#2/N<RGB3UL6,@/V
MR2Q*Y]@<GKE%3U+"V.5B"IZJ4I3FI#5=W)C4[JI?*4Z ,W#H,U*03*RL9@&P
MJIALDA549P?Q 9@44;?LX S@#K,FS5*)!-+U._3KVK$B10@"UFYC[[]\%NIG
M.6.W;G;SQ]GT@[LY)P1N9L9(.T#@;JBRQ>W'T\K\_@TR/T^O6G6N@!*D1MM:
M-RK&1G( .]]JX)XQN!(!Y]0 (R,XZKK0DL4*(4[D7>F@%34="' BX]CKY;J1
MI"098*/4I4$X; .%+#[(!.U>$#' .#EAPP$5WVY:_2"+3_T0D@?$H[XHI4 ^
M![N0Y3: V?[/?AKYR,>C#< Y)))SC&63 UBX=[,:N7^7E$:@R0./7T].4>C9
MU%$<50/IB/[V7V/_ )=/;+_8%XFNB'HOY?,1YLW1$L<O<(/Q/[>2.DW^WISI
M[01M4THA+!RP4D8 ^?/)'. < #)SC/0"#UKUK6T$;J2EAN7(5FR ?N!./;V]
MS\L]+!UU[P-4=?54[QSPR/&T!4AHW:.0$>Q."#P&'L1SC\>F*0X) J&?S\X<
MA2DJ!02% N&+&G&'D=FO&!KKMQ)2P72>:^V>-E3RYGS401!ESMD9E\S:I.5)
M+;OUO?JNK#EW06J:&N[H^T=1LOM3C,$H":I<U#!)+EP-2'+$MONU]TMO9CQO
MZ!U:M)!)=HJ*LFV*])6O'3RQLV>$WN"_X8W#TMSGGJN4%P%BM@JNNXV%35VW
M1Z#A.TV QLDYIW\4 $)4[O;*"3HWF#<L8D TMW:T[=!&\%VIE0;'($\66/I;
M'#?K#&T ??SU?EX5*@A*U%B[6(HUG!]OG%P;2E*EA+ BC*#EKU9Z@7I3C"_4
M?<.UM1Q^57PL F"JR*7)W[>,''& V.,8/SZL2P$T+A.C5' \KU:H>(R)JYF9
MD@&E*;B+\6IZ5OV)W IQR90X/(]<9Y7.,D'(/WYR>?GU!-GD.$++A1 #LP\N
M%+;XM]SX0'231W.X5O1^GCY/W,IMH"U(4C(&2I4'WP K>KWSR,<$\GJHN8M?
MZB[5Y[P:$PY$K*DV!.X<1N'GS@J7[4DM^HVBI)F8LV25;@EMP()#<#DG!(^?
M/!ZC.#F8P&5+N4D&E@00U6W\#S=HU-GXM.$F!:R'#%-WS)+I<4W/RWO&UH.:
M/3\BO72Q E@S@LJ@8^7JP"#[\'&3DGYG0P>PYTC*HI"@WB.INVZWJ06@VYME
M.-2A14,Z:@!F.C,]/?>UH5?4??K0]@MK/7W>W4@@@RS2U4*8* [O>3D_?P "
M1D_/KI9&"64>-2$H3<K--U/G2VF@\[Q&-3*FD%5 :/1WJVEJ.!?T$17>(WXE
M/;K2+U5%IVZQWFXIO2*"AD6<[P'VDE7VQ@EL@NZJ0.,CW%JP&'35IDP*) T>
MK&E:\1J]8R\3MZ5+2H) *JL ]P+%CPOZ<(0>^7C,[J=WYJFEDNM19[&S,%HZ
M:8QRRQG*CS9HV 7<I *Q\X)7>03FA.VC/6E2$J$M&J$  ;P^ZPW;JO')XO:,
M[%*))RAZ,]!3?:PLUK0SB>I>9G=V,C/DNSY8DGDYSZFR<^YS[=9Q)4:DDGXZ
M\>+_ !C/C1:11NWG:N< H"&' &,$\<Y^7/RZ4  >+X5'M2NOQ@C3=PRX3<RD
M'A<;P![9SQ^/&/\ )T$N  [,W'SH7L;'>((U\LB28!88( (Y_83[YS[^_OGI
M 6%:BS-QU^E81PD5/G^T!DE05+K(FUE8YP>&Y. O^-@#G\?V=1OUPZTYPW("
MY>]1Y]<(ZOK!//E/_P!_YNE@R#>8,(W*H+9W8;.U6'I/L"H^TVP*0V <MCCI
MB@LZ4M2WF:;]8L%-CJ-!2PWWNU=T=D;MM ;# *IWKNXW, QY;[.2I'M@\8 '
M04NS,!8N*\Z#UMYV@J2U>=7!;6O#B":O6-B,R#T[@S!@&89^R, D/PON0<#/
M.<#@9:Q!.50+.7&H]/:'#,+D']_IUK';&[9.]% (8+PI/!,8'''N#CG.0<>_
M3 -S^_.GVA0HN01H3I>H#;O;RH#N^?D*J. S!=JC<"<9^RJJ2H=?4WV264X)
M/M9)2H,#3[-I2PI9JPJG)3E+,0*.YOZ/JYW7,; F<, 2,AP0X49QQD%>1_Q=
MP()QG&0>JH3X@]0_Z2'N:WMQ\XF>K<>%KUW4IOC?238Q#%3GG&&W$L/;:?U<
M$D/G!;TC=@D.F2F40,I-3O):I8MK4!_DQ<"2_BH-"=S@-\N5&,;\%3+&\;+(
MT+AFV>6Q5@2#@JW(Y(S[GC[/)'0F2:YP*N6O3STO"IFS$ *0M236Y-*GCYV^
M,*%9.Y^M;(R)17^NBC'*Q2R><%  'O,KL% ])0?,_><-"<.%*\(*3H<Q##=0
M^I;A>VKAMMX^11.(5X: $EM;@FPTYWA2J#Q(]PJ1$$E1250W >N.2-FW*,DD
M2-Z2,*/3C''N#U,<*<KG,56<,1;?\?3EKRNV&TDCQ$4(%5+#CDYY &EKP=(?
M%IK2) CTE*6RR8%1-L;C@@E,# 7&,A<_J@]()2T)RYT@N!^D.PHV:YUYWB9?
M;/'J( <"SI4K*";O7>]@11HZZCQ5ZXFC*14M'&ZIEV,TC%#YNS*@,NU1Z?;(
MQG/.2)DRLIRJ5F44O0.$U:N[31M=8JSNU6-46IFL3FOS(J:4%31KW@C7?O\
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M_//4#Y:U\N6E^JEH<*=:[X#7]*C8S9;.[#%<X/ RWL",^QX)P>F*H'!+F]*
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MG%5K89'O@XU9ST,-PA>]F?UJKQCF/@7_  EA[>!_M./_ ,;UM_VLZ6#O9O\
M6KUCZ/@8?"6&<>"#M/RVX_WWK;[1QS_ZV<>P]OV^Y/2$ U(K!WLS^M7K'(?
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M _VF/S_\ZUK^WY:K^_Y>W3<ZW?,7M>!SO,=/]PI^$A_$<[2_\JUM^S_Y[/\
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MV=TK0J"3=+KVL\1D5F 'N?RTG<J2U$<'D5A!P<$X/1"Y4?U>XA!C],F\? +
M^&7PA@JQ1@;5WGRKJ<,K#^RWPRD8*GD'@CHA<@X^WTCY^[)_'O\ Q9O"%_17
M>;^MOH@R#C[?2,_=D_CW_BS>$+^BN\W];?1!D''V^D9^[)_'O_%F\(7]%=YO
MZV^B#(./M](S]V3^/?\ BS>$+^BN\W];?1!D''V^D9^[)_'O_%F\(7]%=YOZ
MV^B#(./M](S]V3^/?^+-X0OZ*[S?UM]$&0<?;Z1G[LG\>_\ %F\(7]%=YOZV
M^B#(./M](FL^!'\??Q-?%2\6_<?P^]Y^S_8GM_I?1OASU9WDH+SVPHNX%-?J
MF_6#N9VCT336RL?5>N=36\VB:W]P;I53K#00UIK:.@,=6D"U$,Y#5) #A[Q;
M%Z(9$0OQM/B&=TOAE>#"F\2?:#1F@-=ZMF[PZ%[=-8^Y,&HJC3HM6J;7JNNK
M:U8],7_3ES_*%/)8:9*5C<33!)I_-IY6,;1D*D.0(J+?NQWQZ?Q:/")_17>7
M^MOHB3(./M](S]V.^/3^+1X1/Z*[R_UM]$&0<?;Z1G[L=\>G\6CPB?T5WE_K
M;Z(,@X^WTC/W8[X]/XM'A$_HKO+_ %M]$&0<?;Z1G[L=\>G\6CPB?T5WE_K;
MZ(,@X^WTC/W8[X]/XM'A$_HKO+_6WT09!Q]OI&?NQWQZ?Q:/")_17>7^MOH@
MR#C[?2,_=CGCT_BT>$3^BN\O];?1!D&\^WTA2= ?2N/BI]UIEI^U_@4[%]QY
MG8J$T)VS\1>KBI4X8R&P=Q[@L2J>&:0JJGW(Z(0I0+GW'TX0Z:V?'B^/9=:=
M*J#X9G8.CAD,2K^7Z+7NE90TV @>FU1W[L]5&<D!_,A7RSGS-F#@A&1O/7E
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M38LTY8AZ"Q;?\JPR/Z'+^^9=]OY"O<K_ &_^&7HAR[>?R,>D]T1%%8GZ6O\
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MC+9(4$A1G[(ST0@>OL^ND.3>PP5+3.SLBKF5@A QC:0#)L& Q8<EL@88D $
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M5!H_[!GUZ^<$5<-8Z)J]"^)6HLD",#;=<4Z4SHA"O3M<DEIYU8 ,%DC99![
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MK2,!YKN&RI;'2?3G;]S]X;J3O)ZL/A$D-76!GCF\P^DE2IR!AE)SR!DJRJY
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MJ4"@DC 9CR01O)8YC7C:"""Y+9G$:H%1IU0IY84&60YVF1X_1L5=VX,3N(X
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M*_E220*1Y1VH_$29L+M+/[/R_P BB9)V+/VT^*PV.G*7A<'@L;C\6H+PTQ"
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MFAF?M*@=VV=U84$7N"H'PL2IOT,2K* 8TT_BS^)J^ZR?AI.5WP)E%,K:A"P
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MT9F?NELF9ERJ(!<1V:,\=%JU)I_M5J>[VVCT)#JINY%'W?HM4W&AM]3V6O\
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M5@BQ@^ES&,,P')*GC@?,AD*)H?22WO3MMEF6(Q34T,HQ(0':1=^78K&2S$D
MJQ) 8#:V>B"'5=A:.HL=UO6G_*F9;A1R5*/%GRVFBAV*J$@'TE43)3 "[LY;
M/08(7C0UXJ+=<4$[U&YY)(E0;-T<!1Y-A!]7I;@,<OC*J.".DW=>WGTP@A0]
M8=R;/IFTR7[4]Q@ME%!"RT\<W_G4YC!=*>EARLDTKX5F\OA2=SE-KGI8#7[0
MP346O>['B4O7YHZ*H:BS:-6IQ4.6DBBDA# _6[S7?X-POO'2J2H;:$BDD <D
M'77O#TNTG:NR]L-,K8[6\5==7D^L7:Z^4GF5E:!LP6 +"FAP1"C,.?,DV*69
M00E?+7IB_M]%VH+?314RU-8JL1R'G"%1ECN,:D!0P("*P59"#P?GTG6[?NJ.
MN,+UIZ=:PQ7Q=>'G6_?)+#1:1@@@I+7W![(:Z>OJIJ412P=K.[>ENXERM:0R
M5D$ZU5RH=-RV^DF9!#'4U<4TV8TE'7I/9S;.R,/L%&!QNT$83$(VOA\;D7(Q
M,UY6&Q>#Q+9I,E:7F"0I \1RJ+D-'S?^(W8_M=M'MW/VYL;8$W:NSYW9':&Q
M!-E8_9>&*<5M'9>U]G9BC&8R1,*<.O'RILQD,M (0HJH&6ZQ\"/B0NW=75E\
MLEVT;1=M]>=^.PG?_4%HN=LEGUM'?.S5+VLL=3IBU76FU0EDCLU[M?:RTW2G
MN-1:Y:^FNT]7;)('HJA*^DV9VW]B*QLZ=+VYADX7$;0V=M":A> VB9X7@48:
M492%B5W>1:<*B8%%&8+)0V7Q#C\%V#[;2-C8/"XCL3M1>U-G]GNT79S#3I6W
M>SB< J1MR;M7%)Q<Z2K&&>9TB=M6;)5*3-$M4E*)H4)B3+6$6KX:O>"W:8TS
M9&:PR2Z>\.7BG[*RU2)1!);OXA-;:+U7;K_"IN&]**R0Z9N%-=X"?K59/<1)
M =AFW1HVOV<1(DR3MB052]F[7P.;\ECZJVG/DSDK'_IGRRQ*4%BZLSC5[,_L
ME^(D['8O%#L;C@C$]I^R&WA+.VM@NF3V:P.-PDW#J;:;&9B%8F4J2K]*$RF5
M7*P=;? !WY>^W/2%GOVBI^VNLNZ/9'O3K9:NRRR]R*/5?9BU=IK?'8]*WX:H
MI=/II^_UO9O3$T5TNE ]XT[17*_V^CAKC/:ZJV VUL)"U2D[;POY2?C,!CL0
M58#:)Q0G8%&#3W<F8)0EB7,5@9)2M:"N4E<U*0IT%(KL9VXF2Y6+F=A]J?XO
M@=D;?V%@!+V_V=3LI>"VY.VQ,_,8S#G%JGG$8:7MO%I7)E3>XQ4R5AIJU2PF
M;+F2V_#R\-6M_##X?M&]H->4]-^4M)Z:TO8?RE0&F^IWB2UT$T%77T\--554
MM*E14R>:8JQHYRSLS!B68<9VFQF GX?8F%P.+1C/R&#F2)TQ$F?)3GSH(($Z
M6A1S &@!U<B/8/PUV1M_ ;0[;;3V[LB=L<[>VU(Q^"P\_%X+&3.X$J<E253,
M#B,1+!EYDI913IE! B0NJM"& +L4_K-)N3/J5<D %1@C/"Y)YXW8ZY1F9APO
MI[[OON]7A/KY31K2NI]+$%0Y)P7+%P,X !"^G+\8!^XGI!O\Z<2:BYK4\BU2
M((1BMI;@6,U*8S'&V\&5BN-RE9 G!&[8VY, _:Y;VZ4-Y6Z^$$ U=421K,)<
M,S$'_P!F&7)7&W*\G QR1G&?8$=+! &U5@@ OM<,&#,2HRJD' /!]AM&.,8)
MR"2""EJ"*5UBKHXVCJJ5/*=0&)FI2Q8H1R2V=KQ' P^Y 1O8A#[:_7KRXD!-
M96U,-!'6?5G<-GGA3^MF01L=R\MEU.4#[< 9<.:\/?VL*/>[#A!$0WPB-;P:
M\^DN?$)NE)-YU':?!)5:4@;"C:^EM6>#"S7"([1RT=VI;@KELGS P'I"@+#_
M .0<3]8NJ]$,BL1]+9&[X4M$I]CXH>T _P NGNY Z(<G]0\_@8^>&ON$T_A=
M\,/<PUTCP7#M'VCU,:Q% 6HL^L]"6"ME615VDB"6X34CH %CJJ1T]HV7I.M+
M[NA#:B%>[HTTEJ[DZ%[IV,&-KC3S62]JF]1<*2CB_*%LGJ$ ;UHL513R;BWZ
M)X$PA(#+!T86FHU-%=:"&KIG0R2Q"=XT9&:)2C')0D95CD.5.[ /.\. 00DE
MTOBR5<4Y<!5=E5MV"2?+.%;*^S@J#D!0%(/JR4^UM_7KK!'6:T>8)4#&+>CH
M[$$E3N!SD[B-T;C8%4;F].?<FF_ZMR^7E! I63^;3KN!,8C9V<*6C4D'&<E3
MG!!<DL%R22!@](-^MKW+#AK330$7J0@NN[5:YZ6NN)^KPD18$LN6)D8.#)$6
M5=C,0"I5R21G=ZWPZ"$JTCJNDU%)^0IF6/4%$'FL4K1E$K88F+FF&6QYNXY1
M3L.UF\ML>Y!"C0U=WN%).+I3.GU=TAKZ9_M1QA@PD];$NGDC>$S@[ $]>.B"
M%CT<(VD>A:3>0X>D.P-BG90PP%(#R;L@.!L*!<G><JA%&?HGH>\$ /<31T57
MKC0];%'&\_UJ"!O,4K)Y(GA(8@*']'FRCTY54+,REI&W+\H(7F>8"8^2&)#E
M,LH* J<!4]28W?+TD@'<02.D/PU9VW\J<KB\$)QWRT>_>+LSW7[0_E&6VR=S
MNV6M= "Z0TR5DEK_ #OTU<-/?7XZ26>C2J:B6Y?6EI350I.T0B>HB#^:MO F
M1^;DC$S52)"E%$Z<E"IAE2YB52U+"$U64!6;(DNIFL8RMN)QJME8T[.PR<;C
MY<M,[!X1<Y&&1B<1(F(G2I"L0OP24S5RP@S5.$!68@LQCJ[L_#1H.X6JZ74U
MQOU]TW2W/M'J?M3W!L]@:SK3:VFNV@*SM]I_7;235%3#9]9Z2L%TN-)!7M1W
M6&\VU+-:+Q%446G;:L7IV,VOV1Q<Y,T[4Q,H+P4[!XF7+P6*;$%>&.%EXBLH
MA$^3+40%95A: A"P4RQ'S+LCLE^+6R,&K"H[,;-Q2I6VL+MC9L_$;9V:5X!,
MG:*-IXG9WAQ*53\#C<1+0M4L+DJD33.GR2E>(F0KW;#P[=Q='ZRU5W%[C:\H
M^XVNM3:6T;H1*VU:6MFA+';-*:&KM5W:V0PV6'4&I9ZF^7*[:QO=POUUFO(H
MZF0T-/:++9*.F%-+H8/M9L"3/G8K$[7F8K$39&'PX*=F8K#RT2,.J<M $L(F
MDS%KG3%S5%;$Y0B7+2&//;8_"?M[C<!@]E[+[)2-E[/PF,Q^T3+F]I=F[1GS
ML9M"7A),PF>I>%2B1)D8*1*PTD22M([Q4^?/F+S@M]Q/"/)K2'Q)K>+_ '"@
MH?$EVVT[VZKQ;J2@:KTK!IVQ:OLBW>WSS553#<JF?\ZFJQ2U5%3P0O0)$[5"
M5#F*/$=I.R^)_P 6"]ISTC:F%DX5>7 XEY(DRYR M),HA9/?.Q2 ,K5=Q9V=
M^&_XG[,/914KLU@9B^RVU,7M.49FV]FY,8<7B,%/5)F)3B4JDI1^4R9T+6HB
M9F8% "B!I;P=:TNW<$=Q-7=T%UAK"D[F=NNY]U2V:!IM(V4GMOVZUWVWH;);
M+=+JJ]U-#27&BUNMWJJRJNEWJH[I050A7ZE<*>EM5=':#L_^83BL1MJ9.G?G
M,+BU9-EXJ3+_ /2X7$85,M"/XA0E29^<J*UD+26&50"+\[\/NWXV<O96SNQ6
M'P.#.Q]J;(E]]VIV9C)X&U-J[.VK,Q,V;_ 3-7*7@.X1+3*DI,E:7.>6I4T*
MN?@*HKSIJQZ1N.M[O'3V71/B)T?'6VVT6ZEKQ4]^^ZFE>Z<-_IFJZVY44-5H
M>\:4HJ6EHZNCN%%?EE:6N6EC#T<K)FV>RTV3+DJVM/"9<C:<D*3@,2%9MHXN
M5C!,#RU)!P\R4D)24J$RZFL9</V,_%+#8R?C)79/ %<_']F<:43MO;.7+R=G
M-D8S8YPZLF(E+*,?(QDQ:IB52UX8@)EYSXP;[1X,-=5'=32_>ON)W+@U?W T
M_J?35WFFL^C;?I'353IK2';OO)H;3FF+?9OSIU#66^J2M[X:LU5>+Y5WR\SW
M"O,5NI+=:;9'30T<LOM'V>.,DX_$[:7/Q,N=*6Z-EXF3*,J1A<=AI4I*&F*0
M2O'SYRYJIB\ZFEI2A(2U>=^'GX@(V/C-@[,[&X? [-Q6#Q<@"?VGV;C<4G%8
M[:>P]H8G%S)[X9$U/=[ P6#DX=$B2)<L*FKFSII45285 7ZK"(=L%-*B(A^T
M(R5 /I W8YPN#GY."P/7D"O$HD?I4I1T]=X+[GWO'UR@%*$ W"4@ZU  O#-O
M'O=ZC0O@M\5FJY*R.>.V>'SNXL!,:#9<JS0UYM5I<#.U9&N=;21(^UM[.%9&
MC9@35MW3?;EPAPN.8CS*Z@@5$XP>)I1['Y.WX=+$[\_0_2):_A)]X).V??35
MED:>2*#6.CHYXHX_4\]STS<4DIHHHCD/(+;>+Q4L I/ETK%BL:N>B&3 X!%Q
MPZIIYQ82J=1W[N564-J8304+U=+^4YFC;ZS)3Q3I-)#&J[46-E&Y0R@*,\L!
MP1%YUKUP'53$ZN@M 6:+2]CDMJ".@GH*2> IMD5HWBBC2(,#+Y1.T*0K!_?D
M87HZZ^\+"N6C25':;O2UE' QJA33HWU>$H4,WI!DD4LFP*K[MQ)VJ&](&63W
MZZ]8(2S6G<2Q=I[7>-8WC#0VN2JCHJ8N4:ZW6<O]7HX"%'I909)9 NV*'+M[
M#(UM/6WMY._T(9EVUMW<OQA=PC=+O434NE+;(DE6Z^8EOM](7W14-%$"X,LO
MJ"@%FFPTLS$;FZ6$#[N776X\98[/VNM&C-.TNGK*8Z"BID4!:*G1:F>3TAY:
MNJWEYY)< ,XCC4*-H "<I??Z;CZ5]6A8,5#8:42!6FJ?2IW1^:\01,$!5V #
M&2/F3@L#SD=!?3KW'3<8(,U30AZ:*FI9)(DCPT9D?>69=VX$,N5W,.2C$C!+
M<]&O3']N/$MJ"->X-)11P)(L@D#K$(U16)?CU1Y"Y!X))(*IG'R'2\K?6"!N
M@HY*DI+)#N<!5 "#U;@"V6!ROW-D9R6]QC#"2&&^E'+&PO>VMS=H(,ALE2('
M:1"A9<G 4%$(SA=VP#;A1\_GSC.%)K>K6XC@'-GWO1Z@.0D&@* 5^H;G)YNV
M&&IW!E3!\J&4XP,9]3I&6+$\8]AQTO3^K00Z:DK#Y5.D\L321-L4,.7!)]>W
M!X(7Y#(P"?Q2WV]@!U7V(.BT_FVTSE2&1B L9Y*O$"FX 9.0I;@Y]R!T[CUU
M]X1ZMPZZ>$^NE'!6*$*Q97U#<P#*%# ;QZB7!.!S\_\ *TVW:EN WL_MHT+"
M(W0B"M:F)] #E"<'GS",C !'"C*G&0,@'I1U1O8];W@X05+K;MQ:;RV82<9)
M+*OO]AL!O5@@@8!W$  <]+!&M9;(;O<!2QAMD;;7(7'ENQR5;(;&U/NY(8-C
M!)Z2WT^GQZ$$+;)VDIC0B6: LYBW1AB,.Q&29-R^V=_E@8Y*_,GHKR^.M_;J
MD$-IUY8(M,4%TJZN3ZO::2AKIYIJAHT@HHH(V>IGD<^F&.GB$E0[N51%$A+@
M'/0_/IM_/JCD57?HL_<N7O+\:CQM=V)9'D_LC^&/Q!:SIR[,S1T.H?%%X=KG
M;X-S^HK34%134Z9Y"1*,#&.EB109('+X&/0^Z(CBL3]+7_>IJ'^5%V?_ -7N
MX_1#D?J'G\##0_@\ZVH^_GPBNSGEU$=9J#LW7=P>P&K4C823TK6'4=PU=H6%
ME&&1Z71>I--K#O.U5JHL<+PFHZKU06UX"$4&4>;^M?C$GVEUCU9VVLT%=F>M
MHH/)D#8+1U%,OU>.01AN))(R/40C88D[@K +"07_ #JNUI+05$.R*-@L<^.8
MV&XNPP2&DD.P%V;$?L1MR.B"$TO%Q5)MQ#;&WJ""0(B3ZCYA4B238-Q9EPAP
M!M+G!!'?05\E7 85F4@ ;/,+*#&O!8AR@R "Q498QG+,X8CH@Z^GO!NJY]U%
M$M+4&5Y($65(PD<:.J!2H4X'H;?Z\)D( 2W(!Y==?M!"97NFJJ^AKJ1J5%W;
MO-F6-A(/+ R!CW)C9W).4"D'+XV$@A/4[5?D>BHKQ$TGU^"0U,%3$S"HIC'4
M!XI%9#$PDVA/01M)!(V@YB((<KIJFIM5V>DNM=(GY4A5[1J!<K&\C ^=0U;A
M4V[IB6B*Y+-)4DDA0I5//V?X,8([YUI--5\KQ29BM/EI--(Y$;4U2JN4W.0N
M(@ZL-Q"H\4A!(YZ6#KKK[=^F+M^>&H_R_.\<-!;HWM]I1GVLRY(GJP< %ODI
MP<95=OHR4ZZ%3!"AUTD5-'N,BRJCG$2RIYAP2Q#X]&!RA=\[-P5=V<%-=*>M
M7<VUW:W>"#-;;<U0RO!"TE0J8W!3'$J>E=JMC&&)]\;I#CD*,*OSMRZZJT$;
M]SL]S>&?S"FR-0JJI9I"9%Y<8. IR58E3\R1D A>NJ^F@@A)FW"=(2LZNDIC
M;<H&%7>I"AAD*.2&898 ,1@C#;\FKHQ<%Z'HAGO!!CK[9]<HXY5D4K'R!DA1
M'%&ZM%@1Y\QM_MA3G:02..E:U?O\O;T@@FZ&N5&+AJ265./-@4 ,0T<*-6QQ
MASN!V@L&*DJ), L <X4]==><'7K \U'%4?795"R"5FE0#:%0!-F Q*LK2J$=
M@&)9PP''2?&CZ\?;3R)@@O6V6IKJJH@5Q]4I70$D^OUC(5LDAVR& !](&"_)
M (1Z\*_?T8M:"!=J>-"ZYFE@(.%,TH,;^K+83"[2NX\C8>0 ?<HX X5Y>=/+
M>^^"(8/CO]TJCMC\/K6]A2Z20W'O-K30?:^BIV:+?)0K=6UW>!&-H<QM9M#5
MM),R@D+6HKOB5<J/*VG5G>'(_4/,Q01J=WUFHX_]O+^J/_>-^'2PIS.::G^4
M?2%[\/?<6+M-WL[:=P:IF2V:>U5;WOI7);\V[B7M.I"B@J'E6Q5]P:!'.PSK
M'NP!D$2$."(NWZ>T9%;DH;O;C'/1U<*5*^5R&>5 R^4ZRL2DJ@X92^_T%'VD
M9(K@5N_QI<4TM3>[Q*[X:]:VN[::335=([U5@60T0SE:BG=@\*..=TU,7>-D
M;.Q57(P, A8>#Y4%ITU<;F<I65T<D"D>P1B4>5<KM+'*HOEX4   >^4]N@?M
M\((@I\9VNKQJSO=9.U-O:5J*U"TV^GHT#!ZZZWAX9IJ@Q@?I9Y7J8H$8^K;'
M& 0"<K"'??=^_P ?G$X7AT[/6CM%H6Q::H(8C4PTL%9?*PJ&EJKI-$CU,KNH
M&%1\P4ZCA8HQSO8LS218\_+KSLU86%]FMP+^9L8+[J!N='W8*KCDEB>?<9X]
MQCI'XWUI1BSEJ5L#:W." %Z2&.5Z=3L>4%R>,>Q&S!!X!;+$^V<#D-TKG7Z[
MW=ANJ&N?2"#%;+/]>D"8&V,$M(-VU0#R4SR?D,'@<'W..DJ7(+'RK<C@W'RT
M))"#Z\[M:/BN%1:^WZW3N[JZU3_D^X6'MU2PWFWV:M8@"FU-K*IJJ'0NEZZ(
M$--;;YJ.EO;H?,IK95^E.NGP_97:(DRL7M69A=@8&:DS)6*VPM>'F8B75EX+
M9TN7.VGC4JLB9AL&O#O1<^6*Q@3^T6"[V9AMG2\1MO&2E9)F'V4A,^7(F?T8
MO'+7*V=@UI_496)Q<N?E<RY2S0K7HFLK:JV6N>]4--:;K)34\EPM,-='<8J"
MK:,-44D=P2EHOKRT\FZ):I*6 2[&=8P-H'/8A$E&(GR\-.5B,.F8M$G$+DF2
MN;+!.59DF9,,K.D9B@S%Y7 =P8VI"IJY,I<^4F3.4A*ILE,SODRED J0)N27
MW@27&?(G,SL(-MYN\<%KK'C\L. \?(W,6\O.X^^=N6(P3C: 2">HN!=^'%ZZ
M"SZ>IB6$I[6T\$DETE)\LD>;Z@"P3D#.<CU'(Y'&?<\8"U"[;O8VOIS@A6H:
MF,5<?EKODCPP60-ATW,Q( Q[[B![@#D??T4I44%M.F]6<,'@A5&OM"MNA0(L
M$BJ&D0DK&PS( &YY'K#$ ?+GY].>@XMKS\CUQAK5)^76ZD)G.(JZZ3&&5?,*
MS2;26VK3((V,K.N58;B54MRQ95S@*0W5N>AHQ>N_?I__ "AT%>KMBK5"1 )Y
M06*RN$;D,0< @*J@[0"#R =S<]-W-\&TJ0UW&F^[6@@S4BP5J*D])!,J^ADF
M160EL#A2"1E@2I]L8/MSTJ6=]2.;>GD:UXN8('=%]N[93W:IKD(IIY9!),(P
M)(RN$*AJ9V,>Q578H4H5 !5E.3T\ D\J^WW:A^D(2T++=8XHJ9UFAB92FV-H
M25QL7:/0<,F2-WVV+;=HD4'AYM:W'7@SW+OI1KV8ER7U]O/E3BY>K1 %\=SQ
M T'AE^'-X@]3+6?4-5]QK4O9'MX(Y'@JJK4O=,366NFM\RNOE5UAT/'J_5\#
MKEB-.L%!."(A>EO+RXM=G\HE <@>O(?6WG%;SZ'+^^9=]OY"O<K_ &_^&7IT
M2+MY_(QZ3W1$45B?I:_[U-0_RHNS_P#J]W'Z(<C]0\_@8@*^BJ]^16Z]\3_@
MGO%3"T'=#1='WN[<TE5($ADUCH)Z?36L;72HQQ/<=0Z=O6F;@J(-\5OT37SY
M\N.7!"S WB\C\7^-N%-8L[]I ?-N]E=DADH9ZNBKX)PVV.NM]?74)\V$J#$2
MD47F9QZFVEQYFP(>NOWAD"FKK1@LR1HZ#"2&-%8#V.XY;,PCY9QG*PC<P)RP
M-;=<OG>WD0V;6D B294W9]8=5(B,Y5B2(P/MN(P<Y#%4SG:K$E8()UKNZQE!
M.^R8EXU;=OYB4@;E&TG?$I#+G.]2",.N""%6T_>J %8JR0M32'S5VR,<.&Q(
MLB!P"K%R6*G"D8;8QP"" F]WZV45SBA:2$)5RU ^V,B,ABT85"8SSY0CW*%+
M.J>:"[!B"% M=-4M2;*NG<TC#=!5LBE$1590I'##8KOMVE^5]6#C801NV;3D
MMHKY:ZBJS+15AB:OI2KX=$8R)(L9/HJ(SGRV3<Z-OC*RDN61W>C=<*_!Q6""
M#W$NWY3KAI2UR'ZY?*R@6ID<DF.):EGDCP-I18XHY#*<%R%4 %>6!R]W^4$*
MCIRU+9H8*.G=C1QTZ11M"<_9QZ]X 8.[G>S'UEG))(V@)?0CFWF+ZCR\X(4^
M"2AHT5)**,5*,)2\OF2U,[,%"[G8NS$@ 8<_9#>QP5=!!WTK%5UEZA=T6*B;
M8LS."J;%<G8P.UAB0\.I4>XX/NF_Y.^O#DU/6D$'[7,MCM-KK+E<+K1VRGH:
M-JJ6YW&IIZ*W4\$ +LU35U+I30PHRJ))9I4 4R,"%P3)AY$_$S9>'PTB9B)\
MU01+DR):IDZ8LT"$2I86M:SHE(*B:-$4Z=)P\I<_$394B3*25S)TY:)4J6@5
M4I<Q92A"0*DJ( U,,H/=^FOE[,O;W3-9KV&:=W6_2R#3FA@ B)'.=45]+-->
M:*5D(%9HNRZL0;2L@C/(Z0]FOR#J[0[2PVQBEBK9Z1_B&W#9T#9N'F!&#F@%
MRC:V*V<=64*1@CM!^=9.PL!B-KA3@8XG\CL9.Y?^(XA!5BY1TF;*PNTDO0Y;
MP<J"'6GUN:Z:AU19Z@5MO:E_-+2MA-JTQ:@SPS?63<KH]=J2\W*!(O(:O$MD
MM<\4TTGYNQ3^7-%0VEB=BJDIPNR-G8B6$S M>TMH8LS<?/ 0I/=IPV&$K X6
M0HJ[PRLF+Q 4A &-*,R57L!(VL)BL1M/'2)A5+*4X# X82\'()4E6=6(G][C
M<3.2!W8F9\+(*5*)P87E4E.34&R7:M"1EHKA'5+-(7X+><7@ ]B%0.54@AV5
M\C;D]8]^'7$1JP8;=<]MNJ*5"6>=<JS*&9 7W^6"1@'[6<'*9(P>,HU;4IZC
M5F]2]N$$"';^",5-Q28HJR5"N[$+O8%/46+,2=A5X\87. >=Q(77WZ]8(.MT
MMM&)2U%4LT1P[N5!7=N8&-6&U77YLW&,J.#N 0]<:6KOU(%AP@BF3])"\0$.
MI^^79OPUV6Y?6*#M#HVKUWK&G@?]$FM>Y+P+:+?7QEF8UUFT79+?=J1VQMH=
M<N49A.V =;Z==7B1 U\O3[\=(K!5)/UBH]+?X:7YM_[QNE@)+GPJ]50+=$21
M=0^$OWJI?$EX0-.V^OJS-KKLM-!VOUI&\B2W"KH;5;UET)?S&93.]+=-+BFM
ME375!\ZOOE@U%)SY:L2(5!B?7UB4/2%%?M%7B@NE&_EPK4T[UPIMW$7Z,R2^
M65.TK&&!4$JS-G:#T0V)+Z+5%-K*U4$Z*L5L^J)Y$2L6DED" F63'HC57R\:
M98L=K2$'*A-].F]?GP@X]?6(2?&O;+IVU\2ND^Y]+"TB5S6"]4DI&5%=8:A(
M9H6 &T$_5X'(#%@)<XYP5A-_KZ>=?;=%@WL]KVS:_P"WFF]:6N7?17^V4]80
M,EJ>5XU6HIW .]9(*@2PR9PP=/\ %.&:;M6O -OUOY:/K9?>#CJ;6VDM&6>H
MOFKK_9M-V2B"_6;M?KE16NW0%P-HDJZV:&$NQ_P4>[S)G(2*-VVKU:P.!QNT
ML0C";/PF)QV)F$Y,-A9"Y\XL7)[N4%*874HA@ 5*(2"8K8O&83 2%XG'8G#X
M3#RZKGXF:B3*3N!7,4E+DT =R: $PW:\]UM4:XJ/*[0: N=?1O$GEZ_[A)<=
M!:+?=@^?:[9644NNM2#;B6GEI=-VVQ7&((:74\:.DG70C8.S]F,KM#M>3)F
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M2VNFCWB6"3J?5#2M/'#.R1.C1.BMPVX9<[0!C:!C<N#@9"\Y*CJGUZXP1U:
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MN_6W%"'#&#=5ZHI:NE4_6   "P+HK+ZAR0&;V5?=@<Y)]\$+FIZT'TY\+WA
MD!X\\/Z4AXW:?O1XH=&^$G1-V-1HKPVT,E^UZE*ZFANG>37-NI*H0.T<LT56
M=#Z'EMM!33*8IK?>-6ZRM,\>^F)Z3RYUL:4Z^<3(%SY#Y]<(./T.7]\R[[?R
M%>Y7^W_PR]+"KMY_(QZ3W1$45B?I:_[U-0_RHNS_ /J]W'Z(<C]0\_@8\\_P
M/^*/4W@K\6O83Q1:42JJJ_L_W"M&HKI::2<4\VH]'U(FLNO=*+,S+'%^=6B;
MIJ#3PFDRE.UR6I #PHP(D4'!%?*/2HGUCHV_][-2=P.V]YI+MVP[XV'1G>+M
M_>J%@]%<=/:[T=8KG)6TP7>D<=7<'_*1C5P8Y;BT3^6R-@B ;NOB?6#I>;@T
MA\LO$CLQ8LSJBELY90QDVDD+M##)*[VW#/J1ZUY@TX#Y_?2%A"]2VT2TTSQ(
MC&-'<$J7$SABH6-UR,%LY7<RJ(R0A(PRP0@5QL5:DU24_1-#()*<A6#JT:%C
MN884LKF.16"!FE5R%=7=F((UI:V:+*0M]6=8V5")0NV4M'%)+$C9! G+R-&'
M7DK@/A]Q!!+[:Z!O>L^]VEJ:Z7Q+M:%2^W5J2"(TWGUMNI(YK>M2AF J8^?K
M*PK(I=J4#RB 22T'3>O7E$J-)HF"GHE4M&C)Y2')VD[%#-$/3'&J@J%98WR&
M(#-@<(U;-Q8?O]C=[$ <MM^K"JE80S0H[LRE3M=0#YD81<HRL1M4@%B!@$KG
M(V[C[^O1,$-D[7Z5GU/W.O-?4L6IK=%4*X).5JJR=HHXD&TA04BJCG@#) R&
M'2P0Y"YT-+9:R2E$JQPQ[#F8X7S&VA%0[2N^1V"H/GO1?5NY %*HE)46)"0"
M] 5*/D 2:4 ),(2 ') %!4@5)8#F20!O-! 'JKN9H32=RM%/=+AF]5B":ETW
M0T]9?-57-%/KEMNFK-#77FOIXR%#U$-"]/ Q#5<B1<]:VSM@[5VI+7B,)A%?
ME)*LL_:&)7*P>S<.K=B-H8M<G!RE-5*%SA,6!X$JM&9CML[-V=,1)Q6)3^:F
MI*I.!D(FXO:$](H52,!A43L9.0#^I<N2I"/YU)%8VJC77=C5M*HTQIRT=LK*
M[;6NNN#3W_5DJ_;WV[1^G+B;-;3*A#TM5>]6O51. M=I;=OAZTORG9G9;_G,
M=/V_BDU&%V/FP6S4J>J9VU,=A_S,\ N%HPFSA+6*R<>Q"A0&)[0;1;\I@I.Q
M,,27Q&ULN+V@I.BI.SL%/.'E9@RD+Q6T#,1:=@7=,:5'VGIZJJH]0:MKKGW&
MU!;]U10WKN#4Q7R"T5)(<5E@TW%2V_1NEZF(>F*KT]IZW5SQ(6J:NI<;C%/[
M3[0[J;A-EHPVP,#-3W<W";&EKPRI\JW=XS'KF3=IXY!%T8S&SI+ODE('A$LG
ML[@1-EXK:"I^V<;*5GEXG:JTXA,B93QX3!)1*V=@EA@!,PF$DS2 ,\Q9J=M+
M?26ZKEEDC#SM*997W,R,9")%W.PP.<F0-S\C\QUS9/FY_?GUI6-Z.5?J"VB-
M\!HG5BKR+P<A!( #Z04+ @X]>&*[ATGL_!SNXC4G[/!"9W 4=RG4Q3%&5490
MB_;;)>7/FN<D"3 8<XVGD@9=!'P4=31O%L D7T!3O53Q@DE!AU)4J2S>P VX
MW D@@RVNDJ*23Z[Z#M92_F;L2HPVGTXP-F,8/!&3N)STAY?#]JCB_P B.[N-
MW+TAVK[;ZX[H:VO"6G1G;G2.H=::IKCL>6"Q:8MM3=;C]6IVD1IZQZ:D>&BH
MXP)JRJ>GIHM\LR(2_#?O^#'CN@CS'?$AWPU/XD^_'=?OOK!W-][H:UO&IY*5
MW$BVBV5$PIM.Z=IY !OH=+Z<IK3IRW%MSB@M5,'=V!8K$Z0P:&R5*GZS4?\
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M$/WMINZ9_8D-OTI24>C>Z^I].U(,5)=XY*F@R!B4$BMB1 =H?;'))%Z<DL
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M8Z(;#^[!J:#4>C:FJL4,D]R2@GJ/JJ?X1I%5W\G*A61YR J'"^HIAN00=/\
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MY^T.&?2_RUZW00,WC2]U\MZ.V2&I9J-=\;L4V**<(#O(D4@;BP4GD8VX 4]
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M./581GNQ4RQ5-3Y\;/32Q^9N# KM4 $KP1G*X&6/S.#S@@ACU_UWIZ:O^I7
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.._#HB,LY\0O\ T_:/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g504802g07p99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g504802g07p99.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[10@4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 9WL:H         IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ /      0 " \     !  (X0DE-!"8       X
M    /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  #&   $FP         !                          $
M!)L   #&                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   #&     %)G:'1L;VYG   $FP    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    Q@    !29VAT
M;&]N9P  !)L    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     "8\    !    H    !L   '@   RH   "7,
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MC]^U];GLNL:S]'77_.?I%UF/6\0-I('DL7)R;W76>TZ/<UKFM@Z'\[][A.R
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MV']C^VXT>E/K51'VF9WMXW^S_/1L5\LOY?X2.&5_-'^7^"__V0 X0DE-!"$
M     %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M   3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    !
M #A"24T$(@     !1DU- "H    (  @!$@ #     0 !   !&@ %     0
M &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "
M%    )P!.P "    "0   +"':0 $     0   +P   #H !RIQ@  )Q  '*G&
M   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z,3(Z,C$@
M,3<Z,3 Z,S  4E(Q,3<U-S(       .@ 0 #     ?__  "@ @ $     0
M!)N@ P $     0   ,8         !@$#  ,    !  8   $:  4    !   !
M-@$;  4    !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M              !(     0   $@    !.$))30/]       (          #_
MX0%(34T *@    @ " $2  ,    !      $:  4    !    ;@$;  4    !
M    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (
M   )    L(=I  0    !    O    .@   /      0   \     !061O8F4@
M4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHQ,CHR,2 Q-SHQ,#HS, !2
M4C$Q-S4W,@       Z !  ,    !__\  * "  0    !   $FZ #  0    !
M    Q@         & 0,  P    $ !@   1H !0    $   $V 1L !0    $
M  $^ 2@  P    $  @   @$ !     $   %& @( !     $
M \     !   #P     '_X4 N:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.
M5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B
M('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@
M,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL
M;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT
M87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,3<M,3(M,C%4
M,38Z,3<Z,34K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP
M.D-R96%T;W)4;V]L/E!38W)I<'0U+F1L;"!697)S:6]N(#4N,BXR/"]X;7 Z
M0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#$W+3$R
M+3(Q5#$W.C$P.C,P*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @
M/'AM<#I-971A9&%T841A=&4^,C Q-RTQ,BTR,50Q-SHQ,#HS,"LP-3HS,#PO
M>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @
M(" @(" @(#QP9&8Z4')O9'5C97(^06-R;V)A="!$:7-T:6QL97(@,3 N,2XY
M("A7:6YD;W=S*3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT
M<R\Q+C$O(CX*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/E)2,3$W-3<R/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A
M=&]R/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT
M/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B
M/DUI8W)O<V]F="!7;W)D("T@56QY<W-E<R!)22 M($9O<FT@1BTQ("T@1F]L
M;&]W+6]N($]F9F5R:6YG("T@1&5C96UB97(@,C Q-R!V,3 N9&]C/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L
M93X*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL
M;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B/@H@
M(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.CDQ1C$U0C(X-#)%
M-D4W,3$X1#DR.$(R-4,U-T5%,D,W/"]X;7!-33I);G-T86YC94E$/@H@(" @
M(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.CA&1C$U0C(X-#)%-D4W
M,3$X1#DR.$(R-4,U-T5%,D,W/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @
M(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z.$9&,35",C@T
M,D4V13<Q,3A$.3(X0C(U0S4W144R0S<\+WAM<$U-.D]R:6=I;F%L1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS
M879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M:6YS=&%N8V5)1#YX;7 N:6ED.CA&1C$U0C(X-#)%-D4W,3$X1#DR.$(R-4,U
M-T5%,D,W/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z=VAE;CXR,#$W+3$R+3(Q5#$W.C$P.C$W*S U.C,P/"]S=$5V=#IW
M:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z.3!&,35",C@T,D4V13<Q,3A$.3(X0C(U0S4W144R0S<\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3<M
M,3(M,C%4,3<Z,3 Z,S K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO
M=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A
M;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T
M960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM
M86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS
M879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M:6YS=&%N8V5)1#YX;7 N:6ED.CDQ1C$U0C(X-#)%-D4W,3$X1#DR.$(R-4,U
M-T5%,D,W/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z=VAE;CXR,#$W+3$R+3(Q5#$W.C$P.C,P*S U.C,P/"]S=$5V=#IW
M:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @
M(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.CDP
M1C$U0C(X-#)%-D4W,3$X1#DR.$(R-4,U-T5%,D,W/"]S=%)E9CII;G-T86YC
M94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.CA&
M1C$U0C(X-#)%-D4W,3$X1#DR.$(R-4,U-T5%,D,W/"]S=%)E9CID;V-U;65N
M=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM
M<"YD:60Z.$9&,35",C@T,D4V13<Q,3A$.3(X0C(U0S4W144R0S<\+W-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D
M1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O
M<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @
M(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO
M<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^
M"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ 90); P$1  (1 0,1 ?_$
M !\    & P$! 0             %!@<("0,$"@(!"__$ & 0  $$ 0($ P0$
M" <)# 8+ 0$" P0%!@<1  @2(1,Q00D4(E$5%F%Q"ADC,E:!D987)$*QMM?P
M,SAV=Y6AT=+3&"8G-SE25V)TM<'A-#5&4V;Q151R<W6%DI2DI[/4_\0 '0$
M  <! 0$               $" P0%!@<("?_$ %X1  (! @0#! 4'!@@+!08$
M!P$" P01  42(08Q01,B46$'%'&!D147(S*AL? D593!T=4S-D)25+3A\18E
M-#5$8G)T=96U-U-DLM)#17.$DM0F@J*D"%:%D\+$XO_:  P# 0 "$0,1 #\
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MHME"-JDO>RD$LM/PQ?G>@H4&-">420^$N)+7U3UE*D.H6 D$)UOV*2V0I7Q
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M)"T43L$2%2SMI11<%B? &Q)Y#F/;S.&JIX::%IWD6...-I)&;=5106=[\P%
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M:PA :-1U.(7X]/MLIBUK&(R%6#ER\W&KI$)*Y:&5%*2JT4MI:0F)4M*]]E2
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MW 5Z@@I_\^_[3Q7:P"+>)N=[^T=/[_=B0.5O,_?MY<L*:*^KI2L%6X&Q[GY
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M6I;K_*CR[/.K62I:W'=(</6XM2B=RI2U%1)[DGOP\$50%"@!0%  %@ + #R
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M6=E4D(-BY4<A?:YVY]!88G4@$]1#'+)ZM'-)&CS&^B)&DC5Y7M<Z4342$[Q
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M;;';;OV]>%B,A22?9N"2.?[.O4=,$M.RO]8@;\MOCN;?:>O3&VB<7VBWX"U
M;=+HV&X V'PG<]]]MQW';Y<)-UL 596YJ+W(O8\QM\,$46,EBP8[VWN;<_.^
M_(_LPFVF/<[.;*=6L(F.K6ELN*+2.H[[]*4C\H=MMR3V_E<.,P9 HL-(ORW-
MK^SR'7QZX<613%?<&_U0#M:W6P!'4GIYVP; LN(=>D*"D(07%(\,$E'??XCU
M'S ]#V[;$\1V(!OS(]WXM<V]]L+"NFRL0&'=(/=U'F;6W 'F+$>')Q*&(:Z
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M +0.5L6KZ O"1I'B[P.X6W;['YA-U9#T^W?C,5NU5,/]8?\ E7"3>YOSZWQ
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M/+?I?ISL;##D?<77;O[:1[0#>WQ/XV5;"&FDA([) ^9.^_=7EL1W]3MN1W
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M8%DC;WA$QP]B"HNNC;L?S25G;;MU*)^7RXL( JB\C!B>1OM^/$D $?'###P
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MR3S'_P"2=_M[[^?#7S=\9?F*I'MFH?U5> /21P4+7S^GM_\ !KN1ZFU-MO\
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M^?V7\"%O7:OZ+UC?@NZK8[,2$CH4S1W3>P&^_5UUJ%KW^6^X\MCPEO1QQP;
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M[TE<#5LFN2CS4DW+:(8D!)N-QZTQ.UN7PY@[S'.7H7&>0XE_41U((*D+QVK
M4 ?S24W8V!]2.GMY;<!_1+Q?(&_*<LWYZ:J51>UNM(=^IMUY=#AFF](/ M-)
MVB4F<KN#;LU9=C_,];5?C?P(MC);\Y^A=Q'5&=?U+CM'O_$:B)"</_4+[&0)
M?2GT/AK3N._?A">B'BE"6[7+&)%K/63,K>)(]34AO @G?VG%\OIAX0466+.
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M8&!P,#%JO(S_ 'I7/]_BR=_H+J/QQKTC?QU]&?\ Q=?^H91CLWH]_B;Z1O\
M@X_Z?FN.<SF*SNTQK-+EA&LT_2J'CVA]MG5"PPK%G(-_F4#(78T*%/JK^GL9
MN1-2VFF*]5'32(<^4F3TPW6YCC+R=/Q3F4]'69FT6=OEDE!D%/7Y?3 4DD5=
MF,M7F4:P24TL+U%9V[4U+3+!321RDSVC(D>,C-<-9;%64-&6R1,U]=X@^3ZJ
M5O6D>EHO5Z9GDCG@FCAIC$LE14=O5)+$AB+2#LE=27-\VMY'JW8<^GQ9G.JZ
M#J]+N,1<L9#=G7C3;3N'F,)V9 #ZI\2/96,UB!*=>8#8BO-N1%>*H<+DXOE
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M9I.'14BLCD[0F%$F@CI^P"]F7>;6^MDM:5F795+1FCGHSEM714-?5QNE8)1
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M"R8TB,NUAM(5UN26XTV-F5J<PRN&E2DGJ5@^3.*,WKWECGS6JF;*JV@IJ*"
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MB20L&I]/9M/KED)!MH:I[TC7TF?O,3)OBN,>9CNM!67+1Q@-%..^L3&*,+I
MU"!F*):_9$Z1HOC49B::,QJAV.Q@[4.RM'95 XRU0(C3[J:VXP](IUH2&I5I
M+:#K+KL,N2Y#86VM2TA0X2(\K"4RA,O$<K,](H2F"2-*MG:F%M+M*C6=HKEU
M8@DAMUM+F[/.6;,&DBC5:G4:HO'%$Q*)/OJ6*)B=*R60'F"<?7I.G(=77NS,
M+]XDK<HUP7GZ(O2%O,,0'J=<52@X\IV+7QH;E>I"E.,0F&%M*;C(0@,^5EVC
M=Z!I)=<+1L].9)"R1+)"RDZGO'! KQF]XX8@P*HM@@S4!90E<(X]$XE"U(1
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MJM1MZI,14AH^V3L"(R'O"W;+H.\3=H.[<X!UJT?"*IPZD84$7M7,O*<_6*K
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MR1=I2JIL@RFS<SS4R)'7=TPR:2U5-2(U%45$E=1=EM=3%38PDN/R0EQJ7/\
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MIXXGV<*-SB0>IW+IIKGF9Y#*IH&3XW71+/-L*JG<4I\9CX?@"=,L*C9&BSU
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M?$:B9JB?1EM,O:SNJH\S]W>1E1 S=0HP[-Z+>$ZA85FBS"44\0@@#YC4'LH
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;IX*:(R$%S'!$L2%RJJI<J@+$*H)N0H&V/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g504802g15c64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g504802g15c64.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1E84&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             $D   #G          $                          0
M            YP   $D                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   $D     4F=H=&QO;F<   #G    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   !)
M     %)G:'1L;VYG    YP    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      /,0    $   "@    ,P   >
M %^@   /%0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ ,P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M8]>KIEIP.GXM53&P&U5M@NTF8K4XQ 4#9G7%PQ/#P#QDQ2RZ7M&^&R.+B/\
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MD;=VWV_SG^C9^B]_^$:O'^M'UPRFVOW65-)VVO\ 9C5_O>E^^[_B_5N_TB]
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M_]D .$))300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @
M $, 4P V     0 X0DE-!"(      2Y-30 J    "  ' 1(  P    $  0
M 1H !0    $   !B 1L !0    $   !J 2@  P    $  @   3$  @   !X
M  !R 3(  @   !0   "0AVD !     $   "D    T  .I@   "<0  ZF
M)Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C R.C(W(#$T
M.C S.C$Q   #H $  P    '__P  H ( !     $   #GH , !     $   !)
M          8! P #     0 &   !&@ %     0   1X!&P %     0   28!
M*  #     0 "   " 0 $     0   2X" @ $     0              2
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M  4    !   !)@$H  ,    !  (   (!  0    !   !+@("  0    !
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M  (1 0,1 ?_$ !X   (# 0 # 0$            )!P@*!@,$!0L"_\0 01
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MF'=^=P#D5R!VT[K7C+(6.O5=Z8+A:8!1AEL7>[?$21ZYPV5;]R2!8('9)D6
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M]?F\<CI]'.M<6_=W<-OI-[T)R#W[Q\JBK35S*[<J!L3;FMJO8$P-KB,I2HN
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M<0OQZ5)SEX_AX!&P)"00&S^1*D@@,/3T%Y'ZCN5EY'MR"/J#KRX^,EE/5FB
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M<QR9K%1R#GCE'O0*PY'!'*D^X/MIXMURR0;6W)/">V:' 9B6)@.2LD>.LNA
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M?/W_ "S_ %\9Z9/'U?V?;^OV_K)X_P#'2DY:\O#-S^Y?U)Y]OW^_U'YJ.?J
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M.LO#B8\L:=O$#MQUB*=8_23VFKC)M&\DL=^*RYG'4;CK&VM%<-L<X8_DUO\
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2HT:.C1HZ-&CHT:.C1HZ-&O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g504802g21v14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g504802g21v14.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1[^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     #D< 5H  QLE1QP"   "   < E  "4=I;"!(86MI;1P"!0 74&]W97)0
M;VEN="!0<F5S96YT871I;VX .$))300E       0.2EYEG^3EMI5F%K4QQHA
M*CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!3@           "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 \     !  $#P     $  3A"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          3A"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         3@   #$          $                          0
M        Q    3@                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   3@     4F=H=&QO;F<   #$    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   $X
M %)G:'1L;VYG    Q     -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $     SA"24T$#      4E@    $   !E    H    3   +X
M   4>@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M?4-3[,=WHT'TG54_J]5U-%EK?YS^=K_P]A^@X/UAQ,AM?4+Q9B58E5+6M<'
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M?3J_-]OI^S^;5*^K)V/M.-5DEUEE]>'<\"RMMCG6-L-+=S/4VN_2676?J_\
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M!TS'KM]-UKK;JZ&,;/TK3L:YVQMMFUO_  =5KU1Q_K=TRVK'NM#\=F26BLV
M$":*,T^JYA<VO9]J92__ (1EG^#24[J2P/\ GAT\ NLJR*FM>18ZRLM].L,]
M;[5D;O=338QEOH;_ -+=Z?Z-7>G==P>I6BG%]0O%?JV!U;@& 6/QO3M?]!MS
MK:+]M>[_  7J?S:2G!^O'61@WX5-3!;DD.M@F&L#+*;&/='N?OLI]FW_ $:T
MOJCUNKJO2]C:O0NPMN/97.YOM:/2LK?#=S+&?YC_ /MQ0^MW0*.JXK,@-?\
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M[$U.H=3Q^GG%%X>3F9#,6K8)]]@<YN_7VU_HUE-^NO2GU&\57BH5UV%[A6P
MWVVX6)0[U;F?I<C(QK&_Z"K^=R;J*EK=0Z;A]1I;3EL+VL>VVLM<YCV6,.ZN
MVJVES+:WM_D/5.GZK="HQ78M.,65.957I9;N QWV9.*:[?4]6NRB^^VUEU;_
M %?Y:2G/_P"??3@]SS1;]C;C"\Y(=6X"PY%G3?LFUEA:Y_VRKT69%5MF)_A/
M7^S?K"M],^MF!U3*JQ<.B][[*WV6.BLUU"NQ^)9ZUS+GUO=Z]6QGV9V1ZO\
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MS&(B9#4@>EWTDDE8:"DDDDE*22224I))))3_ /_9.$))300A      !5
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M     49-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0
M  $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L
M @    H   "PAVD !     $   "\    Z  +YN   "<0  OFX   )Q!!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C R.C(W(#$X.C0X.C(Q
M $=I;"!(86MI;0     #H $  P    '__P  H ( !     $   #$H , !
M  $   $X          8! P #     0 &   !&@ %     0   38!&P %
M 0   3X!*  #     0 "   " 0 $     0   48" @ $     0
M    2     $   !(     3A"24T#_0      "           _^$!2$U- "H
M   (  @!$@ #     0     !&@ %     0   &X!&P %     0   '8!*  #
M     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "@   +"'
M:0 $     0   +P   #H   #P     $   /      4%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,38Z,#(Z,C<@,3@Z-#@Z,C$ 1VEL($AA:VEM
M      .@ 0 #     ?__  "@ @ $     0   ,2@ P $     0   3@
M    !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,
M   !  (   (!  0    !   !1@("  0    !              /      0
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M 0$!             0($!08' P@)"O_$ $T1  $# P(#!04&! ,%!08'  $
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M<+C7;LVQM,M9063JQV7%4K'V>9AWJ;?V_@7<R>(&"),.!=M&*,FX=!'' A2
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M8JJ5-N8S=@=^^6/[;93G#5Z?B<($:HF.A.PWR1^:S]DUER64G^S4$D$%VPF
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M+U6;"BJL@BV,(%1*H3CPF ![6G>U:[#7,L)+H C.E\9QSW7M2OJ['M%/3,D
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M\\=3$^<#!^?!RAP <?X!Y]V@/;#OY?S^&QY>?DO%[8(($B1[B#.W/:?DJ_\
M>QMGMF94*'D3%DHQALIXKD'SR+;2*B;>.M$&_,U6E*O*N#=!2;/SL$O@W1A.
MFQ5</%#(JBMP36N.\%%[973&BF*IH5 PNU;D$MV<! D\L23NND=A^U9X-6%.
MMW_W:L]O>!C6N@X:XP6.=.D 2"T!H;SWJF=9BQX_F)F*MJJ6)<@U%R2)ME"O
M*Y823+(F<E8"_CVKXS)9_$+NQ,HRD4FY4734Q'"?R"&N,7?!WVI.O2QS(#F\
M]0.8S(SN(WGS7UEP7C=*ZM)IS6IU/%2>WV>Z<):=0U!PT9#A <<#<QRC^QP\
M14[+>GPDAZA7 (Z6N=N=)U6AM) R2ATDSV.1*,=)O%$44W*40DN@X6:J(*@I
MU<$$)LZ.H.<YLL9C6<-!@'2''&KHV9,^%8ZZOJ%&_I4-8->M#V4&^*KW9<0Z
MJ6 ZFTV1#JA&EFQA4IY=W&I;I+C7<08Q3=&H/Z:H6>]6EZW=,7-_GV;P_P"&
M>TP676)'U>'*NNJP8)F5.X<IQCL7BA6QBK>/$*U.FXT@,"'D@072/,D@?AW
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M@F^.D*O0';=V- 0M@NF1[GDN96>L8FMUYBK#%4CT'[X+*Y12?+1T X1]M1;
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MISF(""AR@0!#D/'.4M9K-U3/B$]8.1OMT.2?FO&_HM:UQ($EA(\(\M\R#O\
MW 4\=RX.4,<N[8P5%![27T79FY@$2F*]A%ES*"4P#X,!5R<#]?\ 79N$TS;7
M5*N/#! ) Y2.8SOR_NM-?:#B+ZMF0"TTZCP' .:2T$;$Q S'K &R]/M1L#.S
MU*J6AB<%&EABHJ:9G#GYV\HR1<I&#]WLN '^?U#7T+PU_?6S*D8<QKLY(\(<
M/?./3KNOA'M%0=8\4N;69-M=5;>1LX4JCJ9=CK$QYKOZ?T-^XW_LE'_77H,:
MO^+\P"K7D/3/Q*U-5*$T1-$31$T1-$31$T1-$31%LSB<IE#G,8$>P%/[G $!
M("E$3D$@$,7@3& 3&,8 $OU_(B^VXF$5 4$O<!#D"G[ !!YZ#U\B7L7R "(B
M/YCQHBW.B)HB:(MD<QS"HF7W#CR)C$4**8"GS]$3D @CP/  ;DWCP/(CSHBV
M2BBJ8F5,<P( F*A4!#VSE(GV!<#J' PJ%3 H' I (<O<QCG,4Q +3^+_ )?U
M4CD/-5 3V[G+>^:WR^&]A4RTK6(8:==5_+N]9[%DGJO'&A'RC:9J>WA10QJK
M<+H]=-CL5[!)&L\17FGQ:[JM.%CMU6Y\Z' &,',D?77?$85%40YH/,\\''48
MW !P)V(4%]]^W''&TW;INPA<<M9R0GKGA>DR.0,G6N:>6"_Y%G)F<RTQ?/[%
M/21ED/8,A'MD_P &K[*#@&K<"(Q<4P5!TLYTCM0YXX3Q.'%I%I4((D./AJ9!
M!W'(@ ?#/;OLOIT_\5X8]U-I>VXJ%N*<-,6Q$C1,YD DN$N((!:&X6]-ZI&B
M,=#8VS(7CYG$M4610)V$[IPBFD3KU+R*@ <X%'GL >/H(ZX/P4.>6FK-1V/;
M.O?_ (I\A"[[VC).IK7Z6Z@(!+1CE C<;\H)\XL0F'J+>S/'J3T%D\:P3>D(
M^X8!(.3+J16QVY4P"(@91C5GN/D4#!PLW4*IY # &M[K.[FD0R6AK T@;.<[
M.IH&VEN@$3[\XTO@E,W-?O'MEM2X=5:=.A]*C0<UE.C5P"]M6H*SVS#2"8!S
M&+0>OVBYI%%YW>+,5Y%R0!'N9PL9,JA ,4P' 4P64=*>>3MD%DC_ *HYPUK=
M2J_O'14>W./&[WX)S.QQ!'5=)#6E@8YH+0!#2) TY: -A! C^4@1$*OG=;%.
MZ9^&YJK78DK07"SR6CBA_P!=ITQ[+BQ,D^H>X1.*68A*-4TQ!-JO872Y2D.[
M.=2T<T.DN\?4D3,G/I!!/3,%4N.\8@;@1$>G7;/3WB3UQP'@'<'1J_-66!?_
M *8G@(V64DJ^N1BI&.'+%%XW]PZ:"I.RJIBI<K$,)@4$2B!^I@HKTZ?<.AL5
M#S;#?Q-./#.=L&3@8&]B#<&M!<WN<:9U=XXYU3)T@#,")\]YK^';%C.M97C(
M',%FNSIB1@DO326"><2+5JX1?.E!39$=E!%$P@JV[ W(41 I ,' %U8TV[:B
M3&,DF.AZQM^VZOPWH 3R/OQF(]/6)Q*ST& MS;9E_65M_N5/GXNR?])2]&L
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M;)%2.]K&%YUFW4;,+31ZQ;HUDJ/ZY&,L\0PG(\BBG4I3&29.R$,8$R@<P"(
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MBP<F)(-_TTARD%0Z<=-%<..E@61(H84'$8]D$R$,"1CIFX*&KAM1E0ZF:AJ
M#B0UP!.#B2[G@>?OT5O$ZEM4=0K<,H$ D.JU'A^K3C#=+M)ZG5D^F8IYFRM2
M/_2SV87=%Z[C&QU,G4.Q-IF#>1;IB,IC>Y3[1)PDJE_:0"3AF:8"GW+[G53G
M@O8-A:XW/#[FD[_+ITV/J9F *U)K?#'BEY;N1&8G 6NTK>RJ]I^%5Q<B@^K6
MN:;:3*9T_P"BN*CI= _#3($-R8G3DJ=!\I4$J1"#8&"JJ F57X8.!-T.')?
MHAQSQXY\<^=8/N[5N)$_^68^,?&1*W2[X(*Y_A7M23)&FF9WS!+P/KDMF%_1
MGE6Q:;7GT^[63X!X_(1HP;]D^?<4.H=3@ _N<_S#4?=J-;#0TGKH$ 9Q)_/K
MSRL8S@][;>Q>7+1F(> ?7%3,^4[K$.4\JTG#4(M:,]7V"0]KW1C*97G1W3DJ
M:)16$JB1"))IF,<1 '*'NO#<^V=J4B2)UJF6,/[N"0V"UK-(!G,&" !F/Q'<
MYDQD^#VEUQ2\?9W#B^E2<PNK7$5</D./=EQU.$8!P1B95=N/<=[@?6:S=!4J
ME0LUC;;/7)1S(VJY/R?!LFL*@W<M 1:MVZRB+^:E4UB131),_N'(]4>N#($1
M4(7>> \(J5JK'%@8R!+BUND8P'9),XS$DD'*M^WW;#@G8G@M6VH5 ;BJQS6T
M0VI0N*C2\-UT=#'-#7B2 ][ QD@C4-#O;]MNP10-M6**;AG&D.WAJM281M$M
M4$D4$%7"J?91Q(."H%*11P_<J+K*JB(F'P03'$G(=;MK9MO38&C3#8(Z]23S
MSUR,+X,XYQF[XWQ"K>7-5]8/>X4]3WEM-DRUC6NV@$%VD 22<RL_:N5B$T1-
M$31$T1-$31$T1-$31$T1-$7R)"" @)"B!AY, E 0$>..1Y#R/  '(_;1%]:(
MFB)HB:(FB)HB_! !^H /\0Y^H<#_ (AX_AHBQSEU$BN,;V42%-VJ\J3]D!$2
M_#'X*'(?3Z\!^_QKPN6Z[>LT;NIN ]X5S9L[RZMV?S56-Y<W#KA>=Y!H;_TV
M]S<JVY]F^;7W-DZCST-^,8BG'RRI@\@<QW+E,#G'D3F./81$?/&+VG]VXU0!
MW<WO-6)&JFX\@!L?G)*^C.(WX=V3HT2T 4JUI::1,D6=[:T^1 _!M'I'*PCT
MATP1]/S"K5(!*L52[]A\@;DF0[4 @ ^.  ?V2_0 YXUVCACM5G;'EW! QB9,
MB.?SG"XQ]H#7&ZHO#H;]WHQ!@@&I5GWGG[NBS=O"V,X7WFUAW6LE0)&DJT;B
M->OD"*,?;JV^%,WLKM7_ +*H+)#Y(=LX251,B8Y1('RF##7?!J7$V:R 'DD-
M(T !H.1I<P[XV@B-U<=E_M"[1]D*S*=I7=5X;K#WV56O=F@YV9>*5*YI-#MY
M,0027-)7F3S5Z<._/9)(+3N'W;K.N+V@N5V3ULW>A<FI$C=RMW;:%$C4WMID
M 6[A)@@JJH=8%#J 0@$T_B'9/NBYP!+6R0X&GG>,BG@'T)QA?:GV?_;YV*XW
MP]G#^,<.M*?$WL%/33X*:CG.B"_OJM:IJ@N$/&Q&=I5:VXK>Y9IR0P,XR9C9
M.&L^+LVP$ZNPLE>=PSY=H[KEAK4DW>N4C,'#I'V9E43 MR!U"E,;GCC6O.X9
M7#*UM2<[_>6Z'#4W+6/%8"=(@ T@?0=!"Q/:?LGPVZXM:]HK.^XC0M:=V*=-
MO?4;5H?>N=;TOX7<2TGOPS>();&RSC,>I1BR,(Z>UW'-+_$U0.)';)S,2RJ;
MPJRX?#+QSJ;<MP H>WU3%  ZF .O'TUFZX-<M) =M.>^! (/0"!/,D9]\+H'
M >QM!S>\J\1XBX @'_>J3^AB#0.?+Z.W@]S&^W=&K^BFW3#MC<-GJQ8]26J5
M-DDV$,FN?VP=3#UNV<IQZ"11Y467.!"!Y-]-9K@_9R^N3IIASR&R0UXD-(S^
M';.Y&"//-]QNEV4X!0;7XEQ.\M*3G!G>W-2@QI<=AJ=3 U1,09P9$$$6+;9O
MZ/MDC*LO%Y%WP9AEIA,CM.16QS4)5LH9VKRBL=M-3[]"4(@V4(/PZ[.,9QCP
MG0YOBRB)>N_6/9$4RW[R_2]L>%KJ;BX1S<:9B#B"/+=?.O:G[9.&\'N*]MV>
M94NVD.#+N[H5*602T/(HOI.KMQ+',>P8D@Y*]1>(<&8YP528_'N)*77J55(M
M-LDVC81 40 &Z)4T?B'*ZCB0>+$(4.SA^[=+G-R?W $P\[Q9V=O:M$4PSFUK
M6@M(ZY;,B.;O1?+/:/CW%^TEV;F\NJUP[(-2M5?K )F T$4V #$,IM!C,K-2
M"!B.DU/J'PI4Q'GR(E$PASX 1X$3<?Q'QY'7N3))Y28'18]KFBB*1G7JUS C
M8 Y]?)<GJ%2FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+J5](
M12EVA-0.Q#PD@4P?F MS@(:M[IQ9;5WMC4VFYPG:0)$K(<) /$[$'8W5*?\
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M;<I2N*&$X"5!U 4>2@': *<=$S$<#P)1\EZ^V(=A 2\:JXO73C13<TSB((9
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M4%!,)1  3$!\<FI4G\0KN?3+6ZVC_,)!U&HUT^ .W@YZYV)7U,RV_P +XO\
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MA3KBG7K=W4J,G34=$.#W@D3+3S5MIBE[E^4OV^P?GK>7$ZAGI^:Y; Z!?28
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M. %=R=/F<=1+A$H_1PLDE)N#&,0>4RE.!B^>0L>QETWNJ+"-[:BS5."\-:"
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MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+26'A,1_[R?\
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M7'#*)V89MF<OY<F[N:P04ID:0L0UA:9DJZUKM9LB+N;75@SMBEG7<2B+)".
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M2I6>ZI5J/JU'&7/J.<][B=RYSB7$GJ2NGLILI,;3IL;38P!K6,:&M:!L&M:
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MQ7X>A>XAY&W"O-(R*C8I5O ,)IHT0,Y%R+<17((%!)!QC$#S'7W^2Z-E_(^
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MI^Y^IYK\S)[P$[@8S^6.?SW6[('!0X_?_GJI2OK1$T1-$31$T15:^LAF/'&
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MJ;R2YK'B'.;L"!@Z29$Q&".2["02F*4Q! 2F #%$!Y 0'R @/W =2I$QG?\
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MSAWV2"5VP/)4F-?%48E+^L.!YUC("5=$"I\@"? F(.N76- 6U_<6$?ZAYXD
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M< 4P@//D .( </J'R"8>?''.LRPASFP1DC',;'(W&ZUE[P&ND$$ ^%PAQC.
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MO&M<]K2Z>]=2>"\YEN9PO1+78EE PL=#1Q"IL(MJBQ9$*4"E(U;)E10*!0
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MS&V((!\\>9B=X WE;-2ICO3(,B8W&WG$?O\ !36K;49=6%N12"R3G2)Q[L1
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MG< >^?B3@>41[QU5#A$[B<#5MM[@1N<_GA<E7(!TM2(^8>%*E)Y9LR:*?NE
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?J:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g504802g32j62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g504802g32j62.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2M04&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 6#+1          IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ /      0 " \     !  (X0DE-!"8       X
M    /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  %]   !OP         !                          $
M ;\   %]                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   %]     %)G:'1L;VYG   !OP    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !?0    !29VAT
M;&]N9P   ;\    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     (X0DE-! P     (+\    !    H    (@   '@  #_    (*,
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M%)]3(#?0:P[P_=I4RM[/SW+M<3";TCHV-@"\47.(%EVW=-KW;[]L?ROT>_\
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MSOK#GX61TB^FB^NVUYK#:V.#G$^I7]%C)<Y?.*22G__9 #A"24T$(0
M50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !,
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))
M300B      %&34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;
M  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
MG $[  (    )    L(=I  0    !    O    .@ #L4$   G$  .Q00  "<0
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHQ,CHR,2 Q-CHU
M.3HQ,P!24C$Q-S4W,@       Z !  ,    !__\  * "  0    !   !OZ #
M  0    !   !?0         & 0,  P    $ !@   1H !0    $   $V 1L
M!0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M         $@    !    2     $X0DE- _T       @          /_A 4A-
M30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D
M  "PAVD !     $   "\    Z    \     !   #P     %!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C$R.C(Q(#$V.C4Y.C$S %)2,3$W
M-3<R       #H $  P    '__P  H ( !     $   &_H , !     $   %]
M          8! P #     0 &   !&@ %     0   38!&P %     0   3X!
M*  #     0 "   " 0 $     0   48" @ $     0             #P
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M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %Z ;L# 1$  A$! Q$!_\0 'P
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M?^)7:[^OHPY^9^L-X\$_R(_M@_2\?$/_ 'X3??\ B5VN_KZ,.?F?K#>/!/\
M(C^V,?TO/Q#1T/C#;Z@_P+[6_P!?1AS\S]8;QX)_D1_;&7Z7EXAQZCQA=]R/
MX%MKOZ^C#GYGZPWCP3_(C^V#]+Q\0_\ ?A-]_P")7:[^OHPY^9^L-X\$_P B
M/[8/TO'Q#_WX3??^)7:[^OHPY^9^L-X\$_R(_M@_2\?$/_?A-]_XE=KOZ^C#
MGYGZPWCP3_(C^V#]+Q\0_P#?A-]_XE=KOZ^C#GYGZPWCP3_(C^V#]+Q\0_\
M?A-]_P")7:[^OHPY^9^L-X\$_P B/[8/TO'Q#_WX3??^)7:[^OHPY^9^L-X\
M$_R(_MCC]+Q\0\G(\8;?C'P_Q*[6XR._[(GOT[CMHPY^9^L-X\$_R(_MC@>'
MIXAA.!XPV^Q__P +;79_%SZ,.?F?K#>/!/\ (C^V,OTO+Q#0,GQAM]>Y2?\
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MFS'CAF-$B-SE.R9+G7R66D*+J\H&2D@^BJ6K"23(G)0'>84&S/<DAK>;YZQ
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M $I4K98J<)=>@TXJ;2F;+I:)/M<>(LR(G(\ZV$_?DY/WQHZ@$S>K3,*5--_
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MH$.&A3,J)4'/-26W6)1YW484@H4L&L5C)J,;EX--PRD-.M"!]V%"H3HZ[[I
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M493:!!9D\\B0WRY<*GL@^NPZ9%4G'9LZG0A:25)*D@%#IX!A8Y^[5_2H6M)
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MD(8?P@_UMCA+_@\G_GC<^D3*S'Y4?T)A1<-7ZM?Q(?\ 7OAK_P!V:P=2'/\
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MXOO_ 'EPV_\ DS_Z^D1OP'F?I&8B^+Y_\_PV?^3/_K:1*RN7FKZQ@8GB^_\
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M *^D+\!YGZ0>Q^+[_P!X\-O_ ),_^OI"_ >9^D'L?B^_]X\-O_DS_P"OI"_
M>9^D'L?B^_\ >/#;_P"3/_KZ0OP'F?I!['XOO_>/#;_Y,_\ K:0OP'G^D9F)
MXO7I/X;@?_Z=0_XZ1!E?Q>X1B(?B^9&:CPW8SUPS/SCUQ[_?';2(WX#S_2(\
M[8;^>*UNEN]OMM!2AP\PJQL-5K9I-=GO-S51JD_<],-4C^SH"LI#332TDYZ$
MD=3V0Y>(N=!W99#7/C$A?8_%]_[QX;?_ "9_]?2%^ \S](#$\7T=?I'AM_\
M)G_U](7X#S/TAU=DHWB.)W%HR]]I^RC^VN9/TVS:#<E-:4#'=]G$0NJ*26Y)
M;2[TZ@#Z](?KQ]?32&;XJK1WOV4XPMO.-+:':&M;\4F7M96-D-P[$MV=!AW-
M0J7+JT>XZ7<U';FO,MSFTU&*F%-9+G,VVZE020"0A=^7KUX\HBI=/#SQ+<0V
MWG'5Q W/LY5=N+\WWLBV=N=M-GYM1I\FY)%OV=+]H;K%:>:>5%ASZA(?=#,7
MSL):0G)!.=(C&OXW>#/=.K73PL;Y,[4[@[M4&R-C*;M+?^WNUU[O6-N!0ZF[
M2:6[%K,*;'E1FZE3XT^"N%4H9>P@%+J00.B)<FL2VHSX<=81%/X1-ZMD]H.'
M+<S;_AFKS=8MCB7?W<O3:BF7HW<]]M42JTY5-8GU>KU5YMF=64H6E^HL,O*+
M74 J.3IZX1%[.W/GIG\^41RJ/AZ;OQ=P]TK$N?A9W0W*:WKW4G;CV[>$3=V7
M;>U=(MR^*D*W4:??UN1IODQZO;2WUQ7X\:.ZF<XSE"^HTAZ#GQ'=?R:+4]MN
M&'=NS-U^.M^+M;0:U;E][.;56EMI1KGF(<LV])UL62*14:#*6I2Y"("7TF$I
M^2A"E#D<Z@9TB,0VX&>&WB0M'B^V]NNU-E]X-A-IJ30JR-X[7W0O>%>6WQJ?
ML[<*E0MIXTF5-GT^/[2TN0AY@1T)A%#*LC TB5K\ / '3+_'B,OIF3GF'U=
M>BN7KU/3XXP/ACX:1-'=I"(J<=/3@MXL".XX=MX?S"KND(8;P@OUM?A*_@[G
M?GC<VD3*S'Y4?T)A1\-7ZM?Q(?\ 7OAK_P!V:P=0&9[_ )""LD?E/]:HL!U&
M)8-(0:0@TA!I"#2$&D(-(0:0@TA!I"*K./<__$IX=)P!_P#$%6!\3@6T[^+K
MUT>X')1RMD-?AS:($:]V7?\ "]^3Q:D!@ #L!C\6D1CG2$&D(ZG5\H&.Y/3[
M.^D(Q#G0KSS8.>4=,)5CJ?CR]1GM_2A"2N.]*+;$9V75YS$9+84IMM2_OKGR
M0E))5GTSV[9&=4%7B%/1RRN;-0"'%U 7[LW'=\XKJ3#ZFL6$292E/JS_ *^Z
MW.(NWCQ#U.6AYJVF&H$<$I7/FDA9:QT=9"L!/7L%G[<=]:XUTAR:<JETW$@K
M469OW@6RS'E&P\'V$*P)M85FP(E@75D6;W6)\XB'>V[2$$2JQ5ZG7I2^<!33
MRQ&"\D!IQ#:@V$Y('<C&M';8=+2,/E+548FA )46EJ8AR3>^C%VN>#WC:6"[
M'T<HIEHE;A9+=G2QX7UN0[^$-)5=Q;JE0/:Z6S#I47J6XJN5R7(!]6".I421
MRG'0]SK2&/=*5;44*YV%SE5"SVDH2LJ)=R#KQ=N-A&9R<#P^FG($Y 5D&*6N
M/+QX\!JC(5VU&2%1;A$UV;.=7&:]L*DA+:AE*VVSGF.5 #/P'4YUKBGVYQ;$
MIPD8J)TI2LNT;^\%M#W%XNR\/I4CKJ-*6 R+ /DULLV#V8\',:ZHAJW*G3Y-
M-1(]I<24R3Y/WP-D^\6T^]D^A]?CJR8K75,C%:8RIRYLM?XD%*E6)U!SSO89
M<S%13SDSI,Z7-DHZH#.6D$/<N]FN^7A&PD5!<BY*<[(FSH<9J.$)E2&@RA:W
M?>4CWO=/*GT].NKC6];.Q&F4A,SJ5,ZNK4UVL2W?X&/ (DKI" E)5?[O+B X
MYL+G*V6FW\J(U<K<]JLJ=66W5+<ZJCI4L8"'% <O/_XLCXC4J\,4C$A6)343
M3:_5K.1MH^F7"T><H;U$JG32K6L_\KV&=R_/*Y#9F.6(-OU"L5"36)S<L(;C
M*8>\WD0HE)+B!R' QTR/KZ:NLJE5-JIM5.35F2EF0J4O=3GR&6N42)74TDJ3
MU$N=)"BK>"@02='<.QOE?1\FZ*8\TY<+C#$SZ/IK:2S&>0L)$S)'4=ARD9P5
M? Y],T--6IJL1ZKV=4E&BP%IS!%[96#,7O9V+)I6N3UBTH5^;3GWOG]8]$^:
MU0+HA.NSE3VWHJX[:R&W%1G!T..3/*5YZYZD'IU[RXE5?LK&?9^O:6;%6Z0F
MQ/$:WXW9[/$LJD764UEJEVT[C8:\OAE&,Z'37RY,2F?&J(>4XR\V76U.X/WM
MW&1SI5@82?7L-9)35]0A04B?,2G4)4U^#/S;_,>4I:EKZO=3-+!W +9'1QS?
M(#F85D&Y*E3UQDQY+[TEU*5*BRU!*70G_.*23[X7WY<D9S]6LHHMJ\1IU;ZE
MVX;QO8\QW6<?&/"9029R)TP)2P-F%@S:#7C:WG"]IVX-)>F_151#E/GAL*2Y
ME2$@!.>=MY..7K]1SW)[#;&SNWBOQ3J@(5S7KHY<^-F#V!9XQRNP%,Z6ZD(4
M;787>UO5R\2%LW=NY;?;:5 J7TU3D!M'LLMPND-8_8/<Q(41\1\.VMQ8'M]/
M0=ZIJ$+19PE8(8:B]SW1KK%MC*><VZG<+EB$[KMW#CZXRFLS>FVKC4Q%FK%)
MJ*SCV:2>1!5Z<CG0*]._7YXUMK!]I\/Q= ZF<E*N"RQ/F;.;?"-<8KLM78>2
M4(5,0+V!<#P#?3(\GJ1)0X I*TE)!4%)5S CZQG/RUD8.]DM)_*Q'QO&+J2I
M!W5)4D_\@1\O3CC'I0H+2""/GCTZ]M>D0C/2$&D(-(0:0@TA%5O!D >.?Q*,
MC/\ [[[/_F;-/\YSJ.A[Q\#$-1W'XB+4M0B,&D(XY4GT'?/V_'2$<<J<YP,G
MN?[_ !]?CI"#E3\/[]/^ TA!RI'I_3_/I"#E3G/*,_'&D( E([#2$'*GH<#(
MQC[.VD(.5/P']^O]QI",M(0:0B*G'3^HPXK!Z'AYWA!^8_0#7^FD(8?P@_UM
MCA+_ (/)_P">-SZ1,K,?E1_0F%%PU?JU_$A_U[X:_P#=FL'4!F>_Y""LD?E/
M]:HL!U&)8-(0:0@TA!I"#2$&D(-(0:0C%> .;&2GJ-(1JYU5B0(RI4R4S$:!
M*0X^M+3?,58Y>92AE6.PP=>4Z=+D(*YJ@E(S)RU^FCQ[2J>=4*")*%+4=$A_
M/EY>$4^<=NZ=GO<2WAZ^3/+Z(6_M6=<=;;6XUUMUQL^]Z\I&21Z=<]]6O]N4
M!4E(G!KO<7=FX9-XNQ;6\)V>K@CK%RBY .[>UGN_?W>8BWVC5N%68+50I\EN
M7%?3SM.H.>;)'3Y8!&1W'4'5UE3I<Y(7+6%)(<$%[&+//D3:=9ES4E*@2+\B
MWRUC>#KUU."#\X\8ZU+#>,]>91Z_#Y#\8_+J,(\LMUMI"RMSDPDJ4XK'*VD
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M.=7"HV*V,2DR)6 R%2E?C*92&4WAK8]P,9?TC5^%4^#!%!+3/Q)(='L2=Y(
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ME\H0T.H65$_L1@=>P^OKLZ;-ER$&9-4$(2'))86]VOIHUE*EKG+$N6DJ42P
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M"?=84I3L.02>8J0H'#B@.F5=>FI=Q-QN@$D/8=JYN1KX/\8HU%:QVT[X"GN
M#X#S!9C&\CU=QI7)46O*;6>1,AO+C:\]"IPC_-I/KC(Q\NNO&JE)"=]( 7_$
M '.69L3YQX5$E*4@R3O3"6W+6MGWO;.*WN+2#"HU_46J4VDI:9>;$J4^RD>3
M->0\VI*'%)'+@Y5@*)/51'?&KWARIJY*I:IB$*4'.ZK\5\SRL,WU+ QT3T5S
MZBOP:LPVLJ-\HWDRT3%ON!BD;J5&UVR9BVN3H7=Q BE[7V?)I%%BON5"/[/)
M9E)2XS$<BMH2H>6H%?49"%?(_#.J.HPNDQ8KH<5II,^2S'>0F8G^%P% W]XX
M91BN%;"*K=IL1D3:E6Y+42%@GR!L<\QWVO#>V]<EFWO0*_<$A7Z%ZG16@]-8
MC\RHLM+B#@,HZ)YUJP/P>N,D]]<Y=('V=L%VA17S,!F*H:P**@F4.J)4"2D'
M=8BX#AV#GPNF+8+6X+BE/A\J4JIEU#;LPW+$@ @YY&^31A9T^3N/4K<MJ&^Z
MFG/5)MN5)=;2)7L;6%*2MSO[R1RX!P$GXX&N)MI-E-JMC\8I<%KISH54]7,7
M,4H[R=X)).]>SDW.=K:6W:RG5LWAE54)+S3*!";@A;7Y.3Q#$F+&KGBV_;MF
MN4"G1827WH*85.B(;;+SLM38;0ZOD3G\(\V3G&<YZ==CXJ,*P["9%+2!$VM$
MF6YDI 65E@%$INYM=PQYWCFJBJL1JL0F5]3,4F6F8%/ODL 0>RY:P&AS&<1^
MM:M5"W)[%GW-'53ZJVVB3$D%2N1YO)4EQMWH$N(/N@9&,<@/QS+H_P!LJC#@
M*6<I4M4MB1-40JS$L"?Q<-;@YVC:"A2X[2A2=V<A"-R9O#>T+N^NI.AN> L
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M#DJ#3?WQ2C\LGKJDF3#.9<UY:,VR!UOQ$8O7XIB&-U&_-$Q2B?Q**E$'DHN
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M#9Q E$R?O)4P,L  LDBY8V9B<K 9CA9KL[NHFX&10*R\EJK0V6A%<)2AN?'
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M3UA<)3<A(WCV0. 8<CF&]J,%FCW73[YI=M.5,Q(YDU6>27764>7D,1U#"U
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M#2$&D(-(0:0@TA!I"#2$&D(-(1%;CG_47\5W^SQO!^8==TA#"^$'^ML\)?\
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MK)&>_4<MHGSTH/6[Q([/:)L<K<&OP%N,?5G&\6VRFX"*O<32IW$.4%4M82E
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M7U3'@Q/,4RPPTA(0A)0,!(YSD:PFKKY]2.VI:@19*E%0 T#'*V0X99VZ>PC
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M$$4./"3+2E:\/)5-I*W>0D*7.I)RBE<PNL2U)8AH=';=;-=IP;*4F;!(0^D
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MIG2E^9A]IN*.9D]""$N.]$A1QZ]STY6^T;M8*.BIMGI?XJL@S6L2E\BQN!D
M>0;4[FZ)<*345E3B$Q*5"2@H0E0!"BP+L7[K!W/A$!UN^77)35-:4J0AD/\
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ML2HG2I%)/JIB5&9NE"4?NE;9A+[N9L6?PL*+^.M%%J/'Y MRG951;?F;8T#
M6EU')$;ITFI$*!4%.///OJ<'7[X,G*NNOO\ ="F%4VR70*44R4RA3X/CD\=6
MD((!-7)#[H2Q<)<F[ISRCYB]+DFLVJ^T7@^#S@HF?B6R>%291)*$FLGTTP@(
MN!O"I#L [D%[B/H@VSWL_P 8,]NH4"E2(M-LVK0VW(B$@+<IBVC']H*$@!;2
M4I2H IR!\#G7"'21A-5588?9P2M*1-4F]W&\S"]AH;,&%K#Z*;5;"S,%HY5)
M5SA[7/DH"-\A2G*1;>47?,>C#Q5'B VT;O2B;?P+BCS;MN)#\AFD,.H5*B1(
MR,R9;S/-YC;<<$?A#DP!TQU/)>*RZ^G60*:9NK[,PMV1H6&@!]VIC5Z-BL5I
MZ6;B%13+]CIYBBB:Q"9BTK) ?(I-B ;$/9HB;>O$M1-@-V)]F;XL4VEQ;I?]
MOVZW'E4YLT:?S<ZTTRHRTMAMF3%'E\RN8%0.1G(U08?AE16%<N5)05)49F\4
M EB2JY8G)W<_B?@6SK"MG)VTN'4\W"IBT+E;LNJI$K4DH6D +4E(*0% @L0+
M\02!%%_$U=MT<:7$VFARH=N*H5F.>4U<=K)28M0H;ZRY'2Y*:2/OBDJ"U-*6
MH)5\QC6VMG4SZ"E(FN[.4Z)+/;0<!Q ?D.HMDL/5L?LD9<J;.]HM-6:B8J8H
M**7*=Y:B6WNRW)\C"ZJ&YG"CPEO.4"\:76H4RDPHS\ZX3:\ZI4QI#_*M+RZL
MAHQT*P1A*G<E9*<#MK,\,H5XPK?25A8+=6DJ"5.=0#=_)S?.-7;5](BZ-4Z?
M5U"A+0E1(D2PG($G*QU)+"UQ<7E)M-Q+[([K4BO5:V':E MNUJ*;AJU:NFW'
MJ%1U4@H"_:X<J>AEB0A2.B4(6M1S[@ZZJ5X;5HGF0E*B4D@IN!8LS:OR!\-,
M*F[<R*NEE5\FKG2A8DS$DN"QS-N;\84>W3>P/%K8\B_-N'8U7HS-6G4)NL08
MJH+GTG$/(Z!TY76PHIY%G(4CJ.YU[S*&IHR$ST$/=):X>]AD>>GPB^X5MC/K
M9)FHK)<U&J9:F<I%MX)5F.)[3\&BL3C:V*J.V53IU=2T0VEX0G9C0_SB.CD)
M]U:48YDD!)4<J!ZYZ#'<7V5]KYM118GL573):4TH568=O,3-15 BHEL6&Z">
MTFZ2,QG'#/VR]D9,ZHP3I+PN4HSEKE8=BRY;IF)G4VZNBJ.L':"@IP%OO#=S
M</$FN&"IIW&VXH]2=4B1.I.:1/2X>SL4<J72G/O>8D)*5'JH9^.M%]+.R"]D
M]NL9PY _T4^=[;2D63U-6>N"0P8=6#NJ:SOJ+=== G2-_P!==&6SF)3)Z3B-
M)3C#,6WCO*35T"1+)6[J>>$A040724M81,6F6D7 DMH2CU4H<V<8[(&/='?&
M!C^?6O!+&B0'U9A\/*-GUM4)DM1.MCP+_*^7@(<6!2JK$2EMF=4V6^7HE#Z@
M/A[HY>B>OI^/OB04^X7RYY,Q?/UF'O%GF29,T , +$"UBV@:YMI?(YY^]R@R
MY*D>U/RY:AW]HDET >O3./R:].I>]GS?6QXMPU\^,>2%2Q_Y<MN2 +6' :9G
MW1X';/;#828PPEQ;@Y<^@^PGL?3YDCU]-P<;YO8>NX9^45'M75C[HD@-8.6X
M@O\ $>ZS)N9:&2M>".7.$J[Y[].^/GTZZD$DL-<@]_GEW>=H]T5LW-U Y647
M;@+ZVTN_B>BRJ0FBWQ;E2D -L1YZD+=."D>>SR) R< 9 P/0CYZIZJ4^;\,G
M<V_7C;6*K%:H_LHH22M;74HDJU%R;G,YGGF\-'XQ-CW#='!Q5*;:M$J5?J9W
M'L"4(5&CO5"68R*@EQ3Z&V4%:V4#H^\A&$8Z\H&O3!$RY,\S)K  %GR\G/EH
M\:$VEZ^HD)D)0RW#D A18ZG//AESN8WN]^Z5N;/;/['T'=+9VX]P=M[TLFU;
M<OF;1Z6]6H]JO(H$1#3=:HL<&8\?:6<@I2 A6%+PH:H!14M3B4Z<I>ZQ) !(
MOJ1E;NT=VBYU-1-D8-32$2W61F0-X\;L[:<]!G%4.T-J[SV1P><4=U61MI*G
MTNJ[N/7!LS;EQTI1<HEFB:^B17Z/;TI!4F7!84AV*P^VI7.A*DC(2=7.O]BF
M3Z.4Z7*>T;&^O??/7QBSX8,4E46)A$HDSE=E3=I+V[)S3X*%M,Q#!;!4F) X
MG*A>,!6X=;H4G9!]FZKKOBEU&F+EWM/BN/5.GLIF-L,HCQGW5-166@&D)0$H
M3@8TQ>93'#T2Y)!.C=X&GG_2&L+UT98?BHVF2J=+GB39045+8L7S?YDD:\=G
M7J,A7FK*"3YCA2KD&.4N%0*N_7! S@].FL.1+4/Q7[R3;UG';E(J9*3)!!+B
MY)<\-3S\.Z&4K=+ <7CE0!U02@\Q^*0>^!\.GU:\ILN]K,-'#%OIZ<M%ZIIW
MWH!8C>268-R!![]-8PVOW&N'93<RT]RK=J#T2?;-7CS'/9_=4_##B?:HRT$_
M?&UM9YDG(5WP3UUZ4$[V:>)A)8D#74C,<]<O%X\MHL*IL<PVII)A2I:TKW"H
M J2"E0MFP:S!L^\1]O6S^Z%%W@VKL7=F@2 ]$N&C0WJF&UI4H+>0@/LO-)Y@
M76WBKH1D XR -;1H*E,V0%@))M<<N+7OG?3G'#V,8?,PO$Z^BG!2#3S3[*'
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MR%"I2<V8 -E'R^VVGR)?VVIZY")<R@PG;G!ITF4D)/5G!\+H9QE"S#=53D,
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MF.G@YT&3%Q<6^$;2V?PBCP] F)E-4E2?W0X;@P<<>&K:Q"2OT]24+Y1D]O\
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M.>1(XD6((RBN?B,CWM:VXDFYI%4E,1*N]Y]&?C.%H,,ME"A' R 4A>%<I.<
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M=YJ" P_BOFSFUP 8NHVRW.M?<:B1JI;U19E)"2E]CG >9=!2>1UL'*'$A.%
M^O?KKZD;#;;X1M=AE+/HJA'M")243J=WF(4$@=K]1F_&.7L;P6LP>JF2*J7F
MK?0L9,.%LKBS\-(=1MWG)/[#L/\ Z60,9^O.L^BR1WZ0CC ^ [Y[>OQ^O2$'
M*D]P#]@TA&*T@I5T!)!TA#;VUM58=J7G=]_T"W(%.NZ_#3OT6UMD.>V5GZ*9
M4S $GF<4W_DS*BA/EI2,="-(0Y6!VP,:0@Y4CL ,]^@TA!@? ?B^';2$<Z0@
MTA$5N.?]1?Q7?[/&\'YAUW2$,+X0?ZVSPE_P>3_SQN?2)E9C\J/Z$QO^&]7+
MQI^)$H JQ??#7E((!/\ \,M@D=3T'-^"/B=0&9[_ )"!R3W6[MY7SB,U:X-^
M.FPN('B'W6X:.(?:JR;0W]O&AWO4K>O2PIE?J<"K4RVX-N% FM/-H\EQJ"VX
ME !*5.9ST.HY_H><2WTY^OK" WB\+[?G<S=&^K[@\0%HT9&]E@V]0-W)E4V]
MBW+<%-N&C4$42HO[8SZD'D6]0:^A =FT] 2M"UN.,J\S!T]9]WG$I%W?W ^7
M")$[*< US;:WEMW=M3OJF5$V#PDU#AF]EBTU]GVYQV<V[3[B2MPDH0U":0F1
M&&5%_G(/*1I^I\XBWP \N<:"Q?#>KUH;=\&=D/[@0)CO"W?MPWE4IK5.<0+F
M:K3U9=1"AI4K,5;7THE*G%Y"BT3I!F9M/AKZX^,&R/AOUK:3=7:C<&7N% J\
M?;G=+B#W#=IR*:]'746MZI?MD6GH<42$*HPPAUPX#RCE(Z]$1YZ\=80>ZWA=
MW3>UN[WIMW=>ETF\+\XAX&_=F?2]#74[1BR(4&/"-MWK0UD-UZF/-MK64J'*
MATM+3E2=(A\/CZ^MM8>G@@X']RN&#='=C<R^]T;?W!F[OTFV_IF)0[3CVI!H
ME6H;!BHB4*!"2B,W16VO<82ZGS\ %:CU)0 ;UE%GCCR&6U.O.(;::!6XM:@E
M"$(22M2E*P E*<E2CA*1UR$Z1&&W=WCVF"E-?XS+&"D**'$*NFC)4AQLE*DJ
M2J8%)4#D$=P1CT.D(K>XP]^ML;EN*C61&OVU)4>DH%8?4S<5)<95*4LML(4X
MF2IM2<=<$Y[8^)Y:Z?ZZKJ94K":43YSN5H0@L.(<"[:&[MRC=W1A2R:(JQ"H
MFI1OIW6/XAP;4D.Y',%^,)J_NYMS8RWZC/O"V*PB-25-1*6BOTU2'Y$U3G-V
MD*2/+3GZDCOCMA_0%LE43<5G8A6TBY(I'ZI<X9)&H!NEQFS9'6-\88F3B2YT
MJBK4RIB)AFJ42PS[]>',-FYW4;B,V V]IML5^E"T5W)7S&<D-,UNE*, /!"7
MG%NEXI0A*E*"AD$8ZYZ:[!W.LZYC8(44B[6?\+N!8!@-6\?"IH<6QFHK*.KQ
M9!I::4IDI6P5+0"$N 0[ ,'>_C%.,!^FU?Q;*948,R-,IM?WWA5>/(C2VI$1
MQ%=@L5+D;DM*4VY'0N:IDD*(*?<!*5=>N)4HU7V=%(#[QV="'+D@TV*!)#\>
MPER[VRM'S'7U6&_:IJ)8F$BGV@JTH4Y[:9V"IW5',L4D$ G4C6)G>-1N0FA;
M/,6DA]*)MS5N+0?9PI67J>I(D2WEI'4H84 ,$8"\$:X/VD6$R2$&X200^K^]
MR?6OU:Z(L-7,F>T!((LIVOVC8@CD>67C'S)T5H+4VC [@=1\T#M]6=:^2Y4^
MMS9N/O%SKW&.G)O9DHT.Z 6M=APY\8?^UXX*T) "2VE(3T'J0.P^(^.JV3D!
M9NYG8<^!X<.46RH61*47T8MG;1\]1PYQ):UXI.,IQA0PK'17Q ^'7^_758+-
M<W=[BUK'/A\/",1J2257<[QS=VWK1)FSH?2.HC*5N)&#^UZ=.WX_KU4R'<7X
M9$^>?*+-4+(!N3GKSL_C[XEE9<$<J3RCWE!*< 9]$I[=_C_?.KEQ\QY#RC$,
M245J9S8-Z>X(<>\1+&U*>>1*4C'^;&.WH,C'Y<?DSJOID\=<O']#W1B.(*0!
M^)F=KFU_TN_%N$2$MZ /<21CW4]\9R,?S]_Q]-5^\-2#E\1?X^3@7C&*F=OE
MA9@PN>!?7Q^-[1'/Q"=K!N%PL7LB.V7Y]I")=4;E'OM_1Q4)/)CKU9>5S8Z$
M)P>VMK]"V-KP/;W#"JU/5$8>I5V*:HC<N,_O2!=VUC1G3O@"=I.C?&J<7GX>
MG]HTQMO+72@E0)/"6YO:(^^"[?RZMM?N'MN^_P"8_;%R-UJ"PL]40:U%3SJ2
M">WM49W('3FRHCKK8OVDL'-/C^#XQ+2![?0%"R  55%,LA*20Q4TJ[%V/.-0
M?9;QSVC9/%,$G+._A6)=:!O$[M/7I$QQFP$T3  &'*+NFXZ% \^<Y(QT'3TS
M_?XZYO%PY\6:WQ]".G2HW8V[M/&/26T'IRCMZ#'Y?CHS7S!?CQ]<6B4EKD_I
M'4N.%# .,=L#T^9U"WJ_G_CPAO-=V>VOSRC6.1R2I*NA&3Z=NOP)[Y]-23+"
M[,.]^.EM.?**B5,W6N_$/SX:^LH3TV*%(<. 2$G.  <8. ?E_P ?7.H+&1]V
MA\LC\0/.XR9S-JUQ?7(^LX;"M04*2H921R<^, @YS_-C';^?5.O3@]V\+1>Z
M=;AB_P ,C\W'F^<,E<,%1YU)3@!?7IT/J>G_ ![DXUY_Y\8O<N9HY8WT[W=M
M<F9F!B/-XP@5*6<(!\X'YC/0].OI^7[-4<T#499V\?JVK7B_T4T%)Y>ZY);G
M^O"(YW!:E5J;CR*72ILY1'_[NRL@J]/>Y>7U'7UU:9DZ4E9!+Z<O'T/.,FI,
M3HI'^[,*2-'.7O\ 7"&(NS;*_FTK6[:-50D)5EPL$IP.N>@].IQW/;UQJWSZ
MF6BV7G?W-STRRM%WH\7H)DQ33'%[@\='<<.  B*=V4V1"<7&EQW8S[14HH?0
M4*)&?10&2#Z9Q_32F<CC:[:CA[[ <=(R6AG2:C_:79Q:_CYV^;1'JY8_-SE*
MP"K*E<_3X],>O;MCKZ=M2SAO2G 8A)N+:7RX97);E>,HIDL4DZ*#]W+N,>NT
M>%K>[=R"JJV)8U5JM*"7%"HH:4EA>,J40I6$JP>P]>P[ZP&MVRPK#%+-7,(,
MA82JY+D')LB2S-Q>*7$MK\$P?[FJJY=/,#L%%BHZ#Q-OEK'T<<#K>YMA\,EN
M;?;B6C6XE?H;CD.(PB.N0Y,;1*"XZTK!/(0C*<KPI ZC'87F@Z9L!DHEE)FJ
MW%!AU? CLW#AV]_*.:]LZW!*W&EXC2U<O?FI5UCL&!!=SF6! <]V8B?-OS[O
MNFJ39U(4W1:52X,.+514V%>T+EMM$+;1CKS( R3D'(&1W(Q3:OI@JJR1/7@+
M)':ZS>?LH:Y2SW R;DSQK+%ZK#J"6B6_M"ZA>^@H/\1L VGB,WM"^MZV[=]B
MFP*TRF=4ZPE]3E1>9\Q,A1"@VME2P4M);R E("<X'J#G2L[%AC8FIQI529]0
MA2Y:BE10A2@=PEW 2"Q)S SL\8SB&-8@F=33Z:>4R).X/9DJ*38BR@"'.C^^
M$U9$N]I*KBM4F$]#H4B328<U>4.R674+;"1Z)*$+2E)[%6,ZQ#!)F+S)^(X)
M3KZVG'7*"2HL4D,IGR<.,[$DY7BHQ:3ATL4>*U 6FHJ-Q:DL[J<* (/XMZPN
M[W?.&UC,W/MM=IM&DP*/)A5!+]4E.34,\Q0^\"XRVI?O.N E6%$G&1U(&L3J
MYN+[.X@JEI*>D29JPN<5"6M:995]YN[P)*@@D@"Q-M(RB4<,QK#T5::BHD+I
M4,D +2@% =+L  ' ?QMI#EV+6'-O-QK?J--8;HL.YY0A5FBQG0Y&?6'4$2HZ
M&RI"%@J*W3R@X'4XUNOHEVDK<'VNI*63-5U%;U"IX2HI"5+6D* 8MDX<#R,8
M_789*QG!JU,S[Z93":950SGLH44@J+'=W@+.1F_&+6(,D2F$2&2.1YM+J$9Z
M>\0<_P#TNG;7TBDS!-0F8,E(0K^8/\XT).E]5-F2C<RUJ23GD8V@S@9[^OUZ
M]H\X-(0:0@TA!@#L,:0@TA!I"#2$&D(-(1%3CI_46\6'^SMO#^85=TA##>$%
M^MK\)7\'<[\\;FTB968_*C^A,;_AQY3QI>)#S#*3?G#6DX!*B#PS[?XQZ>XI
M7,2>WU:@,SW_ "$#DG\I_J4/A$=J]QO\7MU[\;_;3<.7"[:FY%O;"W72+-KM
MRU_<+]#LF55JK;L"OI#4 L.CRFHL[D2[S$>8D9QG C$A=[6#CQ&OB_QB16T'
M']M%<FU+%Z;SUBW]BKJH]Z7+MC>-IW=6XS7T7?MHH#M8I=/G*Y&ZBTY"<;J$
M-;(\Q;+Z 4A0.'RB,/36>,#AHMRNV9;==WIL&E5O<.#3ZG9U-GUZ)'EUR#4R
M$4V5&:<6E26YRSRQG'BVEYPAM',2,H<H]^Y/%1P][0S*A3MRMVK,LZH4N-2Y
M<R!7:W&A2F8]8>6Q3'_(6?,4W-=;6&W6TJ3A"U*4$C(0CMOGBDX?]MJ1;-=O
MC=BR;:H]Z0_;K4J%3KD-F+<4,(0ZEZD/!:D34%MQ)"6"H]<]^@0AL[5XM[ 8
M@;K7?N;>&V]G6/9-VLT2CW$W>42:U4:?+IT:H0WZDVX&EPJF\W(2I%-:2ZX&
M2EP]%9"$2*VTW6V\WBMB%>FV-VT6];3J/F"%7Z!-9GT]];2N1YKS65*Y'FE9
M2MIQ*5IP<I';2$+.JTV+6*=-I4UOS850BR(4A',4^8S);4T\V2G"D\Z%$!2<
M$=_GI"*ZY/A6<%LAV7,?VS?4[*?=D2,W#7 5.O+6ZXL8EX 4M1/NC[-2**4[
MRR?PI+WM:_R]&&[O;J<@5  BWIFX%HK#W8X >$5F_J_ H]A\A<E*@H:-=JKQ
MC)C<J0LI5)*P,@D'/0Y/KKAGIAV^Q7#]J:JDH42YF[V4!:4J8!1:^[8Z'R:U
M^D=C\#D_L"1.J4*F(9!(1V2S GM.Y;F+F&.JGAD\.U;I,BNSZ6FBP:-4%B=(
M76ZB4.PV@.9O#CY3YB^? 2.N2,'H=;EZ#ZG%\3P:HQ+$U(0%'LRT)"&! #'=
M&8?Q[XS^AF8;2J5145!.5557X"'WCO=Q=G9^5VS)25P^'-PQW?)ID_;:A,R:
M/'1&AUHR*Y/3[&67$>9)\M<C*/-0#\$Y.<:W?U!W;%0&Z,R06_3+7OL";Y34
MQP=%5(Q2DF2ZJIEJZIR=XA8[*2USGE<&W<8"7E:-M;&^(?9M!LR(8%JVU?\
MMLNC)$EV2I$1Z'2%/N"0ZI;CJ79"I* 5*40A 'PUV/LHA&(]!%92!7:EX-B\
M@D6#R9M9,.7-#N ;\Q;Y@[;R9F#_ &IZ1<R7N)JL=P5@4@G_ %E+2[H5G?=5
MNGN;*$1XM.[\S<3B;J%IHEID4/;]IYEEIETK:54:AY;KZ7 %$><PMMQ"LY4G
MJ!@$Y^<VT=6N;4$(_ I:BG0;I46+<P>X$ 1]JNBS!44> 4,UF*Y145$!R\L-
MHY2PUUO%<M!3A:1GF4M22GU) !ZY^8Y3]?KG6+@]H'GZRC9"PTI7<0.5B->;
M>0B1=IHYG&>@RI&#T_:D#T]<CY]AJYTZ703H_C]&L^8SBS5BMV0KUIKW?,M$
MF+80LAI02%X5GEQT"?P<D]OQ]M5"!<GN]XO^G*,-J% DD![NW$@V;3PY1)^T
M8Y3[/S$) 3GW?B>_3XY/?IVU52?Q?)N'KSBR5:NR;<L^?Z^$2XLF&4"(D>^!
MA0/QP"KM]O\ -GYW-""V;6&=[\!Y&,.KEW5WDB_ L>'TSTB6%JM!:$'(0H*!
M*>G7FZ'T_%]FKG*_!Y? >O>\8C6Y%F[3YWUY_#RO$B+9CH"4AS!4A*>;ZB>4
M?EUZI=W'>,F'Z1C4VWB2?CZ^L*:[;78NNQKOMJ4@.LU^VZW2EH(_^=ITB.@D
M?$.K21Z@C(]-7S"*F905^&5TI_\ 154BI4<GZBH"N][:O],<QRF17T&)4"V,
MJMI9U.Y 8&=3F2HWR?>?F]]8^>OPK;AD;7<8]Y[75%1CMW!2KBH*FEJ/6HV]
M40_"PG]L67).">N 0-=C].5-+QWH\P?:*2Q,B915CL[2*RGW9E_^*DH\3P,<
M(= %7,V<Z3=H=E*D$"K16H0";&905!,L-D?N53"- UN?T^:XKCN06M!I$K.J
M_P##\X-(B X#\!\(Z'6TJZGOG^<?S?+2WKUZY-!*GN+$1H9+8(/P(P1]G4?/
MH?YM.6?AX^Z*V2L-S%^-PW'FS\B8;RL,("%)4D=!U..GJ,#IVS]G?IJEFYYY
MMY,^?EF^G"+[+7?)KCOY&&5N1A/+S)/X8R1GU R/GU/;_P!->&8X9B+M2&8H
MNSC,\>[P;OO#)7=9^X\VTZK7]MK)A7]<=-EQT0[9JE1^B8E18<6?:%&=CW2P
MC\$'J?7KJEZI!7N$E^&HT-OD[:Y1#%L>504M@E)([CYAFO;.V<04VKXZ]_-R
M+\W=VNM'A2MIFJ; S(]/W-1%N,*DP@ZE:O\ V1TS4I7(TX4I!ZN^[J%;A4I,
MD37X7 XO9VU/RXQK.DVKQ"KJ9\L;UC8$DY6MP_0@LT::I\?6X%"O#;MG>/82
MI;<;<;LW8_9MG5R?*6NXE3O.$6+(GTA8"F&I+BD DG 3[WKJU# A-DS9SG\5
MG+MXW8<P/*XB[4NUE723/O=YC;,L?#PS+Y:-9!PMR[,XF]R]]]KJC;-(M&H;
M-U=-$C7*[,CQ!6I#R3Y))=6A'G+'7RP2HDX SC5NK<'GTJ)-0@=@I<C,&[W^
M=HV+L?M[+J:PTM0M2+AF401?O;.[:VM:( ;N6Q/LVOSZ!4V%(=B*<"%<O^<9
MYB6W4$=%(*.4YZY';OJUS%":B9UBBGL+_"X>QM;+E]8Z9PI<FME2%(J.R$NH
MI422D .1_P F>V0(.KQ] WACHOZ1L93RFO6\S2"LI@0E--F=Y9'5#ZE!*BK/
M7KWQ@>NN.=LIBSCU9*D5(EI"U.B87"@%7':</^*^8XY&.9.F>=AXQ65+EIJY
MBA??3O!(.A.=@6)[KF+7J9-7$H<J1683,:1!!27F$-^4\I60E4<C]FLX&>N"
M<_'5)ATV7+H9RIIW2G>8N1=B6&7!O)^6AIAF3)J=R8I04H))*CD['6UG?B_B
M6GO.J711[:\NSX<>7*N65]\3(=2B2AR0X$<WE @K 0<DCH!USK'*ZLQ.13=3
M0K"Q/FA5LR"K(G-B^6OG&48/3T-75F;B,S<E4DI125"SH3O WT!2[L[7+9PH
MJ]<-XVU:=)BHH GUQ:8D4%@!P-J<" ZL8'3RBH*STP1DD]]5^(XCM!3X?3T2
M9"1/FR24+W0I;D$BX#L[/=N#1;J;#<)K:VMFKK&D!2BA6]J'(R<C+@^9O"<H
M%UC;J969=WQJFW(KOE50.(CJ=@H?0CD]G\P=$+)/;H"HYQG7A@^+3-ETKK<2
MI5S:N>A086[9L!=G!4PS?B"Q>Z8I2RMH#0TF&3T*12A$I2K @.!O$MI<OHVF
M83=+JM*W&N>/=EUQG:+#6)E+MII1<2]/0AP>8^XKHEL?M>8C'J=6J34R<>JY
MV,UR#320O="3=Q;LAQJ-6,5-7)5@-"C#:2:*FJF#>GA)#)2Q)'=WACGI9/R*
MK#;W@H$2$MQVE\[<"DR4<ST:/4E82^7'3[@6XE7)T/X1'RSF'1U.E)VUD5$H
M[U.F93H0^I$U(3G;-SE9LHR.@E2J39NH$T 3ILN9-6& .Z4*)YC(L]M(N?M5
MI;-"IB5GW_9F@0>IS[I42?GU&3UZXU]2:%6_1TRQ8*DR#E_Q##X%_#E'+V**
M0K$*HHNGK5MIJWN/FQ.L*C5=%O@TA!I"#2$&D(-(0:0@TA!I"#2$14XZOU%O
M%A_L[;P_F%7=(0PWA!?K:_"5_!W._/&YM(F5F/RH_H3&\X<U+'&GXD*4\N#?
M?#;DG)(_^&2P>P'U ]_34!F>_P"0@?PI/_'_ -R_I%;.TW#CO'O/QF^(U6=N
M.*3<K8*FTW>^SZ?.I%G4FCR8-:D*VVH+HJ3CE4AOK\]L*2POREEE*&DE6%$C
M48D>[</T^ON[XWN^W![MIM7N]X<VT-7CSMU(5>XC]PK\OZX+Y89JDR]+UJUF
M5:=-N&OM-LHB%2I$>.VRP6@RU'0RUA01S%#0.VF>L0[W=?X5=NY?B*[;<2]C
MRF^)&[;C">'F%,H,^H5RN6=(H](A;7P-I)L-AQFF,TRZ67BJ-3G(QB.^9)='
M*#I$8\%D5O8+:SBPIKOB%49U^NP. ;:2BU&J7S39=Q4J!=KL>ILU.G58MMRV
MA<<UK,:GOO,J=5,)2TXVX<ZA;07O[_7IHAKGF,OG[_\ ,;WA9V@I%P[C>'1;
MNX]G3*]M]5+PXIKSVNMF_(+\]-(VSG2G)NW;$N#4TO*C-QH +U.BR#AEAQGH
M.8)$8@,W;/Y6/=D._P +-_N7=EH;;[@;^.UFRK++;_&G6J1;=_[ITFM53:O;
M'%EQ&43ZW;U+;#%2>?CH]CH+,EI<1N4$#& !I$3^O<WPX']28L'\"NI-NT?B
MYIC%RT^XH:-^)52I+U'MB59-!>IU0IK3HJ%OVG*2DTRCS'0IR*IA+;4A.'0G
MKG2 +^OT$7^X]S[#Z?+_ (?;\=(C'D=&6' ._EJQ]?+G^_U_/7C-;<G<=Q7]
M#CWQ$9I[Q\8H@O-QB9NCN/4WU3(ZH=9J$)M]D_>T<B^?F43VYRDCN#D@=M?+
M/I"75G;?:&IGSF"%&7*2HDL.L4!FX!(;M-Y&.R]G0A.SV"R4)25342RJP +H
M#V S'=#<[I4JX:EL33Y\(25P':X_,JJ(JEEUU"5AIE;G+W0H)"BDY"NOKKM3
M[/V^G8:FJ)AWU+J2I3EPY2#S[(?+)LPT9CL;.PZFVQ,FOW1.ER=V0% ,X< M
MDXS>Q\!##;;0J_ M2_JPPJ3&I?T"&2[]\0%3%.*"5CT]T'E4?C]6MZSEH4G/
M/-K!(/$>3#("YTC8>U"\+K,9P6G6H=:N>J8LVWF)=BH?N@NPNUF:T5(<3_M5
ML\2VV%W2_-")<*R*TVZXHJ4IJCU<P5K6M74JYH*LJ/4C/4=<]:=#B_VIT6XW
MA:<Y4W&Z(',_?T"I[YN_^J<#0^4?)[[7%-)P+[26$8E2VDS)&S%<K=LQI\0E
MR"4[H <>S$'7=Y6B"W%+4EU3B;WSFNN*7[1?];=0H]0&G'^=L9/4#E4, =,*
M('?7SAQLE5=4IRW*B:D:!+3%V Y?$"PM'V<V'W9>S.' %TS*2E4G-^U3H]Y?
M36_,MQ04!3K&3@!?X0]T_MOL_O\ ;9=PN>67GF_+SC(IQW7&8<C+0'AI[FB1
M=HX+S('R! ^0&?Q]<ZJJ?\3 EW(S.MW]P/CQBSUBMY)#<;>3#GZ;(1):UE)Z
M(*N3JCJ3\QT/R/K_ .FJ_?;@=+6RRY_+@<XQ?$)(2 Y9P".;O\>7Q$2GM9;0
M\E*7$ I;3GF/7TSC^?T],]-5-.IS>P.K>O#6S:F,<JY0*/O)P %P6=N_GQ\[
MQ+RREL^7"/F]?+0 .G=1^KU!^?\ 2+Q**"USY9L_/SY::QA]9+2%S@)P("2U
MG<?X;O;01*JUA[K9& 1R8'<DY'0?6?[G&=7-+, ,F'EIP^7NC#:U86"!Q(?Q
M9],]6XQ(>A-J^]D=2I(YQZ?A=>V.HP?Z/AJ*<]<_FW$6^48[/_$/7"'5A#H@
M>AP"/B,CH?E\M5Z"0@7S*GYY1::J[@W%['_NCYEKV'^(CQ4(<QDII\"H;ETV
M0%%/*@T^[D>SD#'+[BG)"#GXJ.?AKMS"C_U3T#S9*SU\Z5@\Z2 ,Q.PS[T#4
M@%,L.S?$Q\_\:_\ ]3^T;33Y($F368I3S"2'!D8I),M6FJUN!E?E'U,(6'$(
M6D@I6E*P1V(4 01\B#KB0@@D',$@]XCN<,;YC-]+:^AIR$=1)R?K/34(C'?I
M'B",@,\K\[-;CST@U$6(X:]T3HR/?&AEIQE/;WB!GX>G?XC3XY?**R3\C\1\
MH0];""V0HC/+^#V.<GO_ ,#Z==4DX,69M?7B8ODF_>0#XL?G#(7)@H<^"4+4
M!@9Z]/Q8_+KQ'K_,9!1?[=LR=.\_KX0ZFV)9_0DP$*(<]I<\[D'4$*PC)^H8
M[G\NK5/Z[VJVILUK<<V^CWC#,>F!2Y\N;DD99W/+RL[VYQ0MP"UF)1N-CQ2:
MK4)"8D*EWE2)TZ0E*G/(C1URG9#Z@CF4I26T9*>7)&0.^KAC#BBI]TG\/&V5
MGO>YM&%[,JD(Q2KZV3<$F^A ?NTTMQB._&]>&WEY[\<*.[^VFZ#F[T*Y-WHU
M'59,R4F90K94Q*8CRID:A(0W+@R8[@6Z7W?<!;S@8U"DEE.'5'6J4XD@CM:M
M:US8\>?='I6+7/Q&3U24E/6K)2P(TR&0%^36?**Z-U7K:8W'\1&JKNNHTJ]:
M%<<.J671X<]R)'G3VI+07-1Y)'GRHY]UMCGYL#MG56DB92X?*4'&\H$J N&+
MB[^_7RBWH4:>=BDR3+F"H&XS+4-TOINMKS?5GB4&X%5DURP]C*S69#LZXJKM
MO;\BNR98*9;L]U#('M((YPM:0 2H$E)45'H<ZTQTRD#$I3[LI*9NXM+ I.ZK
M++(A^;.+QW!T5^T?L"FJII)G3*)+A;D#>2>TQ<',GDPCZ'.%BT(;.TMAR9]&
M?I7_ +&BOQVK:>+;<EPM))?F!!)4I1], */0YZYX"QR16KVBQ-<[>G@33[,H
M*)WI;V)S=3<Q\(TUTAU!F8M4H-5)5,$PN"E)*0Y!8D%@+Q/6CJ:30IID)J+D
M(*BI+$U*@MH^:D!;14/>]"H'IW]-5-"E:*.<F=*F,5@$DJ#$ZL3IJ#PX1IC%
M-R75(W9B9AW<Y8 &1((8#S#:-'3?%O)@1:'<E)2\NMQYT5BE-.K*XKJI(2C$
MAI. E(;2HCI@=^_>Y8C@RJ6BHJ^B4I:YDZ6HI4H*%E)5^'Y:AN-I*#$C,744
ME3+0)8ES 2 RE I4"':]F'$/E#GKG"E_08N!3;4B:&F3)">6*W+<2DE!YL\@
M65>6V>;.>I)/367@S955AJ\52$RYM.D)4<D[U@;C,6>P&?,18^K"Q4>R'JTH
M*E%)-R '(MJ6;-\[:PT5ZWS3)-]BR7&O-;98;479$8+CSY$@A91&<PI!+;?;
MYX] =89M5BU%,QZ51S$"?32I8<H &\  5'@Y #,-'%[G)\%P><C#5UHF+E+4
M24EU !;.EVS#@$OH"#F!&=Y1V[C11[)MV&S&5(;=\^>WY29%,CELI7*:"0"A
M:UG#?3!6 2#G5)B:96,BCP7#9/4(5N*F,-U12HC?<@79.N?.UY:.8:!<[$ZV
M;[0H+*!F05&X<.S DVU$:>]*1:-E6H:"R4,U6B-0YU)EJ6/:)E19?CNASS/P
MEJ61AP!63DCN=9'@DJCV=Q*@DH+U$N=3J4]\IJ"1EP!Y9WRBJI)N+8Q.G+2E
M0HYJ2@L[!"@02 +#LGAD!86$6?[=59==M*C5!1*7%TYDOIQ_VOEI)_'RY'3M
MUU]+]D:WV_9_#IV?W" ^MD@CGW/>YC2^.4GL>)U,K@HV\?7'ZN%K)8M,&D(-
M(0:0@TA!I"#2$&D(-(0:0B*W'/\ J+^*[_9XW@_,.NZ0AA?"#_6V.$O^#R?^
M>-SZ1,K,?E1_0F%#PV 'C6\2 GL+[X:_MSPRV&#^3/XM0&9[_D(')'Y3_4J)
MSP:#1:;)J4RG4F#!EUJ0W*JTN+$88D5)]IEMAMZH/-H2Y(>0TVAM+CI6M+:$
MISC48ECF=0Z-4IM-GSZ7 FSZ,\Y(I,N3$8?DTQ]U"VG'H;KJ%+CNN,DM%;2D
MJ4DJ23RDZ0A+U;;VS;CN")<%PV9;%9JE)0V:/6:E1J?.JT)Q"N8*CS9##CT?
MRU$J2$+!0KJG!ZZ0B,[?!_;$[BFW(XAKK52[LIE_;=6E8J;)KM%A5"! >M6J
M2JDW5FU3&W$%U9?"6P$ ME)4#UTB#7=M/7F]XEJ+7MSVJDS10Z4)=!87&HTG
MZ/BA^DQEMI:<CT]U+8,1E;02V6F2A*A@$8TB,:JI[<;?5J'4(%7LJUZG"J\Y
M%3J42?0Z?)8GU%O 1.ELNL*;?FH"4\LASF= 2 #UTA&SHMI6O;KS\F@6]1J*
M]+;99DKI=-B052&HR0F.A\QFFO,0R@!*><'E3A*<=M(0I1[R<?6#UR,_6>^D
M(\3Q"&G0HE*DH5@#)S[A&>W7K@9]/37C,'8G'_@HV-PR#Z8YF(AW'>WOTST]
M!XH>NE+JKXW.I,LB*PJY*J^F4M0'F^8\5(0YG\'H?=]?E\/ECTDU"IFUN-TT
MP,?:)ZY1_P"'6J*>#^_(Y1V;LZN7+P'"ITKM+ZFGED9A*BA()U8O>VK\WVU&
MW0L^Q=O*'1KN'GPJA595-;;4TEP/MA25..J"O=+259][  3\\@=F?9V69FP<
MB6;D52AI;L@G.[AO\YFKG[-XOBV.54_#4K-1*I)4]>[O @L,MUB_+4VS($,[
M3;U@R=Z7+<B(8_Q>7!',=^FEMM,-,53:U(GLY]W\'EYE#W0>O;)UO=:-S>2P
M[9\&+LW  Z>&D9E7X%5(V/E8E.6O]KTRTBZE%76@ K2#<_C2I^6N1%6/B^6M
M3J#N%LW<5O,LHI$VW+@HL)V.!Y7F6]6X=06 M Y.9INXT9.3Z=M=2_9LK.NP
MW:_";/1XIAM61GV<0I9E.P89'V2_$7SCYA_;#36':78;&:@$5<[#ZBFJ'%]W
M#JJ54+)!NX%6&=^%G84H;R"<[NU><Z:K+U9J,:M-K5WDQJG!B3(CW-^R\UE]
M"P?7/3OK@S;:C.'[6;143?\ @\8Q.G+#+V>NJ)18?]A^$?9#HHQ&3C'1[LCB
M5,=Z56[-X#5J(.\'J<,IIQ[OQZ$\3:-91"X'FDE"\CH<()PH^X<^G=/4?'MG
M(UAW6H?M&S#X6X<_.-A3UI0"\Y";FQ;FSL/\MG$B+07E<5/4J5CD2!@Y4K 2
MCXJ4HX Z?#OJLEJW994-1;B7 XEQW/\ "+%B"Y<N4J;O Y.PLQ;@UCF.^T6>
M[,[$6VFE4BYMV[KH]GTRJKYZ9 K53ATJ1/;3RJ)0N8MLK2%9!Y<_S:]I2IDR
MTOM&_P"&YWGR'SOF8TOM;M9*HBR*@ IL4@_A8D-8YW Y:<(L?L"B\.#3T"B4
M.L[?5NJ/#RXL-FX*7/JDM03GD1';D%YT_L^5 ^6",:KS*F2"@3>QO@$:&_#/
M3G](U14[83<0)(J&""0P) ]S/I]8D=#VCLRI)"$T^/3'>3++D5M(#>.F5#(Y
M<''NYZ=NNJN3-W5,/\^>??\ 6+6K&ZJ5,!Z]PJ[$FP//7.[_ *QJY=FU&SI#
M;:\R(+JE&/+ Z% (QS'L!TZ=>V?KU=I2W8WNUM1].&7N$76GQ254C<F;KJ8Y
M"^7?X?,NSG4"0LAKD*".5.#S=R#DX^(./Z.N!JL3J^=LSQ##G9KOPSBFJ@-Z
MQULS'PYEM/1=BGNE2$*Y<D=2/CCO^/IC5=+5V;<3_P#D &]Q?A\+%4I.1]'X
MV?XQ\XOBZTB3:G$_MW?<5M$7Z0MJ@3F9;>$+]NH-6<Y'E$#)<:\IOX],].FN
MU/L]5",2V'QW"9E_9ZJHE!.HD5=*RE#(7+W8M'!?VF*=>%[=;,XW*#==34\P
MJ%B)V'U6\D!B+!) [K.T?2!M_66+CL>TJZP\)#-5MNC36W0<^9[13XZU.#I^
MW*O7Y'H-<?8C33*3$L0I)C@2*^8UF=)66S\+?..S<.JQ4T%#42[HJ*:2HF^:
MI221<<SZS66J"*X9#N$'R_'IE^H^L2=I//S=OE'G=<*4G'?)&?MZ:B^;6?TP
MCT T$:24O'<G/+S9S]8/7X^OV=]>>^,_\^O'/C%9)1FQX^=O=" KKHQU[@92
M<].HR<G\6/M^SP7<MG=^!MJ W![&+W)0 3G8V/<>;^O&&1N"00EP*_8C"?CS
M*SD=>_8=,_S#'@HM?G;SX:6\0-(NM+,F((3Q/@.ZX\\N<)*V=ROT'RY$.>^?
MH>8<*6D^_'='=0^OU^OKJW52K@Z@N_#7X<^7&)L2PA%5+WA>=J&S?OS&F5WM
ME&-$L;9VAUJ[[UL*V;>I=P;B.,R;XJ\(,^UW-(2@A"JHVHE+@Y7%A:2E05S=
M1JWU58N8TM[CB3\+NVF7QC&DX"NDFF:BG?>L[7;.YUS-PSYWB/+7#+P\6;=Y
MW$MW:NV*-=@ER:@FL(CC_)IDHJ5)EQ(ZU*B,.N+)5][:2KO@C5%/Q*>E/4WM
MF<A?N9VYBW!VBZ4.!R>LZR93WS##(CG\1F/=$/\ >VRN%^W7;CKM5V^M.L7#
M7Z@BM55U#+;DNI59@\S$N64$]>?E4ML]"1U!U;YM94@@2RH@9ERR1JV5QG;C
MR$9G@FPLFL3,F39#=?,$QREW[6\UVL/'N$5A[HW+)N.M2*L\ RSRH:A1F6PV
MS#BL'E89CH2 &FVT! 3@#\' [ZIZ^F]J1+&>_+4">/99SQSU]^G0>!X6FAHZ
M>CED =7NVL &:VC %VRSYF+%>$3Q2*%LU0J3M_N-1DNTVF-B.U7AS.R$1D82
M$\JUD$@)Z_;Z'(Y_QKH\K4UU17X?+ZQ2UD%#;P*27.Z-'RXZ\HUEMYT2#'IJ
MJN14%*R[%!;>.:0XXM]0]HFNUXJNVV[&Y%"VHVGBSZE)N1$]R3/=84AIL,L*
M<2&TH/12%@8 ZY],:QFOZ-,?JJ2;,W52"HG=1<;RB"P%G+V -KD'.,!P_H;&
M'@U&,5!$MBI(5RN,^.C6TM8Q(YOB.N9BS#!JU"<G5>BU%L4V8?-;0\MA?(WY
MR2K)(02DJ^'7& =68;';3(P\4:D3":>8D@=HGLFP!/X06;,>!CR1T44TS$C/
MDUR)5+,EJ[)9RD@N 3FX.EW[H]M9XLYMY195FJM=ANHKIJ>26'RI3$]('WYD
M9"@XRLA2.7WLIZ^NKQ7;+[3XMATBCGTRT)E !,W=(4 &OO7+ 7.GNB-/T()H
M9IQ)=<%4AGH61=E("@5)N;ND%QY,(2-3WRO&@VG2HE4MV)*ELSHT=FOE"URG
M&R/>/FXR%!)*0HGH>O?KK#]J-EJ[9C!4SZZD5,#[TN?N]H,,]XN2D?B9VLP>
MPB\4G1S0+Q(*E8D)<DH<R'#$7W@ [ D.+#,YBXA,U_?ZK1I+59MQMZG5"=21
M!GN#S%OK?1D-O'I]Y2A9YPL8Z DC ZZUI\8G*$U=#O&;*0I2R'"PD)OVGMV1
MIJPYQ74'1EARIM32U<V69(F&>D+ W5!)"B^C$6-@&YO$M-C=F+NWDM:U]P;G
MESZC)E*4ZPU(6H,)\N0XR24D84D>421CJ #G.NM.BGHIG[0X-38[4@K7,FRY
MJ2H.HD*! >_?<L]KZZLVLVFP?92JJL*I$TP,M"T@I(W@2E0MG=\C</G%N5D6
MZ;9H,2E%:E*90@+)[I(0/<0/4>[@#MU^>NV=G\,.$X93T1SE) [FX\]3SCF7
M&<0_:5?.JF WR3;F2?T\(Z=RMRK'V?LFO[C;DW)3K1LNUJ>NIU^X:H\EBGTR
M&V0'7Y#BLX3E7H">G09U>XM41:VW\1K@OW:NRE638F_EF5BYZXM+-'I9EO05
MU)]2@&8L%R:PRS)D/9'DLMK4ZZ5)\M))ZH1-A,AI?7FR,_ YZ9'7Y CW5#H1
MUTA&MK]Q4BVJ15*Y6I;<&DT>!)J51F.\WE1H41I3TA]?("KD;;0HJP">G;&D
M(\EJW90+VM^CW7;-29JMOUR$S4:548Y5Y4N&\GF:?1D A"T_L2!G&>O32$*/
MSVOVX_+I"/.J;'2%??,J22,=R%$=.@_F]!Z:0A'5S<BR[9N.U+3KE>BTZX;X
M>FQ[7ICX6)%6=IC DS41L)Y<L,%*UA1'3)/H-(0M6Y+3G4+ QS@I/<%)(SGZ
MLZ0CA4I@(*BK"0<*.,],X/09.,9)P,@9^&D(@]Q0[G6)NSP)<6%T;>7-3;HH
M+.QV^U$=GTMT/1T5:AV?<=.JT-:\>[(A3F7F'FP<I(ZZ0A#^$'^ML\)?\'D_
M\\;GTB968_*C^A,*+AJ_5K^)#_KWPU_[LU@Z@,SW_(05DC\I_K5%@.HQ+!I"
M#2$&D(-(0:0@TA!I"-6\"\5=>484@#YJ]3^,8_IUX34E84@V"D3$^!20#GZM
M$R;'>9]TI_J'GK:*2=VHE-I6Y=VT:<M*G)-<FRY \M:E+8=]]L!8& 4\N,@C
MH3KYN=+$BE&V6)T:93S4[ZBIF+A:GX$ ^+\+1UUL54F=L_1I=F$EK\$B^9[W
M[M7AG*WMW4]RK&D46@,H>JE#K"Z@PRXDMJ7!D8;2TAU?NGW?>Y1T./7707V>
M,2$O I^&@$-4%>Z=& M<6(9_AI&P,*VFD;,8U-GU"AN3Z7<()+7XDY.;<.YX
MQO[:ENS=KF*XVV5WG3Z>S3I[T9P)>@Q5)2'1RMY4 %9 Z^GPUTZM'7M,&2/+
M4F^66GOBIP7:R9BNT?LLT/@]2M4P*4'3OS%/9S:QS ;.VD5D>(#29MP<)>SM
MT*BN2EVEN16*3(JCBE*+,*NT5Y',XL]29<NCL->@*TY()2-;S^SI72:;:C'Z
M*86F5^%O+ .?LDP3TEM2 NQS2">);B?[>^"RTTN"5^'[O5T.+U&\P&572)DE
M)8ADDH##+>#L^=4T7;:X-P]W]BIC-O3J[2+F@692:JN%&=E,)9M^4JC3A(+0
MY$%J%#B!05@@\P./3F/[3%/3[/\ 2'MD$VJ*Y:L02!V6-73)GJ '%YA))[W)
MCK;[,NV-'/\ LY;!54ZN"*RDPJIPY:'NDX7/K*:2GCV1)2#F&#-'TM5K@NX?
MZ%LY?E7?MBUJ%7ZY;P@P:G5Q'C,4A41CW:IR.D%"XJE+?<Y/>==( &=<74.T
M%=-K429I9*UV!)#]J_>VGG<QX8ETC[35N/T<NGF@TJI[SB!:ZR_(6;-K9YQ\
M^&R=#MBJ<1T2Q8%:C731J;=3D9JLM)/LE53!=\Q;T=I79HJ0$(.#D $9UNBC
MFS!1H3F%RT$>*!Q[SRC?E5BAJL"!'^YU"=]K]KJTJ5W.IV<$:9B+HMT]K-M-
MR+!K3-]VA2KD3;5MU]ZWC,#H72'D4UTHD1%-*2 OW$8)[*0<8.#JZX#-(J)8
M.:9RDD&^19L\[:QSCM32*GRJV:IWZHJO?M$/9G\&.C7>(1^$)M5MX[P\5O>"
M3MXU<^X]G7[>+UOUA!=?KA;IDF8J'38#C[A9+R@A+32E>ZE./ATS[&6542$;
MH[4M!RL[)X ZF[WMR>-2[-RB)%4N<2=R;-:Y9@LD=]@_C:'YMSQ5KFMSB1L'
M8_="P;(AP;^NK]"L9RSZC,GW#;%1E>] BW"ZX%T]<GD4@SDL+26E92!T TIL
M)_TZYG D^M>+!N;N(\ZG%4BN1)!L[ N;WL_D_(6UB\VMM,3Z#4([Z$K7#9?4
M <9;+22H$']L<?#XCOWMTI6[/ZHG,D6[VOPMG\-(R:CJ'G2R."7YN/#T[/#.
MVU4<AL!>.5'PZ_A'!/\ Z_#5_ (E#+(CEZX1F$R5,,OK,T@6!M=GU9K>G:'H
MI4_G *\)!  .>AQZ?''H/R_#4)?E;Q]<7N_C%IJ)3@>7<V;Y^%K&*3_&JH'G
MT+9J[DMD^1,KM#<<PCH@IBS&$9^:G'/Z3\>L/LSUN[7;44#_ .Y)IJ@"[#<,
MZ3EW*OR#1QC]K+#&PC9O$_\ [>(5].5:LJ7)F@#47?EWZ6C\#MWHNWA5V8JY
M7S+-H4Z&LG)]^ GV1P$]\\[7I_3K2O270_L[;C:.G8M*Q"H6V08@J8:9EF:W
MC&\.C&N_:NP.R=<,IV#TP\4R=T.>-A?WY/+?S$_MT_B/_'6$C=XCR5]8SJ.A
M4E*<@#/Q5V[?(_+XGZ]0*N0[V'A9N%L\H1XGI1/4G _G.,=NY_)CJ>PUYK-O
M+U?RN\>TM+^-^[,?,_*$[-EA*5'.?=Z8^&/MZ#TZGKTZ8UYS.5BWO/.UR6S9
MLXNE-)[_ $_$?37Q;6M3E>]DH*>3^CY]#\/Q'TQKQSYOGE=C;A;G8'(,28OD
MF3R<A_5K_&W.&0N.I##J3VYLJ..W< ?#M^/OC7G%?(D&67.0TY\??EWODPCC
M=LE"T+!<]TJ6I2!_X2/AU_(">@U;YR-XYD Y'UW>$9'2)WQQSLWCKY>=XCO7
M[DJM)6ZNF39$))0<ICON(&<].<'L1\/B3JCFR)88BS Z#ON?0X1DM/AM+-0'
MD.YS(RR.C9VOIQM#%W9N)>*V2A^Z*LI*TG+:I;JD8]/<R,?;^(:MDR5+FGW:
M\0UG&G@&B^4N&T<H_P"Q8,[AV\2,M2&$1.NFIORG'G)#SS[RR25/++G-WZI)
MSCYX^&2,YUY*DRI=N5LFO\^_D#G&34LF0FTDGP<$\+<&T'G=HC_=#YY5^64=
M2>?K_?)S]GKJDFS-Q@V=A;7+Y^X^.34:2B6D7<D <G?@;<X86Y.5Y2B$IZ(P
MI1QD_$=>GY/EJB6G>[0-\SS\O7SODE8 W2 QMI9_T![L\HGYX2=AM77Q;TFH
M.,)<B6]0:E)E)Z?>TR6'$H4<CH"H?40>^K[@=%*KII1-8D78LQOEGW9>#6?6
MW2[6G#]G9:I!92I@"#9QO,+$9,?"V6D?5E<5DT%5@U29%I[3DMAB2^A*&V^<
MNH*R C_QG&$Y]3TUE<O \*"U(FR "@$Y#OO[]<HYMPG'L0.-T,F;4'JIIEH7
MVB $+4E*^(LDGCE%5CE&KE-DUN]6*?*A"&\^RMYYM2>5<Q:FPF,DC"E!)_#Q
M[I /IJ]2=G\$F)1]P'4S"V;ZL+NPOD+\S'4DC$*"MET6#B>DJ,L+:UV&1.;G
MN[V,.%MW>OTS&1:-PH5.:E28\NG29" I;+S9Y?()]"ILD#N 3GN #IWIXV>P
ME&QQ2)+$[Z02,B4JN& RL>&>MXQS:C /90G$Z LJ590<L ').EK%[_422KEN
M6I#;84*?&2^Y%="T\H)6T0/+!!Z)YE'&1CIWZZX3H\(H,/DS6;>J)G5<WF#<
M;+)RP?X1JZGK\2*JE1GJ("B3VF8!RW)P& OIH\6^\+M*11]E;(A<B6UMP5\R
M!CHI<MYP#KC]B>N.^/CKZ9]%>'(P[8O")2&:9(1,;@Z00+<(Y VYGS)^TE>J
M;,WU!9&GQY:<+<HD6?EC/IG6Q8Q"*R?&"<=:\.[B0<;A?23K=K(6S3\H!G.)
MJ<0MQ,N?>Q[0O+67!R *][W=(@<O+XQ7A<EM<3O%EMCM%M+%X$8G#E#IM4VK
MNZ9OP_>%FS7Z)1[.=I=6DU"C1J##9JZJI68D9;++*W^1(EN!U1/4(,[.,F+Y
M7[L^?J\/JUQC\<VYM\WKQ [32^)BI5BQ=XJG9=K;4V[;MNO<,=4L^T*Z*)58
M-RRY,Z/6)-8J4/S9<FL.O1E0I"D>4RM ZHAXY/ISN.]K"W$WB</Z)>(G=+>W
MC=W'JF_^Y%D6MP_;6VU6[;V/HDJE&T!<%S[;3:E4&JTZ]$ER9\6G3.8QV6Y2
M&S(;2Z<D=41S)\QIKEX:<1QO"=V^XU-TN'FW(5?W=O*H5FU-W^$FA7UM(JJ)
M+R!NQ2H2H,^@4QF*6$1D5*7*A24Q^3[X\2OS0G.40<OKD+"]_C]>.D0_OCB(
MXW+VNY_9M5^\5='NK9/;>U;CE2MA:1;U?7<.XUZTU%S(3N7,J\AEY5"I:I#=
M*9HL1M"1";6%RPL'2(WRT?\ 7G8OWCX.)OCO_P >5]V3P\W_ +P5#B$V-VT>
MVCGO7Q+X68E"J-]T[=*+5E4QFL[A4)Y=6FFUY$!I-0]CI:'$-R5OQQ)1T&D1
M]6]?K\(>[<WC6W7L+:O@:W:HVZM+WA=D6!O37Z]<#%'>H$*_95H6EYM&5<%/
MF SJ=4(\EML5AAA3*536Y..4*&$2N6YWT/@_#0P]NQ6V7&?;%HVAQ3U?CB9N
M&'N[M+<E[;@V%NQ"A.[<695*W0W;@M:?MK$BKB3J=3;3<DM,52-)E3C4*>P7
M'.KA&D1OKP]>K^Z\7N%[B6WDHW&_PY6Q3]_^(/?JP.(1K<NV=RJ[NI9L2V]G
M'KDM:Q:U>,67LDR8T&KP&XL^E(C /M28<NCR5*1(4I:,H/\ /P[XD!PL]?""
MXR<%6!'XVCU QS&5? ("C[W8>F!T[8U*G][\Q]>A^D1D/U^?^8G/X0?ZVSPE
M_P 'D_\ /&Y]31,K,?E1_0F%%PU?JU_$A_U[X:_]V:P=0&9[_D(*R1^4_P!:
MHL!U&)8-(0:0@TA!I"#2$&D(-(1YW0,G(]T)4#Z=QT]1^/KV[=M2,ZE=S>8]
M><(IUXJ8T:V-W*U+>:6XNMLPGX#2&^8+Y,MO\QSUY\\W<?4<C' GV@*65A.U
M\JJ &]6[[V&:U$MIQ^.0CJ+HNG^T;/R)/\"RCG9+ #/4-=RS/"4L.Y2U<<>G
MPVO9DU2E/J;>"0GFD-MJY&2G'O%L^[W[X^1-VZ L;ET>-3\/G'MS5'<N]C8,
M.)?XWX9)C%$\I<RH)*43I823<[N\,R7L4W8'3CG!BZ[[O:W=Q:U%F3GJDENJ
MR?;:7)45QYC!=)$9QM64H:#1RWW('J==R4DB0*>;-FJ^][12'L[NS:Y9\+,S
MF-ZX3L_A%5LM2U%.E*JLRBM$ZG_W)*C+"AO:%2<E#R-HVW&U%M3<?@RW@H-H
M,LM3K#A6??TNF14 (:>@56.NJNH4/_EZ5+J<MS&>L91['.LVZ(<0_9O29@,R
M99&(S)E"H,6(JZ6K12  Y@U") +Z,-(XD^T_LIBE9T8[1FJ*IID)-=1S%W6N
M7A]93+J%K-^U[(J:=.T1?*-7X*4JS[EV+NZ#-H5&FW18M\2$*J4J*U(J#-)N
M*$F9"#3BT%;38E0*BD!!Q@#OUSJ;[<^$*HND;9_&R#['C6S,F7R-1AE89-0X
MR/8J*4:N''(<]= &TF(SNCY6%RJE2)=%B&)2U(2M0"34#KB&W@  YLWB=)J<
M1&WVQ-SW-4*/N#(JU7N"JVW*DP+$;N(4IJO1V$*?>B4*&5)2Y(>"/O@/^<)_
M!&2-<)2J2:G$0J2G[PK)(/\ $3< ,;&]KJ(&L=0[/SL9FTR/9$B:>L 1/TEC
M0&X_#\1>UH^;;?\ XCN%RU=U++IVQ6S%<VQNZP;E$*ZVZD&VTO(9>0Q)8?2P
M.=;O,E1#P/OD\_48UNK Z>N-..M2SH&KD=D9=UFTYYOTIL?1;03J#J<0J!.1
M-EI(2+9@$"V>H/P%R+4[(NZG;O6),<M:7&E/7-;<VGB.%Y7!G5"GNQVO/2?O
MC:0XH+4OJ.3MJ_49]EK$E3 \"X&=R.+G,CBQX1BVU6&5$D5,@C=F +3+!:X!
M(2X!S&O=H#;R<#?"W?G#SPOWULA=MSPX-TW=4KTD0[AM=:W54--S,S40I\93
MH0L3(+DII8"2I.>;'88S6IQ"6JKI5F^Y+EW:UDI&KY-;GEI&G9.&JHZ6?(79
M<Z9,40"^Z5J*B0= YRTMX0JLKPO^*MB\>'&-71LW^AS8S>&;N-5]QH=1EN;@
M;C19DXR?.N)E:E-KGM,* "1A"#D8Z#5_&+254YEOG>P:Y%F[[,&Y6N^(C9ZL
M75]=+))"BSDOF^OAXWCZ&=P+KI$:%+B1Y"?I"H\S?E(PHH9(Y5+<#>"">O(#
M@]LYZ:LR*??G==H[OD[N6?EGK\!&QL(P:J)3-F@]@ -W,V?PUUUAGZ(P\RI'
ME+\T<O0X*#U^.<?'/7ZNG;5V1W=Y]<F],^;(^ZE&61<Z6\;?5G^#FTN?*9"4
MN,N<IZ%!]\_ $?7TZ9SJ9*6?_!\_CD+<XM-1+=W9_/77Q[\[.T5S>+12$UKA
MFI55Y,.VY?5*=;R/>\JH1);3W?M[S#7V=/3.M_?9TJS*VZ73$VJ<'KT'OD+D
M*'Z\XY@^U%AWM'1N)[ _L[&**<_ 3I<^3=^9%N5](=OPJ;H=K7"#:$1Y:2[0
M:[=5*QG_ #3+=8ENQD'J<_>76SWP,C5KZ>*3V7I$Q-4JYJI%%4/9BU!*)M87
M/&Y+O>*K[.]6<2Z+<&,T 3:.?74@&C2*Y;-F;)8#E86BR3VW&.8I_%W_ "]/
M[]]:<:4S.0<G>S\<LN[Z1O T[W///0^7G>!<Y(3E7+@=CGF'3/;_ -,^@!TM
M9K'4.7NV;/R?+OB"*91R=NYFOH3:_>W=>-9(GH0E6#C'?.?F3U]/LST^S'E[
M_P! W'NSUMWU:)+&YOW?#F?&$=4:NV&EY5A8<]T8&.N3@]?CD^H[>NO-2[V'
M#OR#?KXY9Q<*=!-SY\ODVG(B\-K6);KQ5Y25**Q]G7T^??'P_'J2X[]>0&C<
M;/F^3-%XE-WL&]7]S6Y:M#68DU]3H66VT+!!/S_'TZ 'U]?34JR;FSG+X>M"
M>\1<).60L1GQ?NO=V9LVN<F9N:@)Y%K<GJ;(Z<J0%= .X/S/KU&=4*Y<W/CK
M<>L^&G=&04LRUFXV\;@99Z^/!HXWG:KBD.KB35.+/,KD=QC ]['0=<>G_35-
M4IWI>>K>; W[L\\QQC*:*O66!2&=K!A?B"VEM/>\0\N\R(KS[$QM*7FU9;/[
M;KWQZ =Q^3YV+JRB8UQF>1Y]YRM&72)HZIRUW#,#;FX#V&K-$>+DF-J0\L=>
M4D$C[1\^V!_3KRG.3R#>O>8NM(A"KIS)&6GK*_OO#!7+) !/IZ'X$Y(/X_R#
MYC5/-_ &S+CR##X>LHO].CJR'=GU;U?UI#*5>0?>0!^$GJ3D9)/Q^WOG ))U
M3)[((XN]M&TMRY?![U)2Y!9PX?(L";^[Q^ NZ\#RRWG[JWEW%+04S I,"A1)
M)'.A,KF>>=0",]>1??IK+MF*<F8J=</X9:YBY8VRM81H3IOQ$E='22PZ4J3G
MJ-X C1]"3=N[/Z3IC2&+;4RRV%%U$=7+WYU+=27,9[D@GH?CCX:S9>=V#C@/
M+FWO #QS>\U545I9$Q)<$!MUN/(6/@_.&2W\VSEWA8\*GVG$C1GXLSVN3R>7
M'#P<Y0X75>O)[Q./7MCIFH1,FH3+"6<*! \0.-[@-QRXQF^P^T*,(QM51B<\
MJ3NM+22I3F[)3FSFP&5VYQ%R)L=/VVHU-NBN/MR:K,JT6/!B1#S--1ED)45+
M'X3JN8<N#U/0=SC1'VC<831[)TTM/^Y45"92PQ+=:0@]E-U'M?A2'NW 1L2O
MZ0!CBZF@D2&D(ES$ AW)*2'<Y\&XGG$2MYN)OBKLVH5*FTW@JJE[TQRY'Z;;
MMP4#<6DOU&KP(4A7LLMRB,,/RZ8S*3]Y6F0DA14$J'3KSA@NR'1[C%-@<K$M
MNY=%B51-"CAAD5"5+6I:=V2%$ )*SV 5,$OO$YQI?%L<QK#I=9U= I=.$S%)
MGO\ @[)^\4<^S^(]QT,67;)^(WQ.0+$HT.\_#(X@[:J<%"&8T"BURB5J&_#"
M6PW*+[K,9;*G"?.\G!Z''0]-?039F@1A>"X9A\F9ULF12H$F>UILI*7'<2EN
M%],GYGQ.KFUU=55$\=M<XJ[KF_CPMD<XD%:/B);SW+=5N6]-X >(NW8=;K5/
MIDJOU(T0TZC,37VXSM2G!#G/[+"0X9#P1A1;;41UUD$6]_7'NOI$W^(_8:U.
M)?9V[]EKVF5BF6S>T-J#49M!D,Q*O'0U):D),-YYB2TASF9;!66E@)!.,Z1$
MAX=*A4&';]O4BWHA4]$H5'IU'CJ>*%2'8U.A,0F/:%)2E"GW&V 7OO20LDX
M&=(16)6O"DV8G[L5B_J/N%O5:=DW7>4>_P"[MBK7O--)VCN2[&G ^]5JC1&8
M2YK:ISZ&W)\://:COK;4%@9(T]>O1A$E('!KMK3JEQ'5.'4;C:7Q,T.ET"\H
MJ9K#<>D4^DT.10(@MW$53D928<@J5[27N=T)41CII"$->_AT</\ N)MYP\[;
M7C&N&JTGAMJ5"J5D3S4VHT^H?0:4>53[B<:B!NH4V4I"%RX24H0^XE)/4:1
M :W-V/?\;>M(2O$9X;>V._6Y/^-&C[A[Q;'7?4K?8M2\JGLS<S-K(OVVHY2&
M*3<[+E/F"0&64&*S(9\F6TR2E*D]PB,:+=;PP]L]P$66;)W5WSV)FV38:]N?
MI+:B\VZ:]<UJ.9<<@7.U5H55C5.4X^7)1F(::DJ?=<*G$Y T@WTSOZYF%G \
M-7ATB6YL#:;4&X7+6X?J)=]%H-#F5"-)BW1'OFF_1EQKN_SXJG9\B>%/3%NQ
MS%"7WUJ1^"$E!AE^O^8;6Q?"?V4MFZG:K<NY6]^Y5FTNUKILFQ-KKWO,3=OM
MNK;N^*]3ZK3;9I,:%#<2W'@.F#"=FR);D-IM'+RJ0' A;UI\_#*P[H\>TGA(
M[4;1[D;1;J0]Z>(&[+@V+J]3>VN@7C>T2K4*V;8JU"J-O5&S(M%^B8\5VFO4
MVI2&F93@746TI9:]N6V5 H@$@>K9N+>O"%QN9PY6?PN^'EQ<[:V+/KE1H<S:
MCB/O5Q^X)+,R>*G>=NW17ZBVEV.PPVB(U)EEJ&V4A3;*.0^9GS2B(R]?IYMP
M\=KX0?ZVSPE_P>3_ ,\;GTB968_*C^A,*+AJ_5K^)#_KWPU_[LU@Z@,SW_(0
M5DC\I_K5%@.HQ+!I"#2$&D(-(0:0@TA!I".ASISG()('N]B$_CZZ0BNGC<H=
M.CR+7N:3'4'Y0<H\9]""4MR%++HY_B2V@9P/7YC7)OVDL$ESC@F+&1OF5,4A
M2F!N'R\.\Y:6C=_1#7$5$^C473O=8 ^3?#D]K-K$&T\]"DV[<OG .T^J1V)3
M"^J7&UJY%-J3W22%\V.OU=-<S[-8VG MLL(JVZB3/J):5J-G!6 XXNY(X,0T
M;PK0*XU,N[;JF[O'(\VMERC0;EW!L;,W+876*1*:K8;96]566^2G!YS/DO/9
M'*M/FJ&5$G[0-?3+"JN1B5%3U*%E:)E/)FI4+!25H"@JUCSR?5\XO&S=-M=(
MPA4RAG=;02>P95R4(1;=(:Y L3I;2&7H^W-?KM9W5V\J--EBA7[95X4%2V6B
M(4RGUNES6J5(;?Z@I6'VU)1U]TC![:NE#BW[%Q/#L21GA]7254GC]U5)GS;D
M,6ZC/3+C$G2M+PK:[HTK\(F*IIU?4X778952">U+GS9"DE*AEO!2"DDGBX<$
MQ5#X?^]&[6P]8WSI6V4!BL7*S;0K#]J26RM%:?LB=.1(C\OF A3"*E(ST&.7
M& 1UW5]KW9&3M;L?LQM )6],PW$)R92@W:EXO129B6+9$4X)T+@Z6^8?V695
M/-VMV@V0Q$"7)J^I4@ ED5.%5,Z7.2G_ +J@)[A<<8 <47'1Q!<4&^%%W#KK
MSU@7%83CM+H\"W9+]/11G&IB"_E8< ,@NL%"V^J7$<P *2=<!T>SDC#T3 L
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MN#>X[,GII%>NBU;6M3R[JF4!^*U49\""ZW<DM;$R/%6X#(7%4&UHYB@C(TB
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M[Z6MY^7..ERMME7NN^[ZY[=QV[?/T_FTWC>WFVHX_%HEET&?'UQC03J^D)2
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M;<APT9\X=WA_MVIS-^K6CU-29+,=,VHL<W>.RWA;6._^;+H(&!Z@=\'$^@W
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M=03U$V73U4R6G^):)2U $\24I3H2[1[;-[7X5,V.11(GB152TFG$L!M]:QN
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MEK)VGI;014TTF+(K\E"?+7)E+0E<I;Y;'*EQQQ7(,C_-@^F-;.P^F%/1)DH
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MFY:>S3#+1[+Y]2DNN16S,3[B?-"@I0[)Z9 [:RB;BM/5[32\73:5*2G>?B
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MQ.#2$&D(-(0:0@TA!I"#2$14XZ/U&'%7_L];P?F!7](0P_A!_K;/"7_!Y/\
MSQN?2)E9C\J/Z$PHN&L!7&MXD.>N+\X:L#Z^&6PO^)U 9GO^0@<D?E/]2HGR
M&VE=%-I!'8')., ]_M/KJ,2PA[PVQV]OZ7;DN]K+MNZY-HU5JN6P]7:/#JKE
M!K#((:J=,,METQ)C>  ^T4+&>AZ:0A=(::3TY4\PZGI_<?+ ].F-(1R66BKG
M+:2KXXZZ0A+5BR[3KM5HE7K%O4FI5:VI2YEOU*9!8>G4:4ZCRW'Z9)6DO17'
M4**'%-*2' >4Y&-(0J.5LA)*$C/H1V';X?S_ /72$<EEI7="3I" --('*$)
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M4= S$W/+W6-GVS5\U2U($2QMRGVH]0CX:IT]Q?+%E1$@#RPXO 2X@]!G&1U
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MFD(8/>O8VW]WJ#)@5!M,6I--J73JJT B1&D)&4D* /,GF/(>G5/4C&M>[<[
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MSM0M]X,T]CR&77GGE-J0M!99 *E%0P ,YQJVS-GJ"LFB5(0?:*DA .[<J_"
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M$/%*<QV_>.CB&H%K6U3G&XTZ7%@1F8K:FX])H$=Y"9]:F* *$O\ E!QYQ:R
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M"5)S[^ZWRE<3_A<;\\/-T2*UMNBI5BBQ93C]/]E><AUN"$D.-&/+:6EN6EO
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MHJ4"9(0H;K[V; Z@-D(HL0Q&9B-!2U<H*(G)ZN84@G<,O\(4V5Q9\R><(+B
MJ35_W[;5H6^79[E&??;?=CK*#[?.6CD8;<02KF::2KG"2<_('5UV,Z/Y.W^/
M>T5SIPZF*$I"@6*7&^0X _#P<.<GB$C&ZW9/!)\R5*1--:HJ6%$!0=)R![5W
ML+%]+EI$;"<)E?I%ULW1=KJF8U/<9G4]E#KH><=4$\I>!/O$#H0< ]OF.O\
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MRGX5V4NG-PY4B.^N,J<PEIM!\[R_PU I(!4<].FK]M+T<8)M55RZJJ"9-1+
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M^H^L:BL(4&6 4FS$/ $I_"2.[3NB/SG#G9\B_7+]FH,J>HI6TRXRVEEI:3D
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-3?.M:^7F4HF,0C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g504802g50p86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g504802g50p86.jpg
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M 1$  A$! Q$!_\0 'P !  (" @,! 0            <(!@D$!0(#"@L!_\0
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M[@003?=IOUB%Z7R#@+SO38&E86.*Z+1J-3+P2YLIAE(PT\TN"KQ))JP1:)F
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M>*V'6DN;):V'0X&W/]"Q8%)_=XK[Q%@T'S)RLY;MGC5PNS.5-X@@X256:J&
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M6Q.J!L&@NQEJ,W2;F66A7*$O87CN6A6RC9\FB#ETY6+#LSL[LNBR1J'+@_\
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M:G9HRLS.MT^6FJD[*23*YB;FFI!AR:5*RLNV%./S$ULA+,,MI4MQYU"$)*E
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MC:T92(]JZ+)&>OY6;K3N&8/6#M5ZTU)NH"98FI?@TPPI#<NMXO!H)V#S[25
ME#KAY;*G"1:P"5A1"A8YV)0LNL.[5EP+4\AO(5E6U;:<(T4A(LEP)%[FY*2
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M/C[MIEM>D3E"U;,5K=-G4@9!21KU2M=@>6)_ 1%<*OV-2=;5EJFC,F8IJ+-
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M/P$KV4/FAU1W9:__ $.KWN['?VM],U7K";[:'>6C=$TS\!*]E#YH=4=V6O\
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M/P$KV4/FAU1W9:__ $.KWN['?VM],U7K";[:'>6C=$TS\!*]E#YH=4=V6O\
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MT=;90MPV%W%*-M8\KQW296B8JJM/DD;.40XP\PT"2&D34JS,EI-R3D;6ZM"
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ME03I=WK::E=]Q[+MU$B_(]/L5RG):OL.S%9>+CG;U11)?L).@C$7PB9\+$@
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M!$TTR !2$(0H 4A"% "E*4  H     &?,I)))))))))-R2=223J23O,?1P
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MI&O_ )-PE^:E86TT;:[LG.2\>0O4\FC:SV12U,8PY!4*M&QLRS8KE7=%6;J
M[<@K#5#&^**K.R%0J-3X7,TQ9<D=M)4\RS#I-]J)(2@DG'@;%+KLNMQ)2@I4
M"A&67D<&X;IDG.R,A3>"R]12&YW93D^)AYL"VR,X9HSB&B+A333Z&U!2PI)"
MUYHO]''PR[F_:'M7XYR9\*^/^G_9=%^'1$>## W0?M.L?$(>CCX9=S?M#VK\
M<X\*^/\ I_V71?AT/!A@;H/VG6/B$/1Q\,NYOVA[5^.<>%?'_3_LNB_#H>##
M W0?M.L?$(>CCX9=S?M#VK\<X\*^/^G_ &71?AT/!A@;H/VG6/B$/1Q\,NYO
MVA[5^.<>%?'_ $_[+HOPZ'@PP-T'[3K'Q"'HX^&7<W[0]J_'./"OC_I_V71?
MAT/!A@;H/VG6/B$/1Q\,NYOVA[5^.<>%?'_3_LNB_#H>## W0?M.L?$(>CCX
M9=S?M#VK\<X\*^/^G_9=%^'0\&&!N@_:=8^(0]''PR[F_:'M7XYQX5\?]/\
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&*PQ"/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g504802g51j14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g504802g51j14.jpg
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M,%(7&"EQC&,8%Y,29D+*XUSJ7(I_@E5_P]#>KFPLKC7.N\O)B3,FXZ,4*@
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M?/DB)7$G(R4JZ3;E12=2TC(2C@BL@^=N5@.G
M                    !&VLOT0:K=&UY]EY099P<NN72SNXQB8M^<BOC1;P
MX1L8T!/H@V     3UN6/&7T Z9--_:Z)&LQIS0B?0+UX)L;%"'.J&]..OC6)
MK^$%2:P                   !1:U^%-D^_YCUBY%],29DW%A<:YUWEQJ?X
M)5?\/0WJYL+*XUSKO+R8DS)N.C%"H
M                       !&VLOT0:K=&UY]EY099P<NN72SNXQB8M^<BOC
M1;PX1L8T!/H@V     3UN6/&7T Z9--_:Z)&LQIS0B?0+UX)L;%"'.J&]..O
MC6)K^$%2:P                   !1:U^%-D^_YCUBY%],29DW%A<:YUWEQ
MJ?X)5?\ #T-ZN;"RN-<Z[R\F),R;CHQ0J
M                            1MK+]$&JW1M>?9>4&6<'+KETL[N,8F+?
MG(KXT6\.$;&- 3Z(-@    $];ECQE] .F33?VNB1K,:<T(GT"]>";&Q0ASJA
MO3CKXUB:_A!4FL                    46M?A39/O^8]8N1?3$F9-Q87&N
M==Y<:G^"57_#T-ZN;"RN-<Z[R\F),R;CHQ0J
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M;BPN-<Z[RXU/\$JO^'H;U<V%E<:YUWEY,29DW'1BA4
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MF_M=$C68TYH1/H%Z\$V-BA#G5#>G'7QK$U_""I-8
MHM:_"FR??\QZQ<B^F),R;BPN-<Z[RXU/\$JO^'H;U<V%E<:YUWEY,29DW'1B
MA4                  (MUR^A36#HMU ]DY<9F'.<+BTRZ^.8&(B#D%]Z(>
M7!MC&R)[D'@    "PFY,\9S0+I:HOM"Q&KQMS/B;0;RX1J;+!O.R'-,N_B69
MKT$%R:9E)W87C/ZX=($U_60<MKKW2;&NG:U^0ZRW&^BV!>SU2^S2*VCS@]+
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M2J-<D9B*B7+IP=V4D2E,23ANU1;K/56SQRO&L:+GF$6?5+SYP'7@5
M      "+=<OH4U@Z+=0/9.7&9ASG"XM,NOCF!B(@Y!?>B'EP;8QLB>Y!X
M  L)N3/&<T"Z6J+[0L1J\;<SXFT&\N$:FRP;SLAS3+OXEF:]!!<FF92=V%XS
M^N'2!-?UD'+:Z]TFQKIVM?D.LMQOHM@7L]4OLTBMH\X/2P    #7!N;_ !=]
M!>A?2WV'@AU?N=]'\"]CH9]R5$Y"72ND6/NVL5>_:^30-Q-*
M "-M9?H@U6Z-KS[+R@RS@Y=<NEG=QC$Q;\Y%?&BWAPC8QH"?1!L     GK<L
M>,OH!TR:;^UT2-9C3FA$^@7KP38V*$.=4-Z<=?&L37\(*DUBEM_W?6YVTTN=
MBH=IE[.A8:O(J1<LBSJSYXV3=ID(<Q4721^#6)LJ%S@Y?FSOYQ_ >-OZ[O<^
MAM\/!Q/2MO.@\'96*56K5!B[&[9E1:T:-&DJ4&M%?1IT94DPH>V0_P#V?[H\
M3.5W/]U5-UM'<]:M1K54IMGK5V+6DQI+2HHM-E33TJ%*=%?BKA./^4SW*_\
MURX?Z-DOUC$?"2N7_OKW_D]8_J,Q\&*ZO^X.?^=57N'RF>Y7_P"N7#_1LE^L
M/A)7+_WU[_R>L?U#X,5U?]P<_P#.JKW#Y3/<K_\ 7+A_HV2_6'PDKE_[Z]_Y
M/6/ZA\&*ZO\ N#G_ )U5>X?*9[E?_KEP_P!&R7ZP^$E<O_?7O_)ZQ_4/@Q75
M_P!P<_\ .JKW%X*A:(F[U2M7.!465@[; 1%DAU7*!FSA2+G&#>28'7;GWSH+
M':N4C*(GSM)'SDAOG+D>UNEYU5].MVOBHTJ=*I/6H51Y5.DTH*S:4JK7:NSK
M+"E39KAH4U9-**TJ"X:*S1<*'ACX==;<;V>;E>%&A0KSH>%<=E=H,Z:-6=&M
M5&L-*K6*-!I1^*TH(U94THTTP4DE23 IT0R!C@        HM:_"FR??\QZQ<
MB^F),R;BPN-<Z[RXU/\ !*K_ (>AO5S865QKG7>7DQ)F3<=&*%2IUXH^G&IN
MOC^K76LUM;BW2NJ2KQU(6"S1UDMS9S:KF6&81,=$3T-&*0E'>QTF_DW[MK-N
M^,+;'()$A2)$<RGTBJB32U>I,&!,G7^!1415WX\*8<&!3L-STI%MHC4*MQ",
M,HUINILK733==E;!*P=D6Y,U*:,_99LD[9WT>ZBB3*=2GHQ&P2;-K9*W,&34
M:K+.(]G1>K*F3+8B;@G7DMP]2%@10J             $6ZY?0IK!T6Z@>R<N
M,S#G.%Q:9=?',#$1!R"^]$/+@VQC9$]R#P    !83<F>,YH%TM47VA8C5XVY
MGQ-H-Y<(U-E@WG9#FF7?Q+,UZ""Y-,RD[L+QG]<.D":_K(.6UU[I-C73M:_(
M=9;C?1; O9ZI?9I%;1YP>E@    &N#<W^+OH+T+Z6^P\$.K]SOH_@7L=#/N2
MHG(2Z5TBQ]VUBKW[7R:!N)I0             1MK+]$&JW1M>?9>4&6<'+KE
MTL[N,8F+?G(KXT6\.$;&- 3Z(-@    $];ECQE] .F33?VNB1K,:<T(GT"]>
M";&Q0ASJAO3CKXUB:_A!4FL94]V=XTNMOXV>?[5H.75V/I/C33+7[EB=8+BW
M15 ^@V/WK8K&/-#U      UM;F?Q<]!>AO3/V-AAU<N;]'L"]CX:]SU,Y#W3
M>DB/^VD4>^ZZ3<-T-'        "BUK\*;)]_S'K%R+Z8DS)N+"XUSKO+C4_P
M2J_X>AO5S865QKG7>7DQ)F3<=&*%3D+?I]0M0FC9A?J14+PQ9+&<,V5OK4-9
M6C1<^"E.NV;S3)ZB@L<I"E,HD0AS8*7&39QC&\FJ8ED#W8B'B*_&,X6!BHV$
MAXY'#>/B8ABUC8Q@W+G)BH,V#))%JU1+DQLX202(3&<YS@N_G( ]( 0,ON@J
MJ64U#B64+9)->A2%$A6ZS-&*PTN<]J#;IK3Z*BJJY<RK=,YHZ]U^6JL\^F<Q
M$=%R,?(*JNC,&#EV2LL66?LE;[,)2>/)OFJ2PYCS)'=(UJ#>Q\-/5JQ15A5M
M+VHS,*J[JF58249XH:Y,)N5+&@A9#RD7J54)Z$BJMF8L<E#O7F20B<M%OHA)
M)93]O7ER9%QB:=>#VIYLUDV5>PMK7!L[ Q0<(QLF9TM%*.<)X-(Q1'BZ$9--
M\)G4QB/G622$S%9/DJYXQ\S4<HMG!U6R5,17&=!OXQ^W.\ /YOX^O'\\ !OX
M^O'\\ !OX^O'\\ !OX^O'\\ "+=<LX[RFL'SX^BW4#^..:<N,S#G.%Q:9=?'
M,#$1!R"^]$/+@VQC:$]R#P    !83<F^,YH%TM47VA8C5XVYGQ-H-Y<(U-E@
MWG9#FF7?Q+,UY[^/KQ_/ @N33,I6["\9_7#I FOZR#EM=>Z38UT[6OR'66XW
MT6P+V>J7V:16T><'I8    !K?W-^<?W=]!?GQ]"^EO\ 'R'@AU?N=]'\"]CH
M9]R5$Y"72ND6/NVL5>_:^31OX^O'\\#<32AOX^O'\\ !OX^O'\\ !OX^O'\\
M !OX^O'\\ !OX^O'\\ !OX^O'\\ !OX^O'\\ !OX^O'\\ "-M9<X[T&JWSX^
MC:\_Q\F)099P<NN72SNXQB8M^<BOC1;PX1L8T1/H@V     3UN6/&7T Z9--
M_:Z)&LQIS0B?0+UX)L;%"'.J&]..OC6)K]W\?7C^>!!4FL95-V;XTNMOXV>?
M[5H.75V/I/C33+7[EB=8+BW15 ^@V/WK8K&/-#U      UL[FC./[N>@OSX^
MAO3/^/D;##JY<WZ/8%['PU[GJ9R'NF])$?\ ;2*/?==)NW\?7C^>!NAHXW\?
M7C^>  W\?7C^>  W\?7C^> !_=_&?V9WP  %%K7X4V3[_F/6+D7TQ)F3<6%Q
MKG7>7&I_@E5_P]#>KFPLKC7.N\O)B3,FXZ,4*@  !\:R?#)*I;:B?"IG3X1$
M^4U4]LN2[:2F/G(H7?VB'Q\Y38P;'[ !5=MN76<(XD5ZS?;(W22KFCT34H^Q
M%Q8H^ D=&[].WZ%>R)"N8IY.L)%U*I1+YEA[&2>&"M@6+.GD)M)W%UGO7:DE
M*2_#8OG;/)(;+2N3/ W5C.V-D\F-2[BVLUV?Q4*O%QYHXD#5Z:[K]?8N)B3?
MQ17]'J3"O.)@\PXD".WTK/,<,%EF;%DGLQ;5_'P$MOGJ/NZ6:;3.GIK!B4NC
MRUHRRC##%!=*8039E8*29CR+DDM9K&D:?ETG[9O,JP"59K)D8:+)#U.%(DL1
M8JSE@EYS;YKE*^?.$DQ_$Q4KP7&<:PD> V^![N9MW? \)L<)P7#IJ<'PG!DV
M]G>VM@NUO[.-ZDU3$LA)%QI,\[DC5>;4!U/']G%9K:NM2DDL34@Y(U7FU =3
MQ_9PFMJZU$DL34@Y(U7FU =3Q_9PFMJZU$DL34@Y(U7FU =3Q_9PFMJZU$DL
M34A&&MU5K"6B^KJJ5=@TU4],+\HFHG$L"*)J$JDL8AR'*A@Q#D-C!BF+G&2Y
MQC.,XS@9F'%7_$+BPKRRZ^M?WY@8B($3]@OO G)#RZO^3;&/<3V(/@    $_
M[E-!%SNE]!V[A%)P@MJO1TED%DRJI*IGGV)3IJ)GP8AR&+G.#%-C)38SO9QG
M U>-N9\3:#>7"M398-YV0YIEW\2S-;')&J\VH#J>/[.(,36U=:DTI)8FI#+)
MNNFZ#3=,ZV-FJ"+9NC?IDB*""9$44B8.3>(FDG@I"%Q_ I2XQCZARUNO=)L:
MZ=K7Y#K-<;Z+8%[/5+[-(KF/.#TL     UA[G2KUIQN?="EUZ]"++KZ-Z8K+
M+*Q3%15552DP9U%55#H9.=10YLG.<V<F,;.3&SG.<Y'6"YVJ^K^!<*\SH8Z_
M^B5$Y!W2D3UBQ]@3GK%75_UVODR<D:KS:@.IX_LXW&:VKK4TJ26)J0<D:KS:
M@.IX_LX36U=:B26)J0<D:KS:@.IX_LX36U=:B26)J0<D:KS:@.IX_LX36U=:
MB26)J0<D:KS:@.IX_LX36U=:B26)J0<D:KS:@.IX_LX36U=:B26)J0<D:KS:
M@.IX_LX36U=:B26)J0<D:KS:@.IX_LX36U=:B26)J0<D:KS:@.IX_LX36U=:
MB26)J0CG6&JUA+2/5-5*NP::J>G-W434)$L"'3.2LR9B'(8J&#%,4V,&*;&<
M9QG&,XSOX&6<*K^W7+A7E9W=?_.,3%OQ$_8KWP)R6\.K_E&ICN$^2#@    !
M.VY>11<[I'01NX23707U@TZ2616(51)5)2V113IJ)GP8ATSESDIR&QDIBYSC
M.,XR-9C3FC$^@7KP38V*$>=4-Z<=?&L37#R1JO-J ZGC^SB"TUM76I-626)J
M0RW;L9NW:;I[6ELU01;-T;H[(B@W3(BBD3#5IO%323*4A"X^HI<8'+F['TGQ
MIIEK]RQ.L-Q7!<J@?0;'[UL5I'FAZ@     :O=S;5ZTXW/.A3AQ7X1==?1_3
M9599:*8J*JJJ4^'.HHHH=#)SJ'-G)CG-G)C&SG.<YSD=7;FZKZO(%PKS/AOK
M_P"CU,Y#73D3UD1_@3GI%'5_UNNDU<D:KS:@.IX_LXW2:VKK4T>26)J0<D:K
MS:@.IX_LX36U=:B26)J0<D:KS:@.IX_LX36U=:B26)J0<D:KS:@.IX_LX36U
M=:B26)J0]!A#Q,7E4T9%Q\=E;!<+98LF[3*N";6284R@FGD^"9,;)<&W]G:-
MO;V_D4FJXUF5DB8DD>B *+6OPILGW_,>L7(OIB3,FXL+C7.N\N-3_!*K_AZ&
M]7-A97&N==Y>3$F9-QT8H5                  "+=<OH4U@Z+=0/9.7&9A
MSG"XM,NOCF!B(@Y!?>B'EP;8QLB>Y!X     L)N3/&<T"Z6J+[0L1J\;<SXF
MT&\N$:FRP;SLAS3+OXEF:]!!<FF92=V%XS^N'2!-?UD'+:Z]TFQKIVM?D.LM
MQOHM@7L]4OLTBMH\X/2P    #7!N;_%WT%Z%]+?8>"'5^YWT?P+V.AGW)43D
M)=*Z18^[:Q5[]KY- W$TH             (VUE^B#5;HVO/LO*#+.#EURZ6=
MW&,3%OSD5\:+>'"-C&@)]$&P    ">MRQXR^@'3)IO[71(UF-.:$3Z!>O!-C
M8H0YU0WIQU\:Q-?P@J36,J>[.\:76W\;//\ :M!RZNQ])\::9:_<L3K!<6Z*
MH'T&Q^];%8QYH>H     &MK<S^+GH+T-Z9^QL,.KES?H]@7L?#7N>IG(>Z;T
MD1_VTBCWW72;ANAHX        46M?A39/O\ F/6+D7TQ)F3<6%QKG7>7&I_@
ME5_P]#>KFPLKC7.N\O)B3,FXZ,4*@                 !%NN7T*:P=%NH'
MLG+C,PYSA<6F77QS Q$0<@OO1#RX-L8V1/<@\     6$W)GC.:!=+5%]H6(U
M>-N9\3:#>7"-398-YV0YIEW\2S->@@N33,I.["\9_7#I FOZR#EM=>Z38UT[
M6OR'66XWT6P+V>J7V:16T><'I8    !K@W-_B[Z"]"^EOL/!#J_<[Z/X%['0
MS[DJ)R$NE=(L?=M8J]^U\F@;B:4             $;:R_1!JMT;7GV7E!EG!
MRZY=+.[C&)BWYR*^-%O#A&QC0$^B#8    !/6Y8\9?0#IDTW]KHD:S&G-")]
M O7@FQL4(<ZH;TXZ^-8FOX05)K&5/=G>-+K;^-GG^U:#EU=CZ3XTTRU^Y8G6
M"XMT50/H-C]ZV*QCS0]0     -;6YG\7/07H;TS]C88=7+F_1[ O8^&O<]3.
M0]TWI(C_ +:11[[KI-PW0T<        *+6OPILGW_,>L7(OIB3,FXL+C7.N\
MN-3_  2J_P"'H;U<V%E<:YUWEY,29DW'1BA4                  (MUR^A
M36#HMU ]DY<9F'.<+BTRZ^.8&(B#D%]Z(>7!MC&R)[D'@    "PFY,\9S0+I
M:HOM"Q&KQMS/B;0;RX1J;+!O.R'-,N_B69KT$%R:9E)W87C/ZX=($U_60<MK
MKW2;&NG:U^0ZRW&^BV!>SU2^S2*VCS@]+     -<&YO\7?07H7TM]AX(=7[G
M?1_ O8Z&?<E1.0ETKI%C[MK%7OVODT#<32@             C;67Z(-5NC:\
M^R\H,LX.77+I9W<8Q,6_.17QHMX<(V,: GT0;     )ZW+'C+Z =,FF_M=$C
M68TYH1/H%Z\$V-BA#G5#>G'7QK$U_""I-8RI[L[QI=;?QL\_VK0<NKL?2?&F
MF6OW+$ZP7%NBJ!]!L?O6Q6,>:'J     !K:W,_BYZ"]#>F?L;##JY<WZ/8%[
M'PU[GJ9R'NF])$?]M(H]]UTFX;H:.        %%K7X4V3[_F/6+D7TQ)F3<6
M%QKG7>7&I_@E5_P]#>KFPLKC7.N\O)B3,FXZ,4*@    %2'^K>JL.^D8=5QI
MS8GYGU(K#R2KT%9.3.FU]O6H59J;.K2\JZLV#:A.(F!GW]A?M6"5#EB9@8XL
MNQKJ5_@4XJLO9C]LD7-+%+_TI3ROG#GU'^I;5G5^&7GVA8>KS333:Z2,#J%:
MVD&[9Q2\4E5M+M0(YT2,=WQ)Y4$N1U\G\S$^9Q>4&LG3=]G7'2ECC8A&LDUI
M@36EF3)CQB>Q<.;';9MZB<M-KPSO4$H^++UU[+MGKQ.:AX&392+BIJ+NW*T=
M6[#AF_D"MK+$QN6S&?+PI$%)IK(G9)IM,))DHOGS985\^?8=F_E&<;P7=9ER
M\-M\'P#)Z\W^#V-O:[C;K\'^^7>X38V_GV-K9-O4!YW*F&^T?]2S7N\ .5,-
M]H_ZEFO=X <J8;[1_P!2S7N\ .5,-]H_ZEFO=X C#6ZRQ"NC&KJ1%'VVIIA?
MDR;4/,$+M'JDL4NT<[ I"8W\XWS',4I<?.;.,8SD9F'.<+BTRZ^.8&(B#D%]
MZ(>7!-C'N)[D'@    "?]RFLFWW2^@ZZN3831U7HZA\D345/@I; QR;922*=
M50V]CYB)D,<V?F*7.?F&KQMS/B;0;RX1J;+!O.R'-,N_B69K8Y4PWVC_ *EF
MO=X@N33,LFZZ73=;IG6QPCD^4E;],G)DZ2J)\ER<F]M)+$35)G_]5"%-C^.!
MRVNO=)L:Z=K?Y#K+<;Z+8%[/5+[-(KF/.#TL     UA[G2R1*&Y]T*04.]PH
MCHWIBDI@D1+JEP=.DP9#;*B3$Z:A=K&=XZ9S$/C>,0QBYQG/5^YWT?P+V.AC
MW)43D)=*Z18^[:Q5[]KY,G*F&^T?]2S7N\;B:4.5,-]H_P"I9KW> '*F&^T?
M]2S7N\ .5,-]H_ZEFO=X <J8;[1_U+->[P Y4PWVC_J6:]W@!RIAOM'_ %+-
M>[P Y4PWVC_J6:]W@!RIAOM'_4LU[O $<ZPV6(5TCU33(H^VU-.;N0NU#S!"
M[1ZS)E+OG.P*0F-_.-\QS%*7'SFSC&,Y&6<'+KETL[N,8F+?G(KXT6\.$;&.
MX3Z(-@    $Z[EY8C?=(Z"+JY-A-'6#3I13)$U%3X(2V11C;*213JJ&WL9WB
M)D,<V?F*7.<XP-9C3FA$^@7KP38V*$.=4-Z<=?&L37%RIAOM'_4LU[O$%2:Q
MENW8SA)UNGM:7".3Y25NCLY,G251/LY;-/WDEB)JDS\W[IR%-C^.!RZNQ])\
M::9:_<L3K!<5Z*H'T&Q^];%:1YH>H     &KW<VV.)0W/.A2"BCW"B.C^FZ2
MF"1$NJ3!TZ?#D-@JB3$Z:A=K&=XZ9S$-C_$4V2YQD=7+F_1[ O8^&O<]3.0]
MTWI(C_MI%'ONNDU<J8;[1_U+->[QNAHXY4PWVC_J6:]W@!RIAOM'_4LU[O #
ME3#?:/\ J6:]W@#T&$JRDLJX:&<&RC@N3\.Q?,][!]K!=G+QLAA3]W._A/)L
ME^;:WM_&^!Z( HM:_"FR??\ ,>L7(OIB3,FXL+C7.N\N-3_!*K_AZ&]7-A97
M&N==Y>3$F9-QT8H5   !G&_C./K^;YOFS_\ S/\   0M"Z#4>#JQZ6@ZN#NM
M<$PPTCI*Y3[S,8_BIMI9(V>BWIWA9!G96=A8MIU.PIN^-E)<AI%PZ6=JJJG3
MZ_/G(#J8W3.K1L.M"E3DGR#^S,[A-/)26?R,I8;$P=1KMH_G))RL=T^*@I#0
MS=%CDZ<<A%Q,=!H-$H1HE'8K/N]GGS,'ST[3JJT,\BI6VCY TBA',3]W3,O+
ME91$,I(JPT#$EE7KPL3 0ZDO*GBX>/PW8L>,')4$2$,4A*3GY\ZP=R
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MBY%],29DW%A<:YUWEQJ?X)5?\/0WJYL+*XUSKO+R8DS)N.C%"H
M        1;KE]"FL'1;J![)RXS,.<X7%IEU\<P,1$'(+[T0\N#;&-D3W(/
M   %A-R9XSF@72U1?:%B-7C;F?$V@WEPC4V6#>=D.:9=_$LS7H(+DTS*3NPO
M&?UPZ0)K^L@Y;77NDV-=.UK\AUEN-]%L"]GJE]FD5M'G!Z6     :X-S?XN^
M@O0OI;[#P0ZOW.^C^!>QT,^Y*B<A+I72+'W;6*O?M?)H&XFE
M !&VLOT0:K=&UY]EY099P<NN72SNXQB8M^<BOC1;PX1L8T!/H@V     3UN6
M/&7T Z9--_:Z)&LQIS0B?0+UX)L;%"'.J&]..OC6)K^$%2:QE3W9WC2ZV_C9
MY_M6@Y=78^D^--,M?N6)U@N+=%4#Z#8_>MBL8\T/4     #6UN9_%ST%Z&],
M_8V&'5RYOT>P+V/AKW/4SD/=-Z2(_P"VD4>^ZZ3<-T-'        "BUK\*;)
M]_S'K%R+Z8DS)N+"XUSKO+C4_P $JO\ AZ&]7-A97&N==Y>3$F9-QT8H5
M               "+=<OH4U@Z+=0/9.7&9ASG"XM,NOCF!B(@Y!?>B'EP;8Q
MLB>Y!X     L)N3/&<T"Z6J+[0L1J\;<SXFT&\N$:FRP;SLAS3+OXEF:]!!<
MFF92=V%XS^N'2!-?UD'+:Z]TFQKIVM?D.LMQOHM@7L]4OLTBMH\X/2P    #
M7!N;_%WT%Z%]+?8>"'5^YWT?P+V.AGW)43D)=*Z18^[:Q5[]KY- W$TH
M         (VUE^B#5;HVO/LO*#+.#EURZ6=W&,3%OSD5\:+>'"-C&@)]$&P
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MH(+DTS*3NPO&?UPZ0)K^L@Y;77NDV-=.UK\AUEN-]%L"]GJE]FD5M'G!Z6
M   :X-S?XN^@O0OI;[#P0ZOW.^C^!>QT,^Y*B<A+I72+'W;6*O?M?)H&XFE
M            !&VLOT0:K=&UY]EY099P<NN72SNXQB8M^<BOC1;PX1L8T!/H
M@V     3UN6/&7T Z9--_:Z)&LQIS0B?0+UX)L;%"'.J&]..OC6)K^$%2:QE
M3W9WC2ZV_C9Y_M6@Y=78^D^--,M?N6)U@N+=%4#Z#8_>MBL8\T/4     #6U
MN9_%ST%Z&],_8V&'5RYOT>P+V/AKW/4SD/=-Z2(_[:11[[KI-PW0T<
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M)'7+GK0_.27_  "1WKU<GR*\_K:K_41^]2CX^6'=]56.X?)(ZY<]:'YR2_X
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MV\>T;LT#NG:IEW3DR39--,SARN<ZSA;)<J+*G,HH8QS9SD#[P
M   //E96+@HU],S<DPAXB,;*O9*4E';=A',&:!,J+NGKUTHDV:MT28R=59=0
MB:9<9,8V,8WP!XT5>*=.0#ZTP]H@I*N1F)#,G-LI1HO&QN8E,RTH60=)JY28
MJ1R1<JODG1DE&J>-M<I"YQD)=76#Z=0U(T^U [OY#76K6_BL_!27)N<CIG#!
M7NARTRF[S'N%\-U,.F;ML8BNR8J[5PB;&%$5"E25,:2$TM.U
M                   'UGCQI'-'4A(.FS%@Q;+O'KUXNDV:,VC9(RSETZ<K
M&(BW;-T2'5775.1))(AE%#%(7.< <]7;S3;='/I>KVF L$9%KG;23Z(E6;]M
M'N$VB$@9%ZJV64*U4S'NFD@0J_!Y4CW;5\GMM7*"JB4L8/-J>J.F]\>/HZE7
MRI6Q_&$RI(LZ[/QDNY8$+E IC/$&+E=1M@N73;&>&*3..Z$=_P#^83?K)4QH
MHFEIW@H                   HM:_"FR??\QZQ<B^F),R;BPN-<Z[RXU/\
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MSR19YV@CAXU(_>2$BB@R9%22:,V4:L2/220X4I%'2[MTXHJS7)U2P'T2P*
M            *+6OPILGW_,>L7(OIB3,FXL+C7.N\N-3_!*K_AZ&]7-A97&N
M==Y>3$F9-QT8H5
M                                         HM:_"FR??\ ,>L7(OIB
M3,FXL+C7.N\N-3_!*K_AZ&]7-A97&N==Y>3$F9-QT8H5
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MC7.N\N-3_!*K_AZ&]7-A97&N==Y>3$F9-QT8H5
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M4ZD2W-9[<76+%PX\\L"_CX8#PGD!NGSPL;"03VSMI-_I"[MAYV3G&[G,?JO
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MY%],29DW%A<:YUWEQJ?X)5?\/0WJYL+*XUSKO+R8DS)N.C%"H
M                           ?S.,9QG&<8SC.-[.,_/C.,_MQG'\<9 'U
M63!C'(8;1[-HP;8.=3#=DW1:H8.H;:4/A) A$\'.;.3'-L[YC?.;.<@#[8
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@."X793X3@^$V.$X-/;WMK8+O[.+B8$1+"VN%56T__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g504802g53f75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g504802g53f75.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1CR4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 6$)_          IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ /      0 " \     !  (X0DE-!"8       X
M    /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  "Y   !8P         !                          $
M 6,   "Y                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   "Y     %)G:'1L;VYG   !8P    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    N0    !29VAT
M;&]N9P   6,    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     (X0DE-! P     #F$    !    H    %,   '@  ";H   #D4
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MJQL:S(N,5U!SG$:F!X!5&=>Z>ZP5[G N(:TD>TDG9_.MFK^<9=7]/_ 6I*=
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MOT9(=&Q[JOI;6_N*W8(K(F>-3\5D?4]S1]7,23WM_P#/MJU["#62.)'Y5!D
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MU._\3F)\;?\ S[:M>WZ!^7Y5C_4_=_S<Q(CFWG_C;5KV3Z9GF1^55<O\Y/\
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M %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J    "  ( 1(
M P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $  @
M 3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $
M  "\    Z  .SI8  "<0  [.E@  )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7
M:6YD;W=S*0 R,#$W.C$R.C(Q(#$W.C,S.C,R %)2,3$W-3<R       #H $
M P    '__P  H ( !     $   %CH , !     $   "Y          8! P #
M     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "   "
M 0 $     0   48" @ $     0              2     $   !(     3A"
M24T#_0      "           _^$!2$U- "H    (  @!$@ #     0     !
M&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M<2;3E-3PEWFOPVG7H+,L^MU^."*EAJU#%2."#%[URDIW+''3<TT:< Z/=AL
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MVK(?C=8'+H?)9KV55^3EL<CI>A-=B^H@NE]"6V06#(>Q%UBL*E+0\VS1JU=
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M7E+?X9/QH 07;6P_;+?4/^63\: &H::^)M485:+V+V(5!3="5593-/-WLDF
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MG5N?"[NC;<A^-=C?*5KZ.K+],[LY->"GY+P2UK;\3]L4X+)ATOR7J:U^#_;
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M=M5\VBJ^4'#=J\NK'G&-Y VRN E$ U9\-^QV0C8#"J)/Z\YR&GG73;KND.T
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MX0X]U*C_ /A$RUKK]1$]3ZO6-'T[U9R;0_T@@7:,4R#A[--D8CDYC?Q[6X@
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M +=5+\\<\W5K\BK5?^K5-D_9*@N-RR 2^RBRUA[6M]5FUA>I;7I)HD5#+&A
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M"XIPXSO6$M**OY20QQ6[:CA@BB3KE-)J&)IJ24TTG/!WZ<9#7-[I@ VWO?\
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M=K8Z6*3V/,RU]GO[RJD[FZO0:IOP4$Y3OQYS(&[F7+&O="7CQ^(_:<@AR*%
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M1 I2$*4"D(4H#8A2\-K9QX<XL6W/&;<^D^YR IZ1]2F7P!8 7I?DG4MG\"6
M/GTM2+J8U^#" +4[HNE9D"8S"FY*]%(JA4A?2QHZ!(%1+MQ4]O24$@'V"8J;
M 2;,$4[WMGZHXZ6AGX&DCHYRGO8XH9R^*X<,RD>8X(*3\I!1TGQZ."*[1?"S
MX>9YA]_J/2_ 'I#*M8Z@_B.'@B?&:;](I_G:7^8^7B]%\!0?-47](7S/: S
M*(IB_M%*]?P$3XS3?I%8^=IL^'YP\7H?@*#YJB_I+M.0UH^FI>4R3"GI.Q(H
M<IU",I<V;$.8"B4HG*W33*8Y2B8 ,:]@&T?.-Q4CG2Q14DL-_%%&U_R<1]8(
M(*.ZC@@@6B""&#R4N^%Q=NEZ1]2F7P!?F@>@Z7I'U*9? %^: $&GI'8?N4S[
M2!;]J .$O2U/.TSI.9++G""H 11NNS2624*!@. '24**1BB) '8G P;(H"&J
M\3#''1MQT<3@B?NHH6TVKYWJ_.W=?TGF*&&-*&.%1)8*))KGFK\Y;_,^P_\
M]2:8YBE?!K_R$>_&:;X>L?.TW\Q\O%Z+X"@^:HOZ0>9[0 @-J)ICASWAE8@
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MG2?*2M^M)EG"JRCH\HF:"K"8 JBU#;R&.U,Z;;!P(F??O_8=' ! ! ! ! #
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$O.#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g504802g56i55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g504802g56i55.jpg
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M 0$! 0$! 0$! 0$! 0$! ?_  !$( $, 6 ,!$0 "$0$#$0'_Q  =  $  @,
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M5D+7.T@G2TO!=8$V!L+JOY]<8;;?Q$7A_GP+^9M>:>FEA/N=B/\ UOMEFO\
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MF#\8"BL%E *(DDDGI.ZEC1<)HBXS&[BZK<OK<)9T[NFR)G:4P!+)#'B)#.)
MY2)R11]D?W4AF8&XYQ//^#6-I*&8!M9T 4S<BP:=E,F+R<9D1=YH :+"VP/[
MET'?2V7C<M\=/"R'V[+4L"VWV'[L)Q (P^V/+7N9O;+"6BF*"=VF+(7>0+7!
MQ+8VQQ?WE4WM^5(DZ,3BH G 64+  EUI@ _86N 3W[GR*R5HHDT1-$31$T1-
)$31$T1-$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g504802g59q99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g504802g59q99.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M7%DA4D:-,T4:#0Q=9%\DL++)?:G**  HHJ=+RRRRPA 666"KK'"   !UH(
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MI "0)!A\+&'Z?V@P[1/+0>D N) Z>/!8<=M\D3J,51:.PZ_.XCXBX46@Z=D
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MG#-8G9_\5^JW[,=:.34^EW0MW:L6Z-!H=XDG4:46[29YMB6R+-'E)88('_\
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MB81,(F$3")A$PB81:N7T02K4CL_C<A$<8)(G@4]5DI]BWLHM2LD+"2I. #[
M3#RD*0!@M>404Y6M]>@:ZL+]%-SF[ U6M)#9=KZID Z'F##9+DM[L\GSB;=U
MZ.4=ITE:SVV).5QP)U#<?9+1U@7V80XCL%P8P'L[H["U[,YK6)IA$PB81,(F
M$3")A$PB81,(JDTRK4H+BJ5<C.,3*T=GU^J2J"A; :0H3RUH-).+&'JV$PHP
M 1@%K>MA$'6]9L;T)7N9Z(>SFZ2-^6_"_0_A13XF_#-&>RV2*1\;QT.:X@\"
MO+B087#@YMFJ]I'2US;,3FN!ZQ:X @]8A=%?.@EOI,(F$3")A$PB81,(F$3"
M)A$PBT0NDK&,?._DWL8A"WJQ1 UL6][WH!; R  '6]_^4  A"'7V AUK6NK6
MM9I?T:23M%@QKP;LCB0!V ;62<0.QJYQ)^,D]=:4ROLSF?G&3_"*$?JX*QS-
M/JR3")A%Z+FSNS(H D>6MQ:%1B<E66F<T2E H,2J-;$0I 2J**,$G/#K>R3@
MAV69K6]@$+6L]R1R1$-EC?&X@.#9&N82T]#@' '0]8]!ZR].:YAT>US3H#HX
M%IT/0=#IP/6*>"';;7M\TUN.V72S3=MX[R4^"].&RN[Z0;<.Y=Z:6;(_KM)>
M[=WV5_6=CL>7')R<GRO)OY+>W.4W7<GOZ:[F_IN[VG'=UUTXZ:)NNW=_==N;
MV[O:'=WM-=W>Z-[3CIKKIQ7WD1.4JG0#&FC4@4/1B4I<6SD,SB:Z#1'IBUI"
MP#>6F$K$E.1G$JRE 2=DF)C2SP#V4,(]^Q7L.D$38)C*6AXC$3S(6.:'!P8&
M[VZ6D.#M-"T@@Z%?1'(7;@C>7Z!VZ&N+M" 0=W370@@@Z::$'H7PNS,\,*P3
M>^-+DRKP  8)"[(53<L"69U]S,$F6%$G: /JWV!;!H(NK?5O?5O/$D4D+MR6
M-\3]-=V1CF.T/0=UP!T/R+XYCF'=>US'=.C@6GN$ KT4T.ERQA52E'%I&KC"
M(8BELC3,CF>PI# [ZA%JG<I*)O3C#O>M" :H +6]^76>VUK#HG3M@F= W\*9
ML3S$W3IWI W<&GQE>A%*6&41R&,<#(&.+ >P7Z;H[JCF4533")A%EQZ$D8@\
M[&$(1"#H=86.$>M;WK0PZ1-H]!%K7^EK0P!%K6^O7:"'?V=:S?'H,>QVVXZW
M);.G3K:B[= /R@$@'L$]DJ<V8]L-+\GO?NF+<OS:"VXF$3")A$PB81,(F$3"
M)A%JU?1 _P!MKCI^+J:?K*V9A/HJ^T.A_P#5T7\&N+66VOLM0^;I_K,:U],Y
MM6*)A%EAX"*J5:^/7)X^]8HP.\#EMB<>ZGDDJ7-*!9(:[8K&;[C;!3F+.BD@
MY2T+HB_)H_*U DN][5I6(Q/L@XT1'8SW91V-CQ&;.4@BDJV+>)H3SN8TRU(K
MC<@SG,$A!,;J\HBG.GX38B-"=%DF&-1M'(&Y&QT,L]*M)(YK2^!DXM-Y:-Q!
M+3$\,E.G2&=<Z*!6;1KE1O$:_P"!S9E:O'R <W:PB?C&4A3B4N$>4T]:SHWK
MF9T&6);N,2I!IHDK>4$_1"M*I;U1I7=@![%K>Q;\7L]E:EF./G53::G!RP:-
MY\+L==D8Z-^F]R,[.3F8-='!S7$:JA8J&IC;L,K6\M!EZ\7* #5S#5LN:6NZ
M>3D;NR-&NA!:2-5<3TE]?0B6,#O+Z\AT9BTBXQ2:LJLLINB;$VLH72OK=J*&
MSVLYJ[IVM,D)&<AFHYY##UII9BA1WXPE&&BT /9F-M:=:>*2Q4KPP386>E1N
ML@C9'RE3(8^M;I67MC:T$LLFU6+B"X[T0).G"_S\$4C'R011QOQTD%:P(V-;
MO06JT4U>9P: /4R\M"2=2=6<3QT\ZVH%"JQX$6G2@8E&_IFTTY\5I)9TO&R-
MHI8EM*\Q6;+)-$!/O>XEX$4+AB* PY0A)5Z(+>&M^"85HTT_8Z=^K6I;*WL9
MS>'GN-?@IKM@QL-AM[)F[//7Y7=WPVM7;5KEH=H)&2@C4G7S8AAKX:S4Y*/G
M%5V.DL2[C>5%BX9Y)(M_3>TBB$,1&NF\U_#B54*&1!F#S2K=$Q1Z")%Q?1M1
MZ4,@9"SP\J*HYR7Q:&Y-DI>RY0D%$RC$SWHAS<7F0E;0EZ <L=CMI@GCR]K5
MX_3+3;'%5:X;&PS1\K' (&V1AMYD\G+-Y ;LFCWR2C=&A<\[NJK0Q,ZJ0!D<
M(=U CD9OLBY,3=3]6R/Y0<GP=HYSWC3I+CIJJ1<BJTF,WXWT2YV@AIN2W1+.
M2RR %7!0K=5"Z)LM?/4?9DC3#K,D]&I44 6RM3*3ECY%FXP2IW31Y ZB,6$[
M4FD;C<Q2LVL/BWWVXZ;(SYIU3JCBV4'015)(HFQU[LV,:VJZ<S%TL##K((F/
MU<"2%:WH))J--U@57VY+[H>=4VUG1-@<Q@;%8DI[L)DY0N?&TZN$;7<1J0H?
MR1Y,.W'"\)QQVI*OJ?:Z1IQ\-K=5"YE3]>3@ZTE<9 6UR>26=)9#'E<N>W64
M.Y"]1M0UO['MK;1H4K-M 8F[Y,M\SFI,-E+6(QE3'QXS'2FF:UC'U+)NNA 9
M--=FEB=8EDGD#CJR6+<9NMCW"-33OWW4;DU&G#5;3JOY PRU8)><&,;LC[$C
MV&61TCM[BU[-UNZ&;I&IQ9'&:----"663HPP9FB2=#T45H8MBT65HP9@]%@U
MOL@T,P8^SK7:&+?7O>#$ZDG0#4DZ#H&O6'3P'6XK'5_//B*H-2?;7J[\8\%_
M6EJS8GH3_P#S#V9_*K7\.N+P_P#_ (_Q];ZQ&NB_G0BWVF$3")A$PB81,(F$
M3")A$PB81:('24_=W<G/QCF?H-ES2WHT>V/"?_26(^L9%:4ROLSF?G&7]U"K
M'LU K),(F$6>+I-VE1?^[%<F9"8YV1Q+M.#5NZ(T)&SW)VIB](?&'B *AZ#H
M2A6*-6T*21I*G)"+1!<W:RM[_K"0:VGMK&<MSU\3-^[@<A6IO:P:ODQV4KPR
M5#PXNY&_RT+0 =T6&<>( S':!O/><.:-Z?&68:[FM'JG5+D4;H#T:NY.URD8
M Z!,T=<*+\B3V^%\&K>XRL!R50T\8K-XS0B2+$0BS4[S<\B:;CE=V.X5 >LP
M[O.8KO$A-LT6^YMD);BR]:+"'8J&8+*VS%_"Q%ICPES"UIG,T+9,E,S(3Y*3
M4<3NV'<V&IX-K- X!>+I;%B+6/9H6X^?'Q2$$$.MR"U);=KQUW93R([#8@.A
M5/0'*$W.2[E".8_2[5I^C%T<EL#1S\FW!E!7%>O!DS#2B+)'"3D;C1F@O/=H
MX@6OI7>7;:$BA?I.2.\:2-I\D6V>9N&Q>K;>LK>:D8*H18WH&NF'(G^DUA:Z
M4;NL;7/T!K-)&7MD2\@1L_J)]7CD2,;!I+K&'2#D_P /6,%_#U(+M J-6G&%
M5T4'Q(8'V\D_*Q"'E<9 I]R#)<Y2>]5JV6EN)M[#5A^[,;V>S5+4O3M,AF"5
M^?&9&QIUX ,S::;W$L.["] [(XG 12Y,9U@SW-;>6$DQDILN\@R*B>>LCNN8
MX,EL"62-L37:,83P5M8C-JGC&/M]4F]4N1GN[TA?7;9Y)K*YYP&V-UP:^4/>
MT,#M&M5#.5G+[D17W*2UX76-DRZK*[IF>2VHZ\JN)N:ALK9FA,"=UT0;F]7
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MEED%RE[:1E_9RKB)H'\_KVJSGW=6[D]2G!:AK,D&N\9XF61%OZ'>BB9O/)
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M-="+&WLM@8[&+8R@&MGO212CG%OU<8QN1G#3K.= )88W\-#JP#70D&8>A;<
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MOMG;V^LVM"G:00=[<T6M"#]+J ![0>L_RZ[01!Z]>3K#O7V=;R2O12\VP_\
M1R>QK_[#NVN3^)1U&6+G&6_I(_9%G]MO:S&_&IWXR1WU?9?A1#Y_(WD9?<I/
MT'>)2/+1>ZQ_IM\:_P!#(H^,6@A?680A;T$(0N:+8A;WOJUK6M'[WO>]^36M
M>7>\<C+[E)^@[Q)RL7ND?Z;?&O9RFJBU6>5'.*W>0L]DI<3G\L@=*-+TY-$&
MC$%D+I$CY.T-:PY$5,)B^1Y6WO3THDPT_A9O83' ,?9FHUN3>#E3L6N=5?66
MPGH:87'8NI=RU*#(92U"R>4VHQ+'5Y0;PAAC>"QI8#NNDW=^0[QW@PMC9RQM
MOZ(^8R&3M4\5=EHXRM*^&/FKS')9Y-Q:Z661NCG"0C41D[C!N@-WPY[[1/&6
M8^R!9/RDSOYPYL'TL;/=IL=WK%]E8!Z8\]VWR'?4OVE_,V02P\HP@^=V*<2<
M6,HXDVQ9R84:48'8#"S"QR#8!EC!O81@%K81!WL(M;UO>L^MV:V?:X.;A\>U
MS2'-<VM&'-<#J""!J"#Q!'$'B%\.T6=<"UV6ON:X$.:;,A!!&A!!=H01P(/
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M>)9S>@HY]W!QKYJ5+5^I8]NU/7A+V:O)I#'!P4K&@L3Z>%O;9$E3*#1@3.#
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M089KJ":,80AUJ*RF%QV99#'D899F0.<^(1V[E31SP&N)-.Q7+^ &@>7!O$M
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M;I#FA5;M'GAW<^3E.PBMHVYMQR(M#&W&+757UG*G%[+4F 4'(E+7$%K<0%
MT_2]4EV8 *?NII;(8^2Y=P]IDC&-QMR:S(UP)=(V2G/6#6:< X.E#CO:#=!Z
M^@/R*41QV&$$F:-K 1IH"V1C]3^9NG#KJZ1XYH\>(1PVNWC!23=RHDB&^T==
MEC@?(.=P23T[0CU$9FTSA\F=3H8VTI%[O-7Q2V*8NCD&V2OC4T:>5_ALF1JB
MR0[C&8?(3Y>EDKKL9&ZB9])\?!/%<O,EA="R&TZ1Y:V%@<)#'OS@R,&YR8)T
MK&Q$VO)#'RQ$H9ZF5S71Q%K@XN9H 2XZ::Z-X$Z@K%#F4JR3"+KE\ /N(>)_
MX@JP_51MSF#:WVSY[YUN_OWK)-F?:]A?FVI^Y:K(^G]_NK>27_+1#];&K)CT
M.O;54_)K_P!3F5OM5[&1?.F(_B-=<Q#.AU!IA%>!Q:Y(QZ@X/S#BCY'7E]4\
MD^+[S0\=5-1R(HB.OCE9E9S@M[>@K#"S#FHM#!UR,9:'1JS:M8DV$K9.CAEQ
M&3QTE^?$2LD9&,=DF7I X$F1C:]B'<9IT.+IFGU7#0'CKH#<0S")M@$$\M"8
MAIIP)>QVI^+1O65P71]<L.+O%>)W4OLF$7R7?E@M88575[TB\5VCE=-P!V0F
M)9QJOO']M<T<9GTR3'J(^KGR-"KD#)%U"I%$EL<7KW%P5V.>Q63RDM-M>:B:
M-=_+6*-UE@Q6YV.!@Y?D'-,L$) >("1&^0 RB1H:T5*L\$+9"]LO*N&ZR6,L
MUC81ZK=#^ <[HW]"0TD-+=239+>Q_'Q1,TQO&Q+="2!B84FW(%[.D)=YF9*]
MKW,3D<F50)J9V;3"-N$SZ2%'IAN6EX7,Q0>,@Q* N9HB^(3U1-,S\H=WF+9F
M0\ENMW01.][^4WM_4@[N[NZ#4'6WEY+>_H>4W=./*EI=O:G7\$ :::?'KJJ+
MY>*FKTNCF^[NXF?CT@'Z;3Y99/V,RGS9D?J4ZLK_ /4Q?E^+_B=1=.OI$?N%
MN67XB+$_5]7G-VR7MFP?SE6_>!9AM/[7LQ^06/V"N2%G3RQQ,(KQ>"?)",\4
MN0!=O2Y@?9*S JB^X!MKC@F\+GMQMBE)Y6;,MUMS5(TO>3:[2I$O<_Z_N^FY
M.JVE*4*=%)S8C-XZ3*4.:12,C?SJC/O2;V[NU;D%E[?4@G><R(M;PTWB-2!J
M1<5IA!+RC@2 R5N@TUU?&Y@Z>L"[4_$H%0"GBGI1*VWE(UWSIN7I&HR%RVA7
M*!FO,9<D9RWPLG?X98"5*URYJ>TJE)HD2.7Q)P95;: T!SFG7'I2J]\932)V
M,=1WFE_+17FSADK2&[A9-7)=$YA!UUBE:\.TT:6@GQ%R'JA,)=#INNB+=6GK
MZM>-' _$YI!'7Z%7/FARKK2ZH)Q=X_41#IU&:'XC06<Q2!N]LO#*]6M-WJT9
MPHL&=R:6"C2<F/,* QZ.(11F(-![LEC[:E,ZGE8)=LE)98?%V:<^3OWIH)+V
M5F@EG958]E6%E:$001Q<H3)([<U=),\,,CB/4#=U-6Q.R1L,437"*!KFM+R"
M]Q>[?<7;O #7\%HUT'7*L$R=5JI=7_I\A/NNC?Z919[C_K(_[[?V@K+)>QU_
M\BM?N)%T6>GO_N?7[_C4/YB+-![ >W"Q^(R7[84]G_8?$?E^*_9*YO&;Y4<F
M$5\7&B_Z_JKC+S]JB5">@ROD=451PNN MS;I8W#>H7?T#L5Z"^+-J2=M:74;
MC[B-*HT2I[NM 4E[ -FA'D+D:,]K(X*U%N<EC[=J:QO.T=N34)Z[-P:'>/*2
M-U&HT&IZRN896LAM,=KO3,C:S0<-6RM>=>QP!7ITQT@5@5!2L<X]J*8XPVK6
M<9G\DLIJ27+2[=/W5'+9<C9&M\> +53LA+-6C:8\TMB12>F,5I6]&2A*4Z2A
MT5KS<P,%NZ^^+F3JV9((ZSC3N.@:8HG/<QF@8XAN_(]Q .A<2[37BOL=IT<8
MBY.%[ \O'*1AQ!=H"0=1QT' GB.C71>QTH_+&#\SN9MM796<4CL<K]Y>3B(D
MX-L)3PF52]IT8-47)K)((7+Q/,V/-4FH5+N>?HT;4@:DFP!"EUO?C9G%S8?#
MU:=F622=C 96NF,T43^CDZY( 9" -X- _"<X]=+L[;%A\C&M#2?4D-W7.'9?
MQ.KNL3V %CRR?5JJ]\8_MVPW_P!DC_55[RM7_KF?_=^RY8YM9[ 7OEJ_7(%L
MUP;TEQ3W.L_Y@1FPZOK:O^(B_=M7-5OUU8_'2?ME2K*ZMTPB81,(O%DGI=?_
M /!73\Q/RC8];S_B9?V'*K!_7P_C8_VPM2*1^F%]_P 9=/ST_-;'I/RG]:ZT
MJ^MJ_P"(B_=M75HZ+X(A]')Q2"'6Q"%2C2$(=:Z][%L3AK6M:^_O>]]6M9S1
MME[;,S^7?_\ $:R;9GCL]CP.DP2_OIEJS0CTFQ37V-ZCC*'>M^3>MA;D^MZW
MK[V];UO6]?>WK.WZOK:O^(B_=M7$]KA9L?CY?WCE9'TE&M[X[';UK>]:E+#O
M>_\ 9_;2M>7_ &>7>M?\<A]H?6L?XW_19MZ''MDB_)K/[IRU\\PY=!IA$PB8
M1,(NJMT?A)H^BKH@@!8Q'&\:EX"RM!WVQB-:WWN00A^SO9G:#V-:_P!+M:ZO
MLYSAM.0-ML@2= ,M"2>L ##KW%,80$[*0 #4FC; '7)+K&G=7+5GNMAG,T"+
M6]"#+)'K>MZZMZWIX6:WK>OO;UOR;UG2+_PW?WG?K*QO'<<?0(Z#3J_N&*)Y
MY5XF$3")A$PB:UU^37EWOR:UK[^$77/X"DFD<).*!9Q8BC-4!5H]@'K81=DV
M(-9I8NK?WAEC",._L;"+6]>3><O[6$':;/:'7[[7A^<6'@C\Q!!62;,^U["_
M-M,_F,+"#^<<1\2LFZ?=,H4]%9R8V028;I.@B*@_L!V+N1.I>S%;-'U?8!HP
MTL'7^$,.OOY,>AT1Z:J8UXFOD /C(I3N('Y@3\@*M]JO8N,]893$$GL:Y*LT
M:_G('RD+F$YT0H-,(F$3")A$PBO9Z-U,H6<]>)"9*28>H.O>OP%$E!V(PP8G
MM/K00AUY=[WO[&6.4(&+RKB= W%Y$D]8 4I]2597_P"IA'7.0Q30.R3DZ8 '
MQDKIU=(2G/5<&N6)*<H9QNZ&LD>BR]=H6P$QI<<:+J_V%E%C,%O[P0[WO[&<
MW;)$#:;!:G37)U /E=*UK1^<D ?*LPVF]KV9^+'V2?D;&7$_F )7(\SI]8XF
M$3")A$PB813"O0B'/H.  =B$.81H(0ZUU[$+;TBUK6M??WO?DUGN/^L9_?;^
MT%8Y,@8W($G0"E:U/_X)%T7>GS3GE]$%)21DF!-2BJ0*@O8!=HC92391FC==
M7]#L&;T 7:ZM:%O6M^7>:"V (.U\Q!U!KY(CXQO \.SPX_)Q60;0 C$8D$:%
MN0Q0/Q'0CC^?A\JYN6;Z4:F$3")A$PB815]XP &.[H=H 1#WW.1[Z@ZV+?5X
MJO>NOJUU[^_K*T!TE:3P WM2>C\$K'-K/8"]\M7ZW MTOE-PSM+C5/9(0UP>
M42FEE[PY.< F\487.2(69@<5ARQ)$ID0R)5JR-NT:"?IF(<7%*G99 A3(EZ!
M=I<>N:F^SV$]$;#9;%5:F1NP4<M5A9!/%9>V)M@Q@,$U=SR!(V0#><P$OB.K
M7#=#7OUGMQZ'N8Q64M6\?3FNXNS*^:&2O&Z4P"1Q<89VM!+"PG=#W:-DX.:=
M26,M'[FN]19)\6)#_+,V#U<PW;.EWQ']I8'U#S':R[WO)]E.YKO462?%B0_R
MS'5S#]LZ7?$?VDZAYCM9=[WD^ROQ_:O4B0_%J0?RW'5S#]LZ7?$?VDZAYCM9
M=[WD^RG]J]2)#\6I!_+<=7,/VSI=\1_:3J'F.UEWO>3[*H1R!EEA,%?OR.NJ
MKLB;2QV0*6QN3M,'DAB1*8L)&4)2K4G-Q)?<2RQ;V+98]^3>] %L_0"AV&0V
M@QH@?'7N5I9)&EFHFCW6M<#J==X:DC@-.C74D$ &;P.S%RQD(#D(I:52-[9)
M7RQ2!SFM.NZQK6N.\2-!J.!()T;J1AVX\]%[S?Y+6:R02+T'8R';NZ)P/DID
M4?7,L>CZ%0>':QU>GEP)*1(22BQ&#T:I, 68=V"=;V::6 > WLSBL; ^S=R%
M6&-@+MT31/FD(X[D$#'&261W0UK&D:\7%K07#H)EKEP(,;7FN6"-R*.."9L+
M#IHUUBP]C8:\+>!>Y[P[=!$;7OT:>H=QMIM%QZH*H*10+=.1-80"-Q US" 1
M9;DO:VXDIT<22A_UA)"]SVK5D$F;$822< H8AB!L6^8\QD#E<I?R);N<\M33
MMC)U,<;WGDHR>N61[K2>N03UUG^+I=3L=3H[_*.K5XXWR :"24#660#^R'RE
M[@W^R"!UE@ Y3]'?=51SZ2O%00!\M&FY \N+Y&B8.F+=I7!"W=8:O-ASO$BS
M0O;DVM"A0>FCCU'TKP QE*1IWHM O(V:NZ0V&]%7#38NKC\_:%#(5(F0.L3\
M*]ID8#6S"73<8\@ R,>6'?)Y,.:.'.VVOH7Y>')6;^"K&]1M2NF%>'0SUG2$
MN,7)?A/8#J&.8'>ITWR'=...]^%%[W=6<@K]RXX\C4FW,LLY N^D99@N\G-*
M+NJ)3O6HR+>PE':"/JZA:[00"$ S0>YBS._MEL9<K/A],F)#OPHR;D6@> =-
M?5=!U(UZW3QZ#C&$V;VTPN2K9"+9S*.,+O5L-2;1\;ANR,_!_M-)'R$Z$'B,
M'CST-O22MRX].W<2+N?483!:3N".MY>D"<5U[[ S$KBSI5!!FP]6S"^R:  ^
ML(3C0ZT,6)G:'9[709[#$=GJC4'ZY05O"&Y9DC:Z7#9RO(1ZJ)^)NO+3UP'Q
M0O:X:]!X$CB6CH7D^@^])G[2Z^_D^D'\#CTP[/\ ;[#>$Z?E55YS+VLS7@;(
M^;)Z#[TF?M+K[^3Z0?P./3#L_P!OL-X3I^53G,O:S->!LCYLGH/O29^TNOOY
M/I!_ X],.S_;[#>$Z?E4YS+VLS7@;(^;*[/B1]#]<_+VLZ/-%H5$_436Y+DD
M.E\NLE&:Q&I6<L\ E8&MD5[3.CRL/)",E.F;RQ"V<,OO@Y$EV<O31F3VTV=Q
ME=\HR-:_,&GD:M"5ME\S]/4M=+'OPPLUTWWR/!#=2QDCM&'VR+)WCR%*A<KN
MDU:Z[D*SZD%5IX&7DK')SV'M'&.**,M>_0221LWGCHW576L:I^LH%4\13B)B
MU>1!AAC(6?W,1YC:P-B=L)/6;  !9JQ8%/M2N-T .CU1QQO9UV]ZSG2]<FR%
MVU?L$&>Y8ELR::Z!\KR\M;KJ0UNNZP:\&@#K+/:52*C3K4H=>1JP1P,WN+G-
MC8&;SSPWGOTWGNT]4XD]=:2O2;?0X'(35US&V>%32S6!6DZ>ELB,KXYZ;F*2
MP9:Y'B4K&Q,4ZGIBWIH+4&[ UGH#5B\1&A;<RB#"]J%6[]GO1"Q5NG##FK!H
MY"&-L<L\D<LE:X6-#1,V2%DABE>!O2LE:UF^28WD.W&85-B,ABG.BJ5),AC=
MYQJ\V?"+52-Q+A5EAGEA$L4.NY!+#(^0Q!K)8@YAD?BK] 3Z4OVM#Q\.,G\7
MF1^F_9CMW2_]?R*H:W^TV6^@A\X3T!/I2_:T/'PXR?Q>/3?LQV[I?^OY%-;_
M &FRWT$/G">@)]*7[6AX^'&3^+QZ;]F.W=+_ -?R*:W^TV6^@A\X3T!/I2_:
MT/'PXR?Q>/3?LQV[I?\ K^136_VFRWT$/G">@)]*7[6AX^'&3^+QZ;]F.W=+
M_P!?R*:W^TV6^@A\X5]7!KZ&NY?3^V(P]\J6=MI>H6%W0N;^68^-#Q+I&E1'
MEJ#6=E9T!RL:52JV$!/?CP20V%%#-/V-:8FVV*X?,>B#@J%:0X^RW*7BT\A%
M#',*[)"/4OL32,B;R;3Q='"7R/T#/Z,.Y1M1F.RV2/-Q3GQE:3U-BY:= V<1
M'@]E2O%+.\SN:2ULLXACBUY0<JYHC._U&X\S1&.L,4CJ$EKC\896N/,38G[7
M<&YF94)#:V(2>V(0^XI$28A.7VQ"%V"P]H6]]>\Y^FFDL32V)GF2:>22:5YZ
M7R2N+WO.F@U<YQ)TZY6?0PQUX8H(6AD4,;(8F#H9'&T,8T:]9K6@#X@H/=M/
M0GD!4M@4O8S?MRA5D1EPC#\F+V6%06G6@UM.O1#-+.)+<6I:6E=&TTXDXHI>
MC3F&DG "(L5SC;]C%WJN0JN#;%29LL>\-6NTX/C>.&L<K"Z.0:@ECG $:ZJA
M?I0Y&G8I6-[DK$987,.[)&X$.CEC=H=V6*1K)8W:$->QI((&BT)^1_T,-SHA
M-@/*;C[J#W+71ZY2='W<R8,,,=TC:8;O:1*\-<J<D1P%Y96]:. A,<TI6]=C
M3FLWKO@S?-#T1-FK<#7W+$N,GW1RL$U:S8:'_P!KDIJD,P?'K^"7MB>1TL"P
MI]#.U3R3\><D&\&VJ,].'E6CH?+6NV:I@D(_#9')/&':[K]T@"WGZW!Z5OV%
M8;\L%;_.#+_T];(=NV=X93S%>.1S/P?R/?.%_FR?6X/2M^PK#?E@K?YP8]/6
MR';MG>&4\Q3D<S\'\CWSA?YLGUN#TK?L*PWY8*W^<&/3ULAV[9WAE/,4Y',_
M!_(]\X7^;)];@]*W["L-^6"M_G!CT];(=NV=X93S%.1S/P?R/?.%_FR_T/T.
M!TK6]ZU]):&ZZ]ZUU[N"MO)U[^SY9#K7D_\ 7>M?^N/3ULAV[9WAE/,4Y',_
M!_(]\X7^;+/=T./T/W,N*5NL7)_EJZQQ7/H9VE==UG'%Q#XF89 ('9)D4A>D
M@CFLY0SCZE;0G:%2P1K@!,J/5(B$)R)XP;:_;ZI=HS8K"&61MIICMWI(W0M-
M<GU<->)^DIY8#=EDE9'I$71M8XOWV2&.PMZQ:KV\G&RI!4D$]>BV5D\TMEO]
M5-;DBUA8RN?Z2*"%\V],&2OE')B-VU1(X\S2V//T4D: EUCTF9G2//K6I[6T
M[DS/2$]M=$!^@""/9*Q$I/3F]D01=@P79%K?5O-3PS25YHIX7F.:"1DT3V]+
M)(W!['CXVN:"/C"R^:&.Q%+!,P2131OBE8[\%\<C2Q[3\3FD@_*M"+F]]#-<
MLHC:TE?>)),?MZIW]W6NC(@7R1EC,LC"5:>8>%I>$;PH0$+SDHA]P J9 J4:
M@H %>P-G=_!:+?N(]$3!W:\9R<_4RZ&@3L?#/+6DD &])7DKQ3%K'G5PCF;&
MZ/\  #I0 \X$_%Y?&_T#:DN5K1^IKVJTM9MGDAP8RW!9FK S,;HUTT#Y&S:<
MHYD3B6"R#ZWGZ53V &[Y0(=_-,F/3ILIV[K?07O-%3W<IVARO=QO\Q3ZWGZ5
M3V &[Y0(=_-,>G393MW6^@O>:)NY3M#E>[C?YBGUO/TJGL -WR@0[^:8].FR
MG;NM]!>\T3=RG:'*]W&_S%/K>?I5/8 ;OE AW\TQZ=-E.W=;Z"]YHF[E.T.5
M[N-_F*?6\_2J>P W?*!#OYICTZ;*=NZWT%[S1-W*=H<KW<;_ #%96NC#^AN;
MQC]U0ZY>;A,;B<+@+PBD2&KVM\;9.]3-S;CPJ&]&Z*6<]8VMC",XL.W7:E24
MZ[)UWLB1Z-5!=&O&MHO1$QD-.>O@Y7W;L\;XF6A%+#6J![=UTH,[(I99V@GD
M6MCY-K])'2.#>3?<P8;(Y.1C+U4X_'!S7V(YI8)+EQK7!PKAE:2>*"O(1I8>
M^8S/CWHFQ,WS*W;GY?<9X?S!XXVIQUFYHD;+9$=,;"78HG1Y[&])3R7%B>2B
MNV4,T*!U2)3%:8H],-:@VK0:4$!5",#J+!9>;!Y6IDX6B0UWN$D1.@F@E8Z*
M>(GCH7Q/<&N(.X_=?H2T+*\KCVY.C-4,AA>XQRP3!N\8+,$C)Z\N[J-X,EC8
M7LU'*,WF$@.*YU5_= GTD5+3MXC+#0<HMZ.IUJ@#',:Q3&2MK=VW1F])E@PM
MQ0E3>,XOJ%M,Y)4*T/V3T24>]D@Z%I;7[-7H63,RU2L7 %T%Z5E2>)W78\3%
MK'D?]4+Y(SUG+"7]4:IY.YB[W*MX&2C6EOU9=.'*0OK-DD:QW2&6(X96]#F\
M-30KT'GI-/:7WQ\0GS^$R\],6S_;W#^$:OE5XYS+VLS7@;(^;)Z#STFGM+[X
M^(3Y_"8],6S_ &]P_A&KY5.<R]K,UX&R/FR>@\])I[2^^/B$^?PF/3%L_P!O
M</X1J^53G,O:S->!LCYLGH//2:>TOOCXA/G\)CTQ;/\ ;W#^$:OE4YS+VLS7
M@;(^;+] Z'?I-1C"#7#&]@[&+0="'!'L -=>^KK$,236@AU]\6]ZUK7EWY,>
MF+9[M[A_"-7RB<XE[69KP/D1^NOIW5L.]#!T ]J0"S"^17-R+HXTU-+(\MT.
MJ%8J)5O;PL?FQ0U&NLE)2&"&R)6U.K/.3I%!B5U$XD)];2B0&&'"P3:[;VE'
M4=0P5GG-R5[.5NQ!W(5HXWMD+87N Y::4M#"Y@="V(O >YY ;?4\-8RTT<F1
MJ25<9#O/%:SNMLWI7,?&SE(F.<:]>'?,H;(YL\DS8B8XV,/*;G^:26>)A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$5H'(GG'07&.0-,0L-VD3A,'
M=J _%Q:%QQ9)'9 Q'*5*)*[O BAIFYJ2+EB-8G;BUB\I:O$C6&(TIQ"50:7E
MFSNQ6T&U$<T^)J-DKP/Y-\\T@BBY70.,;20YSG!I!=HW=;J 7 D!8OG]L<!L
MU)##E+9CGG9RC((HS+)R>I;RC@-&M:7 @:NWCH2&D E6Z^B\<5O46Z_DY!_/
MLR3[D&VGO6GWU_\ U+'?NL;'>^K7>I^VGHO'%;U%NOY.0?S['W(-M/>M/OK_
M /J3[K&QWOJUWJ?MJ>UETG?%NT)Q'8 B<)W$WJ6NB1BCJN<0M6RL;B_.)P4S
M6R[>$RIR2(%[JJ&6C;?"@D*58O-3MY*D2Y4E3G1N6]#3:W#T9LA:I1OK5FF2
M<UYVROBB:-72%A:QQ8P<7;F\6M!<1N@D2&+]$;97+W8:%6[(VS8<(X&SPNC;
M)(XZ-C#]7 />>#=[0$Z-UU(!R&9@*SI,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(M7'I,M[WS7L7KWU]4&JP.NO[P? B\75K_9KM"$+J^QUB%O[.]YUGZ"_M
M2/Y?9_:7*WHQ'_XK'Q4*VGQ>I*L5S;JU0F$7LQ?>]32O!:WO6PV;60@[UY-A
M$&?1S81:WKRZV'>M;UO7EUO6MZ\N0>TWM>S7S;;_ '+E-;-G3/X<C@>J%7]Z
MU;K^<%KN98R.*/,94@Z--!S)Y22]6\ZA[!><OL.3((\TIW1P9J^MJQX^T-[1
M&HR@9VU6\FLK S1YF;T*-,<\.>T@#S#%RP]487K34@ =.F@^4#LKY7WI(7VN
MD\V07=Q"NNHYRV\;[7Y1UA!7&3U/+7*WX%225B7V?$69QA4R>FV/VY$4$IC2
MUQ@KR;WNJ3O!0F.0/ DB\*4F[T:$$:@:]&A/R\=/CT4Q7])GQR;[JEU/F*WD
M:2(\*U'.-18X"D880XUFWA3NKS'6U:<J*./FC/"G>*S]8V=ST2&*RMI7]WT'
MN_<R^:'37X]-.OK_ ._'3Y%Z_(WF+)*GX G\NHW6YB"?RFOZ:60*KI^KT5IB
MLSD/(X# *[C5@JF0X74BC<WLIA)F_@96$8D+<[%MJXL>R%82^@:G3Y>CX@3P
M[BHY6\D?:JY.UE3UN=*/*[/O&2&*B9EQPF5+T;%Z_G*U77K[+R6^H!PFJ(C.
MX(>RH$0I8VEO=PV>K5QUC7M[^E='!4)V1$ZVN[P[/'7\_'3_  ''N*?5!SVG
M=\0FP;)J_AC=[Y XG()="(I(G&:4;%2;*FL"M1PJZ9$L"2660R+&N%1A2V.K
MVZ3M^)0I%"2.RAM8&M]=T#.DD!"--.(X\>OPUZ->'^'_  > @Z3>+**REKVI
MI*P17=&.3T8X>(^/K%)ZVDKO,+RG$0C-CP])%;);I5JN%$'7UM*4T[=YD[/3
M0&-,3)*2W5I+=64#<M)NG\VF]KQZ-=->STJWVM>D%E%>3[I#Y_R&@]MQ(,$N
MWB13U6\;WZ10-X?4%B6S5$'8VN)P-_33'=8DQVQ)N] F7C@LEC,Q(HXM6RB7
M>+REN>6Q 7W=X#3_ ,Q)^(?\[JR <7.73)R0?;?@*R%K:YM.C7"&$SV(F3"$
M6&S&,EC,R]\@LKBTZKYY>6!]9'TEGD+6<2H\$/K0_1I[;W)F)3EMZ]R+SIW/
M^?\ /]50BJ'"T^3=L](NIC][6;3S1 [DK/BI4KM"?$]]-@7TG:Y@5LV;-&"$
MV?%; JTV3V',[GD,#D3Z^P=X=%4-B4<3)5"!8S-"I 7TZ -X \"3T]<D=8]8
M 'Y>GKJQ=WY'\NZ89^D"F$;Y4S7D+ Z>GO&[AA2$GNNM>/R(A+RUN"T8+ ;4
MFR<%)U'3@7R(4D9<E>L)T>>O"21XFT:L!K4K2P("22B^Z Z:CLDZ'^R!KU]>
M/ GIZ%4FW+2YH\:[2M7C3';XMGDJJD_&RK^0L,L-XJ2HWJ]ZM:6CE-7=-\HC
MX5#Z?J&,Q&Q1M%0V ILZKHHZ5=+7U-+(TI8=IIHA6(V09- 0#H!QT(UX'@2.
MDZCL=/\ BOU6O-V9.CG *:MSD&DIUJA5Y3E[LR^N0"6"T58LZI]!9TI6<6:/
M/B$LCE?-;-=M]5ZVL,XLI&C@,4D48H-$ED*V*PR277!G9N+YIV!KPZ!QZW$\
M#T#]?9 *RJ<E.0T8XS5H"P)!'Y/-7-[F4&K.OJ\A!#6?,;'LZS),W0^"0F.>
M'71C84JQX>W,@2QU?GII9&-F3.;VZKTZ%N/'A? -?'V.YJL8_,7I%+>BW$CG
MXU1ZC+#HGESQVX[:LHN/.TNJN1%,-?6:S3MIAW(2#2YKD:Z.2]FA\AA,J2N[
M#I(7*&Z3QKO#4;<TJMN/<'_/^=9>FM!+>.H+@.@].HU'1IKQ^,*YF<2"S^.?
M1>7_ &"RF6Q";?JCBMR/LR-GWE8[+R!LN+SB)P.>2R,N4DFZMRFL<F>DSJWM
MSTW-RE8\LJ5J-1QY0B C1F-9/P\ 3\2^=+OBU^0::_\ /C5F%:\Z^1YM9\=Z
MGM"7H&_E5!.<W&2A.1;LBB\72([EHR[FF0S"NK;9&(;.<T1QHN>!DH-.IL43
MM9L8L:*6#&F4YI)9N]]?4(&O#H()'Q:=;I/7'7XZ$'KJ;</N9M^///CD_2=^
MS9%(:7F=O<A83Q3,,C46CPH%(^*[E%5-C5@J>6!I;5TC%)JWLV-3]A6RY2Y.
MP"H!80BG(Q(1L@@OI T!'3H-?CUUX_FTT/RA6^QCG[RMG .E$M9!8I+75+-T
M=LJY?\'6 N$PCNU>QYL?>6E=UM9!S@KCBARF.[814%&+Q3-LV6R5C2-LT;69
M,VIV\E2B-^'@">QJA:/4CK[Q:[Y1NZ_)IKIT=;74K^O*;FQ;$+MY ROG,FX>
M/$>9^C$IWDRQMM3\=:TN9/8%Y2B6W&VOY\X1._'VU7MOCR]%#XTETTLLCK-I
M+_M8T3RVG&*%B?Z@&HUT!]5V2.'#X_&>*N49^1W)GE-).$/':%VY'Z"EEK<'
M&CF?RAN:F6^M[/<"@J#*\@Z.MZ"<9HW6;5I*.0V)*Y2YKYNY,$^2HHM%4*2/
M&FJW@#OHF@&\>D Z-!Z_RZ:'H^3B?BT-4KD47GQ=>>"\DF7(J:W:G6\ODW'J
M>.+XQ1N!#G58<E(M((M!PS^*UPEC]<2*>UU;C36S@R3AIA,5V!B/DK8C9&L4
MA?5+L7P:'>ZW#4:=D:?Z:_GT64["\IA$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PBU>^E*1J8[S*DCD^%;:FZ6UU7KA&EZ[>DR)Z3LZ9T9W;3>J-
MV$A0>UN!.BG!*69M2C I0G'E%DKDAAW5?H+6ZQV7F@Y>(30WYN5B+VA[ _1[
M"6D@[KFGU)Z#HX#BTZ<O>C'4LC::&QR,AAFH0\G(&.+'&,ECP' $;S7#B-=0
M""1HX:X]_#C+ZL-?P@D\]FX>6B]UC_3;XUJ3D9?<I/T'>)/#C+ZL-?P@D\]C
MEHO=8_TV^-.1E]RD_0=XE,:U)'+K2JB+1C9;[('NU*X3MC2UFEK5JG:>9LB]
M8=HA.(P8$C>W)5;DY+#-!3-[<D5+E9I*9.:8''MK+E6OLWFY9K$3&#'6AJ7M
MXET3FM: #J7.<0UK1J7.(: 20#/[+4[5C:+#QPUY7O.0K'0,=P D:7.)TT#6
M@%SG'@UH+CH 2MUO.%%VZL/4&Z-6[V_C'..$=E\HZSF7%F61"W(PW((CQGDL
M!O&/++&EDCG<>D9-J+^2TYB"UR@LM?RW0DD=0)TCX6U)$9Y: )AYHR];PU!
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M$PB81,(F$3")A$PBU'/HF#G=RAXU2KC]5%!6O**E9I7$W6;21U@[FH8W]Y7
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5F$3")A$PB81,(F$3")A$PB81?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g504802g61v53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g504802g61v53.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X4VX:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S8Q=C4S/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @
M(#QX;7 Z365T861A=&%$871E/C(P,3<M,#,M,#A4,3(Z-#,Z,C0M,#<Z,# \
M+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR
M,#$W+3 S+3 X5#$R.C0S.C(T+3 W.C P/"]X;7 Z36]D:69Y1&%T93X*(" @
M(" @(" @/'AM<#I#<F5A=&5$871E/C(P,3<M,#,M,#A4,3(Z-#,Z,C0M,#<Z
M,# \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L
M/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R
M5&]O;#X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \
M<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H
M/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=)
M;6<Z:&5I9VAT/C$U-CPO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @
M(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @
M(" @(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!
M0D%G14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!
M04%!04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL
M04=404%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$
M06]+0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'
M>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C
M>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T%N045!07=%4B8C>$$[04%)4D%1
M35)!9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K
M2T-W14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O
M3$5!04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I
M8UE%54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY
M63-00TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+
M0G)Y-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2
M,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C
M>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1
M645#04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-
M2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G
M2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2
M;&195U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S
M3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A
M86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y4U%W>&5K;G=,.6MD
M:#19<74Y1R8C>$$[2"M29G5'2V]05713,')49E).-2LW5V1M5EA%6EI2=U%Y
M3GE906AF:%4Y8U93;69Z>C57=#1H3&-E<$-L4&E,,C=J:7A9<G=A:3=.."8C
M>$$[2DY01$13<#-9,T9J9E=Q6%9S<71"3%@P,S1G8V=#4GE(<V%62'1G5E<T
M5S,X<69C359D=W1V-54K-%EQ-VAB9GEP.7=X5C-#,B]L5"8C>$$[-VAI<G5&
M="]+;C-$1EAC3&(K5E!U1TMU-%<S.'%F8TU69'=T=C55*S19<3=H8F9Y<#EW
M>%8S0S(O;%0W:&ER=49T+TMN,T1&6&-,8B8C>$$[*U90=4=+=317,SAQ9F--
M5F1W='8U52LT67$W:&)F>7 Y=WA6,T,R+VQ4-VAI<G5&="]+;C-$1EAC3&(K
M5E!U1TMU-%<S.'%F8TU69"8C>$$[=W1V-54K-%EQ-VAB9GEP.7=X5C-#,B]L
M5#=H:7)U1G0O2VXS1$988TQB*U90=4=+=317,SAQ9F--5F1W='8U52LT67$Q
M3D1&-E0O028C>$$[=C)4,DAH:7$V2"LU5"]62#9S5E@T<6=D5S!3=S%6655V
M03=*035D558R4E-3<%5H9W!(24934G8T-'%G13AL84%P2$M/5U-I1D-*2B8C
M>$$[<%A$8VEX67-#,C=%3U9R+T%#-V1-8E9-9$HP:E0Y2G-X6C)%6'!7-%IN
M0U9,8G-A;F1I8U929D)0-5(Y,DMU-$HO2U!U>%8S0E U4B8C>$$[.3)+=31*
M+TM0=7A6,T)0-5(Y,DMU-$HO2U!U>%8S0E U4CDR2W4T2B]+4'5X5C-"4#52
M.3)+=31*+TM0=7A6,T)0-5(Y,DMU-$HO2R8C>$$[4'5X5C-"4#52.3)+=31*
M+TM0=7A6,T)0-5(Y,DMU-$HO2U!U>%8S0E U4CDR2W4T2B]+4'5X5C-"4#52
M.3)+=31*+TM0=7A6,T)0-28C>$$[4CDR2W4T2B]+4'5X5C-"4#52.3)+=31*
M+TM0=7A6,T)0-5(Y,DMU-$HO2U!U>%9B3B]C=B]Q;CE72W5H+W55+S%2*W)&
M5BM+=7A6,B8C>$$[2W5X5C)+=7A6,DMP6F,K85!,='1/.79C86I"1DY'94UK
M8D]!=U!G4FPP9%!K27-!=%5S.$%A2D-L+VI(>70O,61,8B]!2D=$1"M6>28C
M>$$[9GI3:CAX:B]!2G=D+VI(>70O,61,8B]K64UF>754*V%6+TU9+W=#8T4Q
M:&UI;FAJ;6AC4U)3<4AJ9&1W>7-+9VHU:DM30T128E%B1B8C>$$[:&9G4S=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<7-M
M+W58+S%4*W)&6%$O,TMF-F\O5FEQ+T962R8C>$$[.'5"8E=K.7=255%X=$E2
M5VQE24HV,%!H:7)!,"]-,U5(=%5L:C V1U=9;WAA,D4O1U0T6&-&,49#3T9)
M-F8V>' X>E-'6&583F)I,28C>$$[<E-O-RM-8T$W3W)2,$E+;%=)-&UO1S1&
M2S R<F=3;4AQ<C1.+W=!0S,Y359D-G$K1&8X04%T+U1&6&5Q=F<S+T%!3&8P
M>%8T4#4Q3B8C>$$[9DYE<&XO:3EV8G=Z<$Y,+T%(569C.#EQ=C=Y4U,U:T]/
M-T98,$(U6FM595<Y2D9'+W="-#=F.$%:8B]F4RLR8WIQ4#=Y6'90,W93628C
M>$$[4#=U4'5#6F5Q=F<S+T%T+U1+5S$S<7(T3B]W3&8P>%8S<7(T3B]W3&8P
M>%8S<7(T3B]W3&8P>%8S<7(T3B]W3&8P>%8S<7(T3B]W3"8C>$$[9C!X5C-Q
M<C1.+W=,9C!X5C-Q<C1.+W=,9C!X5C-Q<C1.+W=,9C!X5C5Z<B]!3UHK<C9D
M<DXS67<R='4X5G9)55)N16Y)9V5.1T=B8B8C>$$[1&])5&=*16YD,6UB6%-H
M37A!1WE8+SA!2S1.9"]W0U=/,2LV5"]M=DQ0-4UH,VQQ+VQ'6&-(9CAR9S$S
M+VQJ=&9U:R\U<G@O:WE(928C>$$[5B]L1UAC2'!M:V%G,3=P5FQE4TQX:W59
M27!N5E9B:4=K44U13W4R*V%J3$AH:U(S1C)U3UA&14AV0TLY5F9"=BM"8BMM
M45IU.59F0B8C>$$[=BM"8BMM2W4Y5F9"=BM"8BMM2W4Y5F9"=BM"8BMM2W4Y
M5F9"=BM"8BMM2W4Y5F9"=BM"8BMM2W5M+W58+W="52]Q>%8P4#A!8W O<28C
M>$$[:CE72W(X5F1I<7A9659P>&I684-G;T%+0W1A9F9I<3565E)244%0064K
M2W0T<3=&6%EQ.$8X-V8X<%AQ;B]'9'8T6C!M;"]U;RLU-28C>$$[-U9F,VMK
M:WI)8V0R2W9C-%AE4#AU,&1'2T]M:T)L6E119VDR<4-#335(=$DP36A(.4PY
M3#%N6F]";&E"-S0O;V52+W!R5U K5RLT+R8C>$$[-4=V+T%&>FAF>D=4*V-F
M;5AV=GDR4#A!;7@K460K;719+S5B-VHO:V$O.$%82#AX:R]N2#5L9GDR4#A!
M;7@K4510>7AQ,G%Y95ET3B8C>$$[:FMV2C-2<FE-36I33U%15T=X0D]:3VIZ
M5$]A24UJ.5$V=4QR8T=-65IK4D@P;F\Y<GIS,VE(67$W1EA9<3=&6%EQ.$8X
M-V8X<%AQ;B8C>$$[+T=D=C1:,&UL+W5O*S4U-U9F,VMK:WI)8V0R2W9O4'EX
M+WEJ5VLO.'=D=B]!36UL>FU.4B]E4SDU*SDV5$(O9'@Y=U1,2VTQ,DMU>"8C
M>$$[5C)+=7A6,DMR2G8W;"\X0590-G-69$0O04A+9C9O+U9I<2]&6%EQ-T98
M67$W1EA9<3=&6&=V;F(O;$LY52\T>G0O1$]K,'8Y,4@S4"8C>$$[4&%R*SAK
M:VU:1&IU>%8W:6XO:W5&+S=9-"\V:&,U1'10-F-V=6PK;#8S<WHV.%AV:BMH
M-'AN05!O8G-65&)Y<"]W07!,<&XO041%>"8C>$$[9CA31UI7:2]V;V8Q9S1M
M=B]U2B\Q4SDQ>G5(9S-9<3=&6%EQ-T9867$X1C@W9CA!2U8V<"]W05HR+VAN
M4V%8*S9J-VYN=%8O95-35"8C>$$[36AX,UEQ*V<O3$@O04-J5VLO.$%-2&(O
M05!*<&,U:E5F,VMV969V96MW9C-C9F-%>7EP=&1I<G-69&ER<U9D:7%Y8BLU
M9CA!,50K<B8C>$$[1EA1+S-+9C9O+U9I<2]&5DLW:VUI=$IP65DO5FU33FUI
M:2]M64%L5BMK-'%W1E!.4&YQ5S)J3G9A<6)P;RM8;WE7<W=5+T<Q5S4O1"8C
M>$$[43%527%N>'%F2$-H;4AL=E5B>E5D2FIU8C(S:W1B<&UC4W=Y2G=)25DW
M2T\V:F]$,W=*5$1M,RLK,B\T6"MU2W4U="]V='8K1B]R:28C>$$[<G5B9C<W
M8B]!25@K=4MV0B]/<'(U<C%-,' K+V)B-W,V5%,O,U5F8S@Y<78W>5-3-6M/
M3S=&6'0V3S,O04-R<%)W3E P3TXY<68W>28C>$$[+U!/43=4*VY,-W!F<&5T
M-TTK=D8W-"]O94Y:=T0V1S=&53$X<3=E6DY-,G(O<$UE,RMY1UI7:2]V;V8Q
M9S1M=B]U2B\Q4SEZ-70O=B8C>$$[='8X06AF-C4S1'=B=6)F-S=B+VAF-C1Q
M-VTS*RLR+S18*W5+=35T+W9T=BM&+W)I<G5B9C<W8B]!25@K=4MU-70O=G1V
M*T8O<FER=R8C>$$[9GIQ82MA.51.2V9V,C(K-T]K,'8Y,4@S4%!A<BLX:VMU
M6D1J=7A6.4%E5UAB+T1E:R]!>"]W0D1T.2]H+W=".4PW-7I/;R]V2F4X+R8C
M>$$[93E*9R]U-"LT2FQZ8B]F8F8X3"]!1GEL=&1Z8B]F8F8X3"]81EAC,B]W
M0CET+W=V.6-69'IB+V9B9CA!0R\Q>%8S3G8Y.70O=W8X028C>$$[6$988S(O
M,S(S+T,O,7A6,#,Y>2\K<68Q67$V2"LU5"]!1E(K<D9732MB.4\X>C9H9#(Y
M<G!J=D193VAA.&U36EEJ5D-75E9)0F17628C>$$[9T1L4FAV=4YH:%9L0T%H
M4417;T$V-VY!<F5+=7A6,DMU>%8R2W9"9D\S+TM6-G O>&YB*T=D2G!F-W%0
M=65E,5@Y-4I*37E(2&1I<B8C>$$[,T90+T%#6$,O=T1B2$@O54QN261P+U1L
M.3!V,'97.6UF6&DY.&8P4$=--$(Y1&1I<6)E5E K56PP>B]M2FDO-&M->71&
M+V91+W)">"8C>$$[3F8X03-%+S9P938U,T1W8G-69&ER<U9D:7)S5F5#*V1V
M*U5R,50O:D\S.$TV5%,O,U5F8S@Y<78W>5-36FM/3S=&6#!(-5DO-5)R4R8C
M>$$[9BM93S,O-4Y,;DUA:BLX;#=Z.3<P;40K-VHW9VU75DYR<U9D:7)S5F1I
M<G-65U1F,TPO-G O5FER;V8W;% X059(-G-6658U-VI$828C>$$[:7)Y6#=7
M:5)7:&5'0FEW4S5K1$XK-&HT>5)L;65O-4PO<311:&TP9CDR=3-(66)5<%1B
M=S-W2EA9<3=&6%EQ-T9867$X1C@W9CAP6"8C>$$[<6XO1V1V-%HP;6PO=6\K
M-34W5F8S:VMK>DEC9#)+=F-5+SA!2F-,+T%.<V-F.5%U8V@R;CE/6#-3+U,Y
M8C):.65,,W@O43A9>F=(,"8C>$$[3C)+<'0U52\U4UA44"M9;4PO:5%Z2S!8
M.3E$*W-(13$O=T1C5"]Q;#=R;F-00G5X5C)+=7A6,DMU>%8T3#4R+S53=E90
M*TTW9G=Z<"8C>$$[3DPO9%(Y>GHR<2]V2DI*;5$T-W-69E%F;&HO;$=T2B\U
M9S=F+VLP=6-X<5 W>5AV4#-V4UE0-W50=4-:6E4R=7A6,DMU>%8R2W5X5B8C
M>$$[6DXO8W8O<6XY5TMU:"]U52]W0E5F<7A69FEQ>5EY:4=1=W%';4-K>'%X
M;W!A;7=*1F%#=4MS049V*UHP:U!P=DY,1F5G4V9V;"MR="8C>$$[05%*6D])
M;V%.>5!W8C R5#-Q34M'6"M7-4Y99E-9>G$X4&\S-%IX2T]1979X13AH>#)!
M.$(R1T)+655M+VU8+T%)12\Q>%8Q2G8U;"8C>$$[+W=#0E Y8U9D4V(K6F8X
M06=4+UA&6&<O;E=V*TLY5')U9EAA=C1:,&UL+W5O*S4U-U9F,VMK;'I)8V0R
M2W9B,$5N+TMU;"M)52]1-"8C>$$[,F]A,"MQ+U!/43=4*VY,-W!F<&5T-TTK
M=D8W-"]O94Y:=T0V1S=&53$X<3$O=T%385I4<CE::G O=T%%37ET1B]F42]R
M0GA.9B]C5"8C>$$[+W%L-VY38BM:9CA!9U0O6$\T941D4V(K6F8X06=4+UA&
M6%5M+VU8+T%)12\Q>%8Q2G8U;"]W0T)0.6-69%-B*UIF.$%G5"]81EA5;28C
M>$$[+VU8+T%)12\Q>%8T4#4Q<B]I=E4V-VXQ,G(K1V1*<&8W<5!U964Q6#DU
M2DIC>4A(9&ER,V)48G%E>3AK5W0T;D9J8F%:2$UQ14AF,"8C>$$[-V--0518
M,GIL3F1K-$1/6&1X1C9N430K4&=J+T%$=45F3F@S+TLR=%4O-5E94'9F*W5C
M>B],:R\U;V5O+VM#2#@T=2\U5S%Q;B],1"8C>$$[0CDW+T%.8V8U8VXO0411
M=CAG42]N1D@V2"M:3W!A;'$Y<EEV85%X<F-/14QG<U-++U1L,FTW6&YK>4-*
M:4YY,&%R<V%'4$A+66MD9R8C>$$[>C9K,SAY+SA#9C8U=C-N;E5M+VU8+V=4
M+UA&6%5M+VU8+V=4+UA&6%1F,TPO=T-Q9C%9<39(*S54+U9(-G-66#1Q-T98
M67$W1EA9<28C>$$[-T9867$X1C@W9CA!2U8V<"]W05HR+VAN4V%8*S9J-VYN
M=%8O95-35$UH>#-9<3EX5"]Y6$,O.$%B2$@O049#-7E(868P-69D3#E,,28C
M>$$[=EIN,31V9D@Y1'AJ3T%F43-9<6TS;%0O04I36%10.$%M2FDO-&M->71&
M+V91+W)">$YF+T%(12\V<&4V-3-$=V)S5F1I<G-69&ER<R8C>$$[5F5#*V1V
M.$%L2SE5+W=#33=F=WIP3DPO04A59F,X.7%V-WE34UIK3T\W1EAU2V8K4S18
M+T%,630O=T-O6$]1-U0K;DPW<&9P970W328C>$$[*W9&-S0O;V5-6G=$-D<W
M1E4V.&TO=T1+539B+T%-6F@K;S5M840K+V@W,T,W4B]U2BLU-VIN8E!#=7A6
M,DMR2G8W;"\Y52]Q>%8P4"8C>$$[.7EN*W%0,5EQ=GA6,DMQ4S-D<3%/37E(
M:T]1;W=.5G)3=EAP6&)&5E)75FA64T=&4TMG,3-";U(Y0GA6=D9867$W1EAG
M=FYB+VQ+.28C>$$[52\T>G0O1$]K,'8Y,4@S4%!A<BLX:VMM6D1J=7A6-VEN
M+VMU1B\W630O-FAC-41T4#9C=G5L*VPV,W-Z-CA8=FHK:#1X;D%0;V)S5B8C
M>$$[5&)Y<"]W07!,<&XO041%>&8X4T=:5VDO=F]F,6<T;78O=4HO,5,Y,7IU
M2&<S67$W1EA9<3=&6%EQ.$8X-V8X04M6-G O=T%:,B]H;B8C>$$[4V%8*S9J
M-VYN=%8O95-35$UH>#-9<3EX5"]Y6$,O.$%B2$@O049#-7E(868P-69D3#E,
M,79:;C$T=F9(.41X:D]!9E$S67%N6&LS+R8C>$$[04I3;E1F.$%J35 Q2$UZ
M468S.%!E-%AA4#EX4#-08V,W6C16,DMU>%9:3B]C=CA!-G O5FER;V8W;% Y
M569Q>%9F:7%Y6D=E1U)&-"8C>$$[.&U5:&59-4Q5:CEO5D92-#1Q=U9V>7AA
M-&DY2SAU64-R:&UL84M&:V(Q5UHR2E5H+VA4.35Y0V1/6'1T:'1$2R],=6Q8
M3VQA5DA9,R8C>$$[1C$Y8F%)='AM2VA$>$Q%9T=L86YX2C8T16\O9S,K+T<O
M=T-&+W!I<G5$9C<X8B]H9C99<3=G,RLO1R\T6"MM2W9"+T]O<#5R,4U6<B8C
M>$$[*R]B9C=S-E13+S-59F,X.7%V-WE34S5K3T\W1EAT-DDS+TMU;%!-,"]1
M-#(R<"]V3#AS-41T4#9C=G5L*VPV,W-Z-CA8=FHK:#0Q;B8C>$$[05!O8G-6
M5%AY<G8U:S!Z96XK:W@W+S=)6FQA3"LK:"]71&EA+W=$=4HO,5,Y>C1.+W9X
M=BM&+W!N8U!"=31.+W9X=BM&+W!I<G5$9B8C>$$[-SAB+T%)6"MM2W4T3B]V
M>'8K1B]P:7)U1&8W.&(O:&8V67$W9S,K+T<O-%@K;4MV0B]/;W U<C%-5G(K
M+V)F-W,V5%,O=T(Q2#-04"8C>$$[87(K.&MK=5I$:G5X5C=E:4XO>7)P5'I.
M4#!/3G1Q9C=Y+TQ/43=4*VY,-W!F<&5T-TTK=D8W-"]O94Y:=T0V1S=&534X
M;D-V;6I44B8C>$$[5VXW-&(O46-Z3WHO04\O:#<S0S=2+W5**S4W9G=B+V9J
M9CA!0R\P>G1N:%AC1R\S-#,O0R]W0DU69'=B+V9J9CA,+U1&6%1F,TPO-B8C
M>$$[<"]6:7)O9C=L4#A!5D@V<U98-'$W1EA9<3=&6%EQ-T9867$X1C@W9CAP
M6'%N+T=D=C1:,&UL+W5O*S4U-U9F,VMK:WI)8V0R2W9C528C>$$[+W=$2F-,
M+S)X>"\Q0S5Y2&%F,#5F9$PY3#%V6FXQ-'9F2#E$>&I/0691,UEQ;3-L5"]L
M2F1-+S5I678K2D1-<E)F,S!0-G=C5%@O,R8C>$$[12\V<&4V-3-$=V)S5F1I
M<G-69&ER<U9E0RMD=BM5<C%4+VI/,SA--E13+S-59F,X.7%V-WE34UIK3T\W
M1EAU2V8K4S18+W1J:B]Q1B8C>$$[>FM/,"]P>2LV6#98<F5Z4')X92M0-DAJ
M1V-!*VAU>%9/=DIV+TM5-F(O>&U(-FIM6F]0-RM(=F-,=$@K-&XW;G5/9',X
M2S=&6%EQ<R8C>$$[;2]U6"]W0E4O<7A6,% X06-P+W%J.5=+<CA69&EQ079D
M9C!3>&Y-1C5F43(X=U5/56MC2U%R1V=/+VII<4QG=4EB:4E3=W5*27E7028C
M>$$[9&5H2VMQ86933596359D:7)S5F5#*V1V*U5R,50O:D\S.$TV5%,O,U5F
M8S@Y<78W>5-36FM/3S=&6'5+9BM3-%@O=&IJ+W%&>FM/,"8C>$$[+W!Y*S98
M-EAR97I0<GAE*U V2&I'8T$K:'5X5DYV2VXO2U,V6B]Z17AF.$%%:&U6;W8W
M-D@Y64]*<B\W:68X059,,UA/-&5$9&ER<R8C>$$[5F1I<G-69&ER=UAZ="]Y
M;&5Q9CA:,B]H;E-A6"LV:C=N;G16+V534U1-:'@S67$Y>%0O>5A#+SES8V8Y
M475C:#)N.4]8,U,O4SEB,B8C>$$[6CEE3#-X+U$X67IG2#!.,DMP,35.+S53
M;E1F*TUW+U5C>DY"+V9W.3=H9&\O=T)X4#-08V,W6C16,DMU>%9:3B]C=B]!
M2W O5FER;R8C>$$[9C=L4#E59G%X5F9I<G-64T174$IU;F%T95-4,V-S:&EL
M5E$Y<T%H5&MQ;$]E-FQQ.$14<G0Q-C1B5DU.0S!A2%(Y3U-W:&UL;6EJ3"8C
M>$$[1TYP;35-1DIQ1D=W,EAT9U9'96I$+TEV,T1&6&5J1"]!0TPY=WA6,V]W
M+WE,.7=X5E%F4V1,:V-V2EIW3S=B<WI2;U-F;5--:TIY2"8C>$$[5FE9:G51
M:VQV-5IJ=EDW1U-#,%<W;%5V2$-9,#5-;S)*1S)(>$ID-5AG:C-+,S9-,$=V
M2#9P83%'-4AP>#$S1F9$=W@X4UAE5C1).28C>$$[>7-Y-F%T=7=947)B;VYX
M03A!9VIP,S=C85I!-S@R43(U25-+3'EX3$TP355D;3AQ26MR<7%X16A*4'--
M841O,V)++T)H+TY(>6)01R8C>$$[;B]/4'I6,#!Z4DA*0U=L<WA(54-/32]W
M>#A'2&-0:VYX<"]Z:C@Q-F%6<&%-2%-Z9U9L3E994F]#1#=';4EX44A)0D)Y
M>E!-;C5Q+R8C>$$[;W<O>4PY=WEX<F0V35 X04EV,T1&6&5J1"])=C-$1EAE
M:D0O04-,.7=X5C-O=R]Y3#EW>%8S;W<O=T%I+V--5E5(,&Y3-4A,>5=C1"8C
M>$$[=3(W33!A16XU:VI*0V-H,5EM23=K23!(;&A,,6)&;TQ16&IR>E-!>'!Y
M2RM.2UEF16PS;&5#4&-R1%1.0DI)1G!A:VIC:C T+VXT628C>$$[*TI,=DLX
M164U6$-A9#99:4-W*VU1145D1C0X5T9&1E!!:G!K1'9Z6D1B:VA28F57>F-Y
M,F]H=$1C47%R>E)C22M32S5)57-+8E9P="8C>$$[;&9G=R]M:C5.;FI4+VY(
M-7%Q85IO:FMH3%,R66IQ0DA'9C19*T1$=4AY5#0P+S5X*V$Y3DLP>$A$<%IW
M2S8W:&QJ445F4T)I3552=28C>$$[045(3$TW16Q8.4=(*U)F=4=73F)V4F@O
M:U@W:&ER=E)H+VM8-VAI<G!V-VPO=T164#9S5F1$+V-P+W%J.5=+<CA69&ER
M<U9D:7)S5B8C>$$[9&ER<U9D:7%787IO1G9Q:G!*2DQ*1$I&13A58DIX,C5Y
M=WIC<4U$56AR6F9X>%9)>"M73VA#36HQ6FI+5D,K=5)%6DYK0V1E1DYW=28C
M>$$[-'!41&%Q-"],+U,Q,'DU<VQM:T0S5'AY4UA81U Q1DUD0T%H0VII3U%Q
M2V1/,DYQ<F%H-4YJ=G)L6C4W-EII:U5-6$)K:&1734I*1"8C>$$[3TA29WA0
M3G$Q,G%F65DR<7!O6&LS4W1&=7ID,FAF,5=2-#-,0D)Y1')!=2]&5DIP.5<U
M1#-:=DA!<699<3=&6%EQ-T9867$W1EA9<28C>$$[-T95<C%F>2]B-FQ*-G)Z
M4U)3:4PP:UI/2G!35T]:5V]W3S1A25EQ:V%F;&AO4TI15%1E<GA#97933&U1
M161$53A+1W908V1$45EB5R8C>$$[:V)A95).2'0Y3W5R1FDX<5@P<7I856I"
M03=C5E9E05I60E909W%!=$].9&E-8E9F<69K-C-V-W=81#-C<4ES8U5A46-)
M<$5!:$I+."8C>$$[:$MJ."]T=#EQ=FHR1TYQ=3!,>6)P5VDS6G4W478V<DDX
M8FQG9S5",6=89FEQ:S K<F-H-W,S:F=64'-69&ER<U9D:7%Y8BLU9B]64"8C
M>$$[-G-69$0O8W O<6HY5TMR.%9D:7)S5F1I<G-69&ER<U9D:7)S5E-F>D(U
M<3!N469Q+W=#:T,T*W,X+U,Y3F58.3-X-58O=T-$1U@T9"8C>$$[4$Q*9D0P
M86,R94]/=4QQ:')V>GIO9&YC>C(Y,EI)6'1N84]A<3%O=V]Y0VEK:RMP2%8Q
M,C9!-5148V@U=GI%,&-3*VYB;S@O=V5O5R8C>$$[,FI!44]9,TQE<'AO5F%G
M<#<Y<4A';%9$-3DP95-+-6US=S$Q0F)2:'I)=G=H;5HQ4E97;S-".5)4569D
M6&)';%5B8CAX.49L4T]7828C>$$[1S1G:&Y#;3-F:#9P9G)Z*T=,;7<T1E0X
M*S).2VTR:V5:=$DQ931M9W-:1VMK=#%2<&=Y3VY(;C!"-4%B*S)"5C)U*UET
M3C!32TM7*R8C>$$[3&A:;4MP=UAL=4)836)5-G5'14%Y-G56<&1(4$]3261%
M2$HU,C!34%9*.4U9>4<U:%=-:$DP36I/,&\U8T523U1K<7!"3S-F36M'>"8C
M>$$[8FI%56%19' K6FYL:65&<'!8:W16*T@P,&UJ64\O2TI:9&=V261(2&9$
M4T5D2C5W,#1.13!-8VLQ=3A#6%5S-F=$:$A--6II*T)Q3R8C>$$[>DTV:V-6
M1F-#<45N-6<K5S%M:6E6-7!';&M%631W=E)4=U8R<5-"+V1I4F5D3GA566%6
M5W1F3V5K6&PW6C)L<C9J>5AC<&I8;6IX,"8C>$$[0WA3>6QH>D$U54U013 V
M131+5E!S5F1I<G-69&ER<U9D:7)S5F1I<G-65U1F,TPO04]Q9C%9<39(*S54
M+U9(-G-66#1Q-T9867$W1B8C>$$[6%EQ-T9867$W1EA9<6<Y43!F4W13.5 V
M+V%X,U!P5CE0,49$8V562S!R-#!'5U%Y>6@Y2G!H4$A'6$U7-C4P8E-B<'!'
M=4Q32U9P:28C>$$[:&Q::T),1TU%25-E=G=H:4(X.'):<4@K1B],=D%**VIB
M8FER0G=05%@W44I)4%0O04-J:7%O;FPO4D5I:VA3>&=72U@K.%%);T(S1"8C
M>$$[9F=60DAY>%9B2#5B.'9X<U=J,#8S5FIX<5)%;U!W3'A8=#)5,'A68G!V
M;'I39$YV<G4Y<V]F4VUV2V5S051W,CA&-EEQ:6(O045V5"8C>$$[=%%2179B
M94\T5D160DEO64%N=W)L5UA"1$HY471T>%HU-#DT16A2;CAV849C9C,Y:$)*
M=5=Q,&%K,4I"2G)4=GA'5VI:<4\V>%!,4"8C>$$[;#%%2TQP='-&4$EK96MV
M-V%H5S=D,55$1E93-#AV-DIC<$-L>%EW4W)B;UEO439+,T9#2V-26'1I<3 K
M6$Y!-&]V-E!T*TU:0E%E;28C>$$[=7A!459',VA#9R\R27A656@P5%(T3&XV
M,41:47@S1E$S<7%I:'%H0V=.45 U6$DK;D958FER<U9D:7)S5F1I<G-69&ER
M<U9D:7%Y8B8C>$$[*S5F+T%&5"MR1E9I*VIX2$AN>'!T5#%/;4MT+W5V.$%I
M>B]K<&ER=C-8+T9N+TI41EAF=78K3% K4VU+=2]D9CA79CAL359D*S8O-"8C
M>$$[<R\U2UEQ-SDQ+WA:+W=!;$U69"LV+S1S+W=#4VU+=2]D9CA!1FXO2E1&
M6&9U=CA!:7HO:W!I<G8S6"]&;B]*5$989G5V*TQ0*U-M2R8C>$$[=2]D9CA7
M9CAL359D*S8O-',O-4M9<3<Y,2]X6B]W06Q-5F0K-B\T<R]W0U-M2W4O9&8X
M049N+TI41EAF=78X06EZ+VMP:7)V,U@O1B8C>$$[;B]*5$989G5V*TQ0*U-M
M2W4O9&8X5V8X;$U69"LV+S1S+S5+67$W.3$O>%HO=T%L359D*S8O-',O=T-3
M;4MU+V1F.$%&;B]*5$989B8C>$$[=78X06EZ+VMP:7)V,U@O1FXO2E1&6&9U
M=BM,4"M3;4MU+V1F.%=F.&Q-5F0K-B\T<R\U2UEQ-SDQ+WA:+W=!;$U686(P
M94HU8RM.3B8C>$$[-BMP,'A6+R\R43T]/"]X;7!'26UG.FEM86=E/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@
M(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @
M(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A
M;F-E240^>&UP+FEI9#I%-38W-T$W13,W,#1%-S$Q0C@V1D0U0C8U-S8Y0D4T
M-SPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT
M240^>&UP+F1I9#I%-38W-T$W13,W,#1%-S$Q0C@V1D0U0C8U-S8Y0D4T-SPO
M>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X
M/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I2
M96YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*
M(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI
M9#HS-T0X,#(Y-#,Q,#1%-S$Q0C@V1D0U0C8U-S8Y0D4T-SPO<W12968Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I
M9#HS-T0X,#(Y-#,Q,#1%-S$Q0C@V1D0U0C8U-S8Y0D4T-SPO<W12968Z9&]C
M=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)
M1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]S=%)E
M9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD
M:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @
M(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI
M<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D$Q,$%"
M.3)$1#,R,44V,3$Y0S$Q1#$Y-T4T-3$R,$)$/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$V+3 U+3(T5#$P
M.C(P.C$V+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I%-38W-T$W13,W,#1%-S$Q0C@V
M1D0U0C8U-S8Y0D4T-SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C Q-RTP,RTP.%0Q,CHT,SHR-"TP-SHP,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T
M;W)Y/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T
M<F%T;W(](FAT=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^
M"B @(" @(" @(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO
M:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @
M(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%10
M9SI(87-6:7-I8FQE3W9E<G!R:6YT/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L
M94]V97)P<FEN=#X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P
M87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*
M(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @
M(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/C8Q,BXP,# P,# \+W-T1&EM
M.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C<Y,BXP,# P,# \+W-T1&EM.F@^
M"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*
M(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!4
M4&<Z1F]N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G1.86UE/D-A;&EB<FD\+W-T1FYT.F9O;G1.
M86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y#86QI
M8G)I/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=$9A8V4^4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O
M;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN
M9SY697)S:6]N(#4N-S(\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O
M<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93YC
M86QI8G)I+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \
M+WAM<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#
M>6%N/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE
M<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.
M86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @
M(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4
M>7!E/@H@(" @(" @(" @(" @(" @(" \>&UP1SI#;VQO<F%N=',^"B @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y7:&ET93PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @(" @(" @(" @/"]X;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X
M;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*
M(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP
M,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z17AT96YS:7-&;VYT4V5N<V4](FAT=' Z+R]W=W<N97AT96YS:7,N
M8V]M+VUE=&$O1F]N=%-E;G-E+R(^"B @(" @(" @(#Q%>'1E;G-I<T9O;G13
M96YS93IS;'5G/@H@(" @(" @(" @(" \<F1F.D)A9SX*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#Y/<&5N5'EP
M92 M(%14/"]%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#X*(" @(" @(" @
M(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3Y#86QI8G)I/"]%
M>'1E;G-I<T9O;G1396YS93I&86UI;'D^"B @(" @(" @(" @(" @(" @(#Q%
M>'1E;G-I<T9O;G1396YS93I/=71L:6YE1FEL95-I>F4^,#PO17AT96YS:7-&
M;VYT4V5N<V4Z3W5T;&EN949I;&53:7IE/@H@(" @(" @(" @(" @(" @(" \
M17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3Y-:6-R;W-O9G0\+T5X=&5N<VES
M1F]N=%-E;G-E.D9O=6YD<GD^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I
M<T9O;G1396YS93I697)S:6]N/C4N-S(\+T5X=&5N<VES1F]N=%-E;G-E.E9E
M<G-I;VX^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I+
M97)N:6YG0VAE8VMS=6T^,#PO17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H
M96-K<W5M/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z
M1F]N=%-E;G-E7S$N,E]#:&5C:W-U;3XR-3,V.34S-3<\+T5X=&5N<VES1F]N
M=%-E;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T^"B @(" @(" @(" @(" @
M(" @(#Q%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3XR-3,V.34S-3<\+T5X
M=&5N<VES1F]N=%-E;G-E.D-H96-K<W5M/@H@(" @(" @(" @(" @(" @(" \
M17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA;64^0V%L:6)R:3PO17AT
M96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA;64^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO
M17AT96YS:7-&;VYT4V5N<V4Z<VQU9SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 04!L@,!$0 "
M$0$#$0'_Q  >  $  @(" P$             " H&!P0% 0,) O_$ $X0   &
M 0$!" X'!0<$ @,    " P0%!@$'$0@2$Q465I75%!<V.%%F=G>3I;6VU.4A
M-U.1E-+3&2(Q0;$)&",R5Y*T,V&6T21")6)Q_\0 '0$!  $% 0$!
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M?4^;,!T0P^'"*VKBH@EB8(.1]3YLP'1##X<(K:N*B"6)@A#*SXPVLMA;-\<
MW;SDL@@@C_AHHHI/W":2229-A$TTR%*0A"XP4A<8*7&,8Q@7DJ30A96M=*DS
M:?W)5?R>AO9S865K72N\O)4FA-QD8H5   #0%XLEUK^M&G[-A.JNJG.T/5%X
MXI#>(BRXD)NIMZV^CWZTTL@ZF3NCYDU&31I'N(U@FF=4SQK)+J(*M*]BZ4_4
MI'/ZE7"'$BG7=6]69";T.JBNK4I(,M>Z=I!<+!;FD'I^D]TX>W&KZJ6MY&T[
M>5,\2A!W1]2HVHUM*WL+5+L"IR"C:8>2ZV':/U!,^:I533G1+<80["D:DCG5
M+--N;/"R-UGDNM6O4+%0UG=V9M/Q+]OJ15XE0L56%2S#2@72ZTU;5.3@HR(C
M9$\@9NQIEIPK'S<#IY-*S<;3&K:!E;3$/R()&%57J5803UQAVKFC5$15$MK]
M<*]&"IBA/F@3[*S4^#EF#F7=I9;*QKA>?29(SN92"=N(*93F21A2Q>95"7C7
MR$@I%;Z)6=)JJQ9U&!VZAOA3Z2KC69"_?J,N"X.-D)#A=_M[ (U/P.\WFSA>
MR7379PF_SO-YO]N\/OM[L+O@^:H[CKN/7'-NP^AB^M0*12_!> X]<<V[#Z&+
MZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU
M12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_
M!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!>
MX]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<
M<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[
M#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&
M+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU
M 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12
M_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!>
M X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]
M<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V
M[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z
M&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+Z
MU 12_!>!SV$@H]RIA2,DH_@\%SC+\C4F%=]DVW"?8SMSG.2[-IM_@F-AB[,Y
M^G8*QC_A4WG9 ""%N[J[/Y0S7M)R+Z5)H3<6%K72N\F93^Y*K^3T-[.;"RM:
MZ5WEY*DT)N,C%"H   8=)Z=Z?S5EC;G,46G2UPABMR1%KDZQ"/[+%%:*J.&I
M8V==,591B5LNLJLWPU=)8155443P4YS&RBMH@=<7232DD3.P)-,M/205H?IR
MMFA2TNMEB;%)I+E=)2,['8C<,Y=^DZ*5RF\D$7#@BY2K%4PIC!A6*UQ6(AQ.
M\Y%T[L+,;R3K7%QJZ6H&C^(HOL'-3(4Q"5C+3L7L?->*0YR%A>#XMP0QBX;;
MW.<"D5MO]=H.XC8R-A8]G$P\>QB8J.;I-(^,C6B#"/8M42X(BV9LVJ:39LW2
M)C!$D44R)IEQ@I2XQC8 .<
M                                      ((6[NKL_E#->TG(OI4FA-Q
M86M=*[R9E/[DJOY/0WLYL+*UKI7>7DJ30FXR,4*@
M
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M\-9-C
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MSW)GTIE3YVX<.F6)0C3Q\]:1AVPRK3E&45III$2*HF?.J(2=&GFV
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M[W;O<&SC&W9MSC RTP<^S+K:;N^.3%SY'Z%GC.G-<X=B_P (^O*=XGT0<
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M)?H ,]J8+Q&VU_9U[TTE^@ SVI@O$;;7]G7O327Z #/:F"\1MM?V=>]-)?H
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MW]/O>>-&L4UZ(4GU%.G<WIL=#^E='-=S9WQT6^1!8FJ
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MB%;G%8?Q+'JX;B:5!;5V<!Q"MSBL/XECU< @MJ[. XA6YQ6'\2QZN 06U=G
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MK.&@HN.A8B.1*VCXJ)9-HZ-8MR;<D09L6:2+5JB7.<Y*D@D0A=N=A<;0!V(
MC&ENH*S)S%EK];JEHL$O%WN$T]JR*!X1BUOTS+QEHE7,A /I"502;5V$:4>Y
M.GTM*8:=FL*ZXD*^VF6S^'-(_7DKVYOTJKQ0IY48PBOZZ,#J8[=@:?O'S=BY
M@;3&KGBGYWC-P2$<33.UQLO8*XZHZ<''S#N0E)<UHK,E46,C$D>P$I;5HJOQ
MDH[?22)2T@OS\[*^V$!']?F_U$IH]9TY8,7#]EF-?.&;99Y'9<).\L'2J)%'
M#++MO_@.LM5C'0RX1_PELI\(G^X; H5.9MQC^.=@ \;<>''WX #;CPX^_  ;
M<>''WX #;CPX^_  UKK-G':>U7^G'U:WK^?BO*#+3!S[,NMIN[XY,7/G,L\:
MKG#NCXII"?1!L     D5N1N^?T$\ZE-]LMAJE.NAU)M32[W#1LU#.EE'=<2'
MW[!;MVX\./OP(-$TBJ;NQ>^AUO\ +V5_HB.6^5_K-IKKR4_E8.L>1GJLH-J"
M2;VR-0\W/30    "V_N;\X_N[Z"_3CZE]+?Y^(\$.K^3OJ_H+Z'49^"2$Y"9
M2NL6GWIK2KX[+S=&W'AQ]^!N)I0VX\./OP &W'AQ]^  VX\./OP &W'AQ]^
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M!HFD53-V+WT.M_E[*_T1'+?*_P!9M-=>2G\K!UCR,]5E!M023>V1J'FYZ:
M   6X-S?WN^@OF7TM]QX(=7\G?5_07T.HS\$D)R$RE=8M/O36E7QV7FZ!N)I
M0             :_U9^JO4OS?W+W<DADYEYYFG6<@[TZ,;//,\ZZMEW=7I3'
M$_2#(    !O_ '*7?-: ^=_3[WGC1K%->B%)]13IW-Z;'0_I71S7<V=\=%OD
M06)JE57=H=]-K;Y:.?\ ALAR[RR=9]--<-^X<'5[(GU4T'U*[]^_(PCS,]2
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MR569.EF+Q)-TT460.HT>MG#-R0JF3(.D%FZN"*I'(4#L
M         <=X\:1[1T_?NF[%BQ;KO'KUXNDV:,VC9(RSETZ<K&(BW;MT2'57
M75.1))(AE%#%*7.< 8I5M1]/+RJ\0I-\IEQ7CTTEGZ-6M$'856*2YCD05>)Q
M+YV=LFL=-0B1UL$*H8ARDSG)<XP@J5I &9@     #KXN6BIQD22A9./EXY19
MVW3?Q;UM(,E%V#M>/?(D=-%%4#K,G[5RR=IE/D[=VW7;+%(LDH0H'8
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M#&2SV8.)S-ESP.TLOE@WXRQGL;)F^W#WAL9['-E';_TLY)O<CY/H[P
M      !!"W=U=G\H9KVDY%]*DT)N+"UKI7>3,I_<E5_)Z&]G-A96M=*[R\E2
M:$W&1BA4
M                                  ""%N[J[/Y0S7M)R+Z5)H3<6%K7
M2N\F93^Y*K^3T-[.;"RM:Z5WEY*DT)N,C%"H
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MQE%/S56*D$1<T54I!?RUYZE2*QT?X3M^AP^3Z
M    @A;NZNS^4,U[2<B^E2:$W%A:UTKO)F4_N2J_D]#>SFPLK6NE=Y>2I-";
MC(Q0J                                        ?DA")E*1,I2$+C!
M2D(7!2EQC^&"E+C&,8Q_+&,; !^@
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)<\:\]5OK/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g504802g64i82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g504802g64i82.jpg
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MX&+-#UK:8"()1NU(CNQHGL"[S8>K*[;9[7;"62UP<)8L((R#KOF3)8X,#?\
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MWIY1TB]#'6 C; (H[4T;3(.'OOE:6G<>'M#8PQFZ='%T/Z*;\.ZG_<W?/_\
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M=S2&=LU:+9@Y5S#;;4LC,AG\9@B^>(4,I/BGC%O)D#,4Z>%&-R1_ U%JQ%H
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M>ZTL>TA[" YK@1JL\VV_D?6(#6FVGV;E@+6M,3\G3<W1NF[H#+R+= 6D:%I
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M<D 0,>][A6\5LS>I5,?:K8^:ICV1LHQ%[6FHR*-L3!7E8]LT.D;6L.Y(TN:
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MJ#(_8-<[M&PN11%33.>-!6A.L==9 QQ6$)HD2YATJ-9@/;JF*$F5GBWI_O\
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M07AITU!T.BE-O<+:M8H5?VF*%6)63E1S(O?H995@7)6,J9[O)CLE;6)[9E<
M8&=J=X1(GQM6*I-$$3<Z/8"2&Y0R/7?K1E*QYLALW1BJY7AUK=%^,B=+6N6\
MC2GCR?!F9%+&ZI%&R2M+(QSIJ[6/D #3'+J[MCDM8JLR*[N13UW5&%\5B>U7
MD;;W)&L>PP1M:Z%[VDR1!KGZ!I8\DZ%8E<T%:TF$67'H21B#SL80A$(.AUA8
MX1ZUO>M##I$VCT$6M?Z6M# $6M;Z]=H(=_;UK/>/(8]#MMQW.%LZ=.YJ+MT
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M3")A$PB81,(F$3"+6M^B JRE2H_C_;Z)M5+(<TH9= W]R3E#,3L;TY+&AY8
M.(PAWH@M\((>"D1HM]WM0U&$#$ T], [6]O\5=S6PEJ/'0OLV<+FJN;LUHFE
M\[L6:-VE<M11M!?(VC-)4?9#6DQUYI+#M(H)7-\XVXA>RWC;I!Z.Z&>DZ30[
ML<[I(I86O/4WC-$H83RWH]WS3F@ZV.?+:TY,(L@R?F+$R9#"7D41D6R8MP)D
M?$923I2V]XJE+S"YW&2)61O9N@ACY2F6)%)R<S>G'N$JC0"A&;+"+;1M%!Q:
MTG1YM(-E)MGR-YFKIY*]J$6!S_L@Z=I+3V^C3RUT"NNRD>_"[A/^UX:3&$:M
MYR/BGC$@_P"@&4$CS6@/+J5 $]U(T?&)!1R) [)).W<AS;J32=.I))0IT?TO
MD,03($^BS KRG8AP1^, *0A"2 GL=@SOM=6JIN2:S",QC&R-G9F.R39P0&-:
M*C:[6C0[XD#V[^NF@&G/50Q; QXIAKA(V]TL2 Z #@"(-&G;!P<-[7N?C5S=
M]<ZHS:L\X^R]CJ@EO::]GR"];BACRI1#8;9O)V5PL=B.II*8E247')$WP1M;
MD0'!,>J3$NKUHU'W2C9)MUE=J(;]K$V(Z ;'4M,RF1K2.;PK^3>:W2Y"&@@1
M2LK,8S?!< ^35NAT-A<S$=B:E+'6W6P3-N6HGD;EFXXP\=QT!&X\0M:"X$C?
M?VHUT/=6]S3J^;U]?T+0;Y)S8^^IE!9@L66Y83$XH(8CBLZ'*5$-B+6@3N!+
M<CVW*UK8FD0=[[\!#(G#%FM(UF:79,AM)1LU,K6;V9LG*V:MASK]N)[*S(+1
MG=6KL8'B-NXYS&S<]0(AP&-8=[FUE:\T-R)O3YC<EAE+K4['"(1RF0Q1-:'!
MHW26A_=T8.&T-Y](IY=U3%J^KRL8*CO6<1B)7W6=QH=W=(HJ\J*S9:_.6C5P
MFJ2V4C1:7<J O"%^=S#&!L4A:&\!452FJ%*H&-VT%""I4HU6Y2U7KY6ED6=D
MY8)'4HJA<75J CY#C[WVQY=%&>&W2!KG.<NIR=:.""O"+DT<5R"T.EOC<:[8
M"=8JP8-!Q0[MW$L:=T:1C4E?K2/.*'5I=O)"?RVMW.;P&X[",N6)PXU<B(51
MNUX?:"NRZC?W0X8Q)3D;*:XNK+)"$6Q&+VYT4E$[.*UW)K&;3UZ62S-J>F^S
M4R-LY&"N7-#H;U>\Z[0E>2=TMC+WQS!O-S7D D<CS4R\5>Y?GD@=+#:GZ5'$
M2 8[$5@V*KW'J(87.:\#K:XZ*GU.<KFYKKBRJEN!RMY,T3VT$EU)+&IJ4(V*
MP&BP]MCBRR'3NB<S43;*H[+&YP*-7H#75H/0.K6B<4YRG8A$EQ,=GHV4[M#(
M.R#8[5YN2;;QT[8K4=O<?%+Q&R%K)X9V/!<TO86O8UX)ZE'JY%H@GK6C9W9K
M MB>K(UDS)]US)-YKM&RQRM<-6[S"US0X$]2MKN"4QJ7310Z1%SM!X8BV]O0
MI7*WY*AE$T5F)BM[5'*5;:C2HF] -28:)O9RC7';>3OLF.BXT8S,ILC/!8LE
M]=]Z2(,8QK\A,V>RXC4N)<QK6L9O$[D8+MT=;W$DJ#9DCDE+HG6',#6AILR-
MDE.@YZEK0&MWB=U@WM!UN)*I=D%1U<)Q/K*57!R1I6!0YM4N3LZ6/$E:CP<H
M9I;8QL[VB=I ^KA "+N&UD9D:UR6GBUU!)3[ #1AQA10_5O(>Q5RSM?6S+87
MMQ>ST%V_DKKFD00N=1M5Z-7B'1AM7[DL->O '<1X=+,&\*"9[.T,+[=NE2A!
M?/9M5PU@YEL;)F23S.[T<$+7R/<>0#0T:N<T'T',]R7NR81,(F$3")A$PB81
M,(F$3")A%I<=,#Q]GM5<O;!LIU9EYE=7,O;I5#Y:!,:-H/<!,+:AD$;5+0A$
MF2OC4ZMZPX+<:;I0>S*&UR #NU PE>=^2ILKE\ZW#[286G8RD-'$18?,5:4+
M[-O'34[=R6M<EK1!TQQ]NK9B:VTV-T,5J">&=\9?!Q?'=HZLF/S-U\X+*]^8
M6JL[AI%(70Q,F@XA[4312L<>&3O&)S'@$;V[BD[8/Q@^^U_^<\0[!9OP-E?@
M^W]"J7C1>JQ_IM^55OH*[55#S!_ER%B1R,U^K2RZX&B5N!C>6F3V/#G6(G.H
M#B4ZH1AS4!SVN*2[+"!6(G2<9Y&C.^!9XFIGL58FL-P.3F,U*Y3+74;C !<K
MO@,@(@=J8]_>#=-':::C752Z>0CIROE#HGE]>Q!H96MT$\3HB[4:^9WM[3NZ
M::CK7YS6ZE,SIRC*@.9$B!)2*BSU")[*7F'J)!NS)&UR)2%4B$G+*0>*3&P*
M4C92A3X4 [9AFB1 T$2Q4SMC'XN@<#E&MQCKKFRBC<)FZ9-',0YO  9PS'NC
M1SM[74Z::)-D(Y:M.J71-%3I&C^*TE_2)&O.HY;N[NZ#F==>XK@&OG(Z(>7=
MA<HUM<1][:K42RQDGM0.;TI-C<CB4PCI;&XQE>\:0:5&)BU*5M>B5'B[0M.#
M:EZR>P'>6T=K/LV@MYQVS60D9>;/%:Q[Z=TPS06(1$^%TG1M[=#FLE!W/-,
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M.KI)</B)9'D\RY\DE%SWN)YESG%Q/,E4)V1V=)U[&1CV&SVF-'XFMG#0/8
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MY[G/>YSWN)<Y[R7.<3UESB223W23J5/:UK&M8QK6,: &M: UK0.H-:-  .X
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MGFM1U;N]U<][=[FJG/79WXL#]](/W,K?N-W\G[U7Y58_=;O8[W[/R)UV=^+
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M?(GA"C_;G?\ 5'^]C4]\^^4W&?\ *W]$?(GA*C_;G?\ 5'^]C4]\^^4W&?\
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M);;=LV!(WURD#HK.;T W)60U,C1X0:)N9VIL*/TD0($"<82DR,@ 2$H.LE,
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M,A).-$86WMR5(I((2-Z0.]$HT9!8$R0@ "$Q1)!990/I:I5K8^%M:A!'3KL
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M&+9;287.AZ$<5L,DL:MFEH4RO(W=;69[O)EJ6,R!X;3#)@N?]+MKC%J\*IQ
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M(_U5>\S5_P"V9_\ =^ZY:YM9Z 7OQU?CD"V:X-]Q<3]SK/\ F!&>AU?.U?\
M(1?PVKYJM^>K'Y:3]XJ59G4=,(KY \J(J?R+N.VSF&8-+#;,)<88F71QR;45
MAP,;@TQE#N21M<9VD&G4 H^>A,+ K0C.:'=<2!P3C$()GG)V+NMV4P&#;9H3
MV<)D(<@^*W%-)BLF(I[<G1+<8TEX!Z4V4$QR 3P1N,3AU>@C;"F[:C.YIU>]
M!7S5":BR2K+$S)XXRPU(^E59#]KXPZ,Z)P#XRZ">1HE83SIG>MSQ>R(94L+C
M"6>#)K'<\+/D%AOR20/\CU+G)E<BEJ@](66!$(DUO5%!; ^$$MZ02),6X.)A
M9ZPVWV;V?N8F_F\A<?C [,#&%M7%5GU:M0T8;$3HV->29 X2L=QCNNE?Q'F*
M(%L8JMHL]3RM'"T*C,D6XCLB'6<I899LVNFRP3"1SF ",M=&\"(;S8V<-@DE
M(<\X8.DI_!X'[J6+\[+RQV@\YQ_EA^ZY6/D<>F2+VM9_A.6OMFFKZ#7K =&!
M_9Q<5/R)M7_VX9\T[9>FS,>WA^Y&K_9KTO4/R$O\:9:L\(^XR)^YMD_1J;/M
M^KYVK_D(OX;5\3VO/-C\O+_$<I1F=8%.ZNEB6!6;74Z7)5"Y%"YW$98L1)!%
M@5+$L<D#>\*$J81VPE!4*"D8R21&B"7HP8=CWH.M[RMS-%^3P^6QL;VQR9#&
MWJ,<CP2R-]NK+ U[PW5Q:QT@<X-&N@.G-6.(NLQV6Q>0D8Z2.AD:5U\;" ][
M*MF*=S&EW:ASFL+6D\M2->2[!UD4/EML2.62M+)4\.D\PD\A7(H\:U@DR=$]
M.#DY(TZ0YR >U^%$'*4Q:D1P!E"* ?W7]/98M88:E^CA*E&D^FZ_3H4ZL<EI
MLQIODKQ0PR.>V$MFW'-8\LW2'!Q;O<M0LLUJC=S-J[<9:;1MWK=J2.L81;;'
M8DEEC:QTH=#OM<]@>7 C0.TYZ+ GTHO)3BGR3D<)4U9%.0D:M"DZ_K;C@$5@
M.E<+("\5_3S=(60+Z(B.HPR$$Q=EJAN/%O2DID E"M#I$6;LCJ\FP^.R^.L9
M 79<=)!<O7LB_HK;(E99N2MD<QIE.YP&]L!J#)YG5QYKZFIS5)L5BC6;8:V/
M'4H8A.8B[@QP-##(8P 92-W>+0&:ZZ <EB0S85D3"+U4>C__ +*:B_\ #0Y_
MHM_SYQVG].]_W6@_; K?"^E.'VA<_>L+RV9Y]W$S]U<B_2ZS/I!_FW?WG?M*
MUS'>A]'VG6_@L44SJIBO!X2\D8_Q;M:9V#)8Z\R9!)N/_(.GTR!C/1$*TSO<
M-3R>OF=V/&O,*)VW-+B^)USD L6U(T1)VDI9I_8+'4YG'R9.K#!'(R-T5^A;
M+GAQ!;4M1V',&Z"=Y[6%K3U D:\E(KS"%[G$$[T4L>@TZY&%H//N G4K\./?
M(Q@IND.:%5NT>>'=SY.4["*VC;FW'(BT,;<8M=5?6<J<7LM28!0<B4M<06MQ
M 4 #3]+U279@ I^]-+9#'R7+N'M,D8QN-N369&N!+I&R4YZP:S3D'!TH<=[0
M;H/=T!XBE$<=AA!)FC:P$:: MD8_4_F;IR[JND>.:/'B$<-KMXP4DW<J)(AO
MM'798X'R#G<$D].T(]1&9M,X?)G4Z&-M*1>[S5\4MBF+HY!MDKXU-&GE?X[)
MD:HLD.ZQF'R$^7I9*Z[&1NHF?2?'P3Q7+S)870LAM.D>6MA8'"0Q[\X,C!N<
M,$Z9C8B;7DACXQ$H9VLKFNCB+7!Q<S0 EQTTUT;R)U!6*'-I4),(O7+X ?@0
M\3_R!5A^JC;GS!M;Z9\][JW?X[ULFS/I>PON;4_@M5D?3^_V5O)+_EHA^MC5
MEQY'7IJJ>UK_ ,3F4?:KT,B]U,1_,:Z\Q#/H=4:817@<6N2,>H.#\PXH^1UY
M?5/)/B^\T/'534<B*(CKXY696<X+>WH*PPLPYJ+0P=<C&6AT:LVK6)-A*V3H
MX9=1D\=)?GQ$K)&1C'9)EZ0.!)D8VO8AW&:=3BZ9I[;EH#SUT!D0S")M@$$\
M:$Q#33D2]CM3[&C>XK@NCZY8<7>*\3NI?9,(ODN_+!:PPJNKWI%XKM'*Z;@#
MLA,2SC5?>7[:YHXS/IDF/41]7/D:%7(&2+J%2*)+8XO7N+@K@Y[%9/*2TVUY
MJ)HUW\:Q1NLL&*W.QP,''X#FF6"$@/$!(C?( 91(T-:,E6>"%LA>V7BN&ZR6
M,LUC81VVZ'\@YW5OZ$AI(:6ZDFR6]C^/BB9IC>-B6Z$D#$PI-N0+V=(2[S,R
M5[7N8G(Y,J@34SLVF$;<)GTD*/3#<M+PN9B@\9!B4!=S1%\0GLB:9GXAW>@M
MF9#PMUNZ")WO?Q-[?U(.[N[N@U!UCR\+>^T\3=TY\4M+M[4Z^9 &FFGLZZJB
M^3%C5Z71S?AW<3/RZ0#]-I\A9/T,RGN9D?B4ZA7_ .QB]OXO^9U%Z=?2(_@+
M<LOR$6)^KZO/F[9+TS8/W2K?Q MPVG]+V8]H6/W"O)"SZ>6N)A%>+P3Y(1GB
MER +MZ7,#[)68%47W -M<<$WA<]N-L4I/*S9ENMN:I&E\";7:5(E[G_7]_IN
M3JMI2E"G12<VHS>.DRE#HD4C(W]*HS[TF]N[M6Y!9>WM03O.9$6MY:;Q&I U
M(D5IA!+Q' D!DK=!IKJ^-S!U]P%VI]A0*@%/%/2B5MO*1KOG3<O2-1D+EM"N
M4#->8RY(SEOC9._PRP$J5KES4]I5*31(D<OB3@RJVT!H#G-.N/2E9[XRFD3L
M8ZCO-+^-%>;.&2M(;N%DU<ET3F$'76*5KP[31I:">D7 [83"70Z;KHBW5I[N
MK7C1P/L.:01W>I5SYH<JZTNJ"<7>/U$0Z=1FA^(T%G,4@;O;+PRO5K3=ZM&<
M*+!G<FE@HTG)CS"@,>CB$49B#0>[)8^VI3.IY6"7;)20L/B[-.?)W[TT$E[*
MS02SLJL>RK"RM"(((XN(3)([<U=),\,,CB.T&[J<MB=DC88HFN$4#7-:7D%[
MB]V^XNW>0&OF6C70=TJP3+U15+J_^[R$^ZZ-_IE%G>/^TC_OM_>"A9+T.O\
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M@!$/?=R/?4'6Q;ZO)5[UU]6NO?\ ?K,T!TE:3R WM2>KS)6N;6>@%[\=7XW
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MZ78['4Z._P 1U:O'&^0#022@:RR ?>A\I>X-^]! [BP <I^CONJHY])7BH(
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MPH0$+SDHA]P!4R!4HU!0 *]@;._\5HO?<1Y(F#NUXSDY^QET- G8^&>6M)(
M-Z2O)7BF+6/.KA',V-T?F Z4 /.A/Q>7QOVAM27*UH^UKVJTM9MGA#DQEN"S
M-6!F8W1KIH'R-FTXCF1.)8+(/L>?I5/8 ;OE AW\TRX\NFRGANM^HO?5%CW<
MIX!ROOXW^HI]CS]*I[ #=\H$._FF/+ILIX;K?J+WU1-W*> <K[^-_J*?8\_2
MJ>P W?*!#OYICRZ;*>&ZWZB]]43=RG@'*^_C?ZBGV//TJGL -WR@0[^:8\NF
MRGANM^HO?5$W<IX!ROOXW^HI]CS]*I[ #=\H$._FF/+ILIX;K?J+WU1-W*>
M<K[^-_J*RM=&']#<WC'[JAUR\W"8W$X7 7A%(D-7M;XVR=ZF;FW'A4-Z-T4L
MYZQM;&$9Q8=NNU*DIUV3KP9$CT:J"Z->M;1>2)C(:<]?!RONW9XWQ,M"*6&M
M4#V[KI09V12RSM!/!:V/AM?I(Z1P;PWR8,-D<G(QEZJ<?C@YK[$<TL$ERXUK
M@X5PRM)/%!7D(TL/?,9GQ[T38F;YE;MS\ON,\/Y@\<;4XZS<T2-ELB.F-A+L
M43H\]C>DIY+BQ/)17;*&:% ZI$IBM,4>F&M0;5H-*" JA&!\BP67FP>5J9.%
MHD-=[A)$3H)H)6.BGB)YZ%\3W!KB#N/W7Z$M"VO*X]N3HS5#(87N,<L$P;O&
M"S!(R>O+NZC>#)8V%[-1Q&;S"0'%>=5?W0)])%2T[>(RPT'*+>CJ=:H QS&L
M4QDK:W=MT9O298,+<4)4WC.+ZA;3.25"M#]L]$E'O9(/H6EM?LU>A9,S+5*Q
M< 707I65)XG=UCQ,6L>1_P T+Y(SW'+27]D:IX=S%WN*WD9*-:6_5ETY<2%]
M9LDC6.ZPRQ'#*WJ<WEJ:%?6>>DT]I??'Q"?/X3)GEBV?\.X?X1J_2KITF7P9
MFO@;(_5D^L\])I[2^^/B$^?PF/+%L_X=P_PC5^E3I,O@S-? V1^K)]9YZ33V
ME]\?$)\_A,>6+9_P[A_A&K]*G29?!F:^!LC]63ZSSTFGM+[X^(3Y_"8\L6S_
M (=P_P (U?I4Z3+X,S7P-D?JR^@=#OTFHQA!KAC>P=C%H.A#@CV &NO?5UB&
M))K00Z_O%O>M:UY]^;'EBV>\.X?X1J_2)TB7P9FO@?(C]M?3WUL.]#!T ]J0
M"S"^17-R+HXTU-+(\MT.J%8J)5O;PL?FQ0U&NLE)2&"&R)6U.K/.3I%!B5U$
MXD)];2B0&&'"T3:[;VE'4=0P5GI-R5[.+=B#N!6CC>V0MA>X#C32EH87,#H6
MQ%X#W/(#9U/#6,M-')D:DE7&0[SQ6L[K;-Z5S'QLXD3'.->O#OF4-D<V>29L
M1,<;&'B;G^>)+?$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*T#D
M3SCH+C'(&F(6&[2)PF#NU ?BXM"XXLDCL@8CE*E$E=W@10TS<U)%RQ&L3MQ:
MQ>4M7B1K#$:4XA*H-+VS9W8K:#:B.:?$U&R5X'\-\\T@BBXN@<8VDASG.#2"
M[1NZW4 N!("U?/[8X#9J2&'*6S'/.SB,@BC,LG#U+>(X#1K6EP(&KMXZ$AI
M)5NOUWCBMZBW7\G(/Y]FR?8@VT]:T_&O_P 2UW[+&QWKJUXJ?GI]=XXK>HMU
M_)R#^?8^Q!MIZUI^-?\ XD^RQL=ZZM>*GYZGM9=)WQ;M"<1V (G"=Q-ZEKHD
M8HZKG$+5LK&XOSB<%,ULNWA,J<DB!>ZJAEHVWQH)"E6+S4[>2I$N5)4YU;EO
M(TVMP]&;(6J4;ZU9IDG->=LKXHFC5TA86L<6,'-VYO%K07$;H)%AB_)&V5R]
MV&A5NR-LV'".!L\+HVR2..C8P_5P#WGDW>T!.C==2 <AF:"MZ3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3"+5QZ3+>]\U[%Z]]?5!JL#KK_N#XD7BZM?^VNT(
M0NK[76(6_M[WGUGY"_I2/M^S^\OE;R8C_P#58]BA6T]CM2K%<]=7E"81=S%]
M[U-*\%K>];#9M9"#O7FV$09]'-A%K>O/K8=ZUO6]>?6]:WKSY1[3>E[->YMO
M^"Y76S9TS^'(Y'LA5_BM6Z_GP6ON98R.*/,94@Z--!S)Y22]6\ZA[!><OL.3
M((\TIW1P9J^MJQX^T-[1&HR@9VU6\FLK S1YF;T*-,<\.>T@#S#%RP]487;3
M4@ =>F@_&!WUQ7WI(7VND\V07=Q"NNHYRV\;[7Y1UA!7&3U/+7*WX%225B7V
M?$69QA4R>FV/VY$4$IC2UQ@KR;X.J3O!0F.0/ DB\*4F[U:$$:@:]6A/X^>G
MLZ*8K^DSXY-]U2ZGS%;R-)$>%:CG&HL<!2,,(<:S;PIW5YCK:M.5%''S1GA3
MO%9^L;.[T2&*RMI7]_H/?]V7&ATU]G33NZ__ #ST_$NWY&\Q9)4_ $_EU&ZW
M,03^4U_32R!5=/U>BM,5F<AY' 8!7<:L%4R'"ZD4;F]E,),W\3*PC$A;G8MM
M7%CV0K"7(&IT_'U>P">7O*CE;R1]JKD[65/6YTH\KL^\9(8J)F7'"94O1L7K
M^<K5=>OLO);Z@'":HB,[@A[*@1"EC:6]W#9ZM7'6->WOZ5T<%0G9$3N:[O+O
M\]?S\]/\!S]Y3ZH.>T[OB$V#9-7\,;O?('$Y!+H1%)$XS2C8J394U@5J.%73
M(E@22RR&18UPJ,*6QU>W2=OQ*%(H21V4-K UOKN@9TD@(1IIS'/GW>6O5KR_
MP_V.@0=)O%E%92U[4TE8(KNC')Z,</$?'UBD];25WF%Y3B(1FQX>DBMDMTJU
M7"B#KZVE*:=N\R=GIH#&F)DE);JTENK*!N6DW3^;3>UY]6NFO?ZU;[6O2"RB
MO)]TA\_Y#0>VXD&"7;Q(IZK>-[](H&\/J"Q+9JB#L;7$X&_IICNL28[8DW>@
M3+RP62QF8D4<6K91+O)Y2W/+8@+G=Y#3_J)/L#_?OK(!Q<Y=,G)!]M^ K(6M
MKFTZ-<(83/8B9,(18;,8R6,S+WR"RN+3JOGEY8'UD?26>0M9Q*CQ0^M#]&GM
MO<F8E.6WKW(NNGO?[_W_ -U;5"+4Y*63:O2 SBD2T$R<Z]Y#TEPZJ."V%*G5
MMJ:"LL$AM=3:\;K>8R@=6W3L[I76^YBH<TC":DF$Y:*KA$/2NR LM,<C+GEV
MNO>).G7UG0?X#WUUMR\AND38>.?)%]^ISAU06!3-*2%T1V>=85;RN#6!/&J4
MI].$SI%E=IB%63#FNHT,AG:1KY!MM>.">?*XU!%:.2LR%^D"D@ U'/K]CJ_'
M^?O:\O>5C$(Z1"UC*8YD63Q[Y*2CDW5\<)X9551MF\D:ZK2&6K!.2_*2S6VM
MI04_5M7M=4BM<ZNA#)9=53YE43JO&($BD )3'HK(95%4!BU(_P!_[_:N=T:@
M$:'MB0#W ->LDZ'D0=3RT[ZKQ;MI<T>-EIVIQHCE\6QR55RGC36G(:%V$\U)
M43U>U6MC+REKFF^4!\)A]/U#&(E8HFFH;#46=5T3=*OESZFED84,&TTT0+4C
M(,F@(UTTT.AY\CR)'6=>YSY]T::+ZK;F[,7)S@--6YR#24ZU0N\IR^67??(%
M+!:)L2<4Z@LV4+>+=('Q"61RO6IFNV^Z^;&2:V,B20&*R*,T @3R1=%(;([J
M@KP@+C3KT&ITZAJ=.^=>]W/Q\NYSO6Z3RR[GJ;AA8$LX]3\FK+A76)QIKZ&6
M$HC,=F1$4.M[E!353/#H;&)8V/$?> !CLV=R=IU[<?V='=^D&F7%)E1)<#37
MGU<_\ K;J7YRVO<-H\!X6\&I8!-7^1<N:9YK5(F;FA:6S7SQTK5E5KFI"YN#
M>I>6V-G/RHBQ(&N97%$&2U]+XJO7FKTBP!02Y+0 X]?5H?8)_;WQW#JJ0=&E
MTA]I.U8<@'+G38Z![.A=<R?F)7]A;B\6B7A/%]LE5AUY-& ;9$&IC9G%SIN?
M5*^$+EQB4+TL8;!@'C,Y6K5!5'%RX#7M1WAIKW?S]]4BA/-GG:BXK<WY[;<]
M+8+CKKEYP.;82QEP6OTXZ7K3E@X<+YW(Z,4)=17P22*87$[[DU<+I1*"'R4F
MKB5;NG?@KRFU8D(0 1IIYD]_F1O#7K[NFO>]A95*JGTLCG2#<J^/[_)7Z0Q.
M5TMQ^Y4UDA>79>[)H2-_76!1-GPZ/@<#S]L<:&Z4_"IPC86WN6HF13B7NA*8
ME4[*Q'%P?,@^R1^PC\?6?\/85^V%U3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(M7OI2D:F.\RI(Y/A6VINEM=5ZX1I>NWI,B>D[.F=&
M=VTWJC=A(4'M;@3HIP2EF;4HP*4)QY19*Y(8=]5^0M;K'9>:#CQ":&_-Q8B]
MH>P/T>PEI(.ZYI[4]1T<!S:=/E[R8ZED;30V.#(89J$/#D#'%CC&2QX#@"-Y
MKAS&NH!!(T<-<>_CQE]6&OX02?/9[#QHO58_TV_*O).#+ZE)^@[Y$\>,OJPU
M_""3Y['&B]5C_3;\J<&7U*3]!WR*8UJ2.76E5$6C&RWV0/=J5PG;&EK-+6K5
M.T\S9%ZP[1"<1@P)&]N2JW)R6&:"F;VY(J7*S24R<TP.O;67*M?9O-RS6(F,
M&.M#4O;S+HG-:T '4N<XAK6C4N<0T D@&_V6IVK&T6'CAKRO><A6.@8[D!(T
MN<3IH&M +G./)K07'0 E;K>?"B^W5AZ@W1JW>W\8YQPCLOE'6<RXLRR(6Y&&
MY!$>,\E@-XQY98TLD<[CTC)M1?R6G,06N4%EK^6Z$DCJ!.D?"VI(C/+0!,/-
M&7;>&H(!U&G601R]C='[5<#6O$>Y'6[8C>W+N\J^O>1U74=@TU5D=KBC5],P
M]*UVTLA9UHSR>-K[;%NJI7.YHW5_&6/:5J6Q:$1YIT]D-L7./>=JD1<:]X:<
M]>O7JUTT.@[ZL.1]!DV$47#J>5\F'YP=&"^]2*13Q379)CG+^(XJ8C7&Q3P]
M5H39L;I''E5$0:#QDR;>'+.J2L)DM'$#E#DK1B+MO\R=.L=_[[77>_,>8"S"
M<C^/T"Y1478O'ZQM.R:&V.P 9E:^-+M-,BCC@WKD3W&)5%W'N5!3=)(=)FIF
MD\<5G)525*\LZ$U2C5)@&)C2Z Z<_P#?XOS]U6=,'#KE?*+<XRS3DGRVK6W(
M?Q0G3_8T'20WC*OJVR[$E;U4E@T\F<K5F0[VFL+%XNC]C/:]8E@=71!(]/):
M=6 EF2A\7Z+MJ-#H--?9UT&H.@_..Z3R7 D/1R+W/A,P\24-M,2M9&+]?+Y*
M>IE6!LGJ^?>,^34OY%@JNWJB+GC2;-ZR<=2H,-E#*"=-6WO38FD&O!@Z\183
M>YZZ?>@=?/DW=U!TY=_J]A4PCG162F*PR<J(W=U9Q"Y5_,VN.;U7/< XWIX1
M2-:V% :8B=)J8$*DFRTSE;W7$GB#7+FMS CL6/2L*>8B<C) MDC:>\NQ<[W5
MRY;NZ>?,C4GK[A_WU'1=C(NBYEUGQOD>NNOD-&IU;U\W1QTY"L\K14$UMU9U
MS8_&UK86J'L6JA?+ E0)Y53@VQY/'G^)2J9#?WB-.#R0NF9KRN(>D!<;P[70
M<FZ]WF0?9T'/V=%>UQ<HJ7TFTRT$U#QG*=Y.O:CBT_&/C:?QSC*=$TI51)0'
MY"X6G:[M+G4Q0M5*"')4\-:5L3'"0(FGM"5KUI<$Z]_\YU_[!4VXN5M-:<Y+
M\]8RXQMV*K.W[=K_ )2UG-!)1F,;BY614T6K"TH2%R!UD@?HK-*0%*5;8=HD
M\#%8T>5%:4 -/,*(3J&]\#0^^2/\#I^958YA<<">6?'N:T69,5$!/DKC Y"T
MRHIB22M$VR"MK#BEF1PN0Q!>M;4,QB#@_1!N;9C$5;DVE22,+'5G\9-QBP"Y
M.0'0Z_[Y\N7>/>/<*LHG/1I3OD&KOR;<E;ZAJFV;<IFK:=B$AX^4FX53%*X^
MDK;GT^*WL)RCLXMFX7NQIJQVJB8GE-XWEC,RM\=;%$5;&Y-MX='M27.]IU#E
MSZ^?6-#ST'<_V57FJ>+][Q^TK(Y+W-=5:6ER0>J.2T/5JF'4W(:JIRO(HV/+
MK,A'KX8XVW9\ODCO-IXH9'N>./EZVD":8TR,$9;&;2-0XN!<$C0 #3O\]=?\
M!U*A=F=%^ME->1>,PV[4+/.'2HN5U0W_ &38-8;L5RND/-=)6OT^+0TUM\\@
MR>,6B6YU>P:K92I4R:&0B(;#79,/71%M9D+>_P!_C7.]^T$>QNZZ?FYJ\KDO
MQJ(Y \?TE#(9<=#DJ"<<=):ED:UI%*E7@M 7E5UQEMBE'MV8Q*5,H(K74;,=
M!+P;;#GC;V)&Y^!;;%A< \]3[/L=8T[RH>_='Q'E72(0'GY%[#7Q12SPF2L-
MF5 5'2G"/6;-%T,55Y%[0"^B>D9L6EC+"%9,4?QDLKP7+V&-PE$I$VF1DE2I
M+G>[7=T[O7WN^/SD#_95N[QT/D9D54\-*S>+I= "XQ3::;L5V9X66V)N1%#V
M':R>YIKQ\E37N5*CF.*26;Q6L3G5P\:O_>MD3>$!;24&5J#&XN=_S7+KT_,1
MRU]XGWU6ZU^CT,LYNYG-^K: R?5<<C^*-_@-W!A./D"7QE2\94PXH('E>A\J
M!S3?'<P87O0X_J/:EP [:7OQ$(3N7&O5RZ@1^/4N/_=3RJJVF;YS^Y5\B)1&
MW:/Q-DIZ@.+51JG-*-$"9((JJGMW6=-FDH[J-6,)LGN&.05 YZ+*(4.]>R4D
MC:@D@L_9<=P#V2?V ?GY'\Q5^&%PF$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB811V20^)3)*2AE\7CLJ1)SO"$Z.2,C8^)2#^SV._)3N:
M9444=V=]GO  "/L^;M=7FS-#8L5G%U>>:!Q&A=#*^)Q'>)8YI(]@\EAFKP6&
MAMB"&=H.H;-&R5H/? >UP!]D*%_2(H_V&JI^3N(?R?)/97*>$K_CECZ11^QF
M-\'T?%*_T:?2(H_V&JI^3N(?R?'97*>$K_CECZ1.QF-\'T?%*_T:[^.UG6\/
M6C<HE7\(B[B82).8OCL4861:-./>MC(&J;$"8\1(MA#L16S-@%O6M[#O>M9B
MFNW;#0RQ;M3L!W@R:Q+*T'OAKWN&OLZ:K+#3IUW;\%6M \C0NA@BC<1WMYC6
MG3V-5-\BJ2F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6HY]$P<[N4/&J5<?J
MHH*UY14K-*XFZS:2.L'<U#&_O*X#XX,Z1"K=4@P*1-B,EL[XI"$>DQJA6<<I
M*.-*1C2^P^1KAL9;HW[]RE6N3MN"I%TN%EB.*-L#)'%D4H=&'O=+HYY87 ,:
M&EH+M[2L_-/-E(J'2+,%6*@VVYE6S/4?---8FA;Q9JSXIBR)D!+8Q(&%TA<]
MKBUF[JH?72>D6]N?R$^45\^?STSL)A? V(^#*/T"J>AM]=97X:S'UY/KI/2+
M>W/Y"?**^?/X["87P-B/@RC] G0V^NLK\-9CZ\JOT%TN'2+1&YJU>A<L;ADY
M!4RCR=7'Y=+W-^C;ND6.J5*H1/#,L.$C<D9I9HNVF5 ,*'O0=[#UZ"+6*;9S
M VX9*TN'QC63-,9?#1K5YH]X:!\,T,3)(I&D[S7-<.8YZC4&/;$U"K9NU+N2
M98J0368C)D\A9B<Z"-T@CE@LVI898I-W<>U[#VIU:6N </3%N^^X3QYH*P.1
MEE =RH'6$ 7V)+2X^A"[/0&5K;PN"XMJ0&*$0%RS1>]@()&J3!-%U=HTO77O
M7RR]NX][-==QSFZ]_=)&O^"]18=]K'=6^UIT[V\ ?^ZY4[O6#5W8]#59(?''
ME3R-DTSBE=:0MX%+=XU@E9RFV'W;\L$I)$V)=12(.VD9Q9*L2ASVE1[++ <)
M05U7922N)]],*$M,T60V;UH)U5NZ/<1L]J;X[,FT;5(7*/DF.C6@=WI$G*?-
MMP'EBV4Z*!K61S:U1A:90I,1D$4$=>0$<:.3$3XR*FAS#(I90UCWZ1*!'(2X
MZAC];6#5E>N3,KT8>%=XU<'"U6M>C- 1M$!&V+PGG /&G ,N=.1/>('OZ_(J
M\&&%E%C--& LHL C###!: 666#6Q#&,8MZ"   ZV(0A;UH.M;WO>M:PN%C]B
M72.538;BV.%;T]RFL:G7F4%Q)JY)0BB9!(*.=E@WOR<-?6-S2*_+R1P%*\Z-
M3*+-C=?N]=A2)E3V7*#8^F.=0%SI[(U[HUYC_P"?8Z^^L@6S2PC 4(P 3#.U
MLLO8PZ&/L:UL?8!O?:%V-"#L79UOLZ%K>^K6]87"^2CR3PB$0<4<$!@RAB*,
M 8$!I0M@,*%L&]Z"86+6PC!OJ$ 6MZ%K6_-A%0@?(*-!Y--'& MI=3Y,[T3)
M;Y)DQ)J <<*8HO8D9K=:Q&=E3MPV]F.LG3JP=E+M&6E2*0&G@4]@K9<Z<M?9
MT5=RSR3MF:).*-V28(D[19@![*.!K6Q%&=G>^P8'0@[$6+J%K0M;WK77K"X5
MO,SY(Q*&7W&*'7)@:6+*5LKD!8$S<'AO98M5595\]1:-)7J5+''L%ZW+7V1K
MRF?7?IDZ=KADS>%ZHE.S:+4DT^3_ '_ONA<J"\K.-UGQ5BFU<W974ZC<HD[[
M!XRMBDD0/JB13>,Q![L%\A3&U-QBAW=IBWP2-ODS'%D" ]^-BS:H?D[><U]A
M4,N=#WO]]7[51ZI>?536A:ZVF'R!7K1$ZW6+S=,61<B*O6U8DGM5QIU;&:43
M&+JW!Q6Z3%Q98^,0I+&Y>7%9HQI'A&M<8TG2A5FIB$$<^1[G(Z\^?+_ ^P>X
M5$J\Z3;CK/G>,D+66XZTAUCP">6G2]KVI6CA$:UO&OJUC^YE+I+6SMM:O>3"
M4D$"9/VUME\?B+Y(H.0IDT>:W1K3*#RR;I]CV>?5^/O*1Q_I"Z/>JKLRTG!A
MM2'BK)/7*E57,LAZ1':$P^G6UMCC1*2 1IL?G9')'>ZU+PWQV L'CE$^[EAI
M\:E3;&'9 X)DI-/Q?C[G+K][_P"5=7/;(9*RJJ:6]-4CLT1NOJ^D=D2U $A&
MXOK6R1..+)._) IFQ>L;USLB0(%9.B&]S5(U*PKNTB\\@9:@1<*VB"=(#QSL
MF@Z0Y'Q!XDCE7=]VQ!J/B10X\:DE#'9\[GPJQ3Q6<1Y4I*4QAPCLS*4M,I+/
M&>)MTF,5I@KTAB4Y07.AU(TY@:G\2D--<V:+O7D#R'XRPAPD95K\9G%J;[ ;
M7^/GL[8Y@<R@;.<82ZF'G$2=N8U1Z%ND1Q(4YS.M=68*E/I.[MRA20M( )ZC
MU?[_ -]WO*([Z0[CD.U.5]/HU\P<95PSJ]5;%RJT47-,CFF!N83)"\MD0?#%
MA*:3R-A3 TWO3<FT00WOFS60Y=IQ0N1"(N=TZ ]\Z*?P_E9#YC;E3U@D8WEN
M1WOQK%R5J*6.AB9.FE;&SO,303:(FM>NT<VR>(-5DUA(%!&E:T+@@E2[N E!
MC:P]27&G=]G3_?O?+W%=-A<)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$6BY]%H??\XO_D@<_P!<Y+GNOD6^@F0]U7?%*RT?,^CY]QZO
MQV\M1K/2U'3"*;UG]\BOO=O%/T\@SLSS;?[S?VA5^6]"LG[GW?BTB]2GI2&%
M\E'17<P8]&F=VD#^\<6YBA:61B;U;L\.:T^,A"2D;FU 2H6+51N_,4G3$&FC
MWY@@WGR%/_;S?E9/WRO38.4<)_Z(^O\ NA6[S3BM-:IYR=&-+]WWRLOYF26M
MR+(?D]QOT2EL4@A"SAM=J-"]Z,AM8PP3$K<7-0E84ZQY<CDBHU:4WIR-K3R=
M[PGK'X_^Q677D>0'+V>^.^5BC>6YV*A_!RKYWQV:+[0E4'TCSFZ4K<=/7]<T
M7BSW+^7[&S16Y#:CX^4A?5F,\MC3">\I(W,Y17K(P.4?E3M'H78$9?W1:O"'
M_<_M/_9=AW]=/,\QIW&]7,@=>FO7^)7K<>>'G%BU[1Z.2N@0^'\E^+-9=%K=
ML=12-PK16QU%/;/9KQXQ,$@>IM6[BVH6$J9/\G+L68.4%L%J5O[//DSK)7)!
MY=1;QV@Y0DZ//42YO=Y_?'D>OO?X*]KAK65C3KHDVJCE2Z11.>/M(<@:3BJ^
M9">T[Y$TNW^T:XK,Q<8Z!$^ 2QR-EQD+<><$U3MI0HCB1':V4,9==>V!_$3[
MPU5@X^3-EQ[C9Q%I^FY9RZXY\RJ/)XF\?)EPD:.,[=(:^DZ>-6954 NN0/,L
MD/&J?D.=:-M/I9Y*H=9]:W?#X29&DS.Z*5?CGPAK&7/+5VH:0=2#J=>HZ<M1
MW=-=1JJQ"H^)1J6=,QRV?N*[CR$NF$6K-T-*QIQ120+_ "J%JN G'QGD47J)
M60F6.#"38Y[[*HA-7ZM6\R22Y.VI8\;M[<(JP-:$G<8 0-1S_'O.Z_S:::\A
MKKRU)5B\>AEEACW24HN(<2B;7'9WT?-/JV=KX7<5;@XDUW)9ZU63;B:R6FM8
MY.9$\*;"O5/4;D;%Q61#"XR[/#@9&XJ;'F^7Q1667QW_ )/]Z_["Y.G+7KWN
M>\03H0.9TYZ:\^[IKW>[485?5RLN3DX^]$]2TNJL+QT0/(2&UZ_PVH;&I&%O
M'(3<YKL^,MD&33)@B+8.Y"$&VH#])FUM*<5TH*;2Y._ND@C#R!CY0'DT.((W
MAW0>U[O5S[_7_P!U<]T8%45TTWLS6!5=CU<P>+N,SA";,I"ENC]Y!\2"GYX4
MRFNW-DEG)&76M=%K,,GOFO5J&2,;>!X(;+3?DLWL!S6N+VRMRT:(N''EIISU
M',N#NX1RT T!_..0T]FZTF*1Z4]*7RD@5GL37*XI<71N\?6)IC\@1$.3%(H
MRW9RAC=R1-8WJP&)G!N4G6/#0R1",LP@]#(VLE6$8%!0=%Q]Z.^''_$-T_8?
M^W=5XKG0''.*6:Z\IE-0PM+;C#$UA*VS6N(:734#$T1XQJ/$C+:4:EP<'HN)
MIA1A*K;T*F3*8X$N)(SSFH9;6(N-3U:\EA;KFQX]TA4UY*6LY'3B$7Q:'$V_
M^+_#FA)14]N1114M72ME<'213JT)W(H,W5XEN*Y)*QQ%Y<FALE)[7 (7&XQ#
M43H^217*E)Q<G0<NO30NYC0D=[\6NG=[O<785J[Q_F";T3E&,U96.G5\88O(
MW?F%&YS5-AP-MIUL;.%UB\:'NH)6\2N.,#,LD4TGUD%,38PQMW<SWF*,#_+$
M7>QY&F<3RY(TWNHZZ:<P>LAVO?ZAW>_S[RA#S3A\"?VGD#5+C:4;X]U_R(K.
MF(E:D]2/MWSA V0]B>JAE?+'Q'+FJ1HCH/4;2@WQTXV+9%&'J/,R*<7#R-?T
MDMU-(C*DI-====-=.H:#GKU<M.Z=3ISZAW-%DA?)3<-Q]$S:TEM*-N)=PSGA
ME>@7-E2Q)TC;R_N2VM9NW1QS! E(#'F//4V:@L[^9#C4X5[,XO8V/P,@Y-I*
M67'4[V-?S=??[H]GN]:Q7V=15NT'-N!2:N:ZF$@H#EKR&Z.JU;29X_'W-<70
M?*.EGRL2YQ.) VI$X?)B'W?4[3I7,G561HAJL>I#'%V-3JYVJ/V7;4'>Y\QO
M:=7,'N?F/5U\C["[68MEN<8Y]RBZ02MJ;G]AS&D>DGON(RJM(O'744INGC5R
M*X^<88B<1&T928*R1H8U?$4J*;(%Z,M<WMZ"+38T!A0=.9@"Y.A#6ZCS YZ\
M@03U_F)Y>R%(6_C#8E(*^4D1?F=ZEEA2?H4Y\[6Q-6IE<%R*P>4%LV[R;LRW
MRVMP3$* .CHYSN9N1C$QE*5;FEC1L?0$%"1DHM;X[I_$/VE==1RY_?CW@- K
MHF- XAO7H-XP4C6(Y1%>,]ZRB8MIZ<Y,Y-$&:>,-405[)>$AH *$).K*F5;H
MS25996_&J8@G8>_3["#G_?\ O\^BX'F7?F'Y^?\ V!6:;"ZIA$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6M;]$:<2*EN6H:GN*5!D22<
MPV1#@[6X,;FD2$'QYX"K=C$S@E6-CB$XQ&M+4&(C"1)M!TX+-*0*MZ1B2>M^
M15?GZ;=Q)W#4F9TTZ@\1D[-V(EC@X -D86AX<UW.-A:6]MO>>;>S/Q<%?,U=
M.EC_ (%[)!O02P.<9FB1@+7[\4F^8W,D9RD>'AX+=W3Y^HYJ[U8G'PJR>CF>
MZ]&C_P"KW_\ X7EGEXR_J&/_ %-CZTGU'-7>K$X^%63T<QT:/_J]_P#^$\O&
M7]0Q_P"IL?6E>+P"Z/FA[0Y>4?#)BKGCA'W*:-ARU(4^M*01_@!P5Q)>SR(Z
M$T!8CB :,[L0#.QU]V,L?9&&AVFM28?"7\C4#38KPN=%Q@7L#CR#BT%A)8>V
M:"=W4#>:X<E:8;/7=H<C6P]UM>*K>D$%AU5DD<SH7@\2-KY99FM$C=6.(9OA
MKCN.:[1P]) HHLDLLDH 2RB@ **+!K00%EEAT$  AUY@A"'6@AUKS:UK6M9\
MG$DDDG4DZDGND]97T$   !R Y >P%]YPBMEN/B13]W3=CLV2&V?$K(8(HN@2
M:>4Y==NTC*ET$<G4I\5PU^=:IFD1-D,?T]$@=V](]Z7&L;F)0O83VM6L6''E
MR"1_\@']JJU555U_2->Q6JJLC*.(0"%-OBJ.1]$>N5@1IAJ#UJHY2X.BI>[.
MSHY."I8Z/+V\+U[R]NZU:[.Z]:Y+%2HTN.OF54#")A$PB81,(F$5.7FIH _V
M?!;E<V'O++K>-SB'Q&4)W)W0*4,5L<Z+JYE'ER- O3-K\T.Z^%11STB?T3F0
MWNK$WN;6%$O*VH$15&PB81,(F$3")A$PB814Z#4\ #;9UY[8>]M(VND]3ER<
M]R=U'@4!(DJJ8',+6SG+QL35XTD2@AP?7)N;$KM(/%$<2O2Y<CC3"G;B:\M.
MYUJHN$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g504802g87e13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g504802g87e13.jpg
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M 0$! 0$! 0'_P  1" $G 6X# 1$  A$! Q$!_\0 '@ !  $% 0$! 0
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M_P"'DE&..SNCKRA?:&TDSVDULG&CGU-H>YK,M4$F$S,,(^X-XB/@IV%@)A"
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M,@FBCJ5GY"4E76&,'"P\)'I+O5$H^'BHV+9$08LFR"4MM[QV^1>@@
M
M
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M/FK9%ZXY)+N770;)'7<K)-T$\=)19=0B229>?&.<ZBF2D+CGSC'.;.,<^<8
M%+[1U[OV&XHQ^_$P>#DR(K%30[1U[OV&XHQ^_"#P<F(K%30[1U[OV&XHQ^_"
M#P<F(K%30[1U[OV&XHQ^_"#P<F(K%30[1U[OV&XHQ^_"#P<F(K%30[1U[OV&
MXHQ^_"#P<F(K%31YG%OJ;3H=:M%=;=/I=#K$W&H]/H\W2Z'K')>ET>D7I<W/
MS<^.?\N!W0V.VVD?H]EM-IW,(]QLZ5*$8PCW*<(P<([X,XI[;9;.'TFUV=",
M8=W3HT8PA&$6HPBHPW11Y^W5(^,:K\PQ'XP?T^J5K]VK'\':?TG'UJK?O&P_
MB[/^H=NJ1\8U7YAB/Q@?5*U^[5C^#M/Z1]:JW[QL/XNS_J';JD?&-5^88C\8
M'U2M?NU8_@[3^D?6JM^\;#^+L_ZAVZI'QC5?F&(_&!]4K7[M6/X.T_I'UJK?
MO&P_B[/^H=NJ1\8U7YAB/Q@?5*U^[5C^#M/Z1]:JW[QL/XNS_J/NA<:BZ-DC
M:TUQR<I>D8J$Y&+&*7GQCI9*FZ-G!>?.,<^<<W/G&/\ 4<4]AM]FD]IL=KLT
MW!.GLZ=%-X)TDKSJAMMCM'"AM=E3:46J&TH4FEC!-W'J[1U[OV&XHQ^_'\X/
M!R9_2*Q4T.T=>[]AN*,?OP@\')B*Q4T.T=>[]AN*,?OP@\')B*Q4T.T=>[]A
MN*,?OP@\')B*Q4T.T=>[]AN*,?OP@\')B*Q4T.T=>[]AN*,?OP@\')B*Q4T.
MT=>[]AN*,?OP@\')B*Q4T.T=>[]AN*,?OP@\')B*Q4T.T=>[]AN*,?OP@\')
MB*Q4T.T=>[]AN*,?OP@\')B*Q4T.T=>[]AN*,?OP@\')B*Q4T.T=>[]AN*,?
MOP@\')B*Q4T.T=>[]AN*,?OP@\')B*Q4T.T=>[]AN*,?OP@\')B*Q4T.T=>[
M]AN*,?OP@\')B*Q4T.T=>[]AN*,?OP@\')B*Q4T.T=>[]AN*,?OP@\')B*Q4
MT.T=>[]AN*,?OP@\')B*Q4T.T=>[]AN*,?OP@\')B*Q4T.T=>[]AN*,?OP@\
M')B*Q4T.T=>[]AN*,?OP@\')B*Q4T.T=>[]AN*,?OP@\')B*Q4T.T=>[]AN*
M,?OP@\')B*Q4T.T=>[]AN*,?OP@\')B*Q4T.T=>[]AN*,?OP@\')B*Q4T.T=
M>[]AN*,?OP@\')B*Q4T5D02 !0K16H2YUN>J-E8XDZ[9XB0@9V-,X=-2R$1*
MM564@R.X8KMG:*;IHLJ@H=LX16P0YN@H7/T@#6=/DCU:&E;#9:=<+G 6E_L:
MI[-KDM+ST]>T*U-U6@_V<=3487*<ELS4=-5I[86$JHX=M9CJ4YU!E+,VT-"E
M93'&&Z&&?#.]<,G?&(><O..Y/T2A7Z_5Y:S34Y$,;-<]@V@BZ+-DYNFQ[?.O
M;*E9Y%1B5%LR95B>F)68K5?:LS-8V5;5&02<X<5%F9TCOEYEV^8A\_7'L[BX
MM+:B8::K4A7V4L>8-*2D=)NG.(MC"M2&AZ94Z''),XJ.YVK3I05,B',F=,^2
MR$^XEY4B3-)\FP:&XOMC'YA*';MP,O&*4Y<E.4IBY^C)38P8N?\ ^\9Y\9__
M -$$GQZHU]V;_8I^$ .J-?=F_P!BGX0 ZHU]V;_8I^$ .J-?=F_V*?A #JC7
MW9O]BGX0 ZHU]V;_ &*?A $''IBTDDI/D_\ JDDT^DPV9TO5D*3GYG%$YN?H
MXQS\W/GFY_R<^1HSF%\%RH])8_PVF9_Y[_"\F_1VM\5G$*PT(4.      !+!
MZ(E--7>>QRJ)D4QC4[K.,'*4^,9[853'/C!L9QS\V<XY_P#]Q27/IXN63TW0
MZA72X^9;QAM3H:GUZIG0AU1K[LW^Q3\(RX:5'5&ONS?[%/P@!U1K[LW^Q3\(
M =4:^[-_L4_" '5&ONS?[%/P@!U1K[LW^Q3\( =4:^[-_L4_" '5&ONS?[%/
MP@!U1K[LW^Q3\( =4:^[-_L4_" '5&ONS?[%/P@!U1K[LW^Q3\( =4:^[-_L
M4_" '5&ONS?[%/P@!U1K[LW^Q3\( =4:^[-_L4_" '5&ONS?[%/P@!U1K[LW
M^Q3\( =4:^[-_L4_" '5&ONS?[%/P@!U1K[LW^Q3\( =4:^[-_L4_" '5&ON
MS?[%/P@!U1K[LW^Q3\( =4:^[-_L4_" '5&ONS?[%/P@#T
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M3TW0ZA72X^9;QAM3H:GUZIG0J,N&E0
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MZZ=^:;/YP,NQ>4EH:4@LYO4=F(SZZ=^:;/YP$7E):""SF]1V8C/KIWYIL_G
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MNEQ\RWC#:G0U/KU3.A49<-*@
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MLGINAU"NEQ\RWC#:G0U/KU3.A49<-*@
M            :=\IUO($N&HI>HY]I;"CF&QT(:JI:@0V^O+U>0+2BVJ4,SD]
MCZS@ZPQ@G[:J$<3SF=3E%G<K'0D8IU>5E8Z6Z6YQW7<8?)QD0]ZAOOX1C[LN
M*,Z:9G.T>M:Y*GD8^4<GS,LI!>,I3[72#67B)^5B)B&7I$E-6)[7)2ORK%Y!
M33!>:?YQ,QK]8BI4U2))P]_^8^U$E^3:S=O#2Z[QBXDVB$6_6=1K1@:5=2#=
M-HJ==BVBRD4-).':93-T6!4SF>**%;X(;*G1S (THZ"MZ=T>;'?5S85YHT;O
M[4]\L5B?::M]*N<[$Q>H=BT'V<TTZ>!9V6<B]6VI[K>SM9Z%IV'TH9T_.U;R
M:E-P]SW&Z%RN:AOXI[[X1W;_ &,Y]5T8[LFMUSNN?N/7':3M;V.8SU78;"J%
MLO>QMI6R'B<QS&#B:CKN-V;M2[4Z:G"35><OZC=UDMJR;NG51.1B7O:2WL%[
M?792!HMJB6B*W9*<%%7/==OOW16]$J[AC+A?[EPCDV;9<F:1MCO6K>/M%10I
MR-<<14#66#>IVFCE<025,J<@Z,>M722EK(U5AK5)6:I*2,@^6[29K?:=N8S6
M91.:*4(W7^M/B\)A;O-=AP6;]YGYR1=1!0C9<K9<Q>9-<R.%RIFY\?XLHY.G
MA3Z.?'-DY?R\_/\ 0.22B=0L7Q"VX&G^/ #J%B^(6W T_P > '4+%\0MN!I_
MCP ZA8OB%MP-/\> '4+%\0MN!I_CP ZA8OB%MP-/\> (1?2_H2"$GH+K\@F_
MR9CLKU64V167JL8<4;IXS@JZ_K.GSEYLYZ/1Z.?R]+Z-&<PO@>5'I+'^&TS/
M_/?X7DWZ.UOBLXAB&A"AP      )5O1)HOEMX;%*Q>IL5<:I=&.HHT*\P<G:
MZJXZ&$S+(X+GI9*;I]+/_CT>;Z>?%)<^GBY9/3=#J%=+CYEO&&U.AJ?7JF=
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M3_'@!U"Q?$+;@:?X\ .H6+XA;<#3_'@!U"Q?$+;@:?X\ .H6+XA;<#3_ !X
MU=Y4BIUYW5L)"JQM:NDHC>UX#8TQMN:TZQ@8V.1JZE@JJ<U!P-D6LDC;RN(R
M1;5%]&&C5FE.D;.=PD_JL>57I8\,(1]ET\\R'P[3<'ON,@<F*R5"P:C@4ZFE
M',<1;VT,YJ,8W9381\SB=SLK:;LQ[>\PC+6AE>YYI+W*(M<NR8/K3'S*4XLS
M;*NU6Z44M\N$."N]2NUWA;KM38,02                !!IZ8[\Z<G[]0V;
M_$40:,YA?!<J/26/\-IF?^>_PO)OT=K?%9Q"D-"%#@      2Q^B%_3IL?\
M9,Z_G"J"DN?3Q<LGINAU"NEQ\RWC#:G0U/KU3.A49<-*@
M                          :C<J4Z^%M>,#N=0-&5L=3%!8O]I9IBCR!N
M%MDZ>A VFHQEPB)9.SR4%"L[<9.HQY"YG9YY6"RR*L&UD5V<KUXW1W878X\"
M'ZO7VPCP<HF2M!5-E5Z-T,-*D>8//6Z)D;#5XBDQB]CC*U=K1#55S934"*AZ
MTK:&U>19I69M%Q[)A&6<\ZS:Q\=@JC-(WY_7'BLPMT]WGAP,WB"0
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M*QBF+6.9E7=+'<.5BMF:2*&%7"ZBBZZF"8.LL<ZBF3'-DV0*D
M(-/3'?G3D_?J&S?XBB#1G,+X+E1Z2Q_AM,S_ ,]_A>3?H[6^*SB%(:$*'
M    EC]$+^G38_[)G7\X504ESZ>+ED]-T.H5TN/F6\8;4Z&I]>J9T*C+AI4
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MEO&&U.AJ?7JF="HRX:5
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M>)D-+5+$1!8AU$TR$1;I>R6?66:;=]T5.M>O5Y?:%^I)?@
M   "#3TQWYTY/WZALW^(H@T9S"^"Y4>DL?X;3,_\]_A>3?H[6^*SB%(:$*'
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MB%_3IL?]DSK^<*H*2Y]/%RR>FZ'4*Z7'S+>,-J=#4^O5,Z%1EPTJ
M          %NV_\ RG:/]NS?_&N1ZJC]MJ?XJK_FT#RU[[%7/PM8_*IG%2/T
M&,(@       !V;ZE_15K/]GU,_ER-& [<^^K8Z4M#K>V-S6-]SV5T;4>J[(R
M"/EGT@           /BX<-VC==V[71:M6J*KARY<*D1;MVZ)#*++KK*&*FDB
MDF4RBJJABD3(4QC&P7&<@##[7E ZG?TQ2_1UD>2=;Q;%Z,T4C*O;9"8F+:@_
MS&^PZ_66D$K9;"Z6<%.JT4A(E^V=QR:LPV75B45GQ)@XP(BMY_(3E!ZEL3^L
MQD19G+E]:S'1CD#UBV-,L'I)6S0/LJTJ/(-NE29M2?I=M@$(2XG@Y5Q.UR8A
MD6:DDR5;80?;Y8^H17;M=ZS(U6M$+=(-G9:XZ._@Y$[SV;(9;.&R$DV:/G+$
MLE']922,\B) S8SN'E4"G83,6LSEHQPZC7K5RM!.\N$           0:>F._
M.G)^_4-F_P 11!HSF%\%RH])8_PVF9_Y[_"\F_1VM\5G$*0T(4.      !+'
MZ(7].FQ_V3.OYPJ@I+GT\7+)Z;H=0KI<?,MXPVIT-3Z]4SH5&7#2H
M           6[;_\IVC_ &[-_P#&N1ZJC]MJ?XJK_FT#RU[[%7/PM8_*IG%2
M/T&,(@       !V;ZE_15K/]GU,_ER-& [<^^K8Z4M#K>V-S6-]SV5T;4>J[
M(R"/EGT@           /DNHHD@LJD@=RJFDHHFV3,D11PH0F3$03.N=)$AU3
M8PF4RRJ:13&QE0Y"8R; &A<-0-Q%;-;&OJ]\RE:7RJ+-O:/J[NVTA1U<*K>J
M]L6H/HB,?,9]Y$,K'7&-V3F^KS[V*B7SQB@T:2_.=1RWZ<,=]%+CO4/? Y4>
M*XMSCGGF?S')DG;##M/;5>9P-KNMWVK>[K,MK5)&:5NN6&XV^U5;7"[*&DVC
M&S3SDMY=1;JRFB7[>I-GNR9.G3<1892M2;MW4(P?!)7>:_V>Y.*$'[7'C",<
M<?-NCNB;$<G^(V?"4EQ'[15<9D$)*/2@&;X]55D(V%:TZJ,I-HY/2VC2N]35
MO36Y2-<09IX.RJ+^OL72+!TU5BV,.$;OG\\B5&%^7N,UN4,.4%$,J+HX4+T<
MJME3(+D^G&>=-4F<&(;Z.;GQG\F<X_U$$E%[.I=[6'C3SQ 1!9S>H[.I=[6'
MC3SQ (+.;U'9U+O:P\:>>(!!9S>H[.I=[6'C3SQ (+.;U'9U+O:P\:>>(!!9
MS>H[.I=[6'C3SQ (+.;U(1?2_P <5A)Z"P5W(.O6L=E<^7[U9YDG0<4;F]5Z
MW.?5]+I?X^C_ .7,7G_\<#1G,+X+E1Z2Q_AM,H#GO4-KR;]':W%O]JSL2&(:
M$*'       E6]$FQ*^WAL5(SEZUP35+H_38NE6BAO_RZJEZ)SI9QDQ/\7/T,
M_1TL%S^7&!27/IXN63TW0ZA72X^9;QAM3H:GQA_K:G@= /9U+O:P\:>>(9<-
M*06<WJ.SJ7>UAXT\\0""SF]1V=2[VL/&GGB 06<WJ.SJ7>UAXT\\0""SF]1V
M=2[VL/&GGB 06<WJ.SJ7>UAXT\\0""SF]1V=2[VL/&GGB 06<WJ.SJ7>UAXT
M\\0""SF]1V=2[VL/&GGB 06<WJ.SJ7>UAXT\\0""SF]1V=2[VL/&GGB 06<W
MJ.SJ7>UAXT\\0""SF]2WK;7DBU2SF]K6#/-7IK/,:9=Y+GFC7.>;..E].,_Z
MX_UP/54?MM3_ !57_-H'EKR_^%7-_P!EK'%_[5/,XR1^@QA(        .QC5
M%?2/JW6I_:L^7IT"G&Z))AV0A>E78[/1(7!N8I<<_,4N/HQCFQC\@P';GWU;
M'2EH=;VQN6QE_P#465O^[:CQ?[KLLR_^SJ7>UAXT\\0^6?2@LYO4=G4N]K#Q
MIYX@$%G-ZCLZEWM8>-//$ @LYO4=G4N]K#QIYX@$%G-ZCLZEWM8>-//$ @LY
MO4=G4N]K#QIYX@$%G-ZEP@2                    0:>F._.G)^_4-F_Q%
M$&C.87P7*CTEC_#:9G_GO\+R;]':WQ6<0I#0A0X      $L?HA?TZ;'_ &3.
MOYPJ@I+GT\7+)Z;H=0KI<?,MXPVIT-3Z]4SH5&7#2H
M6[;_ /*=H_V[-_\ &N1ZJC]MJ?XJK_FT#RU[[%7/PM8_*IG%2/T&,(@
M  !V;ZE_15K/]GU,_ER-& [<^^K8Z4M#K>V-S6-]SV5T;4>J[(R"/EGT@
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MI?T5:S_9]3/Y<C1@.W/OJV.E+0ZWMC<UC?<]E=&U'JNR,@CY9](
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MOEV2_J@+L'-:"_%2>HZO:^]Z]\NR7]4!=@YK07XJ3U+A$$@
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M=-C_ +)G7\X504ESZ>+ED]-T.H5TN/F6\8;4Z&I]>J9T*C+AI4
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M2Y_5I)E*C'>"X@
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M/7N54U'*QN+"4% RJ()
M
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MA6B_PW*&6CU)TMRVO*PY=962U1&I[=$/))C3PA'&_AO?%1]4,.,"8P#D
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M_IR /[@I2YSDI2XR;/2-G&,8R8V<8QG.>;\N>;&,<^?IYL8Q_I@ ?H
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7G+"NZ;FE\1[,0S.X           __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g504802g94n34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g504802g94n34.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $< D4# 1$
M A$! Q$!_\0 'P !  (" @,! 0            4&!P@$"0,*"P$"_\0 8Q
M 00" @  !P41"P@'!@4%!0,$!@<! @ ("1$2$Q06TA4959/3%R$Q-5%25E=8
M='>2E)67T=8B-CES=9:CL;.TM1@C,C1VLL/5)#A!1;;"U HE,U1Q>!HF-Z&X
M)T)#8YC_Q  ; 0$  P$! 0$              @,$ 04&!__$ $\1  (! @,"
M!PH*"@(!!0 " P$" P 1!!(A$S$%%")!45.3%3(T5&%RD9+1TB,S8G%SL;+!
MX>(6-4)#4F-T@:'"1+.T!B1UT_""HO&4H__:  P# 0 "$0,1 #\ R=WI[R=[
MH_WR["5%4?8>\&0]M>!J%U_ 8=(BZGB4=%41P*-QP*QU5767=.W"#(</:)*+
M+N%DD$$]U-]=<_H'!W!_![<'8:>?#8<DP!Y)'5>8$LS,>@"Y)YM37RF+Q>+7
M%S1132@;4JB*3SFP51\YL!6OUJ=OO"V48^%C+HN#MW5#\VW7=A6MA[S.'JF6
MK7=)-VX$X/,6."2+119%-THRROJV45336SIOOKKG5#@N!L0"8(,%,%(#&+(^
M4G<&RDVO;2^_FJF3$\(Q$"63$1DZ@/F6_P UP+V\E8I]\T\(#]UW>?\ /<E[
M7+NY7!OB6'[,57Q_&>,R^M5V"=[O"<2.%3BQ0G9N_B$*K9Q%&DYD",\7U:1U
MQ.'I =%$WB:KI-TIDT]%$&[;+1NXU3W;;^DY1UV3VWK;@_@E9(XFPF&$DN<Q
MKLQ=MF 7MI;D@@FY&_2IC%X]D=Q/*4CRYSG[W.2%\NI!W7JD^^:>$!^Z[O/^
M>Y+VN6=RN#?$L/V8J''\9XS+ZU27OC?A&?<CU@_RINPON![I>XWNWZTG/<CW
M7]%]-]RO=+R/0O=+T+_I?H/GO2O1?^D>:\U^[YSN7P9FR\3PV:V;+D7-EO:]
MM]KZ7W7TKO'<;;-MYLM[9KFU[7M?=>VMM]JRG".U7A?;+A4GLBO+4[A3>OX6
MF[4E<TBWKH<C('4>UP_(^Z1H<Q<,$-AH_;4B2TROG<</VU?O=4&F<+<IDP?
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MB+ F<&QA^#VE[7MDOFO;6UJMXQPEL]KGQ.RW[2S9+7M?-:UKZ7OOK"OOFGA
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MX0Y=,TDI0@KDL*\WN%V>8WP4&[:^/5\URK6N!X'<RA,/@V,)RS!0A,1%[B0
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MTCU@N82DLEX+HPET=1L! [Y-"!&"4N%)(N<!S&>=,AG2LC&:Z'TC8)=U65G
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ME2=BAH]OJ[TQG=!TYD)$6R8[Z?NO3G+?77.,YQG&#A.)IL%+$B&1F:'D 7S
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MB,S"]AN!.E(H))LV46"I(Y9KA;1J7900#RB!H/20-:_)K5MLQ1R[JQD3(V(
M  X];9$;7+B5RB$@/76& 3.\@(,-A;)L+-,@3H:$DAA<8CHBL.R/U*/6+1LO
MOR.:%QMBHB9F:$&4(DC;-V7*#<DJ6!91?4&]@31XY%^#N7 592$S%5SJ#<@@
M68"P8VTM:YM57BU(V]-35? (W7$P?D+5/#8Q76RH1Z-&2\V6<)MF30,<*I,@
MCC3;=3"CE[L0T8,&FJKY^Z;,D%W"<WGAC65FE0"%2\O*!**!<EE%V'D%KDZ
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M#/5%VN78(,%&*#@@QT7R+BX6V^I'%RVTS"VBE@2O\0NC#36^EM15S829>+Z
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M=:J(IVR/LUS9'??<( 2  23RF4:= .8G10:KC3.V7.B7L 7) ))L!R58Z])
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M?,LFU%KY;VV5\Q(S6-QVV=3JKD5%]6NMM)RYV'?RNGZ%J&KY,^CSAX[ /)!
MH!'XJ9=!'9%@*?N1#@B*<*CG#X8.=K,]T5'+%HMMN@GM@0Q0Q1L02D:*2-UU
M4 VO8VONN!\PK#,XDFED6X#R.X!W@,Q87L2+V.MB?GK8#EM5TXI3BE3A;;;4
M''MM-,J;ZLRFVJ>,ZZY4VP3<YUTQMOG&NN=L^+7&=LXUQG/CSG&/'GF6'PC&
M?21?^/'6B7XC#>;+_P!K5H+!^Y#PO++=#6A3!RBXI0[P6.M>R9]952K1")OC
MT)C<]!ZN%P<M?NEV;\)+ FJI-)#T$>\<*(/54?,*;XDL]VD#QF,16SN[QY5)
M4,!HQWA@;[N:]Z-!98RD@E,M\B(DF9@&93O4;BITW\]9>&]J^MY<E!PXVZJ\
M=D[)T8;P9HG(V6%))@N2)A@>@_.^^J?G9"7"EQ<;07W16D1 8^9A$W[AJLGI
M9MHKJ-HMVMEU&MR0+?.00.DC2]5F&4!B8WLG?'*=+"YO\P()Z 03I5'LGO7U
M5JT7*24@N.'OU(3,(U!I0)CID88,"#\DG0ZNMD%V:3Q/51*-28ALTF6[=9;>
M,;CR3,FDD5;8'*P?$PIFO(I*L%8 @D$L%U^8GE=%C?46J28>9RH$;<I2RDJ0
M" I??;G Y/3<6T-ZRG+KMB\5,=>QB2#L^U['6&XKZ&&1&[7<:T63I*UKS;GB
M&ZZR*J@=]&ZG*#VVS)-PYV(EQ6^R.K3TI=&QI #$-^U;*I&[XMY+GR60C3G(
MJ"QDB4[MDN9@=_QB1V'ENX.O,#5"<=P*/C[FST['F(6JV=:W5M16"4[,BA+6
M7S/6KH+:^J,4URZW7([K )R@@@.PE@JNZ$$]DF>Z&J"BL-O&,^9@@239W8@9
MFR*_)Z=&W;]#4MC(<F52Y>/:64$Y5SLG*TTU74[@"-:G3/:_KB"-3>,/;D@.
MTIKL-*CDLC+61C7!L:T@X_0I,&VK/1Q_THK&&2J"\A$-E%2(+1RVV+MF.BZ>
MVW3/$"P,BYD#%EN+C*+MISD#>!J.>@AE(5A&^5B K938YC9=>@G<=QYJP2+\
M)#UD?DZO>/[ B44K:VJ26N2,6),I6,CK?7*$D! 7<1?B76NR;<D'2,JOY*1]
MV-F$>T%O</\ Q,T]R*58Q41*<I0DD>T#,P'.!E(Z1<DF]A;HUJPX2:S@(S.D
MFS*JI/[)(:_0;<G3E7TZ*VD>7K38^R&5/O;-A;:SR.6Z;.$+'V&L@6=/13H\
MQ&^A96\K0P0 ,7QX<&5VT*D 3)X99,UQC5=TG<9(PV0NN<_LW%[D7 MTD D#
M>0+BJ=F^7/D;)_%8VWVO?H!T)W D#>:P=4W<Z SVO@]D33$?JL 0H^C;G?[&
MYV")N1&EZ&I]'XY&W(Q%)@?RJL8@CD5'2ZP1HVG!=R\#QILX* BK5*M)T90[
M60&.*35AIM2P MOWK8&PS'0"X-6/ RN47,Y$DD>B'79A22#J-S7(OR0 6T(K
M($4[(0J?VE"(' 7(F9Q>>4W-K>#6/'I U(A54(3/H= 'P!)HV:JX6=^Z<I<Z
MOU]R*"X=^#>!WHWTS*V6<EE5G54(96C9PX-QR65;:>4F^NA%K7W1:)E1F:ZL
MLBH4(L>4K->_S+IIJ#>_3L1RVJJ<4J>C'T_&??'_  ]^9<;X+-YH^T*T87PB
M+SON->E[87A=^\0BY;A@HFW&0\?#+,GP ,VQ75;N-$P0.6E!(U++ES%%G"BK
M9H@V044<+*++YQY[93??93R?I(,'A'C4NC9BJL3M) #<#4 -8;]WH\GF2R2H
M201EN0-!<>3R^0^GRP7ONG??[=##]&U7_LAR[B&"_@;M)?>JGC$O2/5%/?=.
M^_VZ&'Z-JO\ V0XXA@OX&[27WJ<8EZ1ZHI[[IWW^W0P_1M5_[(<<0P7\#=I+
M[U.,2](]44]]T[[_ &Z&'Z-JO_9#CB&"_@;M)?>IQB7I'JBGONG??[=##]&U
M7_LAQQ#!?P-VDOO4XQ+TCU17(=>%^[_/7"KIS=;!1=;;RE-_F:5;KY6WBQKX
M_)TAVNN/G8QCYV,8Y%.#<!&@1(V"KH!M)M.?^*I/BYY&+LP+-J3E _P!7']]
MT[[_ &Z&'Z-JO_9#DN(8+^!NTE]ZH\8EZ1ZHI[[IWW^W0P_1M5_[(<<0P7\#
M=I+[U.,2](]44]]T[[_;H8?HVJ_]D..(8+^!NTE]ZG&)>D>J*>^Z=]_MT,/T
M;5?^R''$,%_ W:2^]3C$O2/5%/?=.^_VZ&'Z-JO_ &0XXA@OX&[27WJ<8EZ1
MZHKSK^%^[_.?,^?NMAOZ.W2:I?\ ]-*MU\E!'&<)Z?N8=CQ^3C.?W6WCVS_V
MYSR*\&X!,V6-AG8NWPDVK-O/?>2I-BYWRYF!RJ$') Y*[AN\N^O![[IWW^W0
MP_1M5_[(<EQ#!?P-VDOO5'C$O2/5%=M[.;]Y]PM7%GG<I88O9%8>O3=O,>N]
M.U\!>.B?3J<=IF+N"3(D^.-9K!8:3BK*N;6E[\-#V\4)F&B^J*^Z^46WAG$X
M7-,HPF813;.\>*FE<*.$(\$1)&%4QRR*YF@0-)G (OIKZ@PTMHB9K&2/. \2
MHMSA'Q(R.78.B%!'*UDR%AIK6JU>]OO"#E.SS'K/9?8O6-F2*<:W8':ZJ6@K
M$9DD)J'C4FB1D>K(B=9@EHT4B,G8RC8EF18)IC_(:-P3LHOZ&ENE7!#!G%PP
MEU&:Z2S8F$C9LR.IRI,P<2(4MDM?4L%%SFC69L1Q=W"MR;-&L<@.8*RL,TD:
ME2K!KYKVW*3I6@G<GN'VMM=M:G6.Y+:2F<.C\_* '^4ZXBL*<$R-?RATV&EM
MFB,:$R,/YQZ,3>J!WRJ#MOKOEB03PKHIKC9A\/A&CBGC1D:2-9%^$>3+M$!M
M?,4:P:UQH=X.XUGEEE222(L&".R'D9<V1K;B+K<B]C8C<>>L/^#V\(19_@\[
M*P%.Z$);U[FA9-:<0=%;"WHF^V4VBDV@^R^^B+"5#VJ:/IPY11NTDH]! >4R
M@ND)*BLN)P]SNLW[+:V8='S]%];>2]KHI0P\G..<?_O_ /'/7O9T):E?W9'X
M':-72<;,(-,&Z!0$=%JYW0<(*:[Z*MW"*FNCE@28N-%6106^1;D!C]!PQ?MF
M[I!5+3PL<",+B 18B,W!WC=7HX/PF'SQ]1K7OM'U_)=@OF!#6QIZ"#5O?@JS
MY@\"3695[+%(T/J^UH?LVA\J@:S&1#SRAN:A-]L-C0%)8*D835*?/T8/IS1&
M79:V"29VLS(ULCKR62Q!NPYQ<7UJ$,NRVIM<O$46ZJRW+HUV5[@BRGF.MM.<
M:PW7X/47)8[=\4J>.5L#"RKH5:76&IO6UT<*F(S9EA'9W*5Y8;DA(1*9'EB8
ME$C$2B6S/)8]-34F;.Y 29EC":3UQ3)A01*$" -AGA0-<D.Q=LQ)!.K,&9KE
MBPN;G6KH\408RY8E<2DSY; ,BA!E"@JN@4A5L% L!8:5LWVLJV3W!6K:NF=3
MU[<H SJ0;RR/3V\;(HU%/*P9P+8O6<@K>OIV6,M5L$2;8P+=:"-4VJZ1!HJ_
M?-DF6;ID,BY,BR*;Y@TCQ\UA8HK$[S<:=(N=*IA<1MGSO&PME*QI)SW.CN@%
MK C?T:5CN?=?[Q?=5NNE9C)'"K,NJD91U6E\D/S8R7KR+6.:HF50J0S!QL7C
MT+GA".J2K,<(J"]](B5U0<.F^CM'37*JND&BD,,2!E>2-H&)8E0YB92VH5B,
MUC;DGR]-366,32N0R1R+.H"@,R"56"Z%D!RW'[0T%8ME'6SM<9,2VWF)2IP=
MFVC;5?E9U 8Q,GB 8'35;5'/(+&(K#;JF-#3(II.',YF&)G*YFWI*,O'\/<%
M*[![B<)>[YR!BF)9[H'=U+*#H(T1E55D:-CFS-F9MF#EN@MWQF)H0%C(=D2-
MPK,-2[NKL6C651ERKE"[0C-9S>]A2*]Z6=CZGAT,$0U>B7<T9=!7?5QU,)$0
M+%!T'M",:30E 9*,C!&KR;*Q((3)2=D"D0TWZJ[B@(Y5;$?E35;U;5BN'E0+
ME,>88;8YF).5QF*D I9U-P#?+8#<VZI-B(G9BPDRG%">P !9#E# D.,K  D$
M$W)WKOK8KJ?UXM.M?\I(A;[T$J\O:8QV0LVK&7MK/>L6@NH(=6;_ 'DI-U3]
M11@D1=K1?TA,>R@&H5(3E@(6P]0:9\Y=#$Z;7.1\(P.C9SHBH;G9QK<Y=P6W
M-K5,\J/LA&"!&I7O<@N79QE&TD-A?>6O>YTJW=;.G<(ZT')*=BKJ+N'$F$M1
M+K4!0_76HEM46KSTS3+@E2M55\5+I^7\[1B:>D!Z&WC70:IN?\[CL4"Q$E;:
M@#2.)/\ K1"?[DBN2SM* &OH2=9)7_['<#^P!K4&<==.V\6H AUHBE?U39=0
M KP'V,UE(>UR4=NN5U"U[(-+[=UT&KN55X,K9G:F@_#B"LY2?N\3$BB;5.4N
M=P)$ED2*H:*81&)41XQ)G!$A$C)M=J5"L@0/;DW,@4]]R;V%ZS0F3;%G20QE
M,N0&,/L=EF+!\^0]\5$;,.]U&IS[!:%M1SVX8]CBT'@52CDXA8,8ESJ/W'/+
M-E5O!I.^CCR#AST'D,$C<+JSU46"^LAK:(224;^L>VT>'$# %5R==6K&YGVQ
M54&5E-G9V<&V4%2JJEK7.4GE::C4U-*@@V(9G.96%XU18R,V8A@S-)FO89@N
MFNA%A(32J.Q5@=I&,MFL1IZ2=>X.V4&5 BA<TTC\TAA*80YY&+)MLY7^*'.
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M;>PXJ641NPV:K*BY19R)5*W8FX!56.X',P#FW>U9QH*QD13M&:%VS&Z PE6
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M;,KA6!BRW2ZJL0<!2 RW'PC$6*V)&FFM:X@A<C+F4K*'LV5F,I1F;-9K'X-
M=#< C2]ZK8/H'@+$I (4NN2&9@9ICMQ636QBL5#^[[&6]Q+4WM:Q;35:#W[
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M!8R]9)AH^5.CGX8<9([-QSTJR=#V[A1VW52UXV%P27S)&N4!FS.192; F[:
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MXWC!!YU+J 1NW<Q!KLD#Q6+&,W.7X.6.0AAS$(S$?W%CS&K5)^Q]:QBT>O\
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MRF]T20'F99,^6W/^P2=-!;^W6B=!=A;ER1D<ZM%DSWZ -HHO??>HB\>SM?\
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M- PIBFYRBD&\R9*OR2'GW)(> 431:.-Z%VOG3)T#,&)Z=PL!T:DGG K ZHI
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MK\K*"PD<.$#1(1XJ[60R3++*[-F08&9)NFK!:Z:0Q1M($9\JELJD#0 DDEB
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M:@&,8U./5G+L7&F)AR"-2Q1GA02%W5<)MN12=&6(L<K2HC :D N+A<ULMSJ
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M5X1+YWW"H'FJL].*4XI3BE.*5.G?HA_Y"'?U*\RX7_D?U4W^M:,1^X_IX_\
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M.*M>0P&-@Q939"A*H5:0DJ<\I+',XL=0!JS$6!RUV;$"52H1@"X=0SAEB #
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M*#H8$C"A210.:34E'F,W$BAS360,LG# 1C K1RN;/9E(**<T8&:-X9D;75G
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MBG[ZPW+H!*MA]I.C1&91)*TK3;5^\,R4L-/260C:[;3)*$1V1R(T*:E3)^/
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M0#<@"]KWT%O[U0((7NTIO=F*J&(L"3J;;R1S<W.+[L7>]R^%H^YWD?YVI_\
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M:B)&H1%"JNX#<+DD^DDDDZDFYJ#NTC%W)9C:Y/D%AZ  !Y*N_)5&G%*MIO\
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M3^OM)VD%&^4ECR_1) 1%E%?_ (S=DJT\2^;YYGC*A%S @D_!8B3GZ88I /\
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MQ7P:,B(TLXC5V73(8)92=FD\AS*T=A>0!@PT%B:K,6&Y;*SL$B+L@8@AA,B
M9WA3DLK\R75@=3N.X'6&T)-<-*1><S1J#:RY0O/XG)O5EL_8QUZ<K>Q997!,
MN#'%")@D+%''D35,L1+XP8=BFS],<N6)J-MGR^J"1I8E=@ UW5LM\I:-VC)
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MK6&-VL',/'#=V[+0]ND%T2C)-TZ:-'+A^%T9.EW#9NLJKLHBGMK 0P@*!%$
MA)0"- $)U)46Y)) )(MNJ6UE)8F60EP QSM=@-P;74#F!O67N6U73BE6V6_Z
M4;_V2"?V:W,>#_Y7]9/_ *UHQ'[C^GC_ -JJ7-E9ZK$PA,,L, ]BD_B,8G,6
M(Y1R0C4P "I, ?Y;JZKH9>AC31Z.=907TT61\^VW\VKIJIIY.^N,XBRJX*NJ
MNIWJP# _.#<&I*S(0RLRL-Q4D$?,18T$PF& 6\<: HC& K6','(N(MA( 4.;
MQ88\301=CHXBS:(I@V#I%LV2<M!FK5NNFW0T53VU23QJ"J,ME4919; #*#O"
MVW#0:"A9C>[,<VK7).8CG/3_ 'J- UA6L6D\DF\8KR#1R:3';&\NEP&)  \G
ME6^%//8WDA\>/;E3FV%L85QL3=NLX4QYSQ^5\_G!'&K,ZHBNW?,% 9O.8"Y_
MN:%W90K.S*O>J6)5?F!-A_:HN-4K3<,+2,]#ZEK**')BDY0EQF-0.+ BTI0>
M*>=>(R,B+%-7AQ)VK_G7*9-9UHNI^[5QMM\_G%BB0LRQQJ6OF*HH+7U.8@ F
MYU-ZZ9)& #2.P75068A;= )L/[5Y8E3=0P!FS'02JZWA0\<?6E8]C$H/&(XS
M8RAR)>@7$D9M@XMF@U/K@B1$*L80TT(JB7[T=NXV9NET5.K%&@ 2-$ .8!45
M0&(*Y@ !8Y21??8D;J-)(Y):1V)&4EF8DK>]C<[K@&VZXO5W%!Q %EJ-!BQP
M8=JX?/-6 IBV',M791\Y*$W6K5FDBAAP1)O'A%\OA/SKM\Z<NW&RCA=53:0
M L  -38"PN3<G^Y))Z2;U$DG4DDZ"YUW"P] T'DJ1YVN5LC1?TND'WZR_L%N
M?,?^H/C,-YDGVEKVN"N\F\Y/J:OG\^$Y_A!.W7X;YE_?<<^NX(_5N"^@7[Z\
M#'^&8GZ5JS)X-R"UG-$;/7F46%OI%%W\1.1R83>!J$*NBJ;=,XLKB6VD]<JP
MZMWCU^V8;!L6"/91 SNV=8)2)@FSV07HX5DECV.1V".'5TCDM,]\O>0BSR@
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M=RL.:?-RSF5C&PRLEA$3>,@I& 39*TR"1I$"NHPKF%4#2@0Y1D 5U#@W4ZR
M .#F?=RJXU76CV7LE['X$C;<Z'Q4UW5&01.S8AF/3\BO2C[I%/[4-#!%C2GK
MY70,T%VN,"U8HS-&N,+@#+K:*B)41U'#_)1R8B3*FU<*<4$VB9')B.%>0@2-
M BD;46SB/0\D,;4=(4NVS3,N'+E#F4;08E8UN@E<@[,][GU&I N:LM971<)*
M65+&[VN6W*X"M8B890\]'ZZCBA&_;0BG9>SZS*!IQCYE$F:;$M*QB-8&MX[$
MAL.T--;+E<N'))( QA",2BEE+1+-+)&,I"E46\TBXB2,J_P;"^S6,Y4RWSNV
M@ *Q>.,+(T4<;DD%@7;X)&A1P5Y:Z9V=<S%K%%4ZGE8K%7OW->USV9EZ]C#A
M5D1/KSVE//ZDU4=RB<0"U8P7QI4#R+UXOUQA#**BXTT0>BF;,O9]I-K7%$04
MG'.)%L@\D"T!-BC'B&S@2+!B"8@<SQR*?@R(]@N4*+@7DD$H(<7L35C18?-"
MH0E&EA DME5T8<L%]LY8L2#HB%"&6R]Z.Z2!1@I#HF*CIJ;RFQRK##S9],YG
MI'$Y$:</7[I_NH]1B8"+QYNBURZ]!'-1H-DDU&M6;;?TA9)1RMZB*54*79R+
MW9\N8W).N5572]A8#0#>=:\YV#,2%5 ;65;Y18 :9BQUWFY.I/S5<.2J-.*4
MXI3BE.*4XI3BE6V"?ON!_?>W]@MS%PCX%B/,'VEK1A?"(O.^XU4N;:STXI3B
ME.*4XI3BE6Z>?OO._?F/[!+F+@[P+#^8?M-6C%>$2^=]PJH\VUGIQ2G%*<4I
MQ2K;+/HQK_9(+_4XYCP?_*_K)_\ 6M&(_<?T\?\ M52YLK/3BE.*4XI3BE6R
M"_OO ?R@G_N[\Q<(^ XGZ)ONK3@_"8?/'U&M$^[,ZJFOZC'EK0JV+W Y?3(:
M#K2(36)HR>(Z648#GF H]*'CL%(6<-C ,$O(WDHF"@]=ZQCF"HR/L3LE+AHV
M9LQ;Q)&#+&LMW 174,N<@@%B00JA2Q9K7RY@H9B%/,,LC26C=H[*2[*V5L@(
M)"C,I9B<H"@]]8DA06&F-+U?:4:L6E(SUTMNO]XY">@T*@KJRK%I"=6)&Y@I
M'+-.#E&D8$!;EIEQ$<MWC5RH/$D"\BV8 ,#QJ37";75^XR1QR+)&L$B95P2)
MM'B=U>TCBR@2QY=QL"6L+"VESID=&5VFC<%L6S9%E12N9$-V)C?-\X"W-S>L
MCUY)JYJ;P5?4LK>U6;6*.CG6'JD,TJPY"T9$X)6'I6D%'QH23"GAKL9'UADD
MPBL2D4E;M!D*T9.CI1RRU%[;ZV(R1<'X<S1YPN'PXV;*#=\B!00PLMFM=FL$
ML6-K5!P\F.G$3Y"9YSG#6LF=R2"#<W&X"Y;0#?6HC>%4O$(; 0]LC@-L5"]Z
MH=HA=?IQ^N9)*:X#WY95R[SJ=574L>6C2[P,4:#Y$)@=%C_<@3)B,(AC@9&4
M$\,RS%'-EB14$H62(X?$!"L9:,3R2YWBB&4D&S9(18,42RBX85?FE9G,99)!
M/"7S.%D,21Y5DD(-B-"TIN5S-K6Q4/S&8)VIZ([6*OG7L!KU*EE<70>(Z&S)
M7UY+@>M;:+QHB=43?#F&IL\*FQ$:.9NVK!\5Q(32J6Y!X0>KWKECQ&#VA^'X
MLT<K&[',1 %4MJ-6#D"X!.8[R2:6NT&*R#X+C"O&  !E!FN0-#HN4&^X91T"
ML5>#G#+CK[ %,@6F^I6@;;PH-%P\A%;$H)0S=D0F"]6]OI"YCHQI;5W&\E&>
MD;EVZL=?B-H-9NC*+2QO)#=HG:\"")@2!K#)H%*O#>96V>)8K\),;C*UU(R2
M'*V8R&S&->,BYTECU+9DERQ%=IAQF)2(<ZV-\R792H09+BEZ6O(NQCJ,A[?L
M:6'&7;^XZODM)K0(&A78+K>!@<V(I3#>0-Z\8E\J )>SBS0=-]K =M7,A50K
M=1HX)$'K/><<TK3Y1*[$8J6-HC&!&(%5SFS;,&ZL% ?.06M&1<FH-'&L0)C1
M0</$XDS$N9BR76Q<@74DE<O>\N]JPI4USW-!HMX/^N(BYLF-JQVI_!W1";0J
M0:,F@$]$[(CT-BUBD0$%;T7(#YD=%A[M9E-)O*+F@3> S$<+&#1RRZCD3**X
MY947!HNT7+'@E=6M9E<*KE4V+,0M[.[2QA&L!KHUDD<;G%.V1@9,6RLIY09"
M60,VU &;]E5C?.I))YUNL@M+MY#JGEEBM+.M*42B9]9/"/29A'"D$A6XFOY[
M1AM/3KP]A@T/7P\OH8RPW=H:L922DZ,[W<ZN5&+C1B.0:2:3$K&[B21F;#XY
M@I1+(\+6AR 1AKV.YBP?HW5$)AV<)DC"K-@US!FNZR@[7,2Y%K\Z@9>F][W6
MW[ [3U \LV"A[*F\VB@ZQ>L[PW;4X:1J*$X1!+*CMEYLQ1G+8+1DN#Q^+8FD
M(A0UT9S5<K<U\,L VX]T  YJ*.QB<LF(B,B!V90\!,KA5*I(LFTY20LJJ'1!
MFV39!(=PLRQC2"0(Y158K,!&F9@S(8\G):526RNQMM%#E!O)(;"5\6->IJB#
M\,LZ\I8D)E/4[LN_KF0TE#])XPOZP7$XFD:AU;R,V2H42]DI8'4NT/&$-(K!
M:RTGCF032Q0>K<<!&EX_3,\S1%9)6RMAIRAB4.)W+LJH6, N1%D[Q(\^9Y!H
MH*V1)$)0R1+=<1"'60Y3$@52S@"4V!DS6S,^2RHUR;'O KU)1& P=%9/=%9&
M'QI)5)739-1)1,*RTW34TWQC;3?3;&==]-L8VUVQG&<8SC..>LG>KYH^H5YK
M]\WG'ZS5PY*HTXI3BE.*4XI5MEO^E&_]D@G]FMS'@_\ E?UD_P#K6C$?N/Z>
M/_:JES96>G%*<4IQ2G%*<4IQ2G%*V1HOZ72#[]9?V"W/F/\ U!\9AO,D^TM>
MUP5WDWG)]35\_GPG/\()VZ_#?,O[[CGUW!'ZMP7T"_?7@8_PS$_2M6VG@HO6
ME:/WBT8-I('B_NA"G!6Q %OWX%]5RJ;"58%C]Z%Z]676DRMUR<3RX3;F=S@Y
MA#O1MTWI9H@;VQG%PR$S8<DJS\L")H<,V=;I<\8Q44L<.7G&4E[[CEK3P=F*
MRV# 72\@DF&7OM-E"Z-(3TYAEY]#747/-EMYS,]W.RV[C>5R+9?9SJ4T<;+;
M%WF5=E]3A$N:U6SOG;*NI<L4*8WSM@@1>N\*N5?;C^+2V[(NZW\(_A"KZJ@=
M  TKS7[]O.;IZ3TDGTDGI)->X%X'3^#UKC\*MS_XE'.>*_ZRQOT6#^S-7HKX
M)AO/Q'UQUV9\MJ%.*4XI3BE.*4XI3BE.*4XI5M-_O:A7WD;_ ,=><QP>%8[Z
M2#_QXZT2_$8;S9?^UJJ7-E9Z<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2K;!/WW
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M./X+QJ#M%]M.*8GJ)/5-/4B7_8T9_(%_8XX_@O&H.T7VTXIB>HD]4T]2)?\
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M)[U/\H*]OMUVY^D>8_\ .N-EAO%XNRC]E-M-UTW:R>]3_*"O;[==N?I'F/\
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M2G%*<4IQ2G%*<4IQ2G%*<4IQ2I8%]-V/\=_Y-N9\5X/+YOWBK(OC%_O]DUZ
M_8;P8_A.R_8.ZY96G6&5.H[);4L<R(.^[U8[IF0IJ9%B@UXW;$I=JL@W<M%6
MSA/"[9!UXM_$JFEG&=.>^.$,B1I$V7)&BL2M[D* 1J"+ C^_S5Y;8,2-(95O
MFD9E :U@6-C=3S@[N;GUW8C][#\,%]S)*OSK3W[5\=TY>M'9CW:YW/@ZL^NW
MO4][#\,%]S)*OSK3W[5\=TY>M'9CW:=SX.K/KM[U/>P_#!?<R2K\ZT]^U?'=
M.7K1V8]VG<^#JSZ[>]3WL/PP7W,DJ_.M/?M7QW3EZT=F/=IW/@ZL^NWO588C
MX._PTT#E,<FT.Z^3:/2R(FQDCC1T<9IQ)^&.!GB) 639J;2G?71RR>MT7".V
MVFVN%$]<YUSCQXS%^$&D1XW=61U9'4QBS*P(8'D[B"14DP,2,KHC*RD,K"1K
M@@W!'*YC5NB/1_PZU9+J)PZEK'BR^LUBMB*X&G::3V]>80A(D(E)=LYE"F,D
MP2$ODB;!7QYTTU,O,;Z;YWU\FHXY<0H=F216C>,$Q#6.0KG2Q0<EC&E]/V14
MQ@A"2H5T(=7($A[] V1N^(NH=K?.:_!G5?PZ-3U+-H*.JF>QJH2"<@E4UCOI
MU(NPBV5HU@.?-KMUS;UTF[S&67H*CECG1YJT2SHVSJIMGRCXI9)4F?(TR *D
MFSLP ;, "%&@8WL=+T7#*D;1*&$;$EDSD@DKE)L2=2HMIS5UG594W9?NC;<7
MZNTZQ4EDODNR3Z1+(((BP4;#)[([/S,N,-&V$A<2 MEF[LDZ7T44>NW+0:Q;
M/R;D:.<Z,;B9E78N]S8&3* +DZA!:UQ:Q-]]]>2*R08>)GSQQY;$Y<Q)L!H6
M-R;$Z@6W<U]Y^@?X./P<-,>#JIQ"$05LVDEF21NR>6W;KUBFB?G)Q!/.VK-K
MY655@L,"JJK(QN,H+Y0:I[JD7^[TX_)$7/D$EC<_V\GS?>>?R"P'JJH06']_
M*>FNQ+G*E3BE2Q;_ +M_DEG_ ,3F?#_O_P"HD_UJR3]CZ-?OJ)YHJNG%*<4I
MQ2G%*E@7TW'_ 'QK_5GF?%>#R^;]XJR+XQ?[_9-:$]Y;EEU.QRALQ6<%:Z;V
M5V( UK+9;'ZZVM22#8L]J^V9>KB/PM*/RIP2(NCD, MM]FL?)N$!ZKY35)+7
MRW2$IF*A+,4S2!2P7,;%6.@L=Y YJ[$H8O<9LJ9@"V4$YE&IN.8GGK3,7WC[
M/UGAS.KCJJ02N,P/J%.[]M./M6 2H"@F!5U>MIB&5MJP>:[.YL,L>?T1&(Q-
MM:7=NF;4,96-QDN1BI=DR;OZ!-*INZDA82[#1" )&&?*=<Q0 Y-U[C32K3%&
MUE1@"TH13WVK(ARW&A <D9N@7KL*[:R23PZFI!8$;NW%(LH>,?FWAMI7@.Q3
MLG)K-/0H9#0(.0[N$'Q"3REX,#,XV("OY=,BA 9&HJ]$%WR*R^B4D(6#Y+ G
M10Q8VY( .^YMH-3N!&^J8P"X4IG)TMFL!SDDCH%S>X WFXJF6/;]T0:A>L$K
MDPX'$K;L&U.G\$N  T;)DPX4E:\Z@L:MF.A<N7#S.B3-8R=%B"&';IPUT30=
M).5EM-5MC,X2,FP<M$' &@+,H8#?TD#4_/7552\@&JA92I\U6*G_  +U@\UX
M08B_A=B%'%2S2M CFH>Y<LJJQ4)+ I.7,&NHA%_&IFKB(+H$&(-1^Z3]WX K
M(]3# PD*(M98%"Z>YR!RLSFS<@J,LI5K@W,1LVG-TK??S@<\Q"+K9@QS1!EL
M182;M>?H-MW,:KYCN??J$OLZ/D*W'B:WK[LQTJI]I:$9EL=7FN0W8D_UT8Z*
M2.%R*.$@9;64$+<]SSBT=WCCR*14NZ]PMEI,":&'43-)KR;*KQ+G##-9]GO4
MJ0;YM;6L#IJ*;*.P.;4QRME*FUU#Z @@BV7GN"1KH;5_5]>$H)P$+VM US!J
M[D]H4CUQ[(WQ!-4+=CT[CKIOUN/1.*S1C;0F&Y:$(.:8/)W'Y S@S20ORQX<
MR/1M^>A,I8+MVO7Q! D"JN98W=>4&'((#9K6L1>X%S>Q!RG2NI!F,=V.5W13
MR2#RP2,M]^XBY %[$7%9+L'P@HZL;+'53*:O5VF </4Y:U X6=#BQ:+_ #89
M43C0)A !"8))]:CZ-,Q2LPG&B6D21&15PTVCJTKD.Z\>;];$9&"LHS67. VH
M+&P""W+MO.ZPMO.E16#,N8-IRLIRFQRBYS']F^X;]>@5$".W5DV=V*ZWA8E!
MB\0H6>6QV@@/KF].0\IO9^:'C%CQMY[H1CT9230E@M8,-=GH2Z8/W:LACHG=
MU*/5E9VRCY%M6:2,!;1LTBYLP.;(&&[FY2W&IN-]CI0Q*J.2;NJH;6(RYB#O
MW'0V-QH=U]]?T^[<616O8'L>$ET$,R^C8;V$ZR5.VF[0[$!GS,]NP$!HV-@F
M@Z+ZM]9-,V"=JV*W-3=\_=-%HZ!E"#V.*2;4<1!!NF5E=P5S('1<UP,N=4 T
MM<C,UR>8&XOJ!W9*R1D, YCD;+8\K(SDZ[AR5L.DC6VE\Y4-VY 7W(XS$P,-
M-ASN]622>6BR?OV+C:H97';7+TKFLI#Z-IXR!XA/X#=(MH_:ZMFGFZE-+[H_
M^\6B:,DF$A  L<A9M>\(8IE.F\D-SBV4Z56\>0$W!&8*OR@5SYO)8%?6WZ5K
M5#N]BD@\(*:HE2PZN=5*5,V!0$-A+$L 4M%K?E00>)6I(Y049)%5#^D0DHPE
M;]=:-WXQHU%RFC$566[K,QU4S 37G*9ERZH!<9LZJ&)Z;&[+T Q^6K##:$/E
M;-8.3KER,2H TM<$*?F??I6%::\(#-87"8O,KID*L\6E?3KP;!R-AW>8O#1Y
M*\^R<K[:"9S*3<C9A$$(\%(BJRCQJ2K:,B;4,&ASGU0BKPX0]R#4%G* %S>\
M<!%S89W,MR3;DBR D[@!H+Z&;P@M9!:SS7M<G*F2P OJ=; >74VU&VU?]Z']
MH2>EH="J+DA,U9C.Z34M>+R\$PC5?Q6@K3@%7SB6C2[IGH]L4&=7L$1(:UVC
M89!_+!*S/0JQBKA4IJ$L&(+% J7S9R3F%@$958@VY0Y5UW7',#I530Y0Q9K6
MR@::DNI90=>2="&ON/3SX\J?PEPFW8C/9V$@,$$1"*UE1UFBY-(>Q,!'QO5'
ML!))"#AT(LB18%*A:TLN/-(T\)6#!/3I9(03@I& @1G*24E&)J\7$9@QRJ J
MHP)D 'PA-@VG)8 78<HBX%C>I-!E*B[$EG4@1F_( N1KRE-Q8Z"UR;6-<E'P
MD2DAA$-E%<4(<L D>KOMA8\C&C[(A8T+&P_3>W U.6E@;*7VGF)<G(9*4V4K
M)V,&-M)&TW%N#Z<08O2+X(XP2H*QYCEE8\H  1-E:Q(UN>]L->>PN0V%B07L
M,T:@E3<F1<PTYK<^NECO.A['(A)Q<WB<7F@3*^0LNCH23B,NDL(.LBSXUL58
M9<H8W4PBOEH[2\\EA3?":GE:8WV\7CSH4AE##<P!'S$7J@BQ(.\$@_VTJ\%O
MHCOY)8_[FW*8-TOT\OUU.3]CZ-?OJ)Y?5=.*4XI3BE.*4XI3BE.*5D>#_P"K
M/_X]+^SVYY'"/QD?F'[1K=A>\;SON%?.[\)S_""=NOPWS+^^XY]]P1^K<%]
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MFRNTHU N-FH8<YWW(W[A>M6CO;NV2<BN_L79EY]LX9 *F[]RCJ1'ZLZP1;K
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M<DLQ B!LV81*QY18%U%B3ER@W-[%KD:BHM"I,QU7*TA4<D+9&.@&;,=-+A;
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M%O\ NW^26?\ Q.9\/^__ *B3_6K)/V/HU^^HGFBJZ<4IQ2G%*<4J6!?3<?\
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D>N,XQXL^3KXOG9Y1-.\Y!>UU%A86TW]-6I&L8(6]B;ZF]?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g504802kesselman.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g504802kesselman.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M]%]R!+"./;B:X.W;]Z9CT!'K[\^M"I)=7][!U6^B^Y EA''MQ-<';M^],QZ
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MK?1?<A8K)(MN)9VV@#YIF.< CG)]_P >/2G&FH]7][$ZC?1?<ANG,6@D+?\
M/:0=5/\ $?[O']?7FIHZQ?J^W?R_X?N.KHUZ+OV\_P"NQ;K8R.5\=^))_#&E
MV=U#>V5H)KI87>[A>50I!)(564D@#('.>G>E%WJ1AWO^7^>GS';W'+M;\[?\
M'Y$-SXIO]!MYKS7(TF#QR7$5C:0*DT$*'EI'>;8< J#C')P-U%U'1[Z>BO\
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M[=KO[REV3_*WY75B%&T7'T_!W^]O_ANIIPB_;6[J1V=+!8D2-&*$._)9Q@9
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MJ[RWO?RVM;_+7OW-+0-)N-&D-C')-_9=M"L<0E,9,LA)9Y/E (SNQR>H.%
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M>/EYK5FG6*M?=M=UT_*7GVOL:C>)M7A9#;O;7%C:WT&ERM)$6FN9'"!I5*L
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M]/DX1YI1CU;M^5W^*73=_/377/$BGP_'*FG^;J]K@@1L!;W 0.2<OETV[OE
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M,<E9V7E\^_I;N]-/-&S;ZI_:NG7$NF1S1S*"L?VZTFMQOQQE756*].13:=M
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MS6FNHTVKM;N_X[_UH5--\)Z?HVCPZ5IRK!:"?SK@"-09SU.=H"KDA> ,8&T
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9^_Z?\/ON)J^_>_W[FU4C"@ H * "@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g504802pwc.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g504802pwc.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M\J &0ZKIUQ?26,-_;27<0S) DJF1/JH.10 ^\O[/3H?.O;N&VB_OS2!%_,T
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MR"/#_P#UWE_]!6@"_P#"/Q9H/AKX103:KJMM;F*69C$9!YA^8X 3J2: /+?
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/ * "@ H * "@ H * /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
